0001739614-24-000006.txt : 20240228 0001739614-24-000006.hdr.sgml : 20240228 20240228091006 ACCESSION NUMBER: 0001739614-24-000006 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824257312 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39452 FILM NUMBER: 24690538 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 10-K 1 inbx-20231231.htm 10-K inbx-20231231
FALSE00017396142023FYP3Y00017396142023-01-012023-12-3100017396142023-06-30iso4217:USD00017396142024-02-21xbrli:shares00017396142023-12-3100017396142022-12-310001739614us-gaap:NonrelatedPartyMember2023-12-310001739614us-gaap:NonrelatedPartyMember2022-12-310001739614us-gaap:RelatedPartyMember2023-12-310001739614us-gaap:RelatedPartyMember2022-12-31iso4217:USDxbrli:shares0001739614us-gaap:LicenseMember2023-01-012023-12-310001739614us-gaap:LicenseMember2022-01-012022-12-310001739614us-gaap:GrantMember2023-01-012023-12-310001739614us-gaap:GrantMember2022-01-012022-12-3100017396142022-01-012022-12-310001739614us-gaap:CommonStockMember2021-12-310001739614us-gaap:AdditionalPaidInCapitalMember2021-12-310001739614us-gaap:RetainedEarningsMember2021-12-3100017396142021-12-310001739614us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001739614us-gaap:CommonStockMember2022-01-012022-12-310001739614us-gaap:RetainedEarningsMember2022-01-012022-12-310001739614us-gaap:CommonStockMember2022-12-310001739614us-gaap:AdditionalPaidInCapitalMember2022-12-310001739614us-gaap:RetainedEarningsMember2022-12-310001739614us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001739614us-gaap:CommonStockMember2023-01-012023-12-310001739614us-gaap:RetainedEarningsMember2023-01-012023-12-310001739614us-gaap:CommonStockMember2023-12-310001739614us-gaap:AdditionalPaidInCapitalMember2023-12-310001739614us-gaap:RetainedEarningsMember2023-12-310001739614us-gaap:PrivatePlacementMember2023-08-012023-08-310001739614inbx:WarrantsPreFundedMemberus-gaap:PrivatePlacementMember2023-08-310001739614srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2023-12-310001739614srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2023-12-310001739614us-gaap:FurnitureAndFixturesMember2023-12-310001739614us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-31inbx:lease0001739614inbx:PhylaxisBioScienceLLCMember2020-07-31xbrli:pure0001739614inbx:PhylaxisBioScienceLLCMember2023-12-310001739614inbx:PhylaxisBioScienceLLCMember2020-12-310001739614inbx:PhylaxisBioScienceLLCMember2023-10-012023-12-310001739614inbx:PhylaxisBioScienceLLCMember2022-12-3100017396142022-10-310001739614us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001739614us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001739614us-gaap:WarrantMember2023-01-012023-12-310001739614us-gaap:WarrantMember2022-01-012022-12-31inbx:segment0001739614us-gaap:MachineryAndEquipmentMember2023-12-310001739614us-gaap:MachineryAndEquipmentMember2022-12-310001739614us-gaap:FurnitureAndFixturesMember2022-12-310001739614us-gaap:LeaseholdImprovementsMember2023-12-310001739614us-gaap:LeaseholdImprovementsMember2022-12-310001739614us-gaap:SoftwareDevelopmentMember2023-12-310001739614us-gaap:SoftwareDevelopmentMember2022-12-310001739614us-gaap:ConstructionInProgressMember2023-12-310001739614us-gaap:ConstructionInProgressMember2022-12-310001739614us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001739614us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001739614us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001739614us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanAMember2020-07-012020-07-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanBMember2020-11-012020-11-300001739614inbx:A2020OxfordTermLoanCMemberus-gaap:SecuredDebtMember2021-06-012021-06-300001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanDMember2022-02-012022-02-280001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanDMember2022-02-28inbx:tranche0001739614inbx:A2020OxfordTermLoanEMemberus-gaap:SecuredDebtMember2022-06-012022-06-300001739614inbx:A2020OxfordTermLoanFMemberus-gaap:SecuredDebtMember2022-06-012022-06-300001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanGMember2022-10-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanGMember2022-10-012022-10-310001739614inbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMember2023-12-310001739614inbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMemberinbx:DebtInstrumentRateOneMemberinbx:SecuredOvernightFinancingRateSOFRMember2023-01-012023-12-310001739614inbx:A2020OxfordTermLoansMemberinbx:DebtInstrumentRateTwoMemberus-gaap:SecuredDebtMemberinbx:SecuredOvernightFinancingRateSOFRMember2023-01-012023-12-310001739614inbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMember2023-01-012023-12-310001739614inbx:A2020OxfordTermLoansMembersrt:MinimumMemberus-gaap:SecuredDebtMember2023-12-310001739614srt:MaximumMemberinbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMember2023-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanAMember2023-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanAMember2022-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanBMember2023-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanBMember2022-12-310001739614inbx:A2020OxfordTermLoanCMemberus-gaap:SecuredDebtMember2023-12-310001739614inbx:A2020OxfordTermLoanCMemberus-gaap:SecuredDebtMember2022-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanDMember2023-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanDMember2022-12-310001739614inbx:A2020OxfordTermLoanEMemberus-gaap:SecuredDebtMember2023-12-310001739614inbx:A2020OxfordTermLoanEMemberus-gaap:SecuredDebtMember2022-12-310001739614inbx:A2020OxfordTermLoanFMemberus-gaap:SecuredDebtMember2023-12-310001739614inbx:A2020OxfordTermLoanFMemberus-gaap:SecuredDebtMember2022-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanGMember2023-12-310001739614us-gaap:SecuredDebtMemberinbx:A2020OxfordTermLoanGMember2022-12-310001739614inbx:A2020OxfordTermLoansIncludingAmendmentsMemberus-gaap:SecuredDebtMember2023-12-310001739614inbx:A2020OxfordTermLoansIncludingAmendmentsMemberus-gaap:SecuredDebtMember2022-12-310001739614inbx:WarrantsIssuedConcurrentlyWith2022LoanAgreementMemberinbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMember2022-02-012022-02-280001739614inbx:WarrantsIssuedConcurrentlyWith2022LoanAgreementMemberinbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMember2022-02-280001739614inbx:A2020OxfordTermLoansMemberus-gaap:SecuredDebtMember2022-01-012022-12-310001739614inbx:SalesAgreementMember2021-09-012021-09-300001739614inbx:SalesAgreementMember2022-01-012022-12-310001739614inbx:SalesAgreementMember2023-01-012023-12-310001739614us-gaap:PrivatePlacementMember2023-08-310001739614inbx:WarrantsPreFundedMemberus-gaap:PrivatePlacementMember2023-08-012023-08-310001739614inbx:ClassOfWarrantOrRightExpirationDate1Member2023-12-310001739614inbx:ClassOfWarrantOrRightExpirationDate2Member2023-12-310001739614us-gaap:EmployeeStockOptionMember2023-12-310001739614us-gaap:EmployeeStockOptionMember2022-12-310001739614us-gaap:StockCompensationPlanMember2023-12-310001739614us-gaap:StockCompensationPlanMember2022-12-310001739614inbx:PreFundedWarrantsMember2023-12-310001739614inbx:PreFundedWarrantsMember2022-12-310001739614us-gaap:WarrantMember2023-12-310001739614us-gaap:WarrantMember2022-12-310001739614us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001739614us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-01-012023-12-310001739614us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001739614us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001739614us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001739614us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310001739614us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeStockOptionMember2022-01-012022-12-310001739614inbx:LicenseNonAffiliateMemberinbx:PhylaxisBioScienceLLCMember2023-01-012023-12-310001739614inbx:LicenseNonAffiliateMemberinbx:PhylaxisBioScienceLLCMember2022-01-012022-12-310001739614inbx:LicenseNonAffiliateMemberinbx:ChiesiFarmaceuticiSpAMember2023-01-012023-12-310001739614inbx:LicenseNonAffiliateMemberinbx:ChiesiFarmaceuticiSpAMember2022-01-012022-12-310001739614inbx:LicenseNonAffiliateMemberinbx:A2seventyBioIncMember2023-01-012023-12-310001739614inbx:LicenseNonAffiliateMemberinbx:A2seventyBioIncMember2022-01-012022-12-310001739614inbx:LicenseNonAffiliateMember2023-01-012023-12-310001739614inbx:LicenseNonAffiliateMember2022-01-012022-12-310001739614inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMemberus-gaap:GrantMember2023-01-012023-12-310001739614inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMemberus-gaap:GrantMember2022-01-012022-12-310001739614inbx:PhylaxisBioScienceLLCMember2020-07-310001739614inbx:PhylaxisBioScienceLLCMember2023-12-310001739614inbx:LicenseNonAffiliateMemberinbx:PhylaxisBioScienceLLCMember2023-12-310001739614inbx:LicenseNonAffiliateMemberinbx:PhylaxisBioScienceLLCMember2022-12-310001739614inbx:ChiesiFarmaceuticiSpAMember2019-08-012019-08-310001739614inbx:ChiesiFarmaceuticiSpAMember2019-05-31inbx:performanceObligation0001739614inbx:ChiesiFarmaceuticiSpAMember2019-05-012019-05-310001739614inbx:ChiesiFarmaceuticiSpAMember2023-07-242023-07-240001739614inbx:ChiesiFarmaceuticiSpAMember2023-12-310001739614inbx:ChiesiFarmaceuticiSpAMember2022-12-310001739614inbx:LicenseAgreementInitialProgramsAuthorizedMemberinbx:A2seventyBioIncMember2020-06-30inbx:program0001739614inbx:LicenseAgreementAdditionalProgramsAuthorizedMemberinbx:A2seventyBioIncMember2020-06-300001739614inbx:LicenseAgreementInitialProgramsAuthorizedProgramTwoMemberinbx:A2seventyBioIncMember2020-06-012020-06-300001739614inbx:LicenseAgreementInitialProgramsAuthorizedProgramOneMemberinbx:A2seventyBioIncMember2020-06-012020-06-300001739614inbx:LicenseAgreementInitialProgramsAuthorizedMemberinbx:A2seventyBioIncMember2020-06-012020-06-300001739614inbx:LicenseAgreementInitialProgramsAuthorizedProgramThreeMemberinbx:A2seventyBioIncMember2022-06-012022-06-300001739614inbx:LicenseAgreementInitialProgramsAuthorizedMemberinbx:A2seventyBioIncMember2022-06-300001739614inbx:A2020OptionAndLicenseAgreementMemberinbx:A2seventyBioIncMember2020-06-300001739614inbx:LicenseAgreementInitialProgramsAuthorizedMemberinbx:A2seventyBioIncMember2023-12-31inbx:option0001739614inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember2021-02-280001739614us-gaap:DomesticCountryMember2023-12-310001739614us-gaap:StateAndLocalJurisdictionMember2023-12-310001739614us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-12-310001739614us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2023-12-3100017396142017-09-3000017396142019-05-310001739614inbx:LegalMergerContingencyFeeMember2023-12-310001739614us-gaap:SubsequentEventMember2024-01-22inbx:right0001739614us-gaap:SubsequentEventMember2024-01-222024-01-2200017396142023-10-012023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark one)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from         to     
Commission File Number: 001-39452
INHIBRX, INC.
(Exact name of registrant as specified in its charter)  
Delaware82-4257312
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
11025 N. Torrey Pines Road, Suite 200
La Jolla, California
92037
(Address of principal executive offices)(Zip Code)
(858) 795-4220
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act
Title of each classTrading symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001INBXThe Nasdaq Global Market
Securities registered pursuant to Section 12(g) of the Act
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.                                 Yes  ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                                                 Yes  ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☒
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.               ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.                                Yes ☒    No ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.                      ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).     ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).               Yes  ☐ No ☒
As of June 30, 2023, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $892.9 million, based on the closing price of the registrant’s common stock on the Nasdaq Global Market of $25.96 per share.
As of February 21, 2024, the registrant had 47,392,447 shares of common stock outstanding.

Documents Incorporated By Reference
None.



INHIBRX, INC.
ANNUAL REPORT ON FORM 10-K
For the Year Ended December 31, 2023
TABLE OF CONTENTS
Page
Item 1B.Unresolved Staff Comments
Item 1C.
Reserved
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K, or this Annual Report of Inhibrx, Inc., or Inhibrx, or the Company (also referred to as “we,” “us,” and “our”) contains forward-looking statements that involve risks and uncertainties. Except as otherwise indicated by the context, references in this Annual Report to “we,” “us” and “our” are to the consolidated business of the Company. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “design,” “seek,” “should,” “target,” “will,” “would” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:
•our ability to complete the Merger (as defined below) and related spin-out transaction (as described below);
•the initiation, timing, progress and results of our research and development programs as well as our preclinical studies and clinical trials;
•our ability to advance therapeutic candidates into, and successfully complete, clinical trials;
•our interpretation of initial, interim or preliminary data from our clinical trials, including interpretations regarding disease control and disease response;
•the timing or likelihood of regulatory filings and approvals;
•the commercialization of our therapeutic candidates, if approved;
•the pricing, coverage and reimbursement of our therapeutic candidates, if approved;
•our ability to utilize our technology platform to generate and advance additional therapeutic candidates;
•the implementation of our business model and strategic plans for our business and therapeutic candidates;
•our ability to successfully manufacture our therapeutic candidates for clinical trials and commercial use, if approved;
•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
•the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates;
•our ability to enter into strategic partnerships and the potential benefits of such partnerships;
•our estimates regarding expenses, capital requirements and needs for additional financing;
•our ability to raise funds needed to satisfy our capital requirements, which may depend on financial, economic and market conditions and other factors, over which we may have no or limited control;
•our and our third-party partners’ and service providers’ ability to continue operations and advance our therapeutic candidates through clinical trials, as well as the ability of our third party manufacturers to provide the required raw materials, antibodies and other biologics for our preclinical research and clinical trials, in light of the current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, geopolitical events, natural disasters or extreme weather events;
•our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; and
•developments relating to our competitors and our industry.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled “Risk Factors” elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant
1

information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to new information, actual results or to changes in our expectations, except as required by law.
You should read this Annual Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.
This Annual Report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the ® and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.
2

Part I.
Item 1. Business.
Overview
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms superior to current approaches and applicable to a range of challenging, validated targets with high potential.
Recent Developments
Sale of INBRX-101 to Sanofi
In January 2024, we announced that we entered into a definitive agreement, or the Merger Agreement, with Aventis Inc., or Aventis, a wholly owned indirect subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all the assets and liabilities primarily related to INBRX-101, or the Merger, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. Immediately prior to the closing of the Merger, all assets and liabilities not primarily related to INBRX-101 will be spun out into a new publicly traded company, Inhibrx Biosciences, Inc., or New Inhibrx.
Under the terms of the definitive agreements, Aventis will acquire all of our outstanding shares through a merger, and in turn, each of our shareholders will receive: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Aventis will (1) assume and retire our outstanding third-party debt with Oxford Finance, LLC, or Oxford, (2) cause New Inhibrx to be funded with $200 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%. Subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we currently expect the transaction to close during the second quarter of 2024.
Discontinuation of INBRX-105
We have decided to terminate our INBRX-105 program, a tetravalent programmed death-ligand 1, or PD-L1, targeted 4-1BB agonist. During the length of our Phase 1/2 trial, we dosed approximately 150 patients. We initially observed single agent complete and partial responses in non-small cell lung cancer, or NSCLC, and head and neck squamous cell carcinoma, or HNSCC. We also observed partial responses with INBRX-105 in combination with Keytruda® (pembrolizumab). However, after evaluation of the totality of the data from the expansion cohorts, the initial signal was not sufficiently validated to support the continuation of this program. We are in the process of winding down the clinical trial and expect it to be complete within the first half of 2024. Consequently and in conjunction with this decision, Elpiscience Biopharmaceuticals, Inc, or Elpiscience, terminated its rights to commercialize INBRX-105 in greater China.
Current Clinical Pipeline
Our current clinical pipeline includes therapeutic candidates in the following categories:
•INBRX-101, which seeks to maintain the natural function of Alpha-1 antitrypsin, or AAT, in a recombinant format, optimized for less frequent dosing and greater potential therapeutic activity as compared to plasma-derived AAT, or pdAAT; and
•INBRX-109 and INBRX-106, both of which utilize our multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function.
3

INBRX-101 Blank.jpg
INBRX-109 Blank.jpg
INBRX-106 Blank.jpg
INBRX-101INBRX-109INBRX-106
AAT-Fc fusion
protein		Tetravalent DR5
agonist		Hexavalent OX40
agonist
ProgramTherapeutic AreaTarget(s)/FormatSTAGE OF DEVELOPMENT
PreclinicalPhase 1Phase 2Phase 3
INBRX-101*Orphan/RespiratoryNeutrophil Elastase Inhibitor
AAT-Fusion Protein
INBRX-109**OncologyDR5
Tetravalent Agonist
INBRX-106***OncologyOX40
Hexavalent Agonist
__________________
*    Subject to potential acquisition by Aventis as described above.
**    Third party partnership with Chinese biotechnology company, Transcenta Holding, Ltd. (formerly Hangzhou Just Biotherapeutics Co., Ltd.), or Transcenta, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.
***    Third party partnership with Elpiscience, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.

Our Leadership Team
We have assembled a team with deep scientific, manufacturing, and clinical experience in discovering and developing protein therapeutics, as well as an accomplished commercial team with the expertise to successfully bring our therapeutic candidates, if approved, to market. Our in-house capabilities span the disciplines of discovery, protein engineering, cell biology, translational research, chemistry, manufacturing and controls, or CMC, clinical development, and commercialization. Members of our team bring experience from multiple organizations including Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Novartis AG, Pfizer Inc., and Roche. Our board of directors is comprised of individuals with proven business and scientific accomplishments and significant operating knowledge of our company.
Our Strategy
Our mission is to discover and develop effective biologic treatments for people with life-threatening conditions and to evolve Inhibrx into a commercial-stage biopharmaceutical company with a differentiated and sustainable product portfolio by focusing on the following:
4

Rapidly advance and optimize the clinical development of our lead programs.
Each of our clinical programs has key data or milestone events expected in 2024/2025. Since entering the clinic, we have made great strides and believe we have the potential to reach the marketplace as soon as 2026 with our first commercial therapeutic.
Apply our protein engineering platforms to create differentiated, next-generation therapeutics in focused disease areas with particular emphasis on oncology.
We continue to focus our internal clinical development where we believe we can create effective and flexible solutions to address the challenges of validated targets in areas with a high unmet medical need. Our modular protein engineering platforms enable us to efficiently identify optional therapeutic formats customized to the target biology.
Maintain our culture of innovation, execution and efficiency.
We have successfully built an innovative culture that encourages scientific risk-taking within the bounds of our data-driven philosophy. This enables our research and development team to discover numerous promising preclinical candidates cost effectively, from which we select what we believe are highly differentiated programs for clinical development.
Maximize the potential of our therapeutic pipeline.
We have a disciplined strategy to maximize the potential of our therapeutic pipeline in order to bring the greatest value to our shareholders and the most significant impact to patients. We are continuously looking to streamline operations to increase efficiency and to ensure maximum value is achieved with the capital we raise. Additionally, such as with Sanofi, we will enter into strategic partnerships and transactions in instances where we believe partnering will accelerate our development timelines and/or maximize the commercial potential of any approved therapeutic candidate.
Our Pipeline
INBRX-101
INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate that we are developing for the treatment of patients with AATD. We believe INBRX-101 for AATD has the potential to be dosed monthly, while maintaining patients in the normal range of AAT exposure, which would be a significant improvement for patients currently receiving weekly plasma-derived AAT infusions that do not maintain normal AAT exposure. Through our proprietary engineering capabilities, we were able to overcome the challenges of producing AAT recombinantly and manufacturing at commercial scale. Additionally, we believe there is an opportunity for INBRX-101 to be used as a treatment for Acute graft-versus-host disease. It has the potential for a more sustainable dosing schedule and could provide a superior safety benefit over existing approved therapies coupled with greater efficacy.
In January 2024, we announced that we entered into a definitive agreement with Aventis, a wholly owned indirect subsidiary of Sanofi, whereby Sanofi will, indirectly through Aventis, acquire the INBRX-101 program. Subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we expect the transaction to close during the second quarter of 2024.
Overview of AATD
AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. The pulmonary manifestations of AATD include the entire spectrum of emphysema and disorders associated with chronic obstructive pulmonary disease. Patients with AATD harbor mutations in the AAT-encoding gene Serpin family A member 1, which causes AAT protein misfolding, loss of activity, and retention in the liver. AAT is a protease inhibitor that primarily targets human neutrophil elastase, or NE, an enzyme that is released by white blood cells in response to infections and has the capacity to degrade normal tissues, especially in the lung, if not tightly controlled by AAT.
5

Unmet Medical Need
This disease affects roughly 100,000 people in the United States, with a similar number of patients in Europe. Since AATD must be diagnosed using laboratory testing and cannot be diagnosed by symptoms or by a medical examination alone, it is believed that many individuals with AATD are likely undiagnosed or misdiagnosed. In April 2017, the United States Food and Drug Administration, or FDA, allowed for the marketing of direct-to-consumer tests that provide genetic risk information for certain conditions, including AATD. We believe such tests will lead to earlier diagnosis and an increase in the number of patients identified with AATD.
We performed a study where functional AAT levels were measured in plasma samples from 65 normal MM genotype individuals. Consistent with other published data, this analysis revealed the 5th and 95th percentiles of functional AAT levels in the normal MM genotype individuals were 21 and 54 µM, respectively, with a median of 36 µM.
Functional AAT levels in 65 healthy volunteers and 30 Phase 1 AAT study participants at baseline prior to dosing of INBRX-101
Functional AAT.jpg
–Box plots show the minimum, lower quartile, median, upper quartile and maximum.
–The shaded region represents the 5th-95th percentiles of the normal range of functional AAT in healthy MM genotype adults.
–AAT variant determination was conducted by the Mayo Clinic Laboratories using an LC-MS/MS method (A1ALC).
–The Ph 1 baseline data represents the functional AAT levels measured in patients at the beginning of the study prior to dosing of INBRX-101.

6

The approved standard of care for AATD has been augmentation therapy using pdAAT and has not been substantially improved since 1987. Plasma-derived treatments are highly dependent on human donor blood supply, which is costly and can be limited. Due to the short half-life of pdAAT therapeutics, patients require weekly infusions to achieve and maintain serum concentration above the protective threshold, presumed to be 11 µM. Even with frequent treatments, the AAT serum concentration following plasma-derived treatment remains considerably below the normal range of 21 to 54 µM as seen in the adaptation graph below that depicts the pharmacokinetic profile of pdAAT based on published data. There is clinical evidence suggesting that maintenance of higher AAT serum trough levels may better protect against lung function decline.
Functional AAT serum.jpg
Additionally, there are other significant barriers with the current standard of care for patients with AATD, including under-diagnosis, high cost of chronic augmentation therapy, high patient burden due to frequent infusions, and the inherent risks of receiving human blood products with plasma collection practices that may not be sustainable.
7

Our Solution - INBRX-101
AAT w desc.jpg
INBRX-101 is a recombinant AAT protein that is comprised of two human AAT molecules covalently linked to the Fc region of human immunoglobulin G4. AAT has proven difficult to develop recombinantly, often displaying loss of activity and experiencing accelerated degradation. Fusion of AAT to the Fc region allows for production using a standard antibody expression system, which, when combined with our proprietary AAT-function preserving purification process, generates substantial and scalable yields of active recombinant AAT protein.
Clinical Data
In July 2019, we initiated an open-label, dose escalating Phase 1 trial which was conducted in approximately 10 clinical sites in the United States, the United Kingdom and New Zealand and enrolled a total of 31 patients. The trial was designed as single ascending dose, or SAD, administrations of INBRX-101, with doses of 10 mg/kg, 40 mg/kg, 80 mg/kg or 120 mg/kg, followed by multiple ascending dose, or MAD, administrations of INBRX-101, with doses of 40 mg/kg, 80 mg/kg or 120 mg/kg. These doses were administered every three weeks intravenously to patients diagnosed with AATD who were either treatment naïve or previously treated with pdAAT therapeutics. The primary objective of the trial was safety and tolerability. Secondary objectives included AAT serum exposure, immunogenicity, as measured by frequency of anti-drug antibodies, and NE activity. In addition, we measured pharmacokinetic and pharmacodynamic biomarkers in bronchoalveolar lavage fluid, or BALF, for those patients who received MAD administrations of INBRX-101 at doses of 80 mg/kg or 120 mg/kg.
In March 2022, the FDA granted orphan drug designation for INBRX-101 for the treatment of AATD.
In May 2022, we announced topline results from the Phase 1 trial. Data from this Phase 1 trial included patients with AATD with the ZZ genotype, SZ genotype, and the MZ genotype of the SERPINA1 gene. There were no drug-related severe or serious adverse events, or AEs. Drug-related AEs were predominantly mild with a few moderate events, and all were transient and reversible. No signs of neutralizing anti-drug antibodies were seen. Dose-related
8

increases in maximal and total INBRX-101 exposure occurred across the entirety of the single and multiple ascending dose ranges.
The topline data from the multiple ascending dose cohorts of INBRX-101 at 40, 80 and 120 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels. Based on and assuming the accuracy of the PK modeling, accumulation is expected to continue following subsequent doses and to reach a steady state after a total of approximately five to six consecutive doses, administered every three weeks.
Functional AAT levels over time in AATD patients administered
40, 80 or 120 mg/kg INBRX-101 every three weeks
AAT Levels over time.jpg
–Arrows indicate INBRX-101 IV dosing.
–The shaded region represents the normal range of functional AAT in healthy adults.
–Functional AAT samples were not collected immediately following the second dose (Day 21).
–Results shown are from preliminary, unaudited data. Data shown from the 120 mg/kg multiple dose cohort are from the first four evaluable patients; the full dataset is still being collected and analyzed and will be presented at a later date.

The current standard of care, plasma-derived AAT, dosed once weekly at 60 mg/kg, achieves an average concentration, or Cavg, of functional AAT of 17.8 µM over the weekly dosing interval as calculated from steady-state area under the curve, or AUC. INBRX-101 achieved a mean Cavg of functional AAT of 40.4 µM over the 21-day dosing interval following the third 80 mg/kg dose.
In October 2022, we reported BALF data where we observed the post-dose presence of INBRX-101 in every patient and in all three lobes of the lung collected from each of these patients. This data showed emerging evidence of a dose dependent increase of INBRX-101 lung exposure. These BALF samples were from eleven AATD patients in the 80mg/kg and 120mg/kg multiple ascending dose cohorts of the Phase 1 trial and were analyzed using a proprietary and validated mass spectrometry assay developed by Inhibrx to detect INBRX-101 specifically.
In April 2023, we initiated ElevAATe, a registration-enabling trial for INBRX-101 for the treatment of patients with emphysema due to AATD. The primary endpoint of the trial is the mean change in the average functional AAT, or fAAT, concentration as measured by anti-neutrophil elastase capacity from baseline to average serum trough fAAT concentration at steady state (Ctrough,ss). The initial read-out from the ElevAATe trial is expected to occur in mid-2025.
INBRX-109
INBRX-109 is a precisely engineered tetravalent therapeutic candidate targeting death-receptor 5, or DR5, a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand, or TRAIL, receptor 2. DR5 activation induces cancer-specific programmed cell death. The valency of INBRX-109 was selected to maximize the therapeutic index. In our Phase 1 clinical trial, we observed signs of single agent activity in serious,
9

life-threatening medical conditions with limited treatment options. We observed signs of activity with INBRX-109 in combination with standard chemotherapies, the trial of which is still ongoing. In June 2021, based on the initial Phase 1 data results observed, we initiated a registration- enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma. Data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the first half of 2025.
Background on DR5
Apoptosis is a critical process for maintaining healthy tissue homeostasis, but this process is frequently altered in cancer patients leading to the accumulation of malignant cells. Apoptotic signaling pathways are tightly regulated by the balance of pro- and anti-apoptotic factors, and their therapeutic modulation has the potential to be exploited for the treatment of cancer. Targeting the anti-apoptotic proteins has been a clinically successful strategy. For example, Venetoclax, an inhibitor of B-cell lymphoma 2, or Bcl-2, was approved by the FDA for the treatment of chronic lymphocytic leukemia in 2016.
Alternatively, we believe therapeutically targeting pro-apoptotic proteins such as DR5 is a promising oncology treatment strategy. DR5 signaling is induced by clustering of multiple receptors, which initiates an apoptotic signaling pathway resulting in cell death. The strength of apoptotic signaling is proportional to the degree of DR5 clustering. Importantly, although DR5 is expressed throughout the body, cancer cells have been shown to be more sensitive to DR5 signaling compared to healthy cells of normal tissues.
The promise of inducing cancer-specific cell death has led to extensive efforts by pharmaceutical and biotechnology companies to therapeutically exploit the DR5 pathway for the treatment of cancer. These initial efforts centered around developing recombinant versions of the DR5 ligand, TRAIL, and agonistic bivalent DR5 antibodies. Despite demonstrated clinical safety as single agents and in combination with chemotherapies, these first generation DR5 agonists failed to meet clinical efficacy endpoints. We believe these failures were caused by insufficient clustering of DR5, which is necessary for activation of this pathway.
Unmet Medical Need
We are currently investigating INBRX-109 in chondrosarcoma, Ewing sarcoma and certain other solid tumor types. These are some of the most aggressive diseases, some of which are also orphan oncology indications that have shown signs of activity in preclinical studies. These indications and many of these cancer subtypes do not respond well to currently approved therapies and represent a significant unmet need.
Our Solution - INBRX-109
INBRX-109 is a tetravalent agonist of DR5 that we designed with our proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. We believe INBRX-109 has the potential to overcome the limitations of previous DR5 agonists. As shown in the diagram below, INBRX-109 is comprised of four DR5 targeted sdAbs fused to an Fc region that has been modified to prevent Fc receptor interactions. In preclinical studies, we have observed that INBRX-109 has the ability to potently agonize DR5 through efficient receptor clustering, causing cancer cell death. Based upon experience with earlier generation DR5 agonists, hepatocytes appear to be a non-cancerous cell type particularly sensitive to DR5 agonism. We have engineered INBRX-109 with our proprietary sdAb modifications to reduce recognition by pre-existing anti-drug antibodies in humans, which can lessen the potential for hyper-clustering and thereby reduce potential hepatotoxicity.
Primary objectives of the Phase 1 trial are safety, tolerability, and determination of the maximum tolerated dose, or MTD, and recommended Phase 2 dose. Secondary objectives are serum exposure and immunogenicity, as measured by frequency of anti-drug antibodies. Exploratory objectives include clinical anti-tumor efficacy, based on response rate, duration of response, disease control rate, progression-free survival and overall survival, as well as evaluation of potential predictive diagnostic and pharmacodynamic biomarkers.
10

INBRX-109: Tetravalent DR5 Agonistic Antibody
inbrx1image109b.jpg
Clinical Data
We initiated a Phase 1 clinical trial in the United States in November 2018. This Phase 1 clinical trial is designed as an open-label, three-part trial in patients with locally advanced or metastatic solid tumors.
Phase 1 INBRX-109 Trial Design and Status
First in human Phase 1 trial started November 2018
Part 1:
Single-Agent Dose Escalation


⇨




Part 2:
Single-Agent Dose Expansion



⇨





Part 3:
Dose Expansion with Chemotherapy
Completed
Completed
Ongoing
Dose Range:
0.3 to 30 mg/kg

N= 20

Result:
Maximum tolerated
dose not reached
N=20
Colorectal adenocarcinoma
N=10
Mesothelioma with carboplatin or cisplatin
N=10
Gastric adenocarcinoma
N=10
Mesothelioma with carboplatin and pemetrexed or cisplatin and pemetrexed
N=20Malignant pleural mesothelioma
N=20
Pancreatic adenocarcinoma 2L with fluorouracil and irinotecan (mFOLFIRI)
N=20
Chondrosarcoma
N=10
Synovial sarcoma
N=20
Colorectal adenocarcinoma with FOLFIRI
N=12
IDH1/2-mutant conventional chondrosarcoma
N=20-50
Ewing sarcoma 2-4L with irinotecan and temozolomide
N=12
Nonconventional chondrosarcoma
N=20SDH-def solid tumors or GIST with temozolomide
N=12
Solid tumors, BMI>30
Part 1
Part 1 of the trial utilized a traditional 3+3 dose escalation design escalating INBRX-109 as a single agent from 0.3 mg/kg to 30 mg/kg. Twenty patients were enrolled in this portion of the trial, which was completed in August 2019.
11

INBRX-109 was observed to be well-tolerated without significant toxicities observed at doses up to and including the maximum administered dose of 30 mg/kg. No MTD was reached.
Part 2
In September 2019, we commenced single agent dose expansion cohorts, Part 2 is now complete and enrolled 116 patients in single agent dose cohorts in the following tumor types: colorectal and gastric adenocarcinomas, malignant pleural mesothelioma, chondrosarcoma, synovial sarcoma, and solid tumors with BMI>30.
Part 3
In February 2021, we initiated chemotherapy combination cohorts in Part 3 of this trial and will enroll up to 100 patients. We are investigating INBRX-109 in Ewing sarcoma, colorectal cancer cohorts, and SDH-deficient solid tumors, or GIST.
Initial Results from Phase 1 INBRX-109 Ewing
We announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan, or IRI, and Temozolomide, or TMZ, for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Among the 13 patients evaluable as of the data cut of September 8, 2023, the observed disease control rate was 76.9%, or 10 out of 13 patients as measured by RECISTv1.1, with seven patients achieving partial responses (53.8%) and three patients achieving stable disease (23.1%). Overall, INBRX-109 in combination with IRI/TMZ was well- tolerated from a safety perspective. We have expanded recruitment of this cohort as a result of these preliminary findings.
Initial Results from Phase 1 INBRX-109 Chondrosarcoma
Chondrosarcoma is a rare malignant bone tumor composed of cartilage matrix-producing cells. It is reported to be the second most common primary bone sarcoma with an incidence of 1 in 200,000 per year globally. The incidence in the United States is reported to be about 1,400 cases per year. There is currently no approved systemic treatment for patients with unresectable or metastatic disease. The placebo arm of a placebo-controlled trial, which tested the hedgehog pathway inhibitor IPI-926 in this indication had a progression free survival of approximately three months. In this trial, IPI-926 did not result in any partial responses and only a small subset of patients had minor reductions in their tumor size.
In January 2021, the FDA granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. In November 2021, the FDA granted orphan drug designation for INBRX-109 for the treatment of conventional chondrosarcoma. In August 2022, the EMA granted orphan drug designation for INBRX-109 for the treatment of conventional chondrosarcoma.
In November 2022, we announced efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma. Among the 33 patients evaluable as of November 8, 2022, the observed disease control rate was 87.9%, or 29 out of 33 patients as measured by RECISTv1.1, with two patients achieving partial responses (6.1%) and 27 patients achieving stable disease (81.8%). Disease control was observed in patients with and without IDH1/IDH2 mutations. Of those achieving stable disease, 55.6% had decreases from baseline in tumor size. Clinical benefit was durable, 14 of 33 patients (42.4%) who achieved disease control had a clinical benefit lasting greater than 6 months, and the longest duration of stable disease observed was 20 months. At that time, the median progression-free survival, or PFS, was 7.6 months, and five patients remained on study.
Treatment-related AE, were reported in less than 5% of the patients with the most common being increased alanine aminotransferase, or ALT, increased aspartate aminotransferase, or AST, and increased blood bilirubin and fatigue. There were no grade 4 or 5 events reported among patients with treatment-related AEs.
Phase 2 INBRX-109 Chondrosarcoma
In June 2021, we initiated a registration-enabling Phase 2 trial in this patient population, which will enroll approximately 200 patients in total at 50 different sites worldwide, with progression free survival, or mPFS, as the primary endpoint.
12

Primary objectives of the ongoing Phase 2 trial are to evaluate the efficacy of INBRX-109 as measured by mPFS, assessed by central real-time independent radiology review. Secondary objectives are to evaluate the overall survival, mPFS by investigator assessment, quality of life, objective response rate, duration of response, disease control rate, safety and tolerability, pharmacokinetics and anti-drug antibodies to INBRX-109.
In early 2023, the Phase 2 trial was placed on partial clinical hold by the FDA, and we paused patient enrollment in the trial, following the occurrence of a grade 5 hepatotoxicity event and pre-defined stopping rules built into the protocol. The additional insight gained on patients at risk of significant hepatotoxicity led us to believe that elderly patients with fatty liver disease are the at-risk population. We implemented the Hepatic Steatosis Index, or HSI, into the protocol and excluded elderly patients with an HSI score of 36 or higher, which has helped to address the patients at risk of significant hepatotoxicity. The FDA lifted the hold in April 2023 after we amended the trial protocol. We expect to announce data from this trial during the first half of 2025.
Phase 2 Trial Design
Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in
Conventional Chondrosarcoma, Grades 2 and 3, Unresectable or Metastatic
Randomization 2:1

Key eligibility criteria:
• Conventional chondrosarcoma
• Unresectable or metastatic


Stratification by line of therapy. Grade and IDH1/2 mutation status
Until progressive disease (PD) or toxicity

Including interim analysis


      • Primary Endpoint:
progression free survival

• Secondary Endpoints:
overall survival, quality of life, overall response rate, duration of response, disease control rate, safety, etc.
⇨
INBRX-109
N= 134

3 mg/kg every three weeks

(Ongoing)
⇨
⇨
Placebo
N= 67
 (allows for crossover)

3 mg/kg every three weeks

(Ongoing)
⇨
INBRX-106
INBRX-106 is a hexavalent OX40 agonist, currently being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. We continue to enroll and/or have active patients in Part 2, single agent dose expansion, and Part 4, combination expansion cohorts. We expect to announce initial data from these cohorts during the second half of 2024.
Background on Immunotherapy
A notable recent success in cancer treatment is the approval of checkpoint inhibitor immunotherapies as therapeutic agents. Immune checkpoints are key mechanisms that fine-tune and control the body’s immune response. In the cancer setting, tumors have developed strategies for hijacking these checkpoints, preventing an immune response to the cancer and allowing the tumor cells to proliferate unchecked. Checkpoint inhibitor immunotherapies were developed to overcome this phenomenon by relieving immune cell inhibition, resulting in a potentially long-lasting amplification of the anti-tumor immune response. Therapies against checkpoint proteins, such as PD-1 and PD-L1, produced impressive results in clinical development, resulting in marketing approvals in a number of malignancies.
13

Background on OX40
OX40, a member of the TNFRSF, is predominately expressed and is a key co-stimulatory receptor on activated T-cells. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death. The natural mechanism of OX40 activation is via the interaction with its trimeric ligand, OX40L, which serves to effectively cluster multiple OX40 molecules and facilitate downstream signaling leading to nuclear factor kappa-light-chain-enhancer of activated B cells, or NFkB, activation. Based on the capacity for OX40 signaling to enhance anti-tumor immunity in preclinical studies, there have been many efforts to therapeutically exploit this pathway for cancer immunotherapy. Most previously developed agents were bivalent OX40 agonists, the configuration of which we believe to be poorly suited for efficient receptor clustering, evidenced by the lack of clinical responses observed for such molecules.
Unmet Medical Need
Despite unprecedented clinical response rates, the majority of patients fail to respond to therapies targeting PD-1 and PD-L1. We believe this is in part because T-cells require co-stimulation for full functionality. Thus, checkpoint inhibition alone is likely insufficient to fully enable the immune system to attack a tumor, and we believe further benefit could be derived by the addition of immune co-stimulatory agents.
Our Solution
INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor. As shown in the diagram below, INBRX-106 is composed of six OX40 targeting sdAbs and a functional Fc domain.
inbrx1image106b.jpg
As a hexavalent therapeutic candidate, INBRX-106 is designed to bind six OX40 molecules on the cell surface to mediate efficient receptor clustering and downstream signaling. In preclinical studies, we observed that INBRX-106 elicited superior OX40 agonism when compared to the bivalent antibodies, 1A7 (analog of MOXR-0916) or 1D10 using an OX40 expressing NFkB reporter cell line, wherein clustering of OX40 receptor mediated signaling culminated in luciferase expression. We also observed that INBRX-106 can mediate T-cell co-stimulation and reduce the suppressive activity of regulatory T-cells. Additionally, INBRX-106 is able to exploit IgG-mediated effector function via the Fc domain.
14

Clinical Data
We initiated a Phase 1/2 clinical trial in December 2019 for INBRX-106. This trial is designed as an open- label, four-part trial in patients with locally advanced or metastatic solid tumors. Primary objectives of the trial are safety and tolerability, and the determination of the MTD and recommended Phase 2 dose of INBRX-106 as a single agent and in combination with Keytruda. Secondary objectives are serum exposure, immunogenicity, as measured by the frequency of anti-drug antibodies, and clinical anti- tumor efficacy per RECIST (version 1.1) and immune RECIST based on response rate, duration of response, disease control rate, progression-free survival and overall survival. Exploratory objectives will include evaluation of potential predictive diagnostic and pharmacodynamic biomarkers.
Phase 1/2 INBRX-106 Study Design
Phase 1/2 Study of Single Agent INBRX-106 and INBRX-106 in Combination with Keytruda in
Patients with Locally Advanced or Metastatic Solid Tumors
Part 1:
INBRX-106
Single-Agent
Dose Escalation



⇨




⇨
Part 2:
INBRX-106
Single-Agent
Dose Expansion



⇨




⇨
Part 3:
Dose Escalation with Keytruda



⇨




⇨
Part 4:
Dose Expansion with Keytruda
CompleteOngoing CompleteOngoing

N=20
All-comers

N=52-64

CPI r/r:
Basket Dose Regimen #1

Basket Dose Regimen #2

Basket Dose Regimen #3



N=21



N=136

CPI r/r:
Basket PDL1+

NSCLC PDL1+

Basket, MMR-def/MSI-high

Uveal melanoma

NSCLC PD-L1+ (TPS≥50%) or TMB high
(Ongoing)
CPI r/r
NSCLC TMB or PDL1 high
(Ongoing)
CPI r/r
-Dose Regimen #1 a
-Dose Regimen #2 b

Basket HNSCC, PDL1 + (CPS≥1)
(ongoing)
CPI naive
a
Alternating treatment: INBRX-106 0.3 mg/kg followed by Keytruda 400 mg/kg 3 weeks later; Alternates every three weeks
b
Priming: INBRX-106 0.3 mg/kg ⇨ 0.1 mg/kg Q3W + Keytruda
Part 1 of the trial utilized a traditional 3+3 algorithm for single agent dose escalation from 0.0003 mg/kg to 3 mg/kg in twenty patients. INBRX-106 was observed to be generally well tolerated in humans. The most common AEs reported for INBRX-106 were Grade 1 and 2 and notably, cutaneous toxicities, which are common immune-related AEs associated with immune checkpoint inhibitors. These mostly mild or moderate and likely immune-related toxicities were in line with the mechanism of action of this candidate therapeutic. The maximum administered dose was 3 mg/kg and the MTD level was not reached.
Part 2 of the trial, single agent dose expansion, administered INBRX-106 in different dosing schedules to patients with tumor types responsive to checkpoint inhibitors. Part 2 treatment cohorts of this trial were in the following tumor types: NSCLC, melanoma, HNSCC, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma. We expanded the enrollment for Part 2 in order to increase the dataset in the single agent cohorts and to enroll additional NSCLC patients. We expect to announce additional data from Part 2 in 2025.
In Parts 3 and 4 of this trial, INBRX-106 is being evaluated in combination with Keytruda, a PD-1 blocking checkpoint inhibitor. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck
15

& Co., Inc., Rahway, NJ, USA. In the all-comer Part 3 of the trial, INBRX-106 was escalated in combination with Keytruda and enrolled patients with locally advanced or metastatic solid tumors. It was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities noted. We observed durable responses across multiple tumor types.
In Part 4, INBRX-106 combination expansion cohorts, we are enrolling patients who are positive for PD-L1 expression, as determined by immunohistochemistry, and possess adequate hematologic and organ function, to qualify for enrollment. Most of these patients will be checkpoint refractory with NSCLC (both TPS>1% and >50%), and a basket of other indications as well as uveal melanoma. The most common AEs observed in this study related to INBRX-106 were infusion-related reaction, fatigue, rash, nausea, pruritus, and diarrhea. Most patients with related treatment emergent adverse events had events that were mild or moderate (Grade 1 or 2) in severity.
We continue to enroll patients with NSCLC and HNSCC in Part 4, both in combination with Keytruda. The initial data observed from 24 NSCLC patients who all had previous checkpoint inhibitor exposure was tumor reduction or stabilization of target lesions in more than half the patients. Of those patients, one complete response and four partial responses were observed. The initial data observed from 14 HNSCC patients, seven of which were checkpoint failures and seven of which were checkpoint naive, was tumor reduction of target lesions in half the patients. Of those patients, two complete responses and five partial responses were observed. We are in the process of expanding these cohorts and expect to initiate at least one additional cohort by mid 2024. We expect to have a more mature dataset during the third quarter of 2025 and plan to provide an update at that time.
License and Collaboration Agreements
We have entered into various license and collaboration agreements. The license agreements discussed below pertain to intellectual property that we own and license to the parties identified below. We retain ownership of the intellectual property subject to the license agreements.
Elpiscience Agreements
We have entered into two different license agreements with Elpiscience. Each agreement is a standalone license to Elpiscience of a distinct and differentiated protein therapeutic candidate with a separate biological target.
On February 28, 2018, we entered into a license agreement, or the PD-L1 and 4-1BB License Agreement, with Elpiscience, pursuant to which we granted Elpiscience an exclusive license to our bi-specific therapeutic candidate designed to target PD-L1 and 4-1BB, also referred to as INBRX-105. On April 30, 2018, we entered into a license agreement, or the OX40 License Agreement, with Elpiscience, pursuant to which we granted Elpiscience an exclusive license to our multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. The PD-L1 and 4-1BB License Agreement was terminated in February 2024 in conjunction with our decision to terminate the INBRX-105 program.
Each of the PD-L1 and 4-1BB License Agreement and OX40 License Agreement provided Elpiscience with the right to further advance the respective therapeutic candidate through clinical trials, as well as to manufacture and commercialize these therapeutic candidates in China, Hong Kong, Macau and Taiwan. The PD-L1 and 4-1BB License Agreement and OX40 License Agreement also required us to provide Elpiscience with know-how and materials specific to INBRX-105 and INBRX-106, respectively, including process development and manufacturing data and information necessary to develop INBRX-105 and INBRX-106. Additionally, pursuant to each of the license agreements, Elpiscience granted to us a royalty-free, worldwide, non-exclusive research license to intellectual property created by Elpiscience that incorporates intellectual property we licensed to Elpiscience. In the PD-L1 and 4-1BB License Agreement and OX40 License Agreement, we also agreed to negotiate an agreement to supply Elpiscience with INBRX-105 and INBRX-106, respectively, for their development in China, Hong Kong, Macau and Taiwan.
As payment for the license granted in the PD-L1 and 4-1BB License Agreement, we received a non-refundable upfront payment of $2.5 million and reimbursement of $3.0 million for certain costs we incurred. In December 2018, we received the first milestone payment of $2.0 million under the PD-L1 and 4-1BB License Agreement. Additionally, we received reimbursement for specific supply-related costs in the amounts of $1.7 million under the
16

PD-L1 and 4-1BB License Agreement. Following its termination, there are no further payments under this agreement.
As payment for the license granted in the OX40 License Agreement, we received a non-refundable fee of $2.5 million, payable in two installments, and reimbursement of $3.4 million for certain toxicology study costs and chemistry, manufacturing and controls costs. Additionally, we received reimbursement for specific supply-related costs in the amounts of $1.5 million under the OX40 License Agreement. We are also eligible to receive specified developmental and commercial milestone payments of up to an aggregate of $100.0 million under the OX40 License Agreement in addition to the right to receive percentage tiered royalties on future product sales with rates in the high single-digits.
Each of the PD-L1 and 4-1BB License Agreement and the OX40 License Agreement contained representations and warranties, insurance, indemnification and confidentiality provisions customary for similar agreements and arrangements. The terms of the PD-L1 and 4-1BB License Agreement and the OX40 License Agreement commenced on February 28, 2018 and April 30, 2018, respectively, and expire on a country-by-country basis upon the full expiration of Elpiscience’s milestone- and royalty-based payment obligations under each license agreement. The royalty obligations expire upon the later of (i) the expiration of the last valid patent claim for the applicable product in the relevant jurisdiction, and (ii) 12 years following that date of the first commercial sale of the applicable product in the relevant jurisdiction. Each license agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) Elpiscience at any time upon 90 days’ written notice to us. The PD-L1 and 4-1BB License Agreement was terminated in February 2024 in conjunction with our decision to terminate the INBRX-105 program. As of December 31, 2023, and based on current plans, the last to expire issued patent (assuming the issuance of a patent based on our pending patent application) previously licensed under the PD-L1 and 4-1BB License Agreement is projected to expire in January 2037 and the last to expire issued patent (assuming the issuance of a patent based on our pending patent application) licensed under the OX40 License Agreement is projected to expire in August 2039, in each case absent any extension of term.
Chiesi Option Agreement
In May 2019, we entered into an Option Agreement with Chiesi Farmaceutici S.p.A., or Chiesi, which was later amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, pursuant to which we granted Chiesi an exclusive option to obtain an exclusive license to develop and commercialize INBRX-101 outside of the United States and Canada. Additionally, the Chiesi Option Agreement provided Chiesi with a right of negotiation for INBRX-101 development and commercialization rights in the United States and Canada in the event we engaged in discussions with any third parties for such rights during the term of the Chiesi Option Agreement or, as applicable, the term of a definitive exclusive license agreement between Chiesi and the Company. In August 2019, under the terms of the Chiesi Option Agreement, we received a one-time, non-refundable option initiation payment of $10.0 million. Pursuant to the Chiesi Option Agreement, research and development services would be performed for Chiesi during the option period, which would continue until 60 days following the last-to-occur of (i) the Company’s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial for INBRX-101 (including the complete clinical study report), (ii) the Company’s delivery to Chiesi of the finalized minutes from the definitive FDA scientific advice meeting conducted following completion of such Phase I Clinical Trial with the use of the full clinical study report if required by the FDA, and (iii) the Company’s delivery to Chiesi of written scientific advice from the EMA following completion of such Phase I Clinical Trial with full use of the clinical study report if required by the EMA.
On July 24, 2023, we received written scientific advice from the EMA which confirmed CT lung densitometry as the established primary regulatory endpoint to support a marketing authorization application in the European Union, or EU, for the treatment of emphysema secondary to AATD. We provided a copy of the EMA scientific advice to Chiesi upon receipt which, as described above, fulfilled the necessary deliverables to Chiesi and triggered the start of its 60-day option period window. On September 18, 2023, Chiesi declined to exercise its option for the ex-North American rights, resulting in the expiration of the Chiesi Option Agreement (upon the lapse of the option period), and with us retaining global rights to develop and commercialize INBRX-101.
17

Transcenta License Agreement and Technical Services Agreements
On June 21, 2017, we entered into a license agreement, or the Transcenta License Agreement, with Transcenta, pursuant to which we granted to Transcenta exclusive, non-transferable rights to develop, manufacture, and sell its products containing our mono-specific protein therapeutic candidate, designed to target DR5, or INBRX-109, or a derivative thereof, within China, Hong Kong, Macau and Taiwan. We also agreed to provide Transcenta with the know-how and materials, including assays and cell lines, necessary to develop the therapeutic candidate. Additionally, pursuant to the Transcenta License Agreement, Transcenta granted to us a royalty-free, worldwide, non-exclusive research license to intellectual property created by Transcenta that incorporates intellectual property we licensed to Transcenta. As payment for the license we granted in the Transcenta License Agreement, we received a non-refundable upfront payment of $2.5 million. In August 2018, the Company achieved the first milestone under the contract for $0.5 million. In June 2019, the Company achieved another milestone under the contract for $1.0 million. Additionally, we are eligible to receive certain developmental and commercial milestone payments of up to an aggregate of approximately $100.0 million, as well as percentage tiered royalties on future product sales with rates ranging between the high single-digits to the low teens.
The Transcenta License Agreement contains representations and warranties, insurance, indemnification and confidentiality provisions customary for similar agreements and arrangements. The term of the Transcenta License Agreement commenced on June 21, 2017, and expires on a country-by-country basis upon the full expiration of Transcenta’s milestone- and royalty-based payment obligations under the Transcenta License Agreement. The royalty payment obligations expire on a product-by-product and country-by-country basis at such time that there is (i) no valid patent claim for the applicable product in the relevant jurisdiction, and (ii) no Generic Product (as defined in this Transcenta License Agreement) of an applicable product available in the relevant jurisdiction. As of December 31, 2023, and based on current plans, the last to expire issued patent (assuming the issuance of a patent based on our pending patent application) licensed under the Transcenta License Agreement is projected to expire in July 2036, absent any extension of term. The Transcenta License Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) Transcenta at any time upon 90 days’ written notice to us.
On March 19, 2018, we also entered into a technical services agreement, or the March TSA, with Transcenta pursuant to which we provided reasonable assistance with the drug substance transfer between our contract manufacturer and Transcenta. We were reimbursed $0.7 million in April 2018 for the March TSA. The March TSA had a six-month term and expired in September 2018. On October 6, 2018, we entered into a second technical services agreement, or the October TSA, to provide reasonable assistance pertaining to the transfer of the drug substance between our contract manufacturer and Transcenta. We were reimbursed $0.4 million in October 2018 for the October TSA. The October TSA also had a six-month term and expired in April 2019.
Celgene Agreement
On July 1, 2013, we entered into a license agreement with Celgene, a Bristol Meyers Squibb Company, or Celgene, as amended on November 23, 2018, or the Celgene Agreement, pursuant to which we granted Celgene an exclusive, global license for the development, manufacture and commercialization of our proprietary CD47 binding domain, or the Celgene Licensed Intellectual Property. Per the terms of the Celgene Agreement, Celgene is operationally and financially responsible for the development, manufacturing and commercialization activities of Celgene Licensed Intellectual Property and any additional related antibodies covered by the Celgene Agreement.
As payment for the license granted in the Celgene Agreement, we may be eligible to receive development and regulatory milestones of up to an aggregate of $934.1 million, assuming the achievement of all potential milestones in the Celgene Agreement, as well as percentage tiered royalties based on future worldwide sales, with rates ranging from the high single-digits to the low teens, subject to potential reduction when and if comparable third-party products attain certain levels of competitive market share (on a country-by-country basis) and, subject to certain limitations, payments to third parties for third-party intellectual property rights. Celgene’s royalty obligations expire (on a country-by-country basis) upon the later of (i) the expiration of the last valid patent claim for the applicable Celgene Licensed Intellectual Property or related product in a country, and (ii) 12 years following that date of the first commercial sale of the applicable Celgene Licensed Intellectual Property or related product in a country. We
18

are obligated to pay 2% of future amounts received under the Celgene Agreement to advisors who assisted us with the negotiations and other matters in connection with the Celgene Agreement.
The Celgene Agreement contains representations and warranties, insurance, indemnification and confidentiality provisions customary for similar agreements and arrangements. In addition, Celgene has the sole right, but not the obligation, to enforce the intellectual property included in the Celgene Agreement.
The term of the Celgene Agreement commenced on July 1, 2013 and expires on a licensed product-by-licensed product and country-by-country basis on the date of expiration of Celgene’s applicable royalty obligations. As of December 31, 2023 and based on our current plans, the last to expire issued patent licensed under the Celgene Agreement is projected to expire in 2033, absent any extension of term. The Celgene Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, (iii) Celgene at any time upon 30 days’ written notice to us, and (iv) us, upon Celgene’s, or any of its affiliates’, legal challenge to the validity or enforceability of a licensed patent.
2seventy Agreements
The 2018 2seventy Agreement
On December 20, 2018, we entered into an exclusive license agreement with bluebird bio, Inc., or bluebird, pursuant to which we granted to bluebird an exclusive license to use our proprietary sdAb platform to research, develop and commercialize chimeric antigen receptor, or CAR, T-cell therapies. In November 2021, bluebird assigned the agreement, which we refer to as the 2018 2seventy Agreement, to its affiliate, 2seventy bio, Inc., or 2seventy, in connection with an internal restructuring and subsequent spin-out of 2seventy. Under the terms of the 2018 2seventy Agreement, we provided 2seventy the exclusive worldwide rights to develop, manufacture and commercialize certain cell therapy products containing sdAbs directed to various cancer targets. As payment for the license granted in the 2018 2seventy Agreement, we received a non-refundable upfront payment of $7.0 million in January 2019. We are also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. In August 2021, we received a $2.0 million milestone payment under this agreement.
The 2018 2seventy Agreement contains representations and warranties, indemnification and confidentiality provisions customary for similar agreements and arrangements. The term of the 2018 2seventy Agreement commenced on December 20, 2018, and expires on a product-by-product and country-by-country basis upon the full expiration of 2seventy’s milestone- and royalty-based payment obligations under the 2018 2seventy Agreement. The royalty obligations under the 2018 2seventy Agreement expire on a product-by-product and country-by-country basis on the later of (i) the expiration of the last valid patent claim for the applicable product in the relevant jurisdiction; (ii) the date on which any applicable regulatory, pediatric, orphan drug or data exclusivity, which provides 2seventy with the exclusive right to market the applicable product in the relevant jurisdiction, expires; and (iii) 12 years following that date of the first commercial sale of the applicable product in a country. As of December 31, 2023 and based on current plans, the last to expire issued patent (assuming the issuance of one or more patents based on our pending patent applications) licensed under the 2018 2seventy Agreement is projected to expire in May 2040, absent any extension of term. The 2018 2seventy Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) 2seventy at any time upon 30 days’ written notice to us.
The 2020 2seventy Agreement
On June 9, 2020, we entered into an option and license agreement with bluebird, pursuant to which we granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing sdAbs directed to specified targets, consisting of two initial programs and up to an additional 8 programs. Inhibrx retains all rights to the specific sdAbs outside of the cell therapy field. This agreement, which we refer to as the 2020 2seventy Agreement, was also assigned to 2seventy in November 2021 in connection with bluebird’s internal restructuring and subsequent spin-out of 2seventy. In June 2020, we received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and we are entitled to an upfront option fee for each additional program. In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee of $0.2 million in exchange for a development license. Under each of the three programs, we also
19

granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under the 2020 2seventy Agreement, which entitles us to additional fees upon exercise of the option. 2seventy may exercise its option on a program-by-program basis during the option term. Additionally, 2seventy may extend the option term for up to six months in the event that there are additional bona fide development activities that 2seventy desires to undertake. We are also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single digits.
The 2020 2seventy Agreement contains representations and warranties, indemnification and confidentiality provisions customary for similar agreements and arrangements. The term of the 2020 2seventy Agreement commenced on June 9, 2020, and expires on a product-by-product and country-by-country basis upon the full expiration of 2seventy’s milestone- and royalty-based payment obligations under the 2020 2seventy Agreement. The royalty obligations under the 2020 2seventy Agreement expire on a product-by-product and country-by-country basis on the later of (i) the expiration of the last valid patent claim for the applicable product in the relevant country; (ii) the date on which any applicable regulatory, pediatric, orphan drug or data exclusivity, which provides 2seventy with the exclusive right to market the applicable product in the relevant country, expires; and (iii) 12 years following that date of the first commercial sale of the applicable product in such country. The 2020 2seventy Agreement may be terminated by (i) either party for the uncured material breach of the other party, (ii) either party for bankruptcy or other insolvency proceedings of the other party, and (iii) 2seventy at any time upon prior written notice within a specified number of days before the termination.
In May 2021, pursuant to the option extension terms in the 2020 2seventy Agreement, bluebird requested to extend the option term for one of the initial programs by an additional six months in exchange for an option extension fee of $0.1 million. In August 2021, pursuant to the option exercise terms in the agreement, bluebird exercised its option to exclusively license one of the initial programs in exchange for an option exercise fee of $2.1 million, the payment of which was received in October 2021. In May 2023, 2seventy declined to exercise its option for one of the two initial programs.
Intellectual Property
We strive to protect the proprietary technology and information commercially or strategically important to our business. We seek to obtain and maintain, patent rights intended to cover the technologies incorporated into, or used to produce, our therapeutic candidates, the compositions of matter of our therapeutic candidates and their methods of use and manufacture, as well as other inventions that are important to our business. We also seek to obtain strategic or commercially valuable patent rights in the United States and other jurisdictions.
To cover our proprietary technologies and our current pipeline of proprietary products and related methods, such as methods of use, we have filed patent applications representing 42 patent families. As of December 31, 2023, our patent estate included 25 issued United States patents, 28 United States pending non-provisional patent applications, 6 United States pending provisional patent applications, 13 pending Patent Cooperation Treaty, or PCT, applications, 233 issued foreign patents and 367 foreign patent applications currently pending in various foreign jurisdictions.
Specifically, we own more than seven patent families with claims directed to various sdAb and/or multivalent therapeutic antibodies including, for example, our INBRX-106 and INBRX-109 therapeutic candidates, and related methods of using the same to treat diseases, e.g., cancer, inflammatory disease, or infectious disease. Patent applications in these families are pending in multiple jurisdictions, including, for example, the United States, Australia, European Patent Organization, Canada, China, Japan, Korea, and Russia; as well as PCT applications and several U.S. provisional applications. Patents in these patent families, if granted, are expected to expire between 2036 and 2043, depending upon their respective filing dates and absent any patent term adjustments or extensions.
We also own three patent families directed to protease inhibitor fusion proteins including, for example, our INBRX-101 therapeutic candidate. Nine United States and 67 foreign patents (Australia, Canada, Mexico, Europe (validated in 37 countries), Hong Kong, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, and Ukraine) were granted in these families. These patents are expected to expire in 2032 or 2035, absent any patent
20

term extension. Additional patents in these patent families, if granted, are expected to expire in 2032, 2035, or 2043, depending upon their respective filing dates and absent any patent term adjustments or extensions.
Additionally, we own two patent families relating to the Celgene Licensed Intellectual Property that are licensed to Celgene. Two United States and 90 foreign patents (Australia, Chile, Colombia, China, Europe (validated in up to 39 countries), Eurasia (validated in Russia), Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, Malaysia, Macao, New Zealand, Peru, Philippines, Singapore, South Africa, Ukraine, and Vietnam) have been granted in these families and include claims directed to anti-CD47 monoclonal antibodies and/or methods of using the same to treat cancer. These patents are expected to expire in 2033, absent any patent term extension. Patent applications in these families are pending in multiple jurisdictions, including, for example, the United States, Australia, European Patent Organization, Canada, China, Eurasia, Japan, and South Korea. Additional patents in these patent families, if granted, are expected to expire in 2033, depending upon their respective filing dates and absent any patent term adjustments or extensions.
The following patents (including expected 20-year expiration dates) relate to our fusion protein technologies.
JurisdictionPatent NumberExpected Expiration DateTypeTitle
US8,986,6886/28/2032Composition and methodWAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US9,914,7656/28/2032CompositionWAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Mexico3564336/28/2032Composition and useWAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US8,980,266 6/28/2032Composition and methodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US9,920,1094/6/2034MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US10,730,9296/28/2032CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US10,723,7856/28/2032CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US10,400,0296/28/2032CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US11,046,7526/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
US11,827,6916/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Australia20122752876/28/2032Composition, method and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Australia20172797246/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Australia201533950710/27/2035Composition, methodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Australia20192029046/28/2032Composition, method and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Australia20212021316/28/2032Composition, method and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Canada28396196/28/2032Composition, method and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
21

Europe (validated in AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SK, SM, TR)27260926/28/2032UseSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Hong Kong11975446/28/2032UseSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
India3730306/28/2032CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
India36621310/27/2035CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Israel2302096/28/2032UseSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Japan66746046/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Japan673778110/27/2035UseSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Korea10-20849446/28/2032CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Korea10-22311396/28/2032CompositionSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Mexico3565176/28/2032Composition and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Mexico3811836/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
New Zealand6190236/28/2032Composition and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
New Zealand7278466/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
New Zealand7442576/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Russia26423106/28/2032Composition and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Russia26986556/28/2032MethodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Russia27288616/28/2032Composition and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Russia27274526/28/2032Composition and use, methodSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Russia274655010/27/2035UseSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Ukraine1240836/28/2032Composition and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
Ukraine12730510/27/2035Composition and useSERPIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
22

The following patents (including expected 20-year expiration date) relate to our single domain antibody technologies.
JurisdictionPatent NumberExpected Expiration DateTypeTitle
US10,526,3972/24/2036CompositionNON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES
AU20162092472/7/2036CompositionNON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES
JP70014742/7/2036CompositionNON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES
The following patents (including expected 20-year expiration dates) relate to our multivalent therapeutic antibody technologies.
JurisdictionPatent NumberExpected Expiration DateTypeTitle
US10,308,7207/18/2036CompositionMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
US11,117,97311/22/2036MethodMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS AND METHODS OF TREATING NEOPLASMS
AU
2,016,291,7017/18/2036
Composition and use
MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
CNZL201680041274.27/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
EP (Validated in: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
33227347/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
HK12544337/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
IDP0000755137/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
IL2567727/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
IN4019797/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
JP68076067/18/2036Composition and methodMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
JP
72449387/18/2036
Composition and method
MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
MX
4004197/18/2036Composition and use
MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
RU27486207/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
SG11201800223W7/18/2036Composition and useMULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
ZA2018/002387/18/2036MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS
23

US10,093,7427/22/2036Composition and methodMULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS
US10,844,1297/22/2036Composition and methodMULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS
AU2,016,297,2497/22/2036Composition, method and useMULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS
NZ
7391307/22/2036
Composition, method and use
MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS
US11,117,9725/4/2037CompositionMULTIVALENT AND MULTISPECIFIC OX40- BINDING FUSION PROTEINS
ID
P000085528
1/11/2037
Composition
MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
IL
260,5311/11/2037
Composition and use
MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
JP
7,328,7611/11/2037
Composition and use
MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
RU2,773,0527/22/2036Composition and useMULTIVALENT AND MULTISPECIFIC OX40- BINDING FUSION PROTEINS
US11,447,5562/8/2040CompositionMULTIVALENT AND MULTISPECIFIC OX40- BINDING FUSION PROTEINS
RU
2,802,0708/12/2039
Composition, method and use
OX40-BINDING POLYPEPTIDES AND USES THEREOF
US10,501,5518/14/2037Composition and methodMULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
US
11,566,0782/23/2038
Composition
PDL1-BINDING PROTEINS (AS AMENDED)
AU2,017,207,7421/11/2037Composition and methodMULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
ID
P000089844
1/11/2037
Composition, method and use
MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
IL
260,5301/11/2037
Composition and use
MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
JP7,022,9931/11/2037Composition and methodMULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
RU
2,789,6481/11/2037
Composition, method and use
MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS
US11,434,29712/24/2040Composition, method and useCD123-BINDING POLYPEPTIDES AND USES THEREOF
US
11,560,42812/4/2040
Composition and use
CD33-BINDING POLYPEPTIDES AND USES THEREOF
ID
P000090304
12/4/2040
Composition and use
CD33-BINDING POLYPEPTIDES AND USES THEREOF
JP7,164,5444/11/2038Composition, method and useMULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME
NZ758,2644/11/2038Composition, method and useMULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME
The following patents (including expected 20-year expiration dates) relate to our CD47 antibody technologies.
JurisdictionPatent NumberExpected Expiration DateTypeTitle
US9,045,5412/6/2033CompositionCD47 ANTIBODIES AND METHODS OF USE THEREOF
US9,663,5752/6/2033MethodCD47 ANTIBODIES AND METHODS OF USE THEREOF
24

Australia20132171142/6/2033Composition and methodCD47 ANTIBODIES AND METHODS OF USE THEREOF
Chile609432/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
ChinaZL201380017900.02/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
Colombia141717782/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Costa Rica41092/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Eurasia (validated in Russia)347782/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Europe (validated in AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)28124432/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
Hong Kong12051952/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
IndonesiaIDP000058732/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Israel2339342/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
India3954532/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Japan62732122/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
Korea10-21003882/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
Korea10-23388332/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Mexico3607722/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
MalaysiaMY-169341-A2/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
New Zealand6283142/6/2033Composition and useCD47 ANTIBODIES AND METHODS OF USE THEREOF
Philippines1/2014/5017582/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Singapore11201404638S2/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Ukraine1167722/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
South Africa2014058642/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Vietnam100287722/6/2033CD47 ANTIBODIES AND METHODS OF USE THEREOF
Australia20133778868/6/2033Composition, method, and useNON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
25

Australia20192009428/6/2033Composition, method, and useNON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
ChileCL63005B2/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
China (also registered in Macao)
ZL201380075409.3
8/6/2033Composition and useNON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Eurasia
(validated in Russia)		0369638/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Europe (validated in DE, ES, FR, GB, IT)
29536438/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Hong Kong
12188638/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
IndonesiaIDP0000588558/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Israel2403908/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Israel2745668/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Japan67262388/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Korea10-21701968/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Korea10-22769748/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
MacaoJ/0035738/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Mexico
MX393557
8/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
New Zealand7106958/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Peru98978/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
26

Philippines120155017298/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Singapore
10201706383X
8/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
South Africa2015/057458/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
South Africa2019052928/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
Vietnam100294788/6/2033NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property strategy, to adapt to competition or to seize potential opportunities.
The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office, or USPTO. For example, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our therapeutic candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those therapeutic candidates. We intend to seek patent term extensions in any jurisdiction where these are available and where we also have a patent that may be eligible; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.
We also rely on trade secrets to protect aspects of our technology and business not amenable to, or that we do not consider appropriate for, patent protection. We seek to protect this intellectual property, in part, by requiring our employees, consultants, outside scientific collaborators, sponsored researchers and other service providers and advisors to execute confidentiality agreements upon the commencement of employment or other relationship with us. In general, these agreements provide that confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements further provide that inventions and discoveries conceived or reduced to practice by the individual that are related to our business, or actual, or demonstrably anticipated, research or development, or made during normal working hours, on our premises or using our equipment, supplies, or proprietary information, are our exclusive property. In many cases our agreements with consultants, outside scientific collaborators, sponsored researchers and other service providers and advisors require them to assign, or grant us licenses to, inventions resulting from the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.
Further, we expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available.
27

We seek trademark protection in the United States and in certain other jurisdictions where available and when we deem appropriate. We currently have a registration for “Inhibrx” in the United States. We intend to file applications for trademark registrations in connection with our therapeutic candidates in various jurisdictions, including the United States.
Competition
The biopharmaceutical industry is characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. While we believe that our platforms, technology, knowledge, experience, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.
Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our therapeutics, the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics, and price and levels of reimbursement. Our primary competitors fall into the following groups:
•Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Alligator Bioscience AB, Crescendo Biologics Ltd., GlaxoSmithKline plc, IGM Biosciences, Inc., Lava Therapeutics N.V., Molecular Partners AG, Pieris Pharmaceuticals, Inc., Precirix, and Sanofi S.A.;
•Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Regeneron Pharmaceuticals, Inc., Adimab LLC, Genmab A/S, Macrogenics, Inc., Merus N.V., MorphoSys AG, Numab Therapeutics AG, Amgen, Inc., Xencor Inc., and Zymeworks Inc.; and
•Companies developing therapeutics designed to treat AATD, including CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, and Mereo BioPharma Group plc.
Our competitors also include other large pharmaceutical and biotechnology companies who may be developing therapeutic candidates with mechanisms similar to or targeting the same indications as our therapeutic candidates.
The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our therapeutic candidates. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.
Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These early stage and more established competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Government Regulation
Governmental authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are developing. Our therapeutic candidates must be approved by the FDA through the BLA process before they may be legally marketed in the United States and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining marketing approvals in the U.S. and in foreign countries and jurisdictions, and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations, require the expenditure of substantial time and financial resources.
28

United States Government Regulation
In the United States, the FDA regulates biopharmaceutical products under the Federal Food, Drug, and Cosmetic Act and the Public Health Services Act, or PHSA, and implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions brought by the FDA and the Department of Justice, or DOJ, or other governmental entities, any of which could have a material adverse effect on us. These sanctions could include:
•refusal to approve pending applications;
•withdrawal of an approval;
•imposition of a clinical hold;
•warning or untitled letters;
•seizures or administrative detention of product;
•total or partial suspension of production or distribution; or
•injunctions, fines, disgorgement, or civil or criminal penalties.
BLA Approval Processes
The process required by the FDA before a therapeutic biologic may be marketed in the United States generally involves the following:
•completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to good laboratory practices and other applicable regulations and guidance;
•submission to the FDA of an Investigational New Drug Application, or IND, which must become effective before human clinical trials may begin;
•performance of adequate and well-controlled human clinical trials according to good clinical practices, or GCPs, to establish the safety and efficacy of the therapeutic candidate for its intended use;
•submission to the FDA of a BLA;
•satisfactory completion of FDA inspections of the manufacturing facility or facilities at which the therapeutic candidate is produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with current Good Manufacturing Practices, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the therapeutic candidate’s identity, strength, quality and purity; and
•FDA review and approval of the BLA.
Preclinical Studies and IND Application
Once a biopharmaceutical candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as potential animal studies. The Consolidated Appropriations Act for 2023, signed into law on December 29, 2022 (P.L. 117-328), amended both the FDCA and the Public Health Service Act, or PHSA, to specify that nonclinical testing for drugs and biologics, respectively, may, but is not required to, include in vivo animal testing. According to the amended language, a sponsor may fulfill nonclinical testing requirements by completing various in vitro assays (e.g., cell-based assays, organ chips, or microphysiological systems), in silico studies (i.e., computer modeling), other human or non-human biology based tests (e.g., bioprinting), or in vivo animal tests. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Additional nonclinical testing continues even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a study protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.
29

Human Clinical Trials in Support of a BLA
All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report to the FDA serious and unexpected adverse reactions in a timely manner, such as any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator’s brochure or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product or therapeutic candidate. An institutional review board, or IRB, must review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each research subject or the subject’s legal representative, monitor the trial until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.
Human clinical trials are typically conducted in three sequential phases that may overlap or be combined.
Phase 1-The product or therapeutic candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the product or therapeutic candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
Phase 2-Clinical trials are performed on a limited patient population intended to identify possible AEs and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
Phase 3-Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling.
A pivotal trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a product or therapeutic candidate’s efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal trials are also Phase 3 trials but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need. Human clinical trials are inherently uncertain and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the product or therapeutic candidate has been associated with unexpected serious harm to patients.
Congress also recently amended the FDCA, as part of the Consolidated Appropriations Act for 2023, to require sponsors of a Phase 3 clinical trial, or other “pivotal study” of a new drug to support marketing authorization, to design and submit a diversity action plan for such clinical trial. The action plan must include the sponsor’s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. Sponsors must submit a diversity action plan to the FDA by the time the sponsor submits the relevant clinical trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. It is unknown at this time how the diversity action plan may affect Phase 3 trial planning and timing or what specific information FDA will expect in such plans, but if the FDA objects to a sponsor’s diversity action plan or otherwise requires significant changes to be made, it could delay initiation of the relevant clinical trial.
During the development of a new product or therapeutic candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission of an IND, at the end of Phase 2 and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of
30

development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trials that they believe will support the approval of the new therapeutic.
Post-approval trials, sometimes referred to as “Phase 4” clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of “Phase 4” clinical trials.
Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product or therapeutic candidate and finalize a process for manufacturing commercial quantities of the product or therapeutic candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product or therapeutic candidate and the manufacturer must develop methods for testing the quality, purity and potency of the product or therapeutic candidate. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product or therapeutic candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product or therapeutic candidate does not undergo unacceptable deterioration over its shelf life.
Disclosure of Clinical Trial Information
Sponsors of clinical trials of certain FDA-regulated products, including prescription drugs and biologics, are required to register and disclose certain clinical trial information on a public registry maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. The NIH’s Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and the government has brought enforcement actions against clinical trial sponsors that fail to comply with such requirements.
Marketing Application Submission and FDA Review
Assuming successful completion of the required clinical testing, the results of the nonclinical studies and clinical trials, along with detailed descriptions of the product’s CMC, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product.
Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee that is assessed on sponsors of approved prescription biological or drug products. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review.
Under the goals and policies agreed to by the FDA under PDUFA, for original BLAs, the FDA has ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or clarification and the sponsor’s process to respond to such inquiries. This FDA review typically takes twelve months from the date the BLA is submitted to the FDA (for a standard review) and eight months from the date the BLA is submitted (for a “priority review”) because the FDA has approximately two months, or 60 days, after BLA submission to make a “filing” decision.
31

The FDA conducts a preliminary review of a submitted BLA within 60 days of receipt and informs the sponsor by the 74th day after the FDA’s receipt of the submission whether the application is substantially complete to permit a substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission, and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.
Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers these recommendations carefully when making decisions.
The FDA likely will re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. The FDA also may require the development of a risk evaluation and mitigation strategy, or REMS, plan if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the biological product. The REMS plan could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS plan is needed, the sponsor of the BLA must submit a proposed REMS plan. The FDA will not approve a BLA without a REMS plan, if required.
Before approving a BLA, the FDA will typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with GCP requirements and to assure the integrity of the clinical data submitted to the FDA. To ensure cGMP and GCP compliance by its employees and third-party contractors, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.
The approval process is lengthy and often difficult, and notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval or may require additional clinical or other data and information. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve a BLA, the FDA will issue a complete response letter, or CRL, that describes all of the specific deficiencies in the BLA identified by the FDA. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the CRL may include recommended actions that the applicant might take to place the application in a condition for approval. If a CRL is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter to the applicant. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
Even if a product receives marketing approval, the approval may be limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a
32

REMS plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as “Phase 4” clinical trials, designed to further assess a biological product’s safety and effectiveness, and/or testing and surveillance programs to monitor the safety of approved products that have been commercialized. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.
Companion Diagnostics
The FDA issued a final guidance document in July 2014 addressing agency policy in relation to in vitro companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally will not approve such a product if the companion diagnostic is not also approved or cleared for the appropriate indication, and accordingly the therapeutic product and the companion diagnostic should be developed and approved or cleared contemporaneously. However, the FDA may decide that it is appropriate to approve such a product without an approved or cleared in vitro companion diagnostic device when the drug or therapeutic biologic is intended to treat a serious or life-threatening condition for which no satisfactory alternative treatment exists and the FDA determines that the benefits from the use of a product with an unapproved or uncleared in vitro companion diagnostic device are so pronounced as to outweigh the risks from the lack of an approved or cleared in vitro companion diagnostic device. The FDA encourages sponsors considering developing a therapeutic product that requires a companion diagnostic to request a meeting with both relevant device and therapeutic product review divisions to ensure that the product development plan will produce sufficient data to establish the safety and effectiveness of both the therapeutic product and the companion diagnostic. Because the FDA’s policy on companion diagnostics is set forth only in guidance, this policy is subject to change and is not legally binding.
Fast Track, Breakthrough Therapy, RTOR, and Priority Review Designations
The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include Fast Track designation, breakthrough therapy designation and priority review designation. In January 2021, INBRX-109 was granted Fast Track designation for patients with unresectable or metastatic conventional chondrosarcoma.
To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast Track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the BLA for a Fast Track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of the first section of the BLA. In addition, Fast Track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging in the clinical trial process.
In addition, Congress created a new regulatory program in 2012 for product and therapeutic candidates designated by the FDA as “breakthrough therapies” upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs or biologics designated as breakthrough therapies may also be eligible for accelerated approval of their respective marketing applications. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.
33

Specific to oncology drug applications, FDA’s Oncology Center of Excellence has developed a program called Real-Time Oncology Review, or RTOR. RTOR facilitates earlier submission of topline results (i.e., efficacy and safety results from clinical studies before the study report is completed) and datasets, after database lock, to support an earlier start to the agency’s review of a marketing application review. The intent of RTOR is to provide FDA reviewers earlier access to data, to identify data quality and potential review issues, and to potentially enable early feedback to the applicant, which can allow for a more streamlined and efficient review process for the product’s BLA. Applicants can apply for review under RTOR when the database for a pivotal trial has been locked and the oncology product is eligible under FDA’s criteria for the program. Eligibility requires (a) clinical evidence indicating that the drug may demonstrate substantial improvement on one or more clinically relevant endpoints over available therapies; (b) the use of straightforward study designs and easily interpreted clinical trial endpoints (e.g., overall survival, response rates); and (c) that no aspect of the BLA is likely to require a longer review time (e.g., requirement for new REMS or input from an advisory committee). In November 2023, the agency finalized guidance for industry on RTOR.
Finally, the FDA may designate a product for priority review if it is a drug or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months for an original BLA from the date of filing.
Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, Fast Track designation, breakthrough therapy designation, RTOR, and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.
Accelerated Approval Pathway
In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a drug or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. Further, all promotional materials for product and therapeutic candidates being considered and approved under the Accelerated Approval Program are subject to prior review by the FDA.
For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and
34

basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.
The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.
The accelerated approval pathway is usually contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. As a result, a product or therapeutic candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. In addition, as part of the Consolidated Appropriations Act for 2023, Congress provided FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these recent amendments to the FDCA, the agency may require a sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports will be published on the FDA’s website. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, allows the FDA to withdraw approval of the drug. Congress also recently amended the law to give FDA the option of using expedited procedures to withdraw product approval if the sponsor’s confirmatory trial fails to verify the claimed clinical benefits of the product. Prior to the recent statutory amendments enacted by Congress, several oncology sponsors voluntarily withdrew specific indications for their drug products that were being marketed pursuant to accelerated approval, and the FDA’s Oncology Center of Excellence launched an initiative called Project Confirm, aimed at promoting transparency in the area of accelerated approvals for oncology indications. Scrutiny of the accelerated approval pathway is likely to continue in the coming years and may lead to further legislative and/or administrative changes in the future.
Patent Term Restoration and Reference Product Marketing Exclusivity for Biological Products
Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate’s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant BLA.
The Biologics Price Competition and Innovation Act, or the BPCIA, enacted in 2010, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics such as ours, which are also known as “reference biological products.” The pathway authorized under the BPCIA allows FDA to approve, under an abbreviated application, a biological product that has been shown to be highly similar to a reference product notwithstanding minor differences in clinically inactive components; there also can be no clinically meaningful differences between the follow-on product and the reference product in terms of safety, purity and potency. Follow-on biological products approved for marketing using this pathway are commonly known as “biosimilars,” and companies seeking approval of biosimilar products must submit in their abbreviated BLAs data from analytical studies, an assessment of toxicity, and a clinical trial or trials sufficient to meet the statutory standard in order to
35

obtain FDA approval. In addition, an interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. FDA approved the first interchangeable biosimilars, including an interchangeable monoclonal antibody biosimilar, in 2021.
The BPCIA bars the FDA from approving biosimilar applications for 12 years after a reference biological product receives initial marketing approval. FDA also cannot accept an application for a biosimilar product that is based on the reference biological product until four years after the date of first licensure of the reference product in question. “First licensure” typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the “first licensure” of a biological product is determined on a case-by-case basis with data submitted by the sponsor.
The BPCIA is complex and is still being interpreted and implemented by the FDA and by federal judges. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation and legislative amendments. As a result, the ultimate impact, implementation and meaning of the BPCIA continues to be subject to uncertainty.
Orphan Drug Designation and Orphan Product Exclusivity
Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to a therapeutic candidate intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a product or therapeutic candidate for this type of disease or condition will be recovered from sales in the United States for that product or therapeutic candidate. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. In November 2021, INBRX-109 was granted designation as an orphan product by the FDA for the treatment of chondrosarcoma, and in March 2022, INBRX-101 was granted designation as an orphan product by the FDA for the treatment of AATD.
If a product or therapeutic candidate that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the approved product is entitled to orphan product exclusivity, which means that the FDA may not approve any other marketing applications for the same drug for the same indication, except under limited circumstances (such as showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues), for seven years. Competitors, however, may still receive approval of either a different product for the same indication for which the orphan product has exclusivity or for the same product but for a different indication (which could then be used off-label in the orphan indication). Orphan product exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA, or if our therapeutic candidate is determined to be contained within a competitor’s approved drug for the same indication or disease. Further, if a drug designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan
36

product application, it may not be entitled to exclusivity. Recent court cases have challenged FDA’s approach to determining the scope of orphan drug exclusivity; however, at this time the agency continues to apply its long-standing interpretation of the governing regulations and has stated that it does not plan to change any orphan drug implementing regulations.
In addition, an orphan drug credit is available for qualifying costs incurred between the date the FDA designates a drug as an orphan drug and the date the FDA approves the drug.
Pediatric Exclusivity and Pediatric Use
Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to show the product to be effective in the pediatric population studied; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA’s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.
In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric trials for most therapeutic drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original new drug applications, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. Sponsors must also submit Pediatric Study Plans, or PSPs, to the agency for review within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric trial or trials that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric trials along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials or other clinical development programs.
The required assessment must assess the safety and effectiveness of the product or therapeutic candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product and therapeutic candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation, and the FDA publicly posts such PREA Non-Compliance letters and sponsor’s response. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease.
Congress periodically considers enacting new incentives or mandates applicable to pediatric drug development, and the regulatory requirements applicable to pediatric drug developers may change in the future. For example, bipartisan legislation introduced in 2023 in the House of Representatives would increase funding for pediatric trials;
37

mandate that drugs for rare diseases be studied in children; and grant FDA authority to assess penalties against companies that do not complete required pediatric studies.
Post-Approval Requirements
Following approval of a new product, the manufacturer and the approved biological product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., “off-label use”) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the applicant to develop additional data or conduct additional nonclinical studies and clinical trials.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product or therapeutic reaches the market. Later discovery of previously unknown problems with a product or therapeutic candidate, including AEs of unanticipated severity or frequency, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of non-compliance include, among other things:
•restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
•mandated modification of promotional materials or labeling and the issuance of corrective information;
•fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;
•refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product approvals;
•product seizure or detention, or refusal to permit the import or export of products;
•injunctions or the imposition of civil or criminal penalties; and
•consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.
Any therapeutic candidate manufactured or distributed by us pursuant to FDA approvals will be subject to continuing regulation by the FDA, including, among other things:
•record-keeping requirements;
•reporting of adverse experiences with the therapeutic candidate;
•providing the FDA with updated safety and efficacy information;
•sampling and distribution requirements;
•notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and
•complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in-patient populations that are not described in the product’s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet.
FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Therapeutic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with
38

cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the BLA applicant and any third-party manufacturers involved in producing the approved biological product. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of quality control and quality assurance.
In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or the PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. More recently, the Drug Supply Chain Security Act, or the DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10‑year period that culminated in November 2023. However, FDA announced a one-year stabilization period, until November 2024, to give entities subject to the DSCSA additional time to finalize interoperable tracking systems and to ensure supply chain continuity. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. For example, the FDA released proposed regulations in February 2022 to amend the national standards for licensing of wholesale drug distributors by the states; establish new minimum standards for state licensing third-party logistics providers; and create a federal system for licensure for use in the absence of a State program, each of which is mandated by the DSCSA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.
Regulation Outside of the United States
In addition to regulations in the United States, we will be subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the EU, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.
Under EU regulatory systems, a company can consider applying for marketing authorization in several EU member states by submitting its marketing authorization application(s) under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all EU member states. The centralized procedure is compulsory for medicines derived from biotechnology, orphan medicinal products, or those medicines with an active substance not authorized in the EU on or before May 20, 2004 intended to treat acquired immune deficiency syndrome, cancer, neurodegenerative disorders or diabetes and optional for those medicines containing a new active substance not authorized in the EU on or before May 20, 2004, medicines which are highly innovative, or medicines to which the granting of a marketing authorization under the centralized procedure would be in the interest of patients at the EU-level. The decentralized procedure provides for recognition by EU national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for marketing authorization is submitted simultaneously to the national authorities of several EU member states, one of them being chosen as the “Reference Member State,” and the remaining being the “Concerned Member States.” The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labelling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the marketing authorization on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European
39

Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State.
As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the EU before the application for marketing authorization is made.
Orphan drugs in the EU enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder is unable to supply sufficient quantity of the medicinal product or the marketing authorization holder has given its consent.
On January 31, 2020, the United Kingdom formally withdrew from the EU, also known as Brexit. The United Kingdom and the EU entered into a trade agreement known as the Trade and Cooperation Agreement, which went into effect on January 1, 2021. As a result of Brexit, United Kingdom licensing decisions were transferred from European Medicines Agency, or EMA, to the Medicines and Healthcare Products Regulatory Agency, or MHRA, the United Kingdom Regulatory Body. For a period of three years following January 1, 2021, the United Kingdom will continue to adopt decisions taken by the European Commission on the approval of new marketing authorizations. However, companies will be required to submit an identical application to the MHRA upon the Medicinal Products for Human Use, or CHMP, positive opinion of the application. The MHRA will then wait for the European Commission decision on approval. More recently, in March 2023, the United Kingdom government and the European Commission reached agreement on a regulatory framework to replace the Northern Ireland Protocol, referred to as the Windsor Framework. The Windsor Framework is expected to apply as of January 1, 2025 and will change the existing system under the Northern Ireland Protocol, including the regulation of pharmaceutical products in the United Kingdom. Specifically, the MHRA will be responsible for approving all medicines intended to be marketed in the United Kingdom (i.e., Great Britain and Northern Ireland), while the EMA will no longer be involved in approving medicines intended for sale in Northern Ireland.
Since the regulatory framework in the United Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime as it applies to medicinal products and the approval of product candidates in the United Kingdom.
Coverage, Pricing and Reimbursement
Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the U.S. In the U.S., third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. In August 2022, President Biden signed into the law the Inflation Reduction Act of 2022, or the IRA. Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. A manufacturer of drugs or biological products covered by Medicare Parts B or D must pay a rebate to the federal government if their drug product’s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of
40

the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026, the Centers for Medicare & Medicaid Services, or CMS, will negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities and entered into the first set of agreements with pharmaceutical manufacturers to conduct price negotiations in October 2023. However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic and biosimilar products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. If these third-party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement for the pharmaceutical or biological products apply to companion diagnostics.
Moreover, in some foreign countries, the proposed pricing for a product and therapeutic candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, therapeutic candidates launched in the EU do not follow price structures of the United States and generally tend to be significantly lower.
Healthcare Reform
In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product and therapeutic candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. Moreover, among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.
For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted in March 2010 and has had a significant impact on the health care industry in the U.S. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. It also included the BPCIA, which created an abbreviated approval pathway for biological
41

products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program. As another example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020 incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of drugs and biological products covered under Medicare Part B report the product’s average sales price, or ASP, to the United States Department of Health and Human Services, or HHS, beginning on January 1, 2022, subject to enforcement via civil money penalties. The American Rescue Plan Act of 2021 also included a provision that eliminated the statutory cap on rebates that drug manufacturers pay to Medicaid. Beginning in January 2024, Medicaid rebates are no longer capped at 100 percent of the quarterly average manufacturer price, or AMP.
We expect that further legislative changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the health care industry in the United States.
Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.
Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states’ ability to regulate pharmacy benefit managers, or PBMs, and other members of the health care and pharmaceutical supply chain, an important decision that has led to more aggressive efforts by states in this area. The Federal Trade Commission in mid-2022 also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities’ operations, pharmacy networks, or financial arrangements. During the current congressional session, numerous PBM reforms are being considered in both the Senate and the House of Representatives; they include diverse legislative proposals such as eliminating rebates; divorcing service fees from the price of a drug, discount, or rebate; prohibiting spread pricing; limiting administrative fees; requiring PBMs to report formulary placement rationale; promoting transparency. Significant efforts to change the PBM industry as it currently exists in the U.S. may affect the entire pharmaceutical supply chain and the business of other stakeholders, including therapeutic biological product developers like us.
We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services.
Other Healthcare Laws
Our current and future business operations are subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we research, and, if approved, market, sell and distribute our therapeutic candidates. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, physician sunshine and drug pricing transparency laws and regulations such as:
•The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration, directly or indirectly, to induce either the referral of
42

an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is broadly interpreted and aggressively enforced with the result that beneficial commercial arrangements can be penalized in the healthcare industry. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on a variety of arrangements, including sham consulting and other financial arrangements with physicians. Penalties for violating the federal Anti-Kickback Statute include imprisonment, fines and possible exclusion from federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
•The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, prohibit, among other things, knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. Actions under these laws may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government uses these laws, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other allegedly unlawful sales and marketing practices. If an entity is found to have violated the False Claims Act, it must pay three times the actual damages sustained by the government, plus mandatory and substantial civil penalties;
•The federal Health Insurance Portability and Accountability Act of 1996 and its accompanying regulations, or HIPAA, created new federal, civil and criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•The Physician Payments Sunshine Act, enacted as part of the ACA, among other things, imposes reporting requirements on manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), teaching hospitals and certain advanced non-physician healthcare practitioners, as well as ownership and investment interests held by physicians and their immediate family members. The law provides for the imposition of civil monetary penalties, and payments reported also have the potential to draw scrutiny on payments and relationships with physicians, which may have implications under the Anti-Kickback Statute and other healthcare laws;
•Analogous state laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws which require the registration of pharmaceutical sales representatives; and state laws and non-United States laws and regulations (particularly EU laws regarding personal data relating to individuals based in Europe) that govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts.
43

Ensuring that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations.
U.S. and European Data Security and Data Privacy Laws
HIPAA, as well as a number of other federal and state privacy-related laws, extensively regulate the use and disclosure of individually identifiable health information, known as “protected health information” or “PHI”.
HIPAA applies to health plans, healthcare providers who engage in certain standard healthcare transactions electronically, such as electronic billing, and healthcare clearinghouses, all of which are referred to as “covered entities” under HIPAA. State imposed health information privacy and security laws typically apply based on licensure, for example, licensed providers or licensed entities are limited in their ability to use and share health information. State and federal consumer protection laws, including the Federal Trade Commission Act, govern the collection, use disclosure and protection of health and other personal information and could apply to our operations and the operations of our collaborators.
Additionally, all states have enacted legislation protecting the privacy and security of “personal information” such as identifiable financial or health information, social security number and credit card information. These laws overlap and apply simultaneously with federal privacy and security requirements and regulated entities must comply with all of them. The California Consumer Privacy Act, or CCPA, that went into effect January 1, 2020, is one of the most restrictive state privacy laws, protecting a wide variety of personal information and granting significant rights to California residents with respect to their personal information. Regulations under CCPA have been modified several times. While there is currently an exception under CCPA for protected health information that is subject to HIPAA and clinical trial regulations, CCPA still applies to the personal information of employees and may otherwise impact our business. Additionally, an amendment to the CCPA, the California Privacy Rights Act, or CPRA, was approved by California voters in the election of November 3, 2020 and took full effect on January 1, 2023. CPRA modifies CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses stemming from efforts to comply, and additional potential for harm and liability for failure to comply. Among other things, CPRA established a new regulatory authority, the California Privacy Protection Agency, or CPPA, with expanded enforcement authority. The CPPA is currently promulgating additional regulations under the CPRA, which could lead to added uncertainty and operational risks. Other states in the U.S. are considering privacy laws similar to CCPA increasing the regulatory and enforcement risk. In addition to California, several states have similar omnibus privacy laws which took effect in 2023, including Virginia, Colorado, Connecticut, and Utah, that may have operational impacts on our business. In dealing with health information for the development of our technology or for commercial purposes, we will be indirectly affected by HIPAA and state-imposed health information privacy and security laws because these laws regulate the ability of our potential customers and research collaborators to share health information with us. Additionally, we must identify and comply with all applicable state laws for the protection of personal information with respect to employee information or other personal information that the company collects. See Part I, Item 1A “Risk Factors- We face regulation and potential liability related to privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance.”
In the EU, increasingly stringent data protection and privacy rules that have and will continue to have substantial impact on the use of personal and patient data across the healthcare industry became stronger in May 2018. The EU General Data Protection Regulation, or GDPR, applies across the EU and includes, among other things, a requirement for prompt notice of data breaches to data subjects and supervisory authorities in certain circumstances and significant fines for non-compliance. The GDPR fine framework can be up to 20 million euros, or up to 4% of
44

the company’s total global turnover of the preceding fiscal year, whichever is higher. The GDPR sets out a number of requirements that must be complied with when processing the personal data of such EU based data subjects including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be “forgotten” and rights to data portability, as well as enhanced current rights (e.g., access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; and the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual are all classified as “special category” data under the GDPR and are afforded greater protection and require additional compliance obligations. Noncompliance could result in the imposition of fines, penalties, or orders to stop noncompliant activities. We may be subject to GDPR if we undertake operations in the EU, offer products or services to individuals in the EU or monitor the behavior of individuals within the EU.
We could also be subject to evolving EU laws on data export, for transfers of data outside the EU to us, group companies or third parties. The GDPR only permits exports of data outside the EU to jurisdictions that ensure an adequate level of data protection. The United States has not been deemed to offer an adequate level of protection, so in order for us to transfer personal data from the EU to the United States, we must identify a legal basis for data transfer (e.g., the EU Commission approved Standard Contractual Clauses or certification under the recently-adopted EU-US Data Privacy Framework). On July 16, 2020, the Court of Justice of the EU or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18), called Schrems II. This decision (i) calls into question commonly relied upon data transfer mechanisms as between the EU member states and the United States (such as the Standard Contractual Clauses) and (ii) invalidates the EU-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the United States. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on data importers to assess U.S. national security laws on their business and future actions of EU data protection authorities are difficult to predict. While the recently-adopted EU-US Data Privacy Framework was meant to address the concerns raised by the CJEU in Schrems II and provide an approved method for cross-border data transfer from the EU to the US, it will likely be subject to future legal challenges and we have not certified to participate in the EU-US Data Privacy Framework.
Where we rely on third parties to carry out services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse impact on our reputation and business. Any contractual arrangements requiring the transfer of personal data from the EU to us in the United States will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance.
Other Laws and Regulations
Our present business is, and our future business may be, subject to regulation under the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations. See Part I, Item 1A “Risk Factors- If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.”
Manufacturing
We do not own or operate manufacturing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We presently have relationships with suppliers for the manufacture of supplies for all of our required raw materials, antibodies and other biologics
45

for our preclinical research, clinical trials, and if and when applicable, commercialization. We currently employ internal resources to manage our manufacturing relationships.
Human Capital Resources
Our employees are a key factor in our ability to achieve our mission to discover and develop effective biologic therapeutics for people with life-threatening conditions. We believe that our future success depends on our continued ability to identify, recruit, retain, and incentivize our management team and our clinical, scientific, and other employees. Our ability to do so depends on factors including our Company culture, compensation and benefits, growth and development opportunities, and prioritization of employee safety.
Employee Profile
As of December 31, 2023, we had 172 employees, 166 of whom were full-time, 137 of whom were engaged in research and development activity, and 78 of which hold advanced degrees, including but not limited to Ph.D., M.D., PharmD, J.D., MBA, and other master’s degrees. None of our employees are represented by a labor union and we believe we maintain good relations with our employees.
Diversity, Equity and Inclusion
Our employees represent a broad range of backgrounds and bring a wide array of perspectives and experiences. A key component of our culture is our commitment to diversity, equity, and inclusion, or DEI. We believe this commitment allows us to better drive innovation and achieve our mission. Our DEI principles are reflected in our efforts in building a better workplace where employees can be themselves and succeed, and use their voice and influence to create a better world. We are consciously expanding the diversity of our workforce, creating growth and development opportunities for our employees, embracing different perspectives and fostering an inclusive work environment.
Employee Conduct & Ethics
Inhibrx adopted and regularly reviews corporate policies, including a Code of Conduct and Ethics and Whistleblower Policy, which apply to all of our employees. All employees complete a mandatory public company training session and are required to abide by, review and confirm compliance to the Company’s Corporate Code of Conduct and Ethics and Whistleblower Policy, as well as our Insider Trading Policy governing trading by Company personnel in the Company’s securities. We have established a Whistleblower reporting hotline to enable our employees to anonymously report any suspected violations of these policies. In addition, the Company requires employees to complete Anti-Harassment Training, with employees who work in a management capacity required to complete additional trainings in Harassment Prevention and Diversity, Equity and Inclusion.
Employee Compensation and Benefits
Our compensation programs are designed to reward and support our employees in order to continue to attract and retain top talent. Our compensation includes:
•Employee base salaries that are competitive and consistent with employee positions, skill levels, experience, and knowledge;
•Stock-based compensation awards which help to align the interests of our stockholders with those of our employees;
•Bonus award plans for all full-time employees;
•Retirement savings options and matching contributions;
•Fully covered healthcare benefits for all full-time employees and their dependents;
•Unlimited vacation benefit for all full-time employees; and
•Parental leave and other leave options available to all employees.
Employee Growth and Development
Inhibrx is committed to fostering and growing talent within the biopharmaceutical and life sciences space. We provide internship opportunities for students interested in biotechnology and science within our research and development departments. Many of our interns have continued on to join the Company in a full-time position after graduation. Our hiring process is transparent and we are an equal opportunity employer. Many of our employees
46

hold advanced degrees, as well as professional licenses and certifications; however, the Company equally commits resources to advancing all of our employees with a range of educational backgrounds. We offer tuition reimbursement aimed at growth and career development, as well as the opportunity for employees to attend relevant conferences and symposiums. In addition, we offer in-house coaching opportunities to refine or develop professional skills as our employees become managers and plan their career growth.
Employee Wellness, Health, and Safety
We are strongly committed to the health and safety of our employees and strive to maintain the highest possible level of safety in our workplace. We require annual workplace safety training to reinforce workplace safety procedures that may be useful in the event of emergency situations and to assist our employees in helping to prevent workplace accidents. Our Environmental Health and Safety Committee, which is comprised of numerous cross-departmental members, meets regularly to review workplace safety and adherence to safety policies.
Corporate Information
We were incorporated under the laws of the State of Delaware on November 17, 2017 under the name Tenium Therapeutics, Inc. In April 2018, we changed our name to Inhibrx, Inc.
Available Information
Our internet address is www.inhibrx.com, to which we regularly post copies of our press releases as well as additional information about us. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the Investors section on our website as soon as reasonably practicable after such materials have been electronically filed with, or furnished to, the SEC. The SEC maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. We include our web site address in this Annual Report only as an inactive textual reference. Information contained in our website does not constitute a part of this report or our other filings with the SEC.
47

Item 1A. Risk Factors.
Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report, including our consolidated financial statements and related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results, financial condition, and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment.
Summary Risk Factors
Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the section of this Annual Report titled “Risk Factors”. These risks include, among others, the following:
Risks Related to the Proposed Merger and Spin-Off
•The consummation of the Merger is subject to a number of conditions, many of which are largely outside of the parties’ control, and, if these conditions are not satisfied or waived on a timely basis, the Merger Agreement may be terminated and the Merger may not be completed.
•Failure to complete the Merger could adversely affect the stock price and future business and financial results of the Company.
•While the Merger is pending, the Company will be subject to business uncertainties and certain contractual restrictions that could adversely affect the business and operations of the Company.
•Litigation against the Company, Aventis, or the members of their respective boards, could prevent or delay the completion of the Merger or result in the payment of damages following completion of the Merger.
Risks Related to Our Financial Condition and Need for Additional Capital
•We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable, or if we achieve profitability, we may not be able to sustain it.
•Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.
•We expect we will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee this additional funding will be available on acceptable terms or at all. Failure to obtain this funding when needed may force us to delay, limit or terminate our development efforts and, if any of our therapeutic candidates are approved, our commercialization efforts.
•We may be adversely affected by the effects of inflation.
Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates
•Our therapeutic candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we, or our collaboration partners, are unable to advance our therapeutic candidates through clinical development, obtain marketing approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed.
•We rely on third parties to conduct a portion of our clinical trials and certain of our nonclinical studies. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.
Risks Related to Our Organization and Operations
•We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted.
48

•Our business, the conduct of our clinical trials, results of operations, financial condition, and prospects may be adversely affected by the widespread outbreak of an illness or any other communicable disease, or any other public health crisis, including the coronavirus disease.
Risks Related to Intellectual Property
•If we are not able to obtain and enforce patent protection for our technologies or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected.
Risks Related to Government Regulation
•We or our collaborators may be unable to obtain marketing approval for any product that we or a collaborator may develop and the marketing approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time consuming and inherently unpredictable.
Risks Related to Ownership of Our Common Stock
•We do not know whether an active, liquid and orderly trading market will continue for our common stock and as a result it may be difficult for you to sell your shares of our common stock.
•We expect that our stock price may fluctuate significantly.
•Our executive officers, directors and holders of more than 5% of our capital stock own a significant percentage of our stock and will be able to exercise significant control over matters subject to stockholder approval.
•Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
Risks Related to the Proposed Merger and Spin-Off
The consummation of the Merger is subject to a number of conditions, many of which are largely outside of the parties’ control, and, if these conditions are not satisfied or waived on a timely basis, the Merger Agreement may be terminated and the Merger may not be completed.
The Merger is subject to certain customary closing conditions, including: (i) adoption of the Merger Agreement by holders of a majority of the outstanding shares of Company common stock entitled to vote on such matters at the Company’s shareholders meeting and who are present at the shareholders meeting, in person or by proxy; (ii) the expiration, termination or receipt of any approval or clearances applicable to the consummation of the Merger under applicable antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the receipt of certain additional clearances or approvals of certain other governmental bodies applicable to the Merger; (iii) the absence of any law or order prohibiting or making illegal the consummation of the Merger; (iv) effectiveness of the registration statement to be filed with respect to registration of the common stock of New Inhibrx that will be distributed in the spin-off; (v) completion of the spin-off; (vi) subject to certain qualifications, the accuracy of representations and warranties of the Company, Aventis and Art Acquisition Sub, Inc., or Merger Sub, as applicable, under the Merger Agreement and the performance in all material respects by the Company, Aventis and Merger Sub, as applicable, of their obligations under the Merger Agreement; and (vii) the absence of any Company Material Adverse Effect (as defined in the Merger Agreement).
The failure to satisfy all of the required conditions could delay the completion of the Merger by a significant period of time or prevent it from occurring. Any delay in completing the Merger could cause the parties to not realize some or all of the benefits that are expected to be achieved if the Merger is successfully completed within the expected timeframe. There can be no assurance that the conditions to closing of the Merger will be satisfied or waived or that the Merger will be completed within the expected timeframe or at all.
Failure to complete the Merger could adversely affect the stock price and future business and financial results of the Company.
There can be no assurance that the conditions to the closing of the Merger will be satisfied or waived or that the Merger will be completed. If the Merger is not completed within the expected timeframe or at all, the ongoing business of the Company could be adversely affected and the Company will be subject to a variety of risks and possible consequences associated with the failure to complete the Merger, including the following: (i) upon termination of the Merger Agreement under specified circumstances, the Company is required to pay Aventis a termination fee of $54,500,000; (ii) the Company will incur certain transaction costs, including legal, accounting,
49

financial advisor, filing, printing and mailing fees, regardless of whether the Merger closes; (iii) under the Merger Agreement, the Company is subject to certain restrictions on the conduct of its business prior to the closing of the Merger, which may adversely affect its ability to execute certain of its business strategies; and (iv) the proposed Merger, whether or not it closes, will divert the attention of certain management and other key employees of the Company from ongoing business activities, including the pursuit of other opportunities that could be beneficial to the Company as an independent company.
If the Merger is not completed, these risks could materially affect the business and financial results of the Company and its stock price, including to the extent that the current market price of the Company’s common stock is positively affected by a market assumption that the Merger will be completed.
While the Merger is pending, the Company will be subject to business uncertainties and certain contractual restrictions that could adversely affect the business and operations of the Company.
In connection with the pending Merger, some customers, vendors or other third parties of the Company may react unfavorably, including by delaying or deferring decisions concerning their business relationships or transactions with the Company, which could adversely affect the revenues, earnings, funds from operations, cash flows and expenses of the Company, regardless of whether the Merger is completed. In addition, due to certain restrictions in the Merger Agreement on the conduct of business prior to completing the Merger, the Company may be unable (without the other party’s prior written consent), during the pendency of the Merger, to pursue strategic transactions, undertake significant capital projects, undertake certain significant financing transactions and otherwise pursue other actions, even if such actions would prove beneficial and may cause the Company to forego certain opportunities it might otherwise pursue. In addition, the pendency of the Merger may make it more difficult for the Company to effectively retain and incentivize key personnel and may cause distractions from the Company’s strategy and day-to-day operations for its current employees and management.
The Company will incur substantial transaction fees and Merger-related costs in connection with the Merger that could adversely affect the business and operations of the Company if the Merger is not completed.
The Company expects to incur non-recurring transaction fees, which include legal and advisory fees and substantial Merger-related costs associated with completing the Merger, and which could adversely affect the business operations of the Company if the Merger is not completed.
The termination fee and restrictions on solicitation contained in the Merger Agreement may discourage other companies from trying to acquire the Company.
The Merger Agreement prohibits the Company from initiating, soliciting, proposing or knowingly encouraging or knowingly facilitating any competing acquisition proposals, subject to certain limited exceptions. The Merger Agreement also contains certain termination rights, including, but not limited to, the right of the Company to terminate the Merger Agreement to accept a Superior Proposal (as defined in the Merger Agreement), subject to and in accordance with the terms and conditions of the Merger Agreement, and provides that, upon termination of the Merger Agreement by the Company to enter into an alternative acquisition agreement with respect to a Superior Proposal, the Company will be required to pay Aventis a termination fee of $54,500,000 in cash. The termination fees and restrictions could discourage other companies from trying to acquire the Company even though those other companies might be willing to offer greater value to the Company’s stockholders than Aventis has offered in the Merger.
Litigation against the Company, Aventis, or the members of their respective boards, could prevent or delay the completion of the Merger or result in the payment of damages following completion of the Merger.
It is a condition to the Merger that no injunction or other order preventing the consummation of the Merger shall have been issued by any court of competent jurisdiction or other governmental authority of competent jurisdiction and remain in effect. It is possible that lawsuits may be filed by the Company’s stockholders challenging the Merger. The outcome of such lawsuits cannot be assured, including the amount of costs associated with defending these claims or any other liabilities that may be incurred in connection with the litigation of these claims. If plaintiffs are successful in obtaining an injunction prohibiting the parties from completing the Merger on the agreed-upon terms, such an injunction may delay the consummation of the Merger in the expected timeframe, or may prevent the Merger from being consummated at all. Whether or not any plaintiff’s claim is successful, this type of litigation can
50

result in significant costs and divert management’s attention and resources from the closing of the Merger and ongoing business activities, which could adversely affect the operations of the Company.
Uncertainty about the Merger may adversely affect the relationships between the Company and its customers, vendors and employees, whether or not the Merger is completed.
In response to the announcement of the Merger, existing or prospective customers, vendors and other third party relationships of the Company may delay, defer or cease providing goods or services, delay or defer other decisions concerning the Company, refuse to extend credit to the Company, or otherwise seek to change the terms on which they do business with the Company. Any such delays or changes to terms could materially harm the Company’s business.
In addition, as a result of the Merger, current and prospective employees could experience uncertainty about their future with the Company. These uncertainties may impair the Company’s ability to retain, recruit or motivate key management and technical, manufacturing, and other personnel.
If the Merger is not consummated by September 22, 2024, unless extended in accordance with the Merger Agreement, either the Company or Aventis may terminate the Merger Agreement, subject to certain exceptions.
Either the Company or Aventis may terminate the Merger Agreement if the Merger has not been consummated by September 22, 2024, subject to certain extensions in the Merger Agreement. However, this termination right will not be available to a party if that party failed to fulfill its obligations under the Merger Agreement and that failure was the proximate cause of the failure to consummate the Merger on time. In the event the Merger Agreement is terminated by either party due to the failure of the Merger to close by September 22, 2024, unless extended, the Company will have incurred significant costs and will have diverted significant management focus and resources from other strategic opportunities and ongoing business activities without realizing the anticipated benefits of the Merger.
Risks Related to Our Financial Condition and Need for Additional Capital
We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate product revenue or become profitable, or if we achieve profitability, we may not be able to sustain it.
We are a clinical-stage biopharmaceutical company. To date, we have financed our operations through equity and debt financings, license and milestone revenue and grants. We have incurred significant recurring operating losses since our inception. Our net loss for the year ended December 31, 2023 was $241.4 million. As of December 31, 2023, we had an accumulated deficit of $613.7 million. We expect to incur additional losses in future years as we execute our plan to continue our discovery, research and development activities, including the manufacturing of and ongoing and planned preclinical and clinical development and commercialization of our therapeutic candidates. We are unable to predict the extent of any future losses or when we will become profitable, if ever. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.
Biotechnology product development is a highly speculative undertaking and involves a substantial degree of uncertainty. We have never generated any revenue from product sales and may never be profitable.
We have devoted substantially all of our financial resources and efforts to developing our therapeutic candidates, identifying potential therapeutic candidates and conducting nonclinical studies and clinical trials. We are still in the development stage for all of our therapeutic candidates, and while we have demonstrated an ability to successfully conduct and complete certain of our clinical trials, we have yet to demonstrate an ability to conduct pivotal clinical trials, obtain marketing approval, manufacture a commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had more experience developing therapeutic candidates. We previously entered into certain collaboration agreements. Our ability to generate revenue and achieve
51

profitability depends in large part on our ability, alone or with license partners, to achieve milestones and to successfully complete the development of, obtain the necessary marketing approvals for, and commercialize, our therapeutic candidates. Even if we achieve development or commercial milestones, generate product royalties or generate product sales, we may never achieve or sustain profitability on a quarterly or annual basis. We do not anticipate generating revenue from sales of products for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our and our collaborators’ success in:
•completing clinical trials through all phases of clinical development of our current therapeutic candidates, including INBRX-101, INBRX-109, and INBRX-106;
•advancing preclinical therapeutic candidates into clinical development;
•seeking and obtaining marketing approvals for our therapeutic candidates that successfully complete clinical trials;
•obtaining satisfactory acceptance, formulary placement coverage and adequate reimbursement for our approved products from third-party payors, including private health insurers, managed care providers and governmental payor programs, including Medicare and Medicaid;
•launching and commercializing products for which we obtain marketing approval, with a collaborator or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure;
•establishing and maintaining supply and manufacturing relationships with third parties;
•obtaining market acceptance of any approved products by physicians, patients, third-party payors and the medical community;
•maintaining, protecting, expanding and enforcing our intellectual property portfolio;
•implementing additional internal systems and infrastructure, as needed; and
•attracting, hiring and retaining qualified personnel.
Because of the numerous risks and uncertainties associated with biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA, the EMA, or other comparable foreign authorities to perform nonclinical studies or clinical trials in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our therapeutic candidates, our expenses could increase and revenue could be further delayed.
We expect we will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee this additional funding will be available on acceptable terms or at all. Failure to obtain this funding when needed may force us to delay, limit or terminate our development efforts and, if any of our therapeutic candidates are approved, our commercialization efforts.
As of December 31, 2023, we had $277.9 million in cash and cash equivalents. We expect our expenses to increase in future years as we execute our plan to continue our discovery, research and development activities, including the ongoing and planned preclinical and clinical development and commercialization of our therapeutic candidates. Identifying potential therapeutic candidates and conducting preclinical testing and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we, or our collaborators, may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our therapeutic candidates, if approved, may not achieve commercial success.
We believe that our existing cash and cash equivalents will be sufficient to fund our planned operations through at least the 12 month period following the date of this Annual Report. However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. For example, our current and planned preclinical studies and clinical trials for our current therapeutic candidates or other therapeutic candidates we may seek to develop may encounter technical, enrollment or other issues that could cause our development costs to increase more than we expect, or we could expand our clinical trials to additional indications which could increase clinical trial expenses. Because successful development of our therapeutic candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our therapeutic candidates. Our ability to raise additional funds will depend on financial, economic and market conditions and other factors, over which we may have no or limited control. In addition, our ability to
52

obtain future funding when needed through equity financings, debt financings or strategic collaborations may be challenging in light of recent market and macroeconomic conditions, which have been particularly challenging for research and development life science companies.
If adequate funds are not available on commercially acceptable terms when needed, we may be forced to delay, reduce or terminate the development or commercialization of all or part of our research programs or clinical therapeutic candidates, or we may be unable to take advantage of future business opportunities. In addition, any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future therapeutic candidates.
Raising additional capital by issuing equity or debt securities may cause dilution to existing stockholders, and raising funds through lending and licensing or collaboration agreements may restrict our operations or require us to relinquish proprietary rights.
Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic collaborations and license and development agreements. We do not have any committed external source of funds and pursuant to the terms of the Merger Agreement, we cannot incur additional indebtedness or issue additional equity prior to the closing of, or other termination of, the Merger. To the extent that we raise additional capital by issuing equity securities, our existing stockholders’ ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Equity and debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures or declaring dividends.
The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants therein, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely affect our ability to conduct our business. Additionally, during 2020, 2021, and 2022, we borrowed a total of $200.0 million in seven separate tranches from Oxford under our loan and security agreement and its amendments, which we refer to collectively as the Amended 2020 Loan Agreement, which, as further described below, also has covenants restricting our ability to declare dividends or incur additional indebtedness.
If we raise additional capital through collaborations, strategic alliances or third-party licensing agreements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or therapeutics candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market therapeutic candidates that we would otherwise develop and market ourselves.
We may be adversely affected by the effects of inflation.
Inflation has the potential to adversely affect our liquidity, business, financial condition and results of operations by increasing our overall cost structure. The existence of inflation in the economy has resulted in, and may continue to result in, higher interest rates and capital costs, shipping costs, supply shortages, increased costs of labor, weakening exchange rates and other similar effects. Recently, inflation has increased throughout the U.S. economy. Inflation can adversely affect us by increasing the costs of clinical trials and research, the development of our therapeutic candidates, administration and other costs of doing business. We may experience increases in the prices of labor and other costs of doing business. In an inflationary environment, cost increases may outpace our expectations, causing us to use our cash and other liquid assets faster than forecasted. If this happens, we may need to raise additional capital to fund our operations, which may not be available in sufficient amounts or on reasonable terms, if at all, sooner than expected.
53

We maintain our cash and cash equivalents at financial institutions. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments.
Recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure have contributed to increased volatility and could materially and adversely affect our liquidity, our business and financial condition. The closures of Silicon Valley Bank and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation, or FDIC, created bank-specific and broader financial institution liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve, and the FDIC jointly released a statement that depositors at Silicon Valley Bank and Signature Bank would have access to their funds, even those in excess of the standard FDIC insurance limits, future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages. The failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition.
Risks Related to the Development, Clinical Testing and Commercialization of Our Therapeutic Candidates
Our therapeutic candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we, or our collaborators, are unable to advance our therapeutic candidates through clinical development, obtain marketing approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed.
We are early in our development efforts, with only three therapeutic candidates currently in clinical trials (INBRX-101, INBRX-109, and INBRX-106). We have no products on the market and our ability to achieve and sustain profitability depends on obtaining marketing approvals for and successfully commercializing our therapeutic candidates, either alone or with our collaborators. Before obtaining marketing approval for the commercial distribution of our therapeutic candidates, we, or our collaborators, must conduct extensive nonclinical tests and clinical trials to demonstrate sufficient safety and efficacy of our therapeutic candidates in patients. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful. We have previously experienced delays in our clinical trials due to enrollment delays and clinical holds. If we experience additional delays or fail to develop or again terminate development of a therapeutic candidate in our pipeline, we may not have the financial resources to continue development of, or to modify existing or to enter into new license or collaboration for, a therapeutic candidate. Other issues that may again delay or potentially prevent marketing approval of, or our ability to commercialize, our therapeutic candidates, include:
•negative or inconclusive results from our clinical trials, the clinical trials of our collaborators or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional nonclinical testing or clinical trials or abandon a program;
•therapeutic-related side effects experienced by participants in our clinical trials, the clinical trials of our collaborators or by individuals using drugs or therapeutic biologics similar to our therapeutic candidates;
•delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension, partial suspension or termination of a clinical trial once commenced;
•conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
•delays in enrolling research subjects or high drop-out rates of research subjects enrolled in clinical trials;
•unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or the manufacturing location(s) for a therapeutic candidate;
•inadequate supply or quality of therapeutic candidate clinical material or other raw materials or supplies necessary for the conduct of our clinical trials or the clinical trials of our collaborators;
•delay in the development or approval of companion diagnostic tests for our therapeutic candidates;
54

•failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;
•delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight for human clinical testing generally or with respect to our technology in particular; or
•varying interpretations of data by the FDA and similar foreign regulatory agencies.
The therapeutic candidates we or our collaborators pursue may not demonstrate the necessary safety or efficacy requirements for marketing approval. For instance, we independently decided to cease development of INBRX-105 as we determined, after evaluation of the totality of the data from the expansion cohorts, that the initial signal was not sufficiently validated to support the continuation of the program. Further, a clinical trial may be suspended, partially suspended or terminated by us, our collaborators, the IRBs overseeing such trials, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold or partial clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations, administrative actions or lack of adequate funding to continue the clinical trial. Clinical holds may be placed prior to a clinical trial even beginning, in order to address potential safety and risk concerns of regulatory authorities, and partial or complete clinical holds can be imposed at any time during a trial. For example, in early 2023, the Phase 2 trial of INBRX-109 was placed on partial clinical hold by the FDA, and we paused patient enrollment in the trial, following the occurrence of a grade 5 hepatotoxicity event and pre-defined stopping rules built into the protocol. The FDA lifted the hold in April 2023 after we amended the trial protocol to include additional screening criteria and to make other changes to address patients who may be at risk of significant hepatotoxicity. Furthermore, while we perform certain similar functions internally, we expect to rely on contract research organizations, or CROs, and clinical trial sites to ensure proper and timely conduct of our clinical trials and while we expect to enter into and have entered into agreements governing those CROs’ committed activities, we have limited influence over their actual performance.
If we or our collaborators experience delays in the completion of, or termination of, any clinical trial of our therapeutic candidates, the commercial prospects of our therapeutic candidates may be harmed, and our ability to generate product revenue or receive royalties from any of these therapeutic candidates may be delayed. Any delays in completing our clinical trials may increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. If we were to cancel the development of any of our therapeutic candidates, we may still be required to pay certain non-cancellable commitments to our CROs under the terms of our various CRO contracts. Our approach to protein engineering is novel and unproven, and as such, the cost, time needed to develop, and likelihood of success of our therapeutic candidates may be more uncertain than if we employed more established drug development approaches. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our therapeutic candidates.
The results of preclinical studies and early stage clinical trials of our therapeutic candidates may not be predictive of the results of later stage clinical trials. Initial results or observations in our ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.
Success in preclinical studies and early clinical trials does not ensure that later and pivotal clinical trials will generate the same results, or otherwise provide adequate data to demonstrate the safety and efficacy of a therapeutic candidate. Frequently, therapeutic candidates that have shown promising results in preclinical studies or early clinical trials have subsequently suffered significant setbacks in later or pivotal clinical trials. The initiation of registration-enabling trials for INBRX-106 or for any of our other therapeutic candidates, is and would be predicated on positive Phase 1 trial results and acceptance of our IND amendment by the FDA. Our therapeutic candidates in clinical trials, including INBRX-101, INBRX-109, and INBRX-106, may ultimately fail to show the desired safety and efficacy in clinical trials despite having progressed through preclinical studies and despite any initial observations of single agent activity, stable disease or partial responses. As noted above, we ceased development of INBRX-105 after determining that the initial signal was not sufficiently validated to support the continuation of the
55

program even though we observed certain partial and complete responses. There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development, including development in registration-enabling trials, of any of our therapeutic candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies or trials, and any of these setbacks in our clinical development could have a material adverse effect on our business and operating results.
Our therapeutic candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
Undesirable side effects caused by our therapeutic candidates have caused and could again cause us, our collaborators or regulatory authorities, to interrupt, delay or halt clinical trials. These circumstances could result in a more restrictive label or the delay or denial of marketing approval by the FDA or other regulatory authorities. Results of our clinical trials or the clinical trials of our collaborators could reveal a high and unacceptable severity of adverse side effects and it is possible that patients enrolled in these clinical trials could respond in unexpected ways. For instance, INBRX-109 and INBRX-106 are therapeutic candidates targeting oncology indications that are clinically evaluated in very sick populations. Certain trial participants, including participants evaluated in our trials for INBRX-105 and INBRX-109, have in the past and others may in the future, experience side effects or serious AEs that could be related to one of our therapeutic candidates. INBRX-101 is a therapeutic candidate focused on AATD, a rare disease with a relatively small patient population. It may be difficult to establish safety and efficacy in these types of patient populations. Further, we intend to develop certain of our therapeutic candidates in combination with one or more cancer therapies. This combination may have additional side effects that were not present in preclinical studies or clinical trials of our therapeutic candidates conducted as a monotherapy or in combination with other cancer therapies. The uncertainty resulting from the use of our therapeutic candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials.
These side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Further, clinical trials by their nature utilize a sample of the potential patient population. Rare and severe side effects of our therapeutic candidates may only be uncovered with a significantly larger number of patients exposed to our therapeutic candidates.
In the event that any of our therapeutic candidates receives marketing approval and we, our collaborators or others identify undesirable side effects caused by our product (or potentially other therapeutics with similar mechanisms of action), any of the following AEs could occur:
•regulatory authorities may withdraw their approval of the product;
•additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component of the product;
•regulatory authorities may require the addition of safety-related labeling statements, such as a “black box” warning or a contraindication;
•we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients or to implement other aspects of a REMS such as a restricted distribution program or educational programs for prescribers;
•we could be sued and held liable for harm caused to patients;
•the product may become less competitive; and
•our reputation may suffer.
In addition, adverse side effects caused by any therapeutics that may be similar in nature to our therapeutic candidates could delay or prevent marketing approval of our therapeutic candidates, limit the commercial profile of an approved label for our therapeutic candidates, or result in significant negative consequences for our therapeutic candidates following marketing approval.
Any of the above described events could prevent us from achieving or maintaining market acceptance of our therapeutic candidates, if approved, and could delay, impede and/or substantially increase the costs of commercializing our therapeutic candidates thus significantly impacting our ability to successfully commercialize
56

our therapeutic candidates and generate revenue. Any of the above described occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.
We expect to develop certain of our therapeutic candidates in combination with other therapies, and safety or supply issues with combination use products may delay or prevent development and approval of our therapeutic candidates.
We intend to develop certain of our therapeutic candidates in combination with one or more approved or investigational cancer therapies. Even if any therapeutic candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our therapeutic candidates are replaced as the standard of care for the indications we choose for any of our therapeutic candidates, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially.
We also may evaluate our therapeutic candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell any therapeutic candidate we develop in combination with an unapproved cancer therapy if that unapproved cancer therapy does not ultimately obtain marketing approval. In addition, unapproved cancer therapies face the same risks described with respect to our therapeutic candidates currently in development and clinical trials, including the potential for serious AEs, delay in their clinical trials and lack of FDA approval.
If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination our therapeutic candidates, we may be unable to obtain approval of or market any such therapeutic candidate.
If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.
We may not be able to initiate or continue clinical trials for our therapeutic candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Should any competitors have ongoing clinical trials for therapeutic candidates treating the same indications as our therapeutic candidates, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ therapeutic candidates.
Patient enrollment is affected by other factors including:
•the severity of the disease under investigation;
•the patient eligibility criteria for the study in question;
•the perceived risks and benefits of the therapeutic candidate under study;
•our payments for conducting clinical trials;
•the patient referral practices of physicians; and
•the proximity and availability of clinical trial sites for prospective patients.
Our inability to enroll a sufficient number of patients for any of our clinical trials could result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our therapeutic candidates and in delays to commercially launching our therapeutic candidates, if approved, which would materially harm our business.
57

If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our therapeutic candidates may be delayed, and our business may be harmed.
We have provided, and will continue to provide, a number of timing estimates regarding the initiation of clinical trials and clinical development milestones, and the expected availability of data resulting from these trials for certain of our therapeutic candidates. We expect to continue to estimate the timing of these types of development milestones and our expected timing for the accomplishment of various other scientific, clinical, regulatory and other product development objectives. From time to time, we may publicly announce the expected timing of some of these events and we have had to adjust our previously announced timing for certain of our therapeutic candidates. The achievement of many of these milestones and events may be outside of our control. All of these timing estimations are based on a variety of assumptions we make, which may cause the actual timing of these events to differ from the timing we expect, including:
•our available capital resources and our ability to obtain additional funding as needed;
•the rate of progress, costs and results of our clinical trials and research and development activities;
•our ability to identify and enroll patients who meet clinical trial eligibility criteria;
•our receipt of clinical trial clearances or approvals by the FDA, EMA and other regulatory authorities and the timing of these approvals;
•our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our therapeutic candidates;
•the efforts of our collaborators and licensees with respect to the commercialization of our therapeutics;
•the securing of, costs related to, and timing issues associated with, manufacturing our therapeutic candidates and, if any of our therapeutic candidates are approved, associated with sales and marketing activities and the commercial manufacture of our therapeutic candidates; and
•circumstances arising from or relating to pandemics, regional conflicts, sanctions, geopolitical events, natural disasters or extreme weather events, including potential effects on the global supply chain, our manufacturers and the availability of raw materials needed for the research and development of our therapeutic candidates.
If we fail to achieve announced milestones in the timeframes we expect, the future marketing approval and commercialization of any of our therapeutic candidates may be delayed, and our business, financial condition, results of operations, and prospects may be harmed and our stock price may decline.
Initial, interim, topline and preliminary data from our clinical trials that we may announce, observe or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we publish initial, interim, topline or preliminary data from our clinical trials. Certain of our clinical trials are also conducted as “open-label” trials. An open-label trial is one where both the study participant and investigator know whether the participant is receiving the therapeutic candidate and where we (as the sponsor) have access to trial data on an ongoing basis during the trial. These initial, interim, topline and preliminary data from our clinical trials that we may publish from time to time or that we may observe on an ongoing basis in our open-label trials may change as more data become available and, accordingly, they are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues, more participant data becomes available and we issue our final clinical trial report. Initial, interim, topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim, topline and preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the interim data could significantly harm our business prospects.
The market opportunities for any current or future therapeutic candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.
Cancer therapies are sometimes characterized as first-, second-, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually
58

chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to initially seek approval of certain of our therapeutic candidates as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that therapeutic candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.
The number of patients who have the cancers we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future therapeutic candidates may be limited, if and when approved. Even if we obtain significant market share for any therapeutic candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy.
We rely on third parties to conduct portions of our clinical trials and certain of our nonclinical studies. If these third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.
While we expect to continue our current clinical trials and expect to initiate clinical trials in the near term for other therapeutic candidates, we do not independently conduct clinical trials. As such, while we perform certain functions internally, we currently rely on third-party CROs, clinical data management organizations and consultants to help us design, conduct, supervise and monitor clinical trials of our therapeutic candidates. As a result, we will have less control over the timing, quality and other aspects of our clinical trials than we would have had we conducted them on our own. There is a limited number of third party service providers that specialize or have the expertise required to achieve our business objectives. If any of our relationships with these third-party CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative CROs or investigators or to do so on commercially reasonable terms. Further, these investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our nonclinical studies or clinical trials. If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy the legal and regulatory requirements for the conduct of nonclinical studies or clinical trials or meet expected deadlines for any reason, our clinical development programs could be delayed and otherwise adversely affected.
In all events, we will be responsible for ensuring that each of our nonclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the relevant study or trial. The FDA requires nonclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with GCPs including practices and requirements for designing, conducting, recording and reporting the results of nonclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects.
We are currently party to license agreements with Elpiscience and Transcenta for the development and, if approved, commercialization of INBRX-106 and INBRX-109, respectively. We may in the future enter into additional collaborations with third parties to develop our therapeutic candidates. If these collaborations are not successful, our business could be harmed.
We are currently party to a license agreement with Elpiscience, pursuant to which we granted Elpiscience exclusive licenses for the development and, if approved, commercialization of INBRX-106 in China, Hong Kong, Macau and
59

Taiwan. We are also party to the Transcenta License Agreement. We may enter into additional collaborations with third parties in the future. Any collaborations that we are party to may pose several risks, including the following:
•collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
•collaborators may not perform their obligations as expected;
•as occurred with our trials for INBRX-105, the clinical trials conducted as part of these collaborations may not be successful;
•collaborators may not pursue development and commercialization of any therapeutic candidates that achieve marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results;
•changes in the collaborators’ strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities;
•collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a therapeutic candidate, repeat or conduct new clinical trials or require a new formulation of a therapeutic candidate for clinical testing;
•we may not have access to, or may be restricted from disclosing, certain information regarding therapeutic candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such therapeutic candidates;
•collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our therapeutic candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
•therapeutic candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own therapeutic candidates or products, which may cause collaborators to cease to devote, or limit, resources to the commercialization of our therapeutic candidates;
•a collaborator with marketing and distribution rights to one or more of our therapeutic candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of any such therapeutic candidate;
•collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;
•disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;
•collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
•collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable therapeutic candidates.
In addition, we may have disagreements with these collaborators, including disagreements over proprietary rights, collaborator performance, contract interpretation or the preferred course of development of any therapeutic candidates. Any disagreement we may have with our collaborators, may cause delays or termination of the research, development or commercialization of our therapeutic candidates pursuant to the applicable agreement, may lead to additional responsibilities for us with respect to our therapeutic candidates or may result in litigation or arbitration, any of which would be time-consuming and expensive and which would likely divert the attention of our management from our core research and development activities. These types of disputes could materially harm our financial condition and our business.
The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production. If we or any of our third party manufacturers encounter such difficulties, or otherwise fail to comply
60

with their contractual obligations, the development or commercialization of our therapeutic candidates could be delayed or stopped.
While we have found that our therapeutic candidates can be readily manufactured at high yields with established processes used to produce therapeutic proteins, the manufacture of biotechnology products is generally complex and requires significant expertise and capital investment. We and our contract manufacturers must comply with cGMP regulations and guidelines for clinical trial product manufacture and for commercial product manufacture. Manufacturers of biotechnology products often encounter difficulties in production, particularly in scaling up, addressing product quality, product comparability, validating production processes and mitigating potential sources of contamination. These problems include difficulties with raw material procurement, production costs and yields, quality control, product quality, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our therapeutics or in the manufacturing facilities in which our therapeutics are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.
We cannot assure you that manufacturing problems, including supply chain disruptions of any of our therapeutic candidates or products will not occur in the future. Any delay or interruption in the supply of preclinical or clinical trial supplies or supply chain disruptions could delay the completion of these trials, increase the costs associated with maintaining these trial programs and, depending upon the period of delay, require us to commence new trials at additional expense or terminate trials completely.
If we were to experience an unexpected loss of supply of, or if any supplier were unable to meet our demand for any of our therapeutic candidates or future approved products we seek to commercialize, if any, we could experience delays in our research or planned clinical studies or be forced to stop our development or commercialization efforts. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. Moreover, our suppliers are often subject to strict manufacturing requirements and rigorous testing requirements, which could limit or delay production. The long transition periods needed to switch manufacturers and suppliers, if necessary, would significantly delay our clinical studies and the commercialization of our therapeutics, if approved, which would materially adversely affect our business, prospects, financial condition and results of operation.
We rely on third parties to supply and manufacture our therapeutic candidates, and we expect to continue to rely on third parties to manufacture and supply our therapeutics, if approved. The development of therapeutic candidates and the commercialization of any therapeutic candidates, if approved, could be stopped, delayed or made less profitable if any of these third parties fail to provide us with sufficient quantities of therapeutic candidates or therapeutics, fail to do so at acceptable quality levels or prices, or fail to maintain or achieve satisfactory regulatory compliance.
We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to develop and manufacture our therapeutic candidates for use in the conduct of our trials or for commercial supply, if our therapeutics are approved. Instead, we rely on, and expect to continue to rely on third-party providers to manufacture the supplies for our preclinical studies and clinical trials. We currently rely on a limited number of third-party contract manufacturers for our required raw materials, antibodies, and other biologics for our preclinical research and clinical trials, as well as for the manufacture of supplies for our therapeutic candidates. To the extent any of our manufacturing partners are unable to fulfill these obligations in a timely manner, our clinical trials may be delayed, and our business may be adversely affected. In general, reliance on third party providers may expose us to more risk than if we were to manufacture our therapeutic candidates ourselves. We do not control the operational processes of the contract manufacturing organizations with whom we contract and are dependent on these third parties for the production of our therapeutic candidates in accordance with relevant regulations (such as cGMP), which include, among other things, quality control and the maintenance of records and documentation.
61

Our third-party manufacturers may be unable to successfully scale up manufacturing of our therapeutic candidates in sufficient quality and quantity, which would delay or prevent us from developing our therapeutic candidates and commercializing any approved therapeutic candidates.
Our manufacturing partners may be unable to successfully increase the manufacturing capacity for our therapeutic candidates in a timely or cost-effective manner, or at all, as needed for our development efforts or, if our therapeutic candidates are approved, our commercialization efforts. Quality issues may also arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our therapeutic candidates in sufficient quality and quantity, the development, testing, and clinical trials of our therapeutic candidates may be delayed or infeasible, and marketing approval or future commercial launch of any resulting therapeutic may be delayed or not obtained, which could significantly harm our business.
Failure to successfully identify, develop and commercialize additional therapeutics or therapeutic candidates could impair our ability to grow.
Although a substantial amount of our efforts will focus on the continued preclinical and clinical testing and potential approval of our therapeutic candidates in our current pipeline, we continue to innovate and expect to expand our portfolio. Because we have limited financial and managerial resources, research programs to identify therapeutic candidates may require substantial additional technical, financial and human resources, whether or not any new potential therapeutic candidates are ultimately identified. Our success may depend in part upon our ability to identify, select and develop promising therapeutic candidates and therapeutics. We may expend resources and ultimately fail to discover and generate additional therapeutic candidates suitable for further development. All therapeutic candidates are prone to risks of failure typical of biotechnology product development, including the possibility that a therapeutic candidate may not be suitable for clinical development as a result of its harmful side effects, limited efficacy or other characteristics indicating that it is unlikely to receive approval by the FDA, the EMA and other comparable foreign regulatory authorities or to achieve market acceptance. If we do not successfully develop and commercialize new therapeutic candidates we have identified and explored, our business, prospects, financial condition and results of operations could be adversely affected.
Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.
We are exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of biotechnology treatments of any therapeutic candidates for which we or our collaborators may conduct clinical trials. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing any approved products, these claims could result in an FDA investigation of the safety and effectiveness of our future commercial products, our manufacturing processes and facilities (or the manufacturing processes and facilities of our third-party manufacturers) or our marketing programs, a recall of our products or more serious enforcement action, limitations on the approved indications for which the product may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management’s time and our resources, substantial monetary awards to clinical trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by potential product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.
If our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such therapeutic candidates.
We currently have no sales, marketing or distribution capabilities. While we have marketing and commercialization agreements in place for certain territories with our collaborators, we will still need to expand our own internal sales, marketing and distribution capabilities to commercialize our approved therapeutic candidates, if any, in the United States and other remaining worldwide territories, or will need to enter into collaborations with third parties to
62

perform these services. Any internal effort would be expensive and time-consuming, and we would need to commit significant financial and managerial resources to develop an internal marketing and sales force with technical expertise and the related supporting distribution, administration and compliance capabilities. If we were to rely on additional third parties with these capabilities to market our future therapeutics or were to decide to co-promote products with any of our current or future collaborators, we would need to establish and maintain or revise existing marketing and distribution arrangements with these partners, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. Any revenue we receive in connection with third-party license, marketing or distribution arrangements, and license agreements with our licensing partners in China, will depend upon the efforts of these third parties, and there can be no assurance these third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.
The future commercial success of our therapeutic candidates will depend on the degree of market acceptance of our therapeutic candidates among physicians, patients, healthcare payors and the medical community.
Our therapeutic candidates are still in clinical development and our emerging pipeline is still in preclinical development; we may never have an approved product that is commercially successful. Due to the inherent risk in the development of biopharmaceutical products, it is probable that not all or none of the therapeutic candidates in our pipeline, including any that are or may be licensed to third parties, will successfully complete development and be commercialized. Furthermore, even when available on the market, our products may not achieve an adequate level of acceptance by physicians, patients and the medical community, and we may not become profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful, which would prevent us from generating significant revenue or becoming profitable. Market acceptance of any approved products by physicians, patients and healthcare payors will depend on a number of factors, many of which are beyond our control, including, but not limited to:
•changes in the standard of care for the targeted indications for any approved product;
•wording in the FDA- or EMA-approved prescribing information;
•sales, marketing and distribution support;
•potential product liability claims;
•acceptance by physicians, patients and healthcare payors of each product as safe, effective and cost-effective;
•relative convenience, ease of use, ease of administration and other perceived advantages over alternative products;
•prevalence and severity of AEs or publicity;
•limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use;
•the cost of treatment with our therapeutics in relation to alternative treatments;
•the extent to which products are approved for inclusion and adequately reimbursed on formularies of hospitals and third-party payors, including managed care organizations; and
•whether our products are designated in the label, under physician treatment guidelines or under reimbursement guidelines as a first, second, third or last line therapy.
Risks Related to Our Organization and Operations
We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the therapeutic candidates we develop, our commercial opportunities will be negatively impacted.
The life sciences industry is highly competitive. We are currently developing therapeutic candidates that will compete, if approved, with other products and therapies that currently exist or are being developed. Our primary competitors fall into the following groups:
•Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Alligator Bioscience AB, Crescendo Biologics Ltd., GlaxoSmithKline plc, IGM Biosciences,
63

Inc., Lava Therapeutics N.V., Molecular Partners AG, Pieris Pharmaceuticals, Inc., Precirix, and Sanofi S.A.;
•Antibody drug discovery companies that may compete with us in the search for novel therapeutic antibody targets, including Regeneron Pharmaceuticals, Inc., Adimab LLC, Genmab A/S, Macrogenics, Inc., Merus N.V., MorphoSys AG, Numab Therapeutics AG, Amgen, Inc., Xencor Inc., and Zymeworks Inc.; and
•Companies developing therapeutics designed to treat AATD, including CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, and Mereo BioPharma Group plc.
Our competitors also include other large pharmaceutical and biotechnology companies who may be developing therapeutic candidates with mechanisms similar to or targeting the same indications as our therapeutic candidates.
Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the therapeutic candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the therapeutic candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.
Smaller and other early stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our therapeutic candidates obsolete, less competitive or not economical.
Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.
Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Mark P. Lappe, our Chief Executive Officer, Brendan P. Eckelman, Ph.D., our Chief Scientific Officer, and Kelly D. Deck, our Chief Financial Officer, who are all employed at will and for whom we do not have “key man” insurance coverage. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and technologies and the specialized
64

nature of the marketing approval process. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations (many of whom have substantially greater financial resources than us), and we might not be able to attract or retain these key employees on conditions that are economically acceptable. Our inability to attract and retain these key employees could prevent us from achieving our objectives and implementing our business strategy, which could have a material adverse effect on our business and prospects.
We have a significant amount of debt which may affect our ability to operate our business and secure additional financing in the future. If we fail to comply with the terms of the Amended 2020 Loan Agreement, our business, prospects and results of operations could be materially and adversely affected.
During 2020, 2021, and 2022, we borrowed a total of $200.0 million in seven separate tranches from Oxford, under the Amended 2020 Loan Agreement.
Our obligations under the Amended 2020 Loan Agreement are secured by substantially all of our assets. The Amended 2020 Loan Agreement requires us, and any debt arrangements or instruments we may enter into in the future may require us, to comply with various covenants that limit our ability to, among other things:
•dispose of assets;
•complete mergers or acquisitions;
•incur or guarantee indebtedness;
•sell or encumber certain assets;
•pay dividends or make other distributions to holders of our capital stock, including by way of certain stock buybacks;
•make specified investments;
•engage in different lines of business;
•change certain key management personnel; and
•engage in certain transactions with our affiliates.
These covenants may make it difficult to operate our business. A failure by us to comply with the covenants could result in an event of default, which could adversely affect our ability to respond to changes in our business and manage our operations. Upon the occurrence of an event of default, including the occurrence of a material adverse change, the lender could elect to declare all amounts outstanding to be due and payable and exercise other remedies. If the indebtedness were to be accelerated, our future financial condition could be materially adversely affected.
We may incur additional indebtedness in the future. The instruments governing such indebtedness could contain provisions that are as, or more, restrictive than our existing debt instruments. Our obligations pursuant to the Amended 2020 Loan Agreement are secured by substantially all of our assets, including our intellectual property. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against this collateral granted to them to secure such indebtedness or force us into bankruptcy or liquidation. Further, if our business is subject to liquidation, the right to repayment of Oxford and any other holders of indebtedness would be senior to the rights of the holders of our common stock to receive any proceeds from the liquidation.
Our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors may engage in misconduct or other improper activities, including non-compliance with governmental and regulatory bodies.
We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, contract research organizations, consultants or vendors. Misconduct by these parties could include intentional failures to comply with state and federal securities laws, FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish for our therapeutic candidates, comply with federal and state data privacy, security, fraud and abuse, and other healthcare laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud,
65

kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, monetary damages, fines, disgorgement, imprisonment, loss of eligibility to obtain marketing approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting requirements if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.
Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims. As noted in Item 3 of this Annual Report, we and Dr. Eckelman are party to litigation asserting claims against us for misappropriation of trade secrets related to Dr. Eckelman’s service as an expert witness. If we fail in defending against these and any other such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.
Our insurance may not provide adequate levels of coverage against claims which may adversely affect our financial condition.
We maintain insurance that we believe is adequate for businesses of our size and type. However, there are types of losses that we believe are not economically reasonable to insure or that cannot be insured against. For instance, because directors and officers, or D&O, liability insurance has become cost prohibitive with high retentions providing minimal coverage, we have not renewed our D&O policy.
It is possible that we may be subject to securities litigation in the future, including potential class action or stockholder derivative actions. Our indemnification agreements with our directors and certain officers, as well as Delaware General Corporation Law, may require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Without D&O insurance, the amounts we would pay to defend any such litigation or indemnify our officers and directors should they be subject to legal action based on their service to us could have a material adverse effect on our financial condition, results of operations and liquidity.
As we expand our development and regulatory capabilities, we may encounter difficulties in managing our growth, which could disrupt our operations.
We may experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development and regulatory affairs, as well as sales and marketing to the extent any of our therapeutic candidates approach receipt of marketing authorization. To manage our future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to
66

effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.
We may not be able to integrate efficiently or achieve the expected benefits of any acquisitions of complementary businesses, therapeutic candidates or technologies.
Should we in the future acquire any complementary business, therapeutic candidates or technologies, our ability to integrate and manage acquired businesses, therapeutic candidates or technologies effectively will depend upon a number of factors including the size of the acquired business, the complexity of any therapeutic candidate or technology and the resulting difficulty of integrating the acquired business’s operations, if any. Our relationship with current employees or employees of any acquired business may become impaired. We may also be subject to unexpected claims and liabilities arising from such acquisitions. These claims and liabilities could be costly to defend, could be material to our financial condition and might exceed either the limitations of any applicable indemnification provisions or the financial resources of the indemnifying parties. There can also be no assurance that we will be able to assess ongoing profitability and identify all actual or potential liabilities of a business, therapeutic candidate or technology prior to its acquisition. If we acquire businesses, therapeutic candidates or technologies that result in assuming unforeseen liabilities in respect of which it has not obtained contractual protections or for which protection is not available, this could materially adversely affect our business, prospects, financial condition and results of operations.
Our business may be adversely affected as a result of major computer system failures.
Any of the internal computer systems belonging to us or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service vendors’ operations could result in a material disruption of our development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our or our partners’ or collaborators’ marketing approval efforts and significantly increase our costs in order to recover or reproduce the lost data. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability, our development programs, reputation and competitive position may be adversely affected and the further development of our therapeutic candidates may be delayed. Furthermore, we may incur additional costs to remedy the damage caused by these disruptions or security breaches.
Cybersecurity breaches could expose us to material liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business.
We maintain sensitive company data on our computer networks and third-party cloud services, including our intellectual property and proprietary business information. We face a number of threats to our networks from unauthorized access, accidental acts or omissions that expose vulnerabilities, security breaches and other system disruptions. Our third-party partners, including CROs and providers of data hosting or cloud services, as well as suppliers, distributors, alliances, and other third-party service providers, face similar risks, which could affect us directly or indirectly.
We are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies. A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack. Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public.
67

Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, “hacktivists” and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies could heighten these and other operational risks, and any failure by cloud technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption, or loss of confidential or propriety information.
The United States federal and all state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the collection, use, and dissemination of data. Some of these federal, state and foreign government requirements include obligations of companies to notify individuals and others of security breaches involving certain personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and follow-up actions related to a security breach could impact our reputation, prompt regulatory scrutiny and enforcement, cause us to incur significant costs, including legal expenses, or cause us to incur remediation costs that could, under such circumstances, materially harm our business.
Any such security breach may materially compromise information stored on our networks and may result in significant data losses or theft of our intellectual property or proprietary business information, it may also subject us to significant fines, penalties or liabilities for any noncompliance with certain privacy and security laws. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption of breach of our systems.
While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. Further, a data breach could result in regulatory investigations and negative publicity which could damage our reputation and have an adverse effect on our business, financial condition or results of operations.
Our current operations are concentrated in one location, and we or the third parties upon whom we depend on may be adversely affected by earthquakes, medical epidemics or pandemics, or other natural disasters.
Our current operations are located in our facilities in La Jolla, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or man-made accidents or incidents that results in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates or interruption of our business operations. Earthquakes, medical epidemics or pandemics or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. Certain of these natural disasters, including fires and severe weather events may be exacerbated by the effects of climate change. If a natural disaster, pandemic power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or if similar events occurred elsewhere effecting the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our
68

business for a substantial period of time. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material and adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.
Risks Related to Intellectual Property
If we are not able to obtain and enforce patent protection for our technologies or therapeutic candidates, development and commercialization of our therapeutic candidates may be adversely affected.
Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, patents and patent applications protecting, or seeking to protect, our therapeutic candidates and methods for treating patients using our therapeutic candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. Our patent estate includes various issued United States patents, United States pending non-provisional patent applications, United States pending provisional applications, pending PCT applications, issued foreign patents, and foreign patent applications currently pending in various foreign jurisdictions.
While we will endeavor to protect our therapeutic candidates with intellectual property rights such as patents, as appropriate, the process of obtaining, maintaining, and enforcing patents is time-consuming, expensive and sometimes unpredictable, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to any patents we may license to or from third parties. Therefore, such patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.
Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to provide meaningful protection from any competitors. Our competitors may be able to circumvent our patents by developing similar or alternative therapeutic candidates in a non-infringing manner. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and therapeutic candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our business.
The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which non-compliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology patents. As such, we do not know the degree of future protection that we will have on our proprietary therapeutics and technology.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has in recent years been the subject of much litigation. Once granted,
69

patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether, e.g., due to a determination that the claims are invalid or unenforceable. In addition, there can be no assurance that:
•others will not or will not be able to legally make, use or sell products or therapeutic candidates that are the same as or similar to our therapeutic candidates despite the claims of the patents that we own or license;
•we or our licensors, or our collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license;
•we or our licensors, or our collaborators are the first to file patent applications covering certain aspects of our inventions;
•others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
•any issued patents that we own or have licensed will provide us with any competitive advantage; or
•the patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects.
As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
We may not be able to protect our intellectual property rights throughout the world.
Obtaining valid and enforceable issued or granted patents covering our therapeutic candidates in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors or third parties may use our technology to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Third-party or competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biotechnology. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, could provoke third parties to assert claims against us, and, whether or not successful, could result in substantial cost and divert our efforts and attention from other aspects of our business.
We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the PCT is usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, Europe, Japan, Australia and Canada and, depending on the individual case, also in one, several or all of Brazil, China, India, Israel, Mexico, New Zealand, Russia or Eurasian Patent Organization, Singapore, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate or technology.
When a patent is granted by a regional patent office (e.g., Europe or Eurasia), the patent must be validated in individual countries in order to be in effect in those countries. We may decide not to validate regional patents in every available country or at all in any country in the region. In addition, we may decide to abandon national and regional patent applications before or after grant.
70

The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or any licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.
Changes in patent laws could diminish the value of patents in general, thereby impairing our ability to protect our products.
Changes in either the patent laws or interpretation of the patent laws in the United States and other jurisdictions in which we file patent applications could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. In contrast, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, assuming that other requirements for patentability were met. Furthermore, United States patent law under the America Invents Act allows for post issuance challenges to United States patents, including ex parte reexaminations, inter parte reviews and post grant oppositions. If our United States patents are challenged using such procedures, we may not prevail, possibly resulting in altered or diminished claim scope or loss of patent rights altogether. Similarly, some countries, notably members of the EU, also have post grant opposition proceedings that can result in changes in scope and/or cancellation of patent claims.
The United States Supreme Court has also ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
As another example, the complexity and uncertainty of European patent laws have increased in recent years. In Europe, a new unitary patent system was launched on June 1, 2023, which significantly impacted European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications now have the option, upon grant of a patent, of becoming a Unitary Patent which are subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
The USPTO, the European Patent Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. For example, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO, the European Patent Office and foreign patent agencies in several stages over the lifetime of the patent. Some
71

jurisdictions also require payment of annuity fees during pendency of a patent application. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents and patent applications covering our therapeutic candidates, our competitors might better be able to enter the market, which would have an adverse effect on our business.
We may be required to reduce the scope of our intellectual property due to intellectual property claims included in the patents or patent applications of others.
Third parties may have filed, and may in the future file, patent applications covering technology similar to ours. It is also possible that we have failed to identify relevant third-party patents or applications. For example, United States applications filed before November 29, 2000 and certain United States applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with this earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our therapeutic candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover any future approved products or our therapeutic candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies, if possible, or block us from practicing certain aspects of our technology if we are unable to successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned.
If another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed prior to March 16, 2013, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. Similarly, if another party has filed a United States patent application on inventions similar to ours that claims priority to an application filed after March 16, 2013, we may have to participate in a derivation proceeding to determine whether that party derived the claimed invention from an inventor listed on our application and then filed the third-party application without authorization. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our United States patent position with respect to such inventions. In addition, an unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Further, changes enacted on March 15, 2013 to the United States patent laws under the America Invents Act resulted in the United States changing from a “first to invent” country to a “first to file” country. As a result, we may lose the ability to obtain a patent if a third party files with the USPTO first and could become involved in proceedings before the USPTO to resolve disputes related to inventorship. We may also become involved in similar proceedings in other jurisdictions.
We or our licensors, licensees or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our therapeutic candidates, or put our patents and other proprietary rights at risk.
Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. We or our licensors, licensees or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries including patent infringement lawsuits, interferences, derivations, oppositions and inter partes review proceedings before the USPTO, and corresponding foreign patent offices.
72

Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future therapeutic candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If we, our licensees or our licensors, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we, our licensees or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give any competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, the holders of any such patents may be able to block us, our licensees or our collaborators from marketing therapeutic candidates based on our technology until such patents expire, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.
In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management’s attention. Competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.
If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our technology. This loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing our patents or other intellectual property rights.
If we fail to comply with our obligations under the agreements pursuant to which we license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose the rights to intellectual property licensed to us.
We are a party to license agreements under which we are granted rights to third-party intellectual property, and we expect that we may need to enter into additional license agreements in the future. License agreements may impose various development obligations, payment of royalties and fees based on achieving certain milestones, as well as other obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license. The termination of any license agreements or failure to adequately protect such license agreements could prevent us from commercializing therapeutic candidates covered by the licensed intellectual property or otherwise adversely affect our business. Our license agreements may involve sublicenses from third parties which are not the original licensor of the intellectual property at issue. Under these agreements, we would
73

rely on our licensor to comply with its obligations under the primary license agreements, where we may have no relationship with the original licensor of such rights. If the licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate the sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property and, in the case of a sublicense, if we were not able to secure our own direct license with the owner of the relevant rights, which we may not be able to do at a reasonable cost or on reasonable terms, it may adversely affect our ability to continue to develop and commercialize any of our therapeutic candidates incorporating the relevant intellectual property.
Disputes may arise regarding intellectual property subject to a licensing agreement, including:
•the scope of rights granted under the license agreement and other interpretation related issues;
•the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
•the sublicensing of patent and other rights under any collaboration relationships we might enter into in the future;
•our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
•the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborator; and
•the priority of invention of patented technology.
If disputes over intellectual property that we have licensed prevent or impair our ability to maintain any licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates.
Our intellectual property agreements with our licensors, licensees, collaborators and third parties may be subject to disagreements over contract interpretation, which could narrow the scope of, or result in termination of, our rights to the relevant intellectual property or technology or increase our financial or other obligations to such third parties, or reduce the financial or other obligations our licensees have to us.
Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. For example, we may disagree with our licensors, licensees or collaborators regarding whether, when and to what extent various obligations under these agreements apply to certain of our/their therapeutic candidates and products, including various payment, development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement. In either case, such disagreement could have a material adverse effect on our business, financial condition, results of operations and prospects.
In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
Litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable, generally expensive, time consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on
74

the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.
We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material and adverse effect on our ability to compete in the marketplace.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
In addition to seeking patent protection for certain aspects of our therapeutic candidates, we also consider trade secrets, including confidential and unpatented know-how important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. Trade secrets and confidential know-how are difficult to maintain as confidential. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, partners, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
Moreover, even if relevant agreements are entered into, despite these efforts, any of these parties may breach the agreements and unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. Moreover, a competitor who independently develops substantially equivalent proprietary information may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets or confidential know-how. Under certain circumstances, we may also decide to publish some know-how to attempt to prevent others from obtaining patent rights covering such know-how. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.
We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees’ or consultants’ former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.
Many of our employees were previously employed at universities or biotechnology companies, including potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from
75

commercializing, our therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Our trademarks may not be approved by one or more governmental trademark offices or may not be approved for use on our products by regulatory agencies, such as the FDA. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.
If our patent terms expire before or soon after our therapeutic candidates are approved, or if manufacturers of biosimilar drugs successfully challenge our patents, our business may be materially harmed.
Patents have a limited duration. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our therapeutic candidates, their manufacture, or use are obtained, once the patent life has expired, we may be open to competition from competitive medications, including biosimilar medications.
Depending upon the timing, duration and conditions of FDA marketing approval of our therapeutic candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, and similar legislation in the EU. The Hatch-Waxman Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner than we expect. Also, the scope of our right to exclude during any patent term extension period may be limited or may not cover a competitor’s product or product use. As a result, our revenue from applicable therapeutic candidates, if approved, could be reduced, possibly materially.
Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our patents and patent applications may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.
Manufacturers of biosimilar drugs may challenge the scope, validity, or enforceability of our patents in court or before a patent office, and we may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any potential sales of that product. Upon the expiration of our issued patents or patents that may issue from our pending patent applications, we will not be able to assert such patent rights against potential competitors and our business, financial condition, results of operations, and prospects may be adversely affected.
76

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business nor permit us to maintain our competitive advantage. The following examples are illustrative:
•Others may be able to make therapeutic candidates that are the same as or similar to our therapeutic candidates but that are not covered by the claims of the patents that we own or may have exclusively licensed.
•Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.
•Third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.
•We may not develop additional technologies that are patentable.
Risks Related to Government Regulation
We or our collaborators may be unable to obtain marketing approval for any product that we or a collaborator may develop and the marketing approval processes of the FDA and other comparable regulatory authorities outside the United States are lengthy, time-consuming and inherently unpredictable.
Any product that we or our collaborators may attempt to develop, manufacture or market in the United States will be subject to extensive regulation by the FDA, including regulations relating to development, nonclinical testing, performance of clinical trials, manufacturing and post-approval commercialization. Nonclinical testing, clinical trials and manufacturing, among other activities, will be subjected to an extensive review process before a new therapeutic product may be sold in the United States. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. The time required to obtain FDA approval, and any other required approvals for biological products is unpredictable but typically requires several years and may never be obtained.
Any product that we or our collaborators may wish to develop, manufacture or market in countries other than the United States will also be subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing, pricing and third-party reimbursement among other things in such countries. The foreign marketing approval process includes all of the risks and uncertainties associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in such foreign jurisdictions.
In particular, obtaining marketing approval for biological products requires the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process, and in many cases the inspection of manufacturing, processing, and packaging facilities by the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use, or there may be deficiencies in cGMP compliance by us or by our contract development and manufacturing organizations, or CDMOs, that could result in the candidate not being approved. Moreover, we have not obtained marketing approval for any therapeutic candidate in any jurisdiction and it is possible that none of our existing therapeutic candidates or any therapeutic candidates we may seek to develop in the future will ever obtain marketing approval.
Our therapeutic candidates could fail to receive, or could be materially delayed in receiving, marketing approval for many reasons, including any one or more of the following:
•the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
•we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
77

•the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for marketing approval;
•we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
•the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;
•the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other submission or to obtain marketing approval in the United States or elsewhere;
•upon review of our clinical trial sites and data, the FDA or comparable foreign regulatory authorities may find our record keeping or the record keeping of our clinical trial sites to be inadequate or may identify other GCP deficiencies related to the trials;
•the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies may fail to meet the requirements of the FDA, EMA or comparable foreign regulatory authorities; or    
•the medical standard of care or the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner that renders our clinical data insufficient for approval.
It is possible that none of the therapeutic candidates we or our collaborators may develop will obtain the marketing approvals necessary for us or our collaborators to sell the products either in the United States or any other country. Furthermore, approval by the FDA of a therapeutic product does not assure approval by regulatory authorities outside the United States or vice versa. Even if approval for a therapeutic product is obtained, such approval may be subject to limitations on the indicated uses or appropriate patient population that could result in a significantly reduced potential market size for the product.
If we or our collaborators fail to obtain the appropriate marketing approvals necessary for us or our collaborators to sell our therapeutic candidates, or if the approvals are more limited than those that we intend to seek, our business, financial condition and results of operations would be materially harmed.
We will be subject to stringent domestic and foreign therapeutic and drug regulation with respect to any potential products. Even if we receive marketing approval for any of our therapeutic candidates, we will still be subject to ongoing regulatory obligations and continued review, which may result in significant additional expense. If we fail to comply with United States and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties. Any unfavorable regulatory action may materially and adversely affect our future financial condition and business operations.
Even if we receive marketing and commercialization approval for a therapeutic candidate, we will be subject to continuing post-marketing regulatory requirements. Our potential products, further development activities and manufacturing and distribution of a future product, once developed and determined, will be subject to extensive and rigorous regulation by numerous government agencies, including the FDA and comparable foreign agencies. To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and the safety and effectiveness of our therapeutic candidates and, if approved, our future products. The process of obtaining marketing approval or clearance from the FDA and comparable foreign bodies for new products, or for enhancements, expansion of the indications or modifications to existing products, could:
•take a significant, indeterminate amount of time;
•require the expenditure of substantial resources;
•involve rigorous nonclinical and clinical testing, and possibly post-market surveillance;
•require design changes of our potential products; or
•result in our never being granted the marketing approval we seek.
78

Any of these occurrences may cause our operations or potential for success to suffer, harm our competitive standing and result in further losses that adversely affect our financial condition.
The FDA, as well as its foreign regulatory counterparts, also have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. Additionally, the FDA regulates the promotional claims that may be made about prescription products, such as our products, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. However, we may share truthful and not misleading information with healthcare providers and payors that is otherwise consistent with the product’s FDA approved labeling.
We will have ongoing responsibilities under these and other FDA and international regulations, both before and after a product is approved and commercially released. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections by the FDA and foreign regulatory agencies. If we or our collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, adverse regulatory inspection finding, holds on clinical trials, delay of approval or refusal by the FDA or applicable authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of marketing approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, exclusion of eligibility from government contracts, injunctions, civil penalties or criminal prosecution. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively commercializing our potential products and harm our business. In addition, negative publicity and product liability claims resulting from any adverse regulatory action could have a material adverse effect on our business, financial condition, results of operations, and prospects.
The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted outside of their respective jurisdictions. While we currently have partnerships in China designed to provide access to patient populations outside of the United States and in the future may conduct clinical trials in other foreign jurisdictions, there can be no assurance these data will be accepted by the FDA or EMA or other comparable foreign regulatory authorities as a basis for a product’s marketing approval.
To augment our U.S.-centric clinical strategy, we have formed partnerships in China designed to provide access patient populations for clinical trials not readily available in the United States and to facilitate rapid patient enrollment with the goal of generating more robust early clinical data from patients in China. We may in the future pursue partnerships to conduct other clinical trials outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations. For example, in February 2022, the FDA publicly rebuked an oncology product sponsor for submitting a marketing application with Phase III clinical data solely from China and since that time, it has declined to approve other applications that contained primarily China-generated clinical data. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, any foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, including any trials conducted in China.
Our partnerships in China subject us to risks and uncertainties relating to the laws and regulations of China and the changes in relations between the United States and China.
Under its current leadership, the government of China has been pursuing economic reform policies, including by encouraging foreign trade and investment. However, there is no assurance that the Chinese government will continue to pursue such policies, that such policies will be successfully implemented, that such policies will not be
79

significantly altered, or that such policies will be beneficial to our partnerships in China. China’s system of laws can be unpredictable, especially with respect to foreign investment and foreign trade. The United States government has called for substantial changes to foreign trade policy with China and has raised, and has proposed to further raise in the future, tariffs on several Chinese goods. China has retaliated with increased tariffs on United States goods. Moreover, China’s legislature has adopted a national security law to substantially change the way Hong Kong has been governed since the territory was handed over by the United Kingdom to China in 1997. This law increases the power of the central government in Beijing over Hong Kong, limit the civil liberties of residents of Hong Kong and could restrict the ability of businesses in Hong Kong to continue to conduct business or to continue to with business as previously conducted. The U.S. State Department has indicated that the United States no longer considers Hong Kong to have significant autonomy from China. The U.S. State Department previously enacted sanctions related to China’s governing of Hong Kong, and the United States may impose the same tariffs and other trade restrictions on exports from Hong Kong that it places on goods from mainland China. Any further changes in United States trade policy could trigger retaliatory actions by affected countries, including China, resulting in trade wars. For example, the Uyghur Forced Labor Prevention Act bans imports from China’s Xinjiang Uyghur Autonomous Region unless it can be shown that the goods were not produced using forced labor and this legislation may have an adverse effect on global supply chains which could adversely impact our business and results of operations. Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations affecting biopharmaceutical companies are also unpredictable. Any regulatory changes and changes in United States and China relations may have a material adverse effect on our partnerships in China which could materially harm our business and financial condition.
Unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives could harm our business in the future.
There is increasing pressure on biotechnology companies to reduce healthcare costs. In the United States, these pressures come from a variety of sources, such as managed care groups and institutional and government purchasers. Increased purchasing power of entities that negotiate on behalf of federal healthcare programs and private sector beneficiaries could increase pricing pressures in the future. Such pressures may also increase the risk of litigation or investigation by the government regarding pricing calculations. The biotechnology industry will likely face greater regulation and political and legal actions in the future.
Adverse pricing limitations may hinder our ability to recoup our investment in one or more future therapeutic candidates, even if our future therapeutic candidates obtain marketing approval. Adverse pricing limitations prior to approval will also adversely affect us by reducing our commercial potential. Our ability to commercialize any potential products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments becomes available from third-party payors, including government health administration authorities, private health insurers and other organizations. Third-party payors decide which medications they will pay for and establish reimbursement levels. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.
A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Additionally, the IRA authorized CMS to negotiate drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition starting in payment year 2026, and to negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities and entered into the first set of agreements with pharmaceutical manufacturers to conduct price negotiations in October 2023. However, the IRA’s impact on the biopharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
80

We cannot be sure that coverage and reimbursement will be available for any product that we commercialize in the future and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval in the future. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any therapeutic candidate that we successfully develop.
There may be significant delays in obtaining reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Our inability to promptly obtain coverage and adequate reimbursement from third-party payors for approved products could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize potential products and our overall financial condition.
Healthcare legislative reform measures may have a material and adverse effect on our business, financial condition, results of operations, and prospects.
Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
•the demand for our therapeutic candidates, if we obtain marketing approval;
•our ability to receive or set a price that we believe is fair for our products;
•our ability to generate revenue and achieve or maintain profitability;
•the level of taxes that we are required to pay; and
•the availability of capital.
In March 2010, the ACA was enacted, which includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers in the United States. It also included the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The ACA continues to significantly impact the United States’ pharmaceutical industry.
Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme
81

Court held unanimously that federal law does not preempt the states’ ability to regulate PBMs and other members of the health care and pharmaceutical supply chain, an important decision that has led to more aggressive efforts by states in this area. The Federal Trade Commission in mid-2022 also launched sweeping investigations into the practices of the PBM industry that could lead to additional federal and state legislative or regulatory proposals targeting such entities’ operations, pharmacy networks, or financial arrangements. During the current congressional session, numerous PBM reforms are being considered in both the Senate and the House of Representatives; they include diverse legislative proposals such as eliminating rebates; divorcing service fees from the price of a drug, discount, or rebate; prohibiting spread pricing; limiting administrative fees; requiring PBMs to report formulary placement rationale; promoting transparency. Significant efforts to change the PBM industry as it currently exists in the U.S. may affect the entire biopharmaceutical supply chain and the business of other stakeholders, including therapeutic biological product developers like us.
We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our therapeutic candidates, if approved.
In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Our future products, if any, might not be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, an adequate level of reimbursement might not be available for such products and third-party payors’ reimbursement policies might adversely affect our ability to sell any future products profitably.
Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for biologic therapeutics, and FDA’s statutory authorities are periodically amended by Congress. For example, as part of the Consolidated Appropriations Act for 2023, Congress provided FDA additional authorities related to the accelerated approval pathway for human drugs and biologics. Under these amendments to the FDCA, the agency may require a sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The amendments also give FDA the option of using expedited procedures to withdraw product approval if the sponsor’s confirmatory trial fails to verify the claimed clinical benefits of the product. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our therapeutic candidates, if any, may be. Increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-approval testing and other requirements.
We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our therapeutic candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.
If we or our partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.
Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we may obtain marketing approval. Our current and future arrangements
82

with healthcare providers, third-party payors and customers expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations, include the following:
•the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•the federal civil and criminal false claims laws, including the U.S. federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and the civil monetary penalties laws, which prohibit individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. federal False Claims Act;
•HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to HHS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain advanced non-physician healthcare practitioners and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and
•analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to significant civil, criminal and administrative penalties, including monetary damages, fines, disgorgements, imprisonment, loss of eligibility to obtain approvals from the FDA, exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, reputational harm, diminished profits and future earnings, additional reporting
83

requirements if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and the curtailment or restructuring of our operations, any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management’s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.
We received orphan drug status for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma and for INBRX-101 for the treatment of patients with AATD. We may seek orphan drug status for additional therapeutic candidates, but even if it is granted, we may be unable to maintain any benefits associated with orphan drug status, including market exclusivity.
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition or for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for a disease or condition will be recovered from sales in the United States for that drug or biologic. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity.
We received orphan drug status for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma and for INBRX-101 for the treatment of patients with AATD. We may seek orphan drug status for additional therapeutic candidates, but the FDA may not grant any such request. Even with orphan drug status, exclusive marketing rights in the United States may be limited if we seek FDA marketing approval for an indication broader than the therapeutic candidate’s orphan designated indication. Additionally, any therapeutic candidate that initially receives orphan drug status designation, may lose such designation if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, others may obtain orphan drug status and then achieve marketing approval and exclusivity before us for products addressing the same diseases or conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions for a significant period of time.
We received fast-track designation for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma. We may seek fast-track designation for other of our therapeutic candidates. Even if received, fast-track designation may not actually lead to a faster review process.
We aim to benefit from the FDA’s Fast Track and priority review processes. We received fast-track designation for INBRX-109 for the treatment of patients with metastatic or unresectable chondrosarcoma. Under fast-track designation, the FDA may initiate a rolling review of sections of a fast-track drug’s BLA before the application is complete. However, the FDA’s time period goal for reviewing an application does not begin until the last section of the BLA is submitted. Additionally, the fast-track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. Under the FDA policies, a drug candidate is eligible for priority review, or review within a six-month time frame from the time a complete BLA is accepted for filing, if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. A fast-track designated drug candidate would ordinarily meet the FDA’s criteria for priority review.
The fast-track designation for INBRX-109, or for other future therapeutic candidates, may not actually lead to a faster review process and a delay in the review process or in the approval of our potential products will delay revenue from their potential sales and will increase the capital necessary to fund these product development programs. Without fast-track designation, submitting a BLA and getting through the regulatory process to gain marketing approval is a lengthier process.
We are working towards submitting INBRX-101 for marketing authorization through the use of the accelerated approval pathway and may pursue this accelerated approval pathway for future therapeutic candidates. There is no assurance that, upon receipt of our future marketing application for INBRX-101, the FDA will agree to file it
84

and conduct a substantive review of the data or that FDA will agree that we have met the substantial evidence of effectiveness standard necessary to support marketing approval. If unable to obtain approval under the accelerated approval pathway, we may be required to conduct additional nonclinical studies or clinical trials beyond those that we currently contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA for INBRX-101, or other future therapeutic candidates for which the accelerated approval pathway may be appropriate, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.
In October 2022, we announced that, based on discussions with the FDA, there is potential to pursue an accelerated approval for INBRX-101 in patients with emphysema due to AATD using AAT serum levels as the surrogate endpoint.
Under the accelerated approval provisions in the FDCA and the FDA’s implementing regulations, the FDA may grant accelerated approval to a product or therapeutic designed to treat a serious or life-threatening condition that demonstrates an effect on a surrogate endpoint, or intermediate clinical endpoint, that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than IMM, or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on IMM that is reasonably likely to predict an effect on irreversible morbidity, mortality, or other clinical benefit.
The FDA may not accept our application for accelerated approval for INBRX-101, may not grant this approval on a timely basis, or may not grant approval at all. The FDA or foreign regulatory authorities could require us to conduct further studies prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA’s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. A failure to obtain accelerated approval or any other form of expedited development, review, or approval for INBRX-101 would result in a longer time period to commercialization of INBRX-101, would increase the cost of development of INBRX-101, and could harm our competitive position in the marketplace. Following high-profile voluntary withdrawals of accelerated approval indications by several oncology sponsors as a result of post-approval trials failing to verify their drug products’ clinical benefit for those indications, which resulted in December 2022 amendments by Congress to the FDA’s authorities related to accelerated approval, public scrutiny of the accelerated approval pathway is likely to continue and may lead to further legislative and/or administrative changes in the future.
Moreover, even if we receive accelerated approval from the FDA, we will be subject to rigorous post-marketing requirements, including the completion of one or more confirmatory post-approval clinical trials to verify the clinical benefit of INBRX-101, and submission to the FDA of all promotional materials 30-120 days prior to their dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required post-approval study, a post-approval study does not confirm the predicted clinical benefit, other evidence shows that the product is not safe or effective under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false and misleading. Products that receive accelerated approval may be subject to expedited withdrawal procedures if post-approval studies fail to verify the predicted clinical benefit. In addition, as part of the Consolidated Appropriations Act for 2023, Congress provided FDA new statutory authorities to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these recent amendments to the FDCA, the agency may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted. At this time it has not been fully determined how a future confirmatory post-approval clinical trial for INBRX-101 would be designed or implemented, whether more than one trial will become necessary, or what the FDA would expect with respect to the timing of initiating such a confirmatory clinical trial for INBRX-101, should it be granted accelerated approval. If we fail to receive accelerated approval for INBRX-101 or fail to comply with the post-marketing requirements, our business, results of operations, prospects and the price of our common stock may be materially and adversely affected.
85

Our therapeutic candidates for which we intend to seek approval may face competition sooner than anticipated.
Even if we are successful in achieving marketing approval to commercialize a therapeutic candidate ahead of our competitors, our future therapeutic candidates may face direct competition from biosimilar products. In the United States, our therapeutic candidates are regulated by the FDA as biological products, and we intend to seek approval for these therapeutic candidates pursuant to the BLA pathway. The BPCIA created an abbreviated pathway for the FDA approval of biosimilar biological products based on a previously licensed innovator, or reference, biological product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12 years after the original reference biological product was approved under a BLA.
We believe that any of our therapeutic candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our therapeutic candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA, potentially creating the opportunity for follow-on biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only so-called “interchangeable” biosimilar products are considered substitutable for the reference biological product without the intervention of the healthcare provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient’s specific medical needs, healthcare providers are not restricted from prescribing biosimilar products in an off-label manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own nonclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved.
In Europe, the European Commission has granted marketing authorizations for many biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.
If competitors are able to obtain marketing approval for biosimilars referencing our therapeutic candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our therapeutic candidates may have received approval.
We face regulation and potential liability related to privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance.
The regulatory environment surrounding information security, data collection and privacy is increasingly demanding. We are subject to numerous U.S. federal and state laws and non-U.S. regulations, including in Europe and China, governing the protection of personal and confidential information of our clinical subjects, clinical investigators, employees and vendors/business contacts, including in relation to medical records, credit card data and financial information. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act and CCPA), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators, and the privacy regulatory area is in constant flux. The state of California, for example, has adopted the CCPA, which went into effect beginning in January 2020. The CCPA establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for residents of the State of California, imposing special rules on the collection of personal information from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and
86

practices to prevent data breaches. While there is currently an exception under CCPA for protected health information that is subject to HIPAA and clinical trial regulations, CCPA still applies to the personal information of employees and may otherwise impact our business. In November of 2020, California voters approved the CPRA, which took full effect on January 1, 2023. The CPRA amends the CCPA significantly, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply, and additional harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, or CPPA, which has expanded enforcement authority. Further, the CPPA has introduced significant draft regulations under the CPRA which could have operational effects on our business and further uncertainty with respect to enforcement. Comprehensive privacy laws similar to the CCPA in Virginia, Colorado, Connecticut, and Utah all took effect in 2023, and laws in Montana, Oregon and Texas will take effect in 2024, increasing the regulatory compliance risk. Like the GDPR, many of these state laws categorize medical or health data, genetic data, and biometric data that can be used to identify a natural person as “sensitive data” and the processing or collection of such will require additional compliance obligations.
In the EU, the GDPR, which came into effect on May 25, 2018, could increase our burden of regulatory compliance. The GDPR implements more stringent operational requirements for processors and controllers of personal data, including, for example, requiring expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data breach notification requirements, and higher standards for data controllers to demonstrate that they have obtained either valid consent or have another legal basis in place to justify their data processing activities. The GDPR further provides that EU member states may make their own additional laws and regulations in relation to certain data processing activities, which could further limit our ability to use and share personal data and could require localized changes to our operating model. Under the GDPR, fines of up to €20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, may be assessed for noncompliance, which significantly increases our potential financial exposure for non-compliance.
We will be subject to the GDPR where we have a EU presence or “establishment” (e.g. EU based subsidiary or operations), when conducting clinical trials with EU based data subjects (whether the trials are conducted directly by us or through a clinical vendor or partner) or offering approved products or services (if relevant) to EU based data subjects (regardless of whether involving our EU based subsidiary or operations).
The GDPR sets out a number of requirements that must be complied with when processing the personal data of such EU based data subjects including: providing expanded disclosures about how their personal data will be used; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities; the obligation to appoint data protection officers in certain circumstances; new rights for individuals to be “forgotten” and rights to data portability, as well as enhanced current rights (e.g. access requests); the principal of accountability and demonstrating compliance through policies, procedures, training and audit; the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual are all classified as “special category” data under the GDPR and afford greater protection and require additional compliance obligations. Further, EU member states have a broad right to impose additional conditions—including restrictions—on these data categories. This is because the GDPR allows EU member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes). As the EU states continue to reframe their national legislation to harmonize with the GDPR, we will need to monitor compliance with all relevant EU member states’ laws and regulations, including where permitted derogations from the GDPR are introduced.
We will also be subject to evolving EU laws on data export, where we transfer data outside the EU to group companies or third parties. The GDPR only permits exports of data outside the EU where there is a suitable data transfer solution in place to safeguard personal data (e.g. the EU Commission approved Standard Contractual Clauses or the recently-adopted EU-US Data Privacy Framework). On July 16, 2020, the Court of Justice of the EU or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18), called Schrems II. This decision (i) calls into question certain data transfer mechanisms as between the EU member states and the U.S. (such as the Standard Contractual Clauses) and (ii) invalidates the EU-U.S. Privacy Shield on which many companies had relied as an acceptable mechanism for transferring such data from the EU to the U.S. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on data importers to assess the
87

impact of U.S. national security laws on their business and future actions of EU data protection authorities are difficult to predict. While the recently-adopted EU-US Data Privacy Framework was meant to address the concerns raised by the CJEU in Schrems II, it will likely be subject to future legal challenges. Further, the EU-US Data Privacy Framework is only available to companies who have completed a self-certification and application. We have not self-certified to the EU-US Data Privacy Framework, and consequently, there is some risk of any of our data transfers from the EU being halted by one or more EU member states.
Where we rely on third parties to carry out a number of services for us, including processing personal data on our behalf, we are required under GDPR and the U.S. state privacy laws to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse impact on our reputation and business. Any contractual arrangements requiring the transfer of personal data from the EU to us in the United States requires greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance.
Our partnerships in China and our CRO relationships in Hong Kong may expose us to new and stringent Chinese data security laws. The Data Security Law of the People’s Republic of China, or the PRC Data Security Law, took effect on September 1, 2021. The PRC Data Security Law requires data processing, which includes the collection, storage, use, processing, transmission, provision and publication of data, to be conducted in a legitimate and proper manner. Moreover, the PRC Data Security Law provides a national security review procedure for those data processing activities which affect or may affect national security and imposes export restrictions on certain data and information. In addition, the PRC Data Security Law also provides that any organization or individual within the territory of the PRC shall not provide any foreign judicial body and law enforcement body with any data stored in the territory of the PRC without the approval of the competent PRC governmental authorities. Also in China, the Personal Information Protection Law, which took effect on November 1, 2021, introduced stringent protection requirements for processing personal information. We may be required to make further significant adjustments to our business practices to comply with data security and personal information protection laws in China.
In recent years, U.S. and European lawmakers and regulators have expressed concern over electronic marketing. In the EU, marketing is defined broadly to include any promotional material and the rules specifically on e-marketing are currently set out in the ePrivacy Directive which will be replaced by a new ePrivacy Regulation. While the ePrivacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process. Once the regulation is adopted, there will be a two-year implementation period. The current draft of the ePrivacy Regulation imposes strict opt-in e-marketing rules with limited exceptions to business to business communications and significantly increases fining powers to the same levels as GDPR (see above). In the U.S., the state privacy laws in California, Virginia, Colorado, Connecticut, and Utah include provisions regulating certain types of behavioral marketing and require companies to analyze online marketing and, in some cases, require opt-out mechanisms, increasing operational expenses and risk. The Federal Trade Commission has also issued a notice of proposed rulemaking with respect to online marketing and data collection.
We may find it necessary or desirable to join self-regulatory bodies or other privacy-related organizations, particularly relating to biopharmacy and/or scientific research that may require compliance with their rules pertaining to privacy and data security.
The introduction of the GDPR, and any resultant changes in EU member states’ national laws and regulations and the ePrivacy Regulation, will increase our compliance obligations and will necessitate the review and implementation of policies and processes relating to our collection and use of data. This increase in compliance obligations could also lead to an increase in compliance costs which may have an adverse impact on our business, financial condition or results of operations.
If any person, including any of our employees, clinical vendors or partners or those with whom we share such information, negligently disregards or intentionally breaches our established controls with respect to our clinical subject, clinical investigator or employee data, or otherwise mismanages or misappropriates that data, we could be
88

subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution in one or more jurisdictions. As above, under the GDPR there are significant new punishments for non-compliance which could result in a penalty of up to 4% of a firm’s global annual revenue.
Applicable laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. If we become liable under laws or regulations applicable to us, we could be required to pay significant fines and penalties, our reputation may be harmed and we may be forced to change the way we operate. That could require us to incur significant expenses or to discontinue certain services, which could negatively affect our business.
We are increasingly dependent upon technology systems and data to operate our business. In particular, the COVID-19 pandemic has caused us to modify our business practices, including in certain cases allowing office-based employees in the United States to work from home. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies. A breakdown, invasion, corruption, destruction or breach of our technology systems, including the cloud technologies that we utilize, and/or unauthorized access to our data and information could subject us to liability or negatively impact the operation of our business. Our technology systems, including the cloud technologies that we utilize, continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack. Likewise, data privacy or security breaches by individuals authorized to access our technology systems, including the cloud technologies that we utilize, may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public.
We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other marketing approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.
Use of net operating loss carryforwards may be limited and U.S. federal income tax reform could adversely affect us.
Our ability to utilize our net operating loss, or NOL, carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes. Under Sections 382 and 383 of the Internal Revenue Code, as amended, or IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. We are in the process of completing a
89

formal study to assess whether an ownership change for purposes of Section 382 or 383 has occurred and, pending finalization, have not identified any ownership changes to date through December 31, 2023. However, we may experience ownership changes in the future as a result of shifts in our stock ownership (some of which shifts are outside our control), including as a result of the Merger. Corresponding rules may apply under state tax laws. Even if there is no limitation on utilization of our NOL carryforwards as the result of an ownership change, the utilization of NOL carryforwards originating from a loss incurred in a year after 2017 is limited and may reduce taxable income in any post-2020 year by no more than 80% of the pre-NOL taxable income in such year. If we earn taxable income in a future year, such limitations on utilization of NOL carryforwards could result in increased future tax liability to us and our future cash flows could be adversely affected.
Additionally, we use our best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause actual financial results to deviate from previous estimates.
If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
We maintain quantities of various flammable and toxic chemicals in our facilities in La Jolla, California required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these hazardous materials in our La Jolla facilities comply with the relevant guidelines of La Jolla, the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Any insurance coverage we have may not be sufficient to cover these liabilities. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations which would adversely affect our business.
Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
Our future growth may depend, in part, on our ability to develop and commercialize our therapeutic candidates, if approved, in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our therapeutic candidates before we receive marketing approval from the applicable regulatory authority in that foreign market, and we may never receive such marketing approval for any of our therapeutic candidates. To obtain separate marketing approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our therapeutic candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our therapeutic candidates and ultimately commercialize our therapeutic candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. We may need to rely on third parties to market, distribute and sell our products in foreign markets.
Risks Related to Ownership of Our Common Stock
We do not know whether an active, liquid and orderly trading market will continue for our common stock and as a result it may be difficult for you to sell your shares of our common stock.
Prior to our IPO in August 2020, there was no public market for shares of our common stock. Shares of our common stock only recently began trading on the Nasdaq Global Market and we can provide no assurance that we will be able to sustain an active trading market for our shares. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market
90

may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration.
We expect that our stock price may fluctuate significantly.
The trading price of shares of our common stock may be highly volatile and could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:
•results of our clinical trials and preclinical studies or those of our competitors;
•the success of competitive products or technologies;
•regulatory or legal developments in the United States and other countries;
•geopolitical events, such as global conflicts or hostilities;
•the level of expenses related to our therapeutic candidates or development programs;
•changes in the structure of healthcare payment systems; actual or anticipated fluctuations in our financial condition and operating results;
•announcements by us, our partners or our competitors of new therapeutics or therapeutic candidates, significant contracts, strategic partnerships, joint ventures, collaborations, commercial relationships or capital commitments;
•failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public;
•issuance of new or updated research or reports by securities analysts or recommendations for our stock;
•disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;
•commencement of, or our involvement in, litigation;
•fluctuations in the valuation of companies perceived by investors to be comparable to us;
•manufacturing disputes or delays;
•any future sales of our common stock, including the exercise of warrants, or other securities;
•any change to the composition of the board of directors or key personnel;
•expiration of contractual lock-up agreements with our executive officers, directors and security holders;
•general economic conditions and slow or negative growth of our markets;
•share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
•announcement or expectation of additional debt or equity financing efforts; and
•circumstances and market conditions relating to pandemics and natural disasters.
These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance. In addition, the stock market in general, and life science companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have on occasion instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results.
Our executive officers, directors and holders of more than 5% of our capital stock own a significant percentage of our stock and will be able to exercise significant control over matters subject to stockholder approval.
As of December 31, 2023, our executive officers, directors and holders of more than 5% of our capital stock beneficially owned approximately 61% of our shares of common stock outstanding. Accordingly, this group of stockholders will continue to have significant control over our operations. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management.
91

Future sales of our common stock in the public market could cause our stock price to fall.
Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.
As of December 31, 2023, we had 47,369,511 shares of common stock outstanding. In order to raise additional capital, we may sell shares of common stock under our Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which we may, from time to time, sell shares of common stock having an aggregate offering price of up to $200.0 million through the Sales Agent. As of December 31, 2023, shares of common stock with an aggregate offering price of $171.4 million have been sold through our Sales Agent pursuant to the Sales Agreement. Sales of our common stock made pursuant to the Sales Agreement will be made under our $400.0 million Shelf Registration on Form S-3ASR, which became automatically effective upon filing on September 3, 2021. As of the date of this Annual Report, our employees and members of our board of directors hold approximately 3.5 million vested and in-the-money options to acquire shares of our common stock. These shares are registered pursuant to our previously filed registration statements on Form S-8 and are generally freely-tradeable. Future sales of substantial amounts of our common stock in the public market, including sales by our directors, employees, or other significant holders, shares issued upon exercise of then outstanding options or warrants, or the perception that such sales may occur, could adversely affect the market price of our common stock and cause significant dilution to our existing stockholders.
Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.
If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock price could decline. If one or more of these analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the public markets, which could cause our stock price or trading volume to decline.
The Nasdaq Stock Market may delist our securities from its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions.
Our common stock is listed on the Nasdaq Global Market. We cannot assure you that, in the future, our securities will meet the continued listing requirements to be listed on the Nasdaq Global Market. If the Nasdaq Stock Market delists our common stock, we could face significant material adverse consequences, including:
•a limited availability of market quotations for our securities;
92

•a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;
•a limited amount of news and analyst coverage for our company; and
•a decreased ability to issue additional securities or obtain additional financing in the future.
Except as may occur in connection with the Merger and spin-out transaction, we do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
Except as may occur in connection with the Merger and spin-out transaction, we currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. The Amended 2020 Loan Agreement requires, and future debt financing agreements may require us to have the lender’s permission before declaring dividends on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock.
If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial statements and other public reporting, which would harm our business and the trading price of our common stock.
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, our management will be required to report upon the effectiveness of our internal control over financial reporting.
The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Securities and Exchange Act of 1934, as amended, or the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures.
We cannot assure you that there will not be material weaknesses or significant deficiencies identified in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. In the future, if we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.
Effective December 31, 2023, we became a “large accelerated filer,” as defined in the Exchange Act. As a result, our independent registered public accounting firm is now required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.
We will continue to incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.
As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq Stock Market to implement provisions of the Sarbanes-Oxley impose significant requirements on
93

public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.
We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.
Anti-takeover provisions contained in our restated certificate of incorporation and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt.
Our restated certificate of incorporation, restated bylaws and Delaware law contain provisions which could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include provisions:
•authorizing our board of directors to issue up to 15,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as our board of directors may determine;
•specifying that special meetings of our stockholders can be called only by our board of directors, the chairman of our board of directors or our Chief Executive Officer and that our stockholders may not act by written consent;
•establishing an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
•providing that our board of directors may create new directorships and that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
•establishing that our board of directors is divided into three classes—Class I, Class II, and Class III—with each class serving staggered three-year terms;
•providing that our board of directors may amend our restated bylaws without stockholder approval; and
•requiring a super-majority of votes to amend certain of the above-mentioned provisions.
These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.
As a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock.
Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.
Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware, or the Chancery Court, or the federal district court for the District of Delaware, or the District Court of Delaware, or the other federal district courts of the United States as the exclusive forum for certain types of actions and
94

proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Our amended and restated certificate of incorporation requires, unless we otherwise consent, that the Chancery Court will, to the fullest extent permitted by law, be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law (subject to the Chancery Court having personal jurisdiction over the indispensable parties named as defendants): (i) any derivative action or proceeding brought on our behalf, (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or employees of the Company, arising out of or pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Chancery Court, or (vi) any action or proceeding asserting a claim against us, or our directors, officers or employees, governed by the internal affairs doctrine. If the Chancery Court does not have jurisdiction for these actions or proceedings, then the actions or proceedings must be brought in a state court located in the State of Delaware. If these state courts also do not have jurisdiction, these actions or proceedings must be brought in the District Court of Delaware. These limitations in our amended and restated certificate of incorporation will not apply to actions brought to enforce a duty or liability created by the Securities Act, the Exchange Act or to any claim for which the federal courts have exclusive jurisdiction. However, our amended and restated certificate of incorporation also provides that, unless we otherwise consent in writing, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. In addition, any person holding, owning or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. These Delaware and federal court choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Chancery Court or the District Court of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Chancery Court or the District Court of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operations.
On March 18, 2020, the Delaware Supreme Court ruled that provisions of a Delaware corporation’s certificate of incorporation that designate a federal forum for securities claims brought pursuant to the Securities Act, or federal forum provisions, are valid and enforceable under Delaware law, or the March 2020 Ruling. Various U.S. Supreme Court cases offer support for the argument that federal forum provisions do not violate federal policy. However, the March 2020 Ruling applies only to claims brought in Delaware state courts, and it is not binding on any other state court or the federal courts. Therefore, we are unable to predict whether a state court in any other state or a federal court would enforce a federal forum provision such as the one set forth in our amended and restated certificate of incorporation.
We may be subject to securities litigation that materially diverts the attention of our management or pursuant to which we incur substantial costs.
The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. Securities litigation against us could result in substantial costs and materially divert our management’s attention from other business concerns, which could seriously harm our business.
95

Item 1B. Unresolved Staff Comments.
None.
Item 1C. Cybersecurity.
Cybersecurity
We recognize the critical importance of maintaining the trust and confidence of our patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our board of directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. Our cybersecurity policies, standards, processes and practices are based on recognized frameworks established by the National Institute of Standards and Technology, or NIST, the International Organization for Standardization and other applicable industry standards. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.
Cybersecurity Risk Management and Strategy; Effect of Risk
We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a comprehensive cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We employ a range of tools and services, including regular network and endpoint monitoring, audits, vulnerability assessments, penetration testing, threat modeling and tabletop exercises to inform our risk identification and assessment. As discussed in more detail under “Cybersecurity Governance” below, our audit committee provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer, General Counsel, and Director of Information Technology.
We also identify our cybersecurity threat risks by comparing our processes to standards set by NIST and the International Organization for Standardization, as well as by engaging experts to attempt to infiltrate our information systems. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:
a.monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;
b.through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;
c.employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence;
d.provide regular, mandatory training for our employees and contractors regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;
e.conduct regular phishing email simulations for all employees and contractors with access to our email systems to enhance awareness and responsiveness to possible threats;
f.conduct annual cybersecurity management and incident training for employees involved in our systems and processes that handle sensitive data;
g.run tabletop exercises to simulate a response to a cybersecurity incident and use the findings to improve our processes and technologies; and
96

h.carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident.
Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.
As part of the above processes, we regularly engage with consultants, auditors and other third parties, including annually having an independent third-party review our cybersecurity program to help identify areas for continued focus, improvement and compliance.
Our processes also address cybersecurity threat risks associated with our use of third-party service providers, including our suppliers and manufacturers or who have access to patient and employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, and continually monitor cybersecurity threat risks identified through such diligence. Additionally, we generally require those third parties that could introduce significant cybersecurity risk to us to agree by contract to manage their cybersecurity risks in specified ways, and to agree to be subject to cybersecurity audits, which we conduct as appropriate.
We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading “Cybersecurity breaches could expose us to material liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business,” which disclosures are incorporated by reference herein.
In the last two fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements, of which there were none.
Cybersecurity Governance; Management
Cybersecurity is an important part of our risk management processes and an area of focus for our board of directors and management. The audit committee of our board of directors is responsible for the oversight of risks from cybersecurity threats.
At least annually, our audit committee receives an update from management of our cybersecurity threat risk management and strategy processes covering topics such as data security posture, results from third-party assessments, progress towards pre-determined risk-mitigation-related goals, our incident response plan, and material cybersecurity threat risks or incidents and developments, as well as the steps management has taken to respond to such risks. In such sessions, our audit committee generally receives materials discussing current and emerging material cybersecurity threat risks, and describing our ability to mitigate those risks, as well as recent developments, evolving standards, technological developments and information security considerations arising with respect to our peers and third parties, and discusses such matters with our Director of Information Technology. Our audit committee also receives prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed.
Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Financial Officer, General Counsel, and Director of Information Technology. Such individuals have collectively several years of prior work experience in various roles involving managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs, as well as relevant degrees and certifications. These management team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, these management team members report to the audit committee
97

of our board of directors about cybersecurity threat risks, among other cybersecurity related matters, at least annually.
Item 2. Properties.
Our headquarters are located in La Jolla, California where we currently lease approximately 43,000 square feet of laboratory and office space under a lease that expires in 2025. We have an option to extend the lease an additional five years. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.
Item 3. Legal Proceedings.
Except as disclosed below, we are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
On March 1, 2022, I-Mab Biopharma, or I-Mab, filed a lawsuit against the Company and Brendan Eckelman, the Company’s co-founder and Chief Scientific Officer, in the United States District Court for the District of Delaware, C.A. No. 22-00276-CJB, asserting claims for misappropriation of trade secrets related to Dr. Eckelman’s service as an expert witness for Tracon Pharmaceuticals, Inc., or Tracon, in Tracon’s arbitration against I-Mab. The case is currently in the discovery process.
Item 4. Mine Safety Disclosures.
Not applicable.
98

Part II.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock is traded on the Nasdaq Global Market under the ticker symbol “INBX.”
Holders of Common Stock
As of February 21, 2024, we had 47,392,447 outstanding shares of common stock and approximately 14 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in “street name” or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.
Dividend Policy
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and future earnings, if any, for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, our financial condition, our capital requirements, general business conditions, our future prospects and other factors that our board of directors may deem relevant. In addition, the terms of the Amended 2020 Loan Agreement restrict our ability to pay dividends without the prior written consent of Oxford. Investors should not purchase our common stock with the expectation of receiving cash dividends.
Securities Authorized for Issuance Under Equity Compensation Plans
See Item 12 of Part III of this Annual Report for information about our equity compensation plans which is incorporated by reference herein.
Recent Sales of Unregistered Securities
None.
Use of Proceeds
On August 18, 2020, the SEC declared effective our registration statement on Form S-1 (File No. 333-240135), as amended, filed in connection with our IPO. Our IPO closed on August 21, 2020, and we issued and sold 8,050,000 shares of our common stock at a price to the public of $17.00 per share, which included the exercise in full of the underwriters’ option to purchase additional shares. We received gross proceeds from our IPO of $136.9 million, before deducting underwriting discounts, commissions and offering costs of $11.0 million, for net proceeds of approximately $125.9 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.
The joint book-running managing underwriters of the offering were Jefferies LLC, Evercore Group L.L.C. and Credit Suisse Securities (USA) LLC, with LifeSci Capital as Co-Manager.
Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank deposits and money market funds. Through December 31, 2023, we have used the net proceeds from our IPO for research and development of our programs and for general corporate purposes. There has been no material change in the planned use of proceeds from our IPO from those disclosed in the Prospectus.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
99

Item 6. [Reserved]

100

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the section of this Annual Report titled “Risk Factors,” our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Overview
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms superior to current approaches and applicable to a range of challenging, validated targets with high potential.
Recent Developments
Sale of INBRX-101 to Sanofi
In January 2024, we announced that we entered into a definitive agreement with Aventis, a wholly owned indirect subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency, or AATD. Immediately prior to the closing of the Merger, all assets and liabilities not primarily related to INBRX-101 will be spun out into a new publicly traded company, New Inhibrx.
Under the terms of the definitive agreement, Aventis will acquire all of our outstanding shares through a merger, and in turn, each of our shareholders will receive: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Aventis will (1) assume and retire our outstanding third-party debt, including our debt arrangements with Oxford, (2) cause New Inhibrx to be funded with $200 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%. Subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we currently expect the transaction to close during the second quarter of 2024.
Discontinuation of INBRX-105
We have decided to terminate our INBRX-105 program, a tetravalent programmed death-ligand 1, or PD-L1, targeted 4-1BB agonist. During the length of our Phase 1/2 trial, we dosed approximately 150 patients. We initially observed single agent complete responses in non-small cell lung cancer, or NSCLC, and head and neck squamous cell carcinoma, or HNSCC, as well as multiple partial responses. We also observed numerous partial responses with INBRX-105 in combination with Keytruda. However, after evaluation of the totality of the data from the expansion cohorts, we concluded the initial signal was not sufficiently validated to support the continuation of this program. We are in the process of winding down the clinical trial and expect it to be complete within the first half of 2024. Consequently, in February 2024, Elpiscience Biopharmaceuticals, Inc, or Elpiscience, terminated its rights to commercialize INBRX-105 in greater China.
Current Clinical Pipeline
Our current clinical pipeline includes therapeutic candidates in the following categories:
•INBRX-101, which seeks to maintain the natural function of Alpha-1 antitrypsin, or AAT, in a recombinant format, optimized for less frequent dosing and greater potential therapeutic activity as compared to plasma-derived AAT, or pdAAT; and
101

•INBRX-109 and INBRX-106, both of which utilize our multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function.
INBRX-101 Blank.jpg
INBRX-109 Blank.jpg
INBRX-106 Blank.jpg
INBRX-101INBRX-109INBRX-106
AAT-Fc fusion
protein		Tetravalent DR5
agonist		Hexavalent OX40
agonist
ProgramTherapeutic AreaTarget(s)/FormatSTAGE OF DEVELOPMENT
PreclinicalPhase 1Phase 2Phase 3
INBRX-101*Orphan/RespiratoryNeutrophil Elastase
AAT-Fusion Protein
INBRX-109**OncologyDR5
Tetravalent Agonist
INBRX-106***OncologyOX40
Hexavalent Agonist
__________________
*    Subject to potential acquisition by Aventis as described above.
**    Third party partnership with Chinese biotechnology company, Transcenta, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.
***    Third party partnership with Chinese biotechnology company, Elpiscience, currently in place for development and commercialization in China, Hong Kong, Macau and/or Taiwan.

INBRX-101 is an optimized, recombinant alpha-1 antitrypsin, or AAT, augmentation therapy candidate for AATD. In March 2022, the United States Food and Drug Administration, or FDA, granted orphan drug designation for INBRX-101 for the treatment of AATD. In May 2022, we announced topline results from the INBRX-101 Phase 1 clinical trial. We believe the data revealed the potential to achieve normal AAT levels with less frequent dosing than the current standard of care and showed the treatment was well tolerated with no drug-related severe or serious AEs at doses up to and including 120 mg/kg in single and multi-dose administered intravenously. In May 2023, the FDA granted Fast Track designation to INBRX-101 for the treatment of patients with emphysema due to AATD.
In April 2023, we initiated ElevAATe, a registration-enabling trial for INBRX-101 for the treatment of patients with emphysema due to AATD. The primary endpoint of the trial is the mean change in the average functional AAT, or fAAT, concentration as measured by anti-neutrophil elastase capacity from baseline to average serum trough fAAT concentration at steady state (Ctrough,ss). The initial read-out from the ElevAATe trial is expected to occur in
102

mid-2025 and we intend to submit for regulatory approval once completed. In our end of Phase 1 meeting, the FDA requested additional information to support the correlation between serum AAT levels and the clinical benefit in AATD to further support serum AAT levels as a surrogate endpoint reasonably likely to predict clinical benefit. We are in the process of compiling this data through existing registry, health records and published data and plan to submit those analyses to the FDA as part of the BLA submission.
Our most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist currently being evaluated in patients diagnosed with difficult-to-treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, Ewing sarcoma and pancreatic adenocarcinoma. In June 2021, based on the initial Phase 1 data results, we initiated a registration-enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma for which the FDA and the European Medicine Agency, or EMA, granted orphan drug designation in November 2021 and August 2022, respectively. In November 2022, we announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma, which showed disease control was observed in patients with and without isocitrate dehydrogenase, or IDH, mutations. Data from the registration-enabling trial in unresectable or metastatic conventional chondrosarcoma is expected during the first half of 2025.
On November 2, 2023, we announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan, or IRI, and Temozolomide, or TMZ, for the treatment of advanced or metastatic, unresectable Ewing sarcoma. Among the 13 patients evaluable as of the data cut of September 8, 2023, the observed disease control rate was 76.9%, or 10 out of 13 patients as measured by RECISTv1.1, with 7 patients achieving partial responses (53.8%) and 3 patients achieving stable disease (23.1%). Overall, INBRX-109 in combination with IRI/TMZ was well tolerated from a safety perspective. We have expanded recruitment of this cohort as a result of these preliminary findings.
INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor. It is currently being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors. Parts 1 and 3, dose escalation as a single agent and in combination with Keytruda, have been completed. It was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities notes. We observed durable responses across multiple tumor types. We expanded the enrollment for Part 2, single agent dose expansion, to increase the dataset in the single agent cohorts and to enroll additional NSCLC patients. We expect to announce additional data from Part 2 in 2025. We continue to enroll patients with NSCLC and HNSCC in Part 4, combination expansion cohorts. We are in the process of expanding these cohorts and expect to initiate at least one additional cohort by mid 2024. We expect to have a more mature dataset during the third quarter of 2025 and plan to provide an update at that time.
Components of Results of Operations
Revenue
To date, all of our revenue has been derived from licenses with collaboration partners and grant awards. We have not generated any revenue from the commercial sale of approved therapeutic products, and until, if ever, they are approved for commercial sale, we expect our revenue will be derived primarily from payments under our current license agreements and any potential future collaborations or strategic transactions.
Operating Expenses
Research and Development
To date, our research and development expenses have related primarily to research activities, including our discovery efforts, and preclinical and clinical development and the manufacturing of our therapeutic candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track our internal research and development expenses on a program-by-program basis as they primarily relate to personnel, early research and consumable costs, which are deployed across multiple projects under development.
103

Research and development expenses consist primarily of:
•External expenses, consisting of:
◦expenses incurred in connection with the preclinical development of our programs;
◦clinical trials of our therapeutic candidates, including under agreements with third parties, such as consultants and contract research organizations, or CROs;
◦expenses associated with the manufacturing of our therapeutic candidates under agreements with contract development and manufacturing organizations, or CDMOs;
◦expenses associated with regulatory requirements, including fees and other expenses related to our Scientific Advisory Board; and
◦other external expenses, such as laboratory services related to our discovery and development programs and other shared services, and
•Internal expenses, consisting of:
◦salaries, benefits and other related costs, including non-cash stock-based compensation, for personnel engaged in research and development functions;
◦facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities; and
◦other internal expenses, such as laboratory supplies and other shared research and development costs.
We expect that research and development expense will continue to increase over the next several years as we continue development of our therapeutic candidates currently in clinical stage development, support our preclinical programs, and continue to discover new therapeutic candidates, as well as increase our headcount. In particular, clinical development of our therapeutic candidates, as opposed to preclinical development, generally has higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Moreover, the costs associated with our CDMOs to manufacture our therapeutic candidates and future commercial products is also much more costly as compared to early stage preclinical development. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our therapeutic candidates due to the inherently unpredictable nature of preclinical and clinical development. Preclinical and clinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which therapeutic candidates to pursue and how much funding to direct to each therapeutic candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each therapeutic candidate’s commercial potential. We will need substantial additional capital in the future to support these efforts. In addition, we cannot forecast which therapeutic candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.
Our clinical development costs may vary significantly based on factors such as:
•the per patient trial costs;
•the number of trials required for approval;
•the number of sites included in the trials;
•the countries in which the trials are conducted;
•the length of time required to enroll eligible patients;
•the number of patients that participate in the trials;
•the number of doses that patients receive;
•the drop-out or discontinuation rates of patients;
•the potential additional safety monitoring requested by regulatory agencies;
•the duration of patient participation in the trials and follow-up;
•the cost, timing, and successful manufacturing of our therapeutic candidates;
•the phase and development of our therapeutic candidates;
•the efficacy and safety profile of our therapeutic candidates; and
104

•the uncertainties related to potential economic downturn, geopolitical events and widespread health events on capital and financial markets.
General and Administrative
General and administrative, or G&A, expenses consist primarily of:
•salaries, benefits and other related costs, including non-cash stock-based compensation, for personnel engaged in G&A functions;
•expenses incurred in connection with accounting and audit services, legal services, including costs associated with obtaining and maintaining our patent portfolio, investor relations and consulting expenses under agreements with third parties, such as consultants and contractors;
•expenses incurred in connection with commercialization and business development activity; and
•facilities, depreciation and other expenses, which include direct and allocated expenses for depreciation and amortization, rent and maintenance of facilities, insurance and supplies.
We expect our G&A expenses will continue to increase in the future to support our continued research and development activities. We expect increased costs related to pre-commercialization and business development activities, including the hiring of additional personnel as we continue to build our commercial team in preparation for our future product launches. Additionally, we expect other professional service fees to increase, including but not limited to, patent-related costs for filing, prosecution and maintenance of our product candidates, and compliance costs, accounting, legal, investor and public relations and additional personnel.
Other Income (Expense)
Interest expense. Interest expense consists of interest on our loans with Oxford Finance LLC, or Oxford.
Interest income. Interest income consists of interest earned on cash and cash equivalents, which include investments held during the period in highly liquid debt securities with original maturities of less than three months from our date of acquisition.
Loss on Equity Method Investment
Our equity interest in Phylaxis BioScience, LLC, or Phylaxis, is accounted for as an equity method investment and the Company’s proportionate share of the net income or loss of Phylaxis is included as loss in equity method investment in the consolidated statement of operations.
105

Results of Operations
Comparison of Years Ended December 31, 2023 and December 31, 2022
The following table summarizes our consolidated results of operations for each of the periods indicated (in thousands, except percentages):
YEAR ENDED DECEMBER 31,CHANGE
20232022($)(%)
Revenue:
License fee revenue$1,800 $2,178 $(378)(17)%
Grant revenue— 14 (14)(100)%
Total revenue1,800 2,192 (392)(18)%
Operating expenses: 
Research and development191,640 110,186 81,454 74 %
General and administrative29,381 21,123 8,258 39 %
Total operating expenses221,021 131,309 89,712 68 %
Loss from operations(219,221)(129,117)(90,104)70 %
Other income (expense): 
Interest expense(31,840)(18,181)(13,659)75 %
Interest income11,917 2,074 9,843 475 %
Other income (expense), net
(580)1 (581)(58,100)%
Total other expense(20,503)(16,106)(4,397)27 %
Provision for income taxes3 3 — — %
Loss on equity method investment1,634 — 1,634 100 %
Net loss$(241,361)$(145,226)$(96,135)66 %
License Fee Revenue
License fee revenue decreased by $0.4 million from $2.2 million during the year ended December 31, 2022 to $1.8 million during the year ended December 31, 2023. During the years ended December 31, 2023 and December 31, 2022, we recognized $0.1 million and $0.9 million, respectively, of license fee revenue related to the Chiesi Option Agreement. Upon Chiesi’s declination of its option, all remaining deferred revenue under this agreement was recognized during the period. Additionally, during the years ended December 31, 2023 and December 31, 2022, we recognized license fee revenue of $1.6 million and $1.1 million, respectively, related to our agreements with Phylaxis. During the year ended December 31, 2022, we recognized the remaining $1.1 million of license fee revenue under the first phase of our agreements with Phylaxis as we completed our obligation to transfer the exclusive licenses for, and complete development services, to modify the two compounds. During the year ended December 31, 2023, we transferred a second-generation compound to Phylaxis, upon which we received an additional 5% equity interest in Phylaxis, which we recognized as revenue at its fair value of $1.6 million. During the year ended December 31, 2022, we also recognized $0.2 million of revenue under the 2020 2seventy Agreement following the grant of an exclusive option and development license upon initiation of a third program. No revenue was recognized under this agreement with 2seventy during the year ended December 31, 2023.
Grant Revenue
We recognized approximately $14,000 of grant revenue during the year ended December 31, 2022, all of which consisted of revenue earned under our grant with the Department of Defense, or DoD, which was awarded in February 2021 and completed in February 2022. The grant was completed during the year ended December 31, 2022, and no revenue was earned during the year ended December 31, 2022.
106

Research and Development Expense
The following table sets forth the primary external and internal research and development expenses (in thousands, except percentages):
YEAR ENDED DECEMBER 31,CHANGE
20232022($)(%)
External expenses:
Contract manufacturing$77,248 $27,367 $49,881 182 %
Clinical trials42,960 28,988 13,972 48 %
Other external research and development10,480 6,760 3,720 55 %
Internal expenses:
Personnel47,818 35,937 11,881 33 %
Equipment, depreciation, and facility7,361 6,151 1,210 20 %
Other internal research and development5,773 4,983 790 16 %
Total research and development expenses$191,640 $110,186 $81,454 74 %
Research and development expense increased by $81.4 million from $110.2 million during the year ended December 31, 2022 to $191.6 million during the year ended December 31, 2023. The overall increase was primarily due to the following factors:
•contract manufacturing expense increased by $49.9 million due to the nature of the development and manufacturing activities performed during the current period at our CDMO and CRO partners supporting our clinical and preclinical therapeutic candidates, primarily due to large scale drug substance manufacturing services, including the utilization of raw materials, performed by one of our CDMO partners for INBRX-101, in addition to other activities performed with our CDMO partners which reflect the stage-specific needs of each of our programs, including early and late stage drug substance clinical manufacturing, analytical development, QC testing, and stability studies, as well as drug product development, scale-up, robustness studies, and selected BLA-enabling activities;
•clinical trial expense increased by $14.0 million due to costs incurred upon the initiation of the registration-enabling Phase 2 trial for INBRX-101 for the treatment of emphysema due to AATD, which we initiated during the current year, as well as the progression of our INBRX-109 registration-enabling Phase 2 trial for the treatment of unresectable or metastatic conventional chondrosarcoma. We also incurred increased costs associated with the utilization of Keytruda used in combination with INBRX-105 in our Phase 1/2 clinical trial, while costs associated with our Phase 1/2 clinical trial for INBRX-106 remained consistent in each period;
•personnel-related expense increased by $11.9 million, primarily related to an increase in headcount as a result of a significant expansion of our clinical team, as well as the issuance of additional stock options and the expansion of the bonus eligibility pool during the current year;
•facility and equipment-related expense increased by $1.2 million, which was attributable to an increase in software subscriptions to support research and development activities, in addition to increased repairs and maintenance services; and
•other research and development expense increased by $4.5 million, which was primarily attributable to an increase in travel expenses to clinical and vendor sites, clinical-related consulting expenses, the purchase of lab supplies, and preclinical studies.
G&A Expense
G&A expense increased by $8.3 million from $21.1 million during the year ended December 31, 2022 to $29.4 million during the year ended December 31, 2023. The overall increase was primarily due to the following factors:
•personnel-related expenses increased by $5.7 million, primarily attributable to an increase in headcount as we continue to build out our commercial strategy and medical affairs team, as well as increased expense
107

related to additional stock option grants to employees and the expansion of the bonus eligibility pool in the current year;
•pre-commercialization expenses increased by $1.0 million, primarily related to increases in consulting services to support our commercial operations business intelligence strategies and market research expenses related to INBRX-101 and INBRX-109; and
•professional service fees increased by $0.6 million, which was primarily attributable to increases in accounting services performed during the period as a result of our filing status in the current year, consulting services performed related to the proposed Merger, and an increase in legal expenses, including those related to intellectual property and other general corporate matters; and
•facility and equipment-related expense increased by $0.6 million, which was primarily attributable to an increase in software subscriptions and IT services related to software implementations.
Other Income (Expense)
Interest expense. Interest expense increased by $13.6 million from $18.2 million during the year ended December 31, 2022 to $31.8 million during the year ended December 31, 2023, all of which relates to interest incurred and the amortization of debt discounts related to the Amended 2020 Loan Agreement. The increase in interest expense is the result of an increase in the average outstanding principal balance during the year ended December 31, 2022 to the year ended December 31, 2022, as well as an increase in our variable interest rate driven by overall market conditions during the year ended December 31, 2023. For more information regarding the Amended 2020 Loan Agreement, refer to Note 3 to the consolidated financial statements.
Interest income. During the year ended December 31, 2023, we earned $11.9 million of interest income, of which $7.5 million related to interest earned on our sweep and money market account balances and $4.4 million related to the accretion of discounts on investments in debt securities during the period. During the year ended December 31, 2022, we earned $2.1 million of interest income, of which $0.8 million related to interest earned on our sweep and money market account balances and $1.3 million related to the accretion of discount son investments in debt securities during the period. The increase in interest income during the year ended December 31, 2023 is the result of higher cash and cash equivalent balances, coupled with rising interest rates, generating higher returns.
Income Taxes
Income tax expense was approximately $3,000 during each of the years ended December 31, 2023 and December 31, 2022, respectively. For the years ended December 31, 2023 and December 31, 2022, we have applied a 100% valuation allowance against our federal deferred tax assets since it is more likely than not that the deferred tax assets will not be realized.
Loss on Equity Method Investment
During the year ended December 31, 2023, we received an additional 5% equity interest in Phylaxis following the achievement of a milestone under our agreements. Upon receipt of the equity interest, we established an equity method investment at its fair value of $1.6 million. The loss on equity method investment during the year ended December 31, 2023 of $1.6 million consists of our share of losses from our investment in Phylaxis, which reduced our equity investment to zero. During the year ended December 31, 2022, we did not record a loss on our equity method investment in Phylaxis which had been valued at zero prior to this period.
Liquidity and Capital Resources
Sources of Liquidity
To date, sources of capital raised to fund our operations have been comprised of the sale of equity securities, borrowings under the loan and security agreements for gross proceeds of $200.0 million, payments received from commercial partners for licensing rights to our therapeutic candidates under development, grants, and proceeds from the sale and issuance of convertible promissory notes.
Through December 31, 2023, proceeds from the sale of equity securities as a public company consisted of (i) $136.9 million in gross proceeds from our initial public offering, (ii) $171.4 million in gross proceeds under our Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, and (iii) $200.0 million in gross proceeds from the private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which we sold and issued shares of our common stock and, with respect to
108

certain Purchasers, pre-funded warrants to purchase our common stock pursuant to a Securities Purchase Agreement, as amended, or the Purchase Agreement. The Purchasers have certain registration rights pursuant to the Purchase Agreement which have been waived until after the close of the Merger. Sales of our common stock made pursuant to the Sales Agreement have been made under our $400.0 million Shelf Registration on Form S-3ASR, which became automatically effective upon filing on September 3, 2021. As of December 31, 2023, we have used a total of $171.4 million of the $400.0 million under our Shelf Registration, with $228.6 million remaining and available for use.
Future Funding Requirements
Since our inception, we have devoted substantially all of our efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of our therapeutic candidates, establishing our intellectual property portfolio, developing our commercialization strategy, hiring to support these departments and activities, and raising capital to support and expand these activities. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. Our net loss for the years ended December 31, 2023 and December 31, 2022 was $241.4 million and $145.2 million, respectively. As of December 31, 2023, we had an accumulated deficit of $613.7 million and cash and cash equivalents of $277.9 million.
In January 2024, we announced the proposed Merger with Aventis, which, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we currently expect to close during the second quarter of 2024. In connection with the Merger Agreement, we have agreed to various covenants, including, among others, agreement to conduct our business in the ordinary course during the period between the execution of the Merger Agreement and the effective time of the Merger. Outside of certain limited exceptions, we may not take, authorize, commit, resolve, or agree to do certain actions without Aventis’s consent, including, but not limited to:
•acquiring businesses and disposing of significant assets;
•incurring expenditures above specified thresholds;
•issuing equity;
•issuing debt facilities; and
•repurchasing shares of our outstanding common stock.
We do not believe these restrictions will prevent us from meeting our ongoing costs of operations, working capital needs, or capital expenditure requirements.
Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months from the date these consolidated financial statements are issued. Our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.
The process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We expect to continue to incur net losses for the foreseeable future until, if ever, we have an approved product and can successfully commercialize it. We expect our research and development expenses to increase as we continue our development of, and seek marketing approvals for, our therapeutic candidates (especially as we move more candidates into later stages of clinical development), and begin to commercialize any approved products, if ever. At this time, we are preparing to proceed with the commercialization of certain of our product candidates, if ever approved. As a result, we will incur significant pre-commercialization expenses in preparation for launch, the outcome of which is uncertain. Additionally, if approved, we will incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution. We also expect additional general and administrative expenses as we hire additional personnel and incur increased accounting, audit, legal, regulatory and compliance, investor and public relations expense to support the Company as we continue to expand.
109

Until such time we, if ever, can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including strategic licensing and collaborations, strategic transactions, or other similar arrangements and transactions, and from time to time, we engage in discussions with potential acquirers regarding the disposition of one or more of our product candidates. However, there can be no assurance as to the availability or terms upon which such finances or capital might be available in the future. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our intellectual property on less favorable terms than we would otherwise choose. These actions could materially impact our business, results of operations, financial condition, and prospects.
Our future liquidity and capital funding requirements will depend on numerous factors, including:
•the outcome, costs and timing of preclinical studies and clinical trials for our current or future therapeutic candidates;
•whether and when we are able to obtain marketing approval to market any of our therapeutic candidates and the outcome of meetings with applicable regulatory agencies, including the FDA;
•our ability to successfully commercialize any therapeutic candidates that receive marketing approval;
•the emergence and effect of competing or complementary therapeutics or therapeutic candidates;
•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
•our ability to retain our current employees and the need and ability to hire additional management and scientific and medical personnel;
•the terms and timing of any strategic licensing, collaboration or other similar agreement that we have established or may establish;
•our ability to repay, refinance or restructure our indebtedness when payment is due, including in the event such indebtedness is accelerated;
•the valuation of our capital stock; and
•the continuing or future effects of a potential economic downturn, geopolitical events, and widespread health events on capital and financial markets.
We do not own or operate manufacturing and testing facilities for the production of any of our therapeutic candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on a limited number of third-party contract manufacturers for all of our required raw materials, antibodies and other biologics for our preclinical research, clinical trials, and if and when applicable, commercial product, and employ internal resources to manage our manufacturing relationships with these third parties.
Commitments
Our material cash requirements from known contractual and other obligations primarily relate to our lease obligations, debt, and services provided by our third party CROs and CDMOs.
We have two leases for our laboratory and office space, which expire in 2025, with an option to extend the leases for an additional five years. As of December 31, 2023, we have future minimum rental obligations under these leases of $3.4 million, of which $2.3 million and $1.1 million are current and non-current, respectively. For more information regarding these lease agreements, refer to Note 8 to the consolidated financial statements.
Under the Amended 2020 Loan Agreement, and assuming the proposed Merger is not consummated, we are required to make interest only payments through February 2025, with all principal payments and final fee payments beginning in March 2025 and continuing through the maturity date of January 2027. The interest-only period may be extended an additional twelve months if the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, upon which principal payments would begin in March 2026. As of December 31, 2023, we have a minimum obligation of $257.7 million of long-term debt, including minimum
110

interest payments, of which $18.7 million and $239.0 million are current and non-current, respectively. For more information regarding the Amended 2020 Loan Agreement, refer to Note 3 to the consolidated financial statements.
We enter into contracts in the normal course of business with CROs related to our ongoing preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. These contracts are generally cancellable, with notice, at our option. We have recorded accrued expenses of approximately $33.2 million in our consolidated balance sheets for expenditures incurred by CROs and CDMOs as of December 31, 2023.
While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from the cost of work performed to date up to twelve months of future committed manufacturing costs. As of December 31, 2023, the noncancellable portion of these contracts total in aggregate, excluding amounts recorded in accounts payable and accrued expenses as of this date is approximately $62.8 million. The noncancellable purchase commitments relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101.
Cash Flow Summary
The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Net cash used in operating activities$(193,309)$(115,301)
Net cash used in investing activities(4,593)(686)
Net cash provided by financing activities 201,961 258,551 
Net increase in cash$4,059 $142,564 
Operating Activities
Net cash used in operating activities was $193.3 million during the year ended December 31, 2023 and consisted primarily of a net loss of $241.4 million, adjusted for non-cash items including stock-based compensation expense of $24.8 million, accretion on our debt discount and the non-cash portion of interest expense related to our debt of $4.9 million, depreciation and amortization of $1.2 million, and non-cash lease expense of $1.8 million. Non-cash revenue of $1.6 million earned in relation to the equity interest in Phylaxis received during the period was offset by the loss on equity method investment of $1.6 million reflecting our share of losses in Phylaxis. Changes in operating assets and liabilities also contributed to the cash used in operating activities, including an increase in prepaid expenses of $10.3 million, primarily due to the prepayment for clinical drug substance manufacturing services at our CDMOs during the year. Additionally, the operating lease liability decreased by $1.9 million as a result of lease payments made throughout the year. Accounts receivable increased by $0.5 million, primarily as a result of dividends earned and not received as of December 31, 2023. Deferred revenue decreased by $0.2 million following the recognition of $0.2 million of previously deferred revenue related to our option agreement with Chiesi. These uses of cash were offset by an increase in accrued expenses of $26.1 million and an increase in accounts payable of $2.1 million, primarily due to the timing of clinical drug substance manufacturing services incurred at our CDMOs and clinical activities incurred at our CROs, in addition to increases in compensation-related accruals as related to employee bonuses.
Net cash used in operating activities was $115.3 million during the year ended December 31, 2022 and consisted primarily of a net loss of $145.2 million, adjusted for non-cash items including stock-based compensation expense of $20.5 million, accretion on our debt discount and the non-cash portion of interest expense related to our debt of $3.4 million, depreciation and amortization of $1.2 million, and non-cash lease expense of $1.6 million. Changes in operating assets and liabilities also contributed to the cash used in operating activities, including a decrease in deferred revenue of $2.0 million following the recognition of $0.9 million of previously deferred revenue related to
111

our option agreement with Chiesi and $1.1 million of previously deferred revenue related to our agreements with Phylaxis. Additionally, the operating lease liability decreased by $1.7 million as a result of lease payments made throughout the year. Other non-current assets increased by $1.3 million relating to deposits paid to one of our CRO partners, while our accounts payable balance decreased by $0.7 million. These uses of cash were offset in part by an increase in accrued expenses of $7.6 million and a decrease in prepaid expenses of $0.6 million, which are due to the timing of clinical and development activities which were incurred during the year. Additionally, accounts receivable and receivables from related parties decreased by $0.6 million, primarily as a result of the receipt of payments associated with our cost sharing agreements with Elpiscience.
Investing Activities
Net cash used in investing activities was $4.6 million and $0.7 million during the years ended December 31, 2023 and December 31, 2022, respectively, and was related to capital purchases of laboratory and office equipment. During the year ended December 31, 2023, the increased cash outflows related to the expansion of software and office space.
Financing Activities
Net cash provided by financing activities was $202.0 million during the year ended December 31, 2023 and consisted primarily of proceeds of $200.0 million from the issuance of common stock and pre-funded warrants in a private placement transaction, offset in part by issuance costs of $0.4 million. In addition, we received proceeds of $2.3 million from the exercise of stock options.
Net cash provided by financing activities was $258.6 million during the year ended December 31, 2022 and consisted primarily of net proceeds of $128.9 million from the Amended 2020 Loan Agreement and proceeds of $127.4 million from our ATM offering, offset in part by the payment of costs associated with the ATM offering of $0.4 million. In addition, we received proceeds of $2.8 million from the exercise of stock options.
Critical Accounting Estimates
Our consolidated financial statements and accompanying notes are prepared in accordance with United States generally accepted accounting principles, or GAAP, which requires management to make estimates and assumptions that affect the amounts reported. Management bases its estimates on historical experience, market and other conditions, and various other assumptions it believes to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact us in the future, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our consolidated financial statements may be materially affected. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may also have a material effect in our consolidated financial statements. We review our estimates, judgments, and assumptions used in our accounting practices periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. We believe that these estimates are reasonable; however, our actual results may differ from these estimates.
While our significant accounting policies are described in more detail in Note 1 to our consolidated financial statements included elsewhere in this Annual Report, we believe that the following critical accounting policies and estimates have a higher degree of inherent uncertainty and require our most significant judgments:
Collaboration and License Agreements
We enter into collaborative agreements with partners that typically include one or more of the following: (i) license fees; (ii) nonrefundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development, regulatory, or commercial milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, we analyze each unit of account within the contract to determine if the counterparty is a customer in the context of the unit of account.
We consider a variety of factors which may require significant judgment in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements are distinct performance obligations, whether there are observable standalone prices, and whether any licenses are functional or symbolic. We evaluate
112

each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, license fees and non-refundable upfront fees are considered fixed, while milestone payments are identified as variable consideration which must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.
See Note 6 to our consolidated financial statements included elsewhere in this Annual Report for additional information on our collaboration and license agreements.
Accrued Research and Development and Clinical Trial Costs
We enter into contracts for research and development activities, including with CDMOs for clinical supplies and manufacturing scale-up activities related to our therapeutic candidates and with CROs for our preclinical studies and clinical trials. The financial terms of these agreements vary and may result in payment flows that do not match the periods over which materials or services are provided, resulting in either an accrual or a prepaid expense.
These accruals of research and development expenses require us to estimate expenses incurred, including estimates of the time period over which services will be performed, completion of contract components, the enrollment of subjects, and the status of our clinical trials. Such estimates are dependent upon the timeliness and accuracy of data provided by the CROs and CDMOs regarding the status and cost of the studies. If the actual timing of the performance of services varies from our estimates, we adjust the accrual or prepaid expense accordingly.
Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.
Fair Value of Stock-Based Awards and Stock-Based Compensation Expense
We recognize compensation costs related to stock-based awards, including stock options, under our 2017 Employee, Director and Consultant Equity Incentive Plan to certain of our employees and certain members of our board of directors. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards.
We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of subjective assumptions to determine the fair value of stock-based awards. These assumptions include:
•Fair Value of Common Stock—Our board of directors determines the fair value of each share of underlying common stock based on the closing price of our common stock as reported by the applicable trading market on the date of the grant. Our board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of our common stock underlying those options on the grant date.
•Expected Term—We estimate the expected term of our stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.
•Expected Volatility—Due to the lack of company specific historical and implied volatility data indicative of the expected future volatility, we based our estimate of expected volatility on the estimate and expected volatilities of a guideline group of publicly traded companies. For these analyses, we select companies with comparable characteristics to ours including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. We compute the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of our stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available, or we believe the volatility of our own market-traded shares best represents expected volatility.
•Risk-Free Interest Rate—For the determination of the risk-free interest rates we utilize the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption.
113

•Expected Dividend—The expected dividend yield is assumed to be zero as we have never paid dividends and do not have current plans to pay any dividends on our common stock.
Changes in these assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. See Note 5 to our consolidated financial statements included elsewhere in this Annual Report for information regarding certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted in the periods discussed.
Recent Accounting Pronouncements
For information with respect to recently issued accounting standards and the impact of these standards, if any, on our consolidated financial statements, refer to Note 1 in our consolidated financial statements in Part II, Item 8 of this Annual Report.
114

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
Not applicable.

115

Item 8. Financial Statements and Supplementary Data.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
116

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Stockholders
Inhibrx, Inc.
La Jolla, California
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Inhibrx, Inc. (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and our report dated February 28, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Clinical Trial Accruals
As described in Note 1 and Note 2 to the consolidated financial statements, clinical trial activities are accrued and expensed based on estimates of the period in which services and efforts are expended by contract research organizations (“CROs”) and other third parties. Estimates are determined by reviewing cost information provided by CROs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and the
117

scope of work to be performed. As of December 31, 2023, the Company recorded $9.2 million in clinical trial accruals, which was included in accrued expenses on the balance sheet.
We identified the estimation of clinical trial accruals as a critical audit matter. Management’s judgment was required in estimating the period in which services and efforts were expended used to determine the clinical trial accruals. Auditing clinical trial accruals involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters.
The primary procedures we performed to address this critical audit matter included:
•Testing the appropriate measurement of clinical trial accruals by obtaining and inspecting certain agreements and amendments, and confirming total clinical costs incurred and total amounts billed with third-party vendors.
•Testing the completeness of the Company’s clinical trial accruals by evaluating internal materials and publicly available information (such as press releases and public databases that track clinical trials) and inquiring of clinical personnel to gain an understanding of the status of certain on-going clinical trials, and testing invoices received after year-end for certain third-party vendors.

/s/ BDO USA, P.C.
We have served as the Company’s auditor since 2018.
San Diego, California
February 28, 2024
118

Inhibrx, Inc.
Consolidated Balance Sheets
(In thousands, except share data and par value) 
AS OF DECEMBER 31,
20232022
Assets
Current assets:
Cash and cash equivalents$277,924 $273,865 
Accounts receivable778 243 
Receivables from related parties— 14 
Prepaid expenses and other current assets16,656 6,371 
Total current assets295,358 280,493 
Property and equipment, net6,419 2,501 
Operating right-of-use asset2,952 4,717 
Other non-current assets3,164 3,164 
Total assets$307,893 $290,875 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$10,954 $8,326 
Accrued expenses43,295 17,224 
Deferred revenue
— 166 
Current portion of lease liability2,063 1,860 
Total current liabilities56,312 27,576 
Long-term debt, including final payment fee206,968 202,069 
Non-current portion of lease liability1,110 3,173 
Total liabilities264,390 232,818 
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022
— — 
Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 47,369,511 and 43,564,283 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
5 4 
Additional paid-in-capital657,232 430,426 
Accumulated deficit(613,734)(372,373)
Total stockholders’ equity 43,503 58,057 
Total liabilities and stockholders’ equity$307,893 $290,875 
The accompanying notes are an integral part of these consolidated financial statements.
119

Inhibrx, Inc.
Consolidated Statements of Operations
(In thousands, except per share data)
YEAR ENDED
DECEMBER 31,
20232022
Revenue:
License fee revenue$1,800 $2,178 
Grant revenue— 14 
Total revenue1,800 2,192 
Operating expenses:
Research and development191,640 110,186 
General and administrative29,381 21,123 
Total operating expenses221,021 131,309 
Loss from operations(219,221)(129,117)
Other income (expense):
Interest expense(31,840)(18,181)
Interest income11,917 2,074 
Other income (expense), net
(580)1 
Total other expense(20,503)(16,106)
Loss before provision for income taxes(239,724)(145,223)
Provision for income taxes3 3 
Loss on equity method investment1,634 — 
Net loss$(241,361)$(145,226)
Net loss per share, basic and diluted$(5.12)$(3.62)
Weighted-average shares of common stock outstanding, basic and diluted47,130 40,108 
The accompanying notes are an integral part of these consolidated financial statements.
120

Inhibrx, Inc.
Consolidated Statements of Stockholders’ Equity
(In thousands)
Common Stock
(Shares)		Common Stock (Amount)Additional Paid-In CapitalAccumulated DeficitTotal Stockholders’ Equity
Balance as of December 31, 202138,991 $4 $279,526 $(227,147)$52,383 
Stock-based compensation expense— — 20,450 — 20,450 
Issuance of shares upon exercise of stock options241 — 2,757 — 2,757 
Issuance of shares, net of issuance costs4,332 — 126,981 — 126,981 
Issuance of warrants— — 712 — 712 
Net loss— — — (145,226)(145,226)
Balance as of December 31, 202243,564 $4 $430,426 $(372,373)$58,057 
Stock-based compensation expense— — 24,846 — 24,846 
Issuance of shares upon exercise of stock options184 — 2,316 — 2,316 
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs3,621 1 199,644 — 199,645 
Net loss— — — (241,361)(241,361)
Balance as of December 31, 202347,369 $5 $657,232 $(613,734)$43,503 
The accompanying notes are an integral part of these consolidated financial statements.
121

Inhibrx, Inc.
Consolidated Statements of Cash Flows
(In thousands)
YEAR ENDED
DECEMBER 31,  
20232022
Cash flows from operating activities
Net loss$(241,361)$(145,226)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,191 1,225 
Accretion of debt discount and non-cash interest expense4,899 3,448 
Stock-based compensation expense24,846 20,450 
Non-cash lease expense1,765 1,621 
Loss from equity method investment1,634 — 
Non-cash license revenue
(1,634)— 
Loss on disposal of fixed assets
3 19 
Changes in operating assets and liabilities:
Accounts receivable(535)130 
Receivables from related parties14 491 
Prepaid expenses and other current assets(10,285)612 
Other non-current assets— (1,317)
Accounts payable2,109 (705)
Accrued expenses
26,071 7,603 
Operating lease liability(1,860)(1,674)
Deferred revenue, current portion(166)(1,868)
Deferred revenue, non-current portion— (110)
Net cash used in operating activities(193,309)(115,301)
Cash flows from investing activities
Purchase of fixed assets(4,593)(686)
Net cash used in investing activities(4,593)(686)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants in private placement200,000 — 
Issuance costs associated with issuance of common stock and pre-funded warrants in private placement(355)— 
Proceeds from ATM offering— 127,371 
Costs associated with ATM offering— (390)
Proceeds from the issuance of debt— 128,863 
Payment of fees associated with debt— (50)
Proceeds from exercise of stock options2,316 2,757 
Net cash provided by financing activities 201,961 258,551 
Net increase in cash4,059 142,564 
Cash and cash equivalents at beginning of period273,865 131,301 
Cash and cash equivalents at end of period $277,924 $273,865 
122

Supplemental disclosure of cash flow information
Cash paid for interest$26,717 $13,090 
Cash paid for income taxes$3 $4 
Supplemental schedule of non-cash investing and financing activities
Payable for purchase of fixed assets$519 $— 
Fair value of warrants issued to lender in conjunction with February 2022 Amendment (as defined in Note 3)
$— $712 
The accompanying notes are an integral part of these consolidated financial statements.
123

Inhibrx, Inc.
Notes to Consolidated Financial Statements
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company’s current pipeline is focused on oncology and orphan diseases.
The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company’s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.
Liquidity
As of December 31, 2023, the Company had an accumulated deficit of $613.7 million and cash and cash equivalents of $277.9 million. From its inception and through December 31, 2023, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities.
In August 2023, the Company received gross proceeds of $200.0 million before deducting $0.4 million of offering expenses payable by the Company in a private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which the Company sold and issued 3,621,314 shares of the Company’s common stock and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock. See Note 4 for further discussion of this equity offering.
The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements.
If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders’ rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises
124

additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.
The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.
Use of Estimates
The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Fair Value of Financial Instruments
The Company’s financial instruments consist principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity.
Cash and Cash Equivalents
Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep and money market accounts, and highly liquid investments in debt securities with an original maturity of three months or less. The Company’s investments in debt securities have consisted of U.S. Treasury Bills, which were recorded at their amortized cost, reflective of the amortization or accretion of premiums or discounts.
As of December 31, 2023, the Company held no investments in debt securities. As of December 31, 2022, these investments were recorded at their amortized cost of $196.3 million, which was adjusted for the amortization or accretion of premiums or discounts.
Concentrations of Credit Risk
Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has
125

not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.
The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company’s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December 31, 2023 and December 31, 2022, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.
Dividends
As of December 31, 2023, the Company has never declared or paid any dividends on its common stock.
Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company’s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company’s common stock will be at the discretion of the Company’s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company’s board of directors may deem relevant.
Property and Equipment, Net
Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows:
•laboratory and office equipment: three to five years;
•furniture, fixtures and other: five years; and
•computer software: three years.
Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.
Impairment of Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.
Leases
The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company’s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company’s two existing leases are classified as operating leases.
For the long-term operating lease of its corporate headquarters, the Company recognized an operating right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are
126

reviewed at inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement.
The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.
Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented.
Investment in Phylaxis
The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company’s proportionate share of the net income or loss of Phylaxis is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions.
The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company’s share of prior losses of the investee. Following the Company’s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company’s investment in Phylaxis as of December 31, 2023 and December 31, 2022 is zero.
Fair Value Measurements
The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include:
•Level 1 - Quoted prices in active markets for identical assets or liabilities.
•Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
During the years ended December 31, 2023 and December 31, 2022, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which are classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which are classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value. As of December 31, 2023, the Company held no investments in debt securities. The Company’s outstanding debt is classified as Level 2 in the fair value hierarchy. As of December 31, 2023 and December 31, 2022, the Company had no financial instruments measured at fair value on a recurring basis.
127

Deferred Financing Costs and Other Debt-Related Costs
Deferred financing costs are capitalized, recorded as an offset to the Company’s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, Imputation of Interest. If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability.
Deferred Offering Costs
The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering.
Legal, accounting, and filing fees related directly to the Company’s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In October 2022, the Company completed an offering under the Shelf Registration and offset $3.0 million of offering costs against the proceeds. In August 2023, the Company completed a private placement offering, under which the Company offset $0.4 million of offering costs against the proceeds. There were no deferred offering costs as of December 31, 2023 or December 31, 2022.
Financial Instruments with Characteristics of Both Liabilities and Equity
The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 480-10, and ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company’s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company’s outstanding warrants are classified as equity as of and for the years ended December 31, 2023 and December 31, 2022.
Revenue Recognition
The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.
Collaborative Research, Development, and License Agreements
The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2) nonrefundable up-front fees; (3) payments for reimbursement of research costs; (4) payments associated with achieving specific development, regulatory, or commercial milestones; and (5) royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.
Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained
128

and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs.
The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company’s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.
Grant Revenue
The Company has been awarded a grant from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD, under which the Company’s internal costs specifically covered by the grant for a specified project are subject to reimbursement when incurred. Since there is no transfer of control of goods or services to the granting agency, revenue is recognized as the Company incurs expenses related to the grant in the gross amount of the reimbursement and costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.
Accrued Research and Development and Clinical Trial Costs
Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. The Company’s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as
129

amended, or IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending finalization, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur ownership changes in the future. If an ownership change occurs, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common stock equivalents outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive.
The weighted average number of common stock used in the basic and diluted net loss per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.
For purposes of the diluted net loss per share calculation, other than pre-funded warrants as discussed above, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Accordingly, for the years ended December 31, 2023 and December 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, as weighted based on the period outstanding during each year, are as follows (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Outstanding stock options6,336 5,018 
Warrant to purchase common stock47 45 
6,383 5,063 
Fair Value of Stock-Based Awards
The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.
Other Comprehensive Income
The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.
Segment Information
The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting
130

pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption.
Adoption of New Accounting Pronouncements
In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as held-to-maturity debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. The Company adopted ASU 2016-13 as of January 1, 2023, which did not result in a material impact on its consolidated financial statements and related disclosures.
Recently Issued but Not Yet Adopted Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.
2. OTHER FINANCIAL INFORMATION
Prepaid Expense and Other Current Assets
Prepaid expense and other current assets were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Clinical drug substance and product manufacturing (1)
$9,888 $1,171 
Clinical trials (2)
5,409 4,294 
Licenses728 493 
Outside research and development services (3)
265 232 
Other366 181 
Prepaid expense and other current assets$16,656 $6,371 
(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
131

Property and Equipment, Net
Property and equipment, net were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Machinery and equipment$8,480 $7,023 
Furniture, fixtures and other540 524 
Leasehold improvements441 441 
Computer software53 53 
Construction in process (1)
3,592 — 
Total property and equipment13,106 8,041 
Less: accumulated depreciation and amortization(6,687)(5,540)
Property and equipment, net$6,419 $2,501 
(1) As of December 31, 2023, consists of renovations to the Company’s office space and software not yet placed in service.
Depreciation and amortization expense totaled $1.2 million for each of the years ended December 31, 2023 and December 31, 2022, and consisted of the following (in thousands):
 YEAR ENDED DECEMBER 31,
20232022
Research and development$992 $1,003 
General and administrative199 222 
Total depreciation and amortization expense$1,191 $1,225 
Accrued Expenses
Accrued expenses were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Clinical drug substance and product manufacturing (1)
$22,805 $5,381 
Clinical trials (2)
9,224 4,527 
Compensation expense6,506 3,374 
Interest expense2,348 2,124 
Other outside research and development (3)
1,129 1,164 
Professional fees780 428 
Other503 226 
Accrued expenses$43,295 $17,224 
(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s usage of third-party CROs for management of clinical trials. See Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.

3. DEBT
2020 Loan Agreement
In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $10.0 million in gross proceeds, or Term A. The 2020 Loan
132

Agreement was subsequently amended in November 2020, or the November 2020 Amendment, upon which a second tranche in an aggregate principal amount of $20.0 million was funded, or Term B, and in June 2021, or the June 2021 Amendment, upon which a third tranche in an aggregate principal amount of $40.0 million was funded, or Term C.
In February 2022, the Company entered into an additional amendment, or the February 2022 Amendment, to the 2020 Loan Agreement, collectively, the Amended 2020 Loan Agreement, upon which the Company received gross proceeds of $40.0 million, or Term D. The February 2022 Amendment also provided for an increase in the interest rate and for three future tranches of debt to be funded upon the achievement of certain milestones. In June 2022, the Company received additional gross proceeds of $30.0 million, or Term E, following the initiation of part 4 of the Phase 1 clinical trial of INBRX-105, as well as an additional $30.0 million in gross proceeds, or Term F, following the receipt of positive topline data from the Phase 1 clinical trial of INBRX-101.
In October 2022, the Company entered into an amendment to the Amended 2020 Loan Agreement, or the October 2022 Amendment. The October 2022 Amendment amended the milestone terms of the last remaining tranche, Term G, under the Amended 2020 Loan Agreement to provide for the funding of $30.0 million upon the announcement of the regulatory path for INBRX-101 rather than upon the initiation of a potentially registration-enabling clinical trial of INBRX-101. In October 2022, the Company met this milestone and drew the final tranche for additional gross proceeds of $30.0 million.
The Company determined the November 2020, June 2021, February 2022, and October 2022 Amendments should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flows were not substantially changed upon each of the amendments. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date (as defined below).
As of July 1, 2023, a LIBOR Transition Event, as defined in the Amended 2020 Loan Agreement, occurred, and pursuant to the Amended 2020 Loan Agreement, Oxford selected a LIBOR Replacement Rate, as defined in the Amended 2020 Loan Agreement, replacing the 30 day U.S. Dollar London InterBank Offered Rate with the 1-Month Chicago Mercantile Exchange term secured overnight financing rate, or 1-Month CME Term SOFR, causing an amendment to the interest rate of the Company’s outstanding loans. No other terms were changed. The Company has elected the optional expedient under ASC Topic 848-20 and therefore deemed the modification to not be substantial.
As of December 31, 2023, the Company has $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on January 1, 2027, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) 8.30% or (2) the sum of (i) the 1 Month CME Term SOFR on the last business day of the month that immediately precedes the month in which the interest will accrue, (ii) 0.10%, and (iii) 8.19%. Under the Amended 2020 Loan Agreement, the repayment schedule provides for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. In the event of a qualifying financing event in which the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, the interest-only period may be extended an additional 12 months through February 1, 2026, which would then be followed by 11 months of equal payments of principal plus interest, beginning on March 1, 2026. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final payment of $18.0 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment.
133

The Company’s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following as of December 31, 2023 and December 31, 2022 (in thousands).
AS OF DECEMBER 31,
20232022
Term A$10,900 $10,900 
Term B21,800 21,800 
Term C43,600 43,600 
Term D43,600 43,600 
Term E32,700 32,700 
Term F32,700 32,700 
Term G32,700 32,700 
Less: debt discount(11,032)(15,931)
Long-term debt, including debt discount and final payment fee$206,968 $202,069 
As of December 31, 2023, and unless extended in accordance with the terms described above, the Company’s interest-only period will continue through February 2025, with principal payments beginning in March 2025. Future principal payments and final fee payments will be made as follows (in thousands):
AS OF DECEMBER 31, 2023
2025$86,956 
2026104,348 
202726,696 
Total future minimum payments218,000 
Less: unamortized debt discount(11,032)
Total debt$206,968 
The Company’s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company’s assets with a positive lien on intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company’s operations, that may require prepayment of the outstanding term loans. Additionally, following the June 2021 Amendment, the Amended 2020 Loan Agreement requires the Company to maintain a minimum cash balance of $20.0 million. As of December 31, 2023, the Company is in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity.
Concurrently with the February 2022 Amendment, the Company issued 40,000 warrants to Oxford to purchase shares of the Company’s common stock at an exercise price of $45.00. Upon issuance, the warrants were classified as equity and recorded at their fair value of $0.7 million. See Note 4 for further discussion of these warrants.
Interest Expense
Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2023, interest expense was $31.8 million, $4.9 million of which related to non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2022, interest expense was $18.2 million, $3.4 million of which related to non-cash amortization of the debt discount and accretion of the final payment.
4. STOCKHOLDERS’ EQUITY
Open Market Sale Agreement
In September 2021, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an
134

aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. Pursuant to the Sales Agreement, the Company paid the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold, which was amended to 2% of the total sales price per share sold during 2022.
During the year ended December 31, 2022, the Company sold 4,332,354 shares pursuant to the Sales Agreement for net proceeds of $127.4 million, after deducting commissions of $2.6 million. In connection with the ATM Offerings during the year ended December 31, 2022, the Company incurred an additional $0.4 million of expenses which were offset against the proceeds of the offering. During the year ended December 31, 2023, the Company did not issue any shares under the Sales Agreement.
Securities Purchase Agreement
In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with the Purchasers, pursuant to which the Company sold and issued 3,621,314 shares of the Company’s common stock for $19.35 per share and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock in the Private Placement. The purchase price of the pre-funded warrants was $19.3499 per pre-funded warrant, with an exercise price of $0.0001 per share. The Company received gross proceeds of $200.0 million from the Private Placement, before deducting $0.4 million of offering expenses payable by the Company. The pre-funded warrants are equity-classified and carried at the instruments’ fair value upon issuance. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement and will expire when exercised in full. As of December 31, 2023, all pre-funded warrants are still outstanding.
Warrants Issued in Connection with Amended 2020 Loan Agreement
As of December 31, 2023, the following equity-classified warrants were outstanding, in addition to the pre-funded warrants discussed above:
Expiration DateShares of Common Stock Issuable Upon Exercise of WarrantsExercise Price per Share
July 15, 2030
7,354
$17.00 
February 18, 2032
40,000
$45.00 
The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity, with no subsequent remeasurements.
Common Stock Reserved for Future Issuance
Common stock reserved for future issuance as of December 31, 2023 and December 31, 2022 consist of the following (in thousands):
AS OF DECEMBER 31,
20232022
Options to purchase common stock issued and outstanding6,494 5,305 
Shares available for future equity grants533 162 
Pre-funded warrants issued and outstanding6,715 — 
Warrants issued and outstanding47 47 
Total common stock reserved for future issuance13,789 5,514 
5. EQUITY COMPENSATION PLAN
Stock Incentive Plan
The Company’s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted
135

and unrestricted stock awards, and other stock-based awards. As of December 31, 2023, an aggregate of 7.8 million shares of common stock were authorized for issuance under the 2017 Plan, of which 0.5 million remain available for issuance.
Stock Option Activity
The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.
A summary of the Company’s stock option activity under its 2017 Plan for the year ended December 31, 2023 is as follows (in thousands, except for per share data and years):
Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (In Years)Aggregate Intrinsic Value
Outstanding as of December 31, 2022
5,305 $22.95 
Granted1,615 $22.98 
Forfeited(242)$23.88 
Exercised(184)$12.59 
Outstanding as of December 31, 2023
6,494 $23.22 7.6$96,548 
Vested and exercisable as of December 31, 2023
3,322 $21.80 6.6$54,101 
The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and December 31, 2022 was $2.1 million and $3.7 million, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and as of December 31, 2023, respectively. The total fair value of stock options vested during the years ended December 31, 2023 and December 31, 2022 was $24.9 million and $25.0 million, respectively.
Stock-Based Compensation Expense
Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company’s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period.
The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2023 and December 31, 2022 were as follows. 
 YEAR ENDED DECEMBER 31,
 20232022
Risk-free interest rate3.77 %2.63 %
Expected volatility84.31 %85.26 %
Expected dividend yield— %— %
Expected term6.086.08
Weighted average fair value$16.88$17.72
136

The Company determines the assumptions used in the option pricing model in the following manner:
Risk-Free Interest Rate—For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption.
Expected Volatility—Due to the Company’s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company’s market-traded shares best represents its expected volatility.
Expected Dividend—The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock.
Expected Term—The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.
Fair Value—The fair value of the Company’s common stock is determined based on its closing market price on the date of the grant. The Company’s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date.
Stock-based compensation expense for stock options consisted of the following (in thousands):
 YEAR ENDED DECEMBER 31,
20232022
Research and development$16,630 $14,513 
General and administrative8,216 5,937 
Total stock-based compensation expense$24,846 $20,450 
As of December 31, 2023, the Company had $51.8 million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of 2.5 years.
137

6. LICENSE AND GRANT REVENUES
The following table summarizes the total revenue recorded in the Company’s consolidated statements of operations (in thousands):
YEAR ENDED DECEMBER 31,
20232022
License fee revenue  
Phylaxis BioScience, LLC$1,634 $1,101 
Chiesi Farmaceutici S.p.A.166 877 
2seventy bio, Inc.— 200 
Total license fee revenue1,800 2,178 
Grant revenue  
Congressionally Directed Medical Research Program— 14 
Total grant revenue— 14 
Total revenue$1,800 $2,192 
License and Collaboration Agreements
Phylaxis Agreements
In July 2020, the Company entered into a joint venture with Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement, or collectively the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. The Company received $5.0 million in nonrefundable, upfront payments from Phylaxis under the Master Services Agreement, or the MSA. In addition, upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company’s intellectual property and know-how. Pursuant to the terms of the Phylaxis Agreements, during the fourth quarter of 2023, the Company received an additional 5% equity interest in Phylaxis following the achievement of a milestone event. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0 million and $175.0 million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.
The Company recognized the initial transaction price of $5.5 million, comprised of the $5.0 million in upfront payments and the fair value of the 10% equity interest of $0.5 million, over the period of performance of development services on the two compounds. During the third quarter of 2022, the Company fulfilled this performance obligation in full and recognized all remaining deferred revenue under this contract.
During the fourth quarter of 2023, the Company transferred a second generation compound to Phylaxis, which was a milestone event under the agreements. Upon transfer, the Company received an additional 5% equity interest in Phylaxis, which has a fair value of $1.6 million. The Company recognized the fair value of the 5% equity interest as revenue and accounted for the investment under the equity method. In order to determine the fair value of the equity interest in Phylaxis upon this milestone, the Company utilized the investee’s independent valuations based on recent financings from third party investors at fair market value.
During the years ended December 31, 2023 and December 31, 2022, the Company recognized $1.6 million and $1.1 million of revenue under the Phylaxis agreements. As of December 31, 2023 and December 31, 2022, the Company had no deferred revenue related to this agreement.
Chiesi
In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and
138

commercialize INBRX-101 outside of the United States and Canada. Additionally, the Chiesi Option Agreement provided Chiesi with a right of negotiation for INBRX-101 development and commercialization rights in the United States and Canada in the event that the Company engages in discussions with any third parties for such rights during the term of the Chiesi Option Agreement. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019.
The Company identified one performance obligation as of the effective date of the Chiesi Option Agreement, which is to perform research and development services for Chiesi during the option period, which would continue (unless the Chiesi Option Agreement is terminated earlier by Chiesi or the Company) until 60 days following the last to occur of (i) the Company’s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company’s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration, or FDA, scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company’s delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company determined that the option to grant a license in the future is not a material right.
On July 24, 2023, the Company provided a copy of the European Medicines Agency, or EMA, scientific advice to Chiesi upon receipt, which fulfilled the necessary deliverables to Chiesi and triggered the start of its 60-day option period window. On September 18, 2023, the Company was notified that Chiesi declined to exercise its option, resulting in the expiration of the Chiesi Option Agreement (upon the lapse of the option period), and with the Company retaining global rights to develop and commercialize INBRX-101.
The $10.0 million upfront payment was allocated to the single performance obligation. Revenue is recognized over time as services are performed during the option period, based on the Company’s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the years ended December 31, 2023 and December 31, 2022, the Company recognized $0.1 million and $0.9 million in revenue related to this agreement, respectively. As of December 31, 2023, the Company has no deferred revenue related to this agreement. As of December 31, 2022, the Company had $0.1 million current deferred revenue related to this agreement.
2seventy bio, Inc.
In June 2020, the Company entered into an Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. In November 2021, this agreement, or the 2020 2seventy Agreement, was assigned to 2seventy bio, Inc., or 2seventy, in connection with bluebird’s internal restructuring and subsequent spin-out of 2seventy.
In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee of $0.2 million in exchange for a development license. Under each of the three programs, the Company has granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which 2seventy exercises its option, 2seventy will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. As of December 31, 2023, 2seventy has exercised one of its options and declined one of its options as related to the two initial programs, while the third program option remains outstanding.
139

As of the effective date of the 2020 2seventy Agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company re-assesses its performance obligations and transaction price accordingly.
In June 2022, pursuant to the terms regarding the addition of new programs in the 2020 2seventy Agreement, the Company received a $0.2 million upfront option fee related to the selection of a third program and transferred the related know-how and development license. The Company recognized the $0.2 million of revenue at the point in time in which the program was added and the program term began.
During the year ended December 31, 2022, the Company recognized $0.2 million of revenue related to this agreement. The Company did not recognize any revenue related to this agreement during the year ended December 31, 2023.
Government Grants
Grant revenue was recognized in accordance with the Company’s stated methodology discussed in Note 1.
CDMRP funded through the DoD
In February 2021, the Company was awarded a grant from the DoD in the amount of approximately $0.3 million for the development of sdAb based therapeutics targeting SARS-CoV-2 Spike protein for the treatment of COVID-19, or the 2021 DoD grant. Work under the grant began in February 2021 and continued through February 2022.
Revenue from this grant is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant’s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears.
During the year ended December 31, 2022, $14,000 was recognized as revenue under the grant. All work was completed during the year ended December 31, 2022. No revenue was recognized under the grant during the year ended December 31, 2023.
7. INCOME TAXES
The components of income tax expense (benefit) were as follows for the years ended December 31, 2023 and December 31, 2022, respectively (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Current expense:
State$3 $3 
Total current expense$3 $3 
The provision for the years ended December 31, 2023 and December 31, 2022 was related to state income taxes.
140

A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and December 31, 2022 as follows (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Expected income tax benefit at federal statutory rate$(50,684)$(30,497)
State income tax expense (benefit), net of federal benefit(3,568)(2,495)
Permanent items1,524 583 
R&D credits(2,322)(1,261)
Unrecognized tax benefits (FIN 48)1,054 751 
Return to provision true-ups(420)(135)
Valuation allowance54,419 33,057 
Income tax expense$3 $3 
Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
The components of net deferred income taxes were as follows (in thousands):
AS OF DECEMBER 31,
 20232022
Deferred income tax assets 
Net operating loss carryforward$68,254 $52,970 
Research and development credits12,648 9,728 
Intangibles3,289 3,684 
Accruals1,412 696 
Stock compensation8,581 5,130 
Capitalized research and development costs51,772 19,585 
Deferred revenue— 37 
Operating lease liabilities697 1,118 
Other10 — 
Gross deferred tax assets146,663 92,948 
Less: Valuation allowance(146,005)(91,586)
Total deferred tax assets658 1,362 
Deferred income tax liabilities 
Fixed assets(10)(35)
Operating lease right-of-use assets(648)(1,048)
Other— (279)
Total deferred tax liabilities(658)(1,362)
Net deferred tax assets (liabilities)$— $— 
As of December 31, 2023, the Company had unused federal and state NOL carryforwards of approximately $305.1 million and $65.3 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to
141

expire in 2038, if not utilized. As of December 31, 2023, the Company also had federal and state research tax credit carryforwards of $12.4 million and $6.2 million, respectively. The federal research tax credit carryforwards begin to expire in 2038, while the state carryforwards have no expiration.
The utilization of NOL and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending the finalization of the study, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur additional ownership changes in the future. If an ownership change has occurred, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.
The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2023. Such objective evidence limits the ability to consider other subjective evidence such as the Company’s projections for future growth. Based on this evaluation, as of December 31, 2023, a valuation allowance of $146.0 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company’s projections for growth.
The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):
AS OF DECEMBER 31,
 20232022
Beginning balance$3,597 $2,846 
Increases related to current year tax positions1,054 751 
Ending balance$4,651 $3,597 
As of December 31, 2023, the Company had gross unrecognized tax benefits of $4.7 million, none of which would affect the effective tax rate due to the existence of a full valuation allowance. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company’s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December 31, 2023 or December 31, 2022, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2023 and December 31, 2022 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced.
142

The Company is subject to income taxes in the United States and various state jurisdictions. The Company’s tax years from 2019 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority.
8. LEASES
Operating Leases
In September 2017, the Company entered into a seven-year lease agreement as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years, which is not included in the right-of-use asset and lease liabilities. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually.
In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually.
The operating right-of-use asset and operating lease liability as of December 31, 2023 and December 31, 2022 are as follows (in thousands):
AS OF DECEMBER 31,
20232022
Operating right-of-use asset$2,952 $4,717 
Operating lease liability
Current2,063 1,860 
Non-current1,110 3,173 
Total operating lease liability$3,173 $5,033 
During the years ended December 31, 2023 and December 31, 2022, the Company recognized operating lease expense of $3.7 million and $3.4 million, respectively. During each of the years ended December 31, 2023 and December 31, 2022, the Company paid $2.2 million for amounts included in the measurement of the operating lease liability in each period.
As of December 31, 2023 and December 31, 2022, the Company’s operating lease had a remaining term of 1.5 and 2.5 years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% as of December 31, 2023 and December 31, 2022.
143

Future minimum rental commitments for the Company’s operating leases reconciled to the operating lease liability are as follows (in thousands):
AS OF DECEMBER 31,
2023
2024$2,247 
20251,137 
Total future minimum lease payments$3,384 
Less: imputed interest(211)
Present value of operating lease liability3,173 
Less: current portion of operating lease liability(2,063)
Non-current portion of operating lease liability$1,110 
9. COMMITMENTS AND CONTINGENCIES
Litigation
Other than as described below, the Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.
I-Mab Litigation
On March 1, 2022, I-Mab Biopharma, or I-Mab, filed a lawsuit against the Company and Brendan Eckelman, the Company’s co-founder and Chief Scientific Officer, in the United States District Court for the District of Delaware, C.A. No. 22-00276-CJB, asserting claims for misappropriation of trade secrets related to Dr. Eckelman’s service as an expert witness for Tracon Pharmaceuticals, Inc., or Tracon, in Tracon’s arbitration against I-Mab. The case is currently in the discovery process.
Inhibrx is unable to reasonably estimate possible damages or a range of possible damages in this matter given the uncertainty and therefore has not recorded a liability on its books as of December 31, 2023.
Indemnification
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company’s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.
Purchase Commitments
The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of December 31, 2023 and December 31, 2022, the noncancellable portion of these contracts total in aggregate, excluding amounts paid or incurred at each
144

respective date, approximately $62.8 million and $74.8 million, respectively. The noncancellable purchase commitments as of December 31, 2023 relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101. During the years ended December 31, 2023 and December 31, 2022, the Company incurred $44.5 million and $0.3 million of expenses related to its non-cancellable purchase agreements, respectively.
Other Commitments
Additionally, as of December 31, 2023 and December 31, 2022, Mark P. Lappe, the Company’s Chief Executive Officer, Brendan P. Eckelman, the Company’s Chief Scientific Officer, and Kelly D. Deck, the Company’s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.
Contingencies
In connection with its proposed Merger (as defined below), the Company engaged legal counsel under a contingent fee arrangement. Under this agreement, the Company is obligated to pay a fee of $20.0 million, contingent upon the consummation of the proposed transaction. In the event the Merger is not completed, the Company does not owe any fees to its legal counsel. The Company will incur these costs in full upon the consummation of the Merger, if and when it is completed, and has not incurred any portion of this fee as of December 31, 2023.
10. SUBSEQUENT EVENTS
The Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.
Merger and Spin-Off
On January 22, 2024, the Company, Aventis Inc., or Parent, a wholly owned indirect subsidiary of Sanofi, and Art Acquisition Sub, Inc., or the Merger Sub, a wholly owned subsidiary of Parent, entered into an Agreement and Plan of Merger, or the Merger Agreement. Pursuant to the terms of the Merger Agreement, Parent will acquire all outstanding shares of the Company via the merger of Merger Sub with and into the Company, or the Merger, with the Company surviving the Merger as a wholly owned subsidiary of Parent, and in turn each shareholder will receive (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx Biosciences, Inc., or New Inhibrx, for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Parent will (1) assume and retire the Company’s outstanding third-party debt, (2) cause New Inhibrx to be funded with $200.0 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%.
In connection with and as a condition to the Merger, the Company and New Inhibrx entered into a Separation and Distribution Agreement, dated as of January 22, 2024, or the Separation and Distribution Agreement, pursuant to which, immediately prior to the effective time of the Merger: (i) the Company will effect a pre-closing reorganization, which will result in (x) the Company owning, assuming or retaining all assets and liabilities primarily related to INBRX-101, or the 101 Business, and (y) New Inhibrx owning, assuming or retaining all other assets and liabilities of the Company and its subsidiaries; and (ii) thereafter, the Company will distribute to its stockholders as of the record date on a pro rata basis, 92% of the issued and outstanding shares of New Inhibrx common stock, at a ratio of one share of New Inhibrx common stock for every four shares of the Company’s issued and outstanding common stock held on the record date. Following the spin-off, New Inhibrx will be a separate public company and the Company will retain 8% of the issued and outstanding shares of New Inhibrx common stock as of the effective time of the spin-off.
The boards of directors of both the Company and Sanofi have unanimously approved the spin-off and the Merger. Parent will pay transaction consideration totaling approximately $2.2 billion in aggregate value. Parent will also make payments at the closing of the Merger to settle the Company’s third-party debt. Following the closing of the Merger, New Inhibrx will continue to operate under the Inhibrx name. Parent’s acquisition of the Company is subject to the completion of the New Inhibrx spin-off transaction and other customary closing conditions, including
145

receipt of regulatory approvals and approval by the Company’s shareholders. The companies currently expect the transaction to close in the second quarter of 2024.
The Merger Agreement contains certain termination rights for each of the Company and Parent. Upon termination of the Merger Agreement in accordance with its terms, under certain circumstances, the Company will be required to pay Parent a termination fee in an amount equal to $54.5 million, including if the Merger Agreement is terminated due to (i) the Company accepting a Superior Proposal (as defined in the Merger Agreement) or (ii) the Board changing its recommendation that stockholders vote to approve the Merger Agreement. This termination fee will also be payable by the Company if the Merger Agreement is terminated under certain circumstances and prior to such termination, a proposal to acquire the 101 Business or more than 50% of the Company’s stock or assets is made or publicly announced and not publicly withdrawn and the Company enters into a definitive agreement for, or completes, any transaction involving the acquisition of the 101 Business or more than 50% of its stock or assets within twelve months of such termination. The Merger Agreement also provides that Parent will be required to pay the Company a reverse termination fee of $92.1 million if the Merger is not consummated due to the failure of certain conditions to be satisfied as a result of failure to obtain antitrust clearance.
146

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosure.
Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report, our disclosure controls and procedures were designed and operating effectively at the reasonable assurance level.
Inherent Limitations on Effectiveness of Controls
Our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Management’s Annual Report on Internal Control over Financial Reporting
Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, as amended, as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the Company’s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company’s internal control over financial reporting includes those policies and procedures that:
•pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
•provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the company; and
•provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
147

inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework.
Based on our assessment, management believes that, as of December 31, 2023, the Company’s internal control over financial reporting is effective based on those criteria.
The Company’s independent registered public accounting firm has issued an audit report on our assessment of the Company’s internal control over financial reporting. This report appears further below in this Item 9A.
148

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Board of Directors and Stockholders
Inhibrx, Inc.
La Jolla, California
Opinion on Internal Control over Financial Reporting
We have audited Inhibrx, Inc.’s (the “Company’s”) internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years then ended, and the related notes and our report dated February 28, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Item 9A, Management’s Annual Report on Internal Control over Financial Reporting”. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ BDO USA, P.C.
149

San Diego, California
February 28, 2024
150

Item 9B. Other Information.
During the fiscal quarter ended December 31, 2023, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
On February 26, 2024, we terminated the PD-L1 and 4-1BB License Agreement with Elpiscience, pursuant to which we granted Elpiscience an exclusive license to our bi-specific therapeutic candidate designed to target PD-L1 and 4-1BB, also referred to as INBRX-105, including all ancillary agreements related to the PD-L1 and 4-1BB License Agreement. After evaluation of the totality of the data from the expansion cohorts for INBRX-105, the initial signal was not sufficiently validated to support the continuation of the INBRX-105 program. Immediately prior to the termination of the PD-L1 and 4-1BB License Agreement, no amounts were outstanding under the agreement.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not applicable.
151

Part III.
Item 10. Directors, Executive Officers and Corporate Governance.
Management and Corporate Governance
The Company is committed to maintaining strong corporate governance practices that benefit the long-term interests of our stockholders by providing for effective oversight and management of the Company. The board of directors and management believe that the Company has a sound governance structure in place for both management and the board of directors. The Company’s corporate governance documents and policies can be accessed on the Investors page of our website at www.inhibrx.com. The board of directors and its committees regularly review the Company’s corporate governance documents and policies to ensure that they take into account developments at the Company, changes in regulations and listing requirements, and the continuing evolution of best practices in the area of corporate governance.
Corporate Code of Conduct and Ethics
Inhibrx has adopted a Corporate Code of Conduct and Ethics and Whistleblower Policy that applies to all of our officers, directors, and employees. The Corporate Code of Conduct and Ethics and Whistleblower Policy is available on the Governance Documents section of the Investors page on our website at www.inhibrx.com. We intend to disclose any amendments to the Corporate Code of Conduct and Ethics and Whistleblower Policy, or any waivers of our requirements, on our website to the extent required by applicable laws.
Board Leadership and Risk Oversight
We do not have a policy regarding the separation of the roles of Chief Executive Officer and Chairman of the board of directors, as our Board believes it is in the best interests of the Company to make that determination based on the position and direction of the Company and the membership of the board of directors. Mark P. Lappe is our current Chief Executive Officer and our current Chairman of the board of directors. Our Board has determined that having an employee director serve as Chairman is in the best interests of our stockholders at this time because of the efficiencies achieved in having the role of Chief Executive Officer and Chairman of the Board combined, and because the detailed knowledge of our day-to-day operations and business that the Chief Executive Officer possesses greatly enhances the decision-making processes of our Board as a whole.
We do not have a lead independent director. The Chairman of the board of directors and the other members of the Board work in concert to provide oversight of our management and affairs. Our Board encourages communication among its members and between management and the Board to facilitate productive working relationships. Working with the other members of the board of directors, our Chairman also strives to ensure that there is an appropriate balance and focus among key responsibilities such as strategic development, review of operations, and risk oversight.
Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including, but not limited to, risks relating to financial condition, therapeutic candidate development, dependence on collaborative partners, uncertainty regarding patents and proprietary rights, comprehensive government regulations, cybersecurity, and dependence on key personnel. Management is responsible for the day-to-day management of the risks we face, while our Board as a whole, and through its committees, is responsible for the oversight of risk management. In its risk oversight role, our Board has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed. Our Board satisfies this responsibility, in part, through reports by each committee chairperson regarding the committee’s considerations and actions. The Board also has the responsibility of ensuring compliance with the risk management processes designed and implemented by management, which it satisfies through reports directly from the officers responsible for oversight of particular risks within our Company. The Board believes that full and open communication between management and the Board is essential for effective risk management and oversight.
152

Director Independence
Our Board annually reviews the independence of all of our directors and affirmatively makes a determination as to the independence of each director based on whether such director satisfies the definition of “independent director” as set forth in the applicable rules of the Nasdaq Stock Market and the SEC. Our Board has determined that all of our directors are independent directors other than Mark P. Lappe, by virtue of his position as Chief Executive Officer of the Company. There are no family relationships among any of our directors or executive officers.
Stockholder Communications with the Board of Directors
The Company desires that the views of stockholders be heard by the board of directors, and that appropriate responses be provided to stockholders on a timely basis. Stockholders wishing to formally communicate with the Board or any individual director may send communications directly to the Company by mail at Inhibrx, Inc., 11025 N. Torrey Pines Rd., Suite 200, La Jolla, California 92037, Attention: Corporate Secretary, or electronically using the “Send us a Message” option on the Contact Us page on our website at www.inhibrx.com. Communications will be distributed to our board of directors, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the communications.
Our Board of Directors
Our amended and restated certificate of incorporation provides that our business is to be managed by or under the direction of our board of directors. Our Board is divided into three classes for purposes of election. One class is elected at each annual meeting of stockholders to serve for a three-year term.
The table below sets forth the names of the Board’s five directors and their ages, their positions in the Company, if any, and their length of service. Also provided below is information regarding each person’s principal occupations or employment for at least the past five years, additional public company directorships held during the past five years, and each person’s specific experience, qualifications, attributes, or skills that led to our board of directors’ conclusion at the time of filing of this Annual Report that each person should serve as a director.
NameAgePosition(s)
Director Since
Expiration of Term
Mark P. Lappe57Chairman of the Board of Directors, President, and Chief Executive Officer20102026
Douglas G. Forsyth55Director20182025
Jon Faiz Kayyem, Ph.D.60Director20182024
Kimberly Manhard64Director20202025
Kristiina Vuori, M.D., Ph.D.56Director20212024
Mark P. Lappe
Mr. Lappe co-founded Inhibrx in 2010 and has served as our Chief Executive Officer since our inception and served as our Chief Financial Officer until April 2020. Mr. Lappe also serves as the Chairman of our board of directors. Mr. Lappe has extensive expertise in the biotechnology industry with over thirty years of experience in executive management, investment management and executive recruiting, having built the executive teams of over forty start-up biotechnology and medical device companies. Prior to founding Inhibrx, Mr. Lappe was the founder and Managing Partner of Efficacy Biotech Fund, a fund focused on strategic investment in public biotechnology companies. We believe Mr. Lappe’s service as our co-founder and Chief Executive Officer and his extensive experience in the biotechnology and biotherapeutic industries qualifies him to serve on our board of directors.
Douglas G. Forsyth
Mr. Forsyth has served as a member of our Board since April 2018. From 1994 until February 2022, Mr. Forsyth served as a portfolio manager, a managing director and Chief Investment Officer of U.S. Income & Growth Strategies with Allianz Global Investors GmbH, or Allianz. Mr. Forsyth was also the head of the Allianz Income and Growth Strategies team, during which time he had portfolio management, trading and research responsibilities, and oversaw all aspects of the Income and Growth platform’s business, including product development and
153

implementation. Mr. Forsyth was the lead portfolio manager for the Allianz U.S. High Yield Bond strategy since its inception in August 1994 and assumed lead portfolio management responsibility for the firm’s U.S. Convertible strategy in 1998. In addition to management responsibility for institutional clients worldwide, Mr. Forsyth supervised multiple open-end and closed-end mutual funds. Mr. Forsyth has 30 years of investment-industry experience. Mr. Forsyth currently serves, or has served, on a variety of non-public company boards across a variety of industries as well as several charitable boards. Mr. Forsyth received a Bachelor of Business Administration from the University of Iowa. We believe that Mr. Forsyth is qualified to serve as a member of our board of directors due to his extensive experience as an investment fund portfolio manager and his extensive business strategy experience.
Jon Faiz Kayyem, Ph.D.
Dr. Kayyem has served as a member of our Board since April 2018. He is the founder of GenMark Diagnostics Inc., or GenMark, and from May 2010 until February 2018, Dr. Kayyem served in various leadership positions at GenMark including Senior Vice President of Research and Development, Chief Scientific Officer, President, and Chief Executive Officer as the company evolved from Osmetech plc. In 2018, Dr. Kayyem became a consultant to GenMark's board of directors and executive team. In March 2021, GenMark agreed to merge with Roche, which subsequently acquired GenMark through a tender offer. In 2006, Dr. Kayyem founded and served as a member of the board of directors of privately-held Calimmune, Inc. until its acquisition by CSL Behring in 2017. In 1995, he founded Clinical Micro Sensors, Inc. to commercialize technical innovations he developed while serving as a Senior Research Fellow at the California Institute of Technology, or Caltech. In 2000, Clinical Micro Sensors, Inc. was sold to Motorola, Inc. and was subsequently purchased by Osmetech plc in 2005. From June 2000 until December 2004, Dr. Kayyem served as Vice President of Life Sciences at Motorola. In October 2004, he co-founded the biotechnology fund management company, Efficacy Capital Limited, and, until September 2009, served as a managing partner. Dr. Kayyem currently serves as a member of the board of directors of Biodesix, Inc. He also currently serves, or has served, as a director or advisor on various non-public company boards, including non-profit and educational institutions. Dr. Kayyem received a combined B.S. and M.S. in Molecular Biophysics and Biochemistry from Yale University and a Ph.D. in Molecular Biology from Caltech. We believe that Dr. Kayyem’s extensive experience as an executive and serving on other boards of directors in the biotechnology and biotherapeutic industry qualifies him to serve as a member of our board of directors.
Kimberly Manhard
Ms. Manhard has served as a member of our Board since June 2020. Ms. Manhard has served as the Senior Vice President of Global Strategic Planning and Execution for Acadia Pharmaceuticals Inc., or Acadia, since February 2024. Prior to Acadia, Ms. Manhard served as the Executive Vice President, Drug Development of Heron Therapeutics, Inc., or Heron, from January 2016 to June 2023. She also served as a director of Heron from 2014 to 2016 and from 2019 to February 2023. From 2006 to 2016, she served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., or Ardea. In her role at Ardea, Ms. Manhard was instrumental in the development and 2015 regulatory approval of lesinurad (Zurampic). Prior to joining Ardea in 2006, she was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc., and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including nelfinavir (Viracept). Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including paclitaxel (Taxol) and infectious disease compounds, including didanosine (Videx) and stavudine (Zerit). Ms. Manhard began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Ms. Manhard is a member of the board of trustees for the Fleet Science Center. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida. We believe that Ms. Manhard is qualified to serve on our board of directors due to her experience in executive management and as a director with other biotechnology and pharmaceutical companies, as well as her experience in drug development, regulatory affairs, and pharmaceutical operations.
Kristiina Vuori, M.D., Ph.D.
Dr. Vuori has served as a member of our Board since October 2021. Since January 2023, she has served as President and CEO and a member of the board of directors of Sanford Laboratories for Innovative Medicines, or Sanford Labs, an independent, not-for-profit biomedical research institution with a mission to discover and deliver the next-generation of molecular medicines. Since January 1995, Dr. Vuori has also served as Professor, and since January
154

2010 as Pauline and Stanley Foster Distinguished Chair, at the National Cancer Institute-designated Cancer Center, or Cancer Center, of Sanford Burnham Prebys Medical Discovery Institute, or SBP, a non-profit research organization with major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. In addition, Dr. Vuori served as President and a member of the board of directors of SBP from January 2010 to June 2022, and as SBP’s interim Chief Executive Officer from January 2013 to September 2014, and from September 2017 to June 2020. She also served as SBP’s Executive Vice President for Scientific Affairs in 2008-2010, as Director of the Cancer Center in 2005-2013, and as Deputy Director of the Cancer Center in 2003-2005. Dr. Vuori has previously served or is currently serving on the board of directors of Bionano Genomics, Inc., Sio Gene Therapies, Inc., Forian Inc., WebMD Health Corp, Inc., the American Association for Cancer Research, the California Institute for Regenerative Medicine and the California Breast Cancer Research Program. Dr. Vuori received her M.D. and Ph.D. from the University of Oulu, Finland. We believe that Dr. Vuori’s experience as a physician-scientist in biomedical research and drug discovery and as an educator of research scientists, her experience managing a large non-profit biomedical research organization, and her various leadership roles in non-profit, for-profit, and public boards qualify her to serve as a member of our board of directors.
Board Meetings and Attendance
During the fiscal year ended December 31, 2023, our board of directors met eight times and acted by written consent zero times. No director attended fewer than 75% of the total number of meetings of our board of directors and of Board committees on which he or she served during the fiscal year ended December 31, 2023. Our board of directors has adopted a policy requiring that each member of the Board make every effort to attend each annual meeting of our stockholders. All the individuals who were directors of the Company at the time of the 2023 annual meeting of stockholders attended that meeting.
Committees of our Board of Directors
Our Board has established three standing committees: the Audit Committee, the Compensation Committee, and the Nominating Committee, each of which is described more fully below.
Audit Committee
Our Audit Committee is comprised of Douglas G. Forsyth, Jon Faiz Kayyem, Ph.D., and Kristiina Vuori, M.D., Ph.D., with Mr. Forsyth serving as the Chairperson. All members of the Audit Committee satisfy the current independence standards promulgated by the SEC and by Nasdaq, as such standards apply specifically to members of audit committees. Our Board has determined that Mr. Forsyth is an “audit committee financial expert,” as the SEC has defined that term in Item 407 of Regulation S-K. The Audit Committee met four times during 2023.
Our Audit Committee’s roles and responsibilities are set forth in the Audit Committee’s written charter and include the authority to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee reviews annual financial statements, considers matters relating to accounting policy and internal controls, and reviews the scope of annual audits.
A copy of the Audit Committee’s written charter is publicly available on the Governance Documents section of the Investors page on our website at www.inhibrx.com.
Compensation Committee
Our Compensation Committee is comprised of Jon Faiz Kayyem, Ph.D., Douglas G. Forsyth, and Kimberly Manhard, with Dr. Kayyem serving as the Chairperson. Our Board has determined that all members of the Compensation Committee qualify as independent under the definition promulgated by Nasdaq. During 2023, the Compensation Committee met two times and acted by written consent two times. 
Our Compensation Committee’s roles and responsibilities are set forth in the Compensation Committee’s written charter and include reviewing, approving, and making recommendations regarding our compensation policies, practices, and procedures to ensure that legal and fiduciary responsibilities of our board of directors are carried out and that such policies, practices, and procedures contribute to our success. Our Compensation Committee also administers our equity compensation plans. The Compensation Committee may delegate authority for day-to-day administration and interpretation of the Company’s various compensation plans, including the selection of
155

participants, the determination of award levels, and the approval of award documents to our non-executive officer employees. However, the Compensation Committee may not delegate any authority under those plans for matters affecting the compensation and benefits of the Company’s executive officers. The Chief Executive Officer is not present for any discussions relating to his compensation.
A copy of the Compensation Committee’s written charter is publicly available on the Governance Documents section of the Investors page on our website at www.inhibrx.com.
Nominating Committee
Our Nominating Committee is comprised of Douglas G. Forsyth, Kimberly Manhard, and Kristiina Vuori, M.D., Ph.D., with Mr. Forsyth serving as the Chairperson. Our Board has determined that all members of the Nominating Committee qualify as independent under the definition promulgated by Nasdaq. During 2023, the Nominating Committee met two times.
The Nominating Committee’s responsibilities are set forth in the Nominating Committee’s written charter and include, among other matters:
•evaluating and making recommendations to the full Board as to the composition, organization, and governance of the Board and its committees,
•evaluating, nominating, and recommending individuals for membership on our board of directors,
•periodically reviewing and evaluating director performance,
•overseeing the process for CEO and other executive officer succession planning, and
•developing and recommending governance policies and guidelines for the Company.
A copy of the Nominating Committee’s written charter is publicly available on the Governance Documents section of the Investors page on our website at www.inhibrx.com.
156

Our Executive Officers
As of the date of this Annual Report, our current executive officers and their respective ages and positions are set forth in the following table:
NameAgePosition
Mark P. Lappe (1)
57Chief Executive Officer and President
Kelly D. Deck, C.P.A.44Chief Financial Officer
Brendan P. Eckelman, Ph.D.45Chief Scientific Officer
________________
(1) Mr. Lappe is also a director of the Company and his biographical information appears on page 153.
Kelly D. Deck, C.P.A.
Ms. Deck currently serves as our Chief Financial Officer and leads our accounting, finance, information technology, and investor relations functions. She joined Inhibrx in October 2018, bringing decades of experience in the life science industry. Prior to joining our team, Ms. Deck held various accounting and finance positions of increasing responsibility with Apricus Biosciences, Inc., Hologic, Inc., Gen-Probe, Inc., and Cytori Therapeutics, Inc. Ms. Deck is currently a member of the board of trustees for the Fleet Science Center. Ms. Deck holds a B.S. and M.S. in Accounting and is an active licensed Certified Public Accountant in the state of California.
Brendan P. Eckelman, Ph.D.
Dr. Eckelman co-founded Inhibrx in April 2010 and currently serves as our Chief Scientific Officer. Until October 2021, he also served as our Executive Vice President of Corporate Strategy. He served as a member of our board of directors from April 2018 until October 2021. From August 2015 to November 2018, he served as our Chief Operating Officer and Vice President of Biotherapeutics. From 2010 until August 2015, Dr. Eckelman served as our Vice President of Scientific Operations. Dr. Eckelman is the head of our research team, overseeing several key functional areas spanning discovery and protein engineering to therapeutic development. Prior to co-founding Inhibrx, Dr. Eckelman was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received a Ph.D. in Molecular Pathology from the University of California, San Diego, or UCSD, School of Medicine. Dr. Eckelman received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.


157

Item 11. Executive Compensation.
Non-Employee Director Compensation Table
The following table sets forth a summary of the compensation earned by our non-employee directors for their service on our Board during the year ended December 31, 2023:
Name
Fees Earned or Paid
in Cash
($)
Stock Awards
($)
Option Awards
($)(1)
All Other Compensation
($)(2)
Total
($)
Douglas G. Forsyth$63,000 $— $254,030 $— $317,030 
Jon Faiz Kayyem, Ph.D.$52,500 $— $254,030 $— $306,530 
Kimberly Manhard$44,000 $— $254,030 $— $298,030 
Kristiina Vuori, M.D., Ph.D.$46,500 $— $254,030 $— $300,530 
________________
(1)These amounts represent the aggregate grant date fair value of time-based stock option awards granted by the Company during the periods presented, determined in accordance with FASB ASC Topic 718. All awards are amortized over the vesting life of the award. For the assumptions used in our valuations, see “Note 5 – Equity Compensation Plans” to our consolidated financial statements included elsewhere in this Annual Report.
(2)Excludes amounts reimbursed for out-of-pocket expenses incurred in connection with service as a director.
Non-Employee Director Compensation - Equity
As of December 31, 2023, non-employee directors held options to purchase shares of our common stock pursuant to the terms of our Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or 2017 Plan, as follows:
Name
Stock Awards Outstanding at December 31, 2023
(#)
Option Awards Outstanding at December 31, 2023
(#)
Douglas G. Forsyth.— 62,259 
Jon Faiz Kayyem, Ph.D.— 62,259 
Kimberly Manhard— 65,759 
Kristiina Vuori, M.D., Ph.D.— 60,000 
Non-Employee Director Compensation Policy
We have adopted a Non-Employee Director Compensation Policy that is designed to enable us to attract and retain, on a long-term basis, highly qualified non-employee directors. Under the Non-Employee Director Compensation Policy, each non-employee director is eligible to receive the following amounts for their service on our board of directors:
•Initial Stock Option Grant. For new non-employee directors, a stock option to purchase 30,000 shares of the Company’s common stock.
•Annual Stock Option Grants. A stock option to purchase 15,000 shares of the Company’s common stock, on the date of the first Board meeting held following the Company’s annual meeting of stockholders each year.
•Annual Fees. Annual retainers in the following amounts, payable quarterly in arrears:
158

PositionRetainer
Board Member$35,000 
Board Chairperson$35,000 
Audit Committee Chair$15,000 
Compensation Committee Chair$10,000 
Nominating Committee Chair$8,000 
Audit Committee Member$7,500 
Compensation Committee Member$5,000 
Nominating Committee Member$4,000 
All options granted under our Non-Employee Director Compensation Policy will have an exercise price equal to the fair market value of the Company’s common stock on the date of grant and terminate on the tenth anniversary of the date of grant. Subject to the continued service of each non-employee director, each annual stock option grant vests on the first anniversary of the date of grant and each initial stock option grant vests in equal monthly installments until the third anniversary of the date of grant.
Directors may be reimbursed for reasonable out-of-pocket expenses incurred in connection with their service as directors. Directors are also entitled to the protection provided by their indemnification agreements and the indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws.
Summary Compensation Table
The following table sets forth a summary of cash and non-cash compensation awarded, earned, or paid for services rendered to us during the fiscal years ended December 31, 2023 and December 31, 2022 by our named executive officers, consisting of (i) each individual serving as principal executive officer during the fiscal year ended December 31, 2023 and (ii) our other two most highly compensated officers serving during the fiscal year ended December 31, 2023.
Name and Principal PositionYearSalary 
($)
Bonus
($)
Option Awards
($)(1)
Non-Equity Incentive Plan Compensation
($)(2)
All Other Compensation
($)(3)
Total
($)
Mark P. Lappe2023675,000 — 1,706,771 405,000 15,250 2,802,021 
Chief Executive Officer and President2022650,000 — — 357,500 15,250 1,022,750 
Brendan P. Eckelman, Ph.D.2023520,000 — 682,708 234,000 15,250 1,451,958 
Chief Scientific Officer2022475,000 — — 213,750 15,250 704,000 
Kelly D. Deck, C.P.A.2023430,000 — 512,031 193,500 13,368 1,148,899 
Chief Financial Officer2022380,000 — 491,327 133,000 18,168 1,022,495 
________________
(1)These amounts represent the aggregate grant date fair value of time-based stock option awards granted by the Company during the periods presented, determined in accordance with FASB ASC Topic 718. All awards are amortized over the vesting life of the award. For the assumptions used in our valuations, see “Note 5 – Equity Compensation Plans” to our consolidated financial statements included elsewhere in this Annual Report. Awards issued during the year ended December 31, 2023 are reflected in the “Outstanding Equity Awards as of December 31, 2023” table below.
(2)These amounts represent performance-based cash bonuses earned during the year ended December 31, 2023, which were paid out during the first quarter of 2024. The annual performance-based cash bonus for each
159

named executive officer is defined within their respective employment agreement and is measured based upon the achievement of Company objectives for the periods presented.
(3)These amounts represent matching employer contributions under the Company’s 401(k) retirement plan and employer contributions to health savings accounts. The formula for determining the matching contributions is the same for named executive officers as it is for all salaried employees (and is subject to the same statutory maximum).
Narrative Disclosure to Summary Compensation Table
Employment Arrangements with our Named Executive Officers
We have entered into executive employment agreements with each of our named executive officers in connection with their employment with us, the material terms of which are described below. Except as noted below, these executive employment agreements provide for “at will” employment. In addition, each named executive officer has entered into a Proprietary Information and Inventions Assignment Agreement obligating the officer to refrain from disclosing any of our proprietary information received during the course of employment and to assign to us any inventions conceived or developed during the course of employment.
Employment Agreement with Mark P. Lappe
On January 1, 2019, we entered into an employment agreement with Mark P. Lappe, setting forth the terms and conditions of his employment with the Company. Mr. Lappe was entitled to an annual base salary of $450,000 and eligible to receive an annual bonus of up to 50% of his then-current base salary based on achievement of certain corporate goals. In addition, in consideration of the payments and benefits provided under his employment agreement, Mr. Lappe agreed to certain restrictive covenants, including, among other things, non-competition and non-solicitation provisions that apply during the term of Mr. Lappe’s employment and for 12 months thereafter.
Mr. Lappe is also entitled to certain severance and change in control benefits pursuant to his employment agreement, the terms of which are described below under “Potential Payments upon Termination or Change of Control.”
On August 7, 2020, Mr. Lappe entered into an amended and restated employment agreement, pursuant to which his annual base salary increased to $650,000 per year. All other terms remained the same as the prior agreement.
Effective January 1, 2022, Mr. Lappe entered into an amended and restated employment agreement, pursuant to which he is eligible to receive an annual bonus of up to 55% of his then-current base salary based on achievement of certain corporate goals. All other terms remained the same as the prior agreement.
Effective January 1, 2023, Mr. Lappe entered into an amended and restated employment agreement, pursuant to which his annual base salary increased to $675,000 per year and the annual bonus that he is eligible to receive increased to up to 60% of his then-current base salary based on achievement of certain corporate goals. All other terms remained the same as the prior agreement.
Effective January 1, 2024, Mr. Lappe’s annual base salary increased to $695,250 per year. No other terms of his employment agreement changed and thus his employment agreement was not amended and restated.
Employment Agreement with Brendan P. Eckelman, Ph.D.
On January 1, 2019, we entered into an employment agreement with Brendan P. Eckelman, Ph.D., setting forth the terms and conditions of his employment with the Company. Dr. Eckelman was entitled to an annual base salary of $350,000 and eligible to receive an annual bonus of up to 40% of his then-current base salary based on achievement of certain corporate goals. In addition, in consideration of the payments and benefits provided under his employment agreement, Dr. Eckelman agreed to certain restrictive covenants, including, among other things, non-competition and non-solicitation provisions that apply during the term of Dr. Eckelman’s employment and for 12 months thereafter.
Dr. Eckelman is also entitled to certain severance and change in control benefits pursuant to his employment agreement, the terms of which are described below under “Potential Payments upon Termination or Change of Control.”
160

On August 7, 2020, Dr. Eckelman entered into amended and restated employment agreement, pursuant to which his annual base salary increased to $450,000 per year. All other terms remained the same as the prior agreement, other than payments upon termination or change of control, which are described below.
Effective January 1, 2022, Dr. Eckelman entered into an amended and restated employment agreement, pursuant to which his annual base salary increased to $475,000 per year and he is eligible to receive an annual bonus of up to 45% of his then-current base salary based on achievement of certain corporate goals. All other terms remained the same as the prior agreement.
Effective January 1, 2023, Dr. Eckelman's annual base salary increased to $520,000 per year. No other terms of his employment agreement changed and thus his employment agreement was not amended and restated.
Effective January 1, 2024, Dr. Eckelman's annual base salary increased to $535,600 per year. No other terms of his employment agreement changed and thus his employment agreement was not amended and restated.
Employment Agreement with Kelly D. Deck, C.P.A.
On August 7, 2020, we entered into an employment agreement with Kelly D. Deck, C.P.A., setting forth the terms and conditions of her employment with the Company. Ms. Deck was entitled to an annual base salary of $330,000 and eligible to receive a performance bonus of up to 25% of her then-current base salary based on achievement of certain corporate goals. In addition, in consideration of the payments and benefits provided under her employment agreement, Ms. Deck agreed to certain restrictive covenants, including, among other things, non-competition and non-solicitation provisions that apply during the term of Ms. Deck’s employment and for 12 months thereafter.
Ms. Deck is also entitled to certain severance and change in control benefits pursuant to her employment agreement, the terms of which are described below under “Potential Payments upon Termination or Change of Control.”
Effective January 1, 2022, Ms. Deck entered into an amended and restated employment agreement, pursuant to which her annual base salary increased to $380,000 per year and she is eligible to receive an annual bonus of up to 35% of her then-current base salary based on achievement of certain corporate goals. All other terms remained the same as the prior agreement.
Effective January 1, 2023, Ms. Deck entered into an amended and restated employment agreement, pursuant to which her annual base salary increased to $430,000 per year and the annual bonus that she is eligible to receive increased to up to 45% of her then-current base salary based on achievement of certain corporate goals. All other terms remained the same as the prior agreement.
Effective January 1, 2024, Ms. Deck’s annual base salary increased to $460,100 per year. No other terms of her employment agreement changed and thus her employment agreement was not amended and restated.
Potential Payments Upon Termination or Change In Control
The employment agreements of Mr. Lappe, Dr. Eckelman, and Ms. Deck as of December 31, 2023 provided for the following severance payments upon termination by the Company without Cause (as defined below), or by the executive for Good Reason (as defined below): (i) payment of the executive’s then-current base salary for a period of 12 months following termination; (ii) acceleration of unvested equity awards that would have vested during the 12 months following the date of termination; and (iii) continued coverage under our group health insurance plan with the cost of such coverage shared in the same relative proportion by the Company and the executive as in effect on their last day of employment until the earlier of 12 months from termination or the date the executive becomes eligible for medical benefits with another employer.
Further, the agreements provided that upon termination by the Company without Cause or by the executive for Good Reason within a period of one year following a Change of Control (as defined below), or 90 days preceding the earlier to occur of a Change of Control or the execution of a definitive agreement the consummation of which would result in a Change of Control, the executive would be entitled to receive: (i) a lump sum payment equal to 18 months of the executive’s then-current base salary; (ii) a lump sum payment equal to 1.5 times the target bonus for the year of termination; (iii) acceleration of all unvested equity awards as of the date of termination; and (iv) continued
161

coverage under our group health insurance plan with the cost of such coverage shared in the same relative proportion by the Company and the executive as in effect on their last day of employment until the earlier of 18 months from termination or the date the executive becomes eligible for medical benefits with another employer. Payment in each case would be subject to the executive’s execution of a release satisfactory to us following such termination. In addition, if the executive’s employment terminated as a result of disability or death, they would be entitled to receive a pro-rated target bonus for the period during which the executive was employed in the year of termination.
The following definitions apply to the severance terms under each executive’s amended and restated employment agreement:
“Cause” means (i) the executive’s conviction of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (ii) the executive’s willful failure or refusal to comply with lawful directions of such executive’s supervisor, which failure or refusal continues for more than five business days after written notice is given to the executive by such executive’s supervisor, which notice sets forth in reasonable detail the nature of such failure or refusal; (iii) willful and material breach by the executive of a material written Company policy applicable to the executive or the executive’s covenants and/or obligations under his or her employment agreement, provided that the breach is not cured within 5 business days; and/or (iv) misconduct by the executive that materially damages us or any of our affiliates.
“Good Reason” means (i) relocation of the executive’s principal business location to a location more than 30 miles from the executive’s then-current business location; (ii) a material diminution in the executive’s duties, authority or responsibilities; (iii) a material reduction in the executive’s base salary; or (iv) willful and material breach by us or our covenants and/or obligations under the executive’s employment agreement.
“Change of Control” means the occurrence of any of the following events: (i) any person (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the beneficial owner, directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company, or any affiliate, parent or subsidiary of the Company, or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions; (ii) a merger or consolidation of the Company other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; (iii) our stockholders approve an agreement for the sale or disposition by the Company of all or substantially all of our assets; or (iv) a change in the composition of our board of directors, as a result of which fewer than a majority of the directors are incumbent directors.
162

The following table sets forth the amounts payable to each of our current named executive officers based on an assumed termination as of December 31, 2023 based upon certain designated events.
NameCash SeveranceHealth and Other Insurance BenefitsStock Options (Unvested and Accelerated)Total
Mark P. Lappe
Termination for reasons other than Cause, death or Disability, or for Good Reason$675,000 $28,271 $1,739,781 $2,443,052 
Termination in connection with a Change of Control$1,620,000 $42,406 $2,705,552 $4,367,958 
Brendan P. Eckelman, Ph.D.
Termination for reasons other than Cause, death or Disability, or for Good Reason$520,000 $28,425 $581,467 $1,129,892 
Termination in connection with a Change of Control$1,131,000 $42,638 $958,225 $2,131,863 
Kelly D. Deck, C.P.A.
Termination for reasons other than Cause, death or Disability, or for Good Reason$430,000 $28,271 $836,837 $1,295,108 
Termination in connection with a Change of Control$935,250 $42,406 $1,273,677 $2,251,333 
Elements of Compensation
Base Salary
The Compensation Committee reviews the base salaries of our executive officers, including our named executive officers, from time to time and makes adjustments as it determines to be reasonable and necessary to reflect the scope of an executive officer’s performance, role, responsibilities, skills, and experience.
In 2023, the annual base salaries for Mr. Lappe, Dr. Eckelman, and Ms. Deck were increased to $675,000, $520,000, and $430,000, respectively.
Annual Performance Bonus
The Company also provides executive officers with annual performance-based cash bonuses, which are specifically designed to reward executives for overall Company performance in a given year. Corporate goals are established by the Compensation Committee with input from senior management. The target annual cash bonus amounts relative to base salary vary depending on each executive’s accountability, scope of responsibilities, and potential impact on the Company’s performance.
The Compensation Committee considers the Company’s overall performance for the preceding fiscal year in deciding whether to award a bonus and, if one is to be awarded, the amount of the bonus. The annual cash bonus for each executive officer is based 100% on overall Company performance. The Compensation Committee retains the ability to apply discretion in making adjustments to the final bonus payouts.
The evaluation of Company performance for 2023 bonus purposes was based on the achievement, or failure to achieve, a set of weighted performance goals. The Company’s 2023 performance goals generally fell into the categories of executing on the progression of our clinical programs, obtaining sufficient funding through various methods, expanding existing and new business development relationships, and increasing the visibility of the Company to outside investors and the public. For fiscal year 2023, the Compensation Committee determined that the Company achieved 100% of the performance goals and thus the executive officers should be paid their bonuses at 100% of the targeted levels. Accordingly, the following table sets forth the target bonus for each of the named executive officers for fiscal year 2023 and the resulting incentive payout, based on the level of achievement of the 2023 corporate goals:
163

NameTitle
Fiscal Year 2023 Incentive Bonus Rate at Target
2023 Evaluation of Company Performance
Final Ratio Incentive Bonus as a Percentage of Base Salary
Fiscal Year 2023 Incentive Bonus Award
($)
Mark P. LappeChief Executive Officer and President60%100%60%$405,000 
Brendan P. Eckelman, Ph.D.Chief Scientific Officer45%100%45%$234,000 
Kelly D. Deck, C.P.A.Chief Financial Officer45%100%45%$193,500 
Equity-Based Compensation
Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, or any formal equity ownership guidelines applicable to them, we believe that equity grants provide our executive officers with a strong link to our long-term performance, create an ownership opportunity, and help to align the interests of our executive officers and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention. Accordingly, our Compensation Committee periodically reviews the equity incentive compensation of our executives and other employees, including our named executive officers, and from time to time may grant equity incentive awards to them in the form of stock options.
Outstanding equity awards of our named executive officers as of December 31, 2023 are reflected in the “Outstanding Equity Awards as of December 31, 2023” table below.
Rule 10b5-1 Trading Plans
Certain of our employees, including directors and executive officers, have adopted, or may in the future adopt, written plans, known as Rule 10b5-1 Plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule 10b5-1 Plan, a broker executes trades pursuant to parameters established by the individual when entering into the plan, without further direction from the individual. The individual may amend or terminate the 10b5-1 Plan in limited circumstances.
401(k) Retirement Plan
We maintain a tax-qualified retirement plan that provides eligible employees, including our named executive officers, with an opportunity to save for retirement on a tax-advantaged basis. All participants’ interests in their contributions are 100% vested when contributed. Contributions are allocated to each participant’s individual account and are then invested in selected investment alternatives according to the participants’ directions. Our retirement plan is intended to qualify under Section 401(a) of the Code. Our plan authorizes employer safe harbor matching contributions up to 5% of an employee’s annual compensation, which were suspended beginning in the second quarter of 2020 and reinstated at the beginning of 2021.
Health and Welfare Benefits
Our named executive officers are eligible to participate in our employee benefit plans and programs, which include medical, dental, and vision benefits, life and disability insurance, and wellness and tuition reimbursement, to the same extent as our other full-time employees generally, subject to the terms and eligibility requirements of those plans and programs.
Hedging
The Company maintains an insider trading policy that generally prohibits executives and directors from engaging in any transaction in which they may profit from short-term speculative swings in the value of the Company’s securities. This includes “short sales” (selling borrowed securities that the seller hopes can be purchased at a lower price in the future) or “short sales against the box” (selling owned, but not delivered securities), and “put” and “call” options. To date, no directors or executives have engaged in these activities.
164

Compensation Consultant
The Compensation Committee also retained an independent compensation consultant in 2023 to assist in evaluating the Company’s executive compensation program. Market pay data from both the peer group and industry data sources are collectively a primary factor for the Compensation Committee in setting target levels of base salary, annual incentive awards, and long-term incentive awards, and are taken into account along with performance in determining base pay increases. In 2023, Aon Consulting, Inc., or Aon, an independent consulting firm, was retained to conduct a competitive review and analysis of the Company’s executive compensation program. Aon, in coordination with Company management, identified a peer group of similarly situated companies across business segment and size metrics (e.g., business sector, stage of development, market cap, and revenue) and presented an assessment of the compensation of the Company’s executive officers relative to market/peer group pay data for various elements of executive compensation, including base salary, target bonus opportunities, target total cash compensation, and equity ownership. The Compensation Committee analyzed this data in consultation with Company management and Aon, and thereafter established the 2023 compensation packages for the Company’s executive officers.
Outstanding Equity Awards as of December 31, 2023
The following table shows certain information regarding outstanding equity awards as of December 31, 2023 for our named executive officers:
Option Awards
NameNumber of Securities Underlying Unexercised Options
(#)
Exercisable		Number of Securities Underlying Unexercised Options
(#)
Unexercisable		Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)
Option Exercise Price ($)
Option Expiration Date
Mark P. Lappe105,729 39,271 — $33.63 1/15/2031(1)
— 100,000 — $23.30 1/3/2033(2)
Brendan P. Eckelman, Ph.D.29,167 10,833 — $33.63 1/15/2031(1)
— 40,000 — $23.30 1/3/2033(2)
Kelly D. Deck, C.P.A.80,543 — — $10.52 11/26/2028(3)
31,641 2,877 — $11.25 4/21/2030(4)
51,042 18,958 — $33.63 1/15/2031(1)
9,583 10,417 — $34.16 1/11/2032(5)
— 30,000 — $23.30 1/3/2033(2)
________________
(1)These stock option grants were made pursuant to our 2017 Plan with the following vesting schedule: 25% of the shares vested on the first anniversary of the vesting commencement date, or January 15, 2022, and 1/48th of the shares vest monthly thereafter.
(2)These stock option grants were made pursuant to our 2017 Plan with the following vesting schedule: 25% of the shares vested on the first anniversary of the vesting commencement date, or January 3, 2024, and 1/48th of the shares vest monthly thereafter.
(3)This stock option grant was made pursuant to our 2017 Plan with the following vesting schedule: 25% of the shares vested on the first anniversary of the vesting commencement date, or November 26, 2019, and 1/48th of the shares vest monthly thereafter.
(4)This stock option grant was made pursuant to our 2017 Plan with the following vesting schedule: 25% of the shares vested on the first anniversary of the vesting commencement date, or April 21, 2021, and 1/48th of the shares vest monthly thereafter.
165

(5)This stock option grant was made pursuant to our 2017 Plan with the following vesting schedule: 25% of the shares vested on the first anniversary of the vesting commencement date, or January 11, 2023, and 1/48th of the shares vest monthly thereafter.
166

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Equity Compensation Plan Information
The following table provides certain aggregate information with respect to all of the Company’s equity compensation plans in effect as of December 31, 2023:
Plan Category
Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights
(a)
Weighted Average Exercise Price of Outstanding Options, Warrants and Rights
(b)
Number of Securities Remaining Available for Future Issuance under Equity Compensation Plan (Excluding Securities Reflected in Column (a))
(c)
Equity compensation plans approved by security holders (1)
6,493,526 $23.22 532,550 
Equity compensation plans not approved by security holders— — — 
Total6,493,526 $23.22 532,550 (2)
________________
(1)This consists of our 2017 Plan.
(2)The reserve for shares available under our 2017 Plan will be increased on the first fiscal day of each year of the Company during the period beginning in fiscal year 2021 and ending on the second day of fiscal year 2030, in an amount equal to the lesser of (i) 4% of the number of outstanding shares of common stock on such date and (ii) an amount determined by the 2017 Plan administrator. Notwithstanding the foregoing, the maximum number of shares that may be issued as incentive stock options under the 2017 Plan is 60 million.
Security Ownership of Certain Beneficial Owners
The following table sets forth certain information with respect to the beneficial ownership of our common stock as of February 21, 2024 by (i) each person who, to our knowledge, beneficially owns more than 5% of our common stock; (ii) each of our directors, director nominees, and named executive officers (as disclosed in this Annual Report); and (iii) all of our executive officers, directors, and director nominee as a group. Unless otherwise indicated in the table or the footnotes to the following table, each person named in the table has sole voting and investment power and such person’s address is c/o Inhibrx, Inc., 11025 N. Torrey Pines Rd., Suite 200, La Jolla, California 92037.
We determined the number of shares of common stock beneficially owned by each person under rules promulgated by the SEC, based on information obtained from Company records and filings with the SEC on or before February 21, 2024. In cases of holders who are not directors, director nominee, and named executive officers, Schedules 13G or 13D filed with the SEC (and, consequently, ownership reflected here) often reflect holdings as of a date prior to February 21, 2024. The information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power and also any shares which the individual or entity had the right to acquire within sixty (60) days of February 21, 2024. These shares, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other individual.
Applicable percentages are based on 47,392,447 shares of common stock outstanding as of February 21, 2024, as adjusted as required by the rules promulgated by the SEC.
167

Beneficial Ownership (1)
Name and Address of Beneficial Owner
Number of
Common Stock
Percent of
Common Stock
5% or Greater Stockholders  
Entities affiliated with Viking Global Opportunities Illiquid Investments Sub-Master LP (2)
7,150,826 15.09 %
Entities affiliated with RA Capital Healthcare Fund, L.P. (3)
4,735,648 9.99 %
Entities affiliated with Perceptive Life Sciences Master Fund, Ltd. (4)
4,787,602 9.99 %
Entities affiliated with BlackRock, Inc. (5)
2,715,672 5.73 %
Named Executive Officers and Directors  
Mark P. Lappe (6)
3,194,717 6.72 %
Brendan P. Eckelman, Ph.D. (7)
2,400,553 5.06 %
Kelly D. Deck, C.P.A. (8)
192,561 *
Jon Faiz Kayyem, Ph.D. (9)
3,309,060 6.98 %
Douglas G. Forsyth (10)
633,016 1.33 %
Kimberly Manhard (11)
36,743 *
Kristiina Vuori, M.D., Ph.D. (12)
24,375 *
All current executive officers and directors as a group (7 persons)
9,791,025 20.62 %
________________
* Indicates beneficial ownership of less than 1%.
(1)Beneficial ownership of shares and percentage ownership are determined in accordance with the rules of the SEC. Unless otherwise indicated and subject to community property laws where applicable, the individuals and entities named in the table above have sole voting and investment power with respect to all shares of our common stock shown as beneficially owned by them.
(2)Consists of (i) 6,305,866 shares of common stock held by Viking Global Opportunities Illiquid Investments Sub-Master LP, or VGOP, (ii) 333,333 shares of common stock held by KAVRA 104 LLC, or KAVRA 104, and (iii) 511,627 shares of common stock held by Viking Global Opportunities Drawdown (Aggregator) LP, or VGOD. Excludes pre-funded warrants to purchase 1,038,765 shares of common stock held by VGOP. The pre-funded warrants do not allow for an exercise that would result in the holder of such pre-funded warrants (together with its affiliates, any “group” or any other persons whose beneficial ownership could be aggregated with the holder) would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately following exercise. Viking Global Investors LP, or VGI, provides managerial services to VGOP, KAVRA 104, and VGOD. VGI has the authority to dispose of and vote the shares of common stock directly held by VGOP, KAVRA 104 and VGOD. Viking Global Opportunities Parent GP LLC, or Opportunities Parent, is the sole member of Viking Global Opportunities GP LLC, or Opportunities GP, which has the authority to dispose of and vote the shares of common stock controlled by Viking Global Opportunities Portfolio GP LLC (which consists of the shares of common stock directly held by VGOP), and KAVRA 104, and is the sole member of Viking Global Opportunities Drawdown GP LLC, which has the authority to dispose of and vote the shares of common stock controlled by Viking Global Opportunities Drawdown Portfolio GP LLC (which consists of the shares of common stock directly held by VGOD). Mr. O. Andreas Halvorsen, Mr. David C. Ott and Ms. Rose S. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities GP have shared authority to dispose of and vote the shares of common stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott, and Ms. Shabet directly owns any shares of common stock. The address for these entities is 600 Washington Boulevard, Floor 11, Stamford, Connecticut, 06901.
(3)Consists of 4,724,207 shares of common stock held by RA Capital Healthcare Fund, L.P., or the Fund, and 11,441 shares of common stock the Fund beneficially owns based on the right to acquire upon exercise of pre-funded warrants, subject to the beneficial ownership blocker of the pre-funded
168

warrants. Excludes pre-funded warrants to purchase 2,735,804 shares of common stock held by the Fund. The pre-funded warrants do not allow for an exercise that would result in the holder of such pre-funded warrants (together with its affiliates, any “group” or any other persons whose beneficial ownership could be aggregated with the holder) would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately following exercise. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital Management, L.P., or RA Capital, is RA Capital Management GP, LLC, of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the controlling persons. RA Capital serves as investment adviser for the Fund. RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed to have voting and investment power over the shares held by the Fund. RA Capital, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. The address for the individuals and entities listed above is c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston, Massachusetts 02116.
(4)Consists of 4,256,104 shares of common stock held by Perceptive Life Sciences Master Fund, Ltd, or the Master Fund, and 531,498 shares of common stock the Master Fund beneficially owns based on the right to acquire upon exercise of pre-funded warrants, subject to the beneficial ownership blocker of the pre-funded warrants. Excludes pre-funded warrants to purchase 2,397,128 shares of common stock held by the Fund. The pre-funded warrants do not allow for an exercise that would result in the holder of such pre-funded warrants (together with its affiliates, any “group” or any other persons whose beneficial ownership could be aggregated with the holder) would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately following exercise. Perceptive Advisors LLC serves as the investment manager to the Master Fund and Mr. Joseph Edelman is the managing member of Perceptive Advisors LLC. The address for the individual and entities listed above is 51 Astor Place, 10th Floor, New York, New York 10003.
(5)Consists of 2,715,672 shares of common stock held by BlackRock, Inc. and its affiliates. The address for this entity is BlackRock, Inc., 50 Hudson Yards, New York, New York 10001.
(6)Consists of (i) 2,486,192 shares of common stock held by The Lappe Family Trust, (ii) 59,462 shares of common stock held by The Mark Paul Lappe Roth IRA, (iii) 500,000 shares of common stock held by The Lappe Descendants’ Trust-SD DTD 12-21-20, and (iv) 149,063 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.
(7)Consists of (i) 2,035,553 shares of common stock held by the Eckelman Living Trust dated February 5, 2014, of which Dr. Eckelman is the trustee, (ii) 160,000 shares of common stock held by a trust for the benefit of Dr. Eckelman’s immediate family, (iii) 160,000 shares of common stock held by a trust for the benefit of Dr. Eckelman’s immediate family; and (iv) 45,000 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.
(8)Consists of 192,561 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.
(9)Consists of (i) 3,224,301 shares of common stock held by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust, of which Dr. Kayyem is the trustee, (ii) 25,000 shares of common stock held in a custodial account managed by Dr. Kayyem for the benefit of Dr. Kayyem's immediate family, and (iii) 25,000 shares of common stock held in a custodial account managed by Dr. Kayyem for the benefit of Dr. Kayyem's immediate family. Also includes 34,759 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.
(10)Consists of 598,257 shares of common stock held by the Douglas G. Forsyth and Rosanna Forsyth as Co-Trustees of the Forsyth Family Trust, Dated July 20, 2001. Also includes 34,759 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.
(11)Consists of 36,743 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.
169

(12)Consists of 24,375 options to purchase shares of common stock that are exercisable as of February 21, 2024 or that will become exercisable within 60 days after such date pursuant to the terms of the 2017 Plan.


170

Item 13. Certain Relationships and Related Transactions, and Director Independence
Director Independence
Our Board annually reviews the independence of all of our directors and affirmatively makes a determination as to the independence of each director based on whether such director satisfies the definition of “independent director” as set forth in the applicable rules of the Nasdaq Stock Market and the SEC. Our Board has determined that all of our directors are independent directors other than Mark P. Lappe, by virtue of his position as Chief Executive Officer of the Company. There are no family relationships among any of our directors or executive officers.
Policies and Procedures on Related Party Transactions
We have adopted a policy that requires all future transactions between us and any director, executive officer, holder of 5% or more of any class of our capital stock, or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation S-K, or their affiliates, in which the amount involved is equal to or greater than $120,000, be approved in advance by our Audit Committee. Any request for such a transaction must first be presented to our Audit Committee for review, consideration, and approval. In approving or rejecting any such proposal, our Audit Committee is to consider all available information deemed relevant by the Audit Committee, including, but not limited to, the extent of the related person’s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances.
Related Party Transactions
LAV Summit Limited, or LAV SL, a limited company, is a principal shareholder which owned more than 5% of the Company’s outstanding equity interest during the year ended December 31, 2021. Due to this equity ownership, LAV SL was considered a related party. LAV SL’s General Partner, Lilly Asia Ventures, or LAV, through one of its funds, holds a significant equity ownership position in Chinese biotechnology company, Elpiscience, and the Venture Partner of LAV is the CEO, Founder, and Director at Elpiscience. Accordingly, the Company identified Elpiscience as a related party and all agreements entered into between the Company and Elpiscience through December 31, 2021 are deemed related party agreements. As of December 31, 2021, LAV SL no longer holds more than 5% of the Company’s outstanding equity interest. Accordingly, any future contracts entered into with LAV SL affiliates will not be considered related party transactions.
In April 2018, the Company entered into a license agreement, or the OX40 License Agreement, with Elpiscience, whereby the Company granted Elpiscience an exclusive license to the Company’s multivalent protein therapeutic directed to the biological target OX40, or INBRX-106. Under this agreement, the Company is entitled to reimbursement for certain CMC and toxicology expenses incurred. The Company received $0.2 million in reimbursements under this agreement during the year ended December 31, 2022, and has received $5.4 million to date as of December 31, 2023 and December 31, 2022. During the year ended December 31, 2022, the Company derecognized $32,000 as contra-expenses, all of which was received in cash as of December 31, 2022. The Company did not receive any reimbursements or derecognize any contra-expense during the year ended December 31, 2023. No further reimbursements remain under this contract.
In July 2020, the Company entered into an additional cost sharing agreement with Elpiscience related to the OX40 License Agreement. Under this agreement, the Company is entitled to reimbursement for certain formulation development costs. Reimbursements under this contract are recognized as contra-expense as incurred. The Company received $0.3 million in reimbursements under this agreement during the year ended December 31, 2022 and has received $0.5 million of reimbursements to date as of December 31, 2023 and December 31, 2022. The Company did not receive any reimbursements or derecognize any contra-expense during the year ended December 31, 2023. No further reimbursements remain under this contract.
In August 2023, the Company entered into the Purchase Agreement with certain beneficial owners of more than 5% of the Company’s common stock, pursuant to which the Company sold and issued 3,621,314 shares of the Company’s common stock for $19.35 per share and pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock in the Private Placement. The purchase price of the pre-funded warrants was $19.3499
171

per pre-funded warrant, with an exercise price of $0.0001 per share. The holders of more than 5% of the Company’s outstanding common stock shown in the table below purchased securities in the Private Placement.
Purchaser
Shares of Common Stock
Warrant Shares Underlying Pre-Funded Warrant
Aggregate Purchase Price
Viking Global Opportunities Illiquid Investments Sub-Master LP— 1,038,765 $20,099,998.87 
Viking Global Opportunities Drawdown (Aggregator) LP511,627 — $9,899,982.45 
RA Capital Healthcare Fund, L.P.870,340 2,747,245 $69,999,995.03 
Perceptive Life Sciences Master Fund, Ltd. 688,960 2,928,626 $69,999,996.24 
In connection with the execution of the Merger Agreement, the Company entered into an Agreement relating to the Pre-Funded Warrant to Purchase Common Stock and Securities Purchase Agreement, dated as of January 22, 2024, by and between the Company and each holder of the pre-funded warrants, or the Private Placement Warrant Amendment, clarifying the treatment of the pre-funded warrants in connection with the Merger and the spin-off such that the holders of the pre-funded warrants will receive the Merger Consideration (as defined in the Merger Agreement) and, pursuant to the terms of the pre-funded warrants, receive warrants to purchase up to an aggregate of 1,678,661 shares of New Inhibrx common stock with terms, rights and obligations equivalent to the pre-funded warrants, in each case, subject to conditions specified in such amendment.
During the years ended December 31, 2023 and December 31, 2022, there were no other transactions or series of similar transactions to which we were or are a party in which the amount involved exceeded or exceeds $120,000 and in which any of our directors or executive officers, any holder of more than 5% of any class of our voting securities or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than the compensation arrangements with our executive officers and non-employee directors described in “Executive Compensation” and “Director Compensation,” respectively.
Related Party Transaction related to the Merger and Spin Out
In January 2024, we entered into the Merger Agreement with Aventis, a wholly owned indirect subsidiary of Sanofi, whereby Sanofi will indirectly acquire, through Aventis, all the assets and liabilities primarily related to INBRX-101. Immediately prior to the closing of the Merger, all assets and liabilities not primarily related to INBRX-101 will be spun out into New Inhibrx.
Under the terms of the Merger Agreement, Aventis will acquire all of our outstanding shares through a merger, and in turn, each of our shareholders will receive: (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone and (iii) one SEC-registered, publicly listed, share of New Inhibrx for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Aventis will (1) assume and retire our outstanding third-party debt, including our debt arrangements with Oxford, (2) cause New Inhibrx to be funded with $200 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%. Subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals, we currently expect the transaction to close during the second quarter of 2024.
In connection with the execution of the Merger Agreement, the Company entered into the Private Placement Warrant Amendment clarifying the treatment of the pre-funded warrants in connection with the Merger and the spin-off such that the holders of the pre-funded warrants will receive the Merger Consideration (as defined in the Merger Agreement) and, pursuant to the terms of the pre-funded warrants, receive warrants to purchase up to an aggregate of 1,678,661 shares of New Inhibrx common stock with terms, rights and obligations equivalent to the pre-funded warrants, in each case, subject to conditions specified in such amendment.
172

As of February 21, 2024, our directors and executive officers owned, in the aggregate, approximately 20.6% of the outstanding voting shares of our common stock. See “Security Ownership of Certain Beneficial Owners” above.
173

Item 14. Principal Accountant Fees and Services
Fees for Independent Registered Public Accounting Firm
 The following table presents the fees billed to the Company by BDO USA, P.C., or BDO, for professional services rendered for the years ended December 31, 2023 and December 31, 2022, respectively:
20232022
Audit Fees
$690,153 $532,697 
Audit-Related Fees— — 
Tax Fees93,456 44,400 
All Other Fees— — 
Total$783,609 $577,097 
Audit Fees: For the years ended December 31, 2023 and December 31, 2022, the aggregate audit fees billed by our independent registered public accounting firm were for professional services performed by BDO for the audit of our annual financial statements included in our Form 10-K filing and review of financial statements included in our quarterly Form 10-Q filings, reviews of registration statements and issuances of consents, comfort letters, and services that are normally provided in connection with statutory and regulatory filings or engagements.
Audit-Related Fees: For the years ended December 31, 2023 and December 31, 2022, there were no fees billed by our independent registered accounting firm for audit-related fees.
Tax Fees: For the years ended December 31, 2023 and December 31, 2022, the tax-related fees billed by an affiliate of our independent registered accounting firm pertained to services related to tax return preparation, tax planning services, and Section 382 analysis related to the Company’s NOLs.
All Other Fees: For the years ended December 31, 2023 and December 31, 2022, there were no fees billed by our independent registered accounting firm for other services, other than the fees described above.
Pre-Approval Policies and Procedures
All audit and non-audit services provided by BDO must be pre-approved by the Audit Committee. BDO will provide the Audit Committee with an engagement letter during the first half of the fiscal year, outlining the scope of the proposed services and estimated fees for the fiscal year. Pre-approval may be given for a category of services, provided that (i) the category is reasonably narrow and detailed and (ii) the Audit Committee establishes a fee limit for such category. The Audit Committee may delegate to any member of the Audit Committee the authority to grant pre-approval of permitted non-audit services to be provided by BDO between Audit Committee meetings; provided, however, that any such pre-approval shall be presented to the full Audit Committee at its next scheduled meeting. The Audit Committee pre-approved all audit and permitted non-audit services provided by BDO for the years ended December 31, 2023 and December 31, 2022.

174

Part IV.
Item 15. Exhibits and Financial Statement Schedules
Exhibits
The exhibits listed in the accompanying “Index to Exhibits” below are filed or incorporated by reference as part of this Annual Report.
Financial Statement Schedules
See “Index to Consolidated Financial Statements” at Item 8 to this Annual Report. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.



175

Index to Exhibits
Exhibit No.
Description of Exhibit
Filed Herewith
FormIncorporated By Reference File No.Date Filed
2.1
8-K001-394521/23/2024
2.2
8-K001-394521/23/2024
3.18-K001-394528/21/2020
3.28-K001-394528/21/2020
4.1S-1333-2319076/3/2019
4.2S-1333-2401357/28/2020
4.3^
S-1333-2401357/28/2020
4.48-K001-394521/23/2024
4.510-K001-395423/12/2021
4.6
8-K
001-394528/29/2023
4.7
8-K001-394521/23/2024
10.1ΔS-1333-2401357/28/2020
10.2Δ10-Q001-3945211/07/2022
10.3Δ
10-Q001-3945211/09/2021
10.4Δ
10-Q001-3945211/07/2022
10.5Δ
S-1/A333-2401358/12/2020
10.6Δ
S-1333-2319076/3/2019
10.7Δ
S-1333-2319076/3/2019
10.8Δ
S-1333-2401357/28/2020
10.9†
S-1333-2319076/3/2019
176

10.10
S-1333-2319076/3/2019
10.11†
S-1333-2319076/3/2019
10.12
S-1333-2319076/3/2019
10.13
S-1333-2319076/3/2019
10.14†
S-1333-2319076/3/2019
10.15
X
10.16†
S-1333-2319076/3/2019
10.17†
S-1333-2319076/3/2019
10.18
S-1333-2319076/3/2019
10.19
S-1333-2319076/3/2019
10.20†
S-1333-2401357/28/2020
10.21
S-1333-2401357/28/2020
10.22
10-Q001-3945211/13/2020
10.23
8-K001-394526/21/2021
10.24
8-K001-394522/22/2022
10.25
8-K001-394526/16/2022
10.26
8-K001-3945210/4/2022
10.27†
S-1333-2319076/3/2019
177

10.28†
S-1333-2401357/28/2020
10.29
S-3ASR333-2593139/3/2021
10.30^
8-K
001-394528/29/2023
21.1S-1333-2319076/3/2019
23.1X
31.1X
31.2X
32.1*X
32.2*X
97.1Δ
10-Q
001-39452
11/9/2023
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL documentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101X
^    Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.
†    Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
Δ    Management Compensation Plan or arrangement.
* This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
178

Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
INHIBRX, INC.
/s/ Mark P. Lappe
Name:  Mark P. Lappe
Title:  Chief Executive Officer and Chairman
Date: February 28, 2024
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
SIGNATURETITLEDATE
/s/ Mark P. Lappe
Chief Executive Officer and Chairman
(principal executive officer)
February 28, 2024
Mark P. Lappe
/s/ Kelly D. Deck, C.P.A.
Chief Financial Officer
(principal financial officer and
principal accounting officer)
February 28, 2024
Kelly D. Deck, C.P.A.
/s/ Jon Faiz Kayyem, Ph.D.DirectorFebruary 28, 2024
Jon Faiz Kayyem, Ph.D.
/s/ Douglas G. ForsythDirectorFebruary 28, 2024
Douglas G. Forsyth
/s/ Kimberly ManhardDirectorFebruary 28, 2024
Kimberly Manhard
/s/ Kristiina Vuori, M.D., Ph.D.DirectorFebruary 28, 2024
Kristiina Vuori, M.D., Ph.D.
179
 EX-10.15 2 elpisciencelicenseterminat.htm EX-10.15 Document

Exhibit 10.15
TERMINATION AGREEMENT

This Termination Agreement (this “Termination Agreement”), effective as of February 26, 2024 (the “Effective Date”), is made by and between Inhibrx, Inc. (formerly known as Inbrx105 LP), a Delaware corporation located at 11025 N. Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Inhibrx”), and Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company having offices at Offices of Corporate Filing Services Ltd., 3rd Floor, Harbour Centre, George Town, P.O. Box 613, Grand Cayman KYI-1107, Cayman Islands (“Elpiscience,” and together with Inhibrx, the “Parties,” and each, a “Party”).

WHEREAS, the Parties have entered into a License Agreement, dated February 28, 2018, as amended on August 4, 2021, pursuant to which Inhibrx granted Elpiscience an exclusive license to further develop, manufacture, and commercialize INBRX-105 (the “Licensed Molecule”) in greater China (the “INBRX-105 License Agreement”);

WHEREAS, the Parties desire to terminate the INBRX-105 License Agreement on the terms and subject to the conditions set forth herein; and

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1.Definitions. Capitalized terms used and not defined in this Termination Agreement have the respective meanings assigned to them in the INBRX-105 License Agreement.
2.Termination of the INBRX-105 License Agreement.
a.The Parties hereby agree to terminate the INBRX-105 License Agreement in its entirety from and after the Effective Date of this Termination Agreement. As of the Effective Date of this Termination Agreement, all rights and obligations of each of the Parties under the INBRX-105 License Agreement shall cease (including but not limited to all rights and licenses granted by either Party to the other Party thereunder), and , to the extent not already completed, Elpiscience shall cease all development and commercialization activities with respect to the Licensed Molecule and any Licensed Product, and shall have no further obligations thereafter to develop or commercialize the Licensed Molecule in the Territory, except as set forth in this Termination Agreement.
b.The effects of termination set forth in Sections 9.2, 9.3, and 9.4 of the INBRX-105 License Agreement are superseded by the terms of this Termination Agreement; provided, however, that Articles 1, 7, 11, 12, 13 and 14 and Sections 3.2, 3.5, 4.4, 4.5, 5.3, 5.4, 10.3 and 10.4 of the INBRX-105 License Agreement shall survive after termination.
c.From and after the Effective Date of this Termination Agreement, each Party shall cooperate with the other in good faith to take all actions reasonably necessary to ensure the transfer of materials, data and information in accordance with this Agreement.
d.For avoidance of doubt, upon the Effective Date, the License granted by Inhibrx to Elpiscience under the INBRX-105 License Agreement shall be terminated, and neither Party shall owe the other Party any milestone, royalty, or other payments under the INBRX-105 License Agreement.
e.Within ninety (90) days after the effective date of termination, Elpiscience shall return to Inhibrx (or, at Inhibrx’s request, shall destroy) all of the Inhibrx Materials (including all


progeny or derivatives thereof) and all Licensed Molecules and Licensed Product that are remaining in Elpiscience’s possession or control (or to which Elpiscience has the right to obtain possession or control); provided, however, that the Parties shall separately negotiate and agree on the disposal of any remaining cell line, Licensed Molecule and Licensed Products related to INBRX-105 under the INBRX-105 License Agreement and other relevant agreements (such as the Sale and Purchase Agreement dated July 31, 2022 and the Drug Substance Sale and Purchase Agreements dated April 14, 2023), including without limitation the scope of materials to be disposed, method of disposal, timeline, and expenses to be borne by the Parties. In addition, Elpiscience shall provide Inhibrx with all Know-How Controlled by Elpiscience pertaining to such materials necessary or useful for Inhibrx to handle, store and use such materials and not already provided to Inhibrx.
3.Other Agreements.
a.The Parties agree that the Pharmacovigilance Agreement dated March 26, 2020, as amended, and any other agreements or arrangements between the Parties related to INBRX-105 shall also be terminated as of the Effective Date. From and after the Effective Date, those agreements will be of no further force or effect, and the rights and obligations of each of the Parties thereunder shall terminate.
b.For avoidance of doubt, the Parties acknowledge that the License Agreement, dated April 30, 2018, as amended on August 4, 2021, pursuant to which Inhibrx granted Elpiscience an exclusive license to further develop, manufacture, and commercialize INBRX-106 in greater China (the “INBRX-106 License Agreement”), and related agreements, shall remain in full force and effect. Nothing in this Termination Agreement shall be construed to affect the Parties’ respective rights and obligations under the INBRX-106 License Agreement from and after the date hereof.
4.Transfers and Assignments; Covenants.
a.Intangible Property. Elpiscience shall have no further rights under the INBRX-105 License Agreement related to Licensed Molecules or Licensed Products. Inhibrx shall have the exclusive option to negotiate with Elpiscience, on terms and conditions that are commercially reasonable under the circumstances, for an exclusive license under all intellectual property Controlled by Elpiscience necessary to develop, manufacture and commercialize Licensed Molecules and Licensed Products and nothing herein shall be construed as obligating either Party to enter into any agreement with respect to such exclusive license on terms and conditions that are not acceptable to it. Inhibrx shall not use intellectual property Controlled by Elpiscience necessary to develop, manufacture and commercialize Licensed Molecules and Licensed Products beyond the scope of Sections 4.4 and 5.3 of the INBRX-105 License Agreement, until and unless Inhibrx obtains the exclusive license in accordance with this Section 4(a).
b.Withdrawal of Approvals, Filings, and Permits. Elpiscience represents that it has withdrawn or otherwise terminated any and all regulatory approvals, filings, submissions, permits or other rights that Elpiscience obtained in connection with the INBRX-105 License Agreement.
c.Transfer of Regulatory Filings and Clinical Submissions. If not already provided, as promptly as reasonably practicable following the Effective Date of the Termination Agreement, Elpiscience shall provide to Inhibrx the documentation, in Chinese, including the underlying data, reports, protocols, supporting tables, figures and legends, that have been generated as part of the official closeout of the Phase 1 ES101 Study (the


“Abbreviated Clinical Study Report”), and with IND supporting INBRX-105 (the “IND Data Package”).
d.Transfer of Data and Information. To the extent not already provided, Elpiscience will make available and transfer to Inhibrx, at no cost to Inhibrx, originals or copies of clinical and nonclinical datasets, records, reports and documentation generated by or on behalf of Elpiscience or its Affiliates with the Licensed Molecule, that Inhibrx reasonably requests to enable Inhibrx to close out its INBRX-105 program. Further, except as needed for regulatory, compliance, and related obligations, Elpiscience (and any third party CRO) shall return or destroy any such datasets, records, reports and documentation from their databases or network (including copies, backups, etc.). For clarity, all regulatory approvals, filings, submissions or permits that Elpiscience obtained, and the trial master file, safety data and related documents and original medical records generated, in each case in connection with the INBRX-105 License Agreement, could be retained by Elpiscience (and any third party service providers) for 15 years from the Effective Date for fulfillment of regulatory related obligations.
e.Transfer of Clinical Safety Database. The Parties acknowledge that Elpiscience has transferred the ES101 clinical safety database to Inhibrx. Elpiscience represents that the clinical safety database has been maintained, reconciled, and faithfully transferred in compliance with requirements of any applicable Regulatory Authorities. Upon Inhibrx’s reasonable request, Elpiscience will provide clinical data and information generated by or on behalf of Elpiscience, with or related to Licensed Molecules and Licensed Products, in a form sufficient for Inhibrx to use such data and information in Regulatory Filings and for submission to Regulatory Authorities outside the Territory. Inhibrx shall prepare and provide with Elpiscience the development safety update report and investigator brochure for INBRX-105 covering the reporting period from October 19, 2023 to October 18, 2024. The Parties shall collaborate to fulfill obligations of the Parties for compliance with applicable laws and regulations related to pharmacovigilance.
f.Technical Operations Arrangements. The Parties acknowledge that there may be certain technical operations matters to be managed following the Effective Date. Accordingly, the Parties will continue to coordinate such matters after the Effective Date, with each Party bearing its own costs.
5.Financial Terms. The Parties agree that unless otherwise agreed between the Parties, no payments or other consideration is due and payable by either Party to the other Party in connection with the INBRX-105 License Agreement or any related agreements, or the termination thereof.
6.Release.
a.Mutual Releases. In consideration of the covenants, agreements, and undertakings of the Parties under this Termination Agreement, each Party, on behalf of itself and its Affiliates, officers, directors, managers, shareholders, members, successors, and assigns (collectively, “Releasors”) hereby releases, waives, and forever discharges the other Party and its Affiliates, employees, officers, directors, managers, shareholders, members, successors, and assigns (collectively, “Releasees”) of and from any and all actions, causes of action, suits, losses, liabilities, rights, costs, expenses, damages, judgments, claims, and demands, of every kind and nature whatsoever, whether now known or unknown, foreseen or unforeseen, matured or unmatured, suspected or unsuspected, in law or equity (collectively, “Claims”), which any of such Releasors ever had, now have, or hereafter can, shall, or may have against any of such Releasees for, upon, or by reason


of any matter, cause, or thing whatsoever from the beginning of time through the date of this Termination Agreement arising out of or relating to the INBRX-105 License Agreement and any related agreements or arrangements between the Parties pre-dating this Termination Agreement, except for any Claims relating to rights and obligations preserved by, created by, or otherwise arising out of this Termination Agreement.
b.Release of Claims. Each of the Parties acknowledges that it has been advised by its attorneys concerning, and is familiar with, California Civil Code Section 1542 and expressly waives any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to the provisions of the California Civil Code Section 1542, including that provision itself, which reads as follows:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

The Parties acknowledge that inclusion of the provisions of this Section to this Termination Agreement was a material and separately bargained for element of this Termination Agreement.
7.Representations and Warranties. Each Party hereby represents and warrants to the other Party that:
a.It has the full right, corporate power, and authority to enter into this Termination Agreement and to perform its obligations hereunder.
b.The execution of this Termination Agreement by the individual whose signature is set forth at the end of this Termination Agreement on behalf of such Party, and the delivery of this Termination Agreement by such Party, have been duly authorized by all necessary corporate action on the part of such Party.
c.This Termination Agreement has been executed and delivered by such Party and (assuming due authorization, execution, and delivery by the other Party hereto) constitutes the legal, valid, and binding obligation of such Party, enforceable against such Party in accordance with its terms.
d.It has neither assigned nor transferred any of the Claims released herein to any person or entity and no person or entity has subrogated to or has any interest or rights in any Claims.
e.It is not aware of any actual or contemplated claim by a third party against any of the Parties related to the subject matter of the releases set forth herein.
f.EXCEPT FOR THE EXPRESS REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS TERMINATION AGREEMENT, (A) NEITHER PARTY HERETO NOR ANY PERSON ON SUCH PARTY’S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WHATSOEVER, EITHER ORAL OR WRITTEN, WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE, OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND (B) EACH PARTY HERETO ACKNOWLEDGES THAT, IN ENTERING INTO THIS TERMINATION AGREEMENT, IT HAS NOT RELIED UPON ANY REPRESENTATION OR


WARRANTY MADE BY THE OTHER PARTY, OR ANY OTHER PERSON ON SUCH OTHER PARTY’S BEHALF, EXCEPT AS SPECIFICALLY PROVIDED IN THIS TERMINATION AGREEMENT.

8.Indemnification.
a.Each Party (as “Indemnifying Party”) shall defend, indemnify, and hold harmless the other Party, and its officers, directors, managers, employees, agents, Affiliates, permitted successors, and permitted assigns (collectively, “Indemnified Party”), against any and all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys’ fees, and the costs of enforcing any right to indemnification under this Termination Agreement (collectively, “Losses”), arising out or resulting from any claim alleging: (i) material breach by Indemnifying Party of any representation, warranty, covenant, or other obligations set forth in this Termination Agreement; or (ii) gross negligence or more culpable act or omission of an Indemnifying Party (including any recklessness or willful misconduct) in connection with the performance of its obligations under this Termination Agreement.
b.Neither Party will encourage, participate in, or support a third party (i.e., any person that is not a Party or an Affiliate of a Party) in bringing claims against the other Party or its Affiliates based, in whole or in part, on the INBRX-105 License Agreement, the Pharmacovigilance Agreement or this Termination Agreement. Nothing about this provision will prevent a Party from (a) responding to any lawful subpoena; or (b) providing truthful testimony in response to a compulsory deposition or trial subpoena.
c.Notwithstanding anything to the contrary in this Termination Agreement, the Indemnifying Party is not obligated to indemnify, defend, or hold harmless the other Party and the other Indemnified Parties against any Losses arising out of or resulting, in whole or in part, from an Indemnified Party’s: (i) willful, reckless, or negligent acts or omissions; (ii) bad faith failure to comply with any of its obligations set forth in this Termination Agreement; or (iii) breach of the foregoing Section 8(b).
d.An Indemnified Party seeking indemnification under this Section 8 shall give the Indemnifying Party: (i) Notice (as defined below) of the relevant claim as soon as practicable, but in any case, no more than three (3) days after such Indemnified Party becomes aware of the events or circumstances giving rise to such claim; provided, however, that failure to provide such notice shall not relieve the Indemnifying Party from its liability or obligation hereunder except to the extent of any material prejudice directly resulting from such failure; and (ii) reasonable cooperation, at the Indemnifying Party’s expense, in the defense of such claim. The Indemnifying Party shall have the right to control the defense and settlement of any such claim; provided, however, that the Indemnifying Party shall not, without the prior written approval of the Indemnified Party, settle or dispose of any claims without the express consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. The Indemnified Party shall have the right to participate in the defense at its own expense.
e.THIS SECTION SETS FORTH THE ENTIRE LIABILITY AND OBLIGATION OF EACH INDEMNIFYING PARTY AND THE SOLE AND EXCLUSIVE REMEDY OF EACH INDEMNIFIED PARTY FOR ANY DAMAGES COVERED BY THIS SECTION.


9.Confidentiality.
a.Confidential Information. From and after the Effective Date of this Termination Agreement, the non-public information of the Licensed Molecule and Licensed Product will be deemed Confidential Information of Inhibrx under the INBRX-105 License Agreement and subject to Article 12 thereof. All other information disclosed by one Party to the other Party under the INBRX-105 License Agreement will be deemed the disclosing Party’s Confidential Information and subject to Article 12 thereof. In addition, the terms of this Termination Agreement will be deemed the Confidential Information of each Party under the terms set forth in Section 10 of this Termination Agreement.
b.Return of Confidential Information. No later than thirty (30) days following the Effective Date of this Termination Agreement, the receiving Party shall return to the disclosing Party (or, at request of the disclosing Party, shall destroy) all of Confidential Information of the disclosing Party (including copies thereof) in its possession or control; provided, however, that receiving party may retain one archival copy in its confidential files for purposes of compliance with applicable laws or identifying its continuing obligations under this Termination Agreement with respect thereto.
c.Subject to the terms and conditions of Section 10, each Party acknowledges the confidential nature of the terms and conditions of this Termination Agreement and agrees that it shall not (a) disclose any of such Confidential Information to any person or entity, except to such Party’s Affiliates, employees, advisors, and other representatives who need to know the Confidential Information to assist such Party, or act on its behalf, to exercise its rights or perform its obligations under this Termination Agreement, or (b) use the Confidential Information, or permit it to be accessed or used, for any purpose other than to exercise its rights or perform its obligations under this Termination Agreement. Each Party shall be responsible for any breach of this Section 9 caused by any of its Affiliates, employees, advisors, or other representatives. Notwithstanding the foregoing, if any Confidential Information is permissibly disclosed pursuant to Section10, such information will no longer be deemed “Confidential Information” for the purposes of this Section 9.
10.Publicity and Announcements. Neither Party shall (orally or in writing) publicly disclose or issue any press release or make any other public statement, or otherwise communicate with the media, concerning the existence of this Termination Agreement, the transactions contemplated herein or the subject matter hereof, without the prior written approval of the other Party (which shall not be unreasonably withheld or delayed), except to the extent that such Party (based upon the reasonable advice of counsel) is required to make any public disclosure or filing with respect to the subject matter of this Termination Agreement (i) by applicable law, (ii) pursuant to any rules or regulations of any securities exchange of which the securities of such Party or any of its Affiliates are or to be listed or traded, or (iii) in connection with enforcing its rights under this Termination Agreement; provided, however, if a Party is required to make any public disclosure or filing pursuant to subsections (i) or (ii) of this Section 10, such Party shall provide Notice (as defined below) to the other Party as soon as practicable, but in any case, no more than three (3) days after such Party becomes aware of such impending public disclosure or filing.
11.Non-Disparagement. Each Party, on behalf of itself and its Affiliates, officers, directors, managers, shareholders, members, successors, and assigns, agrees that it will not, will cause its Affiliates, officers, directors, employees, consultants, agents, representatives, attorneys and advisors (to the extent directly or indirectly acting on its behalf) not to, directly or indirectly, in any manner, alone or in concert with others, make, or cause to be made, any statement, filing or announcement (in each case, whether written or oral) that relates to and constitutes an ad


hominem attack on, denigrates or disparages, or are detrimental to, the reputation or stature of the other Party or its businesses, or any of its employees, directors, officers, or managers, and existing and prospective customers, suppliers, investors, and other associated third parties, (i) in any document or report filed with or furnished to the SEC or any other governmental agency, (ii) in any public communication, (iii) in any communication that would reasonably be expected to enter the public domain (including to any journalist or member of the media, whether as part of a television, radio, online, newspaper or magazine interview or otherwise), (iv) to any financial analyst (whether sell-side or buy-side), university or medical industry group or institute, or (v) to any stockholder, customer, supplier or business partner of either Party. The foregoing will not prevent (a) the making of any factual statement in the event that either Party or any of its representatives are required to make that statement by applicable subpoena, legal process, other legal requirement or the rules of any securities exchange to which it is or to be subject or (b) a response by a Party to any statement made by the other Party which is in violation of this Section; provided, however, if a Party intends to make any statements pursuant to subsections (a) or (b) of this Section, such Party shall provide Notice (as defined below) to the other Party as soon as practicable, but in any case, no more than three (3) days after such Party becomes aware of such impending statement.
12.No Admission of Liability. This Termination Agreement does not constitute an admission by any of the Parties of any liability or wrongdoing whatsoever, including, but not limited to, any breach or violation of the terms of the INBRX-105 License Agreement or any related agreements.
13.Miscellaneous.
a.All notices, requests, consents, claims, demands, waivers, summons, and other legal process, and other similar types of communications hereunder (each, a “Notice”) must be in writing and addressed to the relevant Party at the address set forth on the first page of this Termination Agreement (or to such other address that may be designated by the receiving Party from time to time in accordance with this Section). All Notices must be delivered by personal delivery, nationally recognized overnight courier (with all fees pre-paid), or certified or registered mail (in each case, return receipt requested, postage prepaid). A Notice is effective only (i) upon receipt by the receiving Party and (ii) if the Party giving the Notice has complied with the requirements of this Section 13(a).
b.This Termination Agreement and all related documents, and all matters arising out of or relating to this Termination Agreement, are governed by, and construed in accordance with, the laws of the State of California, without regard to choice of law or conflict of laws principles. Sections 13 of the INBRX-105 License Agreement shall apply to this Termination Agreement, mutatis mutandis.
c.This Termination Agreement and each of the terms and provisions hereof may only be amended, modified, waived, or supplemented by an agreement in writing signed by each Party.
d.Neither Party may assign, transfer, or delegate any or all of its rights or obligations under this Termination Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may assign this Termination Agreement to an Affiliate, a successor-in-interest by consolidation, merger, or operation of law, or to a purchaser of all or substantially all of the Party’s assets. No assignment will relieve the assigning Party of any of its obligations hereunder. Any attempted assignment, transfer, or other conveyance in violation of the foregoing will be null and void. This Termination Agreement will inure to the benefit of


and be binding upon each of the Parties and each of their respective permitted successors and permitted assigns.
e.This Termination Agreement may be executed in counterparts, each of which is deemed an original, but all of which constitute one and the same agreement. Delivery of an executed counterpart of this Termination Agreement electronically shall be effective as delivery of an original executed counterpart of this Termination Agreement.
f.The Parties acknowledge and agree that they will each cooperate in the execution and delivery of any other or further documentation that may be reasonably necessary to carry out the intentions and purposes of this Termination Agreement.
g.This Termination Agreement is the result of arm’s-length negotiations between the Parties, and the Parties, including through their counsel, have contributed substantially and materially to the preparation of this Termination Agreement. No provision of this Termination Agreement shall be interpreted or construed against any Party because that Party or its legal representative drafted that particular provision. The headings in this Termination Agreement are for reference only and do not affect the interpretation of this Termination Agreement.
h.If any term or provision of this Termination Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Termination Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.
i.Each Party acknowledges and agrees that (i) a breach or threatened breach by such Party of any of its obligations under Section 9, Section 10 or Section 11 of this Termination Agreement would give rise to irreparable harm to the other Party for which monetary damages would not be an adequate remedy and (ii) in the event of a breach or a threatened breach by such Party of any such obligations, the other Party will, in addition to any and all other rights and remedies that may be available to such Party at law, in equity, or otherwise in respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance, and any other relief that may be available from a court of competent jurisdiction, without any requirement to post a bond or other security, and without any requirement to prove actual damages or that monetary damages will not afford an adequate remedy. Each Party agrees that it shall not oppose or otherwise challenge the appropriateness of equitable relief or the entry by a court of competent jurisdiction of an order granting equitable relief, in either case, consistent with the terms of this Section.
j.This Termination Agreement constitutes the sole and entire agreement between the Parties with respect to the subject matter contained herein and supersedes all prior and contemporaneous understandings, agreements, representations, and warranties, both written and oral, with respect to such subject matter.
k.Except to the extent otherwise provided herein with respect to Released Persons, nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever.
l.Each Party shall pay its own costs and expenses in connection with the drafting, negotiation, and execution of this Termination Agreement (including the fees and expenses of its advisors, accountants, and legal counsel).



IN WITNESS WHEREOF, the Parties have executed this Termination Agreement effective as of the date first written above.

Elpiscience Biopharmaceuticals, Inc. Inhibrx, Inc.

By:/s/ Darren JiBy:/s/ Mark Lappe
Name:Darren JiName:Mark Lappe
Title:Chief Executive OfficerTitle:Chief Executive Officer

 EX-23.1 3 exhibit231q42023.htm EX-23.1 Document

Exhibit 23.1


Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (333-259313) and Form S-8 (Nos. 333-270296, 333-263204, 333-252214 and 333-248138) of Inhibrx, Inc. (the Company) of our reports dated February 28, 2024, relating to the consolidated financial statements and the effectiveness of the Company’s internal control over financial reporting, which appear in this Annual Report on Form 10-K.

/s/ BDO USA, P.C.

San Diego, California
February 28, 2024


 EX-31.1 4 exhibit311q42023.htm EX-31.1 Document



Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark P. Lappe, certify that:
1.I have reviewed this Annual Report on Form 10-K of Inhibrx, Inc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 28, 2024
/s/ Mark P. Lappe
Mark P. Lappe
Chief Executive Officer and Chairman
(Principal Executive Officer)

 EX-31.2 5 exhibit312q42023.htm EX-31.2 Document



Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kelly D. Deck, certify that:
1.I have reviewed this Annual Report on Form 10-K of Inhibrx, Inc;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 28, 2024
/s/ Kelly D. Deck
Kelly D. Deck, C.P.A.
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 6 exhibit321q42023.htm EX-32.1 Document



Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Inhibrx, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark P. Lappe, Chief Executive Officer and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 28, 2024
/s/ Mark P. Lappe
Mark P. Lappe
Chief Executive Officer and Chairman
(Principal Executive Officer)
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-32.2 7 exhibit322q42023.htm EX-32.2 Document



Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Inhibrx, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kelly D. Deck, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 28, 2024
/s/ Kelly D. Deck
Kelly D. Deck, C.P.A.
Chief Financial Officer
(Principal Financial and Accounting Officer)
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-101.SCH 8 inbx-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Statements of Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - OTHER FINANCIAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - EQUITY COMPENSATION PLAN link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - LICENSE AND GRANT REVENUES link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - OTHER FINANCIAL INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - EQUITY COMPENSATION PLAN (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - LICENSE AND GRANT REVENUES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - DEBT - Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - STOCKHOLDERS’ EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - STOCKHOLDERS’ EQUITY - Warrants Issued in Connection with Amended 2020 Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - STOCKHOLDERS’ EQUITY - Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - EQUITY COMPENSATION PLAN - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - EQUITY COMPENSATION PLAN - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - EQUITY COMPENSATION PLAN - Fair Value of Stock Option Grants (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - EQUITY COMPENSATION PLAN - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - INCOME TAXES - Reconciliation of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - INCOME TAXES - Components of Net Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 inbx-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 inbx-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 inbx-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Collaborative arrangement, payment received, net Collaborative Arrangement, Payment Received, Net Collaborative Arrangement, Payment Received, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs Deferred Charges, Policy [Policy Text Block] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Number of performance obligations Number Of Performance Obligations Number Of Performance Obligations Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Remaining term of operating lease (in years) Lessee, Operating Lease, Remaining Lease Term DEBT Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Accrued Research and Development and Clinical Trial Costs Research and Development Expense, Policy [Policy Text Block] Non-cash lease expense Noncash Operating Lease Expense Noncash Operating Lease Expense MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Total other expense Nonoperating Income (Expense) Sale of stock, right per share, contingency Sale of Stock, Right Per Share, Contingency Sale of Stock, Right Per Share, Contingency Commitments and contingencies (Note 9) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] STOCKHOLDERS’ EQUITY Equity [Text Block] Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Fair value of warrants issued to lender in conjunction with February 2022 Amendment (as defined in Note 3) Other Noncash Investing And Financing Items, Warrant Liabilities Incurred Other Noncash Investing And Financing Items, Warrant Liabilities Incurred Proceeds from ATM offering Proceeds from Issuance of Common Stock Other non-current assets Increase (Decrease) in Other Noncurrent Assets Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] INCOME TAXES Income Tax Disclosure [Text Block] Expected dividend yield (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Leases Lessee, Leases [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Purchase commitment, future period (in months) Purchase Commitment, Future Period Purchase Commitment, Future Period Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022 Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Nonrefundable, upfront payment Collaborative Arrangement, Nonrefundable Upfront Payment Collaborative Arrangement, Nonrefundable Upfront Payment Purchase commitment, expenses incurred Purchase Commitment, Expenses Incurred Purchase Commitment, Expenses Incurred Schedule of Common Stock Reserved For Future Issuance Schedule of Common Stock Reserved For Future Issuance [Table Text Block] Schedule of Common Stock Reserved For Future Issuance Issuance of shares upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Minimum cash balance Debt Instrument, Minimum Cash Balance Debt Instrument, Minimum Cash Balance Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Receivables from related parties Increase (Decrease) in Due from Related Parties Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Weighted average fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Machinery and equipment Machinery and Equipment [Member] LEASES Lessee, Operating Leases [Text Block] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Schedule of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Deferred revenue Contract with Customer, Liability Warrants, Pre-Funded Warrants, Pre-Funded [Member] Warrants, Pre-Funded Issuance of shares upon exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Equity method investment, ownership percentage, increase during period (as a percent) Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period 2020 Term F 2020 Oxford Term Loan F [Member] 2020 Oxford Term Loan F Non-cash license revenue Other Noncash Income Executive Category: Executive Category [Axis] Other Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Name Measure Name Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Liquidity Liquidity [Policy Text Block] Liquidity Name Forgone Recovery, Individual Name Chiesi Farmaceutici S.p.A. Chiesi Farmaceutici S.p.A. [Member] Chiesi Farmaceutici S.p.A. Issuance of warrants Reclassification of warrant liabilities into equity Adjustments to Additional Paid in Capital, Warrant Issued Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Capitalized research and development costs Deferred Tax Assets, Tax Deferred Expense, Capitalized Research and Development Costs Deferred Tax Assets, Tax Deferred Expense, Capitalized Research and Development Costs July 15, 2030 Class of Warrant or Right, Expiration Date 1 [Member] Class of Warrant or Right, Expiration Date 1 Warrant price (in dollars per share) Exercise price (in dollars per share) Exercise Price per Share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses Increase (Decrease) in Accrued Liabilities Available shares reserved for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant 2026 Long-Term Debt, Maturity, Year Two Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Warrant to purchase common stock Warrants issued and outstanding Warrant [Member] Non-current portion of lease liability Non-current Operating Lease, Liability, Noncurrent ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Class of Warrant or Right [Table] Class of Warrant or Right [Table] Clinical trials Clinical Trails, Prepaid Expense Current Clinical Trails, Prepaid Expense Current Costs associated with ATM offering Costs associated with the ATM offering Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Less: debt discount Less: unamortized debt discount Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Prepayment fee (as a percent) Debt Instrument, Prepayment Fee Debt Instrument, Prepayment Fee Schedule of Operating Lease Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Operating Lease, by Balance Sheet Location Right-Of-Use Asset And Operating Lease Liability [Table Text Block] Right-Of-Use Asset And Operating Lease Liability Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Sale of stock, shares issued/sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Total revenue Total revenue Revenues Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Debt interest expense Interest Expense, Debt Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and development Research and Development Expense [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total fair value of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Award Type [Axis] Award Type [Axis] Antidilutive securities excluded from earnings per share computation (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Payable for purchase of fixed assets Capital Expenditures Incurred but Not yet Paid ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized General and administrative General and administrative General and Administrative Expense [Member] Total property and equipment Property, Plant and Equipment, Gross Weighted Average Remaining Contractual Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Debt Instrument Rate Two Debt Instrument Rate Two [Member] Debt Instrument Rate Two Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Revenue recognized related to performance obligation Contract with Customer, Performance Obligation Satisfied in Previous Period Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Exchange ratio, pro-rate basis, post spin-off transaction (as a percent) Merger, Exchange Ratio, Pro-Rate Basis, Post Spin-off Transaction, Percentage Merger, Exchange Ratio, Pro-Rate Basis, Post Spin-off Transaction, Percentage Loss Contingencies [Table] Loss Contingencies [Table] Outside research and development services Prepaid Expense, Current Current portion of lease liability Current Less: current portion of operating lease liability Operating Lease, Liability, Current License fee revenue License [Member] 2027 Long-Term Debt, Maturity, Year Three Deferred offering costs Deferred Offering Costs Auditor Firm ID Auditor Firm ID Entity Shell Company Entity Shell Company Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Private Placement Private Placement [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Permanent items Effective Income Tax Rate Reconciliation, Permanent Items Effective Income Tax Rate Reconciliation, Permanent Items Common stock, shares issued (in shares) Common Stock, Shares, Issued Deferred revenue Contract with Customer, Liability, Current Schedule of Weighted-Average Assumptions Used to Estimate Fair Value Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name R&D credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Total debt Long-Term Debt Fair Value of Stock-Based Awards Share-Based Payment Arrangement [Policy Text Block] Sales Agreement Sales Agreement [Member] Sales Agreement Sale of stock, proceeds received Sale of Stock, Consideration Received on Transaction 2seventy bio, Inc. 2seventy bio, Inc. [Member] 2seventy bio, Inc. Outstanding stock options Options to purchase common stock issued and outstanding Stock Option Employee Stock Option [Member] Weighted-average period of recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Reverse termination fee Merger, Reverse Termination Fee Merger, Reverse Termination Fee Pre-funded warrants issued and outstanding Pre Funded Warrants [Member] Pre Funded Warrants Maximum Maximum [Member] Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Federal Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] EQUITY COMPENSATION PLAN Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other outside research and development Accrued Outside Research And Development, Other, Current Accrued Outside Research And Development, Other, Current Additional Programs License Agreement, Additional Programs Authorized [Member] License Agreement, Additional Programs Authorized Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Equal payments of principal period if interest only period is extended (in months) Debt Instrument, Periodic Payment Terms, Principal Payments if Interest-Only Period Is Extended Debt Instrument, Periodic Payment Terms, Principal Payments if Interest-Only Period Is Extended Purchase commitment Purchase Commitment Purchase Commitment Phylaxis BioScience, LLC Phylaxis BioScience, LLC [Member] Phylaxis BioScience, LLC Subsequent Event Subsequent Event [Member] Accrual for interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Net operating loss carryforwards Operating Loss Carryforwards Deferred revenue Deferred Tax Assets, Deferred Income Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Issuance of shares, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Clinical trials Accrued Clinical Trials, Current Accrued Clinical Trials, Current Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Related Party [Domain] Related Party, Type [Domain] Dividends Stockholders' Equity, Policy [Policy Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Other Other Assets, Current Income Tax Disclosure [Abstract] Expected income tax benefit at federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Periodic payment terms, final payment amount Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Equity method investment Equity Method Investments 2020 Loan Agreement 2020 Oxford Term Loans Including Amendments [Member] 2020 Oxford Term Loans Including Amendments Proceeds from issuance of common stock and pre-funded warrants in private placement Proceeds from Issuance of Private Placement Statistical Measurement [Axis] Statistical Measurement [Axis] 2020 Option And License Agreement 2020 Option And License Agreement [Member] 2020 Option And License Agreement Entity Interactive Data Current Entity Interactive Data Current Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Supplemental schedule of non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) License fee revenue License, Non-Affiliate [Member] License, Non-Affiliate Term loan aggregate amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Equal payments of principal and interest period if interest only period is extended (in months) Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended Current assets: Assets, Current [Abstract] Leases [Abstract] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Other income (expense): Other Income and Expenses [Abstract] PEO PEO [Member] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location State income tax expense (benefit), net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of programs related to collaborative agreement Collaborative Agreement, Number Of Related Programs To Agreement Collaborative Agreement, Number Of Related Programs To Agreement Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Present value of operating lease liability Operating Lease, Liability Deferred income tax liabilities Deferred Tax Liabilities, Gross [Abstract] Aggregate Intrinsic Value, Vested and Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Expected volatility (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vesting [Domain] Vesting [Domain] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance All Executive Categories All Executive Categories [Member] Unrecognized tax benefits (FIN 48) Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Consideration transferred Merger, Consideration Transferred Merger, Consideration Transferred Debt Disclosure [Abstract] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 47,369,511 and 43,564,283 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively Common Stock, Value, Issued General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Professional fees Accrued Professional Fees, Current Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Licenses Prepaid License Current Prepaid License Current Segment Information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current 2020 Term B 2020 Oxford Term Loan B [Member] 2020 Oxford Term Loan B All Individuals All Individuals [Member] Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Warrants Issued Concurrently With 2022 Loan Agreement Warrants Issued Concurrently With 2022 Loan Agreement [Member] Warrants Issued Concurrently With 2022 Loan Agreement Proceeds from the issuance of debt Proceeds from Issuance of Secured Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Stock Options Activity Schedule of Stock Options Roll Forward [Table Text Block] Statement [Table] Statement [Table] Long-term debt, including final payment fee Secured Long-Term Debt, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Term of option period due from deliverables (in days) Performance Obligations, Term of Option Period Due From Deliverables Performance Obligations, Term of Option Period Due From Deliverables Gross unrecognized tax benefits Beginning balance Ending balance Unrecognized Tax Benefits Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Debt Instrument Rate [Domain] Debt Instrument Rate [Domain] Debt Instrument Rate [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Issuance of common stock and pre-funded warrants in private placement, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues, Common Stock and Pre-Funded Warrants Stock Issued During Period, Shares, New Issues, Common Stock and Pre-Funded Warrants 2020 Term G 2020 Oxford Term Loan G [Member] 2020 Oxford Term Loan G Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Schedule of Prepaid Expense and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Warrants issued (in shares) Class of Warrant or Right, Issued Class of Warrant or Right, Issued Other Other Accrued Liabilities, Current February 18, 2032 Class of Warrant or Right, Expiration Date 2 [Member] Class of Warrant or Right, Expiration Date 2 Return to provision true-ups Effective Income Tax Rate Reconciliation, Return to Provision True-Ups Effective Income Tax Rate Reconciliation, Return to Provision True-Ups Depreciation and amortization Depreciation, Depletion and Amortization Deferred income tax assets Deferred Tax Assets, Gross [Abstract] Furniture, fixtures and other Furniture and Fixtures [Member] Annual interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Costs associated with the ATM offering, additional Payments of Stock Issuance Costs, Additional Payments of Stock Issuance Costs, Additional Less: Valuation allowance Deferred tax asset valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] LICENSE AND GRANT REVENUES License And Grant Revenue [Text Block] License And Grant Revenue Interest expense Accrued Interest Expense, Current Accrued Interest Expense, Current Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Initial Programs, Program 3 License Agreement, Initial Programs Authorized, Program Three [Member] License Agreement, Initial Programs Authorized, Program Three Commission (as a percent) Common Stock, Sale Of Stock Commission, Percent Common Stock, Sale Of Stock Commission, Percent Entity Emerging Growth Company Entity Emerging Growth Company Amortization of debt discount and accretion Amortization of Debt Discount (Premium) and Accretion Amortization of Debt Discount (Premium) and Accretion Gross deferred tax assets Deferred Tax Assets, Gross Purchase price (in dollars per share) Class of Warrant or Right, Purchase Price of Warrants or Rights Class of Warrant or Right, Purchase Price of Warrants or Rights Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Deferred revenue, current portion Increase (Decrease) Contract With Customer, Liability, Current Increase (Decrease) Contract With Customer, Liability, Current Shares available for future equity grants Share-Based Payment Arrangement [Member] Title Trading Arrangement, Individual Title Operating lease expense Operating Lease, Expense Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Legal Merger Contingency Fee Legal Merger Contingency Fee [Member] Legal Merger Contingency Fee Individual: Individual [Axis] 2020 Loan Agreement 2020 Oxford Term Loans [Member] 2020 Oxford Term Loans City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Equity interest percentage (as a percent) Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Audit Information [Abstract] Audit Information Lease agreement term (in years) Lessee, Operating Lease, Term of Contract Computer software Software and Software Development Costs [Member] Recognized interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Minimum Minimum [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Payments for merger Payments For Merger Payments For Merger Exercise Price Award Exercise Price Schedule of Warrants Issued Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Termination fee Merger, Termination Fee Merger, Termination Fee Operating lease liability Increase (Decrease) in Operating Lease Liability Nonrelated Party Nonrelated Party [Member] Other Deferred Tax Assets, Other Payment of fees associated with debt Payments of Debt Issuance Costs, Secured Debt Payments of Debt Issuance Costs, Secured Debt Cash paid for income taxes Income Taxes Paid, Net Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Payments received pursuant to agreement Collaborative Arrangement, Payment Received Collaborative Arrangement, Payment Received Initial Programs, Program 2 License Agreement, Initial Programs Authorized, Program Two [Member] License Agreement, Initial Programs Authorized, Program Two Initial Programs License Agreement, Initial Programs Authorized [Member] License Agreement, Initial Programs Authorized Consummation threshold Merger, Consummation Threshold Merger, Consummation Threshold Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Commercialization milestone payment receivable Collaborative Arrangement, Commercialization Milestone Receivable Collaborative Arrangement, Commercialization Milestone Receivable Total liabilities and stockholders’ equity Liabilities and Equity Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Operating right-of-use asset Operating right-of-use asset Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Exchange ratio, pro-rate basis (as a percent) Merger, Exchange Ratio, Pro-Rate Basis, Percentage Merger, Exchange Ratio, Pro-Rate Basis, Percentage Net deferred tax assets (liabilities) Deferred Tax Assets, Net Aggregate intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Shares of common stock issuable upon exercise of warrants (in shares) Shares of common stock issuable upon exercise of warrants (in shares) Shares of Common Stock Issuable Upon Exercise of Warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Upfront licensing or partnership proceeds raised Debt Instrument, Upfront Licensing or Partnership Proceeds Raised Debt Instrument, Upfront Licensing or Partnership Proceeds Raised Ownership percentage Merger, Ownership Percentage Merger, Ownership Percentage Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Principles of Consolidation Consolidation, Policy [Policy Text Block] OTHER FINANCIAL INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Clinical drug substance and product manufacturing Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Development milestone payment receivable Collaborative Arrangement, Development Milestone Receivable Collaborative Arrangement, Development Milestone Receivable Accounts payable Increase (Decrease) in Accounts Payable Interest expense Interest Expense, Nonoperating Interest Expense, Nonoperating Common stock, shares authorized (in shares) Common Stock, Shares Authorized Number of operating leases held Number Of Operating Leases Held Number Of Operating Leases Held Debt Instrument Rate [Axis] Debt Instrument Rate [Axis] Debt Instrument Rate Number of additional tranches available upon contingent events Debt Instrument, Number of Additional Tranches Available Upon Contingent Events Debt Instrument, Number of Additional Tranches Available Upon Contingent Events Grant award Grant, Valued Awarded Grant, Valued Awarded Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Debt Instrument Rate One Debt Instrument Rate One [Member] Debt Instrument Rate One Total long-term debt Term loan Total future minimum payments Long-Term Debt, Gross All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Additional paid-in-capital Additional Paid in Capital Operating lease right-of-use assets Deferred Tax Liabilities, Leasing Arrangements Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Initial Programs, Program 1 License Agreement, Initial Programs Authorized, Program One [Member] License Agreement, Initial Programs Authorized, Program One Operating lease liabilities Deferred Tax Assets, Operating Lease Liabilities Deferred Tax Assets, Operating Lease Liabilities Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid expense and other current assets Prepaid Expense and Other Assets, Current Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Investment in Phylaxis Equity Method Investments [Policy Text Block] Insider Trading Arrangements [Line Items] 2025 Long-Term Debt, Maturity, Year One Related Party [Axis] Related Party, Type [Axis] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value 2020 Term D 2020 Oxford Term Loan D [Member] 2020 Oxford Term Loan D Financial Instruments with Characteristics of Both Liabilities and Equity Warrants, Policy [Policy Text Block] Warrants, Policy Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Issuance of common stock and pre-funded warrants in private placement, net of issuance costs Stock Issued During Period, Value, New Issues, Common Stock and Pre-Funded Warrants Stock Issued During Period, Value, New Issues, Common Stock and Pre-Funded Warrants Auditor Name Auditor Name Issuance costs associated with issuance of common stock and pre-funded warrants in private placement Proceeds from issuance of common stock and pre-funded warrants in private placement Payments of Private Placement Costs Payments of Stock Issuance and Warrants Costs Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Interest income Interest Income, Nonoperating Interest Income, Nonoperating Entity Central Index Key Entity Central Index Key Accretion of debt discount and non-cash interest expense Amortization of Debt Issuance Costs and Discounts Contingency accrual Loss Contingency Accrual Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Total stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Payments included in measurement of lease liability Operating Lease, Payments Included in Measurement of Lease Liability Operating Lease, Payments Included in Measurement of Lease Liability Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Income Tax Authority [Domain] Income Tax Authority [Domain] 2020 Term E 2020 Oxford Term Loan E [Member] 2020 Oxford Term Loan E Compensation expense Employee-related Liabilities, Current Vesting [Axis] Vesting [Axis] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Issuance of shares, net of issuance costs Stock Issued During Period, Value, New Issues Stockholders’ equity: Equity [Abstract] Number of options declined Collaborative Agreement, Number Of Options Declined Collaborative Agreement, Number Of Options Declined Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Intangibles Deferred Tax Assets, Goodwill and Intangible Assets Tax credit carryforward Tax Credit Carryforward, Amount Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted-average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Exchange ratio Merger, Exchange Ratio Merger, Exchange Ratio Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Property and equipment useful life (in years) Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Leasehold improvements Leasehold Improvements [Member] Net deferred tax assets (liabilities) Deferred Tax Liabilities, Net Weighted-average shares of common stock outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Computer software Software Development [Member] Aggregate offering price Sale of Stock, Common Stock, Authorized Sale of Stock, Common Stock, Authorized Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Deferred revenue, non-current portion Increase (Decrease) Contract With Customer, Liability, Non-Current Increase (Decrease) Contract With Customer, Liability, Non-Current Percentage of principal amount for final payment (as a percent) Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value Congressionally Directed Medical Research Program Department of Defense - Congressionally Directed Medical Research Program [Member] Department of Defense - Congressionally Directed Medical Research Program Operating expenses: Operating Expenses [Abstract] Purchase of fixed assets Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Initial base rent per month Lessee, Operating Lease, Initial Base Rent Expense Per Month Lessee, Operating Lease, Initial Base Rent Expense Per Month Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss from equity method investment Income (Loss) from Equity Method Investments Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Weighted Average Remaining Contractual Term, Vested and Exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Schedule of License and Grant Revenue Schedule Of License And Grant Revenue [Table Text Block] Schedule Of License And Grant Revenue SUBSEQUENT EVENTS Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] 2020 Term A 2020 Oxford Term Loan A [Member] 2020 Oxford Term Loan A Grant revenue Grant revenue Grant [Member] Non-NEOs Non-NEOs [Member] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Term of research and development services option period (in days) Performance Obligations, Term of Research and Development Services Option Period Performance Obligations, Term of Research and Development Services Option Period Construction in process Construction in Progress [Member] Operating lease liability Operating Lease, Liability [Abstract] Total operating expenses Operating Expenses Net increase in cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Loss before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Lease extension term (in years) Lessee, Operating Lease, Renewal Term Clinical drug substance and product manufacturing Accrued Clinical Drug Substance and Product Manufacturing, Current Accrued Clinical Drug Substance and Product Manufacturing, Current Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] State State and Local Jurisdiction [Member] Research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Sale of stock, price per share, contingency (in dollars per share) Sale of Stock, Price Per Share, Contingency Sale of Stock, Price Per Share, Contingency Other Deferred Tax Liabilities, Other Net operating loss carryforward Deferred Tax Assets, Operating Loss Carryforwards Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted-average shares of common stock outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Loss from operations Operating Income (Loss) Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment Revenue: Revenues [Abstract] Total deferred tax liabilities Deferred Tax Liabilities, Gross Number of options exercised Collaborative Agreement, Number Of Options Exercised Collaborative Agreement, Number Of Options Exercised 2020 Term C 2020 Oxford Term Loan C [Member] 2020 Oxford Term Loan C Annual escalations (as a percent) Lessee, Operating Lease, Annual Escalations Lessee, Operating Lease, Annual Escalations Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adjustments to reconcile net loss to net cash used in operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Cliff Vesting Share-Based Payment Arrangement, Tranche One [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] EX-101.PRE 12 inbx-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 inbx-20231231_g1.jpg begin 644 inbx-20231231_g1.jpg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end GRAPHIC 14 inbx-20231231_g2.jpg begin 644 inbx-20231231_g2.jpg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
UN]G^.&CW%NSJ]C+AF4U@? O38O ?P^O-4F4*V=RY'7->Z?L6?!G M_A,M7O-6OEVK9"6';VH Z+Q9X@NO%.M(]Q\PB;+,QYKH[B:[O_"S0^'8_ MMU\J?,A[&O)/VI?'"^'?B-;>&;)O):\E\EI%X*UZC\(]?B^"GA1Y'E%Y*L>9 M)'/- 'E'PK^.WB;X+_&\P>*M+@CAO95B4,=V,FOHGXW:S9Z]=+-:1HJ,BM\H M]J^4;WQ"_P ;/V@KS4&7S+:%A(@ZJ"/2OL3X0>"+'XCP^7>3_9UCC!S]* /. M/#_BJ_DB&GPR2*CM@+G KN_#OPFU'0]0AO+^+9')AMY/8US?Q?T;3_ 7B8?V M?<"5(R#N'J*AU_\ :/NM;T5;4Y41@*&!]* .Q_:1\+:7IUG:SP^7<2>3D[AG M%?.'AKXF6/ACQ0\C6Z[HWX(2NYTK6]1^+_BJUT&WDDN9KC '/2OKOX;_ /!. MWPOIGA:/^T5$UY(V X J/PM?)7:SXKU".W326DDW._EJF>]=;^SK\5F\.W[0W$W^ MB7 "$$_*!4/Q;.ECXL:?<6'ER0M<)P/K0!]!?L:?!"3P+X=75+Y66^F!X([& MO=JH>%W5_#UF578/)7@?2K] !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4RYB\^WDCZ;U*YI]% 'Y"_\%4_@[JG@WX_7.M2 M0R-ILD8 FQ\N37RXM[#C=O&/6OWE^-OP!\/_ !U\-R:?K5C#<;ONLX^Z:^5O M^'-.B?\ "0FX_M&W^R[]WD^6>GI0!\*_LQ?LN:Q^TYXSM[&UMI1IKG$ER%^5 M:^Y_"_\ P10\+Z9?6=S=ZA'<>2 98C%PQKZF^!?[.OASX">'UL]%L8+=L?.Z MC[QKOJ .!M?V;O"UI\-/^$932[5;/R/))"=>.M?CS^V_\"+CX!_&G5(S;M#I MD\Y%L=N%Q[5^XE>/?M6_LL>%?CUX2F?6(;6&:V0LMS(/N>] 'X?+B8;E.15J MT@WM7H7QX^%ND_"SQYJ%A#J5O)8VK';.I^5A7SC\5_VJM)\%2MI^AQKKE]G; MM@.64T >K:CIOVK375E^;!(%>7WL#6EXZR+MY.!7C>IZ[\6O$^H'6+>/4[.T M'S?9MIY KT3X0?%%OB8_]EZG8OI^K1@Y$OWF [T =18ZFVF/YD;?-[&O'?VN M]2NKA89(IFAN"ORS#JE>LW5MY%R\8YVG%>"?MO\ B)H_#_V>S.ZXV#!7JN* M/8/V4/!FG?##3[/5M3CCU2:\42EI!R#7JWQ,\9Z3XR3R[.QAM=V0=O>O@O\ M9W_;?_LL6NAZY&VV("(2R'A*^J/"7B[3/%L<5QI]Y#<*W)"'.V@#\[?VW/#G M_"-?%W5I5&%FN%^,G@F;4[5=4T_K5@ZS^T')X$\!7C:Q"UO=VX**\AP7XQF@#Q?X_ M_M2:UK'QBM] TY98;6WF,XU#XLWFHJ[2-=719&ST&:^EOVJ_%M_IWP.\-E9V6.]MLR+_ 'J /9/V M,/VEK[]H/XSR6;P.UG#*HZY&*_6#X;^$[6VM88$5=H XQ7X^?\$C_#2Z#K,^ MJ2)Q= %"17ZW?#GQ0TMG&ZD]!0!#\?\ ]F'2?'UF[*D5O=@964#YL]J^8KWX M-^(_A?KGF2_:-:M8FRJ-T%?:E]JDNI0_,2:X/Q_;LML[,VT#UH \W\&_'[Q' M<6T<*:#-&J#:%KZB_8J>X\6^,()O$,;0VZY/DR]#7R[X:\6?V?XG6+/RYKZ2 M^#'C 6.K0W#-\BH>* /:OVJ_CUX5F\*WEO-<6UE-8*8H4S]X#TK\I?%?CJ^3 MXFWU[!/(MJ9RR$'AAFO3O^"A/Q:AO/B%;VUN_EK)G> W4UP7A+X>7'Q%@M8X MH&C# /C[U 'V5^SUX4F^*'PXM]0MY&:6TB#L16SXQ^+FHV>CKI%S)(T=OP M37E_[,/Q(NOA3;:GH;W1A6%=ASWK5U7Q)9>)=?%Z\T#4H=(TF%IKQG ;8>0IKJ/&VBZ?X(^&5OJ=G-'<75X3&J)U4UZ+^ MRM\$]'D^'Z>*O$$,4VI,YXD^]M[4 G?MC7MOXCL&U:SF6/5[8&2-E^\[5S/ASQ9XMU#X$-->K=>=+ M;G,C'FN+^"_A7Q%^T5XUL5CN)I(FD&Z(#/X5]C>-O@E=^&?A1?:3]E=9K6V( M(V\YQ0!Y;^QGX5CL_ *:EN6OQ$O-!9X[.9H^,':>U>=_LW6$ MMAX+6QD#+/'NRIZBN<^-WBN]L;^'2=*9EOII0C,G4 T =_KOB.Y\37FQI6D9 MCR%&ATG=MZKG-4_#_[#OC.P\!1Z\VO2,\F'V8Z9KG;KQOK?PU9K75H9 MKR%3@R'H* /5/V%];T_P5\=[.?5FC51(=LC_ ,-?IK97D>H6D<\++)%*H96' M0BOQVTSQ1:ZY,MW8SHLJD'2U CB>5L M9 H ^D?%?@K2_&UB;?4[.&[CQ@!QG%?&W[;/["*:?81:YX/L]LD+&2:*%<9K MZ4\6_M5^$/#,64U6TNF_NI)6K\/?C5X?^*MBT=M=6[NRX:+=F@#\Q_#WB76- M#46]Y82V]S&<;".:]Q_9A^#.O?%7QI!>:C9S6^GP,)$D8?*Q!K[(U']GGP;J MU\;FXT.SDF)R7*\UTV@>&['PQ9+;V-O';PKT510!:L[=;2TBB7A8T"C\!4E% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !5;5=8M=#LVN+R>.WA3EG2188V9F"JHR2>U? /_!1S]LJ M74K]O#/A^X9(>8K@@]6% 'V%#;>613KEA^[.#^]%?)7[>7[>\.HZ-)H MOAJ=A'ADN)$;(<5\J>"=!M]1MO/U"\S7K?[(_[*UCX2\+0>(-:^@O O[3WAO6O!MJK% M;.15 *2,%(Q[4 >D)J&RS>%54+MP.!7R_JMW_97[5N8QLD:W/ XKV!_C]X?, M^U)HY/7#BOFO]IKXH0Z-\6H_$&F6\R[HQ") /E!- 'I7Q+^)%OX'LI9&837D MA(6)3\QS[5YC=?#2Z\5_#[5=6U3,EQ*2\"L.44]JV_ 'PRO/&-_;^(->E6Z8 MJ&0+V!YKTK5+>%]$DMY62&/80N[@8Q0!^6WBZT^R^*M1C8%6CE(KW[_@GMXT MO?\ A+9[.>^VPEPJ1L>HKS']H+X<3^$O'FIW3W4,L-Q,S)M/:N=^#WC>;P)\ M1]+O(7*1K,&?'<4 >N_\%(/AU-HWC"&^9MT=_+A17J_[*'CZ3X>?!_3X5T6[ MF"CYG1>*\Z_;H^)UM\2-/\%M;NLDDUP X!R>U?:W['-CX=\,?!19/$=NGV.& MW+Y;Y<\4 8'@SQ_9^-H_W6(+CO$Q^85NF(*<,VT^A%?*7[0OQ?:;XO75U\-K M2ZL[5F">=C=&?7FN^^#FE_$3Q@O]I:AJUO):LFW;C!#4 >V?:(8I,&>,-Z5\ MO_\ !3"UD?PXHMH9'C>,9D0?*#77>)/@Y\3+[5'FM=:M8X\G"FN)^-'PA^(^ MK?#^ZCUC5K66UCZY7TH ^:?A!^SSJFM_$+0[>1&\N^8.#MX KZ&_X*$>$9/" MWPY\-Z:JEFM8=G ZUY+\-OCEK7A#Q/;M<,&71SY:D+U ]*ZO]K#]JBU^*VCZ M8/)D$UNOS%AU- 'U!^P1X5E\-?"?0;R6-HA/[,OBPZ[^SWX;5?E\F+C Q7N7P\^/VH>"K40[V95&!B@#[+UW7[/0;=FD MDC7:.YKR/QCXR;Q9J;0V\P6.O"_'?Q]U;Q:^%F9$K&T/XH:AI+W'>NH\&_$J;PTOEWBO'M&-QXKQK3_VBY[=E6.*5^.0!FL7 MQM\:;SQ9<+Y>Z-57!!&* .5_:[U]?$GQ@TV.)MWG-G@^]?7GA:SM_A_\#-+N M[>T::^:V#*R#D'%?G#XX^)YG_:$T*UF+,R_:F\.^'/ MA:7E]:@QQ M;2C2#- &CHO@;4O$,G]J27/V'O#,WDR7$GE>9U49KZ2_9OTMO#VCK>7[BZU2X7]Y(#D$T M >\MX*MI/@Q86LDJ?VG"Q;)//Y5B>&/C1JWA-3HNHR2&#HLAX6H+74[FZN-T MFZLSXJVJZSX?RHVSPG>#TZ4 7?'D_P!IT2\.[=OA9A^5?GO\,X[K4OVB)K>. M;[.K3ORW3K7T'XV_:?;PWX?N-/N(YI-08&) !SCH*^31X?\ %UK\16U"VNHX M9KAC+&2.@- 'U=\;/A#:0>&QK<=[ E[9I@<\M7SCX@\/BZ1KJ3YI/O%O6LWQ MO\8_%%KJ$.F:UJ"S1R#!"G%:6CZ__P )<]MIEI\\LV%&.: /HK_@F'XNDT#X MUZ4K-MMS<+OSTQ7Z=?'ZYTFP^T7K20SIJ*[=JD?+Q7YL_LW_ BN_@[J-E?: MA\K7C!H^VVO;/BA\9KRX@%N)'F*\+MYQ0!YSXX^(TGPC^,-U-@_V7>L(XU'1 M#GK70? +P9'\8?VEEE:1)+7:KJQY7-<'\2+3_A*/#^[5!N=@?)SP0W:M#]DO MXA3?![6(HKZ.2&;=\LSC"^W- 'ZX:'\.K32_#UO8W7ER6YC4;:\%_;'^ .@Z M3H\G^CQ;95R![FNU^!_Q1O?B'ID,UQ=)) JA@PZ<5E?M):E_PLP?8[%&FEC7 M;\O/2@#\_?!?PGNO#OQ2CTFW1I(+YBX"C( KKO$_@ZZ\+ZZL3;T;=@=1BMOX MI:S>?!OQQ97/EE+R,852O-;?Q&2]U?2]-U:ZA=&NHQ*25QUH Q?#_@2;4&6: M6&:=>N03Q7=>#M>OOA+XAL]1L/,AACD#3+_>%>N_LZZ'I/B'X970Q&UX(OE& M>[:V1CB@#[+^#'Q=L?BSX4M[RWFC^T,OSQ9^9?K795 M\1_ 'Q4? 'Q;-GI,A:VG=4*J=V :^VHSN13[4 .HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH POB3;75W MX,ODLSBX,9V_D:_&_P"+>FWVG?$[7%U"*<2-=-@N#SR>E?M:PW#'K7CGQ;_8 MC\&_/ME_ \4W))C&,F@#\E(V).%8CVS3GC8GO7V?^TM_P3';PQIS:AX15 MI8X5W2!VR:^9[;X >*KK518BQD\]FVY\LXS0!YYK&CVNM:5-;7D<#]0U>26-;J/<>0KD"OTX\%?\$O?$GB7PB]U>+''-+'F-=V,GZ5 M\>_M$?!?6?@1X[NM+U:WD3R3PX7Y3^- '@&C_LM^%M&?/,D?[Q2W7(Z5V&N^*FMYC'">:PIKM[IFDD; C4L23V% 'A7@+]H% M?@KI=YIOBI6W(Y6#:,?+VK#TW4_B%^T1J-Q/I\B6^B*Y"[QM9E[8KE?VGM/D M_:*^*<&GZ O[FV7]ZRCC*]>:ZSX=?M=V7@_5=/\ "-PB6[6JBWD*KMR1QUH MH_%?]BC4O$?@^XF\Q'O(D./FZFOBOQ!;7/@CQ+<:9>JRS6;[,^]?K=HS_P!M M6<5Q#^^AG7<,<\5\4_MS?LZ6^A^))-9=?+2\8NV.* /F_P &:_<^+/B5H%K= M39@BNT";CPO-?H[\U?F]\,/"*^)?BE M96%NY59)U56W8-?I%\&OV<=/^%DOVZ62:ZO9D&[S6W*OTH T/!OP8TWP#\+) M-)AA5Y%B,N]QN;)'K6?^SKK#P:1-IK,DB_-M7)H_9B M^.I^*&EM#?.OVUG.T=.*]7O-+AU>WDMKB-)$8$?,,T ?G;XDTW3;30%D7*WS M)F0$_P 5>5?$75_.BAA'\(KUK]ISP5-X ^)%TI5EBNY2R#MBO'-9TU]>URWM M8O\ 62M@4 ?HE^PKK2ZK\#M+A5LM##R*]@KYR_X)X&ZT72+S3;HC$$>%&:^C M2,&@ HHK=\-Z!'=6C7$S84 X&: (?!VN0^']3,TR[EVD8QFJ>H7TL_P#"4_M1:>68".WE*YST MYJ_^UUI$-EXMTU;&\E;SB?,593C-<=X6TN<>+KC6&;;MD+*2>:;XIT^ZUK63 M>>8TFUMPW-G% #+#[3X$U*SU*//F1L'!)K]3_P#@G_\ $:/XF_#JRN)FS/L! M;-?!G[./P>7X\7IL[Z&18;7 D8+CBOLKX2>&U_9WC6RTC=]F4!1NH ^OYWM; M6(?,H_&N4\7ZI'<02+&RMM4G KBM*U?6O&MLIA9?FXSGI73:5X"N- L[BZU: MXA:/RFQLDSS0!XKH_P -[3XA_&;[9?Q%H50K@#C-8?[1'PT_X1KQ="^EV[MM MCP %S7KOPQO;:[2:ZB4EEF*@X[9K&^/GQDM_ ?BVT/EQR?NQD,N: /BWXC_# MR35=0:XO(98Y5)QD8KV#]A?X*1OXB_M6^7Y;-P4W]ZZ3XA:SH_Q?U*TCT^/_ M $J1?F54P,UZ'I/A.^\)>&+>.TC$;+& ^!C- 'J?Q=U"VU3PVKVY7SK)XKYO\BBVA9( M@&1EX^85X)^S_H,WB?3SJETS?VQ(F9_"T >F?%OPC9_&7Q%'XHO@HCM#\BCCCZ5>U=&^+O@T M6-JBA=/C\I!C!P*XFX\47$FG?9V;"=,"NT_9Q\26^C>)8X[IAY$S?-F@#A?A M7X_U#X0>-?L\CLL<,F&4]ZZK]H_XJZ3XHL+6735;^U;O@[>YK3_:.^#2WFJ3 M:MIB[H9B7)7L*\^_9F^$FH?$OXSV?G+OMM)N [ ]QGTH ^C?V$?V:[S1[-?% M&N#=)>+F-"?F4_2OJL# J*RLH].M8X846..,855& *EH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@!LL2SQE7565NH(R#5%?">EK-YG]GV?F==WDKG^5:%% #4C6) JJ%5>@ Z M5\^?\% OV6],^.?P?U"X^SPQWVGPO/YJJ S8'K7T+7AO_!0#XXP_!'X!:E<2 M.JMJ$,ENF>Y*T ?@OK.G2:7X@O+.7&Z&5E)SV!KQ?]HKX^'00?#?A[_2-$KJXO%\W5=1W3Y?DJ6&< U\G?M'_#?4O#?CB\ MOIX_L\LDQDC*\<9K[^+DGT]!Z5Y/^UG\&#\3?!LUY:+_ *9;IA57^*@#/_X) M^?M4+J>EMHVH>7)/"!'%OYS@5\__ /!1S]I:\\9>.+G0XXXDBLY"A*^E>??# MGQ#<_"/XA+-(SP26,A#KTW'WKSSXV^-/^$\^(&H:AU,\I;- %/X4:R^A_$;2 M+H,R^7U?K%X U__ (2KP-97^[=YB@9S[5^1]M8S:9%;WVUE7.Y217Z9 M?L7^)?\ A)?@-I9+;F4N6=K#>65U'(S*TD15<>M?!W[1_A6^\(_$6X2Z M:22-LL&5_M2_!Z^CYX') H ^4O@[\0+CX<^-[? M4(BWD@A2.W-?>'@[Q3;^,O#]O?6KJVY 7YZ$U^>T>JW'@JYFL;NU7S$8@;QS M7I?[+'[3HR?Z#=29+,?N>U 'JG[AK];+2:V\6Z%A&6:SODW=>V*_-7]M_X3)\-OB=- M-$S>7J$C,H["@#VS]C;XQV5UXV:S@D^:;:ISWK[$NT\N;'L*_)'X*_$J;X8> M/;'4E;]W%*K29/:OU/\ A)X^M_C'X(M-8LW61ID!95[<4 ;:KN.!4C/+;C9N M9?;->F?#_P"$5GJ7AG^U+B5E95+;3[5POB:8:GJDDD**L:';D#TH R0-QK(^ M(OA636M)9&R;?'.*QOBA\:=.^&U@^)$>\Z!#WKH/V4OBE9_&JVFBU!DB^?"C MVH \-\8?#26*)F@#*JCH.,UR?@70-1U_QK;Z5#$TGG.$)(Z?&+X8V[:U M#::>/,CFZD#I6WX!^ 6F_#>S2^\M9+N<;]S+RA]J /:?V:/@+I7@GX?6P6-4 MOIHP)B%YS77>*_ $,.C2,O55)R:L? RX:ZT<-)CRXU&237$_M;_'=M \.S:; MHZK)-(I1FS@K0!P/BG]KVW^$\$FB64BR7^"C#^[GTKF]%_:1U:_L/*N+R1DD M;)!<]^U?)?BXWVF>)Y-0O)9)))&R2S9KU+]GRQNOBQK,-G:AC&"/,;VH ^Y_ MV=/&&G:OX?D\O[RJS-E>]>=?$"ST?XJZG>7EU<,MQ:NT:HIXP*[;4-+T_P"! MWP>D:W=6DV$%CUR17R_\(-4OO'OCZYMTDD"S2L>#0![Q^P?\.+?QA\=;;3_E MD7S2J[O:OJSXK_#V'PSK,]I(J(J,1[5\H_![1-6_9_\ BS8ZA'Y@61BY#9)FF_P!.O4W1\\G- 'BO[37B?_A);B71-%C63RR8[@J.E>$> M&?A9(OBFWMX;97N8Y!GY>I]Z]O\ A!;S>&-#O]8OX5N;K7$WQ!_FP?:O1OA/ M\+K72DFUZ^C5;B^7*(1]T^U '->#;>]\+7L=JL82Z. ZCH*^F_V=_@9I?Q'U M01ZTS1RW"[5 &>37COA[3XY_&S3, TF1D>@KZS_8PT-/$GQ6\G.U(8PX^HH M\6_:4_9OUK]F/QVKP6\DN@N@<28)()K,\,_$.UO[==K;6'!!ZL^+/ &D^ M.M(-GJEG;WD;)LS(@8K]*_-[]O[]DY_@!XI&O:*)FT9L,^!@(Q[8% &=;ZFE MY#FHX-=DT^Y^1F4YX(-G7-?8G_ M 3:TS['HFH.R_O&C&6]>: /J:BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXA_X M+A^'[_6OV?M.:S5V6&X)?'88K[>KY,_X*]_$*R\$?L[*EU&DC7CM&@;L2.M M'X#_ +4%JMY\,[=\>> +KXC>%+BQM(VDF61 MYL+Z58^ OPSU70_AI,DT$GF),1M(YP* -:G(P *LNY6&"#WI'0QL58893@CT MI ,F@#Y-_;B_9J^R6K?2OC'4/A1KW[/>EZ?XGCAF_P")@/-X M&/*H ^L_VS?V*/#]E^R9X?7P['"^JZ;"7NFC4;CQWK!_X)TWLEOX 729OEGL MU.Y3VKO/@QXYOOB]^S)>27#.9GLF^VEC=ZZ8]2D6.WV'.[H:2T\5OH]K):JNZ, MY -8;2$NS=,G- '@_P#P4!_9VM_$&MMK?AFW79"F&2(<-[U\77T4EI=-&^Z* MXA;!XY!%?JG8:!)X@B>$0F:-@ZE%:R1)N"MWK4O_@#? M1:#:Z]X;EDU)XF\UEA',..]?G[\ /VR=8U#5[3P_XFU*6&*%P%>9NA]*^_\ PMXIAU/P MI!]DN%OK"_$=SXD:&ZCGGDD? #9.,UZ)\._A[KW[/FK6> MI2-,L$R"1D)XYKZ$UC2--U/4%N)+*/S5_BQS7/?%^W?Q!IRP,[?* JJ>PH [ M[X9_&W3?'M_:K,(XRHPS^AKI?C=\8M)^'EC;L]Q&P9?E!/6O%;2#2_@SX*?4 M+@QK-LW 'O7RC\9OC?J7Q*\0R,;B06MNQ\M<\8H ^QO'?_!3./P1X>MH]-2, MOC#!6^]7SU\>O^"B&J_%BPM[6UTU;6YWO IVN==G6&.-KB0G"J/6O< MOV4/V0IO$_B^TU+7LV=K#()/+D'##/2@"/X$Z9XM^)GBBWAUK3YH],F< W#C ML37Z%_#WX/Z+\(?#]O\ V/,DTC*"95&#D]J\\\;PZ7H=ZMEH]M';V\*C#(!S MQ7H'P*\0"ZTTV]TOF(N2&;M0!F_M(^-VF\ _V<;AO,>0<9KK/V+/A9I^D:6N MK7:JLV01N'6O'?C&EIXH^,%O8S7JVMGD$L>@.:^LO!_@[3]-\&VL>FWT:I,WDVZ!HHWZ&NB\5>+;/2-^ZX\M5_U,/8GTK>UCX4W6C":Q34FMTC^41CM M73?##]G;3Q"-0UAH[]%&Y!(* //_ (0^&M6\0ZU-JTUJ\=O<+A?05]G?L1>" M;FU\7^?#N;Y>7JK\$/V?3\3;Q8K2,Z?IL7*E1\K"OK3X8?"C3_AEI*P6R(TP M&&D P30!U$?"+GKBN7^,'PFTWXR^"[C1M3C1X9AP2N=IKJJ* /SU\(I?[%OKNXM96+ +T0>E<_KW_!//QQIUHTUNM[/(HR$]:_2JB@#\O/"?[, M_P 1+_51IEQH=S&C-L:7TK[[_9H^#/\ PJ'P);6\I;[6\8$N17HBVT:2F144 M.W4XY-24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !7PU_P7,\*G6?V?]-N/,V^ M5'[>8!H[C+H/0T ?G'\)O$\/AK7VFF4-&V M8R#7+_M2?M$7WPCU\7FAZ;/?:6Z@/#".,GJ:]&^&_P (D\:>'EGC9?.+$D=Z MT/B3\!5TGP&UU/&LL>_:P(H \+^"G[1GAWXG:_'#J:PZ2TO+^# M-!^'>JQ?80UPSYB);.!0!\<_#GX=^(/CUXZ7Q%XE$UO8V4FZ"UF'\/H*]G^* MGPRT_P")/@&XT=H455B*6^1_JZZF[*I*T<:JL:G"@#H*A:9;6,RR2+%&G)=N MBT ?(?PTUCQ3^SGXS/AC4OM#Z+J#_9XG(Q& 370>*-5LO@)\5[:^@A!CU>98 MO-7@-FNV_:K^-'A[Q9X>M='TK3&U;7+7(BFMOFV/V/%H?; M-0FE4;5D8G%5<\TX(2N[^'N: /(OVE?V:+'XN6/F6,<=K>*OW\E?HM>>.-+T:7;)>6^_T+=*P=6\$VOQXTJ\TZZDBF MAN 5C/84 ?E'HBW.HWT-G#(RFX8( .^:_1/]EGX?Q^"/A):VY+5IHH[6SN08O>OOK]G_ %23QIX?TW3+*WDDNF(1I%&0 M* /"_P!HC]@:Q\2>'O[4T.)+/4%8R?*/F/>O%_ 7Q]^('[+EZMIK=KJ%SI<; M[1N!"FOOWXR^"]1^&FN-;7FN6MJV <2'&,U\^_M->&]/\9?#S-QKVFW$D7"%DV%BW!KT779+;Q=\/KFTT^ZBFN;N4,J(E '9?$_]FVSNI6N)+/\ ?=1)CI7#:1XM MUKX(3L]W=27.G(#A?X5]*[/X>?M2K-(=-D>2=? M.RE?N1J-BNIV$UO)]R92 MK8]#7XV_\%0?V#?%/ACXY:EXHTBUDN=-O3A BEFH ^:?A1\4SX!G^;,8% M=MXH_:!L?%/@^33G1OF.[FO*-<^'GB#PM:^??:7?1PYQN:$@5D+*"/O8]L]* M +%U-FXDVE@I/ IT&HR6\+1JQVM55I0#Q\Q]!UIOGL#\T[#% $RJ9I/;/M7<0* /4?@-\ ]%^#=Y:WL\)FU0,'N'8[@W>NJ_;'@_X6MX4M;KP MVJV>H::WG.0NW=CM6?X*^)^D_%#3([ZQGC0R#)C=L,/PK:4^6W/3N/6@#S'X M _&UO&D/]CZQNAUBWSN,GRY Z5Z81@UXC^TOX(/@K5[/Q;I7[FZGG5)=O"[> M_%>N>"_$:>+O"]O>1_-\BJWUQ0!J1)O?]34OQ7\:Z#H_PZGCL&1=490!\W?Z M5'&,1R,S!5$;')Z5\>_$/XVZ3X?^+XM[ZX>2%9#N"OD#F@#O](^!6K^+YI-0 MOKC;'(VY26Q7K&G_ *\6?!K0;;6ENHY=/9?,VJ,DBH_#WQ$T7XC?#Z,:/<1 M>9"@&S<-Q-=QX9^+MYXO\+1Z#=M'Y-FGE$-U- 'Q?^W1H"?CCKOAEH[?[%91CR0R@G- '0?$7X?^+OVD/&$FM>(KY&LY ME&V,':PK&N?V'M'O()$8R'@INXT ?!OC_P"!6K?"'QDV MDSB1M'D!<,F=H/;FKWP7^):M>QW6G*6P+'<_.: /JB7_ (*V:'H?@>W@ M+K-'Y0"+&1E17"ZY^U[H?[0'AF_59O+DVX52_-?$?@OX2:7X1UZ]L=6DN-D, MA5=S]A7+>*(M4T'7KFZ\'1W@L[5\SNP)4T ?3\FFV[NRK/&-O3+_89'\Z,D*@7G%?(<>C_$S6O#AUJSEADA";V4] 'Z&S0-%]Y2N1WKI/AYXAT/PG/-?:W&TD,<9* 'N*PIM?CU M_3(9HO\ 5LH.?PKD/C%.\?A*%8]VYY-O'>@"MX[\:Q?&;XC1:E;QRIID,@C6 M%>')!X-?:O@#PMKWC/PC8VX98=-6%5*,,,>/6O)?V!?V,KKQQ)#KFI6KM8J> M %[U]\Z#\)FM;*.&&%EAA7:#MQP* /%_!/P^TGX=2_Z/$5E8Y=F/4U[+X*\8 MVUA:@^9&3CIFL/Q'\+Y-8 MPR!6KZHT'P[:>&[%;>TA6.-1C@)=>.O,61?X8GS7LWCW_@B[\, M_$NG[;?[9#(HP.:^R** /Q#_ ."CO[ -G^QM>Z6VEM--:WZ%RS'=C%?)VI:9 M:^)-+:VNXHY89A@EER0/:OVO_P""P?PGC\;?L[W^K&/?)I=NVPXSCO7XI:>- MEHBM]Y1R* /"/B3^S7J'PWO)/$7@V>=VA/FS0N_R #T%>@_ 3XS+\4]$6WO" M(]:MUS-'TQBN_1@1M;YHVX93T(KY_P#C5X=G^!/C^/Q?I:D6M]*!<(.%1!UX MH [[]J"YM[;X;P_:"/FDP@]ZG_9FM[B'X6!;@%7,N1GTKSVTOKC]L'QO#'9L MW_"/6FV59%.,L.HKWZWTF'P]:K9PJJQI&$X]: /#/VQOVB&^'FBOH.CR*VL7 M*949[5^=_C(:BNNS3Z@S_:+AC(3N/?TKZ>_;M^&?B#PG\2E\4PPOW1P9(V8E2/I M7W]X4\?6/BOPK9^(--N%^U3IYLZ[L 'Z5^9=]92:;=R0RC;)&<,/0UZ1\%OC M.?!:-!=WDZVYX"YX H ^M?'7Q.U1?MNM0QKYFD@S D?*<5Y%^S1\4_%/QL_: M&O-6BC3=,5:@#CJFLC^\;_ '3Q7IWQ;_9LO/AQ9?:/O1XSRU>8VV8Y)/4(W\J /A3] MJ"&\UCXW6^EV:[;>ZE/FE.HYKZ5TUO"?@O\ 9PN]%L;=;C4;RV"SN\>YE;'K M7S;K'CN71?CS>WFH0HVF6MRPDD8991GM7?>#/VF_!NC:;KCW5UO$YS$&7M[4 M =I^Q1';ZFFM6-PJM;VZ[2''"BOESXS>$+2]_;(^R:2N^,7J%P@RJ\UU?A;] MI*^CNO$%CX/@\^XUW**2NW;GTKV;]B[]C6XT&\NO%OBXM_:MTOF;7;=ANO% M'T#X=T5-(\,VUOD[D13S]*9?VUOJ=W8VLPW;9E) &<?[%_B?PWX3^"-M:-&JN<$D+ MSTKUS4?B+HMCX$NH[?;]ID;*Y%>*?"']GS5/"O@A(YTVEOWBC/\ #UJTGA2^ MUW4OL:;O+7@X/I0!M_#NPN==O;B\C4%(Y,DFNS^(7C(W?AP6OR@Q+M.*Y[0= M0?P'ILEK&OWOO$^M8MS/2NVH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@#F/C%\,+/XQ?#K4O#M\=MOJ,1C M9L9Q7XD_MR?\$_O$?[+7C6\O(K2:;0[F0M%,1QM]:_=VO,OVM_A%I_QB^!VN MZ;>6\4TIM6\EV&3&?:@#^>:.194W+TKS_P#:GD1_A;+:M&LDEW&T<8([D=J] M<^*/@MOAM\2M4T'.X6,A7/XUQ7Q-^'4GQ&\+E8=WFZ>#*JC^(B@#PC]@GQ+- M\/;63POJ4?V6:-FD$O1FST%?2TY9FW-DYY!KYG\8R6M[X8@BM9%L?%&GS>;< M(G$AC7U]J^BOV8OBE8?$WX>B\N(X_,A/DG/?\%2/ M#.FVZ:?=1PQPS>5DD#EC7/\ _!-CX*W5]JTWB"ZA:.*$B2%B/O"@#US]E_\ M8(K>U4G=<.$!KH/ MBA\+Q\/(X093))(<$'M0!QM:_@SQ?<^#-8CN[=F5E/0'&:R*V?"GA4>(I'#2 M>6%4MF@#J_B?^T!J'Q$MTADRJ*@4\]:\^CE*,S?W@0?QI+J,6T\BYX1B,U7% M]&3][Z\4 > _'']E.XUKQ&VI:1&UUYQ+RQ?PDGUKS33_ /@GAJ'BG65NM0,M MC&&R8U^Z17VC%<,B_*Q ]J<;F0_Q-0!Y#\-_@!9_#BTCM[?2;:22(8$Y0;C[ MUV^H6UUI6FM)<74T$8'W0>*Z@+,1GYJ0Z+-K@\IK4Z)K$U[XJL MY+6/[;MG4J&'!YK] ?@'I.J>(Y[*XU>%M-LH CI$OWX:9>?*(J[%H/B; MPG,+>XTV:)H_E&1UH [/XUM8K=O)9;65B>@KN?V3O@9^\_MK48_ND/"&'WA7 M+_!KX-:Q\0/$4%QJ=K)#8H?FW#Y37U;HVDPZ'ID-K H6.%0H % %H#:,#@>E M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %>:?M@>)KGPA^SCXJU"TW"X@LF*%>H->EU@_$[P-#\2O >IZ' M<;?)U*$Q,3T&: /YR?&?B&Y\7^,;[5+R1I+JZ@P<97I0!Y_\ $3X!6OC# MQ!=:M9R+8W5U&8W(ZL*\S^'7BG5OV6?'G]ESZ7-?:*Q+M-CY,FOHS.*JZSH% MIXEM?+OK/[5!ZXH RO$/[6W@^]$,:S6MFS("WS=#6=_PT-X,6%I&URSX&<;J MJZM^SIX(UESNTF-9#ZFLEOV/?"+R[FL(S'UVYH \=^,ML_[8/Q?T>VL8BVBV M3>7/*O*$>IKZ@^''P_L/AYH5II%C&D,<*A&91]ZJO@?X=Z+\/;9K;0[%86?[ MRKU8UNR0WENVZ2VDC/;(H V=,O%\(^(K2\C;S/L[AL#O6M\5_BG_ ,+ G61H M_*VG.2:H^!_A)XK^)]Z(=)T6^O,G&Z-"V*^I?V9/^".OC#XI:HLVN32:7;+A MBD\9&1Z4 ?&<=[%*VU9%8UV7@/6K73+*43,JOM/)K]#_ (R?\$-[>W\!R2:# M?VZZA;H7.Q#N? Z5\,ZY^PK\2M'\3-I7_"/ZI-F38)A$<8Z9H /V2OV7M2_: MR^+D.BV1DBM9'+M.!E< \BOU(A_X(]>!U^%G]D&"U&J-& ;OR^0V*;_P2A_8 M?F_9L^'2W^LKG6)V)!9<,JGM7V10!^0/CG_@A]XELO%$T=CJDTEJ[G:53@"N M%^+O_!)[Q;\&/#TFJ-)=7T,"[W^3I7[<5\]_M\>+[K1O"-OI\,FV"^0B08Z\ MT ?C+HOP>US6[U;>/3;CYC@MMZ5]=?LZ_LUZ)X4\-PMJVGPW5W(OS!QRIKT' MP-X6L8-/BECA02$9)QUKL=!T1;_4%15^9FQQ0!C^"?A7I^I^,K&TAMX[:U69 M&UL;:."-5'"CJ:^:=?\ A+=>%- T_6K;.Z.4.X Y MP*^A?A)XT'CKP;!>?Q?:AH^I6L<[30LL+,.4 M8CBOPE_:W_9EUS]G'XM:EIRL-/N;F2XD$?[M=VW-?K1^PO\ \$M? M"1GFOAU/\ @EQ\2V\3 M'3=DW#[?-\H[:_>(C(IGV:/.?+3_ +Y% 'P-^QK_ ,$:="\"Z9'?>.88-5NI M '55XV^QKW[6/^":'PCU@KO\.QKM]&KWX# HH \]^$_[+G@KX*I_Q3^CPVK= MV(W9KT(#:*** "H)-,MY9O,:"%I/[Q09J>B@ P**** "OF'_@H9J,,EKI=L MKJ964C /3FOIZOAO]M6ZOK?XF6PO YA:0^5Z 4 <+X8E;3],C1C\V*[_ .%M MTHUR.23[H8&N$L+;[5&&4_+[5MZ1J0TQNM 'TCXW^+FEQ^#9+ ;6/EE1SWQ6 M+^R;\5;>UE?1)I!&NXNI8\9/2O*_#GAN3QO?<3!47EMQ[5;\4Z98^#]3L1IK M?Z=YRABK=LT ?:"MN4$=#TI:R_!UU->>'+1YO]88ESGZ5J4 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>,_MD?!^U\= M?#^XU0QYO-,B+1[1R:]FJOJVEPZUITUK<+NAF7:P]10!^=/@B9FL?)E(62,8 M(;K4FKW:VL_^L7KZU[]X_P#V'WG\37%YH[-Y=PV2"V,53?\ 8%%[IYDFED^U M8R 'XS0!Y;X8\2S:78N\4@&Y3GFO2/V:OA')\0_$HUB_W/9KRN3W%4-'_8L\ M3V^K)#(J?85;EM_45]/?"[X?6_PV\+0Z?;CA>6)ZDT =!;P+;0)&HPL:A1]! M3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$! end GRAPHIC 15 inbx-20231231_g3.jpg begin 644 inbx-20231231_g3.jpg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̒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�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�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�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end GRAPHIC 16 inbx-20231231_g4.jpg begin 644 inbx-20231231_g4.jpg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inbx-20231231_g5.jpg begin 644 inbx-20231231_g5.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#R17AI9@ 34T *@ @ ! $[ ( M - (2H=I 0 ! (6)R= $ : 0T.H< < @, /@ M 6QA($5G M96QK;P 60 P " % $*:0! " % $+J2D0 " S8T "2 MD@ " S8T #J' ' (# ")H '.H ( M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M R,#(S.C Q.C$X(#$Q.C$T.C$R #(P,C,Z,#$Z M,3@@,3$Z,30Z,3( !+ &$ >0!L &$ ( !% &< 90!L &L ;P /_A"Q]H M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTG M[[N_)R!I9#TG5S5-,$UP0V5H:4AZDY48WIK8SED)S\^#0H\>#IX;7!M M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\&UL;G,Z9&,](FAT=' Z M+R]P=7)L+F]R9R]D8R]E;&5M96YT#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@ M96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8 M%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4 M"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ_\ $0@![@)L P$B (1 0,1 ?_$ !\ $% 0$! 0$! M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $ M$042(3%!!A-180'EZ@X2%AH>( MB8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! M @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$' M87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66 MEYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7F MY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHKQ7P#B?5;V_N=,UR[NH-0NC'J'VMC:(%+85D\SGT^Z>HJHQNKB;L> MU45Y[IWQ U.\\/\ A*_DMK59-;OWMKA55L(H=U!7YN#\HZYK.M_B1XD\FVU. MZT_3!I$FKMICE'<3$[RH<#. !CWS[4^1BYD>IT5PVE>)_%7B.^OI]$L=+32K M>ZELT-S(_G%T'^L..-N[''6N+TO7]>N_AC:WVOS17Z2:Q%% _G2I+GS"&WE6 M&0.PZ>H-"@PYCVVBO-M5\?\ B*-=>U31].TY]'T&X,%P+AW$\Q4 N4Q\HQGO M3=6^('B+^T=770K'37M--L8;YGNV<.4= Q7"GD\\'@#'>CD8TN=(AL)$DTZ.^EMY(II95W#)!*#:@_VFXK2\-W MHU/XM7-^$\O[5H%O+MSG;N8''ZT)_'%OJ'PMT:9K];%]=>*":X#E?(4$>HT5X;;S6>O_"G6"=2N;F[\,O/':74%Y(OF1L04=L$;^!CG^Z:] M(\#:1;Z-X.MKNS^U3SWEI%<2B:Y>4N_E@\;R=N2>@XI.-D"E>V?C3Q*FI^&(=7L]-CBU]V91!YC M-''Y>X DG&[\QBH;KXAZU'IL\MI8V4MPOB Z5'&^Y59-N02<\-GOT]J.1AS( M](IKR)$NZ1U14"56( $8/(/N?RK M:^*TZW7PVCG0?)+=6C@'T,BFCD=TF',K'?45Y5KWQ6U>R\4:A9:/HZW=MILX MAE06T\DLQ_BVL@*)C_:ZU=O?B+JMG_:VGM9VIUF#4H;2QA*L%E2;!1F&[/W< MYP1S1[.0)I;:QT=;FP@OOL;K';3M* MV&VLX< Q@ ]CSBJ]MXAU#PS#XPO=*LTN)&\1O'(\B.Z0(5&9&5/F('M3]FQ< MR/7Z*R?"^K2:WX;M-0GDM)))E.YK-RT1PQ&5)YZ '!Y'2M:L]BPHHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "LG0/#=CXZ.=#CTHO=?9X]0.H@^8-WFEBV M,X^[DGBNIHJN:7<7*CF+7P#I-EXB?5[2:^A+SFY:S2Y(MS*1@N8_7FJT/PRT M2WT^2QBN-0%H]VEVD!N,I$ZL6 0$< D\^OK7844]U$WMM]D=KZY,I2'.=BGJ!D _@*=;?#O3(-/O+274- M6NX[JV-KFZO#(8HCCY4!&!T':NLHI\S#E1SNK^"-,UC2],LYI;R Z5M^R7%M M/Y%"_> [@#-5;;X<:)::?%9PO=^5%J(U)=TVYC*!CDD9(_7WKK**.9A9' M,77@#2+NWU^&5[H+K\B27>V09!7ILXX_'-7]8\,6&N>'XM'O&F%M$T3*8W ; M]V05YQ[#-;%%+F861RM]\/-)O=9N-16ZU*S:[8-=06EVT45P1W=1U_2I[OP- MH]YXRM/$TRS?;K5 J*KCRVP" 6&.2,\'/I71T4^9A9'*'X=Z0-8EOX;G4K=) MY_M$UG#>,EO+)G.YD'7GWI\W@'3)8[X17FHVLE[?-?/-;7/ENDC+M(4@?=QV M.:ZBBCF861G:#H5CX;T:'3-+1EMXLD%VW,Q)R23W)-:-%%3N,**** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!"2%) R<<#UK@ M++XBSM'?7%U':S+9VDT]S:V^Y9;)T; BD))!).1D ="<$5WLL8FA>,EE#J5) M4X(R.U+-"MYVAGU.%)$8J MRG.01U'2FZ3H5S::DVHZKJ O[S[.MLCI!Y2J@.3QN;+$\DY], 4NKL1XAT MD W$N1GK^X>C2X];&O'(LL:R1GLDKA1^9K(B\<^&II5C75X%+G"F0,BM]&8 4[-BNC?HI%97 M4,A#*PR"#D$4M(85R6L:RX\3:*O]DZB?*NI0&$2X?]RXR/F_'Z5UM8NL?\C% MX?\ ^OB;_P!$/30F;5%%%(84444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% &1XEM=0N-)+:+#9RW\3AX?MD>Y1ZX]# MCI7/:7K.H76L0:7XCU*U@GFSG3KG2_+:< '.Q_-96_#-=)XBL]4O]%EM]#U! M=.NW(Q<%-VT9Y&/4CO7%>$Q#::Y 3K6@7MQ+*8Y6VR/>2-@\;G/\ _#0VF?\ 0OZA_P!_$_QH_P"& MAM,_Z%_4/^_B?XU?LY]B>>)[!17C_P#PT-IG_0OZA_W\3_&C_AH;3/\ H7]0 M_P"_B?XT>SGV#GB>P45F>'=:C\1>';/5H87@2[CWK'(067DC!Q]*O7)*VDS* M<$(Q!';BHZV+):S]7UNQT*&WEU*1HUN;A+:,JA;+MG XZ=.M>,>'/$FH'_A% M;NW\57NHZI>:@;:\TR6?>JP[R"2G7(7GSUU,^<]QN]>TJQU:UTN\OX(;Z[&8+=VPTGT'X4NK MZWIF@6:W6LWL-E SA!),V 6/0?I7BGB>YU/7=4U_Q'INC75TEA=1I9:C%(@C M@6V.7X)W$$Y)P*VO%6L?\)QKNEVNF:1<:U8PZ8UW/!;2(I1YT*)N+D#Y1DXZ MYH]GL/F/0=2\=>&-(NQ;:GKEG;3E%D"228)4C(/T-:>E:OI^N:>M]I%W%>6K MDA98FRI(.#7C-WJ+:E\(]%BOHPNH:;K5M870<#<&1\8)^F*]P2-(UVQHJ+Z* M,"IE%)#B[CJ***@H**** *>I:M9:1"DVI3BWB=M@D8':#[GH/J:X'4]19=1M M-3B\4>';R:SD+H73RY64J1Y>Y"QP<]-O4"N\U74/[.ME?[!=7P=MICM8PY'' M4@D<5E:;J%I+J4:P^%[VS>0_\?$EDB*ON6!S5QTU)9N64[7-C!/(H1Y(PS*, MX!(]P#^8%3T$X4D]!7GEIXXF.DW&M7EQ=H\MK/<6EB]JJ6[A 2 ),;F; R?F MYR<#I22;V&W8]#K%UC_D8O#_ /U\3?\ HAZHZ-?:I!XC@T[4K_[!K>1AEHF8,5/ID$C\JEJ2@HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "FR()8GC/ 92IQ[TZB@#!\,^#],\,:9:VUM#'//;*ZK>2Q+Y MQ#.6P6 Z?-BM Z'I+3O,VEV1ED8.\AMTW,PY!)QR?>KU%.[>HK(KPV%G;6C6 MMO:016[;MT*1A4.[K\HXYR=Z*UAJ/B>/5K^[N'O$N!% 8+06 MT4N]7VG@EI%PKA\%:9&VR9[BYM5CECAM)G!B@67.\+@ M\@D3B!;>.2Z<,8XEZ(, <9Y).2>YIF ML?\ (Q>'_P#KXF_]$/6U6+K'_(Q>'_\ KXF_]$/1>[$;5%%%(84444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+5+ MJ^M8$?3=/^WR%L-'YRQ[1ZY-Z7IEK-IJM),U[#&8U(!D5FP5R>!GUI]GJ^KS7D45WX?> MUB(- 8\_P"D3?\ HAZW*Y'Q+K^D M6WB+1XKC5+.*2WN)?.1YU!CS X&X9XY(_.JBKLF;M&YTWVQ?[K4?;%_NM5"W MN(;JW2>UE2:&0922-@RL/4$5)6O(CF]K(M_;%_NM1]L7^ZU5**.1![61;^V+ M_=:C[8O]UJJ44U MD6_MB_W6H^V+_=:JE%'(@]K(M_;%_NM1]L7^ZU5**.1![61;^V+_ '6H^V+_ M '6JI11R(/:R+?VQ?[K4?;%_NM52BCD0>UD6_MB_W6H^V+_=:JE%'(@]K(M_ M;%_NM1]L7^ZU5**.1![61;^V+_=:C[8O]UJJ44UD6_MB_P!U MJ/MB_P!UJJ44UD6_MB_W6H^V+_=:JE%'(@]K(M_;%_NM1]L7 M^ZU5**7(@]K(TZ***Q.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH S/$%MJ5UI#QZ)-!#>;@4>=<@8/..#@^AP<>E#Q=O\26FJR73!19SWC^=&KX;?M*?(N>W JX[$O<[^BBBH*"L'7C_P 3 MS0?^OB;_ -$25O5@Z_\ \AS0?^OB;_T1)51W(G\++=%%%;G$%%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M &G1117,>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %< MSH^OZSJ]U#*-/L(=/D9@2UZ3.H!(Y39C.1R,\5TU>9^%186VNVEML\.37/FN M1<17,C73GDYP8P"W/)R.]5%73)>YZ9117'3>-YHM>U!%MHWTJTL;BX24$^9, M\! DQVVY.T<=5-))L=['8U@Z_P#\AS0?^OB;_P!$25#HVMZI+K5O8:PEH?M= MA]MB:V5E\O#*&1LD[OOCYAC//%1>(]5TZ+Q!HJ2W]K&\5Q+YBO.H*9@?&03Q MUJHJTB9OW6:U%(K*ZAD(96&00<@BEK8X@HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH TZ***YCT HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB=&E;7K[3[ZZUK3B MMO,\D=K!;"&?> R;6R[$=3D 9^'-8AG\2I;"RTH7S72DPP6022U3;(9 M 3URI506./O>XJX[,E[GI;*&4J>A&#@XKE?^%>:4MXCPS7D=JME+9FV-W*Z[ M9, XW,<#&>,8S@]A75T5*;6P[)F#HWAR;3[^.\U#43?306HLX"(1&%CR"2>3 MEB0,G@<=*P?B7JUCX8BTO6;NQ6Y"7$@**BYD)A<#)-=Y7E/[0!QX/T[WO7ND:'<6F ML1F&SE*W-I+N#9W#D8&2.QYKTNWU6SNIA%!-N<]!M(_I73*G)=#SO:T[V4E? MU+E%-=UCC9W.%4$D^@JC_;NG?\_'_CC?X5*C*6R'*I"'Q-(T**KVM];WH;[- M)OVXW<$8_.G7-U#:1>9UM1\\7'FOH345G_VYIW_ #\C_OAO M\*N03QW,*RPMN1NAQ0X2CNB8U(3=HM,DHJM=:A:V;*MS+L+#(X)S^50?VYIQ M_P"7@?\ ?+?X4U";5T@=6G%V3L375PMI9SW,@)2&-I& ZD 9_I6#X)\:6?C;29;RTA>W>&3RY(7 M8$KW!X[$?R-3ZUJ]E-X?U%(9PSFTEP-IY^0^U>'_ GUR3PWXJL_M1*6&K*; MF\'Y3^!P/^!57(TM4.,HS5XNY]&T50_MO3O\ GY'_ 'R?\*GMK^VO&86T MH>.VA,L[;$'4XJI_;>G_ //RO_?)_P * M2C)[(W[3((]W3(/-+E=[6'SQ4> M:^A8HJA_;6G_ //ROY'_ J\K!U#*<@C(--QE'="C4A/X7<6BJD^IV=M*8IY MPCCJ"#38]6L99%CCN%9F. ,'FGR2M>PO:T[VYE?U+M%%43K&GJQ!N5!!P>#2 M47+9%2G&/Q.QQVE?$=[GXI:AX7OH88H(Y&AM95SN9U[-SCGG%=_7SGXGT+65 M\5:]XELXVCCM+O[7#*/XEWCYA].#]*]S\.^(K;7_ K:ZRK!$ECS*/\ GFXX M9?P/]*J46A\T6N9/0V:*H_VUI_\ S\K^1JQ;W4-W&7MY Z@X)'K4N$EJT1&I M"3M%IDU%0W%W!:*&N)!&&. 3WJO_ &SI_P#S])^M"C)ZI!*I"+LVB]138Y%E MC62,[D89!'<5!<:A:VLGEW$RHV,X-)1;=D4Y12NWH6:*I+J]@[!5N4))P!SS M5VFXM;H(SC+X7<**IOJMC&[(]R@93@CT-/@U&TN9?+@G5WQG HY)6O8GVL&[ M*2+->3^/_&VH^&?BCI2)=R)IJ0H;BW!^1PS$,2.YQW[8KU9W6.-G(_$W0KOQ+XY\[3XS);"R"K,/N[P"=OY\54(MO8ISA%^\['MZLKHKH=RL 5( M[@TM^=Q&N<9/K4N+ M3L'-&W-?0EHJE_:]A_S]1_G5J*5)XEDA8.C=".]#C);H49PD[1=Q]%03WMM: ML%N)EC9AD!CU%1?VM8'_ )>H_P Z%"3U2!U()V;16]T2+>59"O7:>E-QDMT)5(-V31LT445R'IA1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !7(:=I/B5-3M;R^N@#!(L$D<< MH*W$05MTK<#+$E,#MBNBU.UO;N!$T[438.&RSB%9-P],-7'Z+XDFN?$-M:MK M=_=1R/M&_3$BCEX8C#]<$*2/7%7&]M"6=[1114%!7DW[0AQX/TS_ +" _P#1 M3UZS7C/Q[OY+GPU8P/I]W;K'J'$TP38_[MQQAB??D"M*?QHB?PF)K,]YX6T_ MP5K<4DC:5-9V\=Y;9^1B$!)QZE2?Q KV.UL[%1''B3X,VFG*N9AIL,D&>TBQ@C\^1^-1_"'Q =9\$QVL[$W6FM]GD#==O53^ M7'X5U.4FMS@]G"]TD=VRAT*N,JPP0>XJI_9.G_\ /I%^57**A2:V82A&7Q*Y M#!:06N[[/$L>[KM'6G3V\5S'Y<\:R)G.&J2BE=WN'+&W+;0I?V1I_P#SZ1_E M5J*&."(1PH$0=%':GT4W*3W8HPA%WBK$%Q96UTP:XA60J, L.E1?V18?\^D? MY5'&U?X$)?VBG[9IEY+ZK&AX%N].\ M4^#[/4&MXC<;?*N !TD7@_GU_&NGM[*VM&8V\*QEA@X[UY5X'=O _P 4-3\) M7#$65\?-LRQXSC*_FN1]5]Z]=HE*6UR?90B[I(CFACN(C',@=#U!JK_8VG_\ M^L=7J*E2DMF$J<).\EBES.]Q\ ML6N6VA1_L;3_ /GU2KJJ$4*HP , 4M%-RD]V*,(Q^%6*LVFV=Q*9)H%=SU)I ML>E6,4BO';HK*<@CM5RBGSRM:XO94[WY5]P52_L:P9LFV4DGFKM*OWA]:2DX M[,J4(R^)7/+/ ES-K'CCQ9INH.9["(/"D+=%4O@C\JI_#]V\*>-M5\"ZJ=UM M<,9;,MT;C(_-?U4U/\*?G\>>+Y/^FV/_ !]O\*M?&'1)TM;'Q7I64O=*D7S& M7KLSD'\&_0U;DW+4I1BERI:'?_V+I_\ S[)^M6+>UAM(REO&$4G) ]:I>'-; M@\1>';/5;;&VXC!91_ W1E_ UIU+E)Z-D1IPB[I)$-S:07:JMQ&'"G(![56_ ML73_ /GV7\S5^BDIR2LF*5.$G>23&1QK#&L<8VHHP!Z"H+C3K6ZE\RXA#OC& M35JBDI-.Z*<8R5FM"BNCV"L&6W4%3D')ZU>HHIN3ENPC",/A5BB^CV,DC.]N M"S').3R:?;Z9:6LPE@A".!C.:MT4^>5K7)5*FG=15_0:Z+)&R.,JPP1ZBO+[ MNYE3XYVN@QOC36MP[P=B?++9SUZUZE7E$GS_ +3<8[+9_P#M TX2DKV93IPG M\2N3:9JU]X;^,\^AZC<,^GZA'FSW=%S\RC\PR_A7I=S:PW<7EW";U!SCWKSG MXSZ3*=(L/$=A\MUI,ZDN!R%)!!_!@/SKN] U>+7O#]EJD&-MU"'('\+?Q#\# MD4FV_>'R1Y>6V@O]B:?_ ,^X_,UYBWLHP#GM4']AZ?_ ,^X_P"^C6A134Y)63)=*G)W<5]P52ETBRGF M:66$,[').3S5VBDI..S+E",U:2N4X-*LK>9988=KKT.3Q5L@,I!Y!T4.3 M>K81A&*M%6,[^PM._P"??_QXU8M;"VLF8VT>PMP>2M*?QHB?PL[3PV-OA72AZ6<(_P#'!7FME_Q0GQRF MM#^[TW7EW)V 9B2/R?(_X%7IVA#;X=TX>EK$/_'!7$_&70WOO"T6L68Q=Z3* M)0PZ^6>OY$ _@:W6]CC1Z+16/X4UQ/$?A6PU1"-TT0\P9^ZXX8?F#6Q4B"BB MB@ HHHH **** "BBB@#"\;MM\!ZV?2RD_E6'\'1CX9V/O)*?_'S6QX_;;\.] M=/I92?RK+^$2X^&&F>[3'_R*]5]D?0Q_C)HTRV-AXHTW*WFDRKO9>NPL"#^# M8_.N[\/:S#X@\/66JV^-MS$&('\+?Q#\#FK5_90ZEIUQ97:AX;B-HG![@C%> M8?">^FT'7M7\$ZDQ\RVE:6VW?Q#^(#ZC#?G1N@Z'J]%%%2(**** "BBB@ HH MHH *5?O#ZTE*O##ZT >3?![Y_$_BZ3_IY4?^/R?X5ZE=VD-_936ET@D@GC,< MBGNIEWP5^;4O%DGK>)_Z%+7J]5+<;W/)?AI=S>$_&>J>"-2<[#(9K-F_B MXSQ]5P?J#7K5>7_I[9=/\7Z2-MYIDBB4KW3.5)^AX^C>U=_H&LP>(-!L] M4M#^[N8P^/[K=U_ Y%#UU!FC1114B"BBB@ HHHH **** "O*(/G_ &EYC_4Z9\_[2&HG^Y:G_ - JH]1H]+U33H=6TFZT^Z&8;J)HF]LCK^' M6O./@YJ$U@^K^$M1.+C3IV>,'NN<-CVS@_\ J]2KR/QR#X,^*VD>*81MM+[ M]S=8Z'^%O_'2#]10M= 1ZY12!@RAE(92,@CN*6I$%%%% !1110 4444 %%%% M &G1117,>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4] M5F:WTV287D%B(RK-/< ;$7(SG)'49&<]ZX;0-2TVX\06-]9ZKHEUDW5K/!*XO96MU2 MW,6&X1QU&=FT#GUJX[$O<[.BF3316T#S7$BQQ1J6=V. H'HV&I6>J6WGZ=H'!Q]5VFO6*\M^*]FWA3QKH7C6R1M@D$%V%_B M Z?FN1^ KUNW6VNK6*XMVWQ3('1@>&4C(/Y5T853^%"[?AAI/TE/_D5ZTOBA M#''\,=<89S]F(Z^XJ/X46T9^%^C%@'? M$VC^-M.4[H9%AN@O\0'3/U&5_*O9/LL7H?SK+\2^&[;Q%X:OM*F&!<1%58G[ MK]5/X'%2JB3'[*065Y#J%A!>6KAX+B-9(V'=2,BIZ\[^"FK/+I=]X8U7=A8Y'X-G\Q7J/V6+T/YTY24782I2:NBE15W[+%Z'\Z/LL7H?SJ>=#] MC(I45=^RQ>A_.C[+%Z'\Z.=![&12HJ[]EB]#^='V6+T/YT^RQ>A_.F3VT2V\AP>$/?VHYT'L9'C_ ,$1G_A)7_O7J_S?_&O5J\S^ T"2 MZ;K\C \WP'7V/^->L_98O0_G5SDE(7LY/4RKZR@U'3[BRNTWP7$;1R*>X(Q7 MEWPNO9_#/BK5? ^INBKOV6+T/YT M?98O0_G4\Z'[&12HJ[]EB]#^='V6+T/YT--UQ /M$''.Y>2/Q&1^-=Q]EB]#^='V2(\ M$$CN,U'M$A^RD!+0RONN;/_1IN>3M'RG\5Q795Y1X5C'@?XV: MEX=FREAJP\VVR<#/++_[,M>R?98O0_G52DDQ>SDRE15W[+%Z'\Z/LL7H?SJ> M=#]C(I45=^RQ>A_.C[+%Z'\Z.=![&12HJ[]EB]#^='V6+T/YT<^&(K:+6K9;G3[26^$K[KX:NDDCGGYO+!Y..PZ5W]U> MV]DD;74HC6218D)[LQP!^-?.6U"UEUMH+A[B M74[2ZN[5+:0>3!&<*,%1O8?>;&>>G05Z5123L-JYS?A9&EU/7=02&2.UO;M& M@,D9C+A8U4MM(!'(/4=J\\^/FF16GAFQGCFNW>:_Y2:ZDD0?NW/"L2!^ KV> MO)/V@^?#6C)_>O\ _P!D;_&KIOWT3+X3U6S01V," DA8U ).3T]:FID'%O'_ M +H_E3ZR+.?\<^'E\4>#-0TO:#+)'O@/I(O*_J,?C7,?!/Q"VJ^"O[,NB?M> MDR>0RMUV=5_+D?A7H]>2^(_AUXCT/Q)=^)OAW?\ ES7+&2>P; #DG) S\K G MG!QC/!K2-FN5D.Z=T>M45Y9X=^-%O]L_LOQQ8R:+J"':TC(1&3[@\K^H]Z]/ MM[B&[MTGM94FB<962-@RL/4$5,HN.Y2:>Q)1114C"BBB@ HHHH X[XL-M^%V MM>\0'_CPJ3X6KM^%^AC_ *=\_P#CQJO\7VV_"W5_=4'_ (^M7/AHNWX9Z"/^ MG136G_+OYD?:.IHHHK,L\8\ WZ8;ZJ?6O7= M.U2QU>T6ZTN[ANX&Z/"X8?ITJ+6="TSQ#I[6.LV<=W;L<[''0^H(Y!]Q7F.H M?!F^T6\;4?A[KL^GSCD6\SG:WMN'4>Q!K6\9+7?QZ5+@T M-23-VBBBH*"BBB@ J&\.+&<^D;?RJ:JVHG&EW9](7_\ 030!Y?\ L_C/AG5Y M/[VH'_T ?XUZS7E/[/8SX%OY/[VHM_Z+C_QKU:M*GQLF'PH****S*,'Q#X)\ M/>*(R-8TR&63'$ZC9(OT8TDZ"Z@3 ;WVG@_\ 3^%>CZ#XLT/Q-#Y MFBZC#;Z[\#](N9_MGAB M\GT2\4[D\MBR ^W.1^!I^Y+R%[R\ST^BO&#K_P 3?A_QKUB/$&F1];F/YF"^ M[#D?\"'XUUWAKXN^%O$16%[K^S;L\>1>80$^@;H?T/M2<&M5J-21W-%(K!U# M(0RGD$'.:6H*"O(/ @W?M!>,'](G'_C\?^%>OUY!\.OG^-WC*3_>'_D1?\*T MALR);H]?HHHK,L\I^.&D316&F>*M.&V[TF==[#KL)R/R;_T(UW?A?Q7I?BK2 MH;K3+N*61HU:6$,-\38Y!'48/%:UU:P7MK);7<*3P2J5>.10RL/0@UYAKOP3 MM!=?VCX*U&;1+Y3N1 [&//L1\R_K6B::LR&FG='JE%>,Q?$+QMX#F2U\?:.U M]9@[5OX,9(]=P^4_0X->C>&_''A_Q9"&T;4(Y)<9:WD^25?JI_F,BDX-:C4D MSH****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH SM*O#P10=>TS@?\ M/Y'_ (UIV]Q#=VZ3VLTH(ZU&I9)15&]UO2M.F$.H:G9VDI7< M$GN$1B/7!/3@U OBGP^[!4UW369C@ 7D9)/YT687(_$7A+1?%5IY&MV,<^!A M),8D3Z,.17F%QX#\9_#NX>]\ ZC)J.GYW/I\W+8_W>C?5<'VKVBLV7Q'HD$S MQ3ZSI\#51DUH2XIG$^%OC+I&JS"P\11-HFI*=K)/D1LWL MQ^[]#^9KT='61%>-@RL,AE.017':_P"'_!/CW_1KF>PN+TJ?+FM+A//7Z8/( M]B"*XR3X7>+_ K&\_A+Q@RV\0+>5^4)'_CHKI](^._A>^VIJ*76FR'J94WH/Q7_"DZ MA%;'@W4]/TWX>^'8[^_M;5FTZ$JLTRH2-@Y&35_8^9/VCJZ*S1XBT M0XQK&GG/3%TG^-:0((!!R#T(K,L**HS:WI5M,T-QJ=G%*APR27"*R_4$T0:W MI5S,L-MJ=G-*W"I'<*S'Z &G9@6;BV@N[=H+N&.>)QAHY%#*?J#7G7B'X):% MJ,IN]!EET2]!W*T!)CS_ +NU4/^$@T8]-6L?\ P)3_ M !IQ-.246_B71;[2 MINA(7>OY$!OT->G6NHV5\S+97EO<%1EA#*KX^N#4.JV>DW-HQUN"SDM^C&Z5 M2H_%JKF3W1-FMF9FD>/_ MKF!IVM6K.?^68: MQ\-/AMJF6@NK;3I3R&M+U0,_[I)'Y 5D0?#+Q1I,?VGP'XV,\ )Q&TAVD^G! M93^-/EB]F%Y'L]4M9;9H5^WI;2'_ ,=->27'CWXD^#=H\5:);7\).!-&0K/Z MX*?_ !-6G^.>@:KH=[:7MI>:?OW/\ XX@_I7J5>9_ 5-OPW)_O7DA_11_2O0I]5T^UF,5S?6T,@ZI),JD? M@32J?&QQ^%%JBJ<>LZ9-(L<6HVCNQPJK.I)/H!FKE04%%4CK.F D'4K0$=1Y MZ_XU+;ZA9WZ%AXWTBXT:[!PTBHQ3ZE3\P_#->E_VO MIO\ T$+7_O\ K_C4.IZ+H_B.Q$>IV=M?P.,J74-QZANWU%:W)\O=_NYR/J"*] _M*Q_Y_+?_ +^K_C4L-Q#< F"6.4#J48''Y52D MX[":3W/&TU[XG> '^SZSIO\ PD5@OW;B/+-C_> R/^!"M;3_ (]>'Y9!%K-A M?Z7+_$&3S%'Y8;_QVO3Y9HH$WSR)&N<9=@!^M96H6GAS5HRFIQ:;=J>HF"-_ M.JYHO=$V:V96TOQ]X6UG L-S"\ENCV6BO%QK?Q9\._Z]=/UV!>ZNC,1_P$J?YU;A^.^TZ3H2 MNQUXW\;+.V7Q%X3*6T*O<7I M$K",9D^:,?,>_7O6E/XB)_";"? GP7)&'0W[*PR"MUD']*[[1=(MM!T6UTNP MW_9K5/+C\QMS8]S5N&&*WA6&WC2*)!A410JJ/8"GU+DWNRDDMCD/%?PR\/\ MC+5DU'6/M7GI"(1Y,VP;021QCU8UCP_ OP?!<1S1C4-T;!US<]P<^E>CT4*< MDK7%RH*\^U/X*^%-6U6ZU"Z-_P"?=3--)LN,#$-+M;BW.GF]CG()^UMO9 M,?W6 !'X5V]%5SR?47+'L>6ZO\!/#=[N;2[BZTYSR &\Q/R;G]:X35_@+XEL MMS:7/::F@Z*&\IS^#FQQ*L4FS&5!.01UKT0@,,, 1Z M&EH=1O;0%#N>9#X"^$E<,)-0X.1^_'^%>EQ1B*%(U^ZBA1GT%.HJ')OFXMF+() M)@5SC'(Q[UWM%/GE:UQ9GX">%"Q/GZB,G_ )[C M_"O3Z*2DX[#:3W.3\'?#K1_!%U=3Z1)F-*T"R-(#,VYLL'-'ATW28!!;1#A M1R6)ZL3W)KE/$WPDT'Q5KTVK:C/>)/,JJPBD 7Y1@<8KNZ*2DT[H=D]#SK2? M@IXBT44G)O<$DMCS"?X#>&9[B29KO4 T MCEB!*.I.?2MSP?\ ##1_!>K2ZAI<]U)+)"82)G!&"0?3V%=G15.\&^#;#P3I4UAIDLTL4TYF8S,"02H7''^Z*9XS\$Z?XWL;:UU.:>)+>0R M*86 ))&.5_\* \-?\ /]J/_?Q?\*]&T72H=#T.STNU9WAL MX5A1G.6(48&:O44W*3W!12V.(\7?"O1_&6M#4]1N;N*81+%MAI_ [0-4U:[U":^O MUDNIWF=5=< LQ)QQ[UZ9124G'8;2>YP?A3X2Z/X1U^/5K"[O)9HT9 LK KAA M@]!79:I81ZKH]YI\S,D=W \#LO4!E*DCWYJU12KT4E.25DP<4] MS+\-Z#!X9\/6ND63[QRQ//YUS_C7X9Z;XXU&VO-0O+JW>WB,2K" M1@C.>XKM**2DT[CLK6/*$^ &@I(KC5-0RI!'*_X5ZE):PS6_D7$231XP5D4, M#]0:EHIN3EN"26QCV7A'P_INK?VEI^CVEM>;2HEAB"X!ZX X%;%%%*[8PHHH MI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7EGQ MMO*#.WYHVY_P" JQ_"O4ZQ=7_Y&+P__P!?$W_HAZJ+ ML[BDKHVJ***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 5E^)-6?1-!GOH8EEE4I'$C'"EW8(N3Z989K M4JAKFD1:YHT^GS2/$)0"LL?WHV4AE8?0@&FM]092T?4[^37-0TG5?L\DMHD4 MJ3VT;1JZ/G@J68@@J>_-4M9UW2%\2Z(K:I9!H;F42*;A,H?)<<\\<\5J:3HT MEA>W=]>W?VR]N]BO((_+544':JKDXZD]3UK0-K;EB3!&2>22@YIW5Q:V*/\ MPDV@_P#0;T[_ ,"X_P#&D_X2;0?^@WIW_@7'_C5[[';?\^\7_? H^QVW_/O% M_P!\"EH&I1_X2;0?^@WIW_@7'_C1_P )-H/_ $&]._\ N/_ !J]]CMO^?>+ M_O@4?8[;_GWB_P"^!1H&I1_X2;0?^@WIW_@7'_C1_P )-H/_ $&]._\ N/_ M !J]]CMO^?>+_O@4?8[;_GWB_P"^!1H&I1_X2;0?^@WIW_@7'_C1_P )-H/_ M $&]._\ N/_ !J]]CMO^?>+_O@4?8[;_GWB_P"^!1H&I1_X2;0?^@WIW_@7 M'_C1_P )-H/_ $&]._\ N/_ !J]]CMO^?>+_O@4?8[;_GWB_P"^!1H&I1_X M2;0?^@WIW_@7'_C1_P )-H/_ $&]._\ N/_ !J]]CMO^?>+_O@4?8[;_GWB M_P"^!1H&I1_X2;0?^@WIW_@7'_C1_P )-H/_ $&]._\ N/_ !J]]CMO^?>+ M_O@5E>&$2\\*Z;G?^!+_ +X%+0-2C_PDV@_]!O3O M_ N/_&C_ (2;0?\ H-Z=_P"!G?\ @7'_ (U>^QVW_/O%_P!\"C[' M;?\ /O%_WP*- U*/_"3:#_T&]._\"X_\:/\ A)M!_P"@WIW_ (%Q_P"-7OL= MM_S[Q?\ ? H^QVW_ #[Q?]\"C0-2C_PDV@_]!O3O_ N/_&C_ (2;0?\ H-Z= M_P"!G?\ @7'_ (U>^QVW_/O%_P!\"C[';?\ /O%_WP*- U*/_"3: M#_T&]._\"X_\:/\ A)M!_P"@WIW_ (%Q_P"-5?#=O#)9WADAC8C4;I02@. ) MF %;'V.V_P"?>+_O@4W9!J4?^$FT'_H-Z=_X%Q_XT?\ "3:#_P!!O3O_ +C M_P :O?8[;_GWB_[X%'V.V_Y]XO\ O@4M U*/_"3:#_T&]._\"X_\:/\ A)M! M_P"@WIW_ (%Q_P"-7OL=M_S[Q?\ ? H^QVW_ #[Q?]\"C0-2C_PDV@_]!O3O M_ N/_&C_ (2;0?\ H-Z=_P"!G?\ @7'_ (U>^QVW_/O%_P!\"C[' M;?\ /O%_WP*- U*/_"3:#_T&]._\"X_\:/\ A)M!_P"@WIW_ (%Q_P"-7OL= MM_S[Q?\ ? H^QVW_ #[Q?]\"C0-2C_PDV@_]!O3O_ N/_&E_X2;0?^@WIW_@ M7'_C5W[';?\ /O%_WP*Q?%]I;KX3OBMO$#M7D(/[PIJS8:ES_A)M!_Z#>G?^ M!IP:MUB3HL/C/3$A58U>RNBP08#$/!C/YG\ZV MZ& 4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%5H]1LIKV2SAO+>2ZB&9(%E4NGU7.1UJS0 4444 %%%% !1110 4 M444 %%%% !6-X0!'@W2000?LJ<'Z5LT !0 !@#H!3Z %%%%( HHHH **** " MBBB@ HHHH **** ,O0+6:TM;M;B,HSWUS(H/=6E8J?Q!%:E%% !1110 4444 M %%%% !1110 4444 %9OB&QFU+0;FTM@IED "[C@<,#_ $K2K.M_$&EW6J-I MT%VK72[ODVD;MN-VTD8;&1G!.*:N!HT53LM6L-2GNH;"[BN)+1Q'.(VSY;8S M@^]7*0!1110 4444 %%%% !1110 4457OK^VTVU-Q>R^5$"%S@DDDX ')/L M* *=S;3/XKTZZ5"88K2Y1W[*S-"5'X[6_*M2LH^)M'&FQ7WVU#!,YCC*JQ9G M&\EF621> M9'P['H2$&/[IKJZ@LK&VTVS2UL85A@3.U%Z#)R?U)--/01/1112&%%%% !11 M10 4444 %%%% !7+_$(7J>$+FYL-1GL3;XD;[.=K2<@!=W4#)R<]=Y;31W%K%-!(LLPF F=AAY6?9L"XR%YYR3Z5U]%-.PCD/"IMX?%&NQVEA< MVEM.\+6^[3Y8(R%C ;!9 !\V?K77T44-W!:!1112&%%%% !1110 4444 %9N MOZH^CZ1)=P6-Q?RJ0L<%O$SL6/ )"@D =SCI6E10!YMEM:R:C#,;Z M:YN]3@TZ;S;>5U)(2%DW%&R5R5( '/)KK/!<5Q!X2LXKNV-M*F\;64JSC<<. MRGD%A\Q!Z$UNT53E=6$E8****D84444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 445!>7UKIULUQ?W$5M"I ,DKA5'XF@">BLNU\3:'> MD"SUBQGRZQCR[A6RS9VKP>IP<#VK4H ***BN+NWM%1KJ>.%9'6-#(P7<[' 4 M9ZDGM0!+114=Q/':VTMQ.VR*)"[MC.% R3Q0!)14=O/'=6T4\#;XI4#HV,9! M&0:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@#@=-6[M_!/AQ$BD5_P"UU$BF+)"&:3)((X&.]1:7#K-Y/I)N M]5U51?3W:72AMH5$+&/''R?= SU.:]#HJ^8GE/,;K5?$#Z;I*W5S+;Q/9R9N M7F>W+3ARJ[BD3DG:,X( /)YKIM9DU#_A&]$>1EFNFO;/[0\$>5;+KO8 C('7 MG Q[5U%%+F"QPFER:PMQIU[->W\C7&JW%O-#(/W:P@R!?EQQ]U2&I?&=Q<'4 M;RVN+N^M[8Z:QLX[1"1/,2P*G .[C;\I[$UW5%'-K<+:'F-UK&J6L^F6]D+R M*2W6R0H9'"NC!-^(A&0P )RS,"#]!5M+_6IY]1TJ34Y;-]%AF6:]=2PE,A_< M,<#)PA)..AKT.JUKI]M9SW4UO'MDNY/-F2.X4I,Z!YIVF\T#^)795)7Z@=#6[114O@ R37):'\3_#^OZ[ M'I-H+R*><$P-<6YC2< $DH3UX!-"3>P[H["BN/N?B=H%OXB_L:-;VZG640R2 MVUN7BB,+N!)&5Y.1Q^HHL[7"YU%%+_ !DWABZTNRL]*FU6^U.1UAMX MI AP@!8Y(/0'I[&K7BGQ1%X6\*R:S=6LDI4(%MU.&9V( 7/;K3Y6*Z-VBL_0 M[^ZU/1X;O4-.DTRXD'SVLKAFC/ID=:T*0PHHJGJNK6.B:>]]JMRMM;(0&D?. M 2<#I[F@"Y16;/KD$&N6&EF"Z>2^C>2.:.$F) HS\[?PD]O6M*@ HHHH **P M-?\ %*Z%K>BZ7;[(+>-I)&]% R: M=F*Y/16%X4\7Z9XQTZ6\TD3JL4GEO'<)L=3@'ID\8(JNWCW15\:'PP6G^W@? M>$?[LMM#;-V?O8(.,4-:R:7KOGJ6 C%@=S8."0,Y( M]Z[ZUN%N[2*X17194#A77##/J.QH<6MP33V):***0PHHHH ***K:C>#3]-N+ MLIO$$;2;0<;L#.* +-%9'A;7AXF\+V.LK;FV%VA?RB^[9R1C.!GI6O0] "BB MB@ HHHH **XS5OB9I6C^*$T6X@F,I8JQ&,YQ\NT?Q ^N1C%=F#E0?6FTUN*Z M84444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 96O65[>PPKI\OELK$L=Y7(Q6)_PCVNGK>+_ -_F_P *["BNB&(G"/*K M'%5P5.K/GDW]YA:'I.H6%X\E]<"5"FT 2,W.1ZBMVBBLJDW4ES,WHT8T8*J22%E7>W -0_\(E?GK?+_ -]-7745NL552LCEEEU"3;:? MWE;3K9[/3XK>5][H,%AWYIFJ63:AITELDGEE\?-CI@YJY17/S/FYNIV>SBZ? ML^EK')_\(7(>M]_XY_\ 7JUI_A4V-_%FZSK/AHW= MIINMRPZR-48?V$;'<;D,_P!XR$=,=J]:^+5S/;?#2\F@FD@E5XOGB+/#6&W!-@P#ZX]:?M$N@N5GD?@G1?[ ^)^EV3G-PVA&>X/]Z1WRQ_E6IX[LYM9 M^*WAS11J=[8VUW97+3?9)BC,%Y_IC.*]+\F+S?-\M/,QMW[1G'IF@PQM,LK1 MJ9%!"N5&0/8U//K!7\0#Q#J;W&G:LME!&UP=@3S,'=_>/UK M0\=ZQ=S>.-1CUO5Y-&BCAB;3BUY-!&,H"6Q'$_F#:6QC,9MXBA;<5 MV#!/KCUHFM+:X(,]O%*0,#>@;'YU7M%?8GD/"/&FL[QIEMJNKW?VU=)66.XM M[R6W@N'R<%-L;,[$8R"%''45:BN-0\1VOP]M;G5[R!KZ&>.>:"8J\@ Q],XX MSCBO;7L[:3;YEO$VP87<@.T>WI2K:VZ[-L$8\O[F$'R_3TI>T5MA\IP?PIDN M83XETB>]GO(M*U5[:"2X[)#'$S&.-4+G*1QT9T!(I*:O<.72 MQX9=Z1/&L[_4K]+%]$6&T:=WE,LF/8]R6T$S*TL,QDM9G-RS%4=BP< GEASDCH"!R:^@!;P@N1$@,GW_E'S M?7UI%M+=(FB2WB6-OO($ !^HH]H+D/)M+N[>+QEX%@\.:I=WVGRV-ZRF>=SY MS!/XLXS@],CBN,;69)K/[:?$&LCQP;[;_9J[A&%W]/+QC&/?\*^C$M;>-D*0 M1*8P0A" ;0>N/2D^R6WG^=]GB\W.=^P;OSH51=A\IX[K>FW>O>./&J7.LZA9 M+IEE:W"06EP442&$'GVRIX'7-9>N^(5O_"OA0:SJ%_#+<6#OYT=V]O'(^XJN M61'9F^7IC\>:]X\B'>[^4FZ08<[1EA[^M-:SM61$:VA*Q_&:#J5SJ5EX!EOKEKB1-6FB5Y&RQ50, D\GK7<_%[4;@>&8-"TR(SW^LSK;Q MPJP!9>K#G@9'&3QS7=+:6R[=MO$-AW+A!\I]1Z4]H8WD5WC5G3[K%02OTI.: MO>P*&\-2)&NJ'5_P"U?M*'$;84IY?WL8 &:^B9;:"<@SPQR$="Z X_.E,,1A\H MQIY>,;-HVX],4_:+>PXKKEMH$962&-60;5(0 J/04Z2*.:,I,BR(>JL,@_A4\ MVJ?8=M&>/Z=#J7ACXA6-O8ZM?:B^J:+->/'=R[PTRCC:.@&:Y33]7:7^R+O2 M_$&LW7C":^5;S3Y-WEHA;YODQ@<>_P"5?17D1>8LGE)O4;5;:,@>@-,6TMDF M,J6\2R'JX0 _G5>T\AIKZ&$,2N[K&@:3[Y M"C+?7UIHM;<(B""(*C;E78,*?4>AH52P])%' M'&(XT5$ P%48 _"F?98!"81!'Y1ZIL&T_A24[,.70^?] UF=="\:VMCJMQ-9 M1:;Y]N[7DDQ4Y W+(R(W?^Z*W-#@O=!\5^$KI-;O[QM:LB]U'V M*]B6RM45@MM"H9=K 1CD>A]J2XL;>XMS$T:K\A164 % 1CY3VINHNPH]*JP:QJ%UXJ:6^\1'3 M->.J;%@NKN=4*;\!!"L)7!S@'?\ XUZ#I/P:ATW4K2:;Q!>7-I9R^;#:F-4P M?=@8P3GZU3J*^A*B[&'=^!M#U'5H]3O;3?!0 45']HA_YZQ_]]"C[1"3@31Y_P!X4 2445G:[J-SI>CS M75C827\ZX"01G!)/H8],_2JY6K^0N9'9T53N=6L+ M._MK*ZNXHKF[)$$3MAI2.N!WK#\4>-+;2/">LZII$MO?7.E866'?D(Y8##8Z M=:23871U%%>?^&?B7_:G@/5=;UBVCM;O2PWG6Z$X/&4Z\_,>*M?#?QIJ7C"# M5/[8L8+.>PN%AV0ENZYYSWIN#5QIK?N_$$L?BC2[&VFTYK*\MVF8R3XF8#H47^)<=31RM#NCH**YRZ\ M>^'(-/U&YAU6UN&T^%I98HY1D8. /Q8A?J13= \>:)KOA9=;-W!:Q(BFY224 M$VS'^%SZT/2KG5;6*_D(" M6[2@.Q/3BH4\8^')-6_LM-:LFOM^S[.)1OW>F/6BS"Z-JBN/\)^(-1U3QCXH ML+V97M]/N5CME" ;%QTR.OXUKZCXO\/:3U3>,S #)*^M8/B/XCZ%H&BSW\=S%?M!<" MW:"&4!M^>5^H&3^%)1;"Z.MHK ?QSX9ATRVO[G6[*&VN@3%(\P ?'7![XK/\ M0?$G0] FT97N(9X=5DPLR3*%BB_YZG_9SQ3Y6^@71U]%&:*87'[W]X,Y=>@4]CWK$]8TVPU%U#7LF'M64+W M*AX5>8 NIZ$5-J7BC0]'FBBU35;6UDF&8UED +#U%*S"Z-6BN MO'L=C\0-? MT_Q%JMM::=:B(6HFVI\S#GGJ:ZW4/$6CZ3817NI:E;6MK, 8Y99 %<$9&#WI MN+071I45P_C7QBUKX2L=5\+:A!*D^HPP&:,+(K(Q.X*O&&G:%H][&VJ6 MMOJWV&2:VAD<;F<(2N%/7D=*.5A='345SW@+5KS7/ VEZCJ<@ENKB$-(X4+D M_0<"NAI-6=AK4****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% ',_$#3=Z*N,W%6)<4SR'P3X(^(6D>+ M[.]\0:RUSI\>_P Z(ZE++NRI ^5A@\D5Z]112E)R=V-*QY/X\^'OC#Q#XON+ M_1=9^RV,D<:I%]JD3!"X/RCCK7._\*>\=M]_Q'_Y-RFO>J*I5))6)<$SEOA[ MX=U+POX9;3]9O!>7'VAI!*'9OE(&!D\]C6WKEC)J?A^_L()/*EN;:2))/[I9 M2 ?UJ]14-MNY5M+'@X^ WB%A^\\21^A^5S_[-5FP^!.L6FI6]T_B*%_)E5]O MDMS@]/O5[?16GM9$^SB%97B2^O=/T&XGTS2Y=5N,;5MHG",V>"29"MOWVD#[WUXKU:BK<[WTW)Y=CR_XFWEW8>//"5UIU@^H MW$3RE+5'"M+QT!/ K!DT/Q7=^&_&]E<>&YH9M7"74!696!;IQDD\=*] M?O-$TZ_U.SU"[M5EN[(DV\I8@QD]> U MD72=5@MSK R,*T1#$-SWP!WKM/ NCW^F>)/&$]]:O!#>ZGYMLS8Q*FW&1[5V MM%)S;5AJ*3N>4WO@F;4?%/C6\O\ 1!<"YMU73Y9%5MS;>=G/!SWXIFE>&M;B MU#PA)=:9.R66DS0W0+ ;&.<(3GC(XXKUFBGSL.5'CGASPIK&-7TU="DM='GT MV:.*+4TBDD29N55'49*[@#SZ ]15*/PIK\WP]TFU/A58IM&O8Y+FS=E']IJH M(+''4_4GK7N%%'M&+D1XS;^%=:O[?Q?JD7AH:&FH:4UI;:7$R[I)-O7"X7FM M'5_!=Q#X#\+6VD:($O(IK26^2%%5]P4;V<]R#GUKU6BCVC#E1Y!_PC>L6'CC M5!-X1M]974-1CN8-5FD %N@8'G^($8XQZ5+X6\3>&M-\$WEMI;:O<:0DRW-M% M*%8>8Q(Y/' ./PJG_P (/K][X$\3QW6BA-1N-12[MH7*L2,Y(5OH2.W>O;Z* M/:,7(CQOQ!IOB"_MM%>U\$K!;+;/$UK"ENTMNQQU\Q&0 D9X7/O6='X*URU\ M">%I)?#GVZ]TK4I9+BR<)ODA+L0N3QM.U>ZT4>T8H0Z4NEV!D889 M0Q+,,9QD #/H:]FHH]HQ\J/&/ ?A74;7Q5I#ZIX=U2PDT^-U^V+);+"QVD\+KW5]$2X-Q9(MG(RAE:3;SLR>#GOQ6:_A;7K M"V\*:E=>&O[>CL-.:VGTJ5US'(6)#8.5Z$#OTKVFBCVC#E1XFO@G7U\%S[=( M-O+>Z]#>)IT+ _9HAG)/./R]*G\3^%M9'BOQ \?A6/6X]9M@EK=LZ_Z$VW&? MF&00>>*]EHH]HPY$ GRAPHIC 18 inbx-20231231_g6.jpg begin 644 inbx-20231231_g6.jpg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end GRAPHIC 19 inbx-20231231_g7.jpg begin 644 inbx-20231231_g7.jpg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end GRAPHIC 20 inbx-20231231_g8.jpg begin 644 inbx-20231231_g8.jpg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

0ZQ=3?\U[[E7/;F.O6JW+*VZW?+\<^%:?U@[1M5 M<-5QU?-8Q_3[KVS^2BGY^/V>RY4 !@HUOST^;++N_P -+Q]BL6HXW;9MVTNX MY2,,1%Y"J[J&,MKNN6%5M-Q54-,Q6VS;O2OK&R\K.-ZKMTZ]!6N0;Z] M(SUI=QRG-OE.MV?V_*4 YIK_ &$[EN$:8F-R/XEJ5H=PRD&Z[!ZZ=NVW,7ZP M ! F L0QI<.B/,HF1^;L9+'M=+MYO83(>VW[[DK-;)>S,.C'WZL;(]K;A MZ*)\*QTRX.SN>2JV#%6^B?T#D]4SU[GUS*)8CYR@^/;KEF/H^?S3XW!WOK,Z MYF+LX6][&W2/9357[YMA?;#V?9]?9:PEBBN\#SF[Q2%:_8?; M[=/E\D>'POC>1_U:?VLV6K#2*OA7[\:_<'3Y >(HLEA+%JJI$0Y6WIN5N>>O MV1]OEVQSEX

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inbx-20231231_g9.jpg begin 644 inbx-20231231_g9.jpg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Ĉ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Ƚ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end XML 22 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Feb. 21, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-39452    
Entity Registrant Name INHIBRX, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 82-4257312    
Entity Address, Address Line One 11025 N. Torrey Pines Road    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town La Jolla    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92037    
City Area Code (858)    
Local Phone Number 795-4220    
Title of 12(b) Security Common Stock, par value $0.0001    
Trading Symbol INBX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction false    
Entity Shell Company false    
Entity Public Float     $ 892.9
Entity Common Stock, Shares Outstanding (in shares)   47,392,447  
Documents Incorporated by Reference
None.
    
Amendment Flag false    
Entity Central Index Key 0001739614    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    

XML 23 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
 12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Firm ID 243
Auditor Name BDO USA, P.C.
Auditor Location San Diego, California
XML 24 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 277,924 $ 273,865
Prepaid expenses and other current assets 16,656 6,371
Total current assets 295,358 280,493
Property and equipment, net 6,419 2,501
Operating right-of-use asset 2,952 4,717
Other non-current assets 3,164 3,164
Total assets 307,893 290,875
Current liabilities:    
Accounts payable 10,954 8,326
Accrued expenses 43,295 17,224
Deferred revenue 0 166
Current portion of lease liability 2,063 1,860
Total current liabilities 56,312 27,576
Long-term debt, including final payment fee 206,968 202,069
Non-current portion of lease liability 1,110 3,173
Total liabilities 264,390 232,818
Commitments and contingencies (Note 9)
Stockholders’ equity:    
Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December 31, 2023 and December 31, 2022 0 0
Common stock, $0.0001 par value, 120,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 47,369,511 and 43,564,283 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively 5 4
Additional paid-in-capital 657,232 430,426
Accumulated deficit (613,734) (372,373)
Total stockholders’ equity 43,503 58,057
Total liabilities and stockholders’ equity 307,893 290,875
Nonrelated Party    
Current assets:    
Accounts receivable 778 243
Related Party    
Current assets:    
Accounts receivable $ 0 $ 14
XML 25 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 15,000,000 15,000,000
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 120,000,000 120,000,000
Common stock, shares issued (in shares) 47,369,511 43,564,283
Common stock, shares outstanding (in shares) 47,369,511 43,564,283
XML 26 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:    
Total revenue $ 1,800 $ 2,192
Operating expenses:    
Research and development 191,640 110,186
General and administrative 29,381 21,123
Total operating expenses 221,021 131,309
Loss from operations (219,221) (129,117)
Other income (expense):    
Interest expense (31,840) (18,181)
Interest income 11,917 2,074
Other income (expense), net (580) 1
Total other expense (20,503) (16,106)
Loss before provision for income taxes (239,724) (145,223)
Provision for income taxes 3 3
Loss from equity method investment 1,634 0
Net loss $ (241,361) $ (145,226)
Net loss per share, basic (in dollars per share) $ (5.12) $ (3.62)
Net loss per share, diluted (in dollars per share) $ (5.12) $ (3.62)
Weighted-average shares of common stock outstanding, basic (in shares) 47,130 40,108
Weighted-average shares of common stock outstanding, diluted (in shares) 47,130 40,108
License fee revenue    
Revenue:    
Total revenue $ 1,800 $ 2,178
Grant revenue    
Revenue:    
Total revenue $ 0 $ 14
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   38,991,000    
Beginning balance at Dec. 31, 2021 $ 52,383 $ 4 $ 279,526 $ (227,147)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense 20,450   20,450  
Issuance of shares upon exercise of stock options (in shares)   241,000    
Issuance of shares upon exercise of stock options 2,757   2,757  
Issuance of shares, net of issuance costs (in shares)   4,332,000    
Issuance of shares, net of issuance costs 126,981   126,981  
Issuance of warrants 712   712  
Net loss $ (145,226)     (145,226)
Ending balance (in shares) at Dec. 31, 2022 43,564,283 43,564,000    
Ending balance at Dec. 31, 2022 $ 58,057 $ 4 430,426 (372,373)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 24,846   24,846  
Issuance of shares upon exercise of stock options (in shares) 184,000 184,000    
Issuance of shares upon exercise of stock options $ 2,316   2,316  
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs (in shares)   3,621,000    
Issuance of common stock and pre-funded warrants in private placement, net of issuance costs 199,645 $ 1 199,644  
Net loss $ (241,361)     (241,361)
Ending balance (in shares) at Dec. 31, 2023 47,369,511 47,369,000    
Ending balance at Dec. 31, 2023 $ 43,503 $ 5 $ 657,232 $ (613,734)
XML 28 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (241,361) $ (145,226)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,191 1,225
Accretion of debt discount and non-cash interest expense 4,899 3,448
Stock-based compensation expense 24,846 20,450
Non-cash lease expense 1,765 1,621
Loss from equity method investment 1,634 0
Non-cash license revenue (1,634) 0
Loss on disposal of fixed assets 3 19
Changes in operating assets and liabilities:    
Accounts receivable (535) 130
Receivables from related parties 14 491
Prepaid expenses and other current assets (10,285) 612
Other non-current assets 0 (1,317)
Accounts payable 2,109 (705)
Accrued expenses 26,071 7,603
Operating lease liability (1,860) (1,674)
Deferred revenue, current portion (166) (1,868)
Deferred revenue, non-current portion 0 (110)
Net cash used in operating activities (193,309) (115,301)
Cash flows from investing activities    
Purchase of fixed assets (4,593) (686)
Net cash used in investing activities (4,593) (686)
Cash flows from financing activities    
Proceeds from issuance of common stock and pre-funded warrants in private placement 200,000 0
Issuance costs associated with issuance of common stock and pre-funded warrants in private placement (355) 0
Proceeds from ATM offering 0 127,371
Costs associated with ATM offering 0 (390)
Proceeds from the issuance of debt 0 128,863
Payment of fees associated with debt 0 (50)
Proceeds from exercise of stock options 2,316 2,757
Net cash provided by financing activities 201,961 258,551
Net increase in cash 4,059 142,564
Cash and cash equivalents at beginning of period 273,865 131,301
Cash and cash equivalents at end of period 277,924 273,865
Supplemental disclosure of cash flow information    
Cash paid for interest 26,717 13,090
Cash paid for income taxes 3 4
Supplemental schedule of non-cash investing and financing activities    
Payable for purchase of fixed assets 519 0
Fair value of warrants issued to lender in conjunction with February 2022 Amendment (as defined in Note 3) $ 0 $ 712
XML 29 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization
Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company’s current pipeline is focused on oncology and orphan diseases.
The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company’s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.
Liquidity
As of December 31, 2023, the Company had an accumulated deficit of $613.7 million and cash and cash equivalents of $277.9 million. From its inception and through December 31, 2023, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities.
In August 2023, the Company received gross proceeds of $200.0 million before deducting $0.4 million of offering expenses payable by the Company in a private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which the Company sold and issued 3,621,314 shares of the Company’s common stock and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock. See Note 4 for further discussion of this equity offering.
The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements.
If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders’ rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises
additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.
The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.
Use of Estimates
The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Fair Value of Financial Instruments
The Company’s financial instruments consist principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity.
Cash and Cash Equivalents
Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep and money market accounts, and highly liquid investments in debt securities with an original maturity of three months or less. The Company’s investments in debt securities have consisted of U.S. Treasury Bills, which were recorded at their amortized cost, reflective of the amortization or accretion of premiums or discounts.
As of December 31, 2023, the Company held no investments in debt securities. As of December 31, 2022, these investments were recorded at their amortized cost of $196.3 million, which was adjusted for the amortization or accretion of premiums or discounts.
Concentrations of Credit Risk
Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has
not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.
The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company’s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December 31, 2023 and December 31, 2022, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.
Dividends
As of December 31, 2023, the Company has never declared or paid any dividends on its common stock.
Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company’s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company’s common stock will be at the discretion of the Company’s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company’s board of directors may deem relevant.
Property and Equipment, Net
Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows:
•laboratory and office equipment: three to five years;
•furniture, fixtures and other: five years; and
•computer software: three years.
Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.
Impairment of Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.
Leases
The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company’s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company’s two existing leases are classified as operating leases.
For the long-term operating lease of its corporate headquarters, the Company recognized an operating right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are
reviewed at inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement.
The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.
Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented.
Investment in Phylaxis
The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company’s proportionate share of the net income or loss of Phylaxis is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions.
The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company’s share of prior losses of the investee. Following the Company’s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company’s investment in Phylaxis as of December 31, 2023 and December 31, 2022 is zero.
Fair Value Measurements
The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include:
•Level 1 - Quoted prices in active markets for identical assets or liabilities.
•Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
During the years ended December 31, 2023 and December 31, 2022, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which are classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which are classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value. As of December 31, 2023, the Company held no investments in debt securities. The Company’s outstanding debt is classified as Level 2 in the fair value hierarchy. As of December 31, 2023 and December 31, 2022, the Company had no financial instruments measured at fair value on a recurring basis.
Deferred Financing Costs and Other Debt-Related Costs
Deferred financing costs are capitalized, recorded as an offset to the Company’s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, Imputation of Interest. If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability.
Deferred Offering Costs
The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering.
Legal, accounting, and filing fees related directly to the Company’s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In October 2022, the Company completed an offering under the Shelf Registration and offset $3.0 million of offering costs against the proceeds. In August 2023, the Company completed a private placement offering, under which the Company offset $0.4 million of offering costs against the proceeds. There were no deferred offering costs as of December 31, 2023 or December 31, 2022.
Financial Instruments with Characteristics of Both Liabilities and Equity
The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 480-10, and ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company’s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company’s outstanding warrants are classified as equity as of and for the years ended December 31, 2023 and December 31, 2022.
Revenue Recognition
The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.
Collaborative Research, Development, and License Agreements
The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2) nonrefundable up-front fees; (3) payments for reimbursement of research costs; (4) payments associated with achieving specific development, regulatory, or commercial milestones; and (5) royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.
Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained
and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs.
The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company’s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.
Grant Revenue
The Company has been awarded a grant from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD, under which the Company’s internal costs specifically covered by the grant for a specified project are subject to reimbursement when incurred. Since there is no transfer of control of goods or services to the granting agency, revenue is recognized as the Company incurs expenses related to the grant in the gross amount of the reimbursement and costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.
Accrued Research and Development and Clinical Trial Costs
Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. The Company’s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as
amended, or IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending finalization, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur ownership changes in the future. If an ownership change occurs, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.
Net Loss Per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common stock equivalents outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive.
The weighted average number of common stock used in the basic and diluted net loss per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.
For purposes of the diluted net loss per share calculation, other than pre-funded warrants as discussed above, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Accordingly, for the years ended December 31, 2023 and December 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, as weighted based on the period outstanding during each year, are as follows (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Outstanding stock options6,336 5,018 
Warrant to purchase common stock47 45 
6,383 5,063 
Fair Value of Stock-Based Awards
The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.
Other Comprehensive Income
The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.
Segment Information
The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting
pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption.
Adoption of New Accounting Pronouncements
In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as held-to-maturity debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. The Company adopted ASU 2016-13 as of January 1, 2023, which did not result in a material impact on its consolidated financial statements and related disclosures.
Recently Issued but Not Yet Adopted Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.
XML 30 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER FINANCIAL INFORMATION
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
OTHER FINANCIAL INFORMATION OTHER FINANCIAL INFORMATION
Prepaid Expense and Other Current Assets
Prepaid expense and other current assets were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Clinical drug substance and product manufacturing (1)
$9,888 $1,171 
Clinical trials (2)
5,409 4,294 
Licenses728 493 
Outside research and development services (3)
265 232 
Other366 181 
Prepaid expense and other current assets$16,656 $6,371 
(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
Property and Equipment, Net
Property and equipment, net were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Machinery and equipment$8,480 $7,023 
Furniture, fixtures and other540 524 
Leasehold improvements441 441 
Computer software53 53 
Construction in process (1)
3,592 — 
Total property and equipment13,106 8,041 
Less: accumulated depreciation and amortization(6,687)(5,540)
Property and equipment, net$6,419 $2,501 
(1) As of December 31, 2023, consists of renovations to the Company’s office space and software not yet placed in service.
Depreciation and amortization expense totaled $1.2 million for each of the years ended December 31, 2023 and December 31, 2022, and consisted of the following (in thousands):
 YEAR ENDED DECEMBER 31,
20232022
Research and development$992 $1,003 
General and administrative199 222 
Total depreciation and amortization expense$1,191 $1,225 
Accrued Expenses
Accrued expenses were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Clinical drug substance and product manufacturing (1)
$22,805 $5,381 
Clinical trials (2)
9,224 4,527 
Compensation expense6,506 3,374 
Interest expense2,348 2,124 
Other outside research and development (3)
1,129 1,164 
Professional fees780 428 
Other503 226 
Accrued expenses$43,295 $17,224 
(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s usage of third-party CROs for management of clinical trials. See Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
XML 31 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
DEBT DEBT
2020 Loan Agreement
In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $10.0 million in gross proceeds, or Term A. The 2020 Loan
Agreement was subsequently amended in November 2020, or the November 2020 Amendment, upon which a second tranche in an aggregate principal amount of $20.0 million was funded, or Term B, and in June 2021, or the June 2021 Amendment, upon which a third tranche in an aggregate principal amount of $40.0 million was funded, or Term C.
In February 2022, the Company entered into an additional amendment, or the February 2022 Amendment, to the 2020 Loan Agreement, collectively, the Amended 2020 Loan Agreement, upon which the Company received gross proceeds of $40.0 million, or Term D. The February 2022 Amendment also provided for an increase in the interest rate and for three future tranches of debt to be funded upon the achievement of certain milestones. In June 2022, the Company received additional gross proceeds of $30.0 million, or Term E, following the initiation of part 4 of the Phase 1 clinical trial of INBRX-105, as well as an additional $30.0 million in gross proceeds, or Term F, following the receipt of positive topline data from the Phase 1 clinical trial of INBRX-101.
In October 2022, the Company entered into an amendment to the Amended 2020 Loan Agreement, or the October 2022 Amendment. The October 2022 Amendment amended the milestone terms of the last remaining tranche, Term G, under the Amended 2020 Loan Agreement to provide for the funding of $30.0 million upon the announcement of the regulatory path for INBRX-101 rather than upon the initiation of a potentially registration-enabling clinical trial of INBRX-101. In October 2022, the Company met this milestone and drew the final tranche for additional gross proceeds of $30.0 million.
The Company determined the November 2020, June 2021, February 2022, and October 2022 Amendments should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flows were not substantially changed upon each of the amendments. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date (as defined below).
As of July 1, 2023, a LIBOR Transition Event, as defined in the Amended 2020 Loan Agreement, occurred, and pursuant to the Amended 2020 Loan Agreement, Oxford selected a LIBOR Replacement Rate, as defined in the Amended 2020 Loan Agreement, replacing the 30 day U.S. Dollar London InterBank Offered Rate with the 1-Month Chicago Mercantile Exchange term secured overnight financing rate, or 1-Month CME Term SOFR, causing an amendment to the interest rate of the Company’s outstanding loans. No other terms were changed. The Company has elected the optional expedient under ASC Topic 848-20 and therefore deemed the modification to not be substantial.
As of December 31, 2023, the Company has $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on January 1, 2027, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) 8.30% or (2) the sum of (i) the 1 Month CME Term SOFR on the last business day of the month that immediately precedes the month in which the interest will accrue, (ii) 0.10%, and (iii) 8.19%. Under the Amended 2020 Loan Agreement, the repayment schedule provides for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. In the event of a qualifying financing event in which the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, the interest-only period may be extended an additional 12 months through February 1, 2026, which would then be followed by 11 months of equal payments of principal plus interest, beginning on March 1, 2026. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final payment of $18.0 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment.
The Company’s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following as of December 31, 2023 and December 31, 2022 (in thousands).
AS OF DECEMBER 31,
20232022
Term A$10,900 $10,900 
Term B21,800 21,800 
Term C43,600 43,600 
Term D43,600 43,600 
Term E32,700 32,700 
Term F32,700 32,700 
Term G32,700 32,700 
Less: debt discount(11,032)(15,931)
Long-term debt, including debt discount and final payment fee$206,968 $202,069 
As of December 31, 2023, and unless extended in accordance with the terms described above, the Company’s interest-only period will continue through February 2025, with principal payments beginning in March 2025. Future principal payments and final fee payments will be made as follows (in thousands):
AS OF DECEMBER 31, 2023
2025$86,956 
2026104,348 
202726,696 
Total future minimum payments218,000 
Less: unamortized debt discount(11,032)
Total debt$206,968 
The Company’s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company’s assets with a positive lien on intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company’s operations, that may require prepayment of the outstanding term loans. Additionally, following the June 2021 Amendment, the Amended 2020 Loan Agreement requires the Company to maintain a minimum cash balance of $20.0 million. As of December 31, 2023, the Company is in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity.
Concurrently with the February 2022 Amendment, the Company issued 40,000 warrants to Oxford to purchase shares of the Company’s common stock at an exercise price of $45.00. Upon issuance, the warrants were classified as equity and recorded at their fair value of $0.7 million. See Note 4 for further discussion of these warrants.
Interest Expense
Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2023, interest expense was $31.8 million, $4.9 million of which related to non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2022, interest expense was $18.2 million, $3.4 million of which related to non-cash amortization of the debt discount and accretion of the final payment.
XML 32 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY STOCKHOLDERS’ EQUITY
Open Market Sale Agreement
In September 2021, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an
aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. Pursuant to the Sales Agreement, the Company paid the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold, which was amended to 2% of the total sales price per share sold during 2022.
During the year ended December 31, 2022, the Company sold 4,332,354 shares pursuant to the Sales Agreement for net proceeds of $127.4 million, after deducting commissions of $2.6 million. In connection with the ATM Offerings during the year ended December 31, 2022, the Company incurred an additional $0.4 million of expenses which were offset against the proceeds of the offering. During the year ended December 31, 2023, the Company did not issue any shares under the Sales Agreement.
Securities Purchase Agreement
In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with the Purchasers, pursuant to which the Company sold and issued 3,621,314 shares of the Company’s common stock for $19.35 per share and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock in the Private Placement. The purchase price of the pre-funded warrants was $19.3499 per pre-funded warrant, with an exercise price of $0.0001 per share. The Company received gross proceeds of $200.0 million from the Private Placement, before deducting $0.4 million of offering expenses payable by the Company. The pre-funded warrants are equity-classified and carried at the instruments’ fair value upon issuance. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement and will expire when exercised in full. As of December 31, 2023, all pre-funded warrants are still outstanding.
Warrants Issued in Connection with Amended 2020 Loan Agreement
As of December 31, 2023, the following equity-classified warrants were outstanding, in addition to the pre-funded warrants discussed above:
Expiration DateShares of Common Stock Issuable Upon Exercise of WarrantsExercise Price per Share
July 15, 2030
7,354
$17.00 
February 18, 2032
40,000
$45.00 
The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity, with no subsequent remeasurements.
Common Stock Reserved for Future Issuance
Common stock reserved for future issuance as of December 31, 2023 and December 31, 2022 consist of the following (in thousands):
AS OF DECEMBER 31,
20232022
Options to purchase common stock issued and outstanding6,494 5,305 
Shares available for future equity grants533 162 
Pre-funded warrants issued and outstanding6,715 — 
Warrants issued and outstanding47 47 
Total common stock reserved for future issuance13,789 5,514 
XML 33 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY COMPENSATION PLAN
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
EQUITY COMPENSATION PLAN EQUITY COMPENSATION PLAN
Stock Incentive Plan
The Company’s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted
and unrestricted stock awards, and other stock-based awards. As of December 31, 2023, an aggregate of 7.8 million shares of common stock were authorized for issuance under the 2017 Plan, of which 0.5 million remain available for issuance.
Stock Option Activity
The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.
A summary of the Company’s stock option activity under its 2017 Plan for the year ended December 31, 2023 is as follows (in thousands, except for per share data and years):
Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (In Years)Aggregate Intrinsic Value
Outstanding as of December 31, 2022
5,305 $22.95 
Granted1,615 $22.98 
Forfeited(242)$23.88 
Exercised(184)$12.59 
Outstanding as of December 31, 2023
6,494 $23.22 7.6$96,548 
Vested and exercisable as of December 31, 2023
3,322 $21.80 6.6$54,101 
The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and December 31, 2022 was $2.1 million and $3.7 million, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and as of December 31, 2023, respectively. The total fair value of stock options vested during the years ended December 31, 2023 and December 31, 2022 was $24.9 million and $25.0 million, respectively.
Stock-Based Compensation Expense
Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company’s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period.
The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2023 and December 31, 2022 were as follows. 
 YEAR ENDED DECEMBER 31,
 20232022
Risk-free interest rate3.77 %2.63 %
Expected volatility84.31 %85.26 %
Expected dividend yield— %— %
Expected term6.086.08
Weighted average fair value$16.88$17.72
The Company determines the assumptions used in the option pricing model in the following manner:
Risk-Free Interest Rate—For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption.
Expected Volatility—Due to the Company’s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company’s market-traded shares best represents its expected volatility.
Expected Dividend—The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock.
Expected Term—The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.
Fair Value—The fair value of the Company’s common stock is determined based on its closing market price on the date of the grant. The Company’s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date.
Stock-based compensation expense for stock options consisted of the following (in thousands):
 YEAR ENDED DECEMBER 31,
20232022
Research and development$16,630 $14,513 
General and administrative8,216 5,937 
Total stock-based compensation expense$24,846 $20,450 
As of December 31, 2023, the Company had $51.8 million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of 2.5 years
XML 34 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND GRANT REVENUES
 12 Months Ended
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]  
LICENSE AND GRANT REVENUES LICENSE AND GRANT REVENUES
The following table summarizes the total revenue recorded in the Company’s consolidated statements of operations (in thousands):
YEAR ENDED DECEMBER 31,
20232022
License fee revenue  
Phylaxis BioScience, LLC$1,634 $1,101 
Chiesi Farmaceutici S.p.A.166 877 
2seventy bio, Inc.— 200 
Total license fee revenue1,800 2,178 
Grant revenue  
Congressionally Directed Medical Research Program— 14 
Total grant revenue— 14 
Total revenue$1,800 $2,192 
License and Collaboration Agreements
Phylaxis Agreements
In July 2020, the Company entered into a joint venture with Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement, or collectively the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. The Company received $5.0 million in nonrefundable, upfront payments from Phylaxis under the Master Services Agreement, or the MSA. In addition, upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company’s intellectual property and know-how. Pursuant to the terms of the Phylaxis Agreements, during the fourth quarter of 2023, the Company received an additional 5% equity interest in Phylaxis following the achievement of a milestone event. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0 million and $175.0 million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.
The Company recognized the initial transaction price of $5.5 million, comprised of the $5.0 million in upfront payments and the fair value of the 10% equity interest of $0.5 million, over the period of performance of development services on the two compounds. During the third quarter of 2022, the Company fulfilled this performance obligation in full and recognized all remaining deferred revenue under this contract.
During the fourth quarter of 2023, the Company transferred a second generation compound to Phylaxis, which was a milestone event under the agreements. Upon transfer, the Company received an additional 5% equity interest in Phylaxis, which has a fair value of $1.6 million. The Company recognized the fair value of the 5% equity interest as revenue and accounted for the investment under the equity method. In order to determine the fair value of the equity interest in Phylaxis upon this milestone, the Company utilized the investee’s independent valuations based on recent financings from third party investors at fair market value.
During the years ended December 31, 2023 and December 31, 2022, the Company recognized $1.6 million and $1.1 million of revenue under the Phylaxis agreements. As of December 31, 2023 and December 31, 2022, the Company had no deferred revenue related to this agreement.
Chiesi
In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and
commercialize INBRX-101 outside of the United States and Canada. Additionally, the Chiesi Option Agreement provided Chiesi with a right of negotiation for INBRX-101 development and commercialization rights in the United States and Canada in the event that the Company engages in discussions with any third parties for such rights during the term of the Chiesi Option Agreement. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019.
The Company identified one performance obligation as of the effective date of the Chiesi Option Agreement, which is to perform research and development services for Chiesi during the option period, which would continue (unless the Chiesi Option Agreement is terminated earlier by Chiesi or the Company) until 60 days following the last to occur of (i) the Company’s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company’s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration, or FDA, scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company’s delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company determined that the option to grant a license in the future is not a material right.
On July 24, 2023, the Company provided a copy of the European Medicines Agency, or EMA, scientific advice to Chiesi upon receipt, which fulfilled the necessary deliverables to Chiesi and triggered the start of its 60-day option period window. On September 18, 2023, the Company was notified that Chiesi declined to exercise its option, resulting in the expiration of the Chiesi Option Agreement (upon the lapse of the option period), and with the Company retaining global rights to develop and commercialize INBRX-101.
The $10.0 million upfront payment was allocated to the single performance obligation. Revenue is recognized over time as services are performed during the option period, based on the Company’s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the years ended December 31, 2023 and December 31, 2022, the Company recognized $0.1 million and $0.9 million in revenue related to this agreement, respectively. As of December 31, 2023, the Company has no deferred revenue related to this agreement. As of December 31, 2022, the Company had $0.1 million current deferred revenue related to this agreement.
2seventy bio, Inc.
In June 2020, the Company entered into an Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. In November 2021, this agreement, or the 2020 2seventy Agreement, was assigned to 2seventy bio, Inc., or 2seventy, in connection with bluebird’s internal restructuring and subsequent spin-out of 2seventy.
In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee of $0.2 million in exchange for a development license. Under each of the three programs, the Company has granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which 2seventy exercises its option, 2seventy will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. As of December 31, 2023, 2seventy has exercised one of its options and declined one of its options as related to the two initial programs, while the third program option remains outstanding.
As of the effective date of the 2020 2seventy Agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company re-assesses its performance obligations and transaction price accordingly.
In June 2022, pursuant to the terms regarding the addition of new programs in the 2020 2seventy Agreement, the Company received a $0.2 million upfront option fee related to the selection of a third program and transferred the related know-how and development license. The Company recognized the $0.2 million of revenue at the point in time in which the program was added and the program term began.
During the year ended December 31, 2022, the Company recognized $0.2 million of revenue related to this agreement. The Company did not recognize any revenue related to this agreement during the year ended December 31, 2023.
Government Grants
Grant revenue was recognized in accordance with the Company’s stated methodology discussed in Note 1.
CDMRP funded through the DoD
In February 2021, the Company was awarded a grant from the DoD in the amount of approximately $0.3 million for the development of sdAb based therapeutics targeting SARS-CoV-2 Spike protein for the treatment of COVID-19, or the 2021 DoD grant. Work under the grant began in February 2021 and continued through February 2022.
Revenue from this grant is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant’s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears.
During the year ended December 31, 2022, $14,000 was recognized as revenue under the grant. All work was completed during the year ended December 31, 2022. No revenue was recognized under the grant during the year ended December 31, 2023.
XML 35 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The components of income tax expense (benefit) were as follows for the years ended December 31, 2023 and December 31, 2022, respectively (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Current expense:
State$3 $3 
Total current expense$3 $3 
The provision for the years ended December 31, 2023 and December 31, 2022 was related to state income taxes.
A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and December 31, 2022 as follows (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Expected income tax benefit at federal statutory rate$(50,684)$(30,497)
State income tax expense (benefit), net of federal benefit(3,568)(2,495)
Permanent items1,524 583 
R&D credits(2,322)(1,261)
Unrecognized tax benefits (FIN 48)1,054 751 
Return to provision true-ups(420)(135)
Valuation allowance54,419 33,057 
Income tax expense$3 $3 
Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
The components of net deferred income taxes were as follows (in thousands):
AS OF DECEMBER 31,
 20232022
Deferred income tax assets 
Net operating loss carryforward$68,254 $52,970 
Research and development credits12,648 9,728 
Intangibles3,289 3,684 
Accruals1,412 696 
Stock compensation8,581 5,130 
Capitalized research and development costs51,772 19,585 
Deferred revenue— 37 
Operating lease liabilities697 1,118 
Other10 — 
Gross deferred tax assets146,663 92,948 
Less: Valuation allowance(146,005)(91,586)
Total deferred tax assets658 1,362 
Deferred income tax liabilities 
Fixed assets(10)(35)
Operating lease right-of-use assets(648)(1,048)
Other— (279)
Total deferred tax liabilities(658)(1,362)
Net deferred tax assets (liabilities)$— $— 
As of December 31, 2023, the Company had unused federal and state NOL carryforwards of approximately $305.1 million and $65.3 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to
expire in 2038, if not utilized. As of December 31, 2023, the Company also had federal and state research tax credit carryforwards of $12.4 million and $6.2 million, respectively. The federal research tax credit carryforwards begin to expire in 2038, while the state carryforwards have no expiration.
The utilization of NOL and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending the finalization of the study, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur additional ownership changes in the future. If an ownership change has occurred, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.
The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2023. Such objective evidence limits the ability to consider other subjective evidence such as the Company’s projections for future growth. Based on this evaluation, as of December 31, 2023, a valuation allowance of $146.0 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company’s projections for growth.
The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes.
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):
AS OF DECEMBER 31,
 20232022
Beginning balance$3,597 $2,846 
Increases related to current year tax positions1,054 751 
Ending balance$4,651 $3,597 
As of December 31, 2023, the Company had gross unrecognized tax benefits of $4.7 million, none of which would affect the effective tax rate due to the existence of a full valuation allowance. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company’s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December 31, 2023 or December 31, 2022, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2023 and December 31, 2022 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced.
The Company is subject to income taxes in the United States and various state jurisdictions. The Company’s tax years from 2019 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority.
XML 36 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
LEASES LEASES
Operating Leases
In September 2017, the Company entered into a seven-year lease agreement as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years, which is not included in the right-of-use asset and lease liabilities. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually.
In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually.
The operating right-of-use asset and operating lease liability as of December 31, 2023 and December 31, 2022 are as follows (in thousands):
AS OF DECEMBER 31,
20232022
Operating right-of-use asset$2,952 $4,717 
Operating lease liability
Current2,063 1,860 
Non-current1,110 3,173 
Total operating lease liability$3,173 $5,033 
During the years ended December 31, 2023 and December 31, 2022, the Company recognized operating lease expense of $3.7 million and $3.4 million, respectively. During each of the years ended December 31, 2023 and December 31, 2022, the Company paid $2.2 million for amounts included in the measurement of the operating lease liability in each period.
As of December 31, 2023 and December 31, 2022, the Company’s operating lease had a remaining term of 1.5 and 2.5 years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% as of December 31, 2023 and December 31, 2022.
Future minimum rental commitments for the Company’s operating leases reconciled to the operating lease liability are as follows (in thousands):
AS OF DECEMBER 31,
2023
2024$2,247 
20251,137 
Total future minimum lease payments$3,384 
Less: imputed interest(211)
Present value of operating lease liability3,173 
Less: current portion of operating lease liability(2,063)
Non-current portion of operating lease liability$1,110 
XML 37 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Litigation
Other than as described below, the Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.
I-Mab Litigation
On March 1, 2022, I-Mab Biopharma, or I-Mab, filed a lawsuit against the Company and Brendan Eckelman, the Company’s co-founder and Chief Scientific Officer, in the United States District Court for the District of Delaware, C.A. No. 22-00276-CJB, asserting claims for misappropriation of trade secrets related to Dr. Eckelman’s service as an expert witness for Tracon Pharmaceuticals, Inc., or Tracon, in Tracon’s arbitration against I-Mab. The case is currently in the discovery process.
Inhibrx is unable to reasonably estimate possible damages or a range of possible damages in this matter given the uncertainty and therefore has not recorded a liability on its books as of December 31, 2023.
Indemnification
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company’s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.
Purchase Commitments
The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of December 31, 2023 and December 31, 2022, the noncancellable portion of these contracts total in aggregate, excluding amounts paid or incurred at each
respective date, approximately $62.8 million and $74.8 million, respectively. The noncancellable purchase commitments as of December 31, 2023 relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101. During the years ended December 31, 2023 and December 31, 2022, the Company incurred $44.5 million and $0.3 million of expenses related to its non-cancellable purchase agreements, respectively.
Other Commitments
Additionally, as of December 31, 2023 and December 31, 2022, Mark P. Lappe, the Company’s Chief Executive Officer, Brendan P. Eckelman, the Company’s Chief Scientific Officer, and Kelly D. Deck, the Company’s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control.
Contingencies
In connection with its proposed Merger (as defined below), the Company engaged legal counsel under a contingent fee arrangement. Under this agreement, the Company is obligated to pay a fee of $20.0 million, contingent upon the consummation of the proposed transaction. In the event the Merger is not completed, the Company does not owe any fees to its legal counsel. The Company will incur these costs in full upon the consummation of the Merger, if and when it is completed, and has not incurred any portion of this fee as of December 31, 2023.
XML 38 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
The Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.
Merger and Spin-Off
On January 22, 2024, the Company, Aventis Inc., or Parent, a wholly owned indirect subsidiary of Sanofi, and Art Acquisition Sub, Inc., or the Merger Sub, a wholly owned subsidiary of Parent, entered into an Agreement and Plan of Merger, or the Merger Agreement. Pursuant to the terms of the Merger Agreement, Parent will acquire all outstanding shares of the Company via the merger of Merger Sub with and into the Company, or the Merger, with the Company surviving the Merger as a wholly owned subsidiary of Parent, and in turn each shareholder will receive (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx Biosciences, Inc., or New Inhibrx, for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Parent will (1) assume and retire the Company’s outstanding third-party debt, (2) cause New Inhibrx to be funded with $200.0 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%.
In connection with and as a condition to the Merger, the Company and New Inhibrx entered into a Separation and Distribution Agreement, dated as of January 22, 2024, or the Separation and Distribution Agreement, pursuant to which, immediately prior to the effective time of the Merger: (i) the Company will effect a pre-closing reorganization, which will result in (x) the Company owning, assuming or retaining all assets and liabilities primarily related to INBRX-101, or the 101 Business, and (y) New Inhibrx owning, assuming or retaining all other assets and liabilities of the Company and its subsidiaries; and (ii) thereafter, the Company will distribute to its stockholders as of the record date on a pro rata basis, 92% of the issued and outstanding shares of New Inhibrx common stock, at a ratio of one share of New Inhibrx common stock for every four shares of the Company’s issued and outstanding common stock held on the record date. Following the spin-off, New Inhibrx will be a separate public company and the Company will retain 8% of the issued and outstanding shares of New Inhibrx common stock as of the effective time of the spin-off.
The boards of directors of both the Company and Sanofi have unanimously approved the spin-off and the Merger. Parent will pay transaction consideration totaling approximately $2.2 billion in aggregate value. Parent will also make payments at the closing of the Merger to settle the Company’s third-party debt. Following the closing of the Merger, New Inhibrx will continue to operate under the Inhibrx name. Parent’s acquisition of the Company is subject to the completion of the New Inhibrx spin-off transaction and other customary closing conditions, including
receipt of regulatory approvals and approval by the Company’s shareholders. The companies currently expect the transaction to close in the second quarter of 2024.
The Merger Agreement contains certain termination rights for each of the Company and Parent. Upon termination of the Merger Agreement in accordance with its terms, under certain circumstances, the Company will be required to pay Parent a termination fee in an amount equal to $54.5 million, including if the Merger Agreement is terminated due to (i) the Company accepting a Superior Proposal (as defined in the Merger Agreement) or (ii) the Board changing its recommendation that stockholders vote to approve the Merger Agreement. This termination fee will also be payable by the Company if the Merger Agreement is terminated under certain circumstances and prior to such termination, a proposal to acquire the 101 Business or more than 50% of the Company’s stock or assets is made or publicly announced and not publicly withdrawn and the Company enters into a definitive agreement for, or completes, any transaction involving the acquisition of the 101 Business or more than 50% of its stock or assets within twelve months of such termination. The Merger Agreement also provides that Parent will be required to pay the Company a reverse termination fee of $92.1 million if the Merger is not consummated due to the failure of certain conditions to be satisfied as a result of failure to obtain antitrust clearance.
XML 39 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure    
Net loss $ (241,361) $ (145,226)
XML 40 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 41 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K.
Principles of Consolidation
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation.
Liquidity
Liquidity
As of December 31, 2023, the Company had an accumulated deficit of $613.7 million and cash and cash equivalents of $277.9 million. From its inception and through December 31, 2023, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities.
In August 2023, the Company received gross proceeds of $200.0 million before deducting $0.4 million of offering expenses payable by the Company in a private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which the Company sold and issued 3,621,314 shares of the Company’s common stock and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock. See Note 4 for further discussion of this equity offering.
The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements.
If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders’ rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises
additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.
The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities.
Use of Estimates
Use of Estimates
The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company’s financial instruments consist principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep and money market accounts, and highly liquid investments in debt securities with an original maturity of three months or less. The Company’s investments in debt securities have consisted of U.S. Treasury Bills, which were recorded at their amortized cost, reflective of the amortization or accretion of premiums or discounts.
Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has
not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held.
The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company’s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties.
Dividends
Dividends
As of December 31, 2023, the Company has never declared or paid any dividends on its common stock.
Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company’s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company’s common stock will be at the discretion of the Company’s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company’s board of directors may deem relevant.
Property and Equipment, Net
Property and Equipment, Net
Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows:
•laboratory and office equipment: three to five years;
•furniture, fixtures and other: five years; and
•computer software: three years.
Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements.
Leases
Leases
The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company’s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company’s two existing leases are classified as operating leases.
For the long-term operating lease of its corporate headquarters, the Company recognized an operating right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are
reviewed at inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement.
The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.
Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented.
Investment in Phylaxis
Investment in Phylaxis
The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company’s proportionate share of the net income or loss of Phylaxis is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions.
The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company’s share of prior losses of the investee. Following the Company’s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations.
Fair Value Measurements
Fair Value Measurements
The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include:
•Level 1 - Quoted prices in active markets for identical assets or liabilities.
•Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
•Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
During the years ended December 31, 2023 and December 31, 2022, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which are classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which are classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value.
Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs
Deferred Financing Costs and Other Debt-Related Costs
Deferred financing costs are capitalized, recorded as an offset to the Company’s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, Imputation of Interest. If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability.
Deferred Offering Costs
The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering.
Legal, accounting, and filing fees related directly to the Company’s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In October 2022, the Company completed an offering under the Shelf Registration and offset $3.0 million of offering costs against the proceeds. In August 2023, the Company completed a private placement offering, under which the Company offset $0.4 million of offering costs against the proceeds.
Financial Instruments with Characteristics of Both Liabilities and Equity
Financial Instruments with Characteristics of Both Liabilities and Equity
The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 480-10, and ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company’s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company’s outstanding warrants are classified as equity as of and for the years ended December 31, 2023 and December 31, 2022.
Revenue Recognition
Revenue Recognition
The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.
Collaborative Research, Development, and License Agreements
The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2) nonrefundable up-front fees; (3) payments for reimbursement of research costs; (4) payments associated with achieving specific development, regulatory, or commercial milestones; and (5) royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.
Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained
and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs.
The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company’s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.
Grant Revenue
The Company has been awarded a grant from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD, under which the Company’s internal costs specifically covered by the grant for a specified project are subject to reimbursement when incurred. Since there is no transfer of control of goods or services to the granting agency, revenue is recognized as the Company incurs expenses related to the grant in the gross amount of the reimbursement and costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.
Accrued Research and Development and Clinical Trial Costs
Accrued Research and Development and Clinical Trial Costs
Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. The Company’s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.
Income Taxes
Income Taxes
Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as
amended, or IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending finalization, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur ownership changes in the future. If an ownership change occurs, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect.
Net Loss Per Share
Net Loss Per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common stock equivalents outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive.
The weighted average number of common stock used in the basic and diluted net loss per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.
For purposes of the diluted net loss per share calculation, other than pre-funded warrants as discussed above, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Accordingly, for the years ended December 31, 2023 and December 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.
Fair Value of Stock-Based Awards
Fair Value of Stock-Based Awards
The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur.
Other Comprehensive Income
Other Comprehensive Income
The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented.
Segment Information
Segment Information
The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting
pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption.
Adoption of New Accounting Pronouncements
In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as held-to-maturity debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. The Company adopted ASU 2016-13 as of January 1, 2023, which did not result in a material impact on its consolidated financial statements and related disclosures.
Recently Issued but Not Yet Adopted Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.
XML 42 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, as weighted based on the period outstanding during each year, are as follows (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Outstanding stock options6,336 5,018 
Warrant to purchase common stock47 45 
6,383 5,063 
XML 43 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER FINANCIAL INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Prepaid Expense and Other Current Assets
Prepaid expense and other current assets were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Clinical drug substance and product manufacturing (1)
$9,888 $1,171 
Clinical trials (2)
5,409 4,294 
Licenses728 493 
Outside research and development services (3)
265 232 
Other366 181 
Prepaid expense and other current assets$16,656 $6,371 
(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
Schedule of Property and Equipment
Property and equipment, net were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Machinery and equipment$8,480 $7,023 
Furniture, fixtures and other540 524 
Leasehold improvements441 441 
Computer software53 53 
Construction in process (1)
3,592 — 
Total property and equipment13,106 8,041 
Less: accumulated depreciation and amortization(6,687)(5,540)
Property and equipment, net$6,419 $2,501 
(1) As of December 31, 2023, consists of renovations to the Company’s office space and software not yet placed in service.
Depreciation and amortization expense totaled $1.2 million for each of the years ended December 31, 2023 and December 31, 2022, and consisted of the following (in thousands):
 YEAR ENDED DECEMBER 31,
20232022
Research and development$992 $1,003 
General and administrative199 222 
Total depreciation and amortization expense$1,191 $1,225 
Schedule of Accrued Expenses
Accrued Expenses
Accrued expenses were comprised of the following (in thousands):
AS OF DECEMBER 31,
20232022
Clinical drug substance and product manufacturing (1)
$22,805 $5,381 
Clinical trials (2)
9,224 4,527 
Compensation expense6,506 3,374 
Interest expense2,348 2,124 
Other outside research and development (3)
1,129 1,164 
Professional fees780 428 
Other503 226 
Accrued expenses$43,295 $17,224 
(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See Note 1 for further discussion of the components of research and development.
(2) Relates primarily to the Company’s usage of third-party CROs for management of clinical trials. See Note 1 for further discussion of the components of research and development.
(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.
XML 44 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
The Company’s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following as of December 31, 2023 and December 31, 2022 (in thousands).
AS OF DECEMBER 31,
20232022
Term A$10,900 $10,900 
Term B21,800 21,800 
Term C43,600 43,600 
Term D43,600 43,600 
Term E32,700 32,700 
Term F32,700 32,700 
Term G32,700 32,700 
Less: debt discount(11,032)(15,931)
Long-term debt, including debt discount and final payment fee$206,968 $202,069 
Schedule of Maturities of Long-term Debt Future principal payments and final fee payments will be made as follows (in thousands):
AS OF DECEMBER 31, 2023
2025$86,956 
2026104,348 
202726,696 
Total future minimum payments218,000 
Less: unamortized debt discount(11,032)
Total debt$206,968 
XML 45 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Warrants Issued
As of December 31, 2023, the following equity-classified warrants were outstanding, in addition to the pre-funded warrants discussed above:
Expiration DateShares of Common Stock Issuable Upon Exercise of WarrantsExercise Price per Share
July 15, 2030
7,354
$17.00 
February 18, 2032
40,000
$45.00 
Schedule of Common Stock Reserved For Future Issuance
Common stock reserved for future issuance as of December 31, 2023 and December 31, 2022 consist of the following (in thousands):
AS OF DECEMBER 31,
20232022
Options to purchase common stock issued and outstanding6,494 5,305 
Shares available for future equity grants533 162 
Pre-funded warrants issued and outstanding6,715 — 
Warrants issued and outstanding47 47 
Total common stock reserved for future issuance13,789 5,514 
XML 46 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY COMPENSATION PLAN (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Options Activity
A summary of the Company’s stock option activity under its 2017 Plan for the year ended December 31, 2023 is as follows (in thousands, except for per share data and years):
Number of SharesWeighted Average Exercise PriceWeighted Average Remaining Contractual Term (In Years)Aggregate Intrinsic Value
Outstanding as of December 31, 2022
5,305 $22.95 
Granted1,615 $22.98 
Forfeited(242)$23.88 
Exercised(184)$12.59 
Outstanding as of December 31, 2023
6,494 $23.22 7.6$96,548 
Vested and exercisable as of December 31, 2023
3,322 $21.80 6.6$54,101 
Schedule of Weighted-Average Assumptions Used to Estimate Fair Value
The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2023 and December 31, 2022 were as follows. 
 YEAR ENDED DECEMBER 31,
 20232022
Risk-free interest rate3.77 %2.63 %
Expected volatility84.31 %85.26 %
Expected dividend yield— %— %
Expected term6.086.08
Weighted average fair value$16.88$17.72
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense for stock options consisted of the following (in thousands):
 YEAR ENDED DECEMBER 31,
20232022
Research and development$16,630 $14,513 
General and administrative8,216 5,937 
Total stock-based compensation expense$24,846 $20,450 
XML 47 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND GRANT REVENUES (Tables)
 12 Months Ended
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]  
Schedule of License and Grant Revenue
The following table summarizes the total revenue recorded in the Company’s consolidated statements of operations (in thousands):
YEAR ENDED DECEMBER 31,
20232022
License fee revenue  
Phylaxis BioScience, LLC$1,634 $1,101 
Chiesi Farmaceutici S.p.A.166 877 
2seventy bio, Inc.— 200 
Total license fee revenue1,800 2,178 
Grant revenue  
Congressionally Directed Medical Research Program— 14 
Total grant revenue— 14 
Total revenue$1,800 $2,192 
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Tax Expense (Benefit)
The components of income tax expense (benefit) were as follows for the years ended December 31, 2023 and December 31, 2022, respectively (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Current expense:
State$3 $3 
Total current expense$3 $3 
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and December 31, 2022 as follows (in thousands):
YEAR ENDED DECEMBER 31,
20232022
Expected income tax benefit at federal statutory rate$(50,684)$(30,497)
State income tax expense (benefit), net of federal benefit(3,568)(2,495)
Permanent items1,524 583 
R&D credits(2,322)(1,261)
Unrecognized tax benefits (FIN 48)1,054 751 
Return to provision true-ups(420)(135)
Valuation allowance54,419 33,057 
Income tax expense$3 $3 
Schedule of Deferred Tax Assets and Liabilities
The components of net deferred income taxes were as follows (in thousands):
AS OF DECEMBER 31,
 20232022
Deferred income tax assets 
Net operating loss carryforward$68,254 $52,970 
Research and development credits12,648 9,728 
Intangibles3,289 3,684 
Accruals1,412 696 
Stock compensation8,581 5,130 
Capitalized research and development costs51,772 19,585 
Deferred revenue— 37 
Operating lease liabilities697 1,118 
Other10 — 
Gross deferred tax assets146,663 92,948 
Less: Valuation allowance(146,005)(91,586)
Total deferred tax assets658 1,362 
Deferred income tax liabilities 
Fixed assets(10)(35)
Operating lease right-of-use assets(648)(1,048)
Other— (279)
Total deferred tax liabilities(658)(1,362)
Net deferred tax assets (liabilities)$— $— 
Schedule of Unrecognized Tax Benefits Roll Forward
The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands):
AS OF DECEMBER 31,
 20232022
Beginning balance$3,597 $2,846 
Increases related to current year tax positions1,054 751 
Ending balance$4,651 $3,597 
XML 49 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES (Tables)
 12 Months Ended
Dec. 31, 2023
Leases [Abstract]  
Schedule of Operating Lease, by Balance Sheet Location
The operating right-of-use asset and operating lease liability as of December 31, 2023 and December 31, 2022 are as follows (in thousands):
AS OF DECEMBER 31,
20232022
Operating right-of-use asset$2,952 $4,717 
Operating lease liability
Current2,063 1,860 
Non-current1,110 3,173 
Total operating lease liability$3,173 $5,033 
Schedule of Operating Lease Maturity
Future minimum rental commitments for the Company’s operating leases reconciled to the operating lease liability are as follows (in thousands):
AS OF DECEMBER 31,
2023
2024$2,247 
20251,137 
Total future minimum lease payments$3,384 
Less: imputed interest(211)
Present value of operating lease liability3,173 
Less: current portion of operating lease liability(2,063)
Non-current portion of operating lease liability$1,110 
XML 50 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2023
USD ($)
shares
Dec. 31, 2023
USD ($)
lease
Dec. 31, 2023
USD ($)
segment
lease
Dec. 31, 2022
USD ($)
Oct. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Jul. 31, 2020
USD ($)
Property, Plant and Equipment [Line Items]              
Accumulated deficit   $ 613,734,000 $ 613,734,000 $ 372,373,000      
Cash and cash equivalents   277,924,000 277,924,000 273,865,000      
Proceeds from issuance of common stock and pre-funded warrants in private placement     355,000 0      
Debt securities, amortized cost   $ 0 $ 0 196,300,000      
Number of operating leases held | lease   2 2        
Deferred offering costs   $ 0 $ 0 0 $ 3,000,000    
Number of operating segments | segment     1        
Phylaxis BioScience, LLC              
Property, Plant and Equipment [Line Items]              
Equity interest percentage (as a percent)   15.00% 15.00%       10.00%
Equity method investment   $ 0 $ 0 $ 0   $ 0 $ 500,000
Equity method investment, ownership percentage, increase during period (as a percent)   5.00%          
Furniture, fixtures and other              
Property, Plant and Equipment [Line Items]              
Property and equipment useful life (in years)   5 years 5 years        
Computer software              
Property, Plant and Equipment [Line Items]              
Property and equipment useful life (in years)   3 years 3 years        
Minimum | Machinery and equipment              
Property, Plant and Equipment [Line Items]              
Property and equipment useful life (in years)   3 years 3 years        
Maximum | Machinery and equipment              
Property, Plant and Equipment [Line Items]              
Property and equipment useful life (in years)   5 years 5 years        
Private Placement              
Property, Plant and Equipment [Line Items]              
Sale of stock, proceeds received $ 200,000,000            
Proceeds from issuance of common stock and pre-funded warrants in private placement $ 400,000            
Sale of stock, shares issued/sold (in shares) | shares 3,621,314            
Private Placement | Warrants, Pre-Funded              
Property, Plant and Equipment [Line Items]              
Shares of common stock issuable upon exercise of warrants (in shares) | shares 6,714,636            
XML 51 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Antidilutive securities excluded from earnings per share computation (in shares) 6,383 5,063
Outstanding stock options    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Antidilutive securities excluded from earnings per share computation (in shares) 6,336 5,018
Warrant to purchase common stock    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Antidilutive securities excluded from earnings per share computation (in shares) 47 45
XML 52 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Clinical drug substance and product manufacturing $ 9,888 $ 1,171
Clinical trials 5,409 4,294
Licenses 728 493
Outside research and development services 265 232
Other 366 181
Prepaid expense and other current assets $ 16,656 $ 6,371
XML 53 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER FINANCIAL INFORMATION - Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 13,106 $ 8,041
Less: accumulated depreciation and amortization (6,687) (5,540)
Property and equipment, net 6,419 2,501
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 8,480 7,023
Furniture, fixtures and other    
Property, Plant and Equipment [Line Items]    
Total property and equipment 540 524
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 441 441
Computer software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 53 53
Construction in process    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 3,592 $ 0
XML 54 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Depreciation and amortization $ 1,191 $ 1,225
Research and development    
Property, Plant and Equipment [Line Items]    
Depreciation and amortization 992 1,003
General and administrative    
Property, Plant and Equipment [Line Items]    
Depreciation and amortization $ 199 $ 222
XML 55 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
OTHER FINANCIAL INFORMATION - Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Clinical drug substance and product manufacturing $ 22,805 $ 5,381
Clinical trials 9,224 4,527
Compensation expense 6,506 3,374
Interest expense 2,348 2,124
Other outside research and development 1,129 1,164
Professional fees 780 428
Other 503 226
Accrued expenses $ 43,295 $ 17,224
XML 56 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Narrative (Details)
$ / shares in Units, shares in Thousands
 1 Months Ended 12 Months Ended
Oct. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Feb. 28, 2022
USD ($)
tranche
$ / shares
shares
Jun. 30, 2021
USD ($)
Nov. 30, 2020
USD ($)
Jul. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]                
Proceeds from the issuance of debt             $ 0 $ 128,863,000
Reclassification of warrant liabilities into equity               712,000
2020 Loan Agreement | Secured Debt                
Debt Instrument [Line Items]                
Total long-term debt             $ 200,000,000  
Annual interest rate (as a percent)             8.30%  
Equal payments of principal and interest period if interest only period is extended (in months)             23 months  
Upfront licensing or partnership proceeds raised             $ 100,000,000  
Equal payments of principal period if interest only period is extended (in months)             11 months  
Percentage of principal amount for final payment (as a percent)             9.00%  
Periodic payment terms, final payment amount             $ 18,000,000  
Minimum cash balance             20,000,000  
Debt interest expense             31,800,000 18,200,000
Amortization of debt discount and accretion             $ 4,900,000 3,400,000
2020 Loan Agreement | Secured Debt | Warrants Issued Concurrently With 2022 Loan Agreement                
Debt Instrument [Line Items]                
Warrants issued (in shares) | shares     40          
Warrant price (in dollars per share) | $ / shares     $ 45.00          
Reclassification of warrant liabilities into equity     $ 700,000          
2020 Loan Agreement | Secured Debt | Minimum                
Debt Instrument [Line Items]                
Prepayment fee (as a percent)             1.00%  
2020 Loan Agreement | Secured Debt | Maximum                
Debt Instrument [Line Items]                
Prepayment fee (as a percent)             3.00%  
2020 Loan Agreement | Secured Debt | Secured Overnight Financing Rate (SOFR) | Debt Instrument Rate One                
Debt Instrument [Line Items]                
Basis spread on variable rate (as a percent)             0.10%  
2020 Loan Agreement | Secured Debt | Secured Overnight Financing Rate (SOFR) | Debt Instrument Rate Two                
Debt Instrument [Line Items]                
Basis spread on variable rate (as a percent)             8.19%  
2020 Term A | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt           $ 10,000,000    
Total long-term debt             $ 10,900,000 10,900,000
2020 Term B | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt         $ 20,000,000      
Total long-term debt             21,800,000 21,800,000
2020 Term C | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt       $ 40,000,000        
Total long-term debt             43,600,000 43,600,000
2020 Term D | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt     $ 40,000,000          
Number of additional tranches available upon contingent events | tranche     3          
Total long-term debt             43,600,000 43,600,000
2020 Term E | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt   $ 30,000,000            
Total long-term debt             32,700,000 32,700,000
2020 Term F | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt   $ 30,000,000            
Total long-term debt             32,700,000 32,700,000
2020 Term G | Secured Debt                
Debt Instrument [Line Items]                
Proceeds from the issuance of debt $ 30,000,000              
Term loan aggregate amount $ 30,000,000              
Total long-term debt             $ 32,700,000 $ 32,700,000
XML 57 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details) - Secured Debt - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
2020 Loan Agreement    
Debt Instrument [Line Items]    
Term loan $ 218,000  
Less: debt discount (11,032) $ (15,931)
Total debt 206,968 202,069
2020 Term A    
Debt Instrument [Line Items]    
Term loan 10,900 10,900
2020 Term B    
Debt Instrument [Line Items]    
Term loan 21,800 21,800
2020 Term C    
Debt Instrument [Line Items]    
Term loan 43,600 43,600
2020 Term D    
Debt Instrument [Line Items]    
Term loan 43,600 43,600
2020 Term E    
Debt Instrument [Line Items]    
Term loan 32,700 32,700
2020 Term F    
Debt Instrument [Line Items]    
Term loan 32,700 32,700
2020 Term G    
Debt Instrument [Line Items]    
Term loan $ 32,700 $ 32,700
XML 58 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Future Minimum Payments (Details) - 2020 Loan Agreement - Secured Debt - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
2025 $ 86,956  
2026 104,348  
2027 26,696  
Total future minimum payments 218,000  
Less: unamortized debt discount (11,032) $ (15,931)
Total debt $ 206,968 $ 202,069
XML 59 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Aug. 31, 2023
Sep. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Costs associated with the ATM offering     $ 0 $ 390
Proceeds from issuance of common stock and pre-funded warrants in private placement     $ 355 $ 0
Sales Agreement        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Aggregate offering price   $ 200,000    
Commission (as a percent)   3.00%   2.00%
Sale of stock, shares issued/sold (in shares)     0 4,332,354
Sale of stock, proceeds received       $ 127,400
Costs associated with the ATM offering       2,600
Costs associated with the ATM offering, additional       $ 400
Private Placement        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Sale of stock, shares issued/sold (in shares) 3,621,314      
Sale of stock, proceeds received $ 200,000      
Sale of stock, price per share (in dollars per share) $ 19.35      
Proceeds from issuance of common stock and pre-funded warrants in private placement $ 400      
Private Placement | Warrants, Pre-Funded        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares of common stock issuable upon exercise of warrants (in shares) 6,714,636      
Purchase price (in dollars per share) $ 19.3499      
Exercise price (in dollars per share) $ 0.0001      
XML 60 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY - Warrants Issued in Connection with Amended 2020 Loan Agreement (Details)
Dec. 31, 2023
$ / shares
shares
July 15, 2030  
Class of Warrant or Right [Line Items]  
Shares of Common Stock Issuable Upon Exercise of Warrants (in shares) | shares 7,354
Exercise Price per Share (in dollars per share) | $ / shares $ 17.00
February 18, 2032  
Class of Warrant or Right [Line Items]  
Shares of Common Stock Issuable Upon Exercise of Warrants (in shares) | shares 40,000
Exercise Price per Share (in dollars per share) | $ / shares $ 45.00
XML 61 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCKHOLDERS’ EQUITY - Common Stock Reserved for Future Issuance (Details) - shares
shares in Thousands
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 13,789 5,514
Options to purchase common stock issued and outstanding    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 6,494 5,305
Shares available for future equity grants    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 533 162
Pre-funded warrants issued and outstanding    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 6,715 0
Warrants issued and outstanding    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock reserved for issuance (in shares) 47 47
XML 62 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY COMPENSATION PLAN - Narrative (Details) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares authorized (in shares) 7.8  
Available shares reserved for issuance (in shares) 0.5  
Aggregate intrinsic value of options exercised $ 2.1 $ 3.7
Total fair value of stock options $ 24.9 $ 25.0
Stock Option    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period (in years) 4 years  
Contractual term (in years) 10 years  
Unrecognized stock-based compensation expense $ 51.8  
Weighted-average period of recognition (in years) 2 years 6 months  
Stock Option | Cliff Vesting    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Vesting period (in years) 1 year  
XML 63 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY COMPENSATION PLAN - Stock Option Activity (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Number of Shares  
Outstanding, beginning balance (in shares) | shares 5,305
Granted (in shares) | shares 1,615
Forfeited (in shares) | shares (242)
Exercised (in shares) | shares (184)
Outstanding, ending balance (in shares) | shares 6,494
Vested and exercisable (in shares) | shares 3,322
Weighted Average Exercise Price  
Outstanding, beginning balance (in dollars per share) | $ / shares $ 22.95
Granted (in dollars per share) | $ / shares 22.98
Forfeited (in dollars per share) | $ / shares 23.88
Exercised (in dollars per share) | $ / shares 12.59
Outstanding, ending balance (in dollars per share) | $ / shares 23.22
Vested and exercisable (in dollars per share) | $ / shares $ 21.80
Weighted Average Remaining Contractual Term (in years) 7 years 7 months 6 days
Weighted Average Remaining Contractual Term, Vested and Exercisable (in years) 6 years 7 months 6 days
Aggregate Intrinsic Value | $ $ 96,548
Aggregate Intrinsic Value, Vested and Exercisable | $ $ 54,101
XML 64 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY COMPENSATION PLAN - Fair Value of Stock Option Grants (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average fair value (in dollars per share) $ 16.88 $ 17.72
Stock Option    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate (as a percent) 3.77% 2.63%
Expected volatility (as a percent) 84.31% 85.26%
Expected dividend yield (as a percent) 0.00% 0.00%
Expected term (in years) 6 years 29 days 6 years 29 days
XML 65 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY COMPENSATION PLAN - Stock-based Compensation Expense (Details) - Stock Option - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 24,846 $ 20,450
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 16,630 14,513
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 8,216 $ 5,937
XML 66 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND GRANT REVENUES - Revenue Summary (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue $ 1,800,000 $ 2,192,000
License fee revenue    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue 1,800,000 2,178,000
License fee revenue | Phylaxis BioScience, LLC    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue 1,634,000 1,101,000
License fee revenue | Chiesi Farmaceutici S.p.A.    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue 166,000 877,000
License fee revenue | 2seventy bio, Inc.    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue 0 200,000
Grant revenue    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue 0 14,000
Grant revenue | Congressionally Directed Medical Research Program    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items    
Total revenue $ 0 $ 14,000
XML 67 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jul. 24, 2023
Jun. 30, 2022
USD ($)
program
Jun. 30, 2020
USD ($)
program
performanceObligation
Aug. 31, 2019
USD ($)
May 31, 2019
performanceObligation
Dec. 31, 2023
USD ($)
option
Dec. 31, 2023
USD ($)
option
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Deferred revenue           $ 0 $ 0 $ 166,000    
Total revenue             1,800,000 2,192,000    
License fee revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Total revenue             $ 1,800,000 2,178,000    
Phylaxis BioScience, LLC                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Equity interest percentage (as a percent)           15.00% 15.00%     10.00%
Equity method investment, ownership percentage, increase during period (as a percent)           5.00%        
Equity method investment           $ 0 $ 0 0 $ 0 $ 500,000
Phylaxis BioScience, LLC                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Payments received pursuant to agreement                   5,000,000
Development milestone payment receivable                   225,000,000
Commercialization milestone payment receivable                   175,000,000
Collaborative arrangement, payment received, net                   $ 5,500,000
Equity method investment           1,600,000 1,600,000      
Phylaxis BioScience, LLC | License fee revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Revenue recognized related to performance obligation             1,600,000 1,100,000    
Deferred revenue           0 0 0    
Total revenue             1,634,000 1,101,000    
Chiesi Farmaceutici S.p.A.                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Deferred revenue           $ 0 0      
Nonrefundable, upfront payment       $ 10,000,000            
Number of performance obligations | performanceObligation         1          
Term of research and development services option period (in days)         60 days          
Term of option period due from deliverables (in days) 60 days                  
Deferred revenue               100,000    
Chiesi Farmaceutici S.p.A. | License fee revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Revenue recognized related to performance obligation             100,000 900,000    
Total revenue             $ 166,000 877,000    
2seventy bio, Inc. | Initial Programs                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Nonrefundable, upfront payment     $ 400,000              
Number of performance obligations | performanceObligation     1              
Number of programs related to collaborative agreement | program   3 2              
Number of options exercised | option           1 1      
Number of options declined | option           1 1      
2seventy bio, Inc. | Additional Programs                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Number of programs related to collaborative agreement | program     8              
2seventy bio, Inc. | Initial Programs, Program 1                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Nonrefundable, upfront payment     $ 200,000              
2seventy bio, Inc. | Initial Programs, Program 2                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Nonrefundable, upfront payment     200,000              
2seventy bio, Inc. | Initial Programs, Program 3                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Nonrefundable, upfront payment   $ 200,000                
2seventy bio, Inc. | 2020 Option And License Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Development milestone payment receivable     $ 51,500,000              
2seventy bio, Inc. | License fee revenue                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items                    
Total revenue             $ 0 $ 200,000    
XML 68 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
LICENSE AND GRANT REVENUES - Government Grants (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Feb. 28, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items      
Total revenue $ 1,800,000 $ 2,192,000  
Grant revenue      
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items      
Total revenue 0 14,000  
Congressionally Directed Medical Research Program      
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items      
Grant award     $ 300,000
Congressionally Directed Medical Research Program | Grant revenue      
Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items      
Total revenue $ 0 $ 14,000  
XML 69 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Components of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
State $ 3 $ 3
Provision for income taxes $ 3 $ 3
XML 70 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Reconciliation of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Expected income tax benefit at federal statutory rate $ (50,684) $ (30,497)
State income tax expense (benefit), net of federal benefit (3,568) (2,495)
Permanent items 1,524 583
R&D credits (2,322) (1,261)
Unrecognized tax benefits (FIN 48) 1,054 751
Return to provision true-ups (420) (135)
Valuation allowance 54,419 33,057
Provision for income taxes $ 3 $ 3
XML 71 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Components of Net Deferred Income Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred income tax assets    
Net operating loss carryforward $ 68,254 $ 52,970
Research and development credits 12,648 9,728
Intangibles 3,289 3,684
Accruals 1,412 696
Stock compensation 8,581 5,130
Capitalized research and development costs 51,772 19,585
Deferred revenue 0 37
Operating lease liabilities 697 1,118
Other 10 0
Gross deferred tax assets 146,663 92,948
Less: Valuation allowance (146,005) (91,586)
Total deferred tax assets 658 1,362
Deferred income tax liabilities    
Fixed assets (10) (35)
Operating lease right-of-use assets (648) (1,048)
Other 0 (279)
Total deferred tax liabilities (658) (1,362)
Net deferred tax assets (liabilities) 0 0
Net deferred tax assets (liabilities) $ 0 $ 0
XML 72 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Tax Credit Carryforward [Line Items]      
Deferred tax asset valuation allowance $ 146,005,000 $ 91,586,000  
Gross unrecognized tax benefits 4,651,000 3,597,000 $ 2,846,000
Accrual for interest and penalties 0 0  
Recognized interest and penalties 0 $ 0  
Federal      
Tax Credit Carryforward [Line Items]      
Net operating loss carryforwards 305,100,000    
Federal | Research Tax Credit Carryforward      
Tax Credit Carryforward [Line Items]      
Tax credit carryforward 12,400,000    
State      
Tax Credit Carryforward [Line Items]      
Net operating loss carryforwards 65,300,000    
State | Research Tax Credit Carryforward      
Tax Credit Carryforward [Line Items]      
Tax credit carryforward $ 6,200,000    
XML 73 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Unrecognized Tax Benefits [Roll Forward]    
Beginning balance $ 3,597 $ 2,846
Increases related to current year tax positions 1,054 751
Ending balance $ 4,651 $ 3,597
XML 74 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Narrative (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
May 31, 2019
Sep. 30, 2017
Leases [Abstract]        
Lease agreement term (in years)       7 years
Lease extension term (in years)       5 years
Initial base rent per month     $ 30 $ 100
Annual escalations (as a percent)     2.00% 2.00%
Operating lease expense $ 3,700 $ 3,400    
Payments included in measurement of lease liability $ 2,200 $ 2,200    
Remaining term of operating lease (in years) 1 year 6 months 2 years 6 months    
Weighted-average discount rate (as a percent) 8.20% 8.20%    
XML 75 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
Operating right-of-use asset $ 2,952 $ 4,717
Operating lease liability    
Current 2,063 1,860
Non-current 1,110 3,173
Present value of operating lease liability $ 3,173 $ 5,033
XML 76 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Operating Lease Liability Maturity (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]    
2024 $ 2,247  
2025 1,137  
Total future minimum lease payments 3,384  
Less: imputed interest (211)  
Present value of operating lease liability 3,173 $ 5,033
Less: current portion of operating lease liability (2,063) (1,860)
Non-current portion of lease liability $ 1,110 $ 3,173
XML 77 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Purchase commitment, future period (in months) 12 months  
Purchase commitment $ 62.8 $ 74.8
Purchase commitment, expenses incurred 44.5 $ 0.3
Legal Merger Contingency Fee    
Loss Contingencies [Line Items]    
Contingency accrual $ 20.0  
XML 78 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS (Details) - Subsequent Event
$ / shares in Units, $ in Millions
Jan. 22, 2024
USD ($)
right
$ / shares
Subsequent Event [Line Items]  
Sale of stock, price per share (in dollars per share) | $ / shares $ 30.00
Sale of stock, right per share, contingency | right 1
Sale of stock, price per share, contingency (in dollars per share) | $ / shares $ 5.00
Exchange ratio 4
Payments for merger $ 200.0
Ownership percentage 8.00%
Exchange ratio, pro-rate basis (as a percent) 92.00%
Exchange ratio, pro-rate basis, post spin-off transaction (as a percent) 8.00%
Consideration transferred $ 2,200.0
Termination fee $ 54.5
Consummation threshold 50.00%
Reverse termination fee $ 92.1
EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 155 335 1 false 60 0 false 11 false false R1.htm 0000001 - Document - Cover Sheet http://inhibrx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://inhibrx.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Balance Sheets Sheet http://inhibrx.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 3 false false R4.htm 0000004 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Consolidated Statements of Operations Sheet http://inhibrx.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Statements 5 false false R6.htm 0000006 - Statement - Consolidated Statements of Stockholders??? Equity Sheet http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity Consolidated Statements of Stockholders??? Equity Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statements of Cash Flows Sheet http://inhibrx.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 0000009 - Disclosure - OTHER FINANCIAL INFORMATION Sheet http://inhibrx.com/role/OTHERFINANCIALINFORMATION OTHER FINANCIAL INFORMATION Notes 9 false false R10.htm 0000010 - Disclosure - DEBT Sheet http://inhibrx.com/role/DEBT DEBT Notes 10 false false R11.htm 0000011 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://inhibrx.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS??? EQUITY Notes 11 false false R12.htm 0000012 - Disclosure - EQUITY COMPENSATION PLAN Sheet http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN EQUITY COMPENSATION PLAN Notes 12 false false R13.htm 0000013 - Disclosure - LICENSE AND GRANT REVENUES Sheet http://inhibrx.com/role/LICENSEANDGRANTREVENUES LICENSE AND GRANT REVENUES Notes 13 false false R14.htm 0000014 - Disclosure - INCOME TAXES Sheet http://inhibrx.com/role/INCOMETAXES INCOME TAXES Notes 14 false false R15.htm 0000015 - Disclosure - LEASES Sheet http://inhibrx.com/role/LEASES LEASES Notes 15 false false R16.htm 0000016 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 0000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://inhibrx.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 9954471 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 9954472 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 21 false false R22.htm 9954473 - Disclosure - OTHER FINANCIAL INFORMATION (Tables) Sheet http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables OTHER FINANCIAL INFORMATION (Tables) Tables http://inhibrx.com/role/OTHERFINANCIALINFORMATION 22 false false R23.htm 9954474 - Disclosure - DEBT (Tables) Sheet http://inhibrx.com/role/DEBTTables DEBT (Tables) Tables http://inhibrx.com/role/DEBT 23 false false R24.htm 9954475 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://inhibrx.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS??? EQUITY (Tables) Tables http://inhibrx.com/role/STOCKHOLDERSEQUITY 24 false false R25.htm 9954476 - Disclosure - EQUITY COMPENSATION PLAN (Tables) Sheet http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables EQUITY COMPENSATION PLAN (Tables) Tables http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN 25 false false R26.htm 9954477 - Disclosure - LICENSE AND GRANT REVENUES (Tables) Sheet http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables LICENSE AND GRANT REVENUES (Tables) Tables http://inhibrx.com/role/LICENSEANDGRANTREVENUES 26 false false R27.htm 9954478 - Disclosure - INCOME TAXES (Tables) Sheet http://inhibrx.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://inhibrx.com/role/INCOMETAXES 27 false false R28.htm 9954479 - Disclosure - LEASES (Tables) Sheet http://inhibrx.com/role/LEASESTables LEASES (Tables) Tables http://inhibrx.com/role/LEASES 28 false false R29.htm 9954480 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables 29 false false R30.htm 9954481 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details) Sheet http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details) Details 30 false false R31.htm 9954482 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details) Sheet http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details) Details 31 false false R32.htm 9954483 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details) Sheet http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails OTHER FINANCIAL INFORMATION - Property and Equipment (Details) Details 32 false false R33.htm 9954484 - Disclosure - OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details) Sheet http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details) Details 33 false false R34.htm 9954485 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details) Sheet http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails OTHER FINANCIAL INFORMATION - Accrued Expenses (Details) Details 34 false false R35.htm 9954486 - Disclosure - DEBT - Narrative (Details) Sheet http://inhibrx.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 35 false false R36.htm 9954487 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details) Sheet http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details) Details 36 false false R37.htm 9954488 - Disclosure - DEBT - Future Minimum Payments (Details) Sheet http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails DEBT - Future Minimum Payments (Details) Details 37 false false R38.htm 9954489 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details) Sheet http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS??? EQUITY - Narrative (Details) Details 38 false false R39.htm 9954490 - Disclosure - STOCKHOLDERS??? EQUITY - Warrants Issued in Connection with Amended 2020 Loan Agreement (Details) Sheet http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails STOCKHOLDERS??? EQUITY - Warrants Issued in Connection with Amended 2020 Loan Agreement (Details) Details 39 false false R40.htm 9954491 - Disclosure - STOCKHOLDERS??? EQUITY - Common Stock Reserved for Future Issuance (Details) Sheet http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails STOCKHOLDERS??? EQUITY - Common Stock Reserved for Future Issuance (Details) Details 40 false false R41.htm 9954492 - Disclosure - EQUITY COMPENSATION PLAN - Narrative (Details) Sheet http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails EQUITY COMPENSATION PLAN - Narrative (Details) Details 41 false false R42.htm 9954493 - Disclosure - EQUITY COMPENSATION PLAN - Stock Option Activity (Details) Sheet http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails EQUITY COMPENSATION PLAN - Stock Option Activity (Details) Details 42 false false R43.htm 9954494 - Disclosure - EQUITY COMPENSATION PLAN - Fair Value of Stock Option Grants (Details) Sheet http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails EQUITY COMPENSATION PLAN - Fair Value of Stock Option Grants (Details) Details 43 false false R44.htm 9954495 - Disclosure - EQUITY COMPENSATION PLAN - Stock-based Compensation Expense (Details) Sheet http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails EQUITY COMPENSATION PLAN - Stock-based Compensation Expense (Details) Details 44 false false R45.htm 9954496 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details) Sheet http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails LICENSE AND GRANT REVENUES - Revenue Summary (Details) Details 45 false false R46.htm 9954497 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details) Sheet http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details) Details 46 false false R47.htm 9954498 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details) Sheet http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails LICENSE AND GRANT REVENUES - Government Grants (Details) Details 47 false false R48.htm 9954499 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Benefit) (Details) Sheet http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails INCOME TAXES - Components of Income Tax Expense (Benefit) (Details) Details 48 false false R49.htm 9954500 - Disclosure - INCOME TAXES - Reconciliation of Income Tax Expense (Details) Sheet http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails INCOME TAXES - Reconciliation of Income Tax Expense (Details) Details 49 false false R50.htm 9954501 - Disclosure - INCOME TAXES - Components of Net Deferred Income Taxes (Details) Sheet http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails INCOME TAXES - Components of Net Deferred Income Taxes (Details) Details 50 false false R51.htm 9954502 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://inhibrx.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 51 false false R52.htm 9954503 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details) Sheet http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails INCOME TAXES - Unrecognized Tax Benefits (Details) Details 52 false false R53.htm 9954504 - Disclosure - LEASES - Narrative (Details) Sheet http://inhibrx.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 53 false false R54.htm 9954505 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) Sheet http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details) Details 54 false false R55.htm 9954506 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details) Sheet http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails LEASES - Schedule of Operating Lease Liability Maturity (Details) Details 55 false false R56.htm 9954507 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES 56 false false R57.htm 9954508 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://inhibrx.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://inhibrx.com/role/SUBSEQUENTEVENTS 57 false false All Reports Book All Reports inbx-20231231.htm inbx-20231231.xsd inbx-20231231_cal.xml inbx-20231231_def.xml inbx-20231231_lab.xml inbx-20231231_pre.xml inbx-20231231_g1.jpg inbx-20231231_g2.jpg inbx-20231231_g3.jpg inbx-20231231_g4.jpg inbx-20231231_g5.jpg inbx-20231231_g6.jpg inbx-20231231_g7.jpg inbx-20231231_g8.jpg inbx-20231231_g9.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "inbx-20231231.htm": { "nsprefix": "inbx", "nsuri": "http://inhibrx.com/20231231", "dts": { "inline": { "local": [ "inbx-20231231.htm" ] }, "schema": { "local": [ "inbx-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "inbx-20231231_cal.xml" ] }, "definitionLink": { "local": [ "inbx-20231231_def.xml" ] }, "labelLink": { "local": [ "inbx-20231231_lab.xml" ] }, "presentationLink": { "local": [ "inbx-20231231_pre.xml" ] } }, "keyStandard": 264, "keyCustom": 71, "axisStandard": 22, "axisCustom": 1, "memberStandard": 27, "memberCustom": 30, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 4, "http://fasb.org/us-gaap/2023": 1 }, "contextCount": 155, "entityCount": 1, "segmentCount": 60, "elementCount": 579, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 523, "http://xbrl.sec.gov/dei/2023": 40, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://inhibrx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://inhibrx.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://inhibrx.com/role/ConsolidatedBalanceSheets", "longName": "0000003 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R4": { "role": "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R5": { "role": "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "longName": "0000005 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R6": { "role": "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity", "longName": "0000006 - Statement - Consolidated Statements of Stockholders\u2019 Equity", "shortName": "Consolidated Statements of Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R7": { "role": "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000007 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R8": { "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R9": { "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATION", "longName": "0000009 - Disclosure - OTHER FINANCIAL INFORMATION", "shortName": "OTHER FINANCIAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://inhibrx.com/role/DEBT", "longName": "0000010 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITY", "longName": "0000011 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN", "longName": "0000012 - Disclosure - EQUITY COMPENSATION PLAN", "shortName": "EQUITY COMPENSATION PLAN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUES", "longName": "0000013 - Disclosure - LICENSE AND GRANT REVENUES", "shortName": "LICENSE AND GRANT REVENUES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "inbx:LicenseAndGrantRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inbx:LicenseAndGrantRevenueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://inhibrx.com/role/INCOMETAXES", "longName": "0000014 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://inhibrx.com/role/LEASES", "longName": "0000015 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000016 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://inhibrx.com/role/SUBSEQUENTEVENTS", "longName": "0000017 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-155", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-155", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables", "longName": "9954473 - Disclosure - OTHER FINANCIAL INFORMATION (Tables)", "shortName": "OTHER FINANCIAL INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://inhibrx.com/role/DEBTTables", "longName": "9954474 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYTables", "longName": "9954475 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables", "longName": "9954476 - Disclosure - EQUITY COMPENSATION PLAN (Tables)", "shortName": "EQUITY COMPENSATION PLAN (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables", "longName": "9954477 - Disclosure - LICENSE AND GRANT REVENUES (Tables)", "shortName": "LICENSE AND GRANT REVENUES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://inhibrx.com/role/INCOMETAXESTables", "longName": "9954478 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://inhibrx.com/role/LEASESTables", "longName": "9954479 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9954480 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R30": { "role": "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails", "longName": "9954481 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Potential Dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails", "longName": "9954482 - Disclosure - OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)", "shortName": "OTHER FINANCIAL INFORMATION - Prepaid Expense and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-4", "name": "inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inbx:ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails", "longName": "9954483 - Disclosure - OTHER FINANCIAL INFORMATION - Property and Equipment (Details)", "shortName": "OTHER FINANCIAL INFORMATION - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails", "longName": "9954484 - Disclosure - OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)", "shortName": "OTHER FINANCIAL INFORMATION - Depreciation and Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-56", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R34": { "role": "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails", "longName": "9954485 - Disclosure - OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)", "shortName": "OTHER FINANCIAL INFORMATION - Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "inbx:AccruedClinicalDrugSubstanceAndProductManufacturingCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://inhibrx.com/role/DEBTNarrativeDetails", "longName": "9954486 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R36": { "role": "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails", "longName": "9954487 - Disclosure - DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)", "shortName": "DEBT - Outstanding Debt Balance 2020 Loan Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "longName": "9954488 - Disclosure - DEBT - Future Minimum Payments (Details)", "shortName": "DEBT - Future Minimum Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954489 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)", "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "inbx:SaleOfStockCommonStockAuthorized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R39": { "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails", "longName": "9954490 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Warrants Issued in Connection with Amended 2020 Loan Agreement (Details)", "shortName": "STOCKHOLDERS\u2019 EQUITY - Warrants Issued in Connection with Amended 2020 Loan Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "longName": "9954491 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Common Stock Reserved for Future Issuance (Details)", "shortName": "STOCKHOLDERS\u2019 EQUITY - Common Stock Reserved for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inbx:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails", "longName": "9954492 - Disclosure - EQUITY COMPENSATION PLAN - Narrative (Details)", "shortName": "EQUITY COMPENSATION PLAN - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails", "longName": "9954493 - Disclosure - EQUITY COMPENSATION PLAN - Stock Option Activity (Details)", "shortName": "EQUITY COMPENSATION PLAN - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails", "longName": "9954494 - Disclosure - EQUITY COMPENSATION PLAN - Fair Value of Stock Option Grants (Details)", "shortName": "EQUITY COMPENSATION PLAN - Fair Value of Stock Option Grants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "longName": "9954495 - Disclosure - EQUITY COMPENSATION PLAN - Stock-based Compensation Expense (Details)", "shortName": "EQUITY COMPENSATION PLAN - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-109", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails", "longName": "9954496 - Disclosure - LICENSE AND GRANT REVENUES - Revenue Summary (Details)", "shortName": "LICENSE AND GRANT REVENUES - Revenue Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "longName": "9954497 - Disclosure - LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)", "shortName": "LICENSE AND GRANT REVENUES - License and Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "inbx:CollaborativeArrangementPaymentReceived", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R47": { "role": "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "longName": "9954498 - Disclosure - LICENSE AND GRANT REVENUES - Government Grants (Details)", "shortName": "LICENSE AND GRANT REVENUES - Government Grants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inbx:ScheduleOfLicenseAndGrantRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-145", "name": "inbx:GrantValuedAwarded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R48": { "role": "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails", "longName": "9954499 - Disclosure - INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)", "shortName": "INCOME TAXES - Components of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails", "longName": "9954500 - Disclosure - INCOME TAXES - Reconciliation of Income Tax Expense (Details)", "shortName": "INCOME TAXES - Reconciliation of Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails", "longName": "9954501 - Disclosure - INCOME TAXES - Components of Net Deferred Income Taxes (Details)", "shortName": "INCOME TAXES - Components of Net Deferred Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://inhibrx.com/role/INCOMETAXESNarrativeDetails", "longName": "9954502 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R52": { "role": "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails", "longName": "9954503 - Disclosure - INCOME TAXES - Unrecognized Tax Benefits (Details)", "shortName": "INCOME TAXES - Unrecognized Tax Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "unique": true } }, "R53": { "role": "http://inhibrx.com/role/LEASESNarrativeDetails", "longName": "9954504 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-150", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails", "longName": "9954505 - Disclosure - LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)", "shortName": "LEASES - Schedule of Right-Of-Use Asset and Operating Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "inbx:RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails", "longName": "9954506 - Disclosure - LEASES - Schedule of Operating Lease Liability Maturity (Details)", "shortName": "LEASES - Schedule of Operating Lease Liability Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R56": { "role": "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954507 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "inbx:PurchaseCommitmentFuturePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "inbx:PurchaseCommitmentFuturePeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } }, "R57": { "role": "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails", "longName": "9954508 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-153", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-153", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "inbx-20231231.htm", "first": true, "unique": true } } }, "tag": { "inbx_A2020OptionAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OptionAndLicenseAgreementMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Option And License Agreement", "label": "2020 Option And License Agreement [Member]", "documentation": "2020 Option And License Agreement" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanAMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanAMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term A", "label": "2020 Oxford Term Loan A [Member]", "documentation": "2020 Oxford Term Loan A" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanBMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanBMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term B", "label": "2020 Oxford Term Loan B [Member]", "documentation": "2020 Oxford Term Loan B" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanCMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanCMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term C", "label": "2020 Oxford Term Loan C [Member]", "documentation": "2020 Oxford Term Loan C" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanDMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanDMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term D", "label": "2020 Oxford Term Loan D [Member]", "documentation": "2020 Oxford Term Loan D" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanEMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanEMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term E", "label": "2020 Oxford Term Loan E [Member]", "documentation": "2020 Oxford Term Loan E" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanFMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanFMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term F", "label": "2020 Oxford Term Loan F [Member]", "documentation": "2020 Oxford Term Loan F" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoanGMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoanGMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Term G", "label": "2020 Oxford Term Loan G [Member]", "documentation": "2020 Oxford Term Loan G" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoansIncludingAmendmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoansIncludingAmendmentsMember", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Loan Agreement", "label": "2020 Oxford Term Loans Including Amendments [Member]", "documentation": "2020 Oxford Term Loans Including Amendments" } } }, "auth_ref": [] }, "inbx_A2020OxfordTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2020OxfordTermLoansMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Loan Agreement", "label": "2020 Oxford Term Loans [Member]", "documentation": "2020 Oxford Term Loans" } } }, "auth_ref": [] }, "inbx_A2seventyBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "A2seventyBioIncMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2seventy bio, Inc.", "label": "2seventy bio, Inc. [Member]", "documentation": "2seventy bio, Inc." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r15", "r545" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r198", "r199" ] }, "inbx_AccruedClinicalDrugSubstanceAndProductManufacturingCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "AccruedClinicalDrugSubstanceAndProductManufacturingCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical drug substance and product manufacturing", "label": "Accrued Clinical Drug Substance and Product Manufacturing, Current", "documentation": "Accrued Clinical Drug Substance and Product Manufacturing, Current" } } }, "auth_ref": [] }, "inbx_AccruedClinicalTrialsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "AccruedClinicalTrialsCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trials", "label": "Accrued Clinical Trials, Current", "documentation": "Accrued Clinical Trials, Current" } } }, "auth_ref": [] }, "inbx_AccruedInterestExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "AccruedInterestExpenseCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Accrued Interest Expense, Current", "documentation": "Accrued Interest Expense, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "inbx_AccruedOutsideResearchAndDevelopmentOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "AccruedOutsideResearchAndDevelopmentOtherCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other outside research and development", "label": "Accrued Outside Research And Development, Other, Current", "documentation": "Accrued Outside Research And Development, Other, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r37", "r123", "r426" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r599" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r68", "r545", "r725" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r323", "r324", "r325", "r450", "r655", "r656", "r657", "r705", "r726" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r605" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r605" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r605" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r605" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r45", "r46", "r286" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity", "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of warrants", "terseLabel": "Reclassification of warrant liabilities into equity", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r11", "r39", "r94" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r572", "r584", "r594", "r620" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r605" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r612" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r576", "r585", "r595", "r612", "r621", "r625", "r633" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r631" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r318", "r330" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "inbx_AmortizationOfDebtDiscountPremiumAndAccretion": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "AmortizationOfDebtDiscountPremiumAndAccretion", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount and accretion", "label": "Amortization of Debt Discount (Premium) and Accretion", "documentation": "Amortization of Debt Discount (Premium) and Accretion" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of debt discount and non-cash interest expense", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r252", "r384", "r534", "r535", "r648" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from earnings per share computation (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r171" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r358" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r101", "r125", "r144", "r174", "r189", "r193", "r205", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r359", "r361", "r376", "r419", "r474", "r545", "r558", "r669", "r670", "r712" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r119", "r128", "r144", "r205", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r359", "r361", "r376", "r545", "r669", "r670", "r712" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "inbx_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://inhibrx.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r563", "r564", "r577" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://inhibrx.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r563", "r564", "r577" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://inhibrx.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r563", "r564", "r577" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt securities, amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r200", "r208", "r418" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r628" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r629" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r624" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r624" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r314", "r315", "r316", "r317" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r627" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r626" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r625" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r625" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Payable for purchase of fixed assets", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r26", "r121", "r519" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r26", "r81", "r141" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r81" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental schedule of non-cash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r603" ] }, "inbx_ChiesiFarmaceuticiSpAMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ChiesiFarmaceuticiSpAMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chiesi Farmaceutici S.p.A.", "label": "Chiesi Farmaceutici S.p.A. [Member]", "documentation": "Chiesi Farmaceutici S.p.A." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant price (in dollars per share)", "netLabel": "Exercise price (in dollars per share)", "verboseLabel": "Exercise Price per Share (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r275" ] }, "inbx_ClassOfWarrantOrRightExpirationDate1Member": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ClassOfWarrantOrRightExpirationDate1Member", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "July\u00a015, 2030", "label": "Class of Warrant or Right, Expiration Date 1 [Member]", "documentation": "Class of Warrant or Right, Expiration Date 1" } } }, "auth_ref": [] }, "inbx_ClassOfWarrantOrRightExpirationDate2Member": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ClassOfWarrantOrRightExpirationDate2Member", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "February\u00a018, 2032", "label": "Class of Warrant or Right, Expiration Date 2 [Member]", "documentation": "Class of Warrant or Right, Expiration Date 2" } } }, "auth_ref": [] }, "inbx_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued (in shares)", "label": "Class of Warrant or Right, Issued", "documentation": "Class of Warrant or Right, Issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock issuable upon exercise of warrants (in shares)", "verboseLabel": "Shares of common stock issuable upon exercise of warrants (in shares)", "netLabel": "Shares of Common Stock Issuable Upon Exercise of Warrants (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r275" ] }, "inbx_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (in dollars per share)", "label": "Class of Warrant or Right, Purchase Price of Warrants or Rights", "documentation": "Class of Warrant or Right, Purchase Price of Warrants or Rights" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYWarrantsIssuedinConnectionwithAmended2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r42" ] }, "inbx_ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ClinicalDrugSubstanceAndProductManufacturingPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical drug substance and product manufacturing", "label": "Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current", "documentation": "Clinical Drug Substance and Product Manufacturing, Prepaid Expense Current" } } }, "auth_ref": [] }, "inbx_ClinicalTrailsPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ClinicalTrailsPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trials", "label": "Clinical Trails, Prepaid Expense Current", "documentation": "Clinical Trails, Prepaid Expense Current" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r604" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r604" ] }, "inbx_CollaborativeAgreementNumberOfOptionsDeclined": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeAgreementNumberOfOptionsDeclined", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options declined", "label": "Collaborative Agreement, Number Of Options Declined", "documentation": "Collaborative Agreement, Number Of Options Declined" } } }, "auth_ref": [] }, "inbx_CollaborativeAgreementNumberOfOptionsExercised": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeAgreementNumberOfOptionsExercised", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options exercised", "label": "Collaborative Agreement, Number Of Options Exercised", "documentation": "Collaborative Agreement, Number Of Options Exercised" } } }, "auth_ref": [] }, "inbx_CollaborativeAgreementNumberOfRelatedProgramsToAgreement": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeAgreementNumberOfRelatedProgramsToAgreement", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of programs related to collaborative agreement", "label": "Collaborative Agreement, Number Of Related Programs To Agreement", "documentation": "Collaborative Agreement, Number Of Related Programs To Agreement" } } }, "auth_ref": [] }, "inbx_CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeAbstract", "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]", "documentation": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "auth_ref": [] }, "inbx_CollaborativeArrangementCommercializationMilestoneReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeArrangementCommercializationMilestoneReceivable", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercialization milestone payment receivable", "label": "Collaborative Arrangement, Commercialization Milestone Receivable", "documentation": "Collaborative Arrangement, Commercialization Milestone Receivable" } } }, "auth_ref": [] }, "inbx_CollaborativeArrangementDevelopmentMilestoneReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeArrangementDevelopmentMilestoneReceivable", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Development milestone payment receivable", "label": "Collaborative Arrangement, Development Milestone Receivable", "documentation": "Collaborative Arrangement, Development Milestone Receivable" } } }, "auth_ref": [] }, "inbx_CollaborativeArrangementNonrefundableUpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeArrangementNonrefundableUpfrontPayment", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrefundable, upfront payment", "label": "Collaborative Arrangement, Nonrefundable Upfront Payment", "documentation": "Collaborative Arrangement, Nonrefundable Upfront Payment" } } }, "auth_ref": [] }, "inbx_CollaborativeArrangementPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeArrangementPaymentReceived", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments received pursuant to agreement", "label": "Collaborative Arrangement, Payment Received", "documentation": "Collaborative Arrangement, Payment Received" } } }, "auth_ref": [] }, "inbx_CollaborativeArrangementPaymentReceivedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CollaborativeArrangementPaymentReceivedNet", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, payment received, net", "label": "Collaborative Arrangement, Payment Received, Net", "documentation": "Collaborative Arrangement, Payment Received, Net" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions Line Items", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r358" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 9)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r21", "r57", "r420", "r461" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r89", "r213", "r214", "r514", "r664" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r22" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r548", "r549", "r550", "r552", "r553", "r554", "r555", "r655", "r656", "r705", "r724", "r726" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r67" ] }, "inbx_CommonStockSaleOfStockCommissionPercent": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "CommonStockSaleOfStockCommissionPercent", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commission (as a percent)", "label": "Common Stock, Sale Of Stock Commission, Percent", "documentation": "Common Stock, Sale Of Stock Commission, Percent" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r67", "r462" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r67" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical", "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r67", "r462", "r480", "r726", "r727" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 120,000,000 shares authorized as of December\u00a031, 2023 and December\u00a031, 2022; 47,369,511 and 43,564,283 shares issued and outstanding as of December\u00a031, 2023 and December\u00a031, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r67", "r422", "r545" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r609" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r608" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r610" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r607" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r59", "r111" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r51", "r524" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in process", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r277", "r278", "r280" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r277", "r278", "r280" ] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized related to performance obligation", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": [ "r279" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r148", "r149", "r234", "r264", "r396", "r521", "r523" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r643", "r651", "r704" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://inhibrx.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r90", "r142", "r230", "r236", "r237", "r238", "r239", "r240", "r241", "r246", "r253", "r254", "r256" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r62", "r63", "r102", "r104", "r150", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r385", "r531", "r532", "r533", "r534", "r535", "r649" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total long-term debt", "verboseLabel": "Term loan", "totalLabel": "Total future minimum payments", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r14", "r104", "r257" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan aggregate amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r54", "r56", "r231", "r385", "r532", "r533" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r19", "r232" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r385", "r531", "r532", "r533", "r534", "r535", "r649" ] }, "inbx_DebtInstrumentMinimumCashBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentMinimumCashBalance", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum cash balance", "label": "Debt Instrument, Minimum Cash Balance", "documentation": "Debt Instrument, Minimum Cash Balance" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r150", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r385", "r531", "r532", "r533", "r534", "r535", "r649" ] }, "inbx_DebtInstrumentNumberOfAdditionalTranchesAvailableUponContingentEvents": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentNumberOfAdditionalTranchesAvailableUponContingentEvents", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional tranches available upon contingent events", "label": "Debt Instrument, Number of Additional Tranches Available Upon Contingent Events", "documentation": "Debt Instrument, Number of Additional Tranches Available Upon Contingent Events" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Periodic payment terms, final payment amount", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt." } } }, "auth_ref": [] }, "inbx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentOfFaceValue", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of principal amount for final payment (as a percent)", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value", "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment To Be Paid, Percent Of Face Value" } } }, "auth_ref": [] }, "inbx_DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended": { "xbrltype": "durationItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentPeriodicPaymentTermsEqualPaymentsOfPrincipalAndInterestPeriodIfInterestOnlyPeriodIsExtended", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equal payments of principal and interest period if interest only period is extended (in months)", "label": "Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended", "documentation": "Debt Instrument, Periodic Payment Terms, Equal Payments of Principal and Interest Period if Interest-Only Period Is Extended" } } }, "auth_ref": [] }, "inbx_DebtInstrumentPeriodicPaymentTermsPrincipalPaymentsIfInterestOnlyPeriodIsExtended": { "xbrltype": "durationItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentPeriodicPaymentTermsPrincipalPaymentsIfInterestOnlyPeriodIsExtended", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equal payments of principal period if interest only period is extended (in months)", "label": "Debt Instrument, Periodic Payment Terms, Principal Payments if Interest-Only Period Is Extended", "documentation": "Debt Instrument, Periodic Payment Terms, Principal Payments if Interest-Only Period Is Extended" } } }, "auth_ref": [] }, "inbx_DebtInstrumentPrepaymentFee": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentPrepaymentFee", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee (as a percent)", "label": "Debt Instrument, Prepayment Fee", "documentation": "Debt Instrument, Prepayment Fee" } } }, "auth_ref": [] }, "inbx_DebtInstrumentRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentRateAxis", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate [Axis]", "label": "Debt Instrument Rate [Axis]", "documentation": "Debt Instrument Rate" } } }, "auth_ref": [] }, "inbx_DebtInstrumentRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentRateDomain", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate [Domain]", "label": "Debt Instrument Rate [Domain]", "documentation": "Debt Instrument Rate [Domain]" } } }, "auth_ref": [] }, "inbx_DebtInstrumentRateOneMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentRateOneMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate One", "label": "Debt Instrument Rate One [Member]", "documentation": "Debt Instrument Rate One" } } }, "auth_ref": [] }, "inbx_DebtInstrumentRateTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentRateTwoMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Rate Two", "label": "Debt Instrument Rate Two [Member]", "documentation": "Debt Instrument Rate Two" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r40", "r41", "r53", "r54", "r56", "r58", "r92", "r93", "r150", "r231", "r232", "r233", "r234", "r235", "r237", "r242", "r243", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r255", "r385", "r531", "r532", "r533", "r534", "r535", "r649" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: debt discount", "negatedLabel": "Less: unamortized debt discount", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r55", "r242", "r258", "r532", "r533" ] }, "inbx_DebtInstrumentUpfrontLicensingOrPartnershipProceedsRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DebtInstrumentUpfrontLicensingOrPartnershipProceedsRaised", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront licensing or partnership proceeds raised", "label": "Debt Instrument, Upfront Licensing or Partnership Proceeds Raised", "documentation": "Debt Instrument, Upfront Licensing or Partnership Proceeds Raised" } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Financing Costs and Other Debt-Related Costs and Deferred Offering Costs", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r124" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expense and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r64", "r65", "r103", "r345" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred offering costs", "label": "Deferred Offering Costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r662" ] }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsDeferredIncome", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Tax Assets, Deferred Income", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r346" ] }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGrossAbstract", "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax assets", "label": "Deferred Tax Assets, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets (liabilities)", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r702" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax assets", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r702" ] }, "inbx_DeferredTaxAssetsOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Deferred Tax Assets, Operating Lease Liabilities", "documentation": "Deferred Tax Assets, Operating Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforward", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development credits", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r49", "r50", "r703" ] }, "inbx_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized research and development costs", "label": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Research and Development Costs", "documentation": "Deferred Tax Assets, Tax Deferred Expense, Capitalized Research and Development Costs" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accruals", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails", "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Valuation allowance", "verboseLabel": "Deferred tax asset valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r347" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets (liabilities)", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r47", "r702" ] }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesAbstract", "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax liabilities", "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease right-of-use assets", "label": "Deferred Tax Liabilities, Leasing Arrangements", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r50", "r703" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESComponentsofNetDeferredIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fixed assets", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r50", "r703" ] }, "inbx_DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Congressionally Directed Medical Research Program", "label": "Department of Defense - Congressionally Directed Medical Research Program [Member]", "documentation": "Department of Defense - Congressionally Directed Medical Research Program" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r177" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLAN" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY COMPENSATION PLAN", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r284", "r288", "r319", "r320", "r322", "r540" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r563", "r564", "r577" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r563", "r564", "r577", "r613" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r598" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r561" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r136", "r156", "r157", "r158", "r159", "r160", "r164", "r166", "r168", "r169", "r170", "r172", "r371", "r372", "r415", "r430", "r526" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r136", "r156", "r157", "r158", "r159", "r160", "r166", "r168", "r169", "r170", "r172", "r371", "r372", "r415", "r430", "r526" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r32", "r33" ] }, "inbx_EffectiveIncomeTaxRateReconciliationPermanentItems": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent items", "label": "Effective Income Tax Rate Reconciliation, Permanent Items", "documentation": "Effective Income Tax Rate Reconciliation, Permanent Items" } } }, "auth_ref": [] }, "inbx_EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionTrueUps", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Return to provision true-ups", "label": "Effective Income Tax Rate Reconciliation, Return to Provision True-Ups", "documentation": "Effective Income Tax Rate Reconciliation, Return to Provision True-Ups" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r321" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period of recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r321" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding stock options", "netLabel": "Options to purchase common stock issued and outstanding", "terseLabel": "Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r560" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r560" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r560" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r638" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r560" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r560" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r560" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r560" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r639" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r117", "r132", "r133", "r134", "r151", "r152", "r153", "r155", "r161", "r163", "r173", "r206", "r207", "r276", "r323", "r324", "r325", "r351", "r352", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r377", "r378", "r379", "r380", "r381", "r382", "r392", "r440", "r441", "r442", "r450", "r500" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r202", "r203", "r204" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest percentage (as a percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r202" ] }, "inbx_EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "EquityMethodInvestmentOwnershipPercentageIncreaseDecreaseDuringPeriod", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, ownership percentage, increase during period (as a percent)", "label": "Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period", "documentation": "Equity Method Investment, Ownership Percentage, Increase (Decrease) During Period" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r180", "r201", "r645", "r660" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Phylaxis", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r3", "r52", "r203" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r606" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r569", "r581", "r591", "r617" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r566", "r578", "r588", "r614" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r612" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r374", "r375" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r373", "r374", "r375" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r9", "r13" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r573", "r585", "r595", "r621" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r573", "r585", "r595", "r621" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r573", "r585", "r595", "r621" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r573", "r585", "r595", "r621" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r573", "r585", "r595", "r621" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and other", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of fixed assets", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r5" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r76", "r484" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative", "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r75" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant revenue", "verboseLabel": "Grant revenue", "label": "Grant [Member]", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r673" ] }, "inbx_GrantValuedAwarded": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "GrantValuedAwarded", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grant award", "label": "Grant, Valued Awarded", "documentation": "Grant, Valued Awarded" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r563", "r564", "r577" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r88" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r174", "r188", "r192", "r194", "r431", "r528" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 }, "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from equity method investment", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r5", "r73", "r106", "r178", "r201", "r428" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r211", "r212", "r485" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r212", "r485" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r10" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://inhibrx.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r145", "r333", "r339", "r343", "r349", "r353", "r355", "r356", "r357", "r449" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/INCOMETAXESComponentsofIncomeTaxExpenseBenefitDetails", "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r108", "r116", "r162", "r163", "r179", "r337", "r354", "r432" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r131", "r335", "r336", "r343", "r344", "r348", "r350", "r446" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r700" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected income tax benefit at federal statutory rate", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r338" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits (FIN 48)", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r700" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income tax expense (benefit), net of federal benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r700" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/INCOMETAXESReconciliationofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "R&D credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r700" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r28" ] }, "inbx_IncreaseDecreaseContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "IncreaseDecreaseContractWithCustomerLiabilityCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, current portion", "label": "Increase (Decrease) Contract With Customer, Liability, Current", "documentation": "Increase (Decrease) Contract With Customer, Liability, Current" } } }, "auth_ref": [] }, "inbx_IncreaseDecreaseContractWithCustomerLiabilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "IncreaseDecreaseContractWithCustomerLiabilityNonCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, non-current portion", "label": "Increase (Decrease) Contract With Customer, Liability, Non-Current", "documentation": "Increase (Decrease) Contract With Customer, Liability, Non-Current" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInDueFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueFromRelatedParties", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Receivables from related parties", "label": "Increase (Decrease) in Due from Related Parties", "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r641", "r647" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r647" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r576", "r585", "r595", "r612", "r621", "r625", "r633" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r631" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r565", "r637" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r565", "r637" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r565", "r637" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r78", "r250", "r260", "r534", "r535" ] }, "inbx_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Interest Expense, Nonoperating" } } }, "auth_ref": [] }, "inbx_InterestIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "InterestIncomeNonoperating", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Nonoperating", "documentation": "Interest Income, Nonoperating" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r137", "r139", "r140" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r87" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "inbx_LegalMergerContingencyFeeMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LegalMergerContingencyFeeMember", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Merger Contingency Fee", "label": "Legal Merger Contingency Fee [Member]", "documentation": "Legal Merger Contingency Fee" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r389" ] }, "inbx_LesseeOperatingLeaseAnnualEscalations": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LesseeOperatingLeaseAnnualEscalations", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual escalations (as a percent)", "label": "Lessee, Operating Lease, Annual Escalations", "documentation": "Lessee, Operating Lease, Annual Escalations" } } }, "auth_ref": [] }, "inbx_LesseeOperatingLeaseInitialBaseRentExpensePerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LesseeOperatingLeaseInitialBaseRentExpensePerMonth", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial base rent per month", "label": "Lessee, Operating Lease, Initial Base Rent Expense Per Month", "documentation": "Lessee, Operating Lease, Initial Base Rent Expense Per Month" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://inhibrx.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r710" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r391" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r391" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining term of operating lease (in years)", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r708" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extension term (in years)", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r709" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease agreement term (in years)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r709" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://inhibrx.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r386" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r16", "r144", "r205", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r360", "r361", "r362", "r376", "r460", "r527", "r558", "r669", "r712", "r713" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r72", "r105", "r424", "r545", "r650", "r661", "r706" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r18", "r120", "r144", "r205", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r360", "r361", "r362", "r376", "r545", "r669", "r712", "r713" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "inbx_LicenseAgreementAdditionalProgramsAuthorizedMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseAgreementAdditionalProgramsAuthorizedMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Programs", "label": "License Agreement, Additional Programs Authorized [Member]", "documentation": "License Agreement, Additional Programs Authorized" } } }, "auth_ref": [] }, "inbx_LicenseAgreementInitialProgramsAuthorizedMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseAgreementInitialProgramsAuthorizedMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Programs", "label": "License Agreement, Initial Programs Authorized [Member]", "documentation": "License Agreement, Initial Programs Authorized" } } }, "auth_ref": [] }, "inbx_LicenseAgreementInitialProgramsAuthorizedProgramOneMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseAgreementInitialProgramsAuthorizedProgramOneMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Programs, Program 1", "label": "License Agreement, Initial Programs Authorized, Program One [Member]", "documentation": "License Agreement, Initial Programs Authorized, Program One" } } }, "auth_ref": [] }, "inbx_LicenseAgreementInitialProgramsAuthorizedProgramThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseAgreementInitialProgramsAuthorizedProgramThreeMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Programs, Program 3", "label": "License Agreement, Initial Programs Authorized, Program Three [Member]", "documentation": "License Agreement, Initial Programs Authorized, Program Three" } } }, "auth_ref": [] }, "inbx_LicenseAgreementInitialProgramsAuthorizedProgramTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseAgreementInitialProgramsAuthorizedProgramTwoMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Programs, Program 2", "label": "License Agreement, Initial Programs Authorized, Program Two [Member]", "documentation": "License Agreement, Initial Programs Authorized, Program Two" } } }, "auth_ref": [] }, "inbx_LicenseAndGrantRevenueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseAndGrantRevenueTextBlock", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUES" ], "lang": { "en-us": { "role": { "terseLabel": "LICENSE AND GRANT REVENUES", "label": "License And Grant Revenue [Text Block]", "documentation": "License And Grant Revenue" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "License fee revenue", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r673" ] }, "inbx_LicenseNonAffiliateMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LicenseNonAffiliateMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License fee revenue", "label": "License, Non-Affiliate [Member]", "documentation": "License, Non-Affiliate" } } }, "auth_ref": [] }, "inbx_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity", "label": "Liquidity [Policy Text Block]", "documentation": "Liquidity" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r14", "r104", "r243", "r259", "r532", "r533", "r721" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r150", "r248" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r150", "r248" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r150", "r248" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r38" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r215", "r216", "r217", "r220", "r665", "r666" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r216", "r217", "r220", "r665", "r666" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r215", "r216", "r217", "r220", "r665", "r666" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r215", "r640" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r215", "r216", "r217", "r220", "r665", "r666" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r197", "r538", "r672", "r722", "r723" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r283", "r401", "r439", "r452", "r453", "r507", "r508", "r509", "r510", "r511", "r515", "r516", "r530", "r536", "r539", "r547", "r671", "r714", "r715", "r716", "r717", "r718", "r719" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r604" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r604" ] }, "inbx_MergerConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerConsiderationTransferred", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred", "label": "Merger, Consideration Transferred", "documentation": "Merger, Consideration Transferred" } } }, "auth_ref": [] }, "inbx_MergerConsummationThreshold": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerConsummationThreshold", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consummation threshold", "label": "Merger, Consummation Threshold", "documentation": "Merger, Consummation Threshold" } } }, "auth_ref": [] }, "inbx_MergerExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerExchangeRatio", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange ratio", "label": "Merger, Exchange Ratio", "documentation": "Merger, Exchange Ratio" } } }, "auth_ref": [] }, "inbx_MergerExchangeRatioProRateBasisPercentage": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerExchangeRatioProRateBasisPercentage", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange ratio, pro-rate basis (as a percent)", "label": "Merger, Exchange Ratio, Pro-Rate Basis, Percentage", "documentation": "Merger, Exchange Ratio, Pro-Rate Basis, Percentage" } } }, "auth_ref": [] }, "inbx_MergerExchangeRatioProRateBasisPostSpinOffTransactionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerExchangeRatioProRateBasisPostSpinOffTransactionPercentage", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange ratio, pro-rate basis, post spin-off transaction (as a percent)", "label": "Merger, Exchange Ratio, Pro-Rate Basis, Post Spin-off Transaction, Percentage", "documentation": "Merger, Exchange Ratio, Pro-Rate Basis, Post Spin-off Transaction, Percentage" } } }, "auth_ref": [] }, "inbx_MergerOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerOwnershipPercentage", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Merger, Ownership Percentage", "documentation": "Merger, Ownership Percentage" } } }, "auth_ref": [] }, "inbx_MergerReverseTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerReverseTerminationFee", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse termination fee", "label": "Merger, Reverse Termination Fee", "documentation": "Merger, Reverse Termination Fee" } } }, "auth_ref": [] }, "inbx_MergerTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "MergerTerminationFee", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee", "label": "Merger, Termination Fee", "documentation": "Merger, Termination Fee" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r283", "r401", "r439", "r452", "r453", "r507", "r508", "r509", "r510", "r511", "r515", "r516", "r530", "r536", "r539", "r547", "r671", "r714", "r715", "r716", "r717", "r718", "r719" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r624" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r632" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r197", "r538", "r672", "r722", "r723" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r605" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r138" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r138" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r81", "r82", "r83" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r74", "r83", "r107", "r118", "r129", "r130", "r134", "r144", "r154", "r156", "r157", "r158", "r159", "r162", "r163", "r167", "r174", "r188", "r192", "r194", "r205", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r372", "r376", "r429", "r482", "r498", "r499", "r528", "r556", "r669" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r604" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r573", "r585", "r595", "r612", "r621" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r602" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r601" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r612" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r632" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r632" ] }, "inbx_NoncashOperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "NoncashOperatingLeaseExpense", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Noncash Operating Lease Expense", "documentation": "Noncash Operating Lease Expense" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r77" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r652", "r653" ] }, "inbx_NumberOfOperatingLeasesHeld": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "NumberOfOperatingLeasesHeld", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating leases held", "label": "Number Of Operating Leases Held", "documentation": "Number Of Operating Leases Held" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r659" ] }, "inbx_NumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "NumberOfPerformanceObligations", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of performance obligations", "label": "Number Of Performance Obligations", "documentation": "Number Of Performance Obligations" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r174", "r188", "r192", "r194", "r528" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r707" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 }, "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails", "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r388" ] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityAbstract", "presentation": [ "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails", "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of lease liability", "verboseLabel": "Current", "negatedTerseLabel": "Less: current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r388" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/LEASESScheduleofOperatingLeaseLiabilityMaturityDetails", "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current portion of lease liability", "verboseLabel": "Non-current", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r388" ] }, "inbx_OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "OperatingLeasePaymentsIncludedInMeasurementOfLeaseLiability", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments included in measurement of lease liability", "label": "Operating Lease, Payments Included in Measurement of Lease Liability", "documentation": "Operating Lease, Payments Included in Measurement of Lease Liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/LEASESScheduleofRightOfUseAssetandOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right-of-use asset", "verboseLabel": "Operating right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r387" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://inhibrx.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r390", "r544" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r49" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r61", "r84", "r85", "r100" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r127", "r545" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r124" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncome", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash license revenue", "label": "Other Noncash Income", "documentation": "Amount of income or gain included in net income that result in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r83" ] }, "inbx_OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "OtherNoncashInvestingAndFinancingItemsWarrantLiabilitiesIncurred", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants issued to lender in conjunction with February 2022 Amendment (as defined in Note 3)", "label": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred", "documentation": "Other Noncash Investing And Financing Items, Warrant Liabilities Incurred" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r79" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r604" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r571", "r583", "r593", "r619" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r574", "r586", "r596", "r622" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r574", "r586", "r596", "r622" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r600" ] }, "inbx_PaymentsForMerger": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PaymentsForMerger", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for merger", "label": "Payments For Merger", "documentation": "Payments For Merger" } } }, "auth_ref": [] }, "inbx_PaymentsOfDebtIssuanceCostsSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PaymentsOfDebtIssuanceCostsSecuredDebt", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of fees associated with debt", "label": "Payments of Debt Issuance Costs, Secured Debt", "documentation": "Payments of Debt Issuance Costs, Secured Debt" } } }, "auth_ref": [] }, "inbx_PaymentsOfPrivatePlacementCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PaymentsOfPrivatePlacementCosts", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Issuance costs associated with issuance of common stock and pre-funded warrants in private placement", "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in private placement", "label": "Payments of Private Placement Costs", "documentation": "Payments of Stock Issuance and Warrants Costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Costs associated with ATM offering", "terseLabel": "Costs associated with the ATM offering", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r25" ] }, "inbx_PaymentsOfStockIssuanceCostsAdditional": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PaymentsOfStockIssuanceCostsAdditional", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs associated with the ATM offering, additional", "label": "Payments of Stock Issuance Costs, Additional", "documentation": "Payments of Stock Issuance Costs, Additional" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of fixed assets", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r80" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r603" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r603" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r602" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r612" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r605" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r601" ] }, "inbx_PerformanceObligationsTermOfOptionPeriodDueFromDeliverables": { "xbrltype": "durationItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PerformanceObligationsTermOfOptionPeriodDueFromDeliverables", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of option period due from deliverables (in days)", "label": "Performance Obligations, Term of Option Period Due From Deliverables", "documentation": "Performance Obligations, Term of Option Period Due From Deliverables" } } }, "auth_ref": [] }, "inbx_PerformanceObligationsTermOfResearchAndDevelopmentServicesOptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PerformanceObligationsTermOfResearchAndDevelopmentServicesOptionPeriod", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of research and development services option period (in days)", "label": "Performance Obligations, Term of Research and Development Services Option Period", "documentation": "Performance Obligations, Term of Research and Development Services Option Period" } } }, "auth_ref": [] }, "inbx_PhylaxisBioScienceLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PhylaxisBioScienceLLCMember", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Phylaxis BioScience, LLC", "label": "Phylaxis BioScience, LLC [Member]", "documentation": "Phylaxis BioScience, LLC" } } }, "auth_ref": [] }, "inbx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants issued and outstanding", "label": "Pre Funded Warrants [Member]", "documentation": "Pre Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r66", "r262" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r66", "r462" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r66", "r462", "r480", "r726", "r727" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value, 15,000,000 shares authorized and no shares outstanding as of December\u00a031, 2023 and December\u00a031, 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r66", "r421", "r545" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expense and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r646" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outside research and development services", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r126", "r209", "r210", "r520" ] }, "inbx_PrepaidLicenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PrepaidLicenseCurrent", "crdr": "debit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPrepaidExpenseandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licenses", "label": "Prepaid License Current", "documentation": "Prepaid License Current" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from ATM offering", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants in private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows", "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of debt", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r12" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r195", "r402", "r433", "r434", "r435", "r436", "r437", "r438", "r518", "r537", "r546", "r642", "r667", "r668", "r672", "r722" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r195", "r402", "r433", "r434", "r435", "r436", "r437", "r438", "r518", "r537", "r546", "r642", "r667", "r668", "r672", "r722" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r87", "r122", "r427" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r417", "r427", "r545" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r112", "r115", "r425" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r87" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment useful life (in years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "inbx_PurchaseCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PurchaseCommitment", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitment", "label": "Purchase Commitment", "documentation": "Purchase Commitment" } } }, "auth_ref": [] }, "inbx_PurchaseCommitmentExpensesIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PurchaseCommitmentExpensesIncurred", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitment, expenses incurred", "label": "Purchase Commitment, Expenses Incurred", "documentation": "Purchase Commitment, Expenses Incurred" } } }, "auth_ref": [] }, "inbx_PurchaseCommitmentFuturePeriod": { "xbrltype": "durationItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "PurchaseCommitmentFuturePeriod", "presentation": [ "http://inhibrx.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase commitment, future period (in months)", "label": "Purchase Commitment, Future Period", "documentation": "Purchase Commitment, Future Period" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r600" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r600" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r281", "r283", "r314", "r315", "r316", "r400", "r401", "r439", "r452", "r453", "r507", "r508", "r509", "r510", "r511", "r515", "r516", "r530", "r536", "r539", "r547", "r550", "r663", "r671", "r715", "r716", "r717", "r718", "r719" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r216", "r217", "r218", "r219", "r281", "r283", "r314", "r315", "r316", "r400", "r401", "r439", "r452", "r453", "r507", "r508", "r509", "r510", "r511", "r515", "r516", "r530", "r536", "r539", "r547", "r550", "r663", "r671", "r715", "r716", "r717", "r718", "r719" ] }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "presentation": [ "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized Tax Benefits [Roll Forward]", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r566", "r578", "r588", "r614" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r282", "r393", "r394", "r455", "r456", "r457", "r458", "r459", "r479", "r481", "r506" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r146", "r147", "r393", "r394", "r395", "r396", "r455", "r456", "r457", "r458", "r459", "r479", "r481", "r506" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r282", "r393", "r394", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r455", "r456", "r457", "r458", "r459", "r479", "r481", "r506", "r711" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r148", "r149", "r234", "r264", "r396", "r522", "r523" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r60", "r332", "r720" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development", "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Research and Development and Clinical Trial Costs", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r331" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research Tax Credit Carryforward", "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r48" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r567", "r579", "r589", "r615" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r568", "r580", "r590", "r616" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r575", "r587", "r597", "r623" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r69", "r94", "r423", "r443", "r444", "r448", "r463", "r545" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r117", "r151", "r152", "r153", "r155", "r161", "r163", "r206", "r207", "r323", "r324", "r325", "r351", "r352", "r363", "r365", "r366", "r368", "r370", "r440", "r442", "r450", "r726" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r483", "r517", "r525" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "verboseLabel": "Total revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r135", "r144", "r175", "r176", "r187", "r190", "r191", "r195", "r196", "r197", "r205", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r376", "r416", "r669" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "inbx_RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "RightOfUseAssetAndOperatingLeaseLiabilityTableTextBlock", "presentation": [ "http://inhibrx.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease, by Balance Sheet Location", "label": "Right-Of-Use Asset And Operating Lease Liability [Table Text Block]", "documentation": "Right-Of-Use Asset And Operating Lease Liability" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r632" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r632" ] }, "inbx_SaleOfStockCommonStockAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "SaleOfStockCommonStockAuthorized", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price", "label": "Sale of Stock, Common Stock, Authorized", "documentation": "Sale of Stock, Common Stock, Authorized" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, proceeds received", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, shares issued/sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "inbx_SaleOfStockPricePerShareContingency": { "xbrltype": "perShareItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "SaleOfStockPricePerShareContingency", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share, contingency (in dollars per share)", "label": "Sale of Stock, Price Per Share, Contingency", "documentation": "Sale of Stock, Price Per Share, Contingency" } } }, "auth_ref": [] }, "inbx_SaleOfStockRightPerShareContingency": { "xbrltype": "integerItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "SaleOfStockRightPerShareContingency", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, right per share, contingency", "label": "Sale of Stock, Right Per Share, Contingency", "documentation": "Sale of Stock, Right Per Share, Contingency" } } }, "auth_ref": [] }, "inbx_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "SalesAgreementMember", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales Agreement", "label": "Sales Agreement [Member]", "documentation": "Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Dilutive Securities Excluded from Diluted Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESGovernmentGrantsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/LICENSEANDGRANTREVENUESRevenueSummaryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r358" ] }, "inbx_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Reserved For Future Issuance", "label": "Schedule of Common Stock Reserved For Future Issuance [Table Text Block]", "documentation": "Schedule of Common Stock Reserved For Future Issuance" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://inhibrx.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r99" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://inhibrx.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r20", "r40", "r41", "r53", "r54", "r56", "r58", "r92", "r93", "r532", "r534", "r654" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://inhibrx.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://inhibrx.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r97" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r44" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails", "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r202", "r203", "r204" ] }, "inbx_ScheduleOfLicenseAndGrantRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "ScheduleOfLicenseAndGrantRevenueTableTextBlock", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of License and Grant Revenue", "label": "Schedule Of License And Grant Revenue [Table Text Block]", "documentation": "Schedule Of License And Grant Revenue" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://inhibrx.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Long-term Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONDepreciationandAmortizationExpenseDetails", "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r285", "r287", "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r314", "r315", "r316", "r317" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate Fair Value", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r96" ] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Options Activity", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Issued", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://inhibrx.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r543", "r701" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://inhibrx.com/role/DEBTFutureMinimumPaymentsDetails", "http://inhibrx.com/role/DEBTNarrativeDetails", "http://inhibrx.com/role/DEBTOutstandingDebtBalance2020LoanAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredLongTermDebt", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, including final payment fee", "label": "Secured Long-Term Debt, Noncurrent", "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets." } } }, "auth_ref": [ "r20" ] }, "inbx_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r559" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r562" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r186", "r196", "r529" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r540" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r315" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r314" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r316" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r285", "r287", "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r314", "r315", "r316", "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r542" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available shares reserved for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r297" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r307" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r293", "r294" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r293", "r294" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Vested and Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockbasedCompensationExpenseDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r289", "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r313", "r314", "r315", "r316", "r317" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r299" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r297" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cliff Vesting", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Stock-Based Awards", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r284", "r292", "r311", "r312", "r313", "r314", "r317", "r326", "r327", "r328", "r329" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r541" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANFairValueofStockOptionGrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r313" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r95" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term, Vested and Exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r310" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of stock options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r308" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_SoftwareDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareDevelopmentMember", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATIONPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software", "label": "Software Development [Member]", "documentation": "Internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r23", "r117", "r132", "r133", "r134", "r151", "r152", "r153", "r155", "r161", "r163", "r173", "r206", "r207", "r276", "r323", "r324", "r325", "r351", "r352", "r363", "r364", "r365", "r366", "r367", "r368", "r370", "r377", "r378", "r379", "r380", "r381", "r382", "r392", "r440", "r441", "r442", "r450", "r500" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r151", "r152", "r153", "r173", "r402", "r445", "r451", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r481", "r483", "r484", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r551" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/ConsolidatedStatementsofOperations", "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r151", "r152", "r153", "r173", "r402", "r445", "r451", "r454", "r455", "r456", "r457", "r458", "r459", "r462", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r475", "r476", "r477", "r478", "r479", "r481", "r483", "r484", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r500", "r551" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r570", "r582", "r592", "r618" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for future equity grants", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r658" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r66", "r67", "r94", "r447", "r500", "r512" ] }, "inbx_StockIssuedDuringPeriodSharesNewIssuesCommonStockAndPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "StockIssuedDuringPeriodSharesNewIssuesCommonStockAndPreFundedWarrants", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock and pre-funded warrants in private placement, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues, Common Stock and Pre-Funded Warrants", "documentation": "Stock Issued During Period, Shares, New Issues, Common Stock and Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity", "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares upon exercise of stock options (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r66", "r67", "r94", "r298" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares, net of issuance costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r11", "r66", "r67", "r94", "r450", "r500", "r512", "r557" ] }, "inbx_StockIssuedDuringPeriodValueNewIssuesCommonStockAndPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStockAndPreFundedWarrants", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock and pre-funded warrants in private placement, net of issuance costs", "label": "Stock Issued During Period, Value, New Issues, Common Stock and Pre-Funded Warrants", "documentation": "Stock Issued During Period, Value, New Issues, Common Stock and Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares upon exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r23", "r94" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://inhibrx.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://inhibrx.com/role/ConsolidatedBalanceSheets", "http://inhibrx.com/role/ConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r67", "r70", "r71", "r86", "r464", "r480", "r501", "r502", "r545", "r558", "r650", "r661", "r706", "r726" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://inhibrx.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r91", "r143", "r261", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r276", "r369", "r503", "r505", "r513" ] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r8", "r504" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r383", "r398" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r383", "r398" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r383", "r398" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r383", "r398" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r383", "r398" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://inhibrx.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r397", "r399" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://inhibrx.com/role/OTHERFINANCIALINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER FINANCIAL INFORMATION", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r644" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r611" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit carryforward", "label": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r49" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r48" ] }, "us-gaap_TaxCreditCarryforwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLineItems", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Line Items]", "label": "Tax Credit Carryforward [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r48" ] }, "us-gaap_TaxCreditCarryforwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardTable", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Table]", "label": "Tax Credit Carryforward [Table]", "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances." } } }, "auth_ref": [ "r48" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r603" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r610" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r631" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r633" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inhibrx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r634" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r635" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r633" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r633" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r636" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r634" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://inhibrx.com/role/LICENSEANDGRANTREVENUESLicenseandCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r358" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r630" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails", "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrecognized tax benefits", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r334", "r341" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual for interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r340" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://inhibrx.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r340" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://inhibrx.com/role/INCOMETAXESUnrecognizedTaxBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increases related to current year tax positions", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r342" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r34", "r35", "r36", "r109", "r110", "r113", "r114" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://inhibrx.com/role/EQUITYCOMPENSATIONPLANNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPotentialDilutiveSecuritiesDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYCommonStockReservedforFutureIssuanceDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant to purchase common stock", "verboseLabel": "Warrants issued and outstanding", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r548", "r549", "r552", "r553", "r554", "r555" ] }, "inbx_WarrantsIssuedConcurrentlyWith2022LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "WarrantsIssuedConcurrentlyWith2022LoanAgreementMember", "presentation": [ "http://inhibrx.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Issued Concurrently With 2022 Loan Agreement", "label": "Warrants Issued Concurrently With 2022 Loan Agreement [Member]", "documentation": "Warrants Issued Concurrently With 2022 Loan Agreement" } } }, "auth_ref": [] }, "inbx_WarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "WarrantsPolicyPolicyTextBlock", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments with Characteristics of Both Liabilities and Equity", "label": "Warrants, Policy [Policy Text Block]", "documentation": "Warrants, Policy" } } }, "auth_ref": [] }, "inbx_WarrantsPreFundedMember": { "xbrltype": "domainItemType", "nsuri": "http://inhibrx.com/20231231", "localname": "WarrantsPreFundedMember", "presentation": [ "http://inhibrx.com/role/ORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://inhibrx.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, Pre-Funded", "label": "Warrants, Pre-Funded [Member]", "documentation": "Warrants, Pre-Funded" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares of common stock outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r165", "r170" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://inhibrx.com/role/ConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares of common stock outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r164", "r170" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r640": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 88 0001739614-24-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739614-24-000006-xbrl.zip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

1R\26?_!UX M10U^*KU\(3TM@(9LCTE&J%35S)8+,P_MDW6S8A)X2V5<757$=@9(B3DT1RLN M%HT,M-L"$OYT -*&D>0;R3#M"C2KI9#_'KH$47#PL< M^*&W96P<\+ U5NZ<_#J6;#K*OE26X4SOHK+?4,'="776P_A'K]+>\TI(F'./ M_K>N427UXM?^;2.OD <:GZ<=PI(X54Z#$9E_CAJ*P8L&56+?>,'6JX/M-8#6KOL.5+_?)71\ MR9N7J%"C>4%H>B'0F,"DSF8FD.@BM_A.JG:V9B&G(?GP+JG&?6DW3KMB^N[C MG0SY^I4IQIT,U#[:[2=-WZZ;2VVP8&._7#8>_KXSN",&3LRE! MS\JJG?'#JI][8 &G^7\R+*PZ-4O6HEF7_DE4'+/-FG.H%=0]T]5U(3FW4;&Z MT])+AFB$(L5NJ+D@[AS-(H&UJFTJ0*H#S)^O3YT5 -M/(+92;*TGPC'9#IFE M,U9/EW.:-#@Y&P"N"N\MXD=MP33RBRMUJW\81I;@BVDCM>DN9XTF6F>OBR=F%6S55\N?]XDS[=Z)YM6KO#/ MTB[$P:JX-[!6V]BP1]K3B#3CGD_DO R&/7V>2>,^:]Y@6,SPF9 O:85J0V1@ M@WC75,KOU1E%N:6GD@9JSFA M][/D)0*C^6FM,HA6="GI&%PR_UQ>0F7R(NX_)0DJXSQ;Z7>=U&?+BYBQ_I\B]_J/X77!X!Y"UOFRB#/63(]V#V MPA2G\G;!7C4A/FQTVZLY",$_>JE^%B?]5%TN4G$S%$67+]KE?7G[_[X*#:)J_$+J-,CX%M*+T5::*[% MI[H-.6X:16Z,RN0^,'NBB=3DHY#C)+D&Q WY$WZ^N@.= MW"%P=55U2Q)_>"H]V)[9LS9+$O8G"ZU@S=1$4K2"=EIRMZXSQ/CONC6E#3K@XG*2&DEWM=S$JG(UP3 MC*8,N9(W^OIC[!Z(YR4<\@32(*'[.M(V426#W,[:/-?G%Y!8C#OZ9I3;^F1@ M1;DKD$MK..:YRB=9-?_O"P-74)D3]1ZJ_).C]$*0IYZ/<6M-GJV3YNR&D:60 M/MOXZY( >^E+MX_]@[2VCX@RZ;L'&'4*"6Y-@2; 0 MW"U8")*$ ,$U2./:6&,)[AH< @2G<7=K)$!PE^Y&@M-H PV9O'?NFC7SW9F[ MYL?W8_]]GEI5M<[9^]2N4\W0-"K*)$+V79;&F6]N?;-?]ZOUN_*V= +F=:;] M[>!CDB0E'2F&\HZ,JCM:Z=LX[.?S'3-]$.HF]!1G=ZFM",K [NJ /?S(7#7! MMQ2&>[Z1V8@ZZ)4XCB65(!5AGRS=QNLOP7,/B5Y,GOP= ,I&?ZRT_R?+^$^> MS354;#<.C7QIY*E]F5OQC+P[XU9GISHU<,V\G(/+YD1V),K+ERT7[;HI.4D* M7C&R4?83:I)C@UB23KR2V\O&QQSLRP;_!9!T\*.>#!I\^UE6&*W2T"BH?%7$ MQM.>0KL6ITEX<&#R,1_=W[_.W[+0Z&=)JA?H(-!K1[+IL);BS%]*QWQ_L+>Q MI*72$;=K,F?U+;9XUO7E:IV99,@2H5^0!+*+^Q#MHU-9!J-D7'Z(__6GV!N4 M6[\I^VV9J[]7TJY":D&0#.KNR7E#')I0" #(A.9>PO\"&I &&DA#L0*Y9H4Y MW G)I/%FFBXS'4;[UY[*#N;CQ\.KH\GU=WQ![69OX7S2' M02=X0;V]]%LQ=WI N..SDX$DK8IQ9[S(+*<5\%.K6S/2\^G.$X/320P["["C M/F1E\DOCV<]X+WK]FILV]TG9;QZO]/=8*-&*_M&6^(6&Z MO#O.PIC\?N[*SIU @T7$QO,K7,VBE>R@!Y@:0'M*\J:N'OU-)JOX+Z"XER.+ M(IN%R(JQAN)FT,,@KR?G$2C!3D1 ),_&SWF7L.V_1A51!+/MR#N9Z3(EG'_V^Q:8>21%7+)J>&@(+=JWP1=NWG# MX^]:NF*X7E/;HJ0P*F.42T*.KI;\MU?)/.ZZGQ@M2@]6#ZTP"6J<*VL>%7>V M,]TMR*/TAM95XO+K9HUUECOLQ"*V!*_H+[CRIAL?GC,&DF[\61>8NO#S$6I- M4&<;.AQZ9^G6%D<5NM!Z">6B*A\JFBVQ4W>6S7-CSUF2_8K!XN]O?6;\:CD2 MWF9;GD BK0I#<%0@?E=R2NBHO??I '?UD M-A? \EW:SW_M5$5MML,9GF-_N_.\886D(IE=71!@:K^52C]I@N<'/42Y.F_F M>.TO'Q4M5=!MABGAV'PGL0STS^G!.9FL@D3VH\O=RE0.1';?;LCD"9:GI,Y- M%O_YEU/U_]O=&X#S4>2T=J!8M^F/2IJC++*[\RC \;!==HF5'KX ML4=%2=+SG>4WM99NKQ-&^V6^$@]U6$M\B!&U6]2RW-[ WU_6"H//671'K!+&;!I@,S8PBRQ]M/59ZMOP^EJLAUCP&^HX15!92@0J]\6G]C M9&7:EA'VCY;Y3RS O\C&\(Q;>).3)#;UQ@PN!,#)BK$%H(I6)RA9C->AFCZU MUH8=@+ MQF1Z-BKV*TMGTW,7@-S(O)4T"9N J3%XAQM;N=(G/=@E),VHOM;E^#@TM]OE M5CB[D WF?I,HU!Y+XU> 5U4:Y\I8<+Y#K#)J^%/P' +I\"V.RRI[ MBGNW1B/%[:#1@A%9F+0H?2O,KZ=\,=-8'9-Y;&UOPC/M$=VIEJ<1$O#2\TZZ MO&>C2QGW62U!D& O[I8-UW2=#!!$46!LH%Q=L[&FQ1X\ZDYJ2/<\,F(7%RI] M5^R3&&IU9VY>KN+C4/^^PR= PDFT>8E+'MHJO">1'E^%42O0L.$( M7Z[><1;X"?9OYE\,0]H2Y#-+ZEZ^ J>E/J\87&K>W5[T2E?(&X)2&1O;I]$L M9)8L7^S$/UY)(2!@IR%>6H0UD:M0)U?:,T"R-BO0#OQ\U? M[L[BW)I&.WOQ.[^! MN]$ZXK0:L,D40LCDL9>M-_(8C#-P[9TF4F-@_Q[D3OU,L*6BPBQLDKN90+*- M^#9\$]H;G1=V+9H95AS(O%/@"DR2RAE4V'JL_@HW2>Y0(.[R-E4W0"%:) M+5(/)+:K7]SW?NSP_>8JB=-"HQ]K=G>1/+0Q( 5W?L!HX!VK+;5O5-:&Y"O M&LNF$*"3B+D:T18\,:4 I\,WXHZD!+W:\KZ>%$1K+5=Y^6S97N0* M5?E8\!&?#EF'387KA,3N<@?)U9^D)1DV]&>G$RHECD02(MG]82]VY,;V7T"7 M/47H/[90!>$%F\R#S>^$B(@-U=FC.^3T$]+T M>.QORJM6NHQNJL[GRT&2@2&9@ZNF5!Y^G3)[.YGT;$W!\NP2[7@O Z+2;O4V M?!]R+"MLTYM\,ROT-4AX[E9L2>(T_2RK_2RZ90._\#/8Y3*C@\F+A;.TK.US M#56[ST96MM>.Y7AAG0$YJ'V-3Q &TQPN+\3(;@IN'I>LJ.::X*&&I8%1RC8G MU(JK]BQ^T!EO/],1&E'M3^G)<134;!7F* ]X@FFU!IAED\)K).*D_=WA)Z&& M0R94;:$#;8TSO)G!U#FM7W"3M-9P\%2Z2Z'.X8BY^\&CQM+IZ=,5E1H8&P4/ M/WRARIT%^-O\M\>]C?YT(V?34^;,J=H6@+A<_\IR-_$$_+M.?$,Q'O#TQ&GE MT*=1/+=T&\._"23_#)Y1$2USS>\EC6Y=(M$0'^Y56L8N^^/F^\3D#L6H]?L( MP\]N(%&T0/.+[]69 [@H?/>/S)4\H/22>M/KX5F2UI.E [WF#Z9V N^H3-09 MQV!BDG(C1ILV<:U[)E!G=S\4-D*RZOF@LZ-]G-1=PUE,N6M"8C9+SW;$A"P# MRO:?EB@9,>%5Z=IQ;=.UW2VH1^5%^4LX.5PR@@(DJ!>=$$V%P6'MPZ7^Z:>GGZE;0L8O#4% M>TT]WE?WTS.+.$H";U9@8<3%Q <]O7Q3!P05$9ZQ*SI-S7'Z/ERVL02C:]]K MZ"R#$R^@%FX[43G/^8P]SVXR@:\Q^E,A^R(+"P\68^6RV6>J*ALV'*H7>S=S MIC2F(!$96N/'QR)QW@$_E(8YM%P7XXO]G E9J\ 0 MH5$]\P15H 5QLKVV].+]15&>S6$0 M9OG-&>'.[;YZP3&&S?KZQRY^<8%OKP.7FH3J9S'R3O+GN8S>=.)8\@F6!\FF MH&31CT^(]=OL[ZIXZR3LCE,2CR_>*T$RO?[;FS.ICK6J7M+E4["B&U&";^:D M1"O OK_4 ]T]?LZ.,R#H5J2:D NX7I/2!_W"T#"O=<;:FOJF3D?I+VM@@U5N MV0S.HU]$=ZVD8.8)4#G*.Q1C#)?\^KM@ZKC14?37.6MG7= HW9.IFM=5,58L MTMP@3;0&8I)^W7"\=(4S' 0@R4K#5V:6T3&Z>KCB/N<9"K/.U-79_UBGM^+, MJRG^8GRI<,P?6%P='6#-K<\8^U(YD]M9(-*'^'4&DDT\6 M]V2>S3@VS@3:U_@T)U3FOLFW,F,*(L1E8G6! )F%U@)B0\H:!GHN*LP?&=G6Z)5.^*'\"=M:ATSK-\?2RN=:<#]RJ=\ MD2)0J/VKO4P/,3(I6$QN$-8(UV]L4$?AEP[1JSHTK,1?\)31SGV)6>7C EL2 MH[ZZH^I5<(;^7T#=9Q?)S&,I4=18#X1GRJG16'20P3]-M]S *U.+ _%^+?&T MQP^9B=:[RD9?6J)FM!L>)J9B)'WN+A"HV$HS*Y(3 HK5^#H-W'?J<97U!^O]T8O5U:-)'_ML9F]F1Z>T,E= M\=[,LS_/BZ!Y@= P< ]PJ;&[RDP1@?B/=#%ZWHFGM&.[B*I.E5G& >BIJWZ MTTS)E&QLN"*%NI^\B7FDA-V]'..#W%%.9B<_)-#4\@7<[L)5O@G% C62)D9W M;+.T V50!2U)S[!/,CA.7>@!A1B6&OFV;<;*(8VSZ%9] __98[*46 MVVJ@!.#"F1K--S.0N8^.-O[&@TA-XFZ!O M3U3TK7[S%=_I/*JU9#H]/Q/8#EO8)Q1?F<3O#.]M"XS"*/E<@4C$=AL2S+=\ M9JSL R/#W&]P9J*NQT7A:9&TX0X751]&-S[3'%J=\S_3NX??#>#\]O,E/G<5 M8_B$.*S<^,!!-1G51;4TVN9@@&WG9O]1 K+#J-_,@J^*4QEV+>Q:ZR/+U EK?D$=J>TLB:9?Y*2UWXM4XR"DQ M#:=V&0^LBXWC#*4R3 M^$7]U@H_Q0@B>FQ<^>K6SM&)[W7BD.KG)K,7W!L)6D@3&$5LE3__CW21"6'< M%6>0\[,MU9.SN(<;#)FK[FW@%:2NJ5#C'''NK7!U]R:QC#U!)S'W7G Y_<-< ME:3Y74G*_RC]3^ M;MHQ7_"B\]R-NF;V>]NZ4/1(O;2\W])<^H_;*@7?Z]'6"QX=B% NR8R'X9'O MJ)H#7"7GTU8F-;U_7,G=1BRY9ZEY@2ZE45WG]=[/A^!RM1\+AX.G4 UT!KQI M7DJ)>G22,/KZ57-:EZ4R?3"KT^B6!UM5@.SF7P#VGP?\AC0RSK7"\^]"=2-/ M$U?C,BQ\*32S,U&RX2:O6M%^G+5VUC_Y"HI\-NR203YNRJLOI E9@SI<)WVO M[QEU0XVG'849/VATSJJ_=*(38Q.3N;P5^1C19V&G--TL87"M8BQ*T\#WG[:, M^ 5*5-KX_XWEY/\)%B"J9+/QJK92#7%"]BNP4?<5'X^^E28 Y\6?19PX].7! MK@P6VIL_7NJS'3G4VE/XQ^.%[42X#C$142XA1],IN>_"_&Q,+U7](RK2)#^] M6$/N D-*)N5QYYTOFUFM8W:RI!A9^#W%Q^F+,>6&<.UO!;E:PKG*'XHAYX_! MI*Z7T+$\1GW8:?Q0+N4]R_%4$3O?".0C9',DC?!)!!!TC6=ZC;?MU/=TK M%:+%\[TXU9N)])MY(DQ;FGLAQA)OC-K*UJ ./6)=,%::(W)G\-MCI>6K=:H3 MKWDR3LBQ#C>?NJ?83E?8?>Y?@#UHX^L5A:5O_R"#],-(U1Q__97BQ*&5Z#HN MDXO8I+LII^$:J$F"X>#ZVJ6SN$?;XR9_:5LJ6XEA6'+K1]/)!WFZ00.T.[RU M@PO>8MYF.XZ94?-TJ[D?\++P@M;0,?E^PKI3@P.I%L$+_5X,ZUE<&38^CQ(% MY_RH93:W@*XF>'>^8*_=3V@5ZS)%D46/3B7VS,=@3Q=+@GWZ\,VAID!KX>3> M0#S:]RBR^\ZP'&^W!5VHNT2Y"LG+X#0N')Y*5U/IAX7 !L_P06 -V+OO^J-Z M@:&DAB?W4Z76%"9.P9%/]%)(CLYO /^I4ONK3)DE7-NP(\328A;J+. M3(\W.QK;)M+B^1;&11)RE,JQ3K\^4R-\0]7;-YK0[S.G$(OK:?95S]FMW M?2U)KB_.(, -2 9A6 /==J7"QP4%3>R;<_66^>)O1XRVM]P(S$=Z-DFQEALA M?/ZRS6@.Q)&>7-K5!*H2F]ZF+MX^W4IWI;GZL$E@=6$1B/T78.EW$@YY/HTQ M1N38KW9E_MSSN%-B9\_2VD@X5=B5(E<]B.MF]K=8*$07(.,?@>RA%NG71][D M?20JX7@2(40]],CY(*GNS\P.^ON5MU68M2)%*FEDPL!8_U\ MUS#:KZP9PSWEZ"[E:\3M&%%98,Z3]!; VNY2+HJ5\%JKR@?6UTFA']X/)2]( MFW(J.N?L;(ZF)?P.>-Q)?.K#TDEAL.<));5;2-=>^L-:E9\^XG?#(9G'W?Y4 MI98E]$".AN4PJWG2@7'F*H;QU._OP"B8;HA"3WK(N,Q^ :5H6WN M\\804 32=GP80/\F^#,C6\RF*$OI7"Q"@V6A]VJ/H\L -H:-X-.70,XL"'-% MF,\+F^)/2H\WB%P=?1G'2GKS1&F;6Z*^=G^)]?(0, [P#8BK+45_N?I\$9WF M.;- YNE I/:H2<[%-V;339+XTIGTX7>:+W)%D2_9E6F:%/A2R4*?W*45&'1@ M^AQMBOB2'@#/TC= *WJ[1E2#G7F!/^EKO^W.WNK&YESV53)X1H: K;)?;U1@ MXQ-MO3I:*"D&!$SFHZ-@ _.RH)KT\0@!9=+BS_I>K!?"D2@<^!HTWM'Q>G7$ M,L!>O]>3(6R9D3&E;)^C-HA%(9&B?I M>WB6K)S$G37V'3LKU*%Z997@?;8(Q35HGY_:G[!YCIWV5CE_V:FJ M-W'YE7D*,NF]:TWRY!B,*ZKS%+89%WMZ;7U1"RL%;3$O3'3OGV,$0J^5Q28_ M3DYW/FNOR;#7#[2)NH;.-&. "H5DO&R[DL @&4%',,RS0G]E[X/HR6[S%SOZ M .JW,<"RGFMHOE YX;"=)70@=(+1]#C03HN+H!E\NK<*' M1$$X3P.&0O/MFD493,++5D87TKWR?9+/&W^0^IIK:A).P$WU%Y(@,QM$QS)\ M_GRM,Q<7L8W1XKIGD[^>>K\.H1?U6BT._^F:"<",@H(MV=T&Q:2'MH?6P012 MP(?.?TL\=%)G!%97:XC3"WA[>__CK,E6487RKG["MV 495ZQU1!-565;I6^V%/84+OD49@EXA!9C_B2*JW5'5@!89ST[3 AIO M].TI3/8%SD]EGQZ"6HST??C#,U,E8*(Y?HZ=A\STF+;_,[3?3[0]8WR3FG.;VK'7T3F[%\\ >7\VA1GW#G11%.%4 MY5.^OT[4D688R[?^>T._,I1SX_%S*X*[JAV<>&W7^:Y?^13/[LO94088QKF/ M?8_&I0\K:]=(/O&^:F2]^0;8E<:"B?&:9AKH)HK4!I#%MG >V^&"Z(%&R1># MD.[]Y>*N^))Q;P^$6*%1=FY)#=SZQJ!\4 .9(0B!P29[! M$EM3KBST^0+.Y>@DR//XHN$KW'XZYWQ8^FSTR\Q!^UKF01H6JP:K_24C[-:T MGD@I-^5BY=\"/9,D[5[2%>5U4^\]E@XM&N(F$+,5[%,_9Q)GO,3%Z0ER+Q&9 M@='"&Q3[27L&Q;!C1 M?M">K@)"/['/W:S<)E@Q_#,:BA:-[6K5C2R V=G77"$*6UH]42*!E!FN>\+'/J)_H90IZ"S M)7,L61%OB:-9&YSD?#V@,%:V=VGME.++T!NBD]<"5ILF9VG*K"( M!6]?PM C#=8UW"09!BYF/98B\CP#>-Z;-K0-ZJWA(ENJ1W1[V'K1HRJF%G&@ MLFPQ9VU1US?D2JR>YKFC(]_HL.J-?VN8ILHLZ;U\/D4=$G4=C:& HR_:0>T! M8N5"^1QMSF/NYS0$V93Q#GK4FU\T]+3FG"_%UW<_MWSONC$Z25QJ==-Z'WP; MY?P5(F G(]$8WU__1_GZDY]\TYZI\T0'2PDNN;CLV][T 3WO3,TR]V+>&!ME MY<<<6S_%B_V#:[B8)R%%P"I /"49A/M/,"0%NO^[(E_- ^^"&EQLJLUKA_3 M W[GQ;R<4)3EF7_/P6:94A+"9C^A>L*W'T]J[+O^ 4;SLAUPQ _(I4C#<"!Q/ M%/)]&*/5D]5]/9F '<3G0B4'5F; Z/F!P08+KS>X7JZQMCEJ5WN6=\$U!C\! M2V"Y!4; ME!0;;D98ZF-S@@L&U4HTI[T.!/H,?Z%Q7X%CQ5$ZD5RH"CB&VXP M8I73,%S7E56*1)*;V#!E)WHWR+66+^"R.RY]+!]-H1VR_Z:I-4D5KI,2I$Y M*H>ARNOK6-E,*PA 5,D7=W2$K,C5M_G$\#9"UMQ&\>FU\*C,CH9>J\"1,J_^ M+6BT+BK@J*F[5*W,'O5VQ)7;*')./V"37LT(!S8VZ$L=M;R,X4Z7FZIZFF?0 MHN8LS+CPZ2] N5FWEP>6H/D;.\Z'JQ/@RQ^->>^.F(SM8CR=2YE?\#6)K@N4 M>-)!D?[+BI1<)+0Y_H0<-"/#;KAD@!9\;]-R[E08^Z49W,;3\^45T2XXH)!Z M$U@?'VPQSSDG3/^S+=BA-_$N.;8$^G\($35F!;G^@"0\K/-T^/#T0%>PG*7^KH,:08 RL ME2M7(ZB!SD7=-%^]05/ NTG1BHJHX2^S'?)E!CXAWK+M37K#+QBNS&0^P+A* MZ?"[DO))@8Q@YX?'.?B&2@F#$D 1FJ,=@ M%[;@_LFKYP,5>VS!+.>1VQ<,1 MM\3Y>VR(G+1$D/P>K NT/XHRC?V0(:7Q)4M._RAX;74["_,<9U"H4^%$>\:F MQ9 Q8OE]NFP[\G? _BE%S#JPNZM63 =HDU+Y0[ 5\U-<,OY=B(I\#U?F+ M!3S'Z>5K9-:4EE5/W$X1K@R9ELQW8>O9?+(2;W H3B87R>?LYZ'\A9V@-\. M"K?VK%=\8SNG'E7[%UO)T&?2W#JQ&&':<&%) MBR])O"]5/B2KS"$GI64CR+MS %YY-%+F)?O>CS1L?HYPF_:@#/M=*AD>DV^] M5,%UVUSPADOC4]" B4B'VU+79O$EV]4]\1&"M..MRF+L,7J*G@A\E76_;XQ-[5V(S.YW>H=Z=Z$^;XM_ M/@TF7<^.V\QUSP04;)+Y'CO',#C%EQA&*]P5>'9(FK!JL7$QQ;!H=?IQ+0J% MEMDS?&FE3*//FFQLC;?EYKR?^+IYC8N:%6UTK4&K*,TVJG;(M:7^DKAL;[K[ M@:/VS-&\&=?,\R#>U&@V$QIT>>06(.PDC$MYT^<2C>/SG:! \I2( !?9FD]1 M(8.U"G;LL"Y=4ZA1Z%M_OIFT-]N2L.NB>')T9*JL-QI([B$RY2_M##^2>5[- M[TE/ZY'E324]68.3?4M\^X/PUZNA;]&IVL7Q'X/G@]C_"X'\[^N&^P^X4J'+ MW7PR+\ JVJ? @0U*-&3_2C)C:FE]WS)>G(GH4UU@1(@LT\*^DK_AG:M=%W[\ M ,.7?.=:1+-UV.W$U%QVSZ,4[X_7^LSY5C&A,U$ -'V#VD[6X"L#]G%0A3TW MV<0T( (OML@_&:/ZJ\,FE:6Q$.EW=Q=(O&:T3WM-ZZJ_4A/%J#K_9)+>HB/O MXS =052K*W),U?G$PSIBS!7O@/"P,MECFKO(L;.UYR#VEQRB$I1':OA^UH%M MWO^CIQW(0]UX11]KN[B5]">3>YJ9LM&9))8'C17^%J#$MSW8R;+ED0S=1?/$8RT+2F+A"8=DH M47\J>>^2T=_V"_CZ#@4.M-\(L"U46%J BOO<(:?WQ5L2Q241C;L97Z>C&S/] MDY"!XUQ=JD)8*^"\GF6MOHU0D0U0JQ9:0YA[>.VH9XRP3T#JZA.'2CM#B(:T M%/"4_9U^COJ M_JN^-VZ09+"O8PI!M)*\6\?[R+X8ZH;#7/Z2!'/OV^IT-U5 MW&NU"L]A_H5KI-*I=&=[QN%6W3.Z.9_S:W.89N!7;0+HPR2$)1,&KQ15)P$V MO+LF'Y4@/3)Z(#')E.Q'KMDVI01^=\S[K_:!]2=A\QS6(N.NN,'='9SNB4=AU$?"X9O= M^':R%!A!R_P_:1O6,PX+#JY;M>Q)GR.EU=B3 @[<@HC/NB,@>//"O!9^!\^_ M8=R/L'"^@6L ,#'[ M"]+\ [R4_EH@\D32<)JX+TH?QU A^0^R^5!5=./IK2D1^.[#[_Q9!ML"8I2Z M&&.1BIRJV,46A'IW'3BSH3C+>PC]OOJNCA)O)N\R.CEB(C""-$!%I@$K:S/O MD:UN)J0X_^ %FYT3KH#!&O8T=W+XA I)+[*98+[A HB_C&:9EU;>4&]IFSE; M<2Y-\>:1G _\ZHG[V\%J1IB[ER6V9*!NU="H%A].Q/I"?&+#!(,($NV0M"GA M'6](&DK7:K;:!J\2XC)=C28$,NQ??(?7=Z4%*$SOW Z&##*ES41X/?)+BLV. M?^=1C=T/ZZ*9XXL]3A2Z=O\*MJIK;$Q@O6MG_OX"AXXU0%.U"B3+:-R9M^2( M3%/]NJEFO_IZ) [+)*/W8$\.:(;A/PT,;[A_O6$XS=:2>/)L=,2;\SJ&I52@ M9\MLTZOZK$-O4R6.K7EF07$6>4=Z/GIN<.QBR8H4B%=,T.K2\/OTOQQ__M># MT__:;72N.Y)?U]T\,%AK"O*?FSAFIR4#+#CHU$J0: 7' M<7S56N=<4T%#*M[WYB08^K,OUBI6W"8D>8[,77ZF0Z-XLL1^7N0V]BO2(>U: M(%SY-E0.&"\2>_6Y"/Q#D3UT1Q*+"SNV!*3&YJC$F!%?#$D#)U^YG^:%2W$C MZ#',/PS^W(Z/UYHV.'O=+[)VV.OG!*<\>* M[XD/6@^)'K#M.-:!KZ0P M'*C\!!&B#1B;>6:?;.=K7/[#SG78C,0I__M5 G;POC(C2Y9*E=]6+N>4%",\ MBTSD;&=2(<=QX1X;^%WNL-![M/5D]7(07-)G&HXR0N^OF+3,5GE6.#>)IK(< MOCM61ZAHP8?6T-=7^>0_-C8_Y>; JT@TGO"O%'>,#_Y6H.]_P:'RDUJ9H%2F M<8^6A;&V P7Y]J7I?8<$1^%$!OU9QFB1&83HZ5] 4*BQ:82''Q2MO/"QMOG. M\:AJU=2F-N;A#%[CC?4'VXD]%^]]$THE_"*'DW$EP[_3P,5J=L!EV&OX%;57 M8JIV"X[8",%\D'3TYLGA"8(_>B%ATIEAZ0^);*IGF639V2F6M-=K:H*\0 3L ?1\6],,!(*W(,IL._TM,9'DR3A M])&/3<]3>.TR?ZP9@@0-_F16%<@X=BQP-P0)MNHC99!- MSW&0_(]--O31O85I:[L=&08T-@YYPD;A8RR=%5]1,I%^Q0=$?%5EZO>)XF_2 MIE_GLPE:_L(M6PM1P;6R9+V":J":6F6C.S2\JWKMR)-Q%_I4CV@YXA#*"/?K M[]813'H"*,:>MHU(83*"CT%B4_F= D2$-U]R++_T^^*]))#6_,<#RT]/@B\K M3HCM3J.7S-\TVS5U%$+6#=F3LZ]E=CILD.&AGKRT;V>$13H_F^6J-/<#O[,0 MXCYP=F('^ TP.(@^617N\+H:]8?9B5P<"LY>55(\\O>L6Q#2EY*L0AN7)(E\ M7O!P56NP8:W5'3Y8M=+&!W[KXC0$DPQFFH07K2HWJ>Y;I1SVYWP=A@=M>N^V MW;H:Y#Y!=4 XT9V>O)WP'&&"Q&PNEXSEQ2MZ8*R-VJEL_X/DPV+2V50#;#W/ MQL^'Y/6C#"=#*>;5>/MU--=IO.(I[WQ%H$^YT:0_Y6!1+)U"C*JX5/:6%40( MZ^ V95ZW^9&BL\="C(R95^K3SE<^!Z;6=MICSL5+@X*T&4^5O"R3])^/R,:" M\PY/X..T \NDMXU7B2#/ &>?""A[!,U=A&N>Y603:.W/?ZWF_;>2L?^ (O,O M !0?F3D9OCS6=^N>)2FML#CFZ99_G*A.?=9[*+;+[$:@V9V[P0+E]S!F(3-8 M,U!J_LRF:^*?86JK5OLP>A/$,M@+G8E?]H,'; SPXRMZ%L-V[3,_"HT0 H5J M$T1+_WW^&ZMW+_/!.0RAF^RW8Z1O;V 7,V*O2\>76/A!]:E17!$^L!@ WNV[ MYU*=[V+>&*E0L<=-=TH7S8P$<*?B02SDU8VD_SHBL]24ABEAM' M"0MW?R6)LYN]3_%XBL4E+7!@'-@7'QYO@XRU?(\ROFLJ<01D3L\_:1,7#3,> MC$#BL@#V"=BB%M 9*)N^/-++QW^SF MM]E?I.(^21@[FF269YESDF6T@[!-'TO)@_SCB^HR2'MRRJ,D0X=[F"G>#J)M M HK080=&\1I=(?M+SKE6<5QX(75E7V#:I+GF5%@GP/J\ ;J.%^4&]M?SX]Z@ MDG61 ^/-MY7#/H!+9D+A_0TZ&3Y3S+O9BSVV9C]>LD#D^MS./SFRU&O#>NKG M1U'E?U.^+R$:>NP@S)R4Y_:DMPI\O1E\5]I$RN M"!&'.J/5[_3'?]RWOT5M7>N=5P_5M:M;J0'9=E0 0:]<0R\G[6^:!Q<4-!08 ML[ZL;;(:NH%V!-K36^X,S>GL;M4+L;79E!?2%;O0B TZ:$= I9IEX8JJAY^(P\M: MH)TY1BL>CI-_/;);$H&111=4V$K(7AFG56TM[VML&S4\]O\+>"KEQ%1VZ(=H M)T!WFI]B.)K#"T+?SSI1+!4UNQ6.!;3G\4#^+/M,EE)A%=O!LW8C0+P\UYG9 M^Z0?#9/>O"O!,IP!N$@+Z%QF>%R>9E^+VI^N#KZP.V%W3I5MR_=FWRDZ%8V6 M>B\X*))RIL\QM$ M'?&R>,?M'5O[X-"N<@0,$I0Z.V5 I68[="$TZ,G^Z\>*S!TBYE^3#=\ %I$6 MV/GN$UHUN N.A0>%1G/09ZT=)'A](WZV=3@IB6_38^)ZDEO^;<0@*983!-4Z MZV]GGLO7QV,\Z70C:DQY+80P.?>;^+>FN/NT0#*,&O50Q4_%4BT7-EYG=Z+ ME*!>N4/7>] >],GZGD$C+/QAB=AN3%*%1(.ZO>X%EWU]*H$MC]Q.2]"@;(16+,GSA]K& '%-N<]6&?7H=9^*/YPUMJ26?+3Y(5<8. MOL5*PI>DL$]7;PXW:6_FFW]2I&_W-&3W.C[D=1%6Z@57H\>""67F[J!(PI^F MZX>G^@N3?NJ?]5]B\A\M BREW!,_^0-]?OP%]+W[<*<) I2,)7'$J#PCS25@ MCG>V!]R&PIVC*IVJGDZ93]'VCS.Q>-#4YDQU^/2:N8B/[$J[9V=>,)Q1A/IZ MN(&S#%K3SH_.E_JI.QY76/O_',$\R$G7@!;^UV@KV"_B;O? ..WH]&0LET35 M(O$U^;P.(":.XEG#GQ_E']R2D_>5Q%ZZ:!OR_HNE93S_7R;Z_\M,OQF_(CF@ MFQD.(W0H:5)%3E^@$4DJ'_QWS*:Q>O?.@R_' TY,LP.;CJ(.\IBKCSB[B$1YMM8S?%9/C"Z M3;V*@T"RK2D/XY>.3SZUS%S__G-:2U^@<* MEY:P+ET_@IT:D.<\WTKQR)ZAY)LG]Y?,6[(/0W<[853Q5I%I*]MES$8V8K)@ MF\0HP#+*JYV\0(I(C)LY9G[AQ>,F!CO2@T:]#<+^![PCX^H(KFE/;G1B(,+8 M96B'QO+:BNLZ\F2$5*9JSU3T84ZD+3)G<)*6PG/HX;N;A+FU;>KV&_=6J]UV:3K*.P!%QKJ.F$\ZD=B^(V5WNW5:EQ!@IP;$HM:&,H>UE*I*URN9I;9OBJQUZ!;)?5 MX E'B:^(G@;OS>R9J!6C;V$#>KGT\\>5K.WM<]"D8<-WV]._>"+#-%/?:1/, (F=/&[(NJ^2 [_8Z>VGEWD*?7U Y^LINZE- F)R-4&ST"YFNTQ( MF3MTKVF^BU4-<_+RC?;XM3;WD;][*R-KS'GF)[0SO,I0OBEI L?2AVXU741E MS!5F%-<=40$DO[23XD>H&X)B%4 1E=E"VL-LA(OB_>9N&Y'Y9#F&!G/^LHA) M\H$F!7$>"W50.V/T5[S?E@Y1[7$((G]D7>("=2N"%U_2V&+^BLC,W9TNW4'E MJ?S#DV/N,2D]1(#*T ;UY;B99GO#"X5(>NQPK>_YK)X\:O1_ ;9Z@>;E@7TJ M%<:M=:#/5LUIJJ+4L91]241&%VO!<8+306(GT;=DG3M9G#_?"_OD[G"+'1V- MK%'JKQX/,RN*TUU5 "D:%OUEG_T%.*EL=Q:GIU2P^?=]IE)5N\4![H!^H(L1 M@[7HSP'F^257DDL]]6,]GS,_W>1$!S:>LY"+0W,P\@BQ2PV&FC[EX+H \X*9#T3&#K3^4#O;X]$BI'O=BR'7C>F:CA<5=M&GBF]K M\C3O.%MB>E03 ;U?LY#^@7XE)C_:39>ZAPR\\LI CT U?9EA92^_)2FOD!39 M4T8=W_6_A#&K4&&UG](BG!(W)RGW=9OKE1U.1KE-!"2KEN3[:J2"W"#9>J7@ M)&!8(%6C51VM*ZQ"<$?Z;:]4\Q?8VOG;(_];ICMW$S4D/\&*&F)KMO*PZJ&_ M@O[99U%<_4) W7"/!U:0MM9U+(WLDH@)O6>N<.C'6H=514%J03YE8J I*I_B MIQ3EIK1@CX%_6IMKIFY&J+JK"[PH(3@X"4#'$N1=G=1Z$GY0!@V]F#SZ-U_. MMM<2PV[[14GEL'8\5J"K,=G_0S]3Z^E8M#DN$> J;%$^[%5\8A[@=G5F?Z?Z MF:H 9D09%5GRO"$JNB'99O0OH)Y'AO&TNP](CBY'PE_,G C=/S;\DPIEZ?5^]A)M$L>^F/>BNY*D"N7OBOBW.5Q1!'"-BMV\< MPE\#PR\L(3PVQFT=+1N3^$>G<2US.T'3&$D$G0<0[\_K_=/QXL\C=E3O34Q> M5KZNB;'BQO:Y$N/L\D7'PLG]T%S( M2_"7@SX9OI!?PV;-3Y2OTB7E;K!N])'T9KYW48"[:PUTMWL1VEY:@E'X[BU? MKZ0HW26LRAJ&PMXW]'FTLAQ)K4[$/N%^%'>YFTL[GSP@ ZR9I9S"H$,%8K:] MR>DH"K&Y3;SUD7+#SQ9;OSC=['*M4&$EY3$(:^'9LPCFXC9VM%A:GZT)T(\F MJ#)MA38@XZ<[5:Y Z$C92!Y/SX5M,#0M4."8+B$9)ZD@ #M.)"[O Z@'HW9Z MHML]1WJ54#4RR[&>E;[MR60E>BUW<@G]47E1!>R1)3ZJ?JHK:*@2,:>?E@0I MH=^;W'J.TXCZDFZ#.!C#8?6J.V]25:<^U^$6V7!M>8'A'N%$VUEZ([G%>*OG M']0_9XH[6NKB4=+5$M02Y ;LR3S!*"QT."*46V>A]+Q')%)EK+_L5>&/6 AP MFN6D#^K0IF7[ FL4]&J.6(TR 1WEJ)@.YWE-B03-P'_9.QJV\1C:(5EF2-C0 MXURMDO)IE7 *T)-P%QHD+2>3N@+6TI@5=B1<7K;KUV^L#_^5XX6?]*J5["S) MFS)$<_6"L^7^F9B_N8\/=&,%L2Y9M[] 2$M<2)G/?K'K#F%IO,@[K"U9A2%4 M=VF>G-SO ^ >S+KKTF(KGT<8E'N&8[8D^'V_@F?-[W;S;_5J_=^BL-AP=G[VR\Q0ECE;+EC:VU.VV3Q2"SOU3_U^>3#'3>"B89_WJN M-I'"P;O\/^Z*9+3\[TJ<_Q-8,/!? %PV',+!J#Q?M>7CZ$VX':80VW#Y<5\, M*CX3:&5*9@#2<'Z77B 5V"C=Z9*;QU!Z(QT)M+M:36OWFQV2EH<@&$I6 M&2.K*\ND\3^&S/6FD+^ WK<=G&US>>' (]F.KH;VF?G5J^&/'1 ^+ SW5K0D M"?KP44!+?^ZW5GW19]Y7X,OU.X&=-4H*(@:RA\:I) MQG^46IXL%:%!'PN??<)#PN\RUH+MBSR08X(-0,,EXK_N!M+8/I<9V3FKW0WH MR /7!6-D3?!=IUNAC/[*4P]L_N(=]7,(0PW(G/_!%\"AEXG:QY67A,M^B5&W M[L,1O)WC_453$^,[2O3]U=+*8A-@*"LZ\I1;&?6A\6\" M'WN$>L./E!P/3^CJG8U\HG,7_W1]OX#BH15/K_X"5%#S!? 32J[O/U9&FYI2 M?!+?09^=E6N*#^^3OUY/G3K(U COZWZLNLQ7[_I3R=&7]OT4O)66\B5.^ UV MS3M/+F\R['*)X;VD5K05_B;D,B-,!)L"1_QH;\_$TQ$* M'D-R( Q6]T5I8_ 66^GI>1?VNHVE17(3N196P\1[@O 6"ZP M_OP%D/M+LQNP%!?^\1KT.-"Q=**?V/*>(+(@$H?MZ7GR.CE2]#;E,JK;55[: MB2RS-10C'6'DR)^O2)C,F!*-?F8A\*0G]R*U%5_;I1OA1AV!AK[E]-X_E#N1X<3M^ M_O^H[=S#F5[ ./XCD9C5'GQ MLLAQB6H=&9T=,9?0AM,@V;:QW7DC'F=/X\SSF=\T_GC\__[Q_O^[S/ M]WW>[_/-L/N2./V:T=9_5=$33(D9K*>\CZB!M6;TPC[V*Y/7.RA&69P:\PJ9 M_ $Q%)+BY5[+B^*!7C[.O6-NGI. )EDTDW5V]DS^]G99S.QO]TT[G-;K',&Y MAC /B[&9=5A/=*4E0I35[XEQCR VJYYJ* MQBLP?*M]A*E.0^U0.IJU'Z07M6HP2V@FVXUG7PS ,=1,D"'YB50"]H&)+-2[3<;=I+D M=!%"ZU3;:_JC\\.B89')MBY3;*-@QMOU6_[S55T%F1YUSEG%^PQUBN:#4?$P M6MV-W@Q)!=P_&9=D@$A:*%U62_$X-N0!M*NQ(4HY9U'-VOGR#L-5!=0>1@J? M'3R:,_%J9?]XUH*?0-W>_:);_'1>8A]<6[LW=6AQA!Q.1?'Q:P6.+& OZX/Z M-+S*LK KE=A!235DTC9(8Z1T=NK5CO76DNO(:I6P2@)DE@NCHSKEYMT,/_1G M'"9+"FWU$$@0P?)^7=9SGRR;BURS*R_NC*%/Z)?H,YU>('[4F+6W$J2C.RQ$ M_EBCN$!!AIO.!#1TE5F2IN4FLJ2HZ.MVN;QQI #+TS.0T2.0U!89R#Y/D"P[*"2#: #>)>'. $RX'&MP"S;"9XO M;+YIO.>>,0*8"PUSCJE9PZ0C::K-\ MP3L5E_UF.$5?JAJ582^#2!*#FA8MR?@P#Y-;@4T9GM&-L58HDP=1J1?<;68S M(^X8@,/L5D^D;76Q8@S29ZXA.IJW]&F]KX-ME1Z]6-05BG8V1KPMP1 M72@HLO$U$:/ZRI.+J? 4M+#S'.3E9=^7/>&S>.!,HE6;5C^1G%0T'V3M9TU1 MC)[]74FC]8MRXJM://].T"!>>B'"KZFF];)+E4OA\/X[-W"_4JP"81*"WX>$N[6A+5[#0W<9SO M6'1^\%&5O0@VU&Y]XUFCCM)DW.$S***/&*0H]?M<%);&X-I:N]=_ZO.>L+1L=7+"QO4I>*NW(>;L,<&)1%8 ZH+@= M(-Z7PM->!GMP?E@!G>0(-2$QC^GS1JQ!_TR!8(DBCZ,@Q;?U 'S5%J#=CG8E M"S5>X;/Z6QSV%.8M=!>;%T M;@N8OANMZB4]@G/5!3ZDR\W6IX9=>SL\PHG>5\3@,1(:C"7P&4\O23\P3W8"ZT"Z+O!^YE\NG/_;$ODGY+5CQQI.U+CI^R)][P+**Y4/ MOI#A\1D;RT.N6%+\!Z[%"?GLS[]19+?LTKL(B=WC+4"< M7^L1PQCT[?);8/4$L#!!0 ( $!)7%A%LEQ*7UL *9B M 4 :6YB>"TR,#(S,3(S,5]G-RYJ<&>\NF=8%-VV+MH(B!(E)Z%50! $ M!,FA6T7RAPA(3B(YQX8&&IH@.0D(2&PDYY:<454WOV^6 ^4Y!3E 'AX>("/MP?@9A8@ M \"_<^?O\U8(;D_">X2$! 2$Q$1$=^^1$I.2DA"3D)"14ST@(Z MDIJ&EI:6E(*>@8Z&@8J&EN;O2?#P;\<0$-XG)+Q/0T9"1O-ORTT;@/(>'ND= M5GR\)X [E'CXE'@W70 @ (!'B/_ M0X#_M]>W5WUNKP,(* FI'@N\ODNM9D+TQ)E&T#_V^SVV-^7MM.JC:/:7GUP" M[A/3T3,P,G$\Y>1ZQBTD+"(J)BXA\U963EY!44GC@Z:6MHZNGJF9N86EE;6- MJQO$W0/JZ17X.2@X)#0L/"[^:T)BTK?DE*SLG-R\_(+"HHK*JNJ:VKKZAH[. MKNZ>WKZ?_6/C$Y-3T[]G4,LKJVM_UCT?R/[O@ 7\CY#]$]B_<*$ I/AXMP\/GQ( !EQK M9(5CD3AB#8Q'YPV W U,:&WTK %3/RK\ON8K1+N?STR]4?D&-# M/A&G^(H?J#.D*T6E&U,9\:$B$0VI5?XL"%\4'[*:7M,*7(('MCS1IQV'F_-' M)L8;$EA5AYXP?XV5^1@FRNA^1I1O MU].+ON]ZU?74X"Y$G9S$["C:[SV1HRS->[Q_J',Y5VYA?>/P?]_ZC&/+A%8#7P,]C2F'!S MRH@736/\P 1#/40J =F,1#V+Y/NK<708Y'SV/H-"Z2*K?@2XZ9ZR^/E$9]^! MUVV+,*>#5WV;'5+!07'0XGMWL7G"+9.B#_P93M=$R-]%0O9I?-5@D;!J)G_Q M!G#/HW.>7TW$A0X6E%#&+A"R060GZ;5$?(U ]B/"]=[5HI&O*Z:%#E 'G3C^ M>J:$$N#OJ404-&69U5QKID9N,Z>COS] M//AIP]C^:GVH&"#A^>=(/WG6%3\1*^17N*TC*J(73B3EL^1(CC7N0& X)TZ: M^0;4,:#,QM*:>94GS%;T;&Z-IL^'1O&,0"::(+#OZ")5D^0J,DRD!<\03R@F MV(LEK[)X=ONT0EFDX.CNEW;FDO G=VB'=X')(1]E 3ZNLC 5#/BT!1OQ$GO4 M#:3(1-\ KAXO4AS;L^E,V$'T/5EWM.C+DU%B?W1I/]TG?S&K_]S[&)D/&8EN MI;AZG(F%:V'D(ZN ]U$[-1T[JKCYB:5*T?O5C#6>D:+V5$^=TQQ8L_RDJ-_? M +Z66+>>*JCBTM>0I3LK<)*KMVADUPB6FS:Q<)F":HN5>]P$^^YTS,BJ=M2P M(RY*\UN/D*=^'/:LS0 -=G_@1KYE,)>8>A2,U M]4T!F&I>1+W_WMB;GW_21!PT\*66#GE^V7I]M5244TPDUB:J*T,<6>*^3>ZEZ_!MA.X][A$C0K7X8[3;D"$94F/'TI+=())? M5VK666_LC]>FJK!EN,$@-1W.;_D.;ZW3("AIGH8L/Q [&M$)OW_%=XLZ4W?+ MB!P]E;!L+^@81 'AR(BQ9"E1%9C4_2OH/4"GZ-&( ==P.8 M>0R^\(AKJFSJ M6M9I#;'-VJ$;YYAP>4NY5O_CWGUS?()._J$T6$C*:2F;X3CLM9V#4/.;:?5: M+91Y9;+Y*R=RP9S(I4#L=&'$=ZUT;G(G:Y<3U?.<)R94H_1&ITU#?!((15O_?$K6=KN5)GO6WMN[G9XG7M@/AFT[2P/6P]]2@9B M6=IF1[9&?^@3\[.+U/'7[9O0MV&XEBZM)&U:2Z M'!19[RK/S@0K*Q,]?B52V$3U;>/3T6'XM26R;R0840WL4N0_D7[L^Q@[VP6D MJ;9=I##0MZI%T<1V$ZX,N30D! _>6ZDA8=>-CPPB +R>O=CXY_8"LML #Q.B M1'$_[]\ QIL23IIAL07P?BVAQ4MVSAO NT/MJ>-_.U6H^U95O2=J_[75D!\* MMI^'*V%HOY[%;OD2QTLZ)BLZW/3K*$# VA%&/E50A/K<\ M4&:6]!9*4JA,E*T-,R5?)QAX2*[8MM[B"CS\XABZ>*I*?P.0B6Y)Q,K? -BS MV^&G!!4W@-'[QO89$R[?7_/24O5ND:Z2#=7FE(2 M6@OUI;I'+#EFEAEB?"8A8?8Y25F5;JM,%"L"80]MIN\9+3[)8%][FDP M^-FCU2VCP(%RY\[GIGG7J>ZMB(_2@N'1S*'[6;HFL>91#1(O'EW?*XEALM%; MB%_VOD226U/N-* >T252&Y0VN8A_K/>DF-<<7O5[1[-$[6_DQ.RF/;2(#[/$ M:*^,[$["?5.FXATQ=#ZF:C^8TA+K*RMT#G)"J]1,-RA[\C^U>- :KAVJ$A5< M.6"#+B6-87JCU0<,^=T%5R^7Q6 R]D6&6[&Z ^8^0D,$6AK7:<_-'_IS,9#3 M>WRJPCNUISU*ZN256;'L!$8R47P&/<(>@EEGL4C%^M9@^?%'%3X2AW-=9L%@ M+@"ZHL^Y\3DQ1%P8!=.YSG9S_+S .WXE /)? 5+N7"2FBN2:YF-]>_9^,7[OJ/A%A5O>\1:*0L[6D+,>K>#0)--G'>3OT,KI'FZ7'FC6AHA M.0PE]@?]<79Y7VH'7G#W.Q'O,Y#:\(S,QK0G-AS3P='1V J5IT?Z(9T7\- ; M0$7X5M*9B\%S0I-O/^9HO\5U =Z YG]W WSH96$(S.QJ?M@Q,)3HDLA00CO$ M#<$ ]>BDO\P*S8DSN%O7I+Z?C]^7,D%%05#[ALP+5'JI!=5608MA/C!9U!=M MG34@3T6"[B(LU^=VCHZ.=+OKZ&+6OH0QVR1$_N!P4B"J&C6R1%NN+D1@&HPI M7^=NZ0U'>6>JDI5EFY?I^:1 GT+/SNV2I0J6,D(*V%V-DE\1FD+'9$,ZF&9; M2MQH]9]]V_;#/WWU '>9 3)N'LFUFR**.?@T#B-9X:D_[I[*K!W?Y_ 1_B4Q MS]W3U?4AX)Z=*8.T%?X2?PBXNK9;DI]%UYJ5 J%TG7>\D:8_;XN2#]D8XRM- MJH];DC^U;.M12KOT\HW6_K/123&[VI-HQ-RR+"OC?A0?=WW[->"WS'QF-!X$-6FX\8(02=37<32XU@#JJ3[H- MI#(;VHQ[I)L\+Q?DZ+ WE\RV('_1[Y)- ,FD2!&F.%?J2;T!F'V^ 6PM*%TL MM$J +0X",KBQ%#< 0B85_.Y%ZNJ8\(N$D4Y%Q^RIZG*N%(94M0]TJX,9IE5" M#C< *&D?=%MULQE HR;[;ZJ:P<":_L!CM\@G=(N/.\J(U'VX\)QD?O]3VB+R]NHQYI:&&EP&P.VC/ >S> M:]0?EQ;HO'%8YY# M_ X<=^-U9JM#A+2E<=6OTK)%M=CUZ/:F6465*H?WV<%=)6]M0XB( $O1/" MAV]$M[A=!4K,!L+I6:?1,*XL6SIU^5(I+L)WU^[O ME.3K9O'?0:!5UAH5.GB@YY/TX4?UA+T'T:'#LJZ&TZ;[#S9A]W";=WQ;VT3) M,(7KM"M\#$_;16^PHY1HGDYG09O)I6%"I-H0/D1;CJ3S#EXIF.R*#$T1! /G M;4Z!*$=;>DT<6:KD;!ER7 J^O[;@232-3)2*4Q2>5S-$&'5["\NCE!//JA?&6M+E1)2+NY:3RA$TFE$29:FW%0FH&]C7[/;"!Y58\F!Y6[5( M&O(6[9YJRM\E&66K5E^N6+9"*4L[=!QWW^,%E^XGGW8=RD9 X%C]"-$5-089 M"2+&3B];AK:PSD+II@W&S3TP;UO858P.+]4YE$9<-&G3]M]WQ4=RO0>T 8U& M%2@0($:L_ HB$L2SV?("F_Y]T_>A*NF6*)/]5Z9WF8YZN'578"HD+N)/;\US M;D3JAMVT9NF5Y!2RU8:?&+O ]4GB+F+91T8I0X.+G.]I?4TLX%V.?=CY'G:Z M9/054!AKNN087M7Z&4?XR[*JUE!>$3-@6ZM02ZQIKW)UY$#TW3Z.G\5;>] K M/ZI)#J7=J1HH08"CP#P-RL5>JNA >$5UCJHE(Z#"_$+%,W;S)%VTD66]5O<4 M=HSS:*.LEQ8I?MM.,_VI"S<%WWI3(F, [LNR*F8G1 MQ0:A+3M]'TY4#1C*X6X O;%01-?4X5R0O/^^N:<&E,V]3T_,CR@+(*'-N8HD MQJ:>PM%) ;XS)59R0 #V>S;:+>/)!&&.1%FJ<$Y?C>!05:A%L(B9O$GU9QY$ MD_-IM_J4D(IDEYX=RK?8Q+;P]U\"O*5K/$+O7J8)_GB$>^('LKH.;](HNWJ+ M ?>H,MAJ7:BTGB;6VY*RR31=FA<\F.G)I7,JJJC8QTN&SG^AH#WAT!AS\R8C M4@WH_*NB=KSDD6&L'NIMN2S3!78C@7R7R= MV7(')H$]JU)3/KG0H_N[0!! Z1]/G+F:YOJ*U?92#6K: M!@?@@-LW %HIQJ68>_K8[:G37YT%BGE=NTSZWT;G\")%6**7ASV1Q<5KW;?4 MT^2*XNB3)V^3LEBT;((Z_,%<@X/ZO?[$]C7BBV$_8JZL?R@8#!FAPR:"L<]R M1)UMO P\8K$O+WD9K\0+^B(L(*(@M2B#E\II-X"<@$?M/8)DOO[:_=JMAU^5 M@9?LBY<)BI/.4% +Y#5$;2:9V'D(:4H_=IQ6\;.Q=SC#7N_H\3Q_NX&5H?(R+2Q. M6*ZV- FB45/XOR:3V1E6>\MQNH:F832532'$F:1QJB;J&F:RL8PL,FRDM"9? MY',!OB^OY*:;I-&]IT58_Y41R,BC0%7X%+EY?,J$F^K:94:ZD%V4;5V)CE+!GR;)/(7 M\,8#XP=8BF5XYT@PN*:V1Y781L5B@1;1.?W3DJ MH5;T[O.V?$9"F0;\WWC# MML8K\EVMH:V5FAL=,<18^4X]4.ER#)5U(I55J6]EI4^60K:B?7+XAV&:LE=">)==WO*)5">U+5T\X=R96/&UJ29L^39[A]#]-UZF07I@P; M;*8WOE\X&H$QELLW@!#(R&VA)]_GKRK@LVB9W CXLPANB7*;K=%T\,2+59V4 M]2K[FB2PY6X-?4)O2WS_,^/AV1YSS4::I=B0LS$E>,T7JWL#,!E 7@LO3*\S M/!M.MUC:/;>LQ>IV#5\(Z:Q^4 M2\Y,NG% S9[&^)W5SQU,9 M"]2Z C#F--M<['3HF1'*X8,]W-N4IWL!=-ON^RW7)!E-9(_'+2=_XHN<[0.D M$1+ER6]H2?&O[+'UI!B?1D=X)9UZ#_K:\/ /2D2^(&KV].B!^WD '_!6Y8R> M/.-=F%RS!E<=./"])J5G]J@T_3XLD,&CL[G\7B'.0]O%'0ZJ=919\;> M8WQLT7;-J]1SH]<)*;X0D@?W?*W\2@5JN?<]TQ;$AE7-G]6U.L.Q MH7>]_GS%<8VZ?5'9P\7E1I:_P2.H35XKUWST51YP%'A,?#IQ'F*[::&'F] [ M"+EBPQ V:2_KBTL9+DNF\HCMNC$?\9;E"Z\3ECCW;XH(N!.W^\^V;SQI< R" M,TB9%L(46M!$78XDUCA6S(.Q>/T?]:/(C/WA_=_]GV)%)9[IFOID1K\FSS'- MA?U97@SQJCX+]'VV#2:3(BK;S""NG73CA;]"+U13S\[;T$]IA!W\)=#?/P@1T+]+^:!-VLS#$S%)W^LR+'QGQ: M044D9F+DF']%W_ #ZW/),[NYP(+KFN(5FEF=<&2K$OAI*G1!LR*?[C=7GQ[L M>F5TC'?&O&4+-A\$T]CNCAXC$R\ M8EN)$E4>AYL?X!G!N*>EQ%=:27=$$KT2*R&Y]_;84IC%$RW"M^[K7AU&/?JM M\X*P\LO+32 EB P:L^+1"0_4(JQN);4!/<;PGE86+UJ7[S6.T^U/[?6YR! \ M-E-0E'[I/\R%OW6MOYK?N4?4<82-T< $Q^=O"AB!,B#,Q;$/^9U*-+.B8JA> M/(I\ZKOC]= !*]^;P8(Y*1T:"1$NYG5 S4^)6Y1_4PH?8NK+=EKZP\)@6DE\ M?H=%[P;0*7#%/G6EAEY4GWA^=?<"$2SLPZDX-KB^L,1N2YYK[^B_WK89LA') MTN+,\KKL[)1N8D]X@#]"+P^QK(\DW#KS%:J/8Z$[I"3]1?'DX4&D4V3O!A=H MRT7R/='$/Q@<)F2O.QN[JG.=";94P+$:Z6SY^F!!<['.F]\NT]8GP3 MX*0!95W3GCE9:JWVV/-?1LY(*O_*GQ8JOOYT9I"B\-R^E#V<82!O+MDB(<'4 M. W6N^ G)@G&P\T4>^(;7"EC;4[;)_H+ M8 ZC,/Q< ZS,LEQ"H57IBL+^\?FT8?ING%DH,B-_@*^[1R2(@2A^\9CJMDB6 MI%MVH^A#S*-Y]?7&CW^R,\?R\V5__G&"%]J726;#G3! ML\7>GV<:N8P'%F5-4CI0#-$^\=GG;K:9G\-:+PE!C$O48D?L'EU@FS8:X*L EE@7*G:F(=>]E\= MB[H=:9L#E0Q9691_VO\)>_CM4&#'.'NU0D],YZ.MR08]M+U1%^Q94S.Y>W+H MX^"RZAR7/;#'=W - 2&RZN$UJC< Z9P;0$N49U)OZ %S9X/Y24UU\58MOO[H MKN+XP1\_(6VF]!+! )K(^(?1]=(ONV&&I-2E6D)II1Z.38>KJ>-?OWH:Y3>, M&K@G/VPP0A#F>'AHY/!4*;I**K/!FP9=5.N+P78(G+?B#<"'J7TY_=CL!F"G M@9.#T&CSG_Z\ 6Q4( L MS0T@-EV6=N#Z/ZV7MZ".4*J7FZ,GEG/@FF_70R%/M"&&RIXL?)MG&+6J#2:QI/W0*!4W\I'YAUY,=)_>RVUX> MGWM\35UYZEJ:FEN\65S2I7*VH.P=:F6;&9H==V@;1GFG:OB5Y2.7+L!=52, M+><_%ZG\UG?5_XUU@B>^W_V#XQ**?RV6QE3BQH?1@]VQ MY80RWK7/+P7:GN>8X2#4G4.R==M#S]:/S<4*97-=#T,ZXFPR)*^+JT?V *>U M%]'?8#,'^=KYG#UG1JO*G4\TWS'^.%&*L]04K.T M^*,[# _R,[R7?$TY@]B@ M9AS=IM(IJNWVRWP9SNDD$KJF%^A0;#63G$\5[;&0_- [7 M.TZ$4[;0=Z6HG/S&S=2;Q2WVSW)>*1V(&8[AQZ8=$LGH>[&L780$VX$F>>;N M[U$/4:6W'P9*5DX+8^CW3$TP&FVMS" F%!35: MLZ[^YAZ["_Y# '.F$6B NTT*511I4^3J'-\XQ'WF%3AX08+M #$@ WL:C@(=-O3Z*)/%%PPEF$9XTNB^=+[T)'IASJK/(<_ M9YK_>/@A*)O??,]SZO1([ 90O36;FI"1^U]N%>&8280+_-^/]O_1;M=!27=5 MS+_P9.SI<.J5[K:;EEKNVQW1)PO52?$=XVZ7I=&R?*^F\$Y_,%2+PN4\Z4GG,ZC?)[8 M 6:+X@PD)3YO-3XZ%B]5_7P#J*)-ZFJELVFAF9 2*,,"NU-\ONJE6K4\#F=/ ML14W'.5C$U#8'F@FSG#)!_A9X4]NQ;])HI12?_*3N5!+BY& ]9Y0Z1/D@KEQ M8;97(HK!X7A$"&]UD0)N!@\V)H7I.J[PDL@UZ>\(//H1?O:AH;%V_.R6*5L& MZS(^87=.8 1\><'S>ZOETUK40-HJ(Y)G$FP51:V,_6Z_%)]G\W)NJ+CS>]0; MX9C=';=35>C[N-D6A031CY $HC* ,(X71H9.ZAF0%@12H^:K4&9#TE'[Z7#I MA*'*BCW[N([MW^9+ 4X^//K+R$X@&8P-7<+Z$%V6TF"11-V4^U?,\[C^#=>? M[-'*?;M>E51>[G<:X )WXG1?$1&L)^B(OJ$8\Z/[F_W7QX1Z&0=6.Y(/443S M5NFG4S/&0KI#VZ1O )YM%].JQB#?:7@%>?*ECA6*L'DCU.$*[/U]^$PDAJ5) M6^10TG[%BIW0S/BK$W3M)),B$O=4YI)K$TQ=,M)VK=V=B*"&_0IMO=\TF^I) M\V.N8G]0A>Y57U"#?\JU*G*$!;@$WR.Y%+]R&04]FH6J=@"IJ[RE*:]$?D'E MN([U/]=XQFE()781\!'CA=8Z>9%J;T( M&CD7C+Z0"-F130"Q%-6N$1FT]O1 M0AM$% 13LSR=^?8<*83@.SG\RZ\HI)W3JE?#&**-MPKW Y/[5ZFPVE>L<*'?SC<&K%[=57R],$S\_8^_-O2O^(8MLC<)("N70[:",!1]V)> MZD]4Z>1-=_>T.N8R,\<\N4-T4+Y.;YF:/W]XOLTS#K-&\YVRMN7$57^K6/,-G4=?6USM8/YUGA.7M,0S,O3@BDI 31S MIRN6[JBCY;%RL\VIBK9*G(PSW))M6\- 7R":L6<"9LI.V;_<8F+D>?D>2_]N M"FS#PJ,Z\4B+7ENTT,E4[(C /!WO@LIV'F[>&HAC1@; M7?PCG=L+2M[G@S*T;@#%WA:M?_55VF5X.MS1S.8TE*-(?+>M76S$-\MA+>>" M.EW3F\F(H3:/()ABBQ5[QE[2VLAHVXA21G;[;DPNWKTR+,!.+P^'%.XD,?V5 M\3ACAGWBX^BW;[SK#G_I\.T27X\G2@5J@L3A?4EY-X#?(\N+UU(S6HNA+:Q; MK(_KZ!LYQDX@Z]+Z?\&?;%$TDK/ ?SOU._>GG,N<;D_Z"EV!T3$A$ H*;/"B M^J]XC6K%*5X^_JKJ"0_*(6NV@!)RCC#YGU74?MIWZUSFA%Z2=J19#;VN-QH; MY74T&_.-,#V\>*!I*RN+VKUD-BAOF#@NW"NI?E;E70B8\79\Z"(%?93V/+S? M!>]AX/1TRC+N[@AR.X-*HJQU13G=RSLB(E3M:75MD FE@3(#SQ^Y^N>TKFG' MJ[25Z,1+C8D69JC[JO[D]VGA_$K56N/73')($!@J4H#G7J/-P-!M"2.^ <39 MFM\ C!M"<(DC1FY96^^+56:JV9&.&#M47:NX$L U"#- 4N#V&&"$B-[FBN-4"E%J5J1"^FN M,>7"N>^"W+)6;RV)Q0=#\*]CMXSE<4,XDD:T8^G#H=,;,F:^CY9Z=VI^6CG-+?&BCOY8TI+:EY^&%G_G4L^>49V M?[*9IO00K-.]4E[U0^CP=_5/;@]GI4/5>*2]NC1OY7)CP)+ F(7C-PC=L/<- MH$[5>#\^([F7!\/-M2_E@ZX1IS0/.XFH-O](_$/"<.E1]"KM)IRC2RHH3M3H M*H ,]AW3N#)5N&0],#R]#[UJ M_7!/W5$^OZ>VQ[-M2.'[X[A>&LF MS!"CY8^6;[M(;XTPBX*Q0&A^6'MHO#H#?DK/MD_<+2IYD^$.?GWV[D7.'F[0 M5P*-B/%]8.7!2MD0O(_J1Y$P]P;,+).X?9%??S977!=9IF/F/=&I#%T7!W%2## NTJQ5;0WTSY\N-K1^*S:'7HC;=FGF MLP7==\C7K&KTK;@!C^B()[@7XF:LI M7%F-[P!Y@P9RZR]*GX+>]P(0KN^ROCQ!^D/LE=6GA!G*2GDSPRRN\0R1]YV_6R>YXCT0$#O;"2+X\6,2)C>E M+;#_9+HO>O6G.E1E[2C&U!_5[!*.F=)\(Y8?N9[T4@N;WCJ"J8U=*RGZ[*Q* M.\1G48J1A"-6'9_4(,BZJ]/4Y@VN*R ,GE<_4J]/HPD]*?;>MTBVHLD2HY9B M[AE"6WBU+B3M'4A8Y%#]*]*2A+F4S5VAC3FH_U-XP M?!'YTDFPM#I_18&A[FQE!MMN5H_@VTSAV'Y)@9=ZJELGCS>H4#Y9ZWM&// 7 M#QGO=.QJ8UWPVON0.^DJS "0*-++L$S4G4JFP MPO'-ABEZQCT #]+;KSHO%7XT0@*3K$4[I%\*8%<[P7:.H2#N,4X59:VZICCK M$\XDF91EJD^[,D6#A3]8:0!W>0X2?]38YM>+8)A#(M\4U6O9U_- M?YJ9*EN1,L5 6.7,T4!3*\ E5TNHA-N-J7-/,_OD!Q8%,2W 'D7Z#AUM7C3" M.Y:;I^V!W5,''CS&BNXUX\R=!3T;W%I.LR1^3B#5KRD'+4^M?9]AM -\*;9Q M)!.E5:ITV/&>ANA*T\*%+G,=V>Z$W\$JS3/VB2_J^PBU'_F]/CT@P/U\:042 M&1-NI8+)3\.<3;/>.50-@34K*^5UFVJCS.KKHSE2MA+8G4A+/-F/C,ZODRUK M)GU_WITU\$GSM UU$HE*@S4Y]]H L(R..(9M(T:L:#YTGS(+)A5NKS72+>+5 M/%!:@8U[Y!?USM1OL.O=]OB#DK_,('JGP-]:9YT203'=83!F;U#VLCGF\ZCU M-'7?H4,0;^8K2L2Z5<]\P3L7?T_A;2!#"_'\E4)EY0W@,[Q'(L3O8"E](]$0 M-(S:7CBN>[]H79/.)!Y*+%))6KBFE=1N'#@%)KSB<:'5[2:K^[X25[\_1T#LXAB6SGKX@^B0SW/N(.5]<3H M*??&.F173JKW[IJ\N^] C[CW$O X!@I#VX 9NGZ[RI(I2[KFPP!"AI2C1:_G8BD MO;5G$K KK>61"TQ)[=-1:/T>UD>8=\V6N3]/M_)BOX\+%_ Q0D0F\#Z!1@34 MG@CT]OMJ'#E?LOSK+Y*XV^Y)I:6X$/=;E->[P$9KZ!-GQFA>737H+\E)?"X3 M?T;23NN-:/$A'_RE9TWB2-_!&I'3LU.]X._F2 562=N$([:HDYD7NI0M[_M= M!"58>;YLY@>E.B(=^())QEY(MD5A"*ZB<>\ ML')6%B(8S]LD&/Q;AO+D(?E)'V[4B'>\"DBR)5+K\CE%]8'5RZ*#UX=/D5:# M3CJLX3[%XP/E.IY*05!%+E%FM_EB+R]@I#)^1+"$CEZL0X[9?NVDM(^/"D6X M+_7T\0V '!MBA/6 T,6OK-=8?Q;4#[-'_I$]?UN^!ELC"WA]9.K@ 2"$RN]2 M8^*[?#G1FF/8([6*\>R&ECA>@SU, M):M72A \X_!!L$G0I#QC,'^V',E[G7[%D[L(HZFM:*Z*QO5L'[Q7M.?K327! M@SOW]/2=;?U<;RX!F=[_R/DF5YB#DRX_7U K$64[AMI%_0IBZ*10I]5N2M&W MJ=TYA(]+1X!7:FW >8>O%5?R MJ9U%X&7>40T\*K*:O"RD_> BWG_C"EUH<^5H]C!-&)!-O MZ\CLM/ *(LR( :TR(8):K[3/&WEQ5^A;6LV[NR\D4Q;*)W@ARCK[)?LFC36Q M,NR_Q-P^>CV0)]#FQ"CC7E]07(?8@8]=QCH[!(N^JTGZ+&;?R_EC =%SR+4O ML48;S?Q52Q>?"?UC%)G_G=8BG"<==4%U2]T>_V>@TPHK[)M5PBOFKA,USYLZ M&7P#\\@TT"6UM7K"U9-[8W,_G9E^'G8]X)-S;E^O:.&$O4./=,!)%,N@E9HJ M0"4^WNZNV*; P8_N992*&T35S@A2N#4P..,Y6L_(VHBWLB&X_5-UFETL^U'X M57F68'!L-#DM/K62F)2L4GC38TX28=4( 1C[LA1 M? /@;U[L.SJW;[R+S34OXLD/VG5HTN7GKK1>XLW;3YNKI_Q"81@4NA$ 12;= M &R!,X@/V.Z5&T!PRD'HP?$\^'W3U*=1R\KQC]9LP3/9*:;)"+*7^)1 9Z)A M*(LJRKGG2T]Y3U%HMDU1)(#H%:$GLB?FG 3VX@90WD!QS=Z(E,?[IHIOJ-G! MI\M^,K^+,_:?^5RPK"EFW;IF98UCFVYB=$@T8AOUG39W*'ZHUQJR;/W$#)\Q M;O:I0DR%9P3NUY:A1= *F6C7A8OQENC4151J7):M)W[9U+1)]\- M>LK1&_*3PL\@RI!4N2D. "@W]^>:RE,)SV_,9KT?EX,\YR:*8+8)9_H^BVLX M>8Z)VE];6_%+[8_X/C&K#C=K1V?5%4#X&: JAL+*7%?ZGW*^MHS]>NU./:;L M+FD8XAX5["U77;^\R&C5\J(Z^;CQ.'F%@[/VXZ>Z6CN7BK=M4O:[;4QAHVG: M0A##J6( GW=F1!3;2O;U\JA:]X[QFM2"99?#33'.<+#PS\7833W*W>R)#"NF9#8[IQ MC*W-HNMK1HI5G06J5/D7SSNY"Y:>];Q^1+IV,76H8XD[8;7:J_ :F)^YV%F# MF)_L_"KY$U*P=&Y>9"]-[2/-OQTKOWH6XL:KO-Q4/\Q2F"$3N55.0;I7:.M/V]SK2.)@XM>L\ M^?-. FAS]">D3:GU>2&G6O'"3AZ"K/'E>/ZW=:'#7B5:L\(CMUE#CY,C-N.[ MOV5N *SC-G09$617[?)7!.7&8SFX]L88UG?UL$PWJGN+Y[EVHX9 S:P6AMEQ MU?[>2$Q=&,QE_:2J5?+;XLS%&GS[),):NNRYZT5Q*6P48]IE)%2)C?)^Z''Q MV8).C?BW4/�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

,AS4'1N:F4LDYVF= MKX\Y0 0E>F2,0LTMSJV&NE,G=;P5UDTQ<$P$R%4GI<"Y1K?+)$X=#C41->EV M7\R:,)_19W!#,V936AXJ0P@P!F7]R/:),.6D\.RBU5M!$O5Y%T'K=A$"N:\LITF1)"G%\'G& M1Q&--1_&VV]&I#@6MHIU=:%8%ES/S9\;B*G**8=)N"G'VS<(+YQ"%/$$(1DO M^ :%[WQ%$^NYN9K)OD(3XG2UC[]NUJPLO73V 3PBEJ5\."Q=WJ:U%TX!%.X$ M*L$U#;GS-/::(&4C^8H7@*2WT!!'@YGD]W9)6@LA@ M[2_P*!Z]V.HEY[&]? \R7J>-.5SU7(T,2ZM?-]X)O#/+2^PAW;8$FV2MT _J MWUWPDM&9OYY=/3M]XO=C6]%XY+J/AFS84G[_DF125LL9OO-M6JTTW9?,F%T# M?#UJF#5"_=I1!$"OH;)%'C51L]J7H@2N?=8@CDJ(3JV;=:&;T._BX8A#GZ%* M4CL&=8RHII $>3_\1G+9"2!Q'$@P6^B)^/KVQ08Y,U%*U?D3#*ST>K2THL$P M*8YLW-(P0O@S_B#%C->M)QU5,P5YN8&"1,4JP,3+#$W[N(G69?+4;G./)&G*!+H=QOEQU=3 M.COLE:VY))G:?X>3L(HXIAAEP@=Q^5E95]57-.JV4/2:Q^RX'X 8_;7)KD'8 MD#&5OG1M3QH0J>J"##B_@'QR=K7DR538J MUGD_/O[UV\=Z*?:FFNL,/X&L8P(X>.,7E#[VXDF&-\9&)77X>8X_9/*<65^F M(-/V?]O$PYNJ"\U6R"PE-%:V*W&-1)%)EU;>S EFVH=8"LH2K"JI:FI@^("GU#! :+N44;?%@'M#WQ%KQMNW'(/$A^ZB&>4\_ YS'W4V77U%!<#)HX^XM'L:OL4O..Q'V^8TQ# M]MO_"<(,?9,:(>^X(+$G:NV$Q*,_J4HS)#]QVF1<[!477%/A+C;?.I8(,\M^ M!$116S$C10B?0ZLXL:<\3)0O:$T*^7TD+?FXYOC;ZY]@\B@0];N0B[V?!:7Z M@PX_X%9]UFJH71:ZL-8) ,S.>&W^]+95ICO1+Q%4DRWB7R$6Y^7Z#Y=0#/.D MY:FG&/M#75R-R^W'*0;7'(W&O5A\44D59@P!@%_8*,&?Q_DXYCBIV"&GN[T% MCV&PP#K4R326?EPMC5OGIR)MJ9ILFT%K+\?O_WK^A!@X5W_WZ2*2J(D&[7N% M-%.[?7MY)A=-<0JF/U8KIPA-:0C1YY/MZG8F3^G>]JK?G=4W):>[RC(QM:[ M,@T.YER%+*[83"WR@+[UR96E$5Q44B'6H5V6WF@+[!3];G9&7P5:++Q'1G(MEGCR@I93I#[S.Q8=^'F[F MCB:Y9]3]W=4ZXO:-I>(3-)6!83)6E\V@;-C31"\V^4YI^LI!"&S.%8J(BBP@ M;NR U0[%F%<_C.$"E_TNRECFBZLI4#;;FWW"C^6>KVI31E.1HDSX$WU:<+R; MJ,^\_!7.;<2!"&R3[+XW!S-3^WS3I@>&?3(PVM,E_7C[E8";QXNJDXRESXRQ*$U MM9G%"/[JJI'F(@KKASZ>)_2^GT>X681)&/X#7G$TDW$B5/A=91_ Z=1P$^EJ MTDM>5;%.<<-=5[VSUU(7G8,]?3D_:06OPZQ"YIXYC*"JU#6G]1%Z,>(F6S1Y M8/ZF*3/PXJ28+*5>?XAG M(R/G(GZP]/$4,V<99D6BM5Y,/6Q_6S"L16&8Y<.]4G^\Q&X4RS1G>*+>H-1^ MVXB$.)G69'L :Z'JN'R??^^R,&8BFKH-*K"5R-N0<$2(F\MYOO,^ MQQ;C_D\EQ/G\,#/77"B=IMD,%=40VFT26:]().B>$/HM,J?:=/7I3P5JFWY] M,Z!<($S%OUM&\3A;BL1I#3S;TE4/JS!U&_Y.5PD0 BS:,>Z0'6M_5PPF[V"]@\IZLX*IN^ZLOW@P/--\OUBEV MP09=Z^?8DQLO>ZE(S+.D)%,7Y:?TC655OMRWA>F9D3B(&(+92L@#4R4V&&AW M>#@8$X:7>G.$*L9+$Z^K2&FWAR)[,L=/,=#44I=V(D&>/ZY&W=22<:-G^L=I M9NF%J]H4&Y+4)M&9NM.6;_#)1GD'PY:B@U7*E?K"D4^IRB3FLQC$ M>:VVZ*"8ID_U]JLT!0N$;N?#_D*_'"JKH),:M2@H3BJ=55[XFKON@7^-0(F< MA*Z7(K604:K'MK;YJH**N"NM*TO\=;AGD3&4S6'**@P))F(HT&T/OO'VSD\Q M1CG-UB]^[<6[C,A:E./K(CXFB449\\,Z>WAW7V012IENAC1V2[],RWV9;C44 M?-JMXLTE&/FXH<&^\#6P34\RQ4) +9]WD/3YPE=6-D.#1/2>P0LX-O=Z/PMV/_X#ZC660+MI$C.THRH[2L% M.9,)BH:<9ZK=?IL-,G;I"YJ%D/P7;:NBKAFEE'EN=)F2BZUPCN?S/ROL4[\& M-JVE-LH4ZY.G*5!PC+AN+PD4*B4VOHV"4Y_IE_=:ME[Z^'XQF5D#D8R=XF3] M])TR)N8.^7VA2^CN(@1EZ)0&1J>KY15VADNA[V^EGED^3'A] M$ZVK$RZBDHD*M7T-+%O0IZZ+7D[?OXRE,[]3AFV@>EV.Y'>(7->N+9" % FE%"H/O]A51?3DASETU6O,"VA MP*KOZE11P/=$.<5]%/<1CRW&B7$_AGVQ1(YC-%LQ$=)W*MQ^59E-W>'=+([4 MB! %#DCK :J[?S0(ML\)CP=BMCM=)7NUZ,CAMM=5+91_Q6J9>0,,'>:/-X81"7P%.NBEUN>5$O(#EWR'Z/VV,83 ML6FS">D$X]_RA=-&0=\A<&K,P;[B4F@?)O)?I+DH'HN.7\5(+-45J%GL8F:$ M\5I<1]QU6EQKS8K>NEM>F[ .L]F5&XMC)60CA3S(,HUCNQA9QD+SVHEY!!Z4VCF2W6:JZO>R36 M$_D%09$)XEH;2EW:X6W^^)&M);_85/O:2#XERXJG0;FB-LPOR-ZN_]-9M$K$ MPJT\>TK/SY;:\"CH#S>CLH2IC;TVJ-1'L@.N#6RV1.FI2M.=N]X=)"FJ=A>M M?$$%OTO-=#/,$07]'TW#^*PK++CO>*VULJ0W8EY@BG2TW-8"'WA$""8KOU64 MH9-V46#DW:9%T*C%PB-!LN=N$.5-<$\HKSY, M6=>TI W4RME+@M-7/%_>L?GHL!>]QSAM*O'M)XZ#Z.EP"[>K@I16@G*852U1 M \V6+%+-10\LI<;/Y[-1HH92HL%OK4=3FO'=R=M3U;K^Q]V0EL[@!B1']<_76=\ M(FJM/^CJ%]Z>\B:17;=O#6/D^=9LI]Q$#N645U"+!@:&;\.A]=:/@).,\'2;56^%D**W)+-CMCU]OP_+@YL-2RT;XMED7%7$>(;EOS6<)9Y_6R]ACB M,AA?5U6-D-+ZA'$YGR?8]G;";]8]W^E%-F73)-X0\RR8.)X*/A52QXV'RH41 M?>8;/S8@#XG7>O_6%$Z5,I.T?D50/JFC[KG%#5'[] K[ DX'??D.Z(1N#G7] M0AYLE+U.2;'C^ >7Z)\>QE98J$M);>2K(K";:Q45 I0Y^FOL_ X)4EN!#1/J MJ69E_26H.FV<,=]K=DV4L M$L8)&8%

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

<&*Z,%TBX/#S520&<=3SW\I9::^!O\6;G M?Z>$3R^<=$[X]!%: ^C[(Z[6>!IPD"ARK?.P7HVTMP09E3N7B*B= M*%TZ=>?SSR6X-.3"/E8:[0!I>[: 1FF9B4!Z(H@G#)O7#B-!C4TF#V7BI3V7 M>QNHJZZ.%N-N.!S!TP8 L><<;0X*G"4X;^_G\>:Q#FAB315&DMF$.,[UP"JW M=O<"1R)(2JYT\7:/[34!IF- T,W:&BR1=L'6)YYJ#65*YDXCG,%!Q=HCIR1# M,6I%-2$,L^*] _^9[5#@TCRQ[,\9[?<[<=^91>"TY5$GCJ(#UG.:*YSSE)BD M6-(X!&=3Z;=>Q8EHW$4IC,)2AZ ())[1F?ANI[.LDEXOEK_F&H6)B%1**W(Y M@J:($QSR@W2"0"G9Z"W\P!HJ:8NA.+=%TONO_&ZOT8/Q% @M'((W-.TNX>T M_VPV<4WY))& P4 %A\P;D !W"3FA,:*&..6I5\&.W7SIGOU9LN R\7:SM[,U\OI?#7U?]C959PPQHS&,=>:*X6XWO0> M%@89)@B.QI.0FO&F>]!U]E-*JEP88P&GE<-TC!;9\B1?HWD:UC5#7MOI?Y]>!BBBLM4XBPG(W M,>]!64A&D0Y>&4Y8Q)$6/BFC$7/V4V.&')4V(/*Z$I4&\\(B G.VJ'? (]#C:.0@;3B+S7-')KN6"AL)*J M_(Q@H+?U_FJ]6MMYF,X_?US,9G!.\Q].,!,ZY+*!2/QFOH9"S@F)?! :#$DN M^#A^17%*SOJ!01\TEW;#"P"C 1NI(!>N$SP3K2+5@1!D2"YY"9$CK4E"GJF@ MI77.\]9"5H^(.-,<>$%DCG=8CH#)T>?DV\:V^K2VRT*=70:RX=?KL3K;*,2O MR\5J-5&:)T=H0D$F#DZ5$EJ%0 M&= S[',V5"_+'9J; >,QO+Q:WI8&7%?-W/$U;]- 8>(3-S3EZF6#29Z7"XP7 MU""^_R3)/D(T)^7$$WA.CBMF/"T3MF--B."=@.U"/'KZOW M&3::2$I+=\&MXV*TEP)O]PH8!I.!+L:K>6CBK%RG.2_FN;HF^GR,%_E'6Q62 MZRVWO*$BI-R_"3$<#.(1?#"'LP^6M$@LMY?EK7D=76FKZXJ<<41K%/ \ S_D MCF;YSY@';@"3OL>E_1SOS>7(BC!M%:$BPB=0>$A;GKM*.8-L#/E1-$XV24Y MDHT=K_Y4UO5BSOB@C0RHO\^1F]@HD@,)(NT,^'B4)V099\A18Z1SU+KB+?). M1-JS"4&/@O Z![(7W,XG:+WW4>G.4.1!!DD6+.' $49U0CP/$-28!:1PT,K! M'X3RK=9.1]ZS"7(W<28KP>X<;L>G6+,CW'F8/UYZIC%%8+7G=@>$(RNQ1$IR M:>!_B= GOR8+T_AL0NIG<3;'!.!S.*"/WF@2N[76!]C[IT'/W^QF&^D>F5GEW'YE4XL M)T%2BD&Z>8A1""D/ZA/ )\QS5$SAXC,5*Y!9]^*L?0 ;AM0S.'6]==0^SI$) MM3())1.P2EK$"=?(>$,0%EH[RI7 F. 9>MB&-F:A[B:G[I+[VP:H.CV=P3I[6,!>? M/R\WU:L'J%-/\^LBX M 9SO'PQGI J&\X L]@EQPA@R+(8\OMN9J ,!UA<&Z]]IFE\OG'2>YM=': V@ M[VA7].W/L?(<,RE40E)GBEGTR$CCD D!J 5KB;0S[N)MKS%(9S [<(AY<&+9 MGS/:;WWOB]7JZNMU%.;C=/6OU\N80RP1\+/^")[%Q(=$D]$.69> (4EF7A", M<%)4,$I3Q,V,M^A*5..ZOS!*2QV242#SW,[030#SCP7XY=/9=/UCPQ+'"(7; MUR!O=$#<F;F@;/40'8/->3]'+Z?1KB/&P8 MPA(+25(,JH4[Q 78N<90AKS53CAB=?!G<8[N$G6FKU\:/D5'0Z:5,W1,+<@A MAES7=D@G?'"6(ARCS"WH.+)*>N2I=-B#=R?8*"_)1J'F3)^E%#PU]4'2RG$9 MD'D^^%!U\X* %TL9IY$W05A*#(SYYH?V95S#T M@M4I*ACZR+@!G.]/A@>-HV:2(9*40=P1@AQ6%C$K.)76IZ1*NW]_IPJ&7CCI M7,'01V@-H._-'-P.( .LHLRSM_D?9-;FDVW@+ ?*'6*>6,2#(<@DBY$@B7AB MN$F^]&N* ]MY+C4'0R[T4M)J%W@W9U-0PWV4R/#\XBD"IZPU"CG-J1(X-VXK M;3T>W%!=]5=,[-W@=(0,&@#41Y );. +*/J7\7N<+;YEFK;QD1OE+)*A/K\5 M#[G1N](!&8LIPBE2XD-06I;NMMQA6TV"ZQ@0+,:52 ,@^S7.X]+.@**+\'4Z MG^9XP7KZ/=XG*FDCM$WY@68.'TC-D'.2(DM)"H&G&&QI+Z/3QNI>H>,!K;Q4 M&H!:@>0$CTE90C1**6'$\T 88X5"U'BL.6=P=S0S_N1MK]K2\2H4FK#S3BS[ M!M!^,=O\G1AVD[X]R9/$#3,JYF&0@2%.?9YV'<&%HTYB:YT2O'A4L=/.&O>/ M"^/E89RQO/ :S#^^??/BU;M/KR[>O?SUX\6[RX^O_GCU[O=7GSZ":3._BI^N MOGZURR%CRGNM/S3'>#PQ [.*F>[)B\4,?K2XOJ7OP#3?X#__Z_WZ2UQ>?K'S M^W_])DD38HPT88.$]P GYSG2,E"DM#;IOTXV$"&5R*6508%OP)F-R"B; M4-) E\5,N-@I) D?N(-G^*^?6-[W[582BG6PL"@HF#: E?FUI6"U]4$Y5]8K M0I @!DSVQ( (K24B4E$67%3<=;(NNZ'K\0;J0*R,3!\#9""#*Z)DH_[?PK[! M:H4C=9'2=#8%^W8;2"#,)<*40%II,)59HL@$:9%5(G 7P58VOI/AL?<3U8$P M5':+XHQLP$?=E%3>/%1F+!&:/+(XGPT1$[@Q0B!I8O*":QYLZ9>*=SY?)Y!7 M'A]#.7LT*+['I5L4N$M^L_^]6+ZX6JT77P%F&ZV)L;8*,PS7*HZYRM8@ZW% M+NA(B60T\$Z#YY^X1!Y_N94$:74#9:!0*ILGN4+A?;I'P_:$6>,I$(V1#5C# MR3 QMTF@2#OK@TB.4]XI>_4$LO9NH-ZM-%2BB]+LK6V18$\9P.EAHK1KN9)P<^4@\*A>2W&(&9 MM4'QXLLTKJ:O[?*K]?%J/?733]\NMG1P0K178&K18( Y..@<>_5(:&%3"HXE MP3J!XL!'ZEDE(X"B%#-K@^*"KG),=_T#T/UF[K<4:,\HC6"L48<%XCQ$I"/G MR/+(C0_,._MDO'K_\G52>",!83@#*QL4+Q97N6$&,&_](_-G2X*UNIPX63&5@?8S?KI;^BUW%B\_+ MN&'.0Y*VAX\2$1S)8QQ5;M(B#9P[J0,*(1%GK=32=RJ(>0)MG3=4SWP9+O/% MV *H?6.]C'GWF]Q*>@G?GZ_BB\4<"%RM0$!V-OOQYD5"RJ"NR M!N*!!2Z0M[?U%UJ#)9$H1DXX\&?SNVS#N '>4Z_@OP0)I9_)EMQ_Y0X9;5SJ MU8'1P*'85I"L)LQJ&ZD'SSDF\)>-,_DAC$,T/PHS<+.E6'KLXLVWZZ9JZTG_ M4?WU$:(H&%(?O?1JFUFR\W"'YR#DFVMNR/R*H9\W_)^:K1.!] 0U6WTP43DBL"-/8W&42CL%SJR "PR(01H'@B(78$$%9[ K MX?H?F0X]IWJM7C@XG [M(Y1FTZ$N26R)=TCI_-*:$O 6 U% CN?44!>E9P60 M=1[IT%X2[90.[VB&C0QD\@2GE3!#$)/;@R 6)@!L)L3P8&,SHR"SN9'*< M63JTE_RZID/[,+,V* YE\!1702:CD.0R-YX$-:IE)"!U$2DFW@;1+4=^9NG0 MHT%1BIFU0;$[FR=EC,2J#3/RA4H9,M()Y$AT3F/&R,/\Q+FG0X\&PG &5C8H M?EIFK_Y]-5W_^"VNORS"F_GWN-I$L!__-,;;3(W#7 K!1<[W:Z 3*Z03D&U9 MX"E9#&Y"B0KQ(7M\=F6 Q]J])Q-T94#OHV-[TB5S5#M@GS0T![*M18YB@[!2 M6@H59?2=*I6?@.SA7=0SD$Z'@L4H(JE]81ZR!JFW6.?)GL;8W/P8NZS_";)) M)*]M\-:=<:5A22%VM:_[<+2-9U3WGPPIKQ,Q/B"?"/@'&GQ1YX$S,B8? Q$: MXZKO\\ZIK.C8>V^P8-H UHXG)H8D*QC/,X4USZ:J00:8@:*(*81(/(XEGE:< MR_N\7C+M]#ZO#X-K7TS[GY4Q*XRF6*)@*-S:FDND5LNOV/J\/(QLH/=&GEV%S#'W4SE1-8"WQ\RSN_FU/4Y..VN4(\B$G%<46B,7"$-6I>2Q M]D29TDCLN<6Z.;,"H'C8F&A$"35R_]U6?KR93]=3.]M65*XNKL!O64[_3RZY MW- 6F52,FDT[X@!\!(?683BXRN37_/G=-;-];L6N'Z[2,(>U91#P9282R0I/CT/;TM^L&0*L!KK!0 M6L/P3]WV2P&4BV5&HF$I4[&12/' >+M%NKZ',T" M\3@1G1T0 5.W!\X($CSE2#@&K,7P.R.,0-;3D RFB6@^#A1_;J+NK,=VP7BD MF&K#\0+ @:]'GP _'U)]J^@#T\E:I'Q^*2^M1\YN&KT3*H-2-'9^9_[TUSH! M3)X]P(HSOH%02M$W,R;70F:O"LO<&H9C@ZR4#'F'C1+2>*XZ%8:V_)1NO)FX M;04*JP&CMGK=1_BV>_?'Z"/\09@D1ZT08+)8F?MV\VCA=PXC+ (.]=JF3 MANWXP6?TMJX7'!8CRZ8!);R[0.;]GW/XPI?IMP]QZ;.L/\>)U4 5-G!9\9QY M3'"LC8H,!2,%3LF!+U=\,EW7S=4-_U0'Z+C"K*T5.U/U9NZ7T>;!V-O_?[6< MSC]?3TJ?1"^C=SQ/_J-@>E$A<[4JN'[$)Q+!8-*BVRO$(MNI&RVJ#MA*1:!>>+Q=>OJXJSZTF! M;N:3-' BV; WWEUV4=>):ANHQ:78*EP?V./OXGKB@S,NF-S'13/$&5@\#@N# M=)*8.!J\9)(C0G+MG!<..0=6":/1 M24QTL#B>Q$7J%D]2SQ9_)075 -Y>+.:;+A7_.5U_N7G3!^9O6BR_VKF/[]UL M^GDCW$_PZRI-(Q#[81F_3Q=7JZV9K($BIS%%GGHPDR7FR!A0\C(JJ\$'E$26 M'@LY?->=4*R?/8I/+/Y& ?]V:MUT!L=YXC$66C"&!!=@IMB4D+6Y?R918%TG ML*R+#PH_N*%.,#5_2Y@>)[16;4M@)VSG:AZRM?S[-Y#%K34S44%[:R0&$\:# MJY?@1&BU0?GN*B=YWZ>=FG\%I% 1 MO72(Z4V:C0,I-H K%["EF&-,0[=JC\/?Z0:U9YX+*BB*VJC:3<)E7'Y]GVX: M]@)O[\2Y;IX@75$M9H+S;J(DR^^F& MTN>;$*HEVI;1?)>HEU?Q-4CM99R!!);Y8EA-,!,>CBU&7I& > P"&1DYDI09 M3T@TA':+$@W81#?B(>DD):VX!25"H(H6GJZ*'W^FPW##[?5-#(@FK B+P= M^>#AG#B'77[;"4<')X-,GJ/,&MCWQ=&&JW1B:!F)FEP;P3\'T:8YV<]!/P);9E#! N6@K&IH:Q_! MG,W05JP5BY9)I)($TU<3BIP3$3'O= )6.?>P5/)O-;2UE\R/&MK:1P"UW=]" M$T!59IS2"7F9^]*PX.!4:HEHM)KP: 7N:-7\?8:V]D+)"$-;^XBLCV$0D4PQY;7Q3)1#U^,-5.]4.T"FW5H6]V!P P&Z36AA MJSFY))B $9$=HWQ:P)8P"=C"8F1>:(UE*EV'?>?SU9$Q5)B+,IQM !1%0Y:Y MVS/!$B-/8^X#G0=71\H1EH(%)0BCYNR[GYQ3&_]C[L3JP*CM3FP.\Q]V=A7# MQ9\6A!XF1FG&$B.(2NX1YRPAX\'B#5%&XIP2S'1[5OIX[6?4TZ27D!?E.-Z M%KW-M]CDN3;"(VKRS'2+,7(A!90H ?/#Q?SXH&;NZSQJ38]!TB!1-)CZ>O/N MQ?O?7EU>_.]7GUXLOGY;S#,S%^D-L/)KO+1_O?KK6W:;?XGSF*;K 1FPXSXT M-!%6@+R!^; ;P-Q^\N5TY6>+U=7R9Q*!2,.E"A'I:/5UUV)K>)YT&P7H(>6H M+]TV_\!V!MMZUU6 GT!4,;?O@W\P>\3J28R46D4EXLSE&D&>D,,< ^&>!>J3 M3J+XL[8N&ZM[4Y9"R2,SJ[A,&K@.]YSB"65P#[\?!9K.UL[*OP8_1@3&PF!<%ZC^^+,O=@UZ\4O 2/ M(NP$-Z 45,0$JB8HL,#)9=S2S7N?^'OFQ>W? 2?)&!XYL0X)''UN0I_@MJ$*):N(%3YQ%T\$ MX7U;;/>F'@&D1>14.X#V*J7HLY]_[R3=)_1#S"_K0 !;AY\[2P@VB#I-\XP_ M($]RCHBAVB0P@G#JUDFX_[?K!GU+X^L4 FA7S<$/7L!FINO53;W 1'EB1/0. MF5S\QXF)R)"HD+#$42%#T \G\HREX!YOKFY'RQ.KMH&RZ0\Z?R<7YJ- M";M-)>I%^.^KF[Y>5@?A#4D(:QZSMB9(8_"\ D\V2"^PZ38L>#CH'FZM;F_* M$T-ND%S.X1;]&-=7R_GEXL-R\7V:*ZKW:Q%A-+N'?OB2\[=O)F_W.X*_L+%:A77JYS MNY;N;+;X,[=-F%"K!<=)(B =*';>(Y.OUX^'7OX.R-E8WL0=X)0M#,R.1PTPESF3!@@TS&9 MD,)4,Q$#=K+TN^(10]&/-.ZOR\5J=4MLU$;)@&4>!YE; CJ)M&8111Q=2L98 M5[R'\^$=M1LL[H.+A\JJH!0:N/(>4?/^6\PE-_//;X&J%W:Y_)$6RUQBM9KH MP*/1C"(3\Q!PGCNK9:X%#[Z1D%;!!L<&V/[MU45;250\!;A"(FH1?;4*29O,"13I2A&!.6E@7J?*='?D,0>'B+=7,/IT1A05&UB,1? M%XOPYW0VNYB#(;,&EV?J9O'ZCR9@>#*5)X_EV@IP:^#ZL#($1%42P5HNL1U= M$1[87]W\Q"DQ6$I(+0(P6R[;GVW=HGRVEM]CKH^]\'YY96>K292!@"43$%$6 MW"Y'(BC\Z)%T4@7O,/4/1Q:/HA&?WFG=S,6)%6-AP9T'/+,;"/__6J;SL'7B M5Y.DL"#21J2B$T!IA)O $. U_-B"N1)HHJ>'Z)[=ULUVU(5I"0'6SH%T(=-^ MFZ[S-+$8=C>3?K%8 =6*NI1?X"&9^TER9N F(4XARBUAVE.O'K8OV?NXO]"6 MZF9'1L!F18FUJ%+O!\XF!LMDC>>(.6_ @A8266,,,E3 N0M>>E6ZT.J)+=7- MX((^@O6GP/(VK">?>)D$C8H:!#8(=>&N&2H2U\S1PQ;'L MUCB^^S?K)C!.IL/*\+Q%);6ID)@P03'+W>HEQQQQ#50XXS R0N6!-"%Y,;K; ML=E)W0E6)XWZ]69\B_#9,&ABM+0@7P6^N?*("ZJ0I2E/%\8F\<@25J6?".S> M2>7Y4R>-E?3F?+&4:D'\["@R,))IF:1"8/PYQ.%\(-"E"44BHF,DV8!'#PH? M61,RWKBI4R)KH$R&UFE>CJ>M\H1?H[FC,BJD<(XCVA"0U4[#_2VQ,I8SX48*A3XJDOU]O24W>,O5OV8"F3#S@_P^ 2M&[N%!1QV+S5)%AH3L.( M"8,=.VKWB4RAU/Q0*;1E.]VAYL-R ;[%^L>'F=VT-\Z#HC[?83(I^,#HZ :^,J)J\'N]0F3U<<'3O M-G"92*DI)IXB, ,(>"G)@;TI"8J)@EJGF=810U>'-]=,AOXT(!PJGM;A=^T6 M1Y$T,U$@+8G.K?CR8[3($7%"6Z("UF/&2A]NIYD$_&D@UE\$[8'JUB2Y&ZO+ M/?"HS0V@(H,CX<%+S04?3V'MVE*[KYJ+5NL.D$.S?B;8 MDR9:ZCSR7C+@$+,YJJ>1(M1B"AR28L006#,JZK1^92^NM_T\Y9U=7O=9+/,* MY=%R!1^;'-[J"=Z48&>(H\Z@N'D13'0 .\F M%3 .07*#D@#?@+, %R]1'E&>4C0Q.A)*Y_CV[Z;=MR1]\/!0L13B?@/!JEL. M75RMORR6T_6/30=]RKVT.G>25@*H4$0BYU-"C,"]RJ..EHUV6.[MI"Y^2LEY MW[O)XYG>)'2V_?65U.!4)(%(,N!(2)%R#@#X0X66%$N>Z&BO]Q[LI1'U,T#. M3T+G"*8W ![8=5RMIWXS;FCY8SM10P1R%LX8<1&<2)L(C<5S M=KLVTAILCI'Q0UMX,,,;0,V]IFG_\VHY787IIJ/XEASM95!!@R\H4NYMY2UR M#H..CE9)+&-BIO2LDR>VU$C"KB222@JA 4SMO.,W>CIXJK#FH)AUKKEQF_Z\ MBB.C/%?*&Q]CZ>SOWLW4Q=%(=E 9UK>*H3O3\YPDW&D">I4ZFR.MP"2XZI&C M D>.,1?%NV$_L:4&[>K^@N\"IR.ET "H;IY,;-6J%_G%F4LH2LX0M\(A%[4! MSAA"<#!)D])E O=WT"!DCA7NHT$B1W.Z 9SLY,S;VPDK/E F79<<)H0%('>I4H3GG1$043>[DZ02<"RD= M4LQ:&TFT29:&4ZN]0TK*?#&* !J TNZK_FOV0B?6V\@58^"%9$^!@0MJ?;+( M,^L]3PQ'5[IIX('M-&ABEP%3*1$T@*8N->R*&99(X$!(R$]M@&G:!H\\Y1IS MQUTBH[^_//)=P6EOO3+H*BV2HU'V/2[=HA#.?I\OHU]\GN>GRT#8[9-Z&1SW M7.>!L01,0^XPLLH8I!(1EA-/)2_MR.W92MV,_8AX*L'Z!C35'C)N(W(?XMS. M-I58FQXX$02XWC09B6&B,6AD3W6>@IC+C'.+_D04DCCYP$S0HOAPW0';K=MZ MX_1(+"[",T7KMLG#Q'F77],[%*S1^6DB*/=D/$K.4Y^]*%N\VG+ =NLVXV@, MK<>(L.T!JGNX4*8^ZHG%"U9+]2'C%/UXN0B*>X8TR0-VHS3(,F+!\604?%&9 MW<[SJ9UZ,#HB[6'VJ[_\["KD-Q@;5VGU(2Z!^W/XP>7BU5_V*YS:_->OAP"L M/BYFL]?7YWGBN7*18X,$R2.M66YF!UQ".80M)#/:J=+W]]@T-9(1'XC-QX'? MAI#0KADPP=A*GYF*!1C@W$8,5CB#WU'!F.+&)5RZ+F.(VS,:#MO"2T?'J8_P MCL;@M[B<+L*GM5VN1S9(E[DS3^Y7>S7+ =+7(*3M9.4/FSUD4V>QFF[FS$^8 M$,)CE6T:D:X>TM H,FV29$TG'XN_+RNR\;C#R''$^)C0:5LTJ,>6U%RAA MKN#Z,Q%9SA2R4@(9#B=2O$7!$-4\6H3S'"';2W@#5?.K>1C%]WK[ZN)3F8U8:ZE5UV6 A%VK3-.[GT\H4N9/$9WO4,L2=BDASF1#+3:RQ\4&9TJG2^SL8 MJG/>QM4JQOL]\2[C\NO[]&(QWXX/PM1&HN LY!FBG"2R&1*%E-+6,B,M+CY5 M^.E=U342!Z#@H=XH+( &KK%=%'T$=?BGG67"X%8.Q'$:D.14Y\>=8*P2%A'8 MJ4%A*JWDI:^S)[94UQ(;&4S'LKYVL]1=M+R9@V5G9[]B]P2ZHT'%09O]OU[6,"D#H%#QO$5(7\_F5G;U: M>3NSUUZ#8@%3, 11E#I'FW)]*J,*D8BQ2"QYJ?#1*'KTN;I)WC&!,XRS#5QD M]\FY2:0HD8@Q%.Y@32UXEH8B&WU$E"COA!$VVM(533LW4C;93!@$W43IJ5TT*FDT(!FVFWG?;V.8L25 MX\A08*5P/#"A+.&T].3Z;CNK.ZU@=(-[D" :@-=]>OXS3C]_6<=P\1U^^CGF M_%R.J^59Z6 %^MPT$>YU$I+2B$A-$4_@86BM'5SQ45(L1)+%^UOVW6/=Z0:C M79>%A=-@Y<=U<.^3_Q+#U2PNTL=,\/OT^^IZFIR=A]T3'7X,CE,.^&:9B&8I MHL>)?0HI@K2>H,#SG1F\0DX'@S2@5R4;'-RB3<<^'ZCM^RR><.TB]UZCB'G( MAT4AJSU%SDDF5224NM)UP ,UE9A+:(+I3M?'-Y178U45/C=@'6,)%K64>\6<[\EB1H?A;9 M$O,)+%(*%FF2 @EC!097&+/B34^?W%1=/54!7T?*HV6(312<"1R)1R&8W,4U MP%EQUB#,C67Y+;:FI>L*]VRE;HJF IQZ\;[!+J@/G: ]9/YFUU?+LOY>QR^5 M]O*.(7 Q(9?7L5W MP+_+/^/L>]RD,U<3J1T3VCF@W.;N-%PC:TU"Q$IC280S)$K/OSMVKTUYA'T0 MTR6*6EQ8#1CX7>G\KVB7EW\N@*<1"YT(,I'EMV+8(ILX14D)YWT2@5A1"8O; M+3;E2IX"@L>(YHR0-_$J$06@0$YJC+CV 5D1!,(T:*RDPRR<(F6T:V]-E=B< M FN]A-' !(2#=/T^#]O<1)X=[^&O;MN3D A\DU@C@7.?RB (TI@I9*2S20?O M,2Y?0GO$1ILJU!D-?D7$U,X,H7V>$>-<?(6."@]=PFQ0CCLO2[^S*! MUU.5YXR J2/9?P;%$=TB2),'G3[&#)+!M^J$R1X2>1LH^Q]'\/G%^]]^>W/Y MVZMWEY\NWKU\\?[=Y9MWO[YZ]^+-JT\#PHX=5AW*N[X;+Q1.?+'X^G6ZWC@R M%_.07S*!N.+<3^-J1W\'#-70T8NE[2%B^U0BE[AG:R9,*-;6>>(03EX@3L%1=Y1IY*+QS#D6J._V M/UZQ]?#T13RDFE\J-UG_VL7(6@ MF9'(,V6)CE117CROT'EWE1.I!;#P%+S*"*8YR&VIVLX'"3AP20A!EMH''4-J[>QL]V]EM1Q^-Z619/?&AED S0)J+D5C;G *"@_7V MMK6O%5X)8RTB(A^DD(<*$:#$Q"@45@0'6[RQR=[=5*[,.,&==ASCFX/0CTT_ M<3N[N&X8#3_,TQ7BA$E-DB4&2$DYX<$L,FQ3!NQIUR?=LK"45=3P* M#M]C!4328++@T^^_?'KUOWY_]>[RU1\Y(#P@D@:^P,:1X2$AB9DGP"MO1>G[:,]6F@+.$3)^ C3',+Q- MW&Q=!V:#Y QHH(3EN1>!@(.)DA>S?3%G:.$O73\#F"[^T! M:.L>!I++#A5%]GH68NX(I41^(>7!D0C<>%%\WONNC30'G&.$?!@Z1W"\/=C\ M] ><#Y(EXA#C@@!GJ,\OZASR%GZ?.Z"P4#H G3L++Y/ MG]8+_Z\/RZG/=0*?O@!+)R%$$76B*-#(30N3&R+N1!$FV(!R9M(B2USNO&2 G@A$&8Q59,91 MZ;KUH^WPL:94S#"AUE)@8J=S# M-FI/XV7?Q^H6<(R*ER+\K8V7ZXS)J[_\%PN[_Y@E,V%"*B&P1Q'3B,#J+Y34I$T^<)UYRY(D$)]&% MB Q1#A'//#463"(4F8(SU>=9@E9K86D(DAB:(_SO^,3=5\3C:4%AO*R#432<"H@0IH*P-$K>S2?>M7JWX!H^-S0,8&$;&,APOOKZ]1K-(-75E\4L3, ] M\\02AIP@>9RGAM\I,-F"T$X$%PCPI:>&>/21;H@XCWAK48:V 8R/\7M>[@' M8Z[+P PC1FP")1_B*/=+V< EF??S[>>;K6[5XBY^ZBUSD<'WZF;G9_H6<)W-&; M+U4%EX.D>;A;>+'XFA^W;3&]S ;I)HKRRX^??V<;6=EL[WJ/N81A'C[,[/R= M_7I39%$X-3;&%H>F#G.@^>YV\O+;2H'"U!_X4MV8[8C(>90R?)K=1^NAV?!8 M[3*^OLIG\3_S"&(@?!<0]@5C]_S;NB'9$XBV"^?JR/2&"]L]C7*J[Z]=-^IZ MPG.\DZ5UI QW[>2:@*^;._;6I#K:'MB_8H$M_C;_-LV+7L*]_PO\X;^*;//Q MJE7*39Z4Q0V..G&DHJMR;W]Q_641"LOKP9I5BCZ.D]9N;C0B*[B'PGKY=1Y> MS^SG(I*ZOV*58HNCY+23$XU(*9_X%_-56)83TX,EJQC41VN_Q[QH1%#_L?CS MY_[*:L ]2U5!;@[9TZ_1K#Z\4R6X1_V-G@XW9HW2K&;R_1=>!* M"P=O]6*V6,7+Q>UV+[HQ MH(%'.#^#2(/![==\%G3JGV(7UM0V87;<'W.B9PO+>P,W"5M5XU>1WD^Z(3$_[6>8!1K).N0ODG _!/!J"7;-XMYN_B MHH10[J]4+V-VB->+)PAOZ%Z)ZY]/@K)^+7;!/%JXFE([UC+HPJ;:*N_SY_66 MJ,'1IOM+5:MD/%9:NUE163XW&YK;V8_5=%6F2&?OHM6J&@?:WGO94UEZG];_ M^K#T[Y>7J^6KU7IZ_:RV9+EWIP]4*WD\5JI]V%99PN^OUJ#CX1Z??RZH2O>O M6JT&\EA9/LF@=B[ =XOU?\7;FSJ6JD?N\H%J)9$%+LLGV599PJ]AT<4\WE!: M(B&Z9\EJI9''2O$P:]J2V\NK>+G8CE4%.N=IL?0;TWJHLNWSG6K)[D(2[L+$ M!L7^QW0QV[#Y??J/Q=?X8G$U7R]_O+5_CB'[@Q^KES@OB8 N_&P0!D#QOZ_L M;)JF?KO[2_O7+W$>TW0]N%CBJ _62]67A$-7OK8%"5!C,SO?;OC-UV]Y*!,0 MX*:SZ?I'&=OMN"_6JPTH!(I^G&W' RMIXAU8MEX!00$GK$U;;\<&"_O1#Y?M M),2F8EU/\ZBAK, BKL O_!C_?35=WNJ5,DJYQVR(?4UTX(_17]U7KZ/;X -?%YL?PQN'1D]XKUQ/20WXN.Q-<.),]F#[V]*Z(.!ZN M5>]1;T^A[&'"/[6*I[QI_JE/_*<^L9]LPG]?+C;^^-#C<7^E:F54AT['3F)K M"V VN]U6F:/Q<+EZU_I.=B^ZT%Z[35BTV<$:?";NKE.M2.W0B=A!:&VC=KO; M,D&WQZO5N[:'^?&MY2]>+#[%6?3K&+88&IRZV+UBO8OD.'D=Y$MM/P6V$FZ- M^OYJP]O7H]%7B<+#OSJ[;.C''YZW)Q]>W-:G554**'UJU6G7NL M'GV:1[4UZF9&7KC=:"DI'EJW6EWNL=KU:1Y5/XN+R\7:SDKD@1^N5:W<]N@S MMY,7]25TX=?@B<]^?+#34$A0NY:L5EA[O+P.<*:VHYP]1=AAWE4IU;AOS6KU MLD<*[@G>U#8[;R+#%]\_%].->Q>M5^IZK)7Y!'L:DMYF9W8%8+JO1VJ\45ZMZ5ZU68#M&K3S&J=F7%OZ^FZQ^Y1]8U*\&]^;KI!?IR MFF S$:@M)=V>GZI7<'JDN(]C96VW\8&:^6.UN40V743S%-RX_+@NY4GV^U2] M6M6C8W?'L+(Y^;^+ZS=SO_A:*(;>Z0/U2E:+R7H_VYJ3\*,@\UB2/O"A3A)O M*G9T!!LK2WZ'^LF4;X-?983>]1N=Y-U2]*DG\YH[Y._77^)RY/.]^QN=1-U2 MX*HG\VJ?:NNN9G;Y=KI:%TQU[U^UDSA;"F<]R:#: GRL689&0O8LV:E:H:5@ MUF'65(_\WRC_\@)\:NU.DFPIE-6160W,&+DUW-\N5J4G+-U?NY,06PE@'61/ M=6OG@>4]]/CM7+"3N%H*0!UB2^VGSMF@RA05$MBN]3K)JZ6 T0&FM!#B+](> M\^Y"G0344I1G%QNJ&R&+P:62-VMTDD=+,9@'Q+=1YCU8''WK56E+89(&RU07 M\U_!<-EN[&5<^>5TDX8I5*?Z]/*=A-A2 *0[RZK?2V&:]V5G'-/O/ZDKE7Y^ M:O5.DFTI%M*98:TVU'@S7TV!K9=+NVFF>F?4X?V=#^RN<> S15IM="6C0-^- M1Y]Z!) CWZ_N779(+.QVN5]R=3LK@7_3K C-HQR]NM#7[5 M]F"I:K(YR.V=4FGHG=O%;+9#EY1Y ;I_X09D=> QZ),,^:>90*TS]$]C@7\: M"_3SK=?+V65IG(SS-F.J60MY5B6:D]U>J]I*W MKPVW@_Q61'(Y70\VK^\M5>U)[I%"N<> VHU#KV:18"=(MFK"XMLZAM/:M6>VY;3\Y/<&2^H'%,61V8-EJ[VO[B>UIQC2A #?[*C&O;\=RU=[6'J,( M=S&B(65XN?PZ7Y?5A7>6K/:J]GA5^)@A;6G"0@+;OVJU![6#]&!S8KMQ&,I- M+MV]8KTWM,=HPSW\:$)6+Z^6FXT5$-+M4O5>Q1XCG8<<:$(LGZ*_6D[7T[BZ M^/SYXKN=S@87\!Y8M]Z[UV,$=I WYY%E_+"833T0\&&Y\"-F&>]]9H0LXWXR MBF<9[W[J$48*I!MWKS\H%K]=/MQ=NI1+]_3JC60D#\KM?@"_([^JYUAV[?/= M8KW=:IDPO-!)5'BCG _P;7Z-O_R#_XNPJ_G__S_\%4$L! A0#% @ M0$E<6"/#N' H*P \ D! !X ( ! &5L<&ES8VEE;F-E M;&EC96YS971E&AI8FET,C,Q<30R,#(S+FAT;5!+ 0(4 M Q0 ( $!)7%CY?W=DW < ,,G 4 " 6HN !E>&AI M8FET,S$Q<30R,#(S+FAT;5!+ 0(4 Q0 ( $!)7%C(>V5&AI8FET,S$R<30R,#(S+FAT;5!+ 0(4 Q0 M ( $!)7%A(QP-]V@0 &,3 4 " 8@^ !E>&AI8FET M,S(Q<30R,#(S+FAT;5!+ 0(4 Q0 ( $!)7%@]JYD!X 0 & 3 4 M " 91# !E>&AI8FET,S(R<30R,#(S+FAT;5!+ 0(4 Q0 ( M $!)7%CN[,":6@ $ %#G(P 1 " :9( !I;F)X+3(P,C,Q M,C,Q+FAT;5!+ 0(4 Q0 ( $!)7%BQJUQ&Q!, .'2 1 M " 2])! !I;F)X+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0 ( $!)7%BZ\LR@ M21X *(F 0 5 " 2)=! !I;F)X+3(P,C,Q,C,Q7V-A;"YX M;6Q02P$"% ,4 " ! 25Q8GO':#LE5 "PP0, %0 @ &> M>P0 :6YB>"TR,#(S,3(S,5]D968N>&UL4$L! A0#% @ 0$E<6 ,Z[)WR MG0 -:8 !0 ( !FM$$ &EN8G@M,C R,S$R,S%?9S$N:G!G M4$L! A0#% @ 0$E<6$=[\&2=&P( RHL" !0 ( !OF\% M &EN8G@M,C R,S$R,S%?9S(N:G!G4$L! A0#% @ 0$E<6+2GYA\8" ( M^'L" !0 ( !C8L' &EN8G@M,C R,S$R,S%?9S,N:G!G4$L! M A0#% @ 0$E<6$?1QX\T1 /F !0 ( !UY,) &EN M8G@M,C R,S$R,S%?9S0N:G!G4$L! A0#% @ 0$E<6#CNR@N24P ?G\ M !0 ( !/=@) &EN8G@M,C R,S$R,S%?9S4N:G!G4$L! A0# M% @ 0$E<6.:*GGW)AP -HX !0 ( ! 2P* &EN8G@M M,C R,S$R,S%?9S8N:G!G4$L! A0#% @ 0$E<6$6R7$I?6P IF( !0 M ( !_+,* &EN8G@M,C R,S$R,S%?9S XML 89 inbx-20231231_htm.xml IDEA: XBRL DOCUMENT 0001739614 2023-01-01 2023-12-31 0001739614 2023-06-30 0001739614 2024-02-21 0001739614 2023-12-31 0001739614 2022-12-31 0001739614 us-gaap:NonrelatedPartyMember 2023-12-31 0001739614 us-gaap:NonrelatedPartyMember 2022-12-31 0001739614 us-gaap:RelatedPartyMember 2023-12-31 0001739614 us-gaap:RelatedPartyMember 2022-12-31 0001739614 us-gaap:LicenseMember 2023-01-01 2023-12-31 0001739614 us-gaap:LicenseMember 2022-01-01 2022-12-31 0001739614 us-gaap:GrantMember 2023-01-01 2023-12-31 0001739614 us-gaap:GrantMember 2022-01-01 2022-12-31 0001739614 2022-01-01 2022-12-31 0001739614 us-gaap:CommonStockMember 2021-12-31 0001739614 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001739614 us-gaap:RetainedEarningsMember 2021-12-31 0001739614 2021-12-31 0001739614 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001739614 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001739614 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001739614 us-gaap:CommonStockMember 2022-12-31 0001739614 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001739614 us-gaap:RetainedEarningsMember 2022-12-31 0001739614 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001739614 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001739614 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001739614 us-gaap:CommonStockMember 2023-12-31 0001739614 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001739614 us-gaap:RetainedEarningsMember 2023-12-31 0001739614 us-gaap:PrivatePlacementMember 2023-08-01 2023-08-31 0001739614 inbx:WarrantsPreFundedMember us-gaap:PrivatePlacementMember 2023-08-31 0001739614 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0001739614 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0001739614 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001739614 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2020-07-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2023-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2020-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2023-10-01 2023-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2022-12-31 0001739614 2022-10-31 0001739614 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001739614 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001739614 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001739614 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001739614 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001739614 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001739614 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001739614 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001739614 us-gaap:SoftwareDevelopmentMember 2023-12-31 0001739614 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001739614 us-gaap:ConstructionInProgressMember 2023-12-31 0001739614 us-gaap:ConstructionInProgressMember 2022-12-31 0001739614 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001739614 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001739614 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001739614 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001739614 inbx:A2020OxfordTermLoanAMember us-gaap:SecuredDebtMember 2020-07-01 2020-07-31 0001739614 inbx:A2020OxfordTermLoanBMember us-gaap:SecuredDebtMember 2020-11-01 2020-11-30 0001739614 inbx:A2020OxfordTermLoanCMember us-gaap:SecuredDebtMember 2021-06-01 2021-06-30 0001739614 inbx:A2020OxfordTermLoanDMember us-gaap:SecuredDebtMember 2022-02-01 2022-02-28 0001739614 inbx:A2020OxfordTermLoanDMember us-gaap:SecuredDebtMember 2022-02-28 0001739614 inbx:A2020OxfordTermLoanEMember us-gaap:SecuredDebtMember 2022-06-01 2022-06-30 0001739614 inbx:A2020OxfordTermLoanFMember us-gaap:SecuredDebtMember 2022-06-01 2022-06-30 0001739614 inbx:A2020OxfordTermLoanGMember us-gaap:SecuredDebtMember 2022-10-31 0001739614 inbx:A2020OxfordTermLoanGMember us-gaap:SecuredDebtMember 2022-10-01 2022-10-31 0001739614 inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember inbx:SecuredOvernightFinancingRateSOFRMember inbx:DebtInstrumentRateOneMember 2023-01-01 2023-12-31 0001739614 inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember inbx:SecuredOvernightFinancingRateSOFRMember inbx:DebtInstrumentRateTwoMember 2023-01-01 2023-12-31 0001739614 inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2023-01-01 2023-12-31 0001739614 srt:MinimumMember inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 srt:MaximumMember inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanAMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanAMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoanBMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanBMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoanCMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanCMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoanDMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanDMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoanEMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanEMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoanFMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanFMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoanGMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoanGMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:A2020OxfordTermLoansIncludingAmendmentsMember us-gaap:SecuredDebtMember 2023-12-31 0001739614 inbx:A2020OxfordTermLoansIncludingAmendmentsMember us-gaap:SecuredDebtMember 2022-12-31 0001739614 inbx:WarrantsIssuedConcurrentlyWith2022LoanAgreementMember inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2022-02-01 2022-02-28 0001739614 inbx:WarrantsIssuedConcurrentlyWith2022LoanAgreementMember inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2022-02-28 0001739614 inbx:A2020OxfordTermLoansMember us-gaap:SecuredDebtMember 2022-01-01 2022-12-31 0001739614 inbx:SalesAgreementMember 2021-09-01 2021-09-30 0001739614 inbx:SalesAgreementMember 2022-01-01 2022-12-31 0001739614 inbx:SalesAgreementMember 2023-01-01 2023-12-31 0001739614 us-gaap:PrivatePlacementMember 2023-08-31 0001739614 inbx:WarrantsPreFundedMember us-gaap:PrivatePlacementMember 2023-08-01 2023-08-31 0001739614 inbx:ClassOfWarrantOrRightExpirationDate1Member 2023-12-31 0001739614 inbx:ClassOfWarrantOrRightExpirationDate2Member 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember 2022-12-31 0001739614 us-gaap:StockCompensationPlanMember 2023-12-31 0001739614 us-gaap:StockCompensationPlanMember 2022-12-31 0001739614 inbx:PreFundedWarrantsMember 2023-12-31 0001739614 inbx:PreFundedWarrantsMember 2022-12-31 0001739614 us-gaap:WarrantMember 2023-12-31 0001739614 us-gaap:WarrantMember 2022-12-31 0001739614 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001739614 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001739614 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001739614 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember inbx:LicenseNonAffiliateMember 2023-01-01 2023-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember inbx:LicenseNonAffiliateMember 2022-01-01 2022-12-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember inbx:LicenseNonAffiliateMember 2023-01-01 2023-12-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember inbx:LicenseNonAffiliateMember 2022-01-01 2022-12-31 0001739614 inbx:A2seventyBioIncMember inbx:LicenseNonAffiliateMember 2023-01-01 2023-12-31 0001739614 inbx:A2seventyBioIncMember inbx:LicenseNonAffiliateMember 2022-01-01 2022-12-31 0001739614 inbx:LicenseNonAffiliateMember 2023-01-01 2023-12-31 0001739614 inbx:LicenseNonAffiliateMember 2022-01-01 2022-12-31 0001739614 inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember us-gaap:GrantMember 2023-01-01 2023-12-31 0001739614 inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember us-gaap:GrantMember 2022-01-01 2022-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2020-07-31 0001739614 inbx:PhylaxisBioScienceLLCMember 2023-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember inbx:LicenseNonAffiliateMember 2023-12-31 0001739614 inbx:PhylaxisBioScienceLLCMember inbx:LicenseNonAffiliateMember 2022-12-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember 2019-08-01 2019-08-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember 2019-05-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember 2019-05-01 2019-05-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember 2023-07-24 2023-07-24 0001739614 inbx:ChiesiFarmaceuticiSpAMember 2023-12-31 0001739614 inbx:ChiesiFarmaceuticiSpAMember 2022-12-31 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedMember 2020-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementAdditionalProgramsAuthorizedMember 2020-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedProgramTwoMember 2020-06-01 2020-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedProgramOneMember 2020-06-01 2020-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedMember 2020-06-01 2020-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedProgramThreeMember 2022-06-01 2022-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedMember 2022-06-30 0001739614 inbx:A2seventyBioIncMember inbx:A2020OptionAndLicenseAgreementMember 2020-06-30 0001739614 inbx:A2seventyBioIncMember inbx:LicenseAgreementInitialProgramsAuthorizedMember 2023-12-31 0001739614 inbx:DepartmentOfDefenseCongressionallyDirectedMedicalResearchProgramMember 2021-02-28 0001739614 us-gaap:DomesticCountryMember 2023-12-31 0001739614 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0001739614 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0001739614 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2023-12-31 0001739614 2017-09-30 0001739614 2019-05-31 0001739614 inbx:LegalMergerContingencyFeeMember 2023-12-31 0001739614 us-gaap:SubsequentEventMember 2024-01-22 0001739614 us-gaap:SubsequentEventMember 2024-01-22 2024-01-22 0001739614 2023-10-01 2023-12-31 iso4217:USD shares iso4217:USD shares inbx:lease pure inbx:segment inbx:tranche inbx:performanceObligation inbx:program inbx:option inbx:right false 0001739614 2023 FY P3Y 10-K true 2023-12-31 --12-31 false 001-39452 001-39452 INHIBRX, INC. DE 82-4257312 11025 N. Torrey Pines Road Suite 200 La Jolla CA 92037 (858) 795-4220 Common Stock, par value $0.0001 INBX NASDAQ Yes No Yes Yes Large Accelerated Filer true false true false false 892900000 47392447 <div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> BDO USA, P.C. San Diego, California 243 277924000 273865000 778000 243000 0 14000 16656000 6371000 295358000 280493000 6419000 2501000 2952000 4717000 3164000 3164000 307893000 290875000 10954000 8326000 43295000 17224000 0 166000 2063000 1860000 56312000 27576000 206968000 202069000 1110000 3173000 264390000 232818000 0.0001 0.0001 15000000 15000000 0 0 0 0 0.0001 0.0001 120000000 120000000 47369511 47369511 43564283 43564283 5000 4000 657232000 430426000 -613734000 -372373000 43503000 58057000 307893000 290875000 1800000 2178000 0 14000 1800000 2192000 191640000 110186000 29381000 21123000 221021000 131309000 -219221000 -129117000 31840000 18181000 11917000 2074000 -580000 1000 -20503000 -16106000 -239724000 -145223000 3000 3000 -1634000 0 -241361000 -145226000 -5.12 -5.12 -3.62 -3.62 47130000 47130000 40108000 40108000 38991000 4000 279526000 -227147000 52383000 20450000 20450000 241000 2757000 2757000 4332000 126981000 126981000 712000 712000 -145226000 -145226000 43564000 4000 430426000 -372373000 58057000 24846000 24846000 184000 2316000 2316000 3621000 1000 199644000 199645000 -241361000 -241361000 47369000 5000 657232000 -613734000 43503000 -241361000 -145226000 1191000 1225000 4899000 3448000 24846000 20450000 1765000 1621000 -1634000 0 1634000 0 -3000 -19000 535000 -130000 -14000 -491000 10285000 -612000 0 1317000 2109000 -705000 26071000 7603000 -1860000 -1674000 -166000 -1868000 0 -110000 -193309000 -115301000 4593000 686000 -4593000 -686000 200000000 0 355000 0 0 127371000 0 390000 0 128863000 0 50000 2316000 2757000 201961000 258551000 4059000 142564000 273865000 131301000 277924000 273865000 26717000 13090000 3000 4000 519000 0 0 712000 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx, Inc., or the Company, or Inhibrx, is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company combines target biology with protein engineering, technologies, and research and development to design therapeutic candidates. The Company’s current pipeline is focused on oncology and orphan diseases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, risks associated with preclinical studies, clinical trials and regulatory applications, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. The Company’s therapeutic candidates currently under development will require significant additional research and development efforts, including clinical and preclinical testing and marketing approval prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had an accumulated deficit of $613.7 million and cash and cash equivalents of $277.9 million. From its inception and through December 31, 2023, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company received gross proceeds of $200.0 million before deducting $0.4 million of offering expenses payable by the Company in a private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which the Company sold and issued 3,621,314 shares of the Company’s common stock and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock. See Note 4 for further discussion of this equity offering.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders’ rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep and money market accounts, and highly liquid investments in debt securities with an original maturity of three months or less. The Company’s investments in debt securities have consisted of U.S. Treasury Bills, which were recorded at their amortized cost, reflective of the amortization or accretion of premiums or discounts.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company held no investments in debt securities. As of December 31, 2022, these investments were recorded at their amortized cost of $196.3 million, which was adjusted for the amortization or accretion of premiums or discounts.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company’s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. As of December 31, 2023 and December 31, 2022, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company has never declared or paid any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company’s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company’s common stock will be at the discretion of the Company’s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company’s board of directors may deem relevant. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and office equipment: <span style="-sec-ix-hidden:f-267">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture, fixtures and other: five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: three years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company’s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company’s two existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the long-term operating lease of its corporate headquarters, the Company recognized an operating right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviewed at inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Phylaxis</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company’s proportionate share of the net income or loss of Phylaxis is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company’s share of prior losses of the investee. Following the Company’s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. Accordingly, the Company’s investment in Phylaxis as of December 31, 2023 and December 31, 2022 is zero.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and December 31, 2022, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which are classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which are classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value. As of December 31, 2023, the Company held no investments in debt securities. The Company’s outstanding debt is classified as Level 2 in the fair value hierarchy. As of December 31, 2023 and December 31, 2022, the Company had no financial instruments measured at fair value on a recurring basis.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company’s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal, accounting, and filing fees related directly to the Company’s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In October 2022, the Company completed an offering under the Shelf Registration and offset $3.0 million of offering costs against the proceeds. In August 2023, the Company completed a private placement offering, under which the Company offset $0.4 million of offering costs against the proceeds. There were no deferred offering costs as of December 31, 2023 or December 31, 2022.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments with Characteristics of Both Liabilities and Equity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 480-10, and ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company’s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company’s outstanding warrants are classified as equity as of and for the years ended December 31, 2023 and December 31, 2022.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2) nonrefundable up-front fees; (3) payments for reimbursement of research costs; (4) payments associated with achieving specific development, regulatory, or commercial milestones; and (5) royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company’s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been awarded a grant from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD, under which the Company’s internal costs specifically covered by the grant for a specified project are subject to reimbursement when incurred. Since there is no transfer of control of goods or services to the granting agency, revenue is recognized as the Company incurs expenses related to the grant in the gross amount of the reimbursement and costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development and Clinical Trial Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. The Company’s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amended, or IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending finalization, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur ownership changes in the future. If an ownership change occurs, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common stock equivalents outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of common stock used in the basic and diluted net loss per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, other than pre-funded warrants as discussed above, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Accordingly, for the years ended December 31, 2023 and December 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, as weighted based on the period outstanding during each year, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,336 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,018 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as held-to-maturity debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. The Company adopted ASU 2016-13 as of January 1, 2023, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued but Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.</span></div> <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div>The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or the SEC, related to an annual report on the Form 10-K. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation </span></div>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and have been prepared in conformity with GAAP. All intercompany accounts and transactions have been eliminated in consolidation. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had an accumulated deficit of $613.7 million and cash and cash equivalents of $277.9 million. From its inception and through December 31, 2023, the Company has devoted substantially all of its efforts to therapeutic drug discovery and development, conducting preclinical studies and clinical trials, enabling manufacturing activities in support of its therapeutic candidates, pre-commercialization activities, organizing and staffing the Company, establishing its intellectual property portfolio and raising capital to support and expand these activities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company received gross proceeds of $200.0 million before deducting $0.4 million of offering expenses payable by the Company in a private placement transaction, or the Private Placement, with certain institutional and other accredited investors, or Purchasers, in which the Company sold and issued 3,621,314 shares of the Company’s common stock and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock. See Note 4 for further discussion of this equity offering.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its existing cash and cash equivalents will be sufficient to fund the Company’s operations for at least 12 months from the date these consolidated financial statements are issued. The Company plans to finance its future cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses, strategic transactions and other similar arrangements. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company does raise additional capital through public or private equity or convertible debt offerings, the ownership interests of its existing stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect its stockholders’ rights. If the Company raises capital through additional debt financings, it may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt or making certain capital expenditures. To the extent that the Company raises </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional capital through strategic licensing, collaboration or other similar agreement, it may have to relinquish valuable rights to its therapeutic candidates, future revenue streams or research programs at an earlier stage of development or on less favorable terms than it would otherwise choose, or to grant licenses on terms that may not be favorable to the Company. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future. If the Company is unable to secure adequate additional funding, it will need to reevaluate its operating plan and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of its development programs, or relinquish rights to its technology on less favorable terms than it would otherwise choose. These actions could materially impact its business, financial condition, results of operations and prospects.</span></div>The rules and regulations of the SEC or any other regulatory agencies may restrict the Company’s ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities. -613700000 277900000 200000000 400000 3621314 6714636 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The Company’s most significant estimates relate to evaluation of whether revenue recognition criteria have been met, accounting for development work and preclinical studies and clinical trials, determining the assumptions used in measuring stock-based compensation, the incremental borrowing rate estimated in relation to the Company’s operating lease, and valuation allowances for the Company’s deferred tax assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. The Company’s actual results may differ from these estimates under different assumptions or conditions.</span></div> <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of accounts receivable, investments in debt securities, accounts payable, accrued expense, long-term debt, and warrants. The carrying amounts of financial instruments such as accounts receivable, accounts payable, accrued expense, and investments in debt securities classified as cash equivalents approximate their related fair values due to the short-term nature of these instruments. The carrying value of the Company’s debt approximates fair value due to its interest being reflective of current market rates for debt with similar terms and conditions. The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity.</span></div> <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are comprised of cash held in financial institutions including readily available checking, overnight sweep and money market accounts, and highly liquid investments in debt securities with an original maturity of three months or less. The Company’s investments in debt securities have consisted of U.S. Treasury Bills, which were recorded at their amortized cost, reflective of the amortization or accretion of premiums or discounts.</span></div> 0 196300000 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits by the Federal Deposit Insurance Corporation, or FDIC, of up to $250,000. The Company’s cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in operations. The Company has </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial condition of the depository institutions in which those deposits are held. </span></div>The Company continually evaluates its accounts receivable for all outstanding third-party balances to determine the potential exposure to a concentration of credit risk. The Company’s major third-party contracting parties, some of which account for significant balances in both accounts receivable and revenue, are generally large, credit-worthy biotechnology companies and government bodies. The Company assesses the collectability of accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions, and credit status of these third parties. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company has never declared or paid any dividends on its common stock. </span></div>Additionally, the Amended 2020 Loan Agreement limits, among other things, the Company’s ability to pay dividends and make certain other payments. Any future determination to pay dividends on the Company’s common stock will be at the discretion of the Company’s board of directors and will depend upon, among other factors, the results of operations, financial condition, capital requirements, contract restrictions, business prospects and other factors the Company’s board of directors may deem relevant. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and office equipment: <span style="-sec-ix-hidden:f-267">three</span> to five years; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">furniture, fixtures and other: five years; and</span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">computer software: three years.</span></div>Amortization of leasehold improvements is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are expensed in the periods incurred. P5Y P5Y P3Y <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div>The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during any of the periods presented within its consolidated financial statements. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two existing leases for its corporate headquarters in La Jolla, California. Its first lease commenced in June 2018. In May 2019, the Company signed an amendment to its lease agreement to expand the Company’s facilities, which commenced in January 2020 and is accounted for as a separate lease. The Company’s two existing leases are classified as operating leases. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the long-term operating lease of its corporate headquarters, the Company recognized an operating right-of-use asset and lease liability on its consolidated balance sheet. The lease liability is determined as the present value of future lease payments using an estimated incremental borrowing rate that the Company would have to pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The operating right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The lease term at the commencement date is determined by considering whether renewal options and termination options are reasonably assured of exercise. Agreements are </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviewed at inception to determine if they contain a lease. Leases are reviewed and classified as operating or financing leases at commencement. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to exclude from its consolidated balance sheets recognition of leases having a term of 12 months or less (short-term leases) and has elected not to separate lease components and non-lease components for its long-term operating leases.</span></div>Rent expense for the operating leases are recognized on a straight-line basis over the lease term and is included in operating expense in the consolidated statements of operations for all periods presented. 2 2 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Phylaxis</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the equity method of accounting for equity investments in companies if the investment provides the ability to exercise significant influence, but not control, over operating and financial policies of the investee. As discussed in Note 6, the Company received an equity investment in the form of a 10% equity interest as consideration in a series of agreements with Phylaxis (as defined below), which was later increased to 15% in the fourth quarter of 2023 following the achievement of a milestone. This equity interest is accounted for as an equity method investment and the Company’s proportionate share of the net income or loss of Phylaxis is included as loss in equity method investment in the consolidated statement of operations. Judgment regarding the level of influence over each equity method investment includes considering key factors such as the Company’s ownership interest, representation on the board of directors, legal form of the investee (e.g. limited liability corporation), participation in policy-making decisions, and material purchase and sale transactions. </span></div>The investment had been reduced to zero prior to the beginning of 2021 as a result of the allocation of the Company’s share of prior losses of the investee. Following the Company’s increase in equity interest of 5% in the fourth quarter of 2023, the Company established an additional equity method investment and subsequently recorded its proportionate loss as loss in equity method investment in the consolidated statement of operations. 0.10 0.15 0 0.05 0 0 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices in active markets for identical assets or liabilities. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. </span></div>During the years ended December 31, 2023 and December 31, 2022, the Company’s investments in debt securities consisted of U.S. Treasury Bills, which are classified as Level 1 in the fair value hierarchy. Due to the short-term nature of these securities which are classified as cash equivalents, the amortized value approximated fair value and the Company did not remeasure these instruments at fair value. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs and Other Debt-Related Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs are capitalized, recorded as an offset to the Company’s debt balances and amortized as interest expense over the term of the associated debt instrument using the effective interest method, pursuant to ASC Topic 835-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the maturity of the debt is accelerated as a result of default or early debt repayment, the amortization would then be accelerated. Amounts paid related to debt financing activities are presented on the consolidated balance sheet as a direct deduction from the debt liability. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with equity financings until such financings are consummated at which time such costs are recorded against the gross proceeds of the offering. </span></div>Legal, accounting, and filing fees related directly to the Company’s Shelf Registration are capitalized as deferred offering costs. Deferred offering costs associated with the Shelf Registration are reclassified to additional paid-in capital when the Company completes offerings under the Shelf Registration. In October 2022, the Company completed an offering under the Shelf Registration and offset $3.0 million of offering costs against the proceeds. In August 2023, the Company completed a private placement offering, under which the Company offset $0.4 million of offering costs against the proceeds. 3000000 400000 0 0 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments with Characteristics of Both Liabilities and Equity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, or ASC 480-10, and ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 815-40. Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in other expense, net in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or under another applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. The Company’s outstanding warrants do not meet the requirements for liability classification under ASC-480-10 or ASC-815-40. Therefore, the Company’s outstanding warrants are classified as equity as of and for the years ended December 31, 2023 and December 31, 2022.</span></div> <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government agencies and private not-for-profit organizations.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Research, Development, and License Agreements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the performance of research and development activities. The terms associated with these agreements may include one or more of the following (1) license fees; (2) nonrefundable up-front fees; (3) payments for reimbursement of research costs; (4) payments associated with achieving specific development, regulatory, or commercial milestones; and (5) royalties based on specified percentages of net product sales, if any. Payments received from customers are included in deferred revenue, allocated between current and non-current on the consolidated balance sheet, until all revenue recognition criteria are met.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments, including option exercise fees, are identified as variable consideration, which is constrained </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and excluded from the transaction price. The Company will recognize revenue for sales-based royalty if and when a subsequent sale occurs. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether contractual obligations represent distinct performance obligations, including the assessment of whether options represent material rights, determining whether there are observable standalone prices and allocating transaction price to performance obligations within a contract, assessing whether any licenses are functional or symbolic, determining when performance obligations have been met, and assessing the recognition of variable consideration. The Company evaluates each performance obligation to determine if it can be satisfied and recognized as revenue at a point in time or over time. Typically, performance obligations consisting of a transfer of a license or the achievement of milestones are recognized at a point in time upon the transfer, while performance obligations consisting of research activities are recognized over time using an input method which is representative of the Company’s efforts to fulfill the performance obligation, based on costs incurred with third-parties or internal labor hours performed.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has been awarded a grant from the Congressionally Directed Medical Research Program, or CDMRP, funded through the DoD, under which the Company’s internal costs specifically covered by the grant for a specified project are subject to reimbursement when incurred. Since there is no transfer of control of goods or services to the granting agency, revenue is recognized as the Company incurs expenses related to the grant in the gross amount of the reimbursement and costs associated with these reimbursements are reflected as a component of research and development expense in the consolidated statements of operations.</span></div> <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development and Clinical Trial Costs </span></div>Research and development costs are expensed as incurred based on estimates of the period in which services and efforts are expended, and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place. The Company’s preclinical studies and clinical trials are performed internally, by third party contract research organizations, or CROs, and/or clinical investigators. The Company also engages with contract development and manufacturing organizations, or CDMOs, for clinical supplies and manufacturing scale-up activities related to its therapeutic candidates. Invoicing from these third parties may be monthly based upon services performed or based upon milestones achieved. The Company accrues these expenses based upon estimates determined by reviewing cost information provided by CROs and CDMOs, other third-party vendors and internal clinical personnel, and contractual arrangements with CROs and CDMOs and the scope of work to be performed. Costs incurred related to the Company’s purchases of in-process research and development for early-stage products or products that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. Costs incurred related to the licensing of products that have not yet received marketing approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of unused federal and state net operating losses, or NOLs, and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the Internal Revenue Code, as </span></div>amended, or IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending finalization, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur ownership changes in the future. If an ownership change occurs, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of common stock outstanding during the same period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common and common stock equivalents outstanding during the same period. The Company excludes common stock equivalents from the calculation of diluted net loss per share when the effect is anti-dilutive. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average number of common stock used in the basic and diluted net loss per common stock calculations includes the weighted-average pre-funded warrants outstanding during the period as they are exercisable at any time for nominal cash consideration.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, other than pre-funded warrants as discussed above, warrants for purchase of common stock and stock options are considered to be potentially dilutive securities. Accordingly, for the years ended December 31, 2023 and December 31, 2022, there is no difference in the number of shares used to calculate basic and diluted shares outstanding.</span></div> <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, as weighted based on the period outstanding during each year, are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,336 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,018 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,063 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 6336000 5018000 47000 45000 6383000 5063000 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock-Based Awards </span></div>The Company recognizes compensation costs related to stock options based on the estimated fair value of the awards on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model. The grant date fair value of the stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes forfeitures as they occur. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income </span></div>The Company has no material components of other comprehensive loss and accordingly, net loss is equal to comprehensive loss in all periods presented. <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information </span></div>The Company operates under one segment which develops biologic therapeutic candidates. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. 1 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies. The Company believes that the impact of the recently issued accounting </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pronouncements that are not yet effective will not have a material impact on its consolidated financial condition or results of operations upon adoption. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adoption of New Accounting Pronouncements </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 326), which intends to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets, such as held-to-maturity debt securities. Subsequent to the issuance of ASU 2016-13, the FASB issued several additional ASUs to clarify implementation guidance, provide narrow-scope improvements and provide additional disclosure guidance. The Company adopted ASU 2016-13 as of January 1, 2023, which did not result in a material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued but Not Yet Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the disclosure requirements related to the new standard.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.</span></div> OTHER FINANCIAL INFORMATION <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expense and Other Current Assets</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,656 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,480 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,023 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,106 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,041 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,419 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) As of December 31, 2023, consists of renovations to the Company’s office space and software not yet placed in service.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $1.2 million for each of the years ended December 31, 2023 and December 31, 2022, and consisted of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company’s usage of third-party CROs for management of clinical trials. See Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div> <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expense and other current assets were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,888 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside research and development services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expense and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,656 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company’s prepayments to third-party CROs for management of clinical trials and prepayments for drug supply to be used in combination with the Company’s therapeutics. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div> 9888000 1171000 5409000 4294000 728000 493000 265000 232000 366000 181000 16656000 6371000 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net were comprised of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,480 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,023 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,106 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,041 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,419 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9.5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) As of December 31, 2023, consists of renovations to the Company’s office space and software not yet placed in service.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $1.2 million for each of the years ended December 31, 2023 and December 31, 2022, and consisted of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total depreciation and amortization expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 8480000 7023000 540000 524000 441000 441000 53000 53000 3592000 0 13106000 8041000 6687000 5540000 6419000 2501000 1200000 1200000 992000 1003000 199000 222000 1191000 1225000 <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical drug substance and product manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other outside research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,224 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates primarily to the Company’s usage of third-party CDMOs for clinical and development efforts. See Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates primarily to the Company’s usage of third-party CROs for management of clinical trials. See Note 1 for further discussion of the components of research and development. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to the Company’s usage of third parties for other research and development efforts. See “Accrued Research and Development Clinical Trial Costs” in Note 1 for further discussion of the components of research and development.</span></div> 22805000 5381000 9224000 4527000 6506000 3374000 2348000 2124000 1129000 1164000 780000 428000 503000 226000 43295000 17224000 DEBT<div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a loan and security agreement, or the 2020 Loan Agreement, with Oxford Finance LLC, or Oxford, pursuant to which it received $10.0 million in gross proceeds, or Term A. The 2020 Loan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement was subsequently amended in November 2020, or the November 2020 Amendment, upon which a second tranche in an aggregate principal amount of $20.0 million was funded, or Term B, and in June 2021, or the June 2021 Amendment, upon which a third tranche in an aggregate principal amount of $40.0 million was funded, or Term C. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into an additional amendment, or the February 2022 Amendment, to the 2020 Loan Agreement, collectively, the Amended 2020 Loan Agreement, upon which the Company received gross proceeds of $40.0 million, or Term D. The February 2022 Amendment also provided for an increase in the interest rate and for three future tranches of debt to be funded upon the achievement of certain milestones. In June 2022, the Company received additional gross proceeds of $30.0 million, or Term E, following the initiation of part 4 of the Phase 1 clinical trial of INBRX-105, as well as an additional $30.0 million in gross proceeds, or Term F, following the receipt of positive topline data from the Phase 1 clinical trial of INBRX-101. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company entered into an amendment to the Amended 2020 Loan Agreement, or the October 2022 Amendment. The October 2022 Amendment amended the milestone terms of the last remaining tranche, Term G, under the Amended 2020 Loan Agreement to provide for the funding of $30.0 million upon the announcement of the regulatory path for INBRX-101 rather than upon the initiation of a potentially registration-enabling clinical trial of INBRX-101. In October 2022, the Company met this milestone and drew the final tranche for additional gross proceeds of $30.0 million.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the November 2020, June 2021, February 2022, and October 2022 Amendments should be treated as modifications of the original 2020 Loan Agreement since the terms and resulting cash flows were not substantially changed upon each of the amendments. The Company will continue to amortize the existing debt discounts prior to modification through the Amended Maturity Date (as defined below).</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 1, 2023, a LIBOR Transition Event, as defined in the Amended 2020 Loan Agreement, occurred, and pursuant to the Amended 2020 Loan Agreement, Oxford selected a LIBOR Replacement Rate, as defined in the Amended 2020 Loan Agreement, replacing the 30 day U.S. Dollar London InterBank Offered Rate with the 1-Month Chicago Mercantile Exchange term secured overnight financing rate, or 1-Month CME Term SOFR, causing an amendment to the interest rate of the Company’s outstanding loans. No other terms were changed. The Company has elected the optional expedient under ASC Topic 848-20 and therefore deemed the modification to not be substantial.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company has $200.0 million in gross principal outstanding in term loans under the Amended 2020 Loan Agreement. The outstanding term loans will mature on January 1, 2027, or the Amended Maturity Date, and bear interest at a floating per annum rate equal to the greater of (1) 8.30% or (2) the sum of (i) the 1 Month CME Term SOFR on the last business day of the month that immediately precedes the month in which the interest will accrue, (ii) 0.10%, and (iii) 8.19%. Under the Amended 2020 Loan Agreement, the repayment schedule provides for interest-only payments through February 1, 2025, followed by 23 months of principal and interest payments. In the event of a qualifying financing event in which the Company raises at least $100.0 million in upfront licensing or partnership proceeds by February 2025, the interest-only period may be extended an additional 12 months through February 1, 2026, which would then be followed by 11 months of equal payments of principal plus interest, beginning on March 1, 2026. Upon the Amended Maturity Date, a final payment of 9.0% of the original principal amount will be due to Oxford. This final payment of $18.0 million is being accreted over the life of the Amended 2020 Loan Agreement using the effective interest method. The Company has the option to prepay the outstanding balance of the term loans in full prior to the Amended Maturity Date, subject to a prepayment fee ranging from 1.0% to 3.0%, depending upon the timing of the prepayment. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following as of December 31, 2023 and December 31, 2022 (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount and final payment fee</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, and unless extended in accordance with the terms described above, the Company’s interest-only period will continue through February 2025, with principal payments beginning in March 2025. Future principal payments and final fee payments will be made as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,956 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,000 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s obligations under the Amended 2020 Loan Agreement are secured by a first priority security interest of substantially all of the Company’s assets with a positive lien on intellectual property. The Amended 2020 Loan Agreement includes customary events of default, including instances of a material adverse change in the Company’s operations, that may require prepayment of the outstanding term loans. Additionally, following the June 2021 Amendment, the Amended 2020 Loan Agreement requires the Company to maintain a minimum cash balance of $20.0 million. As of December 31, 2023, the Company is in compliance with all covenants under the Amended 2020 Loan Agreement and has not received any notification or indication from Oxford of an intent to declare the loan due prior to maturity. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the February 2022 Amendment, the Company issued 40,000 warrants to Oxford to purchase shares of the Company’s common stock at an exercise price of $45.00. Upon issuance, the warrants were classified as equity and recorded at their fair value of $0.7 million. See Note 4 for further discussion of these warrants.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div>Interest expense is calculated using the effective interest method and is inclusive of non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2023, interest expense was $31.8 million, $4.9 million of which related to non-cash amortization of the debt discount and accretion of the final payment. During the year ended December 31, 2022, interest expense was $18.2 million, $3.4 million of which related to non-cash amortization of the debt discount and accretion of the final payment. 10000000 20000000 40000000 40000000 3 30000000 30000000 30000000 30000000 200000000 0.0830 0.0010 0.0819 P23M 100000000 P11M 0.090 18000000 0.010 0.030 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s outstanding debt balance under the Amended 2020 Loan Agreement consisted of the following as of December 31, 2023 and December 31, 2022 (in thousands).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term A</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,800 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including debt discount and final payment fee</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,968 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,069 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10900000 10900000 21800000 21800000 43600000 43600000 43600000 43600000 32700000 32700000 32700000 32700000 32700000 32700000 11032000 15931000 206968000 202069000 Future principal payments and final fee payments will be made as follows (in thousands):<div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31, 2023</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,956 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,000 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,032)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,968 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 86956000 104348000 26696000 218000000 11032000 206968000 20000000 40000 45.00 700000 31800000 4900000 18200000 3400000 STOCKHOLDERS’ EQUITY <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into the Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or the Sales Agent, under which it may, from time to time, sell shares of its common stock having an </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate offering price of up to $200.0 million through the Sales Agent, or the ATM Offering. Pursuant to the Sales Agreement, the Company paid the Sales Agent a commission for its services in acting as an agent in the sale of common stock in an amount equal to 3% of the gross sales price per share sold, which was amended to 2% of the total sales price per share sold during 2022. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company sold 4,332,354 shares pursuant to the Sales Agreement for net proceeds of $127.4 million, after deducting commissions of $2.6 million. In connection with the ATM Offerings during the year ended December 31, 2022, the Company incurred an additional $0.4 million of expenses which were offset against the proceeds of the offering. During the year ended December 31, 2023, the Company did not issue any shares under the Sales Agreement.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Purchase Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Company entered into a Securities Purchase Agreement, as amended, or the Purchase Agreement, with the Purchasers, pursuant to which the Company sold and issued 3,621,314 shares of the Company’s common stock for $19.35 per share and, with respect to certain Purchasers, pre-funded warrants to purchase 6,714,636 shares of the Company’s common stock in the Private Placement. The purchase price of the pre-funded warrants was $19.3499 per pre-funded warrant, with an exercise price of $0.0001 per share. The Company received gross proceeds of $200.0 million from the Private Placement, before deducting $0.4 million of offering expenses payable by the Company. The pre-funded warrants are equity-classified and carried at the instruments’ fair value upon issuance. The pre-funded warrants are exercisable upon issuance pursuant to certain beneficial ownership limitations as defined in the Purchase Agreement and will expire when exercised in full. As of December 31, 2023, all pre-funded warrants are still outstanding.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants Issued in Connection with Amended 2020 Loan Agreement</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the following equity-classified warrants were outstanding, in addition to the pre-funded warrants discussed above:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:27.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Common Stock Issuable Upon Exercise of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,354</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.00 </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2032</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s warrants are equity-classified and carried at the instruments’ fair value upon classification into equity, with no subsequent remeasurements.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance as of December 31, 2023 and December 31, 2022 consist of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,494 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future equity grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,789 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,514 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 200000000 0.03 0.02 4332354 127400000 2600000 400000 0 3621314 19.35 6714636 19.3499 0.0001 200000000 400000 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the following equity-classified warrants were outstanding, in addition to the pre-funded warrants discussed above:</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:27.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares of Common Stock Issuable Upon Exercise of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 15, 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,354</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.00 </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 18, 2032</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7354 17.00 40000 45.00 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock reserved for future issuance as of December 31, 2023 and December 31, 2022 consist of the following (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,494 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future equity grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,789 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,514 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6494000 5305000 533000 162000 6715000 0 47000 47000 13789000 5514000 EQUITY COMPENSATION PLAN <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Incentive Plan </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s share-based compensation plan, the Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, or the 2017 Plan, provides for the issuance of incentive stock options, restricted </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and unrestricted stock awards, and other stock-based awards. As of December 31, 2023, an aggregate of 7.8 million shares of common stock were authorized for issuance under the 2017 Plan, of which 0.5 million remain available for issuance. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation costs related to stock-based awards, including stock options, based on the estimated fair value of the awards on the date of grant. The Company grants options with an exercise price equal to the fair market value of the Company’s stock on the date of the option grant. The options are subject to four-year vesting with a one-year cliff and have a contractual term of 10 years.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s stock option activity under its 2017 Plan for the year ended December 31, 2023 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.95 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,494 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,322 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2023 and December 31, 2022 was $2.1 million and $3.7 million, respectively. Aggregate intrinsic value of stock options exercised and outstanding is calculated using the fair value of common stock on the date of exercise and as of December 31, 2023, respectively. The total fair value of stock options vested during the years ended December 31, 2023 and December 31, 2022 was $24.9 million and $25.0 million, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are valued using the Black-Scholes Merton option pricing model on the date of grant. This option pricing model involves a number of estimates, including the expected lives of the stock options, the Company’s anticipated stock volatility, and interest rates. Stock-based compensation expense is recognized using the straight-line method over the vesting period. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2023 and December 31, 2022 were as follows. </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.72</span></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the assumptions used in the option pricing model in the following manner:</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company’s limited historical stock price volatility data indicative of the expected future volatility, the Company based its estimate of expected volatility on the estimated and expected volatilities of a guideline group of publicly traded companies. For these analyses, the Company selected companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available, or until the volatility of the Company’s market-traded shares best represents its expected volatility. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected dividend yield is assumed to be zero since the Company has never paid dividends and does not have current plans to pay any dividends on its common stock. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the expected term of its stock options granted to employees and non-employee directors using the simplified method, whereby, the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this method since it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value—T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company’s common stock is determined based on its closing market price on the date of the grant. The Company’s board of directors intended all options granted to be exercisable at a price per share not less than the per share fair value of its common stock underlying those options on the grant date. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,630 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,513 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>As of December 31, 2023, the Company had $51.8 million of total unrecognized stock-based compensation expense related to its stock options, which is expected to be recognized over a weighted-average period of 2.5 years 7800000 500000 P4Y P1Y P10Y <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company’s stock option activity under its 2017 Plan for the year ended December 31, 2023 is as follows (in thousands, except for per share data and years):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.95 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,494 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable as of December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,322 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5305000 22.95 1615000 22.98 242000 23.88 184000 12.59 6494000 23.22 P7Y7M6D 96548000 3322000 21.80 P6Y7M6D 54101000 2100000 3700000 24900000 25000000 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option pricing model, as well as the resulting weighted-average fair value for the years ended December 31, 2023 and December 31, 2022 were as follows. </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.72</span></td></tr></table></div> 0.0377 0.0263 0.8431 0.8526 0 0 P6Y29D P6Y29D 16.88 17.72 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense for stock options consisted of the following (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,630 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,513 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 16630000 14513000 8216000 5937000 24846000 20450000 51800000 P2Y6M LICENSE AND GRANT REVENUES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company’s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phylaxis Agreements</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a joint venture with Phylaxis BioScience, LLC, or Phylaxis. In connection with the joint venture, the Company entered into the following agreements: Contribution Agreement, License Agreement, Limited Liability Company Agreement, and Master Services Agreement, or collectively the Phylaxis Agreements, pursuant to which the Company licensed certain intellectual property and know-how to Phylaxis and agreed to provide services to develop certain compounds. The Company received $5.0 million in nonrefundable, upfront payments from Phylaxis under the Master Services Agreement, or the MSA. In addition, upon closing, the Company received a 10% equity interest in Phylaxis as consideration for the contribution of the license of the Company’s intellectual property and know-how. Pursuant to the terms of the Phylaxis Agreements, during the fourth quarter of 2023, the Company received an additional 5% equity interest in Phylaxis following the achievement of a milestone event. Under the License Agreement, the Company is also entitled to specified development and commercialization milestone payments of up to an aggregate of $225.0 million and $175.0 million, respectively. The Company is also entitled to share in a percentage of the profits of Phylaxis under the Limited Liability Company Agreement.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the initial transaction price of $5.5 million, comprised of the $5.0 million in upfront payments and the fair value of the 10% equity interest of $0.5 million, over the period of performance of development services on the two compounds. During the third quarter of 2022, the Company fulfilled this performance obligation in full and recognized all remaining deferred revenue under this contract.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, the Company transferred a second generation compound to Phylaxis, which was a milestone event under the agreements. Upon transfer, the Company received an additional 5% equity interest in Phylaxis, which has a fair value of $1.6 million. The Company recognized the fair value of the 5% equity interest as revenue and accounted for the investment under the equity method. In order to determine the fair value of the equity interest in Phylaxis upon this milestone, the Company utilized the investee’s independent valuations based on recent financings from third party investors at fair market value.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and December 31, 2022, the Company recognized $1.6 million and $1.1 million of revenue under the Phylaxis agreements. As of December 31, 2023 and December 31, 2022, the Company had no deferred revenue related to this agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chiesi</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company entered into an Option Agreement, as amended by the First Amendment to Option Agreement, dated August 19, 2019, or the Chiesi Option Agreement, with Chiesi Farmaceutici S.p.A., or Chiesi, pursuant to which the Company granted to Chiesi an exclusive option to obtain an exclusive license to develop and </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize INBRX-101 outside of the United States and Canada. Additionally, the Chiesi Option Agreement provided Chiesi with a right of negotiation for INBRX-101 development and commercialization rights in the United States and Canada in the event that the Company engages in discussions with any third parties for such rights during the term of the Chiesi Option Agreement. Under the terms of the Chiesi Option Agreement, the Company received a one-time, non-refundable option initiation payment of $10.0 million in August 2019.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified one performance obligation as of the effective date of the Chiesi Option Agreement, which is to perform research and development services for Chiesi during the option period, which would continue (unless the Chiesi Option Agreement is terminated earlier by Chiesi or the Company) until 60 days following the last to occur of (i) the Company’s delivery to Chiesi of the trial phase data for the first Phase I Clinical Trial, (ii) the Company’s delivery to Chiesi of the finalized minutes from the definitive U.S. Food and Drug Administration, or FDA, scientific advice meeting conducted following completion of such Phase I Clinical Trial, and (iii) the Company’s delivery to Chiesi of the finalized minutes from the definitive parallel European Medicines Agency health technology assessment, or EMA-HTA, scientific advice meeting conducted following completion of such Phase I Clinical Trial. The Company determined that the option to grant a license in the future is not a material right.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2023, the Company provided a copy of the European Medicines Agency, or EMA, scientific advice to Chiesi upon receipt, which fulfilled the necessary deliverables to Chiesi and triggered the start of its 60-day option period window. On September 18, 2023, the Company was notified that Chiesi declined to exercise its option, resulting in the expiration of the Chiesi Option Agreement (upon the lapse of the option period), and with the Company retaining global rights to develop and commercialize INBRX-101.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $10.0 million upfront payment was allocated to the single performance obligation. Revenue is recognized over time as services are performed during the option period, based on the Company’s effort to satisfy the performance obligation relative to the total expense estimated to be incurred during the option period. During the years ended December 31, 2023 and December 31, 2022, the Company recognized $0.1 million and $0.9 million in revenue related to this agreement, respectively. As of December 31, 2023, the Company has no deferred revenue related to this agreement. As of December 31, 2022, the Company had $0.1 million current deferred revenue related to this agreement. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2seventy bio, Inc.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Option and License Agreement with bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single domain antibodies, or sdAbs, directed to specified targets, consisting of two initial programs and up to an additional 8 programs. The Company retains all rights to the specific sdAbs outside of the cell therapy field. In November 2021, this agreement, or the 2020 2seventy Agreement, was assigned to 2seventy bio, Inc., or 2seventy, in connection with bluebird’s internal restructuring and subsequent spin-out of 2seventy.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company received a non-refundable upfront option fee of $0.2 million in connection with each of the two initial programs, or $0.4 million in aggregate, and is entitled to an upfront option fee for each additional program, on a program-by-program basis. In June 2022, 2seventy selected a third program and paid a non-refundable upfront option fee of $0.2 million in exchange for a development license. Under each of the three programs, the Company has granted an option in which 2seventy may acquire an exclusive license with respect to all binders and cell therapy products developed under this agreement, which entitles the Company to additional fees upon exercise of the option. In connection with each program for which 2seventy exercises its option, 2seventy will be required to pay the Company a one-time, non-refundable, non-creditable fee in the low-single-digit millions. The Company is also entitled to receive certain developmental milestone payments of up to an aggregate of $51.5 million per therapeutic, as well as percentage tiered royalties on future product sales with rates in the mid-single-digits. Due to the uncertainty in the achievement of the developmental milestones and future sales, the variable consideration associated with the future milestone payments has been fully constrained (excluded) from the transaction price until such time that the Company concludes that it is probable that a significant reversal of previously recognized revenue will not occur. These estimates will be re-assessed at each reporting period. As of December 31, 2023, 2seventy has exercised one of its options and declined one of its options as related to the two initial programs, while the third program option remains outstanding. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the effective date of the 2020 2seventy Agreement, the Company identified one performance obligation, which was the transfer of the exclusive development license to bluebird for the two initial programs. The Company determined that the option granted for an exclusive license in the future was not a material right. For the eight programs not identified upon execution of the contract, the Company evaluated the customer option for additional purchases and determined that those options for additional programs did not constitute material rights nor variable consideration. As additional programs are identified, the Company re-assesses its performance obligations and transaction price accordingly.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, pursuant to the terms regarding the addition of new programs in the 2020 2seventy Agreement, the Company received a $0.2 million upfront option fee related to the selection of a third program and transferred the related know-how and development license. The Company recognized the $0.2 million of revenue at the point in time in which the program was added and the program term began.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recognized $0.2 million of revenue related to this agreement. The Company did not recognize any revenue related to this agreement during the year ended December 31, 2023.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was recognized in accordance with the Company’s stated methodology discussed in Note 1.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CDMRP funded through the DoD </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company was awarded a grant from the DoD in the amount of approximately $0.3 million for the development of sdAb based therapeutics targeting SARS-CoV-2 Spike protein for the treatment of COVID-19, or the 2021 DoD grant. Work under the grant began in February 2021 and continued through February 2022. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from this grant is based upon internal and subcontractor costs incurred by the Company that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provided funding for overhead expenses. Revenue is recognized when the Company incurs these covered expenses related to the grant’s continued progression. The Company submits requests for reimbursement to the DoD for only those expenses which have been incurred by the Company in each period, resulting in reimbursement in arrears. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, $14,000 was recognized as revenue under the grant. All work was completed during the year ended December 31, 2022. No revenue was recognized under the grant during the year ended December 31, 2023.</span></div> <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total revenue recorded in the Company’s consolidated statements of operations (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">License fee revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phylaxis BioScience, LLC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chiesi Farmaceutici S.p.A.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2seventy bio, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total license fee revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Congressionally Directed Medical Research Program</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total grant revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,192 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1634000 1101000 166000 877000 0 200000 1800000 2178000 0 14000 0 14000 1800000 2192000 5000000 0.10 0.05 225000000 175000000 5500000 5000000 0.10 500000 0.05 1600000 0.05 1600000 1100000 0 0 10000000 1 P60D P60D 10000000 100000 900000 0 100000 2 8 200000 200000 2 400000 200000 3 51500000 1 1 2 1 2 8 200000 200000 200000 0 300000 14000 0 INCOME TAXES <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense (benefit) were as follows for the years ended December 31, 2023 and December 31, 2022, respectively (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for the years ended December 31, 2023 and December 31, 2022 was related to state income taxes.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and December 31, 2022 as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,684)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,497)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,057 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred income taxes were as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,663 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,948 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had unused federal and state NOL carryforwards of approximately $305.1 million and $65.3 million, respectively. The federal NOL carryforwards may be carried forward indefinitely but are only available to offset up to 80% of pre-NOL taxable income each year. The state NOL carryforwards will begin to </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expire in 2038, if not utilized. As of December 31, 2023, the Company also had federal and state research tax credit carryforwards of $12.4 million and $6.2 million, respectively. The federal research tax credit carryforwards begin to expire in 2038, while the state carryforwards have no expiration. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of NOL and research tax credit carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that have occurred previously or may occur in the future. Under Sections 382 and 383 of the IRC, a corporation that undergoes an “ownership change” may be subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes otherwise available to offset future taxable income and/or tax liability. An ownership change is defined as a cumulative change of 50% or more in the ownership positions of certain stockholders during a rolling three-year period. The Company is in the process of completing a formal study to determine if any ownership changes within the meaning of IRC Section 382 and 383 had occurred and, pending the finalization of the study, has not identified any ownership changes as of December 31, 2023. It is possible that the Company may incur additional ownership changes in the future. If an ownership change has occurred, the Company’s ability to use its NOL or tax credit carryforwards may be restricted, which could require the Company to pay federal or state income taxes earlier than would be required if such limitations were not in effect. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established a full valuation allowance against its deferred tax assets due to uncertainties that preclude it from determining that it is more likely than not that the Company will be able to generate sufficient taxable income to realize such assets. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2023. Such objective evidence limits the ability to consider other subjective evidence such as the Company’s projections for future growth. Based on this evaluation, as of December 31, 2023, a valuation allowance of $146.0 million has been recorded in order to measure only the portion of the deferred tax asset that more likely than not will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence, such as estimates of future taxable income during carryforward periods and the Company’s projections for growth. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had gross unrecognized tax benefits of $4.7 million, none of which would affect the effective tax rate due to the existence of a full valuation allowance. The Company does not expect any significant increases or decreases to its unrecognized tax benefits within the next 12 months. The Company’s policy is to recognize the interest expense and/or penalties related to income tax matters as a component of income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets as of December 31, 2023 or December 31, 2022, and has not recognized interest and/or penalties in its consolidated statements of operations for the years ended December 31, 2023 and December 31, 2022 as the unrecognized tax benefits relate to tax positions for which no cash tax liability has been reduced. </span></div>The Company is subject to income taxes in the United States and various state jurisdictions. The Company’s tax years from 2019 and forward are subject to examination by the United States and state tax authorities. The Company has not been, nor is it currently, under examination by the U.S. federal or any state tax authority. <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense (benefit) were as follows for the years ended December 31, 2023 and December 31, 2022, respectively (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3000 3000 3000 3000 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and December 31, 2022 as follows (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YEAR ENDED DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected income tax benefit at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,684)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,497)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,261)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (FIN 48)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision true-ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,057 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -50684000 -30497000 -3568000 -2495000 1524000 583000 2322000 1261000 1054000 751000 -420000 -135000 54419000 33057000 3000 3000 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net deferred income taxes were as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,585 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,663 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,948 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,048)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 68254000 52970000 12648000 9728000 3289000 3684000 1412000 696000 8581000 5130000 51772000 19585000 0 37000 697000 1118000 10000 0 146663000 92948000 146005000 91586000 658000 1362000 10000 35000 648000 1048000 0 279000 658000 1362000 0 0 0 0 305100000 65300000 12400000 6200000 146000000 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company’s unrecognized tax benefits (in thousands): </span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,651 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,597 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3597000 2846000 1054000 751000 4651000 3597000 4700000 0 0 0 0 LEASES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company entered into a seven-year lease agreement as its sole location in La Jolla, California. The lease expires in June 2025 with an option to extend the lease an additional five years, which is not included in the right-of-use asset and lease liabilities. The lease contained an initial base rent of approximately $0.1 million per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company executed an amendment to its lease agreement to expand its facilities and began occupying this space in January 2020. The amended lease terminates coterminously with the initial lease agreement and contains an initial base rent of approximately $30,000 per month with 2% annual escalations, plus a percentage of taxes and operating expenses incurred by the lessor in connection with the ownership and management of the property, the latter of which is to be determined annually. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating right-of-use asset and operating lease liability as of December 31, 2023 and December 31, 2022 are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,717 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and December 31, 2022, the Company recognized operating lease expense of $3.7 million and $3.4 million, respectively. During each of the years ended December 31, 2023 and December 31, 2022, the Company paid $2.2 million for amounts included in the measurement of the operating lease liability in each period.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and December 31, 2022, the Company’s operating lease had a remaining term of 1.5 and 2.5 years, respectively. The Company discounts its lease payments using its incremental borrowing rate as of the commencement of the lease. The Company has determined a weighted-average discount rate of 8.2% as of December 31, 2023 and December 31, 2022.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental commitments for the Company’s operating leases reconciled to the operating lease liability are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384 </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P7Y P5Y 100000 0.02 30000 0.02 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating right-of-use asset and operating lease liability as of December 31, 2023 and December 31, 2022 are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.925%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,952 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,717 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,033 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2952000 4717000 2063000 1860000 1110000 3173000 3173000 5033000 3700000 3400000 2200000 2200000 P1Y6M P2Y6M 0.082 0.082 <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum rental commitments for the Company’s operating leases reconciled to the operating lease liability are as follows (in thousands):</span></div><div style="margin-bottom:9.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AS OF DECEMBER 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,384 </span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,173 </span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of operating lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2247000 1137000 3384000 211000 3173000 2063000 1110000 COMMITMENTS AND CONTINGENCIES <div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company is not party to any material legal proceedings. From time to time, it may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I-Mab Litigation </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2022, I-Mab Biopharma, or I-Mab, filed a lawsuit against the Company and Brendan Eckelman, the Company’s co-founder and Chief Scientific Officer, in the United States District Court for the District of Delaware, C.A. No. 22-00276-CJB, asserting claims for misappropriation of trade secrets related to Dr. Eckelman’s service as an expert witness for Tracon Pharmaceuticals, Inc., or Tracon, in Tracon’s arbitration against I-Mab. The case is currently in the discovery process. </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inhibrx is unable to reasonably estimate possible damages or a range of possible damages in this matter given the uncertainty and therefore has not recorded a liability on its books as of December 31, 2023.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company’s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has several ongoing contracts with CROs for preclinical studies and clinical trials and with CDMOs for clinical supplies and manufacturing scale-up activities. While these contracts are generally cancellable, some may contain specific activities that involve one or more noncancellable commitments, including minimum purchase commitments, binding annual forecasts, and capital equipment investments. Additionally, depending on the timing and reasoning of the exit, certain termination penalties may apply and can range from cost of work performed to date and up to twelve months of future committed manufacturing costs. As of December 31, 2023 and December 31, 2022, the noncancellable portion of these contracts total in aggregate, excluding amounts paid or incurred at each </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective date, approximately $62.8 million and $74.8 million, respectively. The noncancellable purchase commitments as of December 31, 2023 relate to the purchase of raw materials and future contract manufacturing of drug supply for INBRX-101. During the years ended December 31, 2023 and December 31, 2022, the Company incurred $44.5 million and $0.3 million of expenses related to its non-cancellable purchase agreements, respectively.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as of December 31, 2023 and December 31, 2022, Mark P. Lappe, the Company’s Chief Executive Officer, Brendan P. Eckelman, the Company’s Chief Scientific Officer, and Kelly D. Deck, the Company’s Chief Financial Officer, and certain other members of management have agreements that provide for severance compensation in the event of termination or a change in control. </span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its proposed Merger (as defined below), the Company engaged legal counsel under a contingent fee arrangement. Under this agreement, the Company is obligated to pay a fee of $20.0 million, contingent upon the consummation of the proposed transaction. In the event the Merger is not completed, the Company does not owe any fees to its legal counsel. The Company will incur these costs in full upon the consummation of the Merger, if and when it is completed, and has not incurred any portion of this fee as of December 31, 2023.</span></div> P12M 62800000 74800000 44500000 300000 20000000 SUBSEQUENT EVENTS <div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated subsequent events to assess the need for potential recognition or disclosure in this report. Based upon this evaluation, it was determined that no additional subsequent events required recognition or disclosure in these consolidated financial statements, other than disclosures related to those outlined below.</span></div><div style="margin-bottom:2pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger and Spin-Off</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2024, the Company, Aventis Inc., or Parent, a wholly owned indirect subsidiary of Sanofi, and Art Acquisition Sub, Inc., or the Merger Sub, a wholly owned subsidiary of Parent, entered into an Agreement and Plan of Merger, or the Merger Agreement. Pursuant to the terms of the Merger Agreement, Parent will acquire all outstanding shares of the Company via the merger of Merger Sub with and into the Company, or the Merger, with the Company surviving the Merger as a wholly owned subsidiary of Parent, and in turn each shareholder will receive (i) $30.00 per share in cash, (ii) one contingent value right per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone, and (iii) one SEC-registered, publicly listed, share of Inhibrx Biosciences, Inc., or New Inhibrx, for every four shares of Inhibrx common stock held. In addition, in connection with the transaction, Parent will (1) assume and retire the Company’s outstanding third-party debt, (2) cause New Inhibrx to be funded with $200.0 million in cash, and (3) retain an equity interest in New Inhibrx of approximately 8%.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with and as a condition to the Merger, the Company and New Inhibrx entered into a Separation and Distribution Agreement, dated as of January 22, 2024, or the Separation and Distribution Agreement, pursuant to which, immediately prior to the effective time of the Merger: (i) the Company will effect a pre-closing reorganization, which will result in (x) the Company owning, assuming or retaining all assets and liabilities primarily related to INBRX-101, or the 101 Business, and (y) New Inhibrx owning, assuming or retaining all other assets and liabilities of the Company and its subsidiaries; and (ii) thereafter, the Company will distribute to its stockholders as of the record date on a pro rata basis, 92% of the issued and outstanding shares of New Inhibrx common stock, at a ratio of one share of New Inhibrx common stock for every four shares of the Company’s issued and outstanding common stock held on the record date. Following the spin-off, New Inhibrx will be a separate public company and the Company will retain 8% of the issued and outstanding shares of New Inhibrx common stock as of the effective time of the spin-off.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The boards of directors of both the Company and Sanofi have unanimously approved the spin-off and the Merger. Parent will pay transaction consideration totaling approximately $2.2 billion in aggregate value. Parent will also make payments at the closing of the Merger to settle the Company’s third-party debt. Following the closing of the Merger, New Inhibrx will continue to operate under the Inhibrx name. Parent’s acquisition of the Company is subject to the completion of the New Inhibrx spin-off transaction and other customary closing conditions, including </span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receipt of regulatory approvals and approval by the Company’s shareholders. The companies currently expect the transaction to close in the second quarter of 2024.</span></div><div style="margin-bottom:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger Agreement contains certain termination rights for each of the Company and Parent. Upon termination of the Merger Agreement in accordance with its terms, under certain circumstances, the Company will be required to pay Parent a termination fee in an amount equal to $54.5 million, including if the Merger Agreement is terminated due to (i) the Company accepting a Superior Proposal (as defined in the Merger Agreement) or (ii) the Board changing its recommendation that stockholders vote to approve the Merger Agreement. This termination fee will also be payable by the Company if the Merger Agreement is terminated under certain circumstances and prior to such termination, a proposal to acquire the 101 Business or more than 50% of the Company’s stock or assets is made or publicly announced and not publicly withdrawn and the Company enters into a definitive agreement for, or completes, any transaction involving the acquisition of the 101 Business or more than 50% of its stock or assets within twelve months of such termination. The Merger Agreement also provides that Parent will be required to pay the Company a reverse termination fee of $92.1 million if the Merger is not consummated due to the failure of certain conditions to be satisfied as a result of failure to obtain antitrust clearance.</span></div> 30.00 1 5.00 4 200000000 0.08 0.92 4 0.08 2200000000 54500000 0.50 0.50 92100000 false false false false

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�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�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�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�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

B+N<+Q_6EK+ ^P*'#ZDM:&RB(Z9]X.8L4IK!QGB M#9;"]7',M-9S5CVA^*\!SU/4ROO#K;<''< VFUY7<46"DX,Y?N@(@K9)N8@8 M ]8Q34 RCFEC;E-18R5;-\T9CU-'=4S@+S:86EL9?15S"<-=<0VTHQ9Z5ZP,) Q1WUQ C MN@CK+;Q<05Q=E'1*I:%=S5*O3B$[F;9#CH^JP.H:0L'#QLS&15Z&S6Y23@05HQ>9F<4(TZU.4V]LPT6"[1! M1"%*3"2_>;??Z3?(,1;J43H W MF8C74S'%?* %9SNLL0PP(C5"O[@^>K.7,L-.'/CWCV$M*;)4.$YES8;CR02$ MM[Y,_P!)B3)+66>F90;H#5Q2N[W*2Z57-;$<)!IQ!CH/,%B^X*E0K9@HF3$' M-G":9P5<._G"R/>U^\P'YD.XI 3&Q]IGG&HWU4**2]EE>%:KFLQ&[),GG^IT MH4?DKJ)X+\ZKC'# >"" EOW0",-?I+0]*BL<,XG=5 UOQ*^K8.ZF9X'/ )4[ MXJD3'LF;,N-!>Y36/:476H%72[]R6);WB4PSV=UJ=0*J]14#:+]O#J[BV@L74"7:1)^?:6^>S_2' M14K537.*7$K>U6F50/ \VI_/Y4\G$KX8#RJPR><;N64QUHO#2O298S**:4:G M%##I'E*L4%]+F*!&4OWGX(U%7<) "8#([@]H!?B!XU'EJGNBOTVHY[5XS!5\ M2ST@L4:QT!$$XR 2^DA80,/G%H3LP]=SW\H=H0 MA\KE-L-K!?I& #F"9&<%K]JB>7I@#VO&/,!H VJ G9CQ,S)?988JKV-.S;MYBKO9(M":O@ASM&0:JN#(>\]O)TA6O-7[RDWPSVS M>/+OVZE/.6L_*K$LO.\H:,#UA2;U@]4%U!"K$..:9*48+">7&(?42(/$05Z3 M 5>>%/H$OHZ[A%U0:R']O-PG:T'NS 4**2Q[)?$T<'E3&1CJ9]=\.8Z&M]V0 M./E#:.[&<%&^AIOHEQ)L*K%K..74.UZ$%89&N3J5AIRS(>DJ2:82'HJ?(.R: MGR[L"-?I+#%!%M*-_EPNX3@ZO$VP )VE?*'?'@>"WB7RML"BC!,U,64C#A-^ MR74S[T\PZ96::B@J^/ZB(6*U>H@ M2\.9J"/36X ET1'>1-\!<%,#DRYJF^( M;BF5%ANEOJ#!P"BK?SN,)67.+B9H'LP$P-=QS6PN0#9\5B5)]\NFUJS/*@P6 M9"3 ?^?:8IQ>>'?$K:<"=_6"C,F* 7:R(&QSL MG*!OJH21I8P8M?(\1$IBW[R]SNM?6/*%@&%W=N("3@;*E]U_;JP-4:;K-,N; MDJI^2YEV%/OR6R:7;/-T]('3P>!JW$OD4<\U&$EZ9R-AZ\8% 1M_"6H8#6; M/5U,VYD-6]-XY@QF2W!'DPR IJ5%.1D^M38EHS^8IF.0FVO=F\3%> CS47.? MIR,BZ"PZK6U+S8^*A4MFA2\Y#G\K$!)5'01[1P.RB^SPS 8ERVXS;S"JP M;C64%:BZ^?\ 4*"ZCZ4=4R"FW9/)F M!;M];S\X#@@+II8EF=7^LZ&+-8C.H"VZ0$\6-J2ERI+)LY(.5?3?M$S6EZU! MV-&MYCBHSB.KO'511LU],'B^9NA\KCUG"T:-O']N7C5#L<.YY89[S%EVU-3Y M'<7IN#CGB,O,L :WC-$KXL\DQ[ MRU#Q0 I-\:\0Y?$-KN6V!VMH$RA=I1'0 ;%;&:G*2RVT;RYE!HR$KOJ/K+99% = M@U5P82_/5S4MN& 6Y$SN("%-:HR;E-5PKK*S\KEHRP%E+:7'UE%QJ[7-ED]I M3E>!1^4$%PICQ&=J"IZ$N-%AOGYQQD%$2KZG.V/[94"W ;6;6(;UYS"QH5X3 M7-$.MG@]-3G068ER.U:( Z*I$1.?K!-@JM1JE8706&@=,^(POJLG*4^I7@%. MZS-ZH,P-_OF/N'81=?CWAO\ *U^"G\N=5,H52*U,[-*CP76?E%( M<-5W?YI?K6;NZ]IMJ%R=.;ASD"@0MA5PSV6G3+[I?4XG1[J";R#(O [@Y4E9 MXHG]2>D/:-$+-9=)59(M"@HP2][@/\J,0X8=E%[UJ(L"TBBG>XLL\LYJ -\U@F];= M,9$Q(XL:"JL->R,JJ&]JUJ_G"X']KV(L%\/I&0P]BL)-%F4RQ7I+VNX;.A-\ M.3[S4 0VN?/RCH.MV4/^<,PL9NDOY?VNOU/7@7 ^IN\C>G4<,C*[>E_:/E.L M.7*JA(04\*C"($=,%-E>T)8730(#F;PDSC(LL0*\E;\&JJ%80R.QDH4^H8>M M]?2$XDCK3*_I'Y""JI.)DC['0-M=8^<191(PQ$R-YF=GR*N7G!**TW"-9>T_ M[/M*-4U(LJ_G,<%ZEI;OWBGTXF%M82%+0R5ZB+<:UB'P_* 4]( B.1>8 !0 M%!T']2)4N(7RS %OKEL3(&)JN0:G)K;=&L3,>-F-8U"8SN6(YUXYE%7F@"K] M4.2Z4]H>#IW\JF][B5 %OP77^I;/*HMF5+CUBR*+2YL4Z((97$76@WGLGN)7K^\/T+6-N>I0]TBO.&"%B27)_Z,_K=YS>-=S/(MM=^FC4NP MF3FJ>/G*/A5JL07KJ-"V@[NE_*9T!%DY*2G@.= 31\1;OUB"R/F_,",)R0ZZ M:)\D * T']39AYT)1I2MU%M1Q_P!0/5\1.=6J1W5QQ^T=:::KD*HG+Z-7B59+K2VT M/K.&!4,@^;<26$TH_*#<;H'*U5-!PQ8N_5*[Z"S E9C?5J#Y8U%H;E@.KQDE M_F3/4%SQ&QK;1]Y0Q3O5.V9+A*-*GHB/G K+2SH]RE[<2Q?9#68$XLNO[3<, M!::"7%NI%X[_ .1AF*FBY=>JL:]8Q0U%1W$L(U85N-\4=K>OU2^UE'@G+Q%) M1Q!JU;S>)M*%,V-_:6/PJJRCZ<^T5*/Y&O)S+B "D')"UX$L0A!0DY?ZGK+ BF:-])=$3*N_G-DRPI6!>&H:'9.LQ94 MNLMMN)4* :KGWOJ'&N!8,7]C[0%XA@KLXX8/9,071T2SIKN+5SR[533.O+YN96)A(%550E@F%&8GWEL&&@ALDI M:J4F\<_--3"5#EO_ ' *+&!KJ5=48'SF-?1*[)'FP7E>9E^2HA5+:#RP,2V$ M7X8_M)$X"U=!'1$6+SY:U'&;'(QV& Q$8@Z -QI0(BG#//$)+BVG'Y^TP&9\Z+?M**M%SG1^=2IX*(,'GR3*LU]F:&FW4JBE>Q5V^C+MT M?TE_Q-A\U%(,0EU5RN*6:\)N4YJZ;:ZZ743G7(KL^L(.&0PKS?/YU+TC8%%? M*$+WXP?9_6WV(NK[S7[31AA"1&+K7E\1Y5,BN+[EC"P'A#/8%D#U=?F98_P" MF[L]0@;:V&ZA8$&:M#VN-&$++$,^L*(*CH5_:5W)\!.R1#O,PFQRD58Q]0?I M+N[#*' ,/ZGK,@%WFGHNZ/$O.#;/$*MM5]XIH3(^*U[W+@3)?##GJ%>3S@ R MUJ'<7H'-*@\ZB_:MHMH!KA7F60R=%V,1[5WRMC[&%G+_ &G(7+'[1W0.?, O M'\B:D^P:8>T8>ES:U1C_ $]H"6HF#74'QAQ.,LE&S::W,Z$J0VV<^8IG#K&5H#1,OB"0\Q+*[<2M,5J5BOS4<.+:YB8%M=R_BW>NHE16.0M8=RSAK-Y9C M$)5O0*.98!>PNO6,7A!TM#EF))"*17/6XATX)RU$?NE=8LRJZW!#F-JP4M/; M^TUV'C\S>NA65M=2@!;@7<6)[=^D554LYP+]8:@'S)V%?69_-VFJ0W *8=PR M3ZMQVY?IXC=B-[8XP8J <-0;+9NG4*T8/]2@IP%*\EF<3&+,^IZ MQ?I!%S:!6++Q6"(0'0BFC'2%4=,\,R-MD.>5.!@Y]YHDH%Q:/[H@M?U!($L$ MYA,93H5*LA-)8:F M$BK2OL9/B4T[!H:+13'=I!QB_P N K2"6H+UBWWG(5C*OBMG=&6$##R7_3MCH7M 8W\EO,T+ MX+\2NKO]R;&EK.B;(2,L+EAS+: ,'84%\&C)Q]_'FX'B@->T MPO3^B)B,[8SK6I_S-1?[3LJ+WGK#+([UV7+>Y1P1POF$$"L%65,E6>(X5@!0 MP#>4EI,%,%Z_/^RPP>A:>B4@<@RH6W%:W;4.?0C/QZEOQ3F1XZ7,K]->N_Q# M#' &1H/VA 0ZU5[*[W #QDCX+1B-Z-7<8;(-[:[E'!0)+>'%SE6 JBU-0567 M[JA3["4&F"QMX_/I"[0,:J)0')W#F"@987(.&O&8.6%L\,?I_3E/PL$LW.63 M//<#6RHI?O C;1CR0#HW5K(:B\[W]P!?3XXF+/%T6XO2I^#_:3Q4[71"=I0N2Z_.Y#ELN<6U M'Z-,*P[XESP&=]4=.J@ ]C#-0!7R(72@95H-H6T5X%#1!#L5;YGX$%01G3?RE MF=@'5N/Z< 3GQR^S-[8\*RQ[2JM/2_*_0F;JC90PV(]IDW.!N[O>84 AQ'$- MS!AB,59,)=AXU,8( C$+6EC$LJ">B0A67VEY:JOF[P5*@0(-O;"W#++P()>> MD]J98.8F%6?M+?)[3L!Q!S]JO$1]P!;XG(+. MYB9&OO?0Y%,0H5Q#:P8KFVLQ%;OCY/,0XU*EPQ'L^49O40-5J3=:_.G^TJ'L MI#8SE."VPU;EPA,1)R([F(\ BJ6ONQ=HZ%ZOQU$J9\7C*)OD*KJUG/=>91X8U)V*XSY:+Q* R&C&, MKN8!:),V2S7$ZC]>M=,)9U,5&GKN8P^!"9JR_VW&X: MQJ7R:J4R8!QKB&*E03+<*J6+ [72\Q6O;?1_31 JI3JY1E*H^LOT[7*O"!=) M=:PF"%FL:5*BCQ,:H\4RG):N?/4H; H"DSZ)B\-]74O#JH0"VC MYQ72D%E,A^C?[3H S+8DO=9<_G.MR_M%8.?UF%!X:U$(+%.1S Y+,#)UL)3M M%4I107W#I"# M9QB?I*L'T+6.JB&ZM%T[82\"=LCH^\()[J4YF(;VJ! 4^,SN",2FO1_30&60 M2Y?M@C0/$0I:!8GJ@2RY&Q:.#:16,%13/!6SV -0$< :E=S3=5LQQ! M[9!"5P>*A(-<#-%EC);2]0G^TJ .6XAW<4_L2@W'/I#:L/_9B[HN7C MX+O13]9CT1[V^BX4YN]K"^I6,2CKB"7(+K<*=47->B';'%U0P^DN68&W9U]' MM%#&,2TO(@$&NX4:KYSE?^HV0W'>:+A)LXP@[($;,V#Y1]Q(FM*"+, 0>X_: M9!E7ZQHF7GJ_:9>>5QCN_P ^\+0#&[>#K,>.D* FG[,R/8R'1X@V-#A66XD5 MG9$8M'ET:_IVYU"='I ZK/TC*(O]3&D%%/%#"DZUC!J+E=Z*U^Q$)M^; ACH M%+UJ*'@:,T0D!2_5^R/X9E>L55L>>!?TC%6VM]IN&YB0Y6@M&OYJ(RC!U Z2 MI;'K$?8Q"CKW.S ['!B[F'2#-G;;>NY>0+8N[,1MIRH]]0\(_NS);-1TQQ , M:2,J_'9%,H\#[1@D;BC%/YS "E:ZG]IWY#(DGF#UA7E*9:A-?/E1 GB9O[2R MP=;NE=Z@(L8(;-XE,IW+VAG;*^08%F(T,567@'EESC,K;&PT9S*BL[.^7ZPW M&ZAYNOUC*P,S.S\XFZZ-S:_ O6./S4PUOJAQVX6R3)B-5)-;@&'REDNT3T#Z MS06[;UM"*#8/%QD[L%I)*?O &K<&>SSN-U@79R;\0R@@=8QW-"TPGI%L.\?M M\ 7_ $XT,7!:>_VF#UC^LNY7'1NJ"HN=+\+G$Z0V6:O&YH5&&RK/F[F",):" M%?2KA+E:*::N%0C WUU*Z8 ]$V"<%&3A2?7%+?K'_<*!OZ3E# @K?((V"4%M MV/QE;0!E20'X<9F+(K@2B]\7<-YV*K3Z2V>?IQ1Q#&,1UF_\ 5_!P;9O56C]T=>KJ M84K3ZSQ]L\_2]RI185(:J+SB66C8[0"^PLI>6!KIQ1J="_,^\$W@;,M=<<3/ M8LL+U8:=D?EC]!F%BO\ 6)&='?B%=#+V3"[AT;#7M_O^G) M US[P"6#>8GU&+N?A&?%X,VO@B: AJ;*?]1Z0AAI7_ 06*^L ,L$+ MT0.&Q9>&54MHV_[7#&@<52K1G,9@]H9J#5, P49*B'&OM&,7E[3F/7,$0[(> MIL>LM)&=$?67H[(+5X77O_;K4EG;X42;/:OEAZ@. W:Y7[>S"#S$';1;:"II:<2KALQ!J#WE07,]CYE*3/11\VB/PW!T\2K+!+M%V-6*45EK,SXQ<73* M$LI!TPR4I42#N0'HFU^8QBS%$Y\%UX)51@Z)0MC648?D2M#,'L#,+ (%1OMS M])_;FM!NU>,1HK,\!QOZK6^XM"<0''P$R :2_! M<1)!I?.+WOY3(7;'S=2PR&=1+Z_Y0%@5#5YE&!28*B]9(;BU@IZETU'.F/\ M5+IT;>UDJKJ$K4"#QF*YSNN#N7@M#38OV M[@3+$QO?Y0F-N7FU80PRP/Z:+""M>1EFX]GC&\S LAL7P<2A$ K;H"I8$VQ@ MRR2HZ5E##>""*4GB(!<]'SC\MK2MFE>7@Y@<]RJE:W:6;B/^%*<:FL6QRDBH MQV8KCAN"/$"[[EB2NI,? % 5@S%,"%TS8(CJ_>$8LI6L!O%S<7]EGJ M"8$Y;XA';$>-F7T^!%@7J*3;D ;!ISDB[1"T*KQ*/0A;4FITZ>)8#(;$?_2OY=!:L\1H4=J,RG36) MAIA#=#A%FQJ_K-[X+2\V: KF8)W<-;1KK*W9^T&F5%EYJ'Z1U@HZ+E&1H:Z: MB^EL"S[",80C9#91FHURBSD8SAWBXB-WYT5FJ_,P-UK?-Q+(;,GK#\HQ07&M M\3HGUV;+IF!0T$2AS;]X7N%M\#7W@#>0@%28Q,UT:O("[\:A-<5M^<>FT_&V M*P>R_P"DZSU'I5M')Q+G@Z4YBQ4:3@OF5["TF[KYRUBI+;PJR,B7N M7G?9%(4N8392T^D-2C+*_P!3F(J&+J*SM("R\ZRN4@!36J)2L*\P@D^Q9DX? M2.J74*^"@3762BN8H84]KA6\6:4**+_,P^25!-5LEO.S128M%OUA&=V%:MWS M^D+X,18*([DI:M\PG2I-]-PS@8&=)S!-38.*C2TY,IG): @@HL/F'\[40+0Y MG 7 X4S_ !9AV%M',AE0C)%+#7JQF6M730:_\S6Z;;JU"E(7 *?R6VU/\&AI M@6@&0G=R'V!(H2(!&A;N8!$:"6@/2HK+4 >?!^7"%U(.S,J:SR$"*^*B+Q<( M(@C4+Z:Y Z5H'(43NJH\:U7!*;$.Q?Y/16M#;VT(D1QA8 -(8#GVP/4^+,9@ M6U_[N;AUH4-?)^L5BBH:KE-*U:;:C6)Z^ JJFX S#B( &(WG,HH5-,)4.%[CPK2I\0BLJU%W>^YA6T^0?,KAA3S M=DK" HX.AY_/0'0-SY2SAZ"LX^G]*UC*Z\B6;@MDE\19V#K,!Z*5"!KDC@Y+ M@U?QR90/-QM1M*Q98MO$M<3Y? @$(IE/8BJ5 JT^W,&=K97HU M12<):-\D1 MF38-15]H)JW7TAAXC09UCU_*:K8O65>?G<-=C8.3&EH?#U+/G% 9;.ZEUANR MJ 6U;6[@68KBVY?UZT7SBX--J%*S[,\7]>4)!2LJ46=G)'AD:AQI'B8ER9\! M?7^+([[H=5-6JMTJF,:JL5G=@(K-UA[MI\=[,#HV"HA9R!0W6? ?*D!.+H1 M:R\!B!(Y$&:)J%)+2+(P!"X12W];KJXHJ7@>I]&%+;^3!1*:%EY ;C4L1%C] MR>Y=MILBH_R"^7[?@.Y RG@KBH>$2-"FZ?K^>SR2H]MSF9G%5,S0T &<(2'6 M( &D;/B7;/8TIM\AY;K@&"6EIN/>_>;70CB H$U0>4Y*[Q*K2?,'-5;N:/B; M-Y0##36#*@DL3^'.4R!F*2V*J\ \[/[_J_]QW",[U!^$08)H"POX'SXI]H9 M1WR?";OHQ7RQ\!FY_!:5+GE.1W9+PQIQ%#53TM!\T5FOX'*2DNV$+; R0%U2 ML8KHC8FI;NKC([DG&0=(B&4,*<88KU@0! :T$1&-<, M;& 6*+/VF4K!=I+C^=+PXO<7VTN#O&[CFR55H0'E#3[G +MVQ&.!6"B6 4&' M+1*H0VL<2E+&^8A^[;7DH@!%:VAI?3]8O+L ,Y+F2W 8AK%?R@R.#7RS\2O< M;:$/3F;P"O.=:1="L#NM\PS:17I>(E5]3.YY#!_2&YQ^PRCN@:0Q<6BADO<[ MY#,N*"DXB]L=8\&G50%@T=&E^\4Y-JF)^<24EY?JZ^I4,8=IK'D/#+5SO4:< M'NOS$1"W>BJY9*[LQ'0N7,7AYB+]--UKAK<'4+XAP_49GH!,+ /M3\H5F@Z- MH+>-LH(D?(^9#Z^, 5])B+\)7I+ MI%S.$-&15(M5<0U"%!JW'UF@&R4N5L3 MJYM>J'"U0['Y]/\ P!O'IT-(X5AGQ/*+A%.N:CH,0H +U@7]F2JL9*T%/BAR MI+\Y24N4%%8C4(!0U17"CN$4P,6QO>5K$*=;;$"6=!7#"KDS.,*Z%E BC_P"7;\!W\;F,<4_Z91+.6(0L MG;:M.4Q6Q>?@7JM=@B'AM"R+(R/;6#:*7=7(=L>K+&:CY,\71KG>CY;0G7E+ M3S/E^/U(]'#3TRT=OX-GF_\ GR<3?G9M0)Z.>;T$NLK5KFC*\E8@"TEO067/ MP$,%H:$#81S&"/:8168QIHIS@B/<_G@U\42'N<,I<,FKKMRY*Z-K C"G#H0# MQH=!9> 0T&MN, 67KU+3\4GQF,"?':[PL0:1A9BE")9D4%?$HWEZVQUB8^G MG8W27!,N_QLRA-U51B_O+3I-JSJVSTCZBE)D^ UJ[SD^GC&YC.LW"VQ'?' M99E_2+0WH;+1[&+T=TMG0]/V@<)V+J97?;S>954&J"S;\J&,$5?4&>^<[B;: M>QIN40G8*S'J[S/PXS*#7@>U [B%:=3G 1T8U!5@,&S>H\"*;B4[X_U,?&CO M0BH[;.Z_'M%^2*W>XZRD=M1QL&1RQTNG';&76)MQ9ZQ ]8RB%^-=W ,.3!>!&!Y!HUU>N3BS$63ON3M);F0 MD!!#T >4!,.9)3-%_-2H"7Y6FEY?PSZ?^5QHI/AU9+B:MIWU:C5P!@-V41X2 M 6G0R,!N_AF#K35> BK'X<"M5I,GXX242J[K$"M52W*:#J$^;*K G,!MF]J<60!E,8&6OFMG^52 M4L)HVSYCUW)%-?2$=,IH'7C_ '$0,P)8';*3@IDLO?+])1IDX@P06$<=3B1@ MW$XE2!4.;/$V4ZWC'](TF'/?$PBM"K[S,I73<7L?-9 MECP6W(>+VJ9FFR3J#C*& Z4P MH.5E=0/5,C1;T(_15\8,59IIPK/=3!5RXNE32(2K!" MSC"&IFTO@PP?>HH -=AXGNP1?+P0]2^*:E *H1@,+E+-L//-<.SXJ@5 M'X/ MEHC 1".P@91,BE-'#RW'7P;RQWGK$(.$CV28[SDMA?,MAE3&"S .00"M 78])@%'>QH6$ MK%@&$1/X+Y<#124!^ QK@HU8K_R[?@.Y4!5 "U< &U>IJH1:([4(X42)E?:" MI:1N-_7#,!YPA(.H % 4?$NVP8/QLPEU2PZ5!;SMVO*IL6UBX?"DT)!H@O" MI!#96@JI*@LYLEAQ&44C;96U3!86P!2ZLDU(DLH$:8I"5E]UA2AXXV:AH7? M0!D=4@1^()G0! I1A$PCA(^L 0UIVJ;89#35MN+"\'ES;T1M#K(XNI"N5N!+ M@Z"V\-730U["(A TJ)O;0!?/Y:HRM)8F)8+Q2Z:DPEA@:]HF/B>/8-+RX\L! MO0P81PPM(Y48H=4/'P$@[_ +[&A%+ 0A#V&OM*%:N;Q"HI%7+P1$%7QD'U9OU/QZRB!16_X M_+AS#0:/O7M+G[)P;@I#%!NZ7J&:^Y#*GC4H(733 M#YB7#ZJME!8Y@$--1XNO,('J*;+EG.(:W%>(P*A)"$YXOF;!>DTI>L2G+C;# M [S'9J')_67W+K6^3'\@#O?D/&,/5K3N M,5#NRD\>1%9-;0Y>F\>,VPV23HJ?%#EM/%8"2(R:98F^K/W.B>Q2@*"VV_#, M/T"J^:H54+4(D#GL*I.-)!8M9J61HZ*MN0L&@).9FRJ-]7IC!)KB_>FY7(/) MT9)46 YPI1J,0LV3\>Q JST[R,G.N"^OQ6)A:=JQP1-"_F'LUN59316L[[YW MR5+R<@VLNI@#+)D[AC;X.XJ$Z06QTCE.AG5$QA)32ZSH%Y31;^!X&D;U=YD* M-D2B5C<0;!2C+9DU_!E\/ 9VY)JPHPUNS:Y<7M %N!V05&ZP%&^D :R9)?\ MAHVS/Y[:$+*+'XL:X7_@1FM4PJ-YP!Y?1+C_ $(WR-E6D=.?U=3 +:@ KX7A MV6*X@X9S0V'N4PBJ:'/0Q(!$$1$2Q'8G(\D"S2$B;7KJDJBSKAQ3U9=>BEC2 MO@1=>-0>P>5D;69=R:J7>H+BWF^]G:._!V *U(MY)Z+J6XKC-VQ"C9E@:>(= M0@Y7J#@VKBOP,1:LQ 44Q)#O LTANMEP&@DVPM307L)"@&!XO*,0E(%!1<%X MMFHTZUWJ<[*RWU\K]!6WJU>TS/KM>WML:6( 8Q\N!.E5SA4ECTAK2]2213U? M$4/T$F&JV!$"Q,%53;D9_6./-J\4Z&5F1N!$4[%#U58;V:+A9.6ANJLU [8( M"5M]G?<./B#,4_\ ,.*T@'[Q97W=*%^E0;5MC->M2JI*0!I\U""%WAGIQ!XF M<+2S794P\0 OB]HQ=C\N)0'VB8>@2ZRF$NW!H)2JU47VS 2&OX5[XBI?8':^ M<:UCP$L7PQ4F>I3W8R9BTM_../:(H*%!\/Z6@[!]2M"MCSX=CS+_#'R(I57S8/+BW M(\**IZVJG%^OXQ@M/S<>3F=EI6/>*Q72^HL$'>4+N.L:[OR/ZL@$(O?_ )W@ M;=:S(/C0?.'SAH@Y:E3&<:^,UPC#Y$,$1%POT,36IFNUFAP'!!N*ZXJX(*ZX M?LIK8.U#(EO6^( 4'3FF F, HGO>Q&A5)MP$W6J9^C$SH1_ "+CLU@UBOBG$ MJ;@L51:;);+%3V(5M@*@DU95]@5D"%+IU3)2N#))4R/T%E35D3F0@+_".PJ= M$E>LPVZ^E_6_REOS8J@C(<=K4(/>HFUO:RW2E$I>4-S_ '!=&V@>TZ_ %;9A M.SR"U_I)*7 #WA *A!8V5F8S[T3O!]GVW!#;WC^HRXW1C!GV/,QQ'+??K""W M@A1MD?E.<) 0WAYY[A"T,S!*8=)>#%&R]0O%6$ .!969C!G )EXK_>.UX4^8 M-&D9"V*L3Q+;M+6JEK]9HD/. O)W_3<@C9\U++[?<<, T9.?WQ(%LS3-_I2J M]5]V92?,BD .Q3$V-K2\2ZVPT>#&26U#;BY,/>'2<,$4M-U' A?* NGK/\PJ MI"4 RVBE(D8HR$%0M8'""^J'F4R!63PJ$4&L"/F-SO2G+T@#_23/!'!='-54 MRM%EA1%PGIMVVFDU+$'3FB8PX:_(?TI;Q47\R$ZFLQ#U:(@2MIG=H1AXQB/ M$+QRBWDDLM<3E"JZ&6C,.HS.9-?[B(8BL''>-H0EW5J\8]OPE:62TLHX^4QK MX67RS9Q*2ZE56,J^L\0#.V9?5C+R5GSS*1AI:GT@!@*#@_IN\,87#*(LL'86 MT(Q+RJLQF];](87$4A>H$1.Q;M9])4L1M!R#Q< 2-JT++E-;,)^L5<$M!/3U MZAJNX?V2NYE4=KB3+2J4Q$(0@B+=^Q[P * T& _F,\L)$4+R6L- &(9!>!/ MWWOV$+G: 1P8+-V& K^U@6R1FPZB9&C%/A5;@>G'P17 GB,P!@.N=$K*7%N' M?W0B!HU1CTFFH:TLGVI+F.?Q<=)RR<+]94)QXN55,0K+;B&*EG?6/ZE=OUY( MCZ\3)J[IG^D>W^*(-<[@D[(8%88P\&*WZP7\4C5V9=J6 !=.'Y,=9CZKAY,G M$I*K&]C.#S#TI#T%'T_O&E(&*%(II)HS2R-?6H6+0<&(F MI8@R(A0*AP88]G$-YBAL]4+PFQSIS_2_D**"W5@+S]+@B"9'(_Q6&I9O5./, M=YG&U#&8[K>/O% ;O ?ZE\$5QK@'51Z-SR>HJG)?E%C4NH*XC#U6^D!*D/O_ M 'L187<94$WI8X09_&E0=2KGHL^,3CVFTVN2 H2B[>+C]YGD1](RCYN//4D( M52VT$8()8MOK_I*":V7-#B<;J<68WNR"[>^YH(.R@']D-A)A9;^$ESR#5^$, MMS/D.?,(TKT;OLR];6K*JW=?GO*>TW7E'"\3C%U-FM<1=.D>(#8"L-5-?WPT M_/Q$5@K_ #)9.97TF4-NI9. NW1#68W6BF27DOSK/2X% M^*U<'7+[RVAN0/,SY-]@(2S :TM=Y_6 M!V!8C?\ /U&$RJ-7XF"G4^0"9,PW9*D'+A*446==+JEEHZ]G"Z:6P@"#D-<5 M#((MRO1%!6CQRLT,$"],$WPD?:;(5='WF*DIPF;N6 [?37#O<%T*;RB8"ID: M6%*OA^>T0I"K%*=!N.\\L8 V7GTE 9T']]"P 8QW^["[C N05+3=2Z+\LVFA M0YXC%F0?7F-L6BBS?&B_3U@^!7POZ_!#8>J$5AY: )6 M;9W+3L1ES>TU/K+%(4-%QYXDQ21+T1?C^=UZNF*>&9A-@>:,K"6MQ?@F0N(X M)RQ\IG$!*,51 V507->T<:77.9O:8#V_)Z?F8-2(L02 ;O*G=0$!\[E4*,Z\ M/QZP.J1W*V!OU-08;TJ/HWAF[G&ZK8M!U1C&.1@F5CZI6..];G'MR1\8-B9E M$(-V(>I<_P"X01TCZ9_O@:F[/-1?Z0\=]?SB M+J&O= QW8O5-M9@O1W<.("IPIXFD'*J$[!]FH?=:81B0F W+#/E+2O2JF7]> M)>N])BKP6$*:HAI4[5@,RBBQCL)3I<\Y;'RY^4+[XT"AIC\\2N? S*&,+F B MGMR3XQCTS4V _I*NL)?O' -G5PL54UP^L"+H2OGG%S@:"\#&B+Q;T ^]XF4E!7>YF>['LE!F05 M4/3\YB-!XXWY4/8@Q>(^Y:V]*A *'UEG"] M.HP4-3&XC$$65!&VQN_6)+D(>M2TH*W;;WQ_>CDT+3P1X)E&M3A*8H[@Y+1? M33B7[A%6\YEYC ]\W+6<%NH\ MZKTEJH@WKLM)*.@#%CL(=;:*^2YH<"(+KCS N:!5.&O,]#KH\8CO;LCLJSQB M;MF*_)'^-07:5"$6^LWS+43CLWY:U,DRUZDR>W]Z)DK@TY)*+E+$K134^[[?/;%C)T#9FF:[*)1"+VSVCT@E?5MN>%;,.JEZ8:JW_: M^L1YQ4K-W+#98"M-:%'N1@HC?/$$-ULE]/C%>9B/#!9%MWG])C7#@CQ&B]RK M)OF5@NN(Q8H4+L66>Z93AJW@%&AVAMS$TINJZEG#S6Z3*X?S$928QN*\('N=JA;2I M;@8>AQI%%K$7B&GG,X1*,N,AF'C,%**ZQFN-RRJ:;&C-B"*Q]%ZCHW2JNBS[ M2M9"N4G-3,:3\CLL!E(E=61^!MB4+EP= MGB9>H$;TV?.:$;[NE7[_ ,V5)S4.987V+3G+,%5P8 /:<^!( ! = MLTA_YT )O+2X[W%""'IH.*8=2CE,QB9SQ4/ \U](:5%1?ZPV M$!=*ZS,PH'UO$*&,0:YA]X 'JX4;PUS K&]>W=BYUXCM%=Z*\S3BH M^5BU@W9B(S?#1YS:_,=@,,4+!?RP1] E\V6XRX&/J<2W$=0WL-KW+%],8 74RXJG\S%8:%I]):=RZ1 US>-_.+V&P N;[EQ3LQEQ4Q2RG',Y,2.:+^OO!@WK-F MR6KJL_K#!X%;:C(YC.1M!8<5=_*6PU$;]2[^\I0A "RO0,K$E$-F;0O9 V" M0':,9X&@B;4 4+J![=$W/.GC-4OVGO$_+_>IQ#S;#W-<+W*W-#G-2ZK#D#BN2G'O!" M"C#!EW'\7G1;60W4RM0':]IYI%85L6+IL@QU^RM=CE_O,K&[KUJ6)-^'S$;C M'U@OP9+4673;BO'O,D)4ZN$:N]N)A^>9%G/Q8[ ;R6*B]7>("':($:]D^DR) MY*@GD_&7:B:4H>%7B$?W)++XFY8-S%VSO'"5RU?CT?S*8FXJCZS+:QJ']$3L[>.([I7"F4>8?&4.!DK]9@NK:=D+-%RG_C P-D<\RGHK M%+9,>%U](T4MK:SV7\X#%+*IY6BSS=0PPH31J_U-PH$@8.M4W'X SHP+^?>% MI;1&\0;%KHYI1T\#^DI8=PVCQ>UDS-=*=@7E=?:;$ ;7)B8 F56;@HL/"7TT M6CQ,)*K%X+# : #T"C^],9XG[0-T0V(9X.(J#EV@L:[.8U94HBDKT MO ?HB-Q2T8]0LER1#)"6IP'K4S]ZH5F.!N6+6X 3E.V7"+:G/L6K>?U1HH6, MJ)P9UXB(!LFL%ZL;M!?-*->(=BJWI* "O%\A"R)"T!.I@7/7^Z".1L\?RR)@ M!5> BE>17\G)]IE/=]WO*624QN-[X%EI;;*@6G>\7'#(T'%*;^D, >+!U!IH ME!@,"!O)S^L5>R5E'1I,"%E9FS-0U5]8 HK4.7(YOU^4%N$7F(S8@MP=-.&* MMA3;+HK9&).18AZ_/T4AA?$%<6W*:'_0+ =C/-^\MOD!#Q+.-RD8,T9QS[Q+ MO@(C2\,MU=<;CQ6XAD<\0JCEN,%7>TIE]D3(!<[,?[T\]OS1?*IJP^\NG(R0 MMX?2Y8*7->;-UUW,2TX7^ME0-*4R!?:UXF'!ID 4Y27P!@XK=C[0<(0=[J$] M3"F^'VO MME%'DQN_7#.!$<<5JH> >WP;1EQR]X@7="^TK:/S'VA-A;?%[QJ)S-T4Y5Y] M8:S>@?Y4OWZF4TJXCREP0"AZCVC5@&OF!( M!:0HWZPB+JPO0X?G.9)[OUJV5% &UV#KE>XUEM1$T!:_FI7X5F&@*RN-XOK M$X[AM5U;A8FJCTCY55CB"#7QH,?[X;Q@4!FRX0RR_KAE=#CTAR""+3^\RT(OJVBKUE13B&LLHDW\2M-K87OS-+M2 #ZUCSF99$(IUY$F M=T%K&@ZWK6(PU1+B+URSS*30 :E[X2UX=3=<-BZ-:YW]I::1\&D99J7A M25C1=?:H[QA#E,Z"%#.Q,C\>D0@4A?R,C-2@!,X7#94Q:C!U@YJ4A@5;=^ M+P9C6Y%LHM9\3E+/L8;LN@3Y5%7J7S![I\ZL7V#/S8DU-^*T1I (4H3(,UB96(&LS0 M/D@#88QP7ZX@DT >+CF*Z$?/-U>?6!M +,+;KP1IKRSDK%%![3$3U3DV[M:@ M8#=P:<<-QT5'!!2ZZQ-K-C(6AD3H1S1%\,#CF>,<)>FGPA_TC.K MPWI$<1M52L*N@[B/ '+*4)<65QF:DTA*)>Z])80D_7J77J14(IFXE*3,D,J] M-2OO:FZPRF)?5D%0=NO>$<2Z_7 M-E>WG7< ^I8<"^L<648L9EZBE=0N:,GEGZ3$4IO4_6" 1L2Q\?WC:4[1PF:@ M !K;:]L::NU0%6D_>*H,@LL02O,'VA7W19N%P%I:JMT$*KE,-1V;(PMQ>Q 5 MTEEQ8]6V?[@.1:RFNY8,BZRL8A":=47N&RB.$8_;Y#UO<'EA7=1Z (8[ 8\=2P.XU;F+.-05))TB@;^D)2 VBM&466+'M8ZU$_-WX MN!@3K!8RLYQ M@8CS"NQPQEQ! )IS_(('A-=-1W:YG*$I:K58Q]X)H+:>XR' MK"Y=DSW5=:%2K62 7:8C''G2&?M$?'6<#-]L$[;:TD>%-K6;$]R/!@<06@JFNJLA/A"6-B*^%DX(NXF+4&5*52L MU%!: ^@.X)1L+_D,-6G^J8E^D4OS8@YV<+A6P_\ : WA'*B #TB5CSXO-5ML MHO?KS^D) M'RW+P, T>(UXSQA%YB]69MX?[O(ZW"%3P!%BFFPQ 4LM^EX0HRYA;U+Q%< MUK#%#+:^B9YI&D:0-E7V1N'IKY&B9OY9BS/C23PN\:E#FOL%70,6K@;@F9"+ MPY2X@@E<6[7,(W(">Y?_ +NF\1/!90#,(5\%-ZPZ/QBU,['#311S'96BUYW& M0L, !Q[PP2*@N!E?M C/$--J?K BG^8;^:UZ2X+K7I1*"/9$R_CDW'O/DHN= MXO4$%2G1]A-FM1\J4=Z0^WUA0P4$QLS7TN$6P$(V=^J>@( ME JLRZ7+M&_E*I6-&WUB5,'$%87'J_67T.W;!.ZYFK'@A2BP;E?5,2O'K)G_ +BM8T:[Q7?TAV!ZV_JRHT5$AUK7T0);T]LNY">4RTZFF+Z\:/E?6:P/!M<7YZ@B'&;E$7A3KFJI?O$RYKQ *O3-,'BW4#1?1#!U0*&3:9=;A"$^R MU+X8WVS0Y/K WYI*T:8(?H8=+E#4"X: MEX*FEO2.KR4PY>9FI73]Y4;8Y%'KN&R=VLIA0>)C7NY5.$Y24/1 3::'5?*/ M,PQ5![H@-F-.09?[8R=@R':+;'@NV9?,F1S9?8D>W;( MX:X+*S=YA!]6S'REAZ"LLBX&6&960 YW 2'W3-K;Q+!8@;9B]IQF#02 >A?3 MF"(R*"L:G_L6-:H3([-RZTV464\S$(/)F(]1Z]N S4M4,)VK,7[Q6;U7MPXO'^XUX!T M4R6/!]8>K%@;L0?M I1E+!0_68D@$\$Z[?QBN^P5?)'Q<2*YCP[7I@XWW9GP MNX0 S&*Q3>8#V*L!ZQ*ZY[%K]D*.$KRW-REO<>J#>?R=@R':+;'@NV9?,F1S9?8; ,C;2L9E0<.0?#"4DP(8$8@E, M_ 8;Z:2^8X4J(WX?P#.F0K5U/;8'BCQ741TX+\O$(L\;:'50"6V07E9,S5#=;8X8-%1B> MU#$KA..-9:YC*-TT.KG6(S'29_IX(._7UA".>ZE0@93%;+]LP86J[X,B5?3//4O0=.Y M&E:>Y^\/W6NX1;L\Q$D(7H=F;WT?5OX$"M*IJ"W:':5I=5^>)@6+A@0QVPRE MLN6PWZ[F8F=O5AD1@CG2XN7"NTF[SO\ 7B4/4+0\>7O_ %*V&]7H2DS"VN(^ M28')AFHU>DP0-WTP5R[J)Q:IX;^5"WCK<[KX=)&E'"(%!KD#$MXKI7YOVY29X%&QRF!3TQM6&I5F &'#LF*_ MDS,2KFD)K6010$VM.I724+06R:Y'^?70V:4(I@7721C6/'T.\A3E=1X0%! Y M6%A*0YD0!C1@V+-B/0?9^ N,JHVATC:;FT#NG3 MPTM6VE28!!1^+VXL54 '9+'*N0%^F@=.@X4>?_1$),(EC$3%6S,MNIO/T*J% MR[I[3V88R$IQ*M'# [-&]&:SBNYQN,ZQ%# VR]'D-4KP>\(&Q2 M\^JU!K2M,I](@JX&:H*D9 'CD6\^D M18 &**,=2OGK](.A_5?_ (%TS/Q=\3IJ2BK$\;N+3 T--N M[QRR+F%RJI%. M:$'Q5RVU='P69=UY%K>_]*;0,:)VU3U%$JFB8) AS/0E<-"* M9TUDB,%6'%17G^'M2MPB/#\8B5'!5Z(]!]GX"XRJC:'2-IN;0.Z=/#2U;:5) M@$%'XCBZ9O"5&@&O3>7J"%]-E4N:=?S3/Z1]OA:OU%JD M\F/RD@UJYQ]HV'/H3?7X$^Y+B4XW4BL\D.1$"C+!KQPXBR[&JI3"6N+XEQ,\ M0L40NX"<4G=F,N!(%C!1O+MTWJ7I]RT\+?F0IR^+TB@.+DB.-M16;CY2GO*N M75'"M:ED@202M" QF@Z;-WG15P(/G%5Y7_JO@54?.,2N(K]C$MW Y58YUPU< MSV :69KJ 7>1"NZ">)7K&05JSCY3RK@E>:=1H"@4:M0]R6%48IEP_,:C')4H M"&VJG #'U G#1HQ=P7Z,?!MIL8H#&P*4F;J.];5GD8=JEWNO;>Y>^ M(A@Y+&Z9C\ V\.?4YMN,+0VM,(SO='&7CFHI;0\S*6LX>^8BL!L,TV7LXE!7 MNJ)-RMO^A?I')IZR*OJL,:VP+/I]HN51*RA0#&A/(UF.9AGD^L$DU+&?U'=0 M P4GDRI14K]8GRAPFA5?A1EWH]G648:E]9Z\]2^%8@PBJH._%Q$[MC ;EUL" M]_\ R+MM#Z(R$G;#9H0&-1I206 <.5U**.NY$ + MWF74V/3_ #)G](^WP8M(H,J_#Q RQ7"C&E(^IP[;X^%-6M3R[*FM6E(8!+E M_1.;0#RM20@7(-8C?!]4YG0Y!&NDVZ&55M5A^&&T-1X 5B5+ ['IY+O[_'5: M8-6&U\("Q,3[F\%7B"\%V'X+:C9;R;=PTEI4'26+X#E.\X&JP])2TF%X*P+% M(;5NB'Y9%/(SQ#SV(%$KO/:L4(G\%F(>A>>M7%J@Y?]*/I46Z'P:W MO6L@:5YV@!OB!;#1_8B6#^ ]N!(VH"P>R)V:')@BTL4NC;3]9 '_ *D+'W%P M(F17LHMG=IE+@71W8U?L,(CA?45^>8=SS0T'CF9=V"-OAAC""(BPU<95CB"C M\1Z^)2X>[99N5Y@64!RSFG72\GM$6H$6NHSQO(B$WAMFBS,#G:[.,:9RY4#P M%<=8BJKPN8/Y2W2JR';*6LQQ:Q&M<("P+MZRM>DOS*:3$4+H.YAK^Q!0QZ+PSU(K%*T, MY'G6+%&?+:(ZF%"8 L7_1KT MT:/'8KX$^*V'29CR3:QEBGFGH&M[HM*!ND#"\&.(A6="F-+-BKDN.T7J'X8; M0U'@!6)4L#L>GDN_O_!Q03O <-4%C1R^+Y](?7>?F(@\!U@U).EM,QG&S"-6 M +1..K M VC=$'Y9!/(SQ#SV(%$KO/:L4(G\%F(>A>>M7%J@Y?]*/ MI46Z'P:WO6L@:5YV@!OB!;#1_8B6#^ .+XK]-L8-#93#8H.#6P1MZ)*_F7!G M](^T#ZYBNU@)1@RL0\5S,3S#E(D"_L4CAXH)VT>U)\*?.VA2$*D[!=66AGJQ M1P(2U)%&V>>I,8\C:RB)FV4J0E M;-$#7KKT%K$/VX7D3![9E4VPWY-PF>MCK#1&88)BTV17(FA-NO'7RE4F H'6 MD]:GK4P59*]H7H#J)IH3HI6>FX5L@@1S"7(+U:K53*Z&F?-S)#!&^OR2MSW1 M*[5U,',G^U'7UW8](U1KQ4"XQ%RD5<<)=YEC;?=!%^HL_P 9\,/F5+Q:U#^G MYF5X8*$L\0FJZ*; M-*+]HCSU&B(UYTQ*\(>:5 Y'$1C8%]3[U[2W/R:G*_\Q0X%3*8SJ:'HOY[;B)1XU_:6E6.(MZ-Q/E$V YG#5W M;QLCK14$PZ RR9#]?UE=-V*T#_Q+ME H "JM &55T'+*W<<=IX-'TT2*Z*9! M(X9Z\%F7X ]*T$M&'$"_JL&:*;*;8.,8+[%Q%88BJDH$4D'Z6(3N,;*$& MD^E7J6Q#BE+*!OW!6@JT8I)874B_XM >N6@PX+R@8 T5Z.B8B:1ZM M2:0P,DSYU[B1+:)5%RS49?@TAJE!RT[8@W+F"R@U]Q0(WR)K(IH9FS2$:RD# M%880#MEX_9;3\/U!4,JZB6FK(*L>6AA.SMV:?%P@XM&8BXQ1:-:JJE4KB'AG MP;$2B0=28+:Z7Q_E3IEDUXG@<#9DA0 XLR89\4I0@$O&(PZ_(J 6D;$^:#0# M[&01'X&(\32N&#JH.2T EU8*#3&BY7>U <]@@I*!-.XS0%6KE,M9ZL*' !=Z ( M,?B1;!&",*JUIT<)7!=$;XRPUI1_W*Q5UF8-*E[W5TOY!#(7T# M$+E7 ZHQJM=\232Y:,Z:&A #'_KH!:85KX,$'U+,E7(L\3IVZ'Q#>$]DLLW M! !#0:%0W+EJF"'"ZN WJWB9$6QIP7J@%4RFEE6SC9F,H X$_/>XESE8;RT7 M ]7F@P!=%1ED;=^\05.&X1B#M*\C"'O%H%;T8BNJQXR \DLU+95HZGH"4 M&4DY;UZ[FS4B ?!ZH"G'+F!%LF9B(P^0K3-08XHK ED0SUIB!="-@YR#D5GL01[$ M$Y/ARITRR:\3P.!LR0H <69,,^*4H? ,E$WY.1&"UHF)58IM,JK.PQV#KR!IAC0@4A$ $N2@$J*B0):V/0_BRI"('"!<\P M4E[E=[4!SV""DH$T[C- 5:N4RUGJPH< %WH @QS:T)(=N?1,+EN<73,;JK/6;GV55S"%1@9+4MX5JX^\JZ1A]LK!2FN\S00KV< MU'!44+S##-Z =LS$[I6%5IWJ#DS91A2CFBZ/E#CG$Y)JW%>9MVYJP#5?/\S, MD, >ES1+4A:!U*4O.=*WSS$DI=%!6/L@"D55=\)>G@ TW+OF=^9YXC;7ML?( M\,O8)94YP-\Y^D,OMK68)<@ MQ>)2Z:)6>QDV0[);CT7$$8&.'4H&ZJU,B->:W_"@,6H%X,P/#)? /WCK5YV5Q\H;" Z@ LWFMR@V%B&Z$;YC%VI0J-1![H]3) = Y]875H(.P+.KA@/ZQW6V6["N"J&M8:3.B._S, M%!3:$NS 4)L%G/B;U>&QY!N>-^;,[)2']#PH$8J\W-6O5'^H3G!=< SXE55V M]4@W-4_7X4%&H ;>*_/T.YD4RQN++<&%EUIN9.F>+X-N@S&2HP/(AX"M8[6! M@*2#%51HE#@ZF^LVN"M9SM^K#>!G::KW8/I/#OCZ)SEXE8-'NX::H+!7)29D MZ8[_ #2<&H#T.+@AS8L88K.WOJ-&H%75]KZ.;F1J+8 A#HK,3D"V9F!W2G,,VU,43NPVO??7$"15;644D>&"S- MK<#69I:T"0]FYD421J*,Y #UA)VUQFM&9I;Y(<5:INPY"&V)NI]6%.?$789= MR)]+1S"P*X.8"PS2BV&89T;,//=0[:2LQJ_2+,*0N5M:K$0' AR<%5M@^IBJ M;]$F$@T5E(?BUMOY1^&["1!O]F\(+D/#&QY!N>-^;,[)2']O%6.NP=%BG,P"QO;*CK!TL> M4X_.<_P9/J3V++8[2872Q%K1YWK'SE6U6.U[WQ"EM5'1600?6DWK(@+'LG4? M5GCE_GD:@ !6NNHY4L>)PYI$9NQ-GF4F9H\@6"?>5'A52!H-98<;<.%>;KQZ MREQ$J)A2(3!0)G95(ZSV<_>956K@<-[$QN/JF?6]_K*>Y5%-OH//M*[/5TL!UI2T-PL#AAY-[YA>*IH M>M_Q/ZM$PITL*Z]6%L^4LI=*9F<(FTH=KK4UG(@<74?$ NA]YEZ#4[\B>2%> MU+07ECUB^D6>Y^YL+KR X*>Y0:X)5JLIJ\<0;QTU$F0B'(N_]0^5,G0)O+J< M2.LL@,N#>9AS+A:13#=TZF+@L6(RY33^G]%O(I< #2"1HX24:O34M*+4$2 [ M @I>V_$W^L\/[HC%6X!/Z#>;J-+L%^O]]794>Z/X;Q-FQ9U9OZ3B"25DV7$Z MY@QEUS"GIPHT2G54?GO.PD/!C LAAX;N5BKN@P;%,W^LM8O0*I@MD;+[AVC;G$,8Z)HO\ Z38-A]1M+'*X=/,=,ND: M5+JL Y5ZAWK6S JU1RF_P"+65C]8P_Z))H*7EP?, M178 NG>X&B Y%!ZKJ6-BU*%RJZ+J#&"+\LN\E1.KRA1ZJG@3%T9QU"6!B^@G M]_\ _;2&5Q#PYA0L[AJ HZ(OM9H7S#DE8:8$7EIYIV3,8V*[A),<5H7ZM1:B M%+;"F7DXF+HMK5R=GK#H.?X%S?O,)4C+[HHF.JH*]I=95E&?FW"B^?6S%+LA MEJ]:<<5!08E?(05UQ 2U+OE#['YW!8@, KR9^L0I27.R%0QV@"B6,Y0+SC3X MGU<$0U#^43B\?T($-E#WSF7NJ%2)V9ZJ"Y6'L!U_&LU:#ZRW(BK69/:5 TUA MTRS9#BKPR@'5B/;+8^"UF,>E@9RH9>@.@_GM+XUFL&98^F/UW#XK55"UCQ-% M-")'0T>THGE=IXRCGB^]3-1&1LXW<Z&5LHM1\"+:R4O;7_ ",Y,H/8Q!>% MF!P[QQ J?6R^:&YM'IP@7P#$<:JN/@K5B#+H&%>F&H>> .170H*_-RZ"O'8>P7Z2OVP4 P=?-,17:A;CQ>'RTP5[2Y4;8S1A<-H_:JV:%=3EDL!5E5W#9%C==,LH$L#!T=>D(] M,!M$>N89^5OR_B>@ NXETO8Z;F:V]Y54L[ M+>AZK3<2V)52#AFM<0D?Z0*N#8NP1>-XK#V#\S_ 3484 ?06/:6R@8]MP')! MXDL>M@/ 4NQE;G! ]!;I?R@$RY "?13+ZG-3^P/^_W@8QHN6.3 M6+,>);CT%W?K\!&F/[XA>M9G)9D7)A$;E #EZU+<=+VU%WO3^7I&L =Z'UA M>[O/VE6;'(9/27%"[J8ILEH6.;K<5FCCQ'RC[-G8(/6E_&ZT\AVG:^9Z?4$L MWKO">DP#SD+PYEV7:EWZ)<4*"L*:(8*Z_P "'4%0+$\PY!+CI?-$W+=#:A7F M'2-;@\QLQ< F5MD#Q3"70"4O+KWE62+ EW!PJDYJ5R>(E?J($?**1=1"G#X@ MN):D!,^DW,73P3$&#KG[P.UVB$51@7$6=$8S/&-'&6,PBOVS-%(ZYVJ^*SXJ M_?,<2!88]'YZSF\=2OSIHKP_M*X(7@%UGN4[-CPJH?>(H+6RUVF>KL_=>I&) MQ2#(?[@,D)X1^TI(+ET$XEA4@+3P]IY!J>?C5QF M[_TC)JF.%JX/ ^17\3-2V-D]U.M7W!6LAT'^!1:-6)\Y;;OU3+BY@/HZHL] MDR?6IPP+MEI[2H*[?[0@AOV'O,(H0#@/@2UMTU(S-PN=D5&XJE]2X;66NWY^ M\I7,-"KW!"^&<;\]9:_+--U +D (*QH&0IG>+XF_$9'0= *^>#G]XAJQ17FW#.,$'*%'4X12*R//F6^Y933AO)U MS&]X8>$"2KLW5\H^ 7XFJ4D:/#->?7OW3[H%U3Q!W+:++K)?O\-XBAPZ_/YS M+; N(QLJ@VO4&.1"JG%^G.Y9W3'(&W^#S&5U!]#B)6ZY*]B M,GDU_J@- #@*_BU71@P?.8)X:;AU,K'%PY>FP)=W/34,3R4]Y9X7P;>('>J3 MG!X?GZ2E5C9>.T&'-4*'"@ M6]>L0XS(LW1;*9,BRN!;,0LQ\"Y!5>I_R6_"0V+79\HUE4(X!@@BN"#T8ZVC MY6T6K(I?8@50 JN8YM.DQ;48[*[#Z'/K T >B7\7..X+2=Y2]>OYZ]N2:'Y M7,4*Q*><,+C:@%?X9MWZ;(-W6#WCS@NM8\,OC1]X]^2P)8 MM8D);*4U^\N< M@>"GI^=2GO?6#X&58*/#* X:E0H:RI6G$VV ,0ENX1+FF_$O?D^2^\"/*LMB MQU7(U!Y&5K9Y$M6_6T>S>25.>.TUWSJ;(X/5AE])1N+;=@I1++"UC84N?,,F M7N8.7-(JV.C>1K+&YK=QU'J67C,.]4G-#KK>![TU^TIS-L-!;5XW C<*-:]B)IT\!JY0W #/)G.? M'$SPK- 7WG$T*1F1E1GU^T(IJ#"GK'N^U[_>->UCN946$[LF M2>&P)AFL=?X= L#M ?6#U+U_29P1+&QY-?&M].H_>E(;;;[3'@=0_/\ QB64 MH++IJ9BJ Y51:>\:JJO4SH!A72\U4H-CL"GF^T-BZ%G+Q%YH>659P-SB5-*< M%0 T:EA%,DN"_M'0WR$98P&/1>HM:[QT9Q+X8PFEZ('!YXUF73"CY1><17S+ M^DX.B%;!:/\ #CT"Y< %OT)F=X"T] >,D+:A]?\ #FU#0::$U](M,&S--M[Q85**NH:&\$VGX#H2J^__ *B,:*3883#% MWJGM9T /H^8FT*PH_M%2 MR;0I3&0E73%);YQ6N(X""Q--(&L0CITJQ:\+ K2 %A^86V-H(K3L'Z?X;5I: MI:M+])?NV?*LMK%40S M)?KX@*5&KQN,>+K-II"HC<;K;?"^(TH.&AT.[$P<3(6*#T.Y0BUIS#D1R,I3 MP,Q AT.H+2/),), 8B'I-(Y/#-2GR$O0TW>16_:4S&V: ,S UI\CC$K:;W>D M4B>YS\X(EF1_PO<<,K0]]42KG[DQ8,M&!R\1\B.BU)1&JS17&H58+90\Q3WL M*-D.\P0-&^@']?X:'0Q..*.9EW\2V:^4SF)9*\O,(&<,4D<;XG4Y P!IYA8O MC9?O$6N#Z'"8$>]^ #Q4M1-ZQ6'#0 NKTF#C[:CO]4]SO@49^74S8="X R\< MD:A9I-KPX@XS1,;U!:%5$1;1P,N&#. ,<>((5M>"+_66\/LV;SB-ER9H MM=,.*E"-7SB7J'_8-E^L)1YN;E2_>!RL,(HI^C*I^E^7$4#KC&5:US")&-=" MQN^^EC7I<>H!7$%81DY]BGL0M*H%,*893;C XCW!AS%X'!>$H.V$USP-K_3$?"Z/B#V=,O"\ ,MNBV]++_@7@7EP?)+H MMUNY:CKO&F],6RTJK=B,"[3'N@]7&P&-G=QIS'"O,N7(G$Q97O)#=9AR&A4B M1E0\8#NID]P[C=6;S\4LITX9W%* R[@M&I=)K]XGKS@AQ2\\33.%,;R(8,X@ M&&OVX8!EMTM&^FI4%T' T2P2%6+1V5;;44S5< M'Q3(/KF40P=-;>(6K TR\Q"\GWGQ@1&Z;)+HVKK>;1\I2K&PW7A+BS\!4P%+ M-VJ.4RX%(](2V[,#F<1YRLN4SK'+*C8Y"\ M1_JA13]?@E@"J-P?NJ6M:I>_!YC_ $<9J5UF96CG:]RTMA<8IMOHA$!JJ7S8 M.IP AEX#])K0IIY:Q-\8* ;KS,9_S2<#B4."N<%$2)$@ :*$Q7UCM$6X8 NH ML!;8*RGF/_+)M#56L\+O[><=0< N"#"DQ)X(M@16B0QR7U$YQJ"):9\3MU 5 M"#AU_9!C##0VP9@3*CDPO5<>L "@ Z,'^$F(^BG0/652@*T,&+/M'=*C8>'@ MB:I,O/,NPP+[KEMW@L"K-<2M3E@&#Y0F-#*86URY7UEP:+G(@# M%DK[(ZU!)TXAQ' 9!LSOS\&4'DJ6JG.ICL(8;"PH">IJ+XI6VO0XC\"#V!A[ MS+M#V*N;D2U:%MS=VIH.6B!O4!ANTLQ,;2^U7CS+GR,LH&#+JHQMA;>'_ M DU<(5VUQQ4PUJKV9;O,HFK:7C%W06[AH!Z*0> -K5KUB-30,2_1&1TMIUO M,;.2\:TY&IDT-,\W#MEJH.?33*-'5VIE;6.41:47/.8[S7_ )D:@#'FL"\[, *CWC;3J+ $-HH\U*HM M"CDY84(!BJ!T\PZ 1GLR>L7%![H'"&M3=&?>3 +_ '90Z\QKQG%X.>HA]$8M MT'#;4J-S'%#MS4U@K#AN _R1D8RJ<0!E?@"&NVA=PE],!9C:;)2NEMY%XN5F MV"HM<1334',PECK,97SXE76E6VF#OB5< M)Y&6GS:Y2@A42 2O@#=5![V1*=Z(@ 5BP M77LRZ>7&%B_-2X7D=U[Z]I70.9?6I=-8+#J'BX%LV(:[9[=P&4: I((08 H# MP$0R! O;'\8)NYZ5\+[R=,195#"[74NXZ.U6JIO!*'%;5-JM-0M*NC9DQ1+N[U*21.GS*T$-33;$ MPR7FC+M<0?7U4>JB"X^%1AFTT+ZXH@;A*H[CE@SD5#?\ M8.50*V4/,)TCD"V(O-P -!1Z'QM+%E9!$9BCP(VDVV\_#EVCYHV+%*UG,3K ML!$(PE\CJ/%TEN.2&:#'-Y;<&_::@'#'> M-[E.757RHE%M'R-7/ CI^\;U;SXW#6.AE-YB]&)&K2WMA^H7O3_@MJ:!O!:= M:8;ZQ[C1S4O^NM986^)?"25UP6S?-D4(TK6@26["U4/M@'3L+%R#CF$@2]SF MT=S$4*T[_P"X331?T'[RH#";R6/K&8%'GQ5+Y9:Z@0;554?4/E' ;Q!IDPH& MK^J )M;6#7M48YE.09^L7 V5+0OE?(;EP_%6W4V0]TS2QTB0$BGJ"41L=,%Z+S$72\#%6Y5$ 'R*E98$H>^":"9&Z6J]YO63>0?S]8A6 MN$'-A7Z09NB:AN_VA2'*J+UB"1SF9@HELPS84$C?,LUQ>%MC&F73B+OD1V/H\! MD)Z#'KA-TC-*&3YP)%3JN(WW,N54QI*V0=FR+GL27VT_VOCV_B(#!>XN&!,_ MB&%3X5$R=DC2V;\0J]P#?&XU9/I"\1?5[)\KF)M-B?7JU UW$34S=)@E3A0I6"6GB$B^L7H[E]/>%*N_R@-&D[>(WA!. XJ?3\P'^! M6JX?#@=Z[A3C;;ZNYFJ"BES<2E"R\9F^'A6DJ,(1-VI;F6$ -8I9E<"0TI& MU'71'*$9"JD0^]I]8XHZQ%BI-.XDO68.]QKI5 ('"]LTH05)>" '-!YP; O< M*M-%ZA[05.-5&2OB>WE5&6CM$%CDIBDGMFV'L/FG-1,>H_B<#-YSZ)=-!N%V MS&8*2KKB-S,:M8(W-M4!;AJ#'<3RP<^\)\V3&+@87J,;1VM.$CPHF.N(].DR M>L+Q*P<%\S 5"3Z2F"N;X9GYB5V+()L3J,MOU^\46CGC)@3OE8AFPYD[93XE M*V2"T-/,,&:6TWF%DQ]'K*RHV7P\3,"COC/A+#>63V_P(WT+J#<"-<'-Y52_ M!;IB#*PF!N.PY-Q3OM 97_3"PCH)M\Y6#Z3S2W%25M-Y*=RKO1/GS$.L9QU& MGE79Z!%,1XG#%:35'9#3CF&Z'0-H#]8+*E2E&]/*6;&KF I0F$,2>012J!+" M+^D01;F8$>>(6&*N#4MP.!BSU_@<3%JP5\0Z-YT<%<,I@<6'/ MM-SE]ISN #7)A6M18M?FTS,TUFT+%>8$7W%DF[73+>7!-L+B>GBIISB$4P_FLZQY):$K:WRRN3<4;ABM M"JWI W!%[0N8(0M2]NY7"WBQATEN756FKX(6JEH.H#ZJ>VB#?^ V>9R*@':M M!$YR$ !=CB7CO,,[:0[PT%L#T3#R-\D]R68#@5[X[:4KS,_*HQ]H@QG ]69N M!.C3.R2KMQ75H]_//!1)?#](V5Q<=I6G6-T6\%RJ*'(HZ\HLIQNE*A3I!NFU MMK/') ]6?=K6LQ0:44TU%DRHIBA&&[,+-/,)P7&\P*0VH%?*<[L$NU59^4ND M+B0:WMU_!3D4N^WR@N J#:_,J_*5]]B8NIV1 #>92*6#+.2D]AE=VD_6,?JM M!>#+&EU;(KY-4,Q11HKT;BK,EZ8O?HINH4Y*A6<,0F"P><4LW@;B%KW"+Z)9 MN'!O<:JU#P2'JHRTQ\X64M+1:UY;EFNNEXA:KY7RS@/Z+YB:<')W*52VD5.W M &L=/^ VM/\ %-;#/$M PG>]%J63!@R?E,*^-^.X&1N/D+%=NV18564E+R!F MCCWFU*RK?O*RL 5K<8J,87BGB4TA0_4J,UJC;K-C**E&T%["$>18GVFD ?1NR M5XX7R;*KB92.ZO,L"HR&>14 _(-0 5H_@(\\(+,DN%]DIHXHC@OL3,^HD2O, M=B0$SP6Z?I$9XR/"%M+W"R+*Z=5Y5QZ2TALYNJQ?$=G*MUE@J.D 8<2W(Q&G MAJ93-9LO$0?0+Z2I\IF 1%S34Q@AFF!,&7BG 9TX\4Q)Q=N5ZH%7Y.FJBJ9OD7Q*G("HZJO M%!*RB-FR'!XF3TZ[YWEN:X\DT;^B8_N_937+8T5"JN=Z)BD]F:8>\Q2;'B7S MN0V^:AQHBF/FF3>85H$;,6[EG;!MI74RMZ1B@X-<6],#69Q5$-8!4[\YW@B6 M! 1U9??^)F9!0IUF&U3?1OF *0 &CN*%]OGW/P0TYF/<'AU ;3SFC+\QOQPJ MMS"UI4J$!?0S+:UNB4-BK/J05IJ@T#CF%2J0HVP K+Y6A3?$(2/!%H:/TG"P M-O9_:$"Z X?$'5KFC]T%]HC6?*!D% %=72Y>$G&HVHZ\2YLX.QL+\LMVL _ M7*6PBO\ 9&DYOD"<5P_X#8!-H0[:EDA*L]S]XV' M,J.H#=!3?F8%LL@/VBAFBBOK,Y01\BO<2,TUL%2*-,1UNZ 4)G M*M:88?DP;<7E?G,G!]Y LHNO>!7#GZ7+4-.YLNJU!A%K$/-\F%E26MRJL1\^ M5-9IBIJ*68/=<7\&!J/8A,],)! T*' #K^-,J-5](&SK$ZN:I;KVS(EE?6>B M&(:UY#1XE^."GMW"AE5@Y92J^1K,?QJDU;-5#->0#EYBHH87]"9W ?\ ,R]@ M%L"^^)G=XSR&=5 \&HRY!F 6:V7D>\'6SHQ ><5 8Q/F'M%2Z%1A3!PBE:+ M:0PQK>PW$6Z8!MEHB7@+EUWJ%[? K\*F ]2 *%6\OJ_X#:V$R,WLCL!$T<^ MY[B.!^6MRC49AK+U<07'%(=*B4D VK80^"VU-.MZC4EC1R]()F9A0Q&$0-8"-5RT(!%=,SA HW5O$4@&0 M-%W)GGZ Z+N72"4=QFBC)Z7 0I%:ZS+BU3(0AL;CZOE!_'1O8]3,\V MV[E_+D[E8 9 RO6&"L:2W,_1Q*?>4?HL^\/-\D;HW&,,_21\P STQYE,"]DP MF\1HJ9Q6)>HC+GKF%9,HR#@@[(53#A7Z! ZZ4[JWY,YH[2P&-1@(&@%;Q*4> MEG)O;"&$1IW&@ T!2DPF:6&!;*%"VM94+^L%#>Y9/$K37@65X_P(S\ MP#&X MM^*NM07MB(^XW>-A*U["I%\U]H,R^X:_Y,22*6;&/27G8,L+R M<$$-PP$\RXPSTUPB@VW#F P3U2RG4&K!0^A,K -9!7,08=J[AMRE76[Y@R%MLY" "F>P1=?2$F MS9]HR9F\JK]8E,]H\)'&FA&ZP8- EF.2\0[D!'&'=>T),7Q)GE"K6,RA&D0M M#F/5267;RP.J@%+JTKL*;.,3#(LE+NU5+KP)9@36;E\IA9[5,N7B5:# N2F? ME_@-K-4LC:I"9\]5;=_-G80/JD0H\5M4M2NO! >Q^D$G-4XQ51@+5GZII53O MBKJ)"<%BRVBXOEMWN:J*EVO&"IY@\<:=RO[+P-ID1J53*9,/:.I.[J!Q:N.H M2K+;Z$+)A^P/,MRU*)^*E&18.M0K0BEH+'NRPFY+:0,:0B,"AZHD:*XV7:E* MYH+]/XQ47%&+CFBYK!HA:36KY@2X3P/,) -$I J2\Y(A=ZU^L!4<;JXW/7!X M(5'R^ J"7QJCS2HN40K;RF!R.RN9 MDQ2V8:U*JT;>J?Y5N9[>(U!8E$* %_@1HT>I#2,"DBGH(&RW?_IK+@-L6\ / M+]#*T!+E8&AYF]E%081;6"Y4+D@15P:6 WC+CG)Y0-;RUN-()Q_@,&N!:,!N M+_MG6 IDS[LJJG('T?"X'V(L)\XB5=OPSSB2Y9:$;:=K%8FRT;$@2A^J,T[E MJ[$XG-1Z85OR.8_/R,P>3(^:74L$^#N#1U>9=4NA2,TT0DX$X!,DM#1;MB/A M W#VG4&1U.U6]=S5ZH0S\_:(55#UG;)_XI%E;V9ZWP;?A06Q_.!5. M8A?3*KLHHK53/K1(.&4T>8?3(C$')?!>Y3[-2K\Q8>IAS5&@'S&G)9Q$JE,*\BTA,:8L M$JVM!S WOD+R?JX@&2*S5K_< 9F258*IEI,C+>&I:UX+7L2ZB<:Q:A8,97G" M].H%]94-=.[8UF6I>Z+]:_\ 8$K!$['9&CO0XSI%O.-9:N=)P<6F!I@-IFT5 M46>"G8BF#RR^JH@V+,&T\V>:)0!UR%6/1(4&!J"E\!GGJ M('^B;*_E#;*Y%T5 Q\:@70ZNVA55*V41@]MN%7=LL7J0VB'I8Q0J"$QM$B;S MM!RL%#X.4,>T;(_D4$R+C9L]7\O(6 ME)/W)[%]Q\=L)$01$2Q,B.D>H87=T.I=K<4A:$S A2BP! L^X&U,6*'+=P64 M@%O]D'(K2 "AHM(L\+BN.2PEI8*FY\^D1A$[N<^DH*^K* VC@89JBLE*J M8BT54=I5N)3@ +&E1#VEY ERO\ &6UW7(7 K+?$ M?F5=@%HUASA60JMDT4_NYEP7\,D#HQ)+W"DFZ/>]*,5AP52*YPIB^BI^_@;- M674JZ5'IY;'=BSQ\1;G\OU\$K?B&_J85*[FK(BEX!V/K@\7J4V%X5VJ'O9D#;P M.?, ,!1T?R1'* $)?4(T:S\LRI";$I6:+@>>HB$I2V1\YX: G4"C;4X>@_&! MC&H8X-0C;!RNO")3MN[QU^)L,*8M7F43H9NOT1RQ_P")F^\HU>952NW&>892 M>[B$)A80^O\ ,#&?R'?QFOY>L8447XC>< @>EL>:V\_XP1>_A34B6XH@IQ O MW+,(4$MA0_!I5@41"NK3+6#%<_P"W/Y?KX)641Z)W7*:G.$,7@R!LYZX+:TK M\6C0!H((+4J"NAQ&_+!2LQ>%?NOXKU*XAT'>U?F E;5'=.4YL-@_!AP%O+ZS M!C FT>&Q13[>2.[=JC^S2&-\Y"PNY@MN!6IU&P2@J:'G,SBZV-+3S".C QBO M((DCIC @ CVK8J,\9YE5FJM1-_*5!I),Q:18Q"O!;%%$H((19?(.HAO$(>TX%XJ;8/1U$KI; M2?>2TP"3)7SRFIQ$F>4O)J4(9PI0->3E,.W$_=8 MF:JP//F^)8(.'B];(#R%D1N!^\W :6;0S5.8J= 8,=]?S#&?R'?QY: Q7)T8 MQZ>8(\U.\WE1"!H54Q%/ $VT ,#?*960\)44+/@A1RIF)*A M11:94A^!44^F4HI=['=IV*H2@;^8 )AP&*H5&+4]#F_?:-IJ\7BS@VX68VQ$ M426!L>:/ILY:VG@7"@M,H_LP@G#N_:$49F9K!I,)=QQ2$[;VRQPT4$CA@GB# M5=&$SDTRLPVSE"]9C4M$C6+FZ$2:$8#NMPAE%7J'[@=KPZADL*QXVF'7^472 MJ9Q$?/ 4%T-X%^D:,$LJ 8:5-FIVY1FFDU?E3%33*#G;J5_Z&M4%_?\ DG V M$=C&HQUEORA#=#Z0UL+7+ZE=YBOK>M$%C)GL>UW<7?(2T';S+8X9 M%\)U#)$I;< MCA@1#2.1_EF*:!&HIF,P!Z!/R"7N9_=6?B"9.5ZHX7FGS$B" MLB'HUT)' 0(U8X5SYD$!'4X0?SH8-1XM8+8\VB$P<)UOM$^3XUQ=#?T.-PD9 MHS+#N\+3[(_T(A%;:B@0?0%Y&LL034@ ,?\ ,#)(86I-1 ;R55E+!^'Y1CW, M_L[+4;IO)9ZR%@+7X(]?@- 8%A4N2/%*TLN\>=*+YE$;4T62O3A0<9, H, M :#HB " *"D1PB81PDNDIL^MK#,L.JBP4/#Y^1C]7-\'V%8O--@8UQ(RHJC M+YUU$?$-*A#X9CTAQS3$/4X65D&SG#UXLHCPI MU\M3L::8R)S&.W.2VCUBFO,4W/,L!!>\9>>(0U#L,9*5T-3,:^@H[S<2W$/: MZ^<$K!3N@0U6TQW0I\/M+/WE*NRN[Q_[U@#Y ;GH!_6C$6P*9:F#+P)1#38' MG)FP_PY;KRC@I5P.H+\>P9NYF*-R127#Z$JD@<3\?U@]":V_/\\1N M2VWE#L/-MC9N" !\AB8LL5%V4(E8.KCZ-1%:#_ S,J0S%U2P=)^Q4EH:/,LO M@+G(@"R]6 +JYE[S( ?\A:4HL_;ZRP,G AHMSZ1Y4%=9^Y"46.7;%>T,O?Z0 MQCUVV<'U@>*NN:,/(8"..AQ*L2V&+\8RB/JY@$%@^$[@+QZ*-CY&X =@YNP, M=3<1T7QS6X<\T0P!T0^[,S4E_P T!((6)I/XW3@+5T$2O[& ^#NYAV6PUB;6 M/7+T?7[_ 33E,91:GZ1N'E@Q3])0.0P"TIGH5-L"8S9K-2L_*^K7ZRY7P0Z MK*;>R;'7T%VQN_QDY,?JA@EV?1S,]0;L"^)DZL&#ME\YC8*J(&$.]PWHM[K# M$"V('%\ M64'[!K%_PG^VUZ+K!%:M** Z;W4$59&TH\'.(6^G#$?6\+U842A(/AY-1-WK5P=)S@!AK>XK%Q*N@A4"KNX[6 M"W;B7/'!/1N%Q!92+VQK?>J;J_\ 4:.^6'L[F+DL@7/F97#37;<9Y@A&;G'* M_6.BD8X?T)<&MWH(P53O N?:-52.J1S M-K3K>R62N].'BXH6G0QK37RA"\SVKWF'B!PZ,Y&"].+CZTOFW\%=8='.6)0Y M^:$.+E[RF+-0%+7C/M7 $[8V%A"P=DOWA;VTQ%.6H3ZD#4.P M<5=3$@BVZ./>!@PH#Q*^!N"80*]-=1< (ZCY);7+R+2O>+B]P45TSWT2F!*0 MVE^T/8BVBL[FS*5* 8U4 /A/\T\\4_'>L%[U^/O>#]\_9Y]?Y LP0QU+U)L-UR6O-JGSC'LG5!11DJK,76HQ< MU#_VNY%@+;]9RV4)4=NXV.3L'BX1RY\63WC_ '5GUE)] MF"RPAC4>29_Y!Y@0,-@@ES(+?:#8O[RMV.ZY:+>8 $[];<+QB6FU*0<7PP_8 M L=,2MBP Z=0?*QAD/E&CG() KIE1;"5&T2R]^7F/@DCU/<"O4M,7YB@V/QY M(FLUYY4BV?%CA/2YQ4M9A"*@=O($NOA>YB[YEL+] Q,MFFYRU.*A=&)<7D$J MU0GV4J*T(XC"6B!'G"ZJ&W%SFYE10"9:,C4=ZU>(8'N\'JRK M-E&2L;BX4/7.O$35&RC+L]L3 A1+@[(&T#*]&\SNJZBH8O6E8KTE&AESJ&%! M9"EZE93(*K](Z0YL,)3',.]-4%@I!\8TF'UKU M(7I_4'FM1R:!P2=R\X(0:OJAZ4!X7M#DH3!FXR>=)NX-BCU1G ZA;6+"@ZG5 M$Y<0NI4X2-P0*VP3%^(ZQ-=U*==<2C_0#E:"WU_G6#G_ #ZB%#G6;,4*U0MJ M([+*Y#E %C9'5V9@"&=HE$WW/6V^JHX4 6%II_L;JW!;<4 (_8KL%BSIN_(C M+X6HYGW^\P-:BFAY8_%TLTPYZ]&EFN9?T-*/<65[8B>1A:V](DYO>-'X3OD2(%4) 8V7B<@BL2/+$[2U+R6H>!/4.&8TWH,Z!N:(/ZDL M%ZT-!_V@TS8,[T99DJ65\GF'/%>^K6^81%2'=WZ7,3FH-M3:?JC5$^J)K77E MKHN&&NE8U;C?,MD["JV>#4$IJAD ]-S>,%IP]4%Z2J<(8&7UE=S [:10)@*>C*S "H"B^)B[@"H!Y>37K&& +]C[#X@LL(0QAG."#;,W8 M!=I=0QF%+:WX]);&Y/ONILP@L6=JE/@Q+2WM471B#0W9F)@&)L-<]3%$Q#5] M7J6884J.^)86Y6W;U*/R2[/08V^T.5-:\0P-9K=YH;?.KYJH^XFS$NT"+:1+ M#V?1*3TS 41'BW2)]2,.WE31WZ3;]PN+#DY4V UI7#Y9(J8A=9($UK)[/*4G43NW893T^#4$@+GZP?B M5SKD,GCD,L*YXHEEF Q"$)+Q8@YJM?\ :'5+#=9EHJP[*(M5:DSQP:J8M,+\ MKE1:I#UV8F>8T#!16HBKQ:./I(D?H(/D<2JD:IOS0VIBP';?!,MZ=JH%M6<= MJ.LO#U@J+1#%7RYC'-S*-OE++P1Y15Y M<8,9Z'$!88FAHVD&[5Q@[#Z3&8.\ARQ6HPC(&0G5[ MF4N@J])H/#PAU#3*4ELZEZBJ*QPOTE\[9&>7[LS-W"^JQ,GN7KY!5ZF,-,U^ MDJZNA[U,SM E;BU6F[)5MY4YM*U-WY#Q+J&Y.G;Y0MP16*8Z->1WY/W@N WO M>VX@950GOUE19YAJF-Q"X@?1X_H#_P!&!&%^X*7C"%/7^.<._.*0]ASPD\19LNX!+-!F MK'PVF68;[4>R:@%TB[5DGJK'.]5S3?\ ::2WZ:7V>RI;ROK,*BLT;&X">+9C M/XP.'.JC2^8,&5:UBW.'K_5#:=.']F%#W2H>Q![8OK(TNL&Y0W9//-.H/M70 M?=X]XPJ#OV2UP*=031QT'0#9+X-%UZTH:P66-8#28@:0_(EKSB5X]W+EKS)] M( \%7D]^7*@E7AU$M9[,91J*%29[/74%"-+9O%GS@)=&U8:R8E/F/U5A:;@ M@*(]> MHZQD,W%SJC6[OLF X2O/ES%UB+M#6,Q:28=2@L/1F+G5T9M!@E8N"WQ-TN#* MHP#>M!M6I8L&D7W"4OL,#$VT3>X!K&E8I?WEL0]IVM&/6,P%@./#?I_0&Y8N M]L'-=BNJH<@C)* <$=<#=48WJD)7!J9+^S48U&2?EQQ!MR69;!O$'+I#M&E= M^DI+ LV"M,03$6=%\W.*M)'8(*^#'$6RE M=%FY>[&-='D38R!ZO,P.*74I=;8]*B#([M"MU+JVPVCXE>"+V.V437F(#8 W M0.*N#!"%U5R+E-JJIAY(_46E$'"ZEI8:>:P/,Q";D6SSY@.4M5V-XS<>EG^' M$L0VX+W8Z,*_3L78U\I?I)>NIF=W$(F&D\PLLT7.[^DS/$#DWE]8-966&Z?[ ME>*+WLMV@7UT3;B[@_K5W2[NX%W.LF9X<3'[#>..LPK0X:=JX[+! 5Q3\0R5 M"ZE.P:)E +T[C8\"47BO$L4A#: M68J7XFH[:E7=4F[46D*""QQ-)2S6;\CDJ 5:2[2(< !@/@0;;XY&E)?2+IG MHEF_H>15ZU*16X&'HA: +K$OPIY'6\*H^/0P$0FN""-CI3J\(*"HBM(CB@ 8 M"7!;Q2-B$ ,2*QGY%&/H E2#]>,S55*J!CP0-72(H..E&OA0ZG$CDPU< MEM.3,HXV79+? ^L 8 )G"X">4OM6TYS\*7B&*VJH2R"7 >1UZ@BX^( A_P) M'T,4"((BB5&ZVI_9G?@K.%%?V=P7F/4J&\*5?$LAPM=P:^T1?IQ+6W+T6:NI ML[ AMTM^T<"-;&7V0K,;)>S3P2&+U*U65'B.[O9#%V:^1-,?,7,44SF"[&'' M.)2)0H3*6Z+MYAFX90SRIZ00M*[QW*(O3Y N:KU,#K/%L2# 8'N?6.[C;NQ" M45G#1U#T84!_R3P1FBFR'"B'+C Q(H;X89YE[C_ DH_1#KXF%B*0'4W=7N%' M[ 6.H%G;]X+96YHA=UQ,M'F5%A]R7"Q,L$$S"=1Z>T!Y4R5HJ,PUR^BE9N9H MW0WIE-YA^18SB!&]>B6ZK)N/?RM?FHIX'02T!< H;<31?I /P!^P?I_@EK0H;Q58?:9WHBZNX4XL89JI??XCLE]6 M.[%21L&9PWQ+X@WCT-'F-@?RV:MG3*JS9/E'+6!6U%3*VD:P&.8 MLB9"'3FF&A8G4V>LMXVER_H-R@[$4G8Q5+D/,VZ[BHR&MP-]L&=QYI85XC07 M'TD,3 I:)YA!>'VF;EA%:!>ZE#?%_K"=PK&N)I(@%2OG_<$&(!7UW&UY.P-1 M)8.:XZ G>(PS (@X.=I7<5*L49C(!:N%Q^9F]7ET9AY'A>0;E*BA'!8JZAIM M?C4& Y1V+>(_(V<#5M>L'(^0L!=1]8K+ XA$M%C+&[4[@(*Y[ KGB6[KQE=; ME5(X2+V1M65POH ='^#6R Q"#U6*++1_ZQY90!2.^$:-"TN>O7F )%=K)P:@ MH(6@<'$RAOPF,)T1A!*,S[FU'I+U6IN 6+^L1=:645"R"3HN)%=/Y4+# V.' MK4UKSC#U-RAAH]), F]195;#%\U'7TBVC;,$R4<#>H\(LL5?O!;!ISXBY1'+ M%H?H1;A%9-L.S,-!JH>QAN]RA]"V:7AF:'MHGT2XWQN6Q0.,QM=VZY'B"%75 M^3 $M=X3[KN6(C+IO!U?V5([J >RNYYBNH\C67F6.'W[6YDI TP;,G3ZP2[^ M.?AMQCX@_!!-67$<2@5:7)3F6[RK+"^D7@ 4W,/5 6C"F%QJ-H@J@.(=K"BHQ4&!4 MLSW%@P^0L^80R P)3@CIE8>,0/PB@<#I8?5L3P7CB #+N6+DHGCV]):!3T3# M>D<;@P9ODK=>9;%OC*;+\U#3!2*BCN6]?'LU.S4@+WFX-#L,C3J90672?>S* M9.UG*E+0.E0ZH:N?MF9=$N&NER-8&%VZ7I'DA!1!6QP=;C)>A-+\QW1EEH+] M)D#X/Z"RQI JT"S5TQ>QUAY[V5X\MZGG_P B.ZX70O.9#%+,[B:C/)@*16E? MX"^P;3X*QI--%J11R1+/.F@E%+NE/XR=TQ6Z%L"+KAID$F*"#OE_:2/4OO"& MU]50/F<1.A'O%>?K$:#H%IW5\RXHFSVP$2V#M2QCGZ-*\M[@*X.J*8_1'C5M ME7)8O',O0U6]C/O$S"+:R,OM:PAV5<:CY:KE6'+QN5_4YFZY]HW0 5XZ(N:N MRXY@?,6_:6M!$+[K/64WP5#&V&G\"7(-*O9U!V6@<=LL0%GN@+0QOEK6]%B9 M]50E=>6+)=;?P5&;(]R$0-)H\2S]&H58\:EJFD KB.#]:L5N*UA[![[B1Y<5 M&ZZ-RN ;LKGBYF(/F0/R92,X)8Q:9JXX%UJG2,[U%!V!1]AXAV!\-9&RX(2@ ME0:&/M+4<@E(>&:CC>S,4'F$"R(9APJR?T1@Z.]=RI#J,8:%48BY3YXIXUZR M9W_=%H1.&5N^\.F;H\J 3RZC)G7I]B"A9R[EUNHII3FFF,;EG;X#MGVL54S' MZ 9EQ63.)\K1?L/1WZ19_E3UW>39N+BEJO!.=]S&&=91SX869)I[E.3=O&L; MW3Z1P72KPH3+5+FS.XEAJX(!)3@H*'SC"TI]>UI W 60 4 >#^@-0%PH%>G#OP2)F MBDUF%LAN#)2+BNXW@7%>K.S\&UZ(PM.PB+F@NF+9-8&)@@J *C[>M0U,_;I8 MI^EAE#S\)$(3586HE@+TS"Q3"!),V)AM.1L-@(L!5K.X5-X/4F1U0X.VPR^3 MWC=S5Y%&C8=[*2T%]\5O0M#58A#T5XA"<5WT('>7''7L4T(Q6;9_ 2<,.KK8 M2B#B"VAX?P1Y3L0GS_8)W:AHZYG*"M^#=]T 5J@]!;: *!O4W&SD,8K&QB?[4[HA)L+'U& U9-\EZP - 4'H3=AAIF5;=2@?(;Y9N-?2 MX,"IR$WAN;D$9"V:@V]VMW*DFV2X-OI%U^W''M"LBV;XN9[P=W>H4 J[NPA] M8NUH)P53+&;H0L[.H*FRST629&HNL9W.H&/2;F7E8O%KCWAP^#[0+P1?K00^ M4W+>FN:SF+! T67*][HC1IO7SAZ!! O#N.NRNCCME%8AW3 5W,SIPIA:9ZG- MDLJ%3/O<2\ F*;,(CK547[3C6;*Q,YX2/N(82Z^RO*%);@0@I4\A? 0"=10& M6J.)6C2806OT99;F82O",. 5_?!>H:32W%7_ $!B7-7>6L&J%8%=0%C$ " + M@R&DU=LX>2N8,C"OJ%REB/SB:^1RJS5/X"$J](1:E(RF[T0/6UU_!?VP[@CL)RUX^<+C.UYL4'O.(ZY+5<; 5X M.);Z='1T2M>A[]&H8,XR7Y3D)O>[BAL+"#'3+ T#/M!IL@6-FPT>]P(U,V8? M/4WCU/=%P+XF>3MK*<,1J6DM!74?#:#P8;EDYE#PE#*P=F'G M'<5;.#&O1E=N &OE*AS*;D95<)45E5X]XYBP]3%K*RF3AS_0&S1QA\V<%1;Q6LV"@ M,$O,G6%@SE'&,_PAT6H1]P$NNIKNIFD\! &5WJ'AG@T. 4 %HA2=["_RFPBW(AMTN1[J M9M[M9@ * P : Z_MFMW+3J5!97V@C7,^JENW0^3X"9!8(K394U3 "BV?N MB%=-M,TW.6B\4 NH6/E%?&!32P*% X<(D&J%N>B7:=0A89PZEIO27G/_8:,7$IELWH"9=G>6Y?UK+F;WG^@,3*N#TMGGSS1JH,HVX.PA@!JR"*PQ N9G!;+@ ;U' M,893Q= %=,/X#TW-64,^'I MJRBE[50.RV@S6HE+<,M.4QCJ;B$5IB_$&M " @T""->SA5PLP@Y="P-UJ5*T M(P4YHQ0Z/27O&]H/-]BQPH'PG#"S#BW6U>I)K<,R(@D03KC>U/W(WKZ+;21R M'$>+;L1.&?D'!L1S**(TYC9V0<)0:]KSXE=D^Y"I;PD8Q67 2S.$) M9\;1%T8W/#C0NXT7!/@<%<1],'H%L\^8Z@SR]$C*T-':WJ7.:JB!)4DY4WGQ' M#'>$1LCEY**C_" 1)[IE]_Z$V/<;#!K< EYS96)2\ULN&C)0+BD7D=?/4/=! MA?-_WW$2[QZU[SZQD 5]#JNS'\[]B+N?@JWFZX,?'4P 2"(P@S?*.>!=#2^8 MNNJBG@:?B8L&*R[4R# V[O))_9FB:.X%D8C* R,)LO\ 1+P:K3,NO]?6DCI1 M#\XO'M/$-NE]>>AM*7=$2_DK#S*PYJF4Q'%MR\'JOLZ^%(]3M,_,EU3EF15_ M%RU$?RZL%IWE[OS1IB8B+M/ZA8;+=# I%+:9H_>-N3(G7R"L&VW0[*B"*#06 MBP@%+#?6GK+02QSD#\3\UR)Q?'::.XO0G.\. H5:*+Z5@DA5'N73^UEY&QZ# M^L6D: ]73](!!<.^6UC',)M\Z)9PW6IL5&\0NC%Y(7-&MWSDQB!8@[PX<1K6 MD!#04O"4P/;K1:.>=S]H*1 #%:$$P8!7K*C4*KU921N/*MN(7*[8"R30 MN&Y=)P\W* 8L>:8&/,HSH7#-;?$%.JH=!F($'A0NO$2=K0.?AQQ$Q6P=!/E M0X0&0I:@&\OD( HH\R E^- M*M+.YX"&/25&T]6O/^&F#0 0JZIN!+BT.8UJ\V*B9=IY>GSE0$]%OQ_AEMP;]+*.>6LL"8C[S1*/,R3QEW M-R1*B^(15: ^9F7=UQG&S40,#K8Z%I7NR8*Q8#9Q,Y+G-XZ#\!;]7T(0JB&* MX9[;F;@BK;,2PMFAZEF8ZC(KL/248X5B]+#CF(!U$M3LQQ$.JWDA?G?<+LC" MEYN<8]8-D@%E&;(6@+1 "NTS379W?-M@=O:U9U, '84M]B7)>MGI-7*A^H_PRW#[ M5UA!_*#O3=#,MAP)?JFH#NO%Y/6(XRZR?E+_ %,5]X(!&H&L_P!$O%:BG<%& M'&N=PRSKDX2/X>2--$3&_H5.*].YA J&0^I% =3$ MM6^,R\/@D@XVU$AXN*Y*U?*.P+.L&&!ED3('/7$#@C0ONX^D9[4F^9G,KMD[ M9E6VZN$L4MD[L_25^&JP*\6_-0U?>9,W+WU+Z=!B#]U?>)?SE]:S\=G/'QJ M17!!ZR,/,,$\*WDR.LW& MF#(;ZOKQ'+ 3=>T.2[(^3_$+,O*3)LN'SF#M#9[L$]$/HZ2'\@>$T+!XN.8Y M^U@K'M!H!L.A5RPMVLA#@+Z@&'#-N[A.V$.DBA;T%E.@2[X5E;44&\RAE@3R M89BJYJ$O-3K0'-MSU ^DHNB8"SMZOE*R]J&X\$Q[3*7[7?@+XB[.KALI9M]Y M=<8EGH$M1H+SEX\;E[M0:;8?2&I2RR-U3?!LF#&P'=D&ZWP#_B%GQLZUY:8$ MO5&JO3!B +-1IP\%TX/5F<7XIN79U+G(WD?$% B8E+*TQM;;.%PA@:O,N$%&6:(@KV!]E1&J_Y'3F"&)=VS=0 M6=@@).U7<"@M*T]YFXP%10171^@M7DRYNN&P%):H" RQES&+T'3M\3PD"+L] M8 8,'1_B)D6>KE/-]1+6EI[HBLJ!P+#W@'=*S5YX;!WJ#;@7>W8_69?E:\$L M?4()D!4%L_>:_P"2BL JVTG&+^!E:+3TA6V+CT:F;?KA_:H R!XGD M2I;U:,+G%*ZZQ/$T2C_$C5*#YD'9F[!V"JM55+') MKX>K9T5?K4>:2[R^\6LMOD_>(NX)4?6+6IQ9!UA0J)?."&B'*=RT.)X!- (6 M9MF6M1&4?8IADRKSBZ^-)=-!T05]%M#+#)908E[M,#.%@<]OZD/\4,'A M/M.$>KF?_P "9,4K'K,M?IY]6T."XMZLM0$$<\U.PD0:-X\^\'XKI8:NZF/G M@C"7-O37!?7P-X0*:8 BF@$A_P MYD!IIE^6XZZ!H8)Z\P_TY"OEMY\<0-SHO/?,PF"?04?XVNU(?8QN5U%5NB)3 M%E ^8S*;&WL;Y^D 3&2=JWG_ /:(1(J;4< V*8LL/\ '*7[IE5JLL PB$JFR5"8#NQZ5^;J MN\5E5KP5?,H"@@=] (!\[Y15E!>G_$] 8H?;R_"FTL0%EJ32%Z#JF32Q67 6 MLUNE&=K(W%"",! +^Z#J#5V1=PE_K0+G@E?+!676A F4F.06O8E_M>IRIV/)BOA'H.$+1WH/:K5S M4Q\(/]2@XM\OX)90EN3G/'U@ F.90]U9-6HKD24JD0?^N^1P-#@ '\-/EPC@ MO?O/T:G+>0WS/G*%A9Z&3(&C61'X,*#V,>HA,R9_AND4E*+MJ^DB+2NY1'M_ MQ*]F&JJ4-@(.:.C+=&95[>RD'VT*&;-/@6]K[%:O'-)J$UU7'#$V>,)T8VBX M&@FU:7UE'-0U038K(=4WH3('O@*QI'?U<$:N0\P8B4UXVT!0-M/&[FAL^6)6M%S5&]O;KV3%FJGX"M7!"= M.P"@LK] !PR/2FL;7 MZ!IV17^*2_%U!QFA3:8A!K#M3O&5K>EGF5,QHJPF':OQ("18'7M.7:Q"C/\ M]4/_V@ , P$ @ # $ M M M M M M M $ M M /I)@ M S[L M !O$@ M ->7.@ M [M( B7;("! M *&5[0 M .\(@+A]SHKV M !6$N:A^ ) 5F M_%VL !P 7T0W MLN !2 ! +\^TB7"IV\ M *&0 M "5CM6 5W\!L M RX M !/'B^9(]W)Z@0^ M !"C*C)Z.WV2$[0 !,/KIOE-5> M _VF !$5A"QS;2;!YA ML %:A-F@$P@ER=2 M #6*W4B$:%*-/" U M) !$.LQ= RGN %^^BMR MHP0&JA8 !? *#):/,QW_ &S@ M +#XV9BD8*P1A: M 3>SY)39P*FF5N H M *=.Q/LP.9(+06T 2N*+F##.FPRU$W% M "/9V4FACB2RKY_H M !H;L*B0Y''=PGC%@ M <]^F56K_ *E1F&9) 'KAI=ZVV\D6:9 M^C ":I'S.2[HGO\ =K! M /?; -EN/MS _A70 M .NV]:>#E%:&]P,0 M GSQ'N2G^>BU58%W0 M )Y76:>])95$O.!7P M (?5W R5_;[(4/J9. ,:*[_ "EK=M80@ M (]O'/P/[DHG,,CL M #]K7V"7+#>82"@ M 9P# 5OJS7)@'HV, #\=U\[LHK M1 22]P2C.RV-?[.D@ ( M ( #%_@U #P!4 < 9?D/H_5P#5O=>P M "4/)G_%%?0X %]@ >T<7 !@< *@ %]HLI&;8 #-CV"$ ! M -Q*P?XX^N3$5T$ 8*RJ%K@K), 8'4 ('\OK?9 M@ .\-L:R!%]DP;: ,X ,'^\W6+7H,<%R\ M #CW* )&/J,2BG ! %D[!K?8 'TR#[0*<@ %@&O$ $ 4))# M>".8#Y@ 1HM]$,*< 'XLX2 DO*8T!O]P!L M( TXH @4 ?ZX,1+E4< N%%G 7OI :;J1+;,(0 "1[KH&EJ9^Y-"(( M !Z+V6X0K,@ ! KE\@&,< =F2"#"H2@ )\P0K MH!!$8@#N1@,J1 #:G4E982!]42LX !47\>^AC ML --A<+@((@7]$?, O,( G ",6T MB:XR< "'(.P*22 1\ M !0@ "2N#C!79B M0=Q;%XUP +< M ;G3R'_P!U !0/'2\ M 1;WH]]QH M $+[)A4 M JO\ "'D > !V,UH@ M (KI=IF M >X0 -[RKQ M !RY'80 -XT/#>1,+ M #V=9& M@ ,-@ F-V&U+:90 M /5\SEQI7!@ #C^771NO M+RD M !O$>;MN246)\ M !2SHMK7@ M "O.T_4W- CY[H(B %%Y?M"':SY"5BM61P M !3]+Y*BS#R4 MS:L=< !'D!'F9>)#@ &L4Z9 Q(& M"-L[X*9 &L0!40 #@-1J 1F6Z*#& '1/L#8![ M CHNF]-AK0E83J;&!@ !(MLYM<[OPG"'2344 ]NPN.#& &Q/L#8% M2 "P^\Y0YG .>'?A10.- (V.*;XP3,SLZ4!6W@ !^YK MGTQ;2I?@KNJC ;P &0:&'PYAP'U'?A10O=@ 6%V8;: . GJQ< M%M!Q, ,)T@A3Q 3."]NQR> !-UN>IUSNOA7FGHR[.: R)! ?: ,! M_2Q<%M%1H "WHRR"IP !X@'K9, -P !+O00C RWA"<9]S[N M -_KW4YPDZ#]:0EY?EJ &5\%'2IP _@'K9,D)0 96G0( M4V \E/7^!8?F +YT\'S)&CT2@NGNK -N-M?%F;V7K< _P.<0 3L M!@2@4" \]/7^!8PH +S /1UGCC)H8 MT2-O(@6OP #) ==G6AN^5&(0 #H +S M !WL #@Y,M&F=;50K$>P%(P +P%"5M7I=Z%*&OP M !WL 8 MX ,QZ]KJ")F786P< "Q*V)*^'J_F=)_ M @ '-174MK/%?94%)@ #44=]U+- M\W:*7@ M %MU1(51,(Q,4FR0 %N>\A4W&;D)KIX M F^N*7R8GG^LX#" !> M%9- "WX(W.E M !M.2UP-S,EZ$4 0)*X/)>1_)SP.:VX M (>NG;GL$D@ M:TU!"8!!CB'&48 < M !(>V\)O0[.;O8 () !E! \[L M Q( M (5%AFK+#0 4@"! (XT M !(\*.)T:0;)TG M M &I@ \3*)()1) M ( KP #5R )! ) M M ( /V )! )) M )!( ()(!( M !)( M ))) ! )!) ))! ) M !( M ) )( ! ))) ! M !) ) ! (()!)! (( M M! !)(!!) )!!) (! M !))!!) !!!!! (!!( )( M M !( !!!!! ( !(!( (! M (! ))((!(()! !) !! ) M( M ! )( !!! ) ! !!)!)(! M )(( ()(!) M )) ) )! M !( )) !(! !(( )()() !( )!!( M !! )!!) ! M)) !(!) )!!!!) ) M )!(())! !! ! ! !!(!) ! M ()) M !!) ()!)! !)) (( ! ))(!( M (! !) (!!( ( )! ))! () (()( M M ))!(!(!)!) )( !( )(! ())!)) M !!))(((! )(!! ! (( )!( M()! ) M ! (! ))))((() !()( ) )(!!) M !())( )!((! M!! )))))!! ) M !()(! ())) (( ))(((!) !()( M !!! ( M!)( !)!(!!)(!()( ! !)! M () ) (!((!)( !(!! ()( ((( M ()( ( M )!)) (!! !(! !!(()) ! )) !())(! !) ))!( M !(!)!!!)! ! () (() M ))! ) (( )(! (!!) M ( (((!(((( )((!( !(( ! ! !( ))) ! M( ( )!))(( ) )(( M!( )() ( !! )) ( ((! !) M ()!) !! ) !((!!!())( ! ()( )! M( !) ()( !()( ( ( M )((!! ()( M ! ( ! ()) ! !!!) )!( !) M !) )! ! M (!) ! )() !() ()( M ) ())) ( ( !(!) !) ! (! 2' M !! ) M (()(( )(!!!!) ))()(!(( ( (0X ) ( M !(!( !)!( ( ( !()!() !!(!) M ! ( !!!( !!))(( M )( )(( !!() ! !() ( ! )!!(!(! () M !(!(()( ()(! )!!() M))!!)(! ! (!( ( ! (( M )) ) (( )) () !( ! !!! ( )!! M(! !!! (! !))! !! M!))!!! !)((!!( ! )( (!((! )!! M (!)) !)!!))! ( )()!!!( M ! !( M ((!! (!()! ) !!))! M (((()! !)! ((! ()) )( M M ! ( ( !) ()!()!) ((( ! ) ( M !(!!(() ( !(()) !!( M! ( ( M ! !!)!)(( !) !(! ) ) ( ! )!( ! M!!( ()!!((! ))() ) M )(!(!( ! (!) ) ) ! M ()()( !( )!((!) ( ! ! M) ) )) !!( M) !) (((! !!)! (( (!(((! )(( M !( )((!(! !) ))!( ! M !!( ) !(()) M ( ))))()!! )!!!( M )!! ))((!)( )( M M ((!!() () (!( (( M !() !(!)()( ( ( M M ! (((()!! (!((( M ! (!!( M) ( M ))! ) !( ( (( M ! M)( (!)(!( ( M !( !)! !) ( ( M M ( !!!!! ) M !)()! ()( M)ZD M ! ! !-4 M !( M M )( M M M M M M M M M M M M M M M M () M !!) M M (( ! !( ))( M !(!( ( (! (( M M ( !(! (!(!! M !!!(!!(()!! (( M M (!! ! ( ( )) M M M M M M M M !__ MQ N$0$ @$$ 0,#! (# 0$! !$2$Q $%187&!D:&QP? 0T>'Q4& @,$!P MP)#_V@ ( 0,! 3\0_P#ZW9 'G6$'Q_\ .9?*,'>V=&E(F^W!FHA,B.DC.%QO MLS+!.9*K'# *O,[WY.-]&U)Q-_GQ_P#-\$DW\G]>6I-2FKM\(25S6=\,19I4 M#!]&_)+OGZ<)(0,RO&-GD(0V(P1)PM*&)53V]Z#S_N 4K/0 MDZC@228JV.(E2';?,Y'<*L%0SX^5Q"8_T14#GUVKL^_KHL<++XU2$RQ4L:&JV5EKYWK92W0J!"-8C:2&6MG,8PZ M20()D,F9&??/>-&4R]S^(FL7QZ;ZA)033N>3A<^62:^3:*D])-8D ![#BIK@?#G3(5[3B%\SF2["M\A M-*6NL,0_:>R&-!)0UXOU@ZGYRI;/1/W_ )U5DK^3LXAJ/IIB&1_+N,^ "\:& M;/\ 95!*QJ6NS;]MGW]=.H56VYL=/+!-,16BF PWYIV,NRPYF-$D!F0"!O=. MCWG0K+$M[2+#AJ.9<9T&7,'?AIS@=MM)<((GS/[?F?\ -H$@- :ZKS+=.W"S MUK>X:[GQUK*!_/VO_@@C%,\<3."Q_;AFED$'J6-J9S1"&Z:MI%@7,F[5;F_V MTK:(02.+\01+7HZFI@;GICE&>4Z,#J#&5%1 W-E*WXC2(4%*./$#!$5&1J&= M%!24@P1%&\$QQM2QH#%%=Y_.P_G0BR0N8VY?'Q1.A4R)Y4VP$P>;]=( M1:H MGABO6V)\PP-@UR$RG40R;2;N@-JHG^W\L/\ 84%*'\UJ1PC^ALF..W4)D$W# MCV-^BYR0&E&V5MF/[\VI$[UL)C,R&26\?2-Z_G1"&).>/2/ML&E4*1VJLY/9FK?)1#,-2L[ MYS\]X;-XTN-K2Q@SY9-L;R1Q*T*?:O&)8MT 0M)V MK(D(E8G$Y93?,3&K0<3/)FQ@UYLMOQ9N5DW=X$001)(W.3?X]Z=0,HE[59B; M^N_&VH!E+Q5[X=8!+,.(^C'\,.I5I!/;,3+QF+L*<:2Q>1!OD'+^\F\,:EA@N8^/7X MKU DF(/[\5]/&J$P-FBIS=.[#:QF- << ,-*,2,[K41MC&I\R+C>Q7:SA=$=A/ECVB?/'IH6T7$U$9G^-&8+UM^?32JB#9C]XC?,; M'$Z5)*,LOMF@FW@'QHH5K"23AG;/FM\W M(YK8FY\]\L8HH@B@;6&=LLU$UC&C@D*$R^AL2;>%0 M:=AB28]&+XC6%Q-D[7&(MK2V*#,)@)^,Q.+VE=3X25.(S"&W,K.T#0.E%E6: MCS-';GN-"4PS]#"4BB8VD:VDKWT5'.!S( \M$^DZ%28LB4C,][1[8T% + MC/'5UX^^H\7J?RO3YP&09J_/^P$@DR?F="+0[,_'UA^J:1 09GQWCNYG3!FL MTM3]\'MJI YA'GUK=:CEK2/ED%DC#0&;PQZW\1O,/"^CMV .AF3H(0W^/I+)J$VA7>,W%' <=5H(" "IFJGQO!<[D M#I:&:@V$/>3Z7OJ+4"V\X./[9&P>1S3]9/,NT9U$F8&(#S1-DQNF>2)49( " M>""YW/?Q;>H@P0+M6=I]<3H:0E=JGH\V;YT1T# @\]+[W-#(#I5(-MSUCNUQ M4L3HC,2DY#R\WDR54Z0O"W0CO?CU4<:5D!D*JDYKTE-NX=%"-F,;L[Q';WHB M.21M4\>;Z:(+$T00,*54,8T.$Q98<\WB\^E5H >8(\YZSSB,\*"$DCE\;9._ M+HR'JH!!DD( MG(M7M&:B-^3!N);AAG]C*?SH9(BJ1#UO4[^OG0F08G:8;<3W$14RNF6S%%K4 MTK,YJGAVHJ4;HK-W,1AJ](D# M(S_6I:AE*\$+;$2K?T,B=!!$8,IQN]Y/;4$1F/MGPM^-1D3S%'VJ MFL0Q[R%-_4YP<]^LY_UV0RQJ^GK/]^@QMZ&F-B65B3SF?1C2)R2Q=,W@C,GI!HT8 MRP),QOAVAS0HQW%!_!.BV6 /-5NAV1F'%:=,(S_ M #Q4<^<8U$RAM<0.TT;OIB,?Y&2'!^C7KZXQKFZ&7:)V8X:!,=&HI*1G:HQ!9/K66C74 M(LR6%"4P(4F8?7V9?30'S@$ M'L05[UW.KO6,"4DWQMC;UF3#8&D) 47OA?E[15:"O$WP>OX*7$6BHS$Q#P15U%(U@HW+..NG%;:+ TT8GX=ZVN:C3$5$,%_G[6\1#"!4^W&F4 RA,XWS6T/#=3J0(4PWXG-XC?USIDG(ESS,1B3!9 MM2:"1"0*\L1>,>'!Q+GDHMU+MG1%M*6RD&3NC.9EF=$D9^9VBZV\7T3%' MYN02TZ)YK%$W8YHLV%*\%VJ9Q<&7:?2_&#R0R1)#)-_=_>)=66%ES#7EG)0> M&--# #Z<&BU-I$-:,@(91.IE81 MWW<4)J(+D>SOGC?E/"PB69FK%]Y^O4Z2E3<3%692[XU;63S\P^?BM%R#]?\ M7!$<1OPG@SQZZ0E&&Y8JI/7' &D!/\>?RX=4XE,^3%$2,Q#$]YT56HBUN1SL M87?HU$EP9G*YRFC-E@S>31M% MFR=?8?.#K029&TM0-GVFX/ 51*[_ #]_\B="'D-2Y"UK8XG+WZV5>F%0>(A; MKZ>]=Z=1,P11#'<39U?J&DJ4:C$Q4]21NW(PZ($$R/ C=5+N]MZN6Q6TX,S% M!D@RRJO. ("Z,/)..>7"8MT02U-53"SC?8BG-Z$)9@[V("8WE?&%T(6;6UG= MA??)'KMJ@3&5EP6@]_*Z,@" VBSM [>6] DR"E #"[1M(QB[U($2BP9BV!:S MI!G,!SQNNTUSQ)JPD;><.)O&YQH6 HE09F9@BOMZ:F23*J >W,=[%;:@%B"1 M"&&=C D&YX]-(0C/>24X8O8F"=YT-DLHWGR M5XVD'%8&0>?]:!Q!??AZZ]Y\>"9]"^LRM_UHD,KQM\F=OD>=0$-PSC?;&QWB M934X#4#.>98)S5'\Z1MHF[)=RYJRH*[, Q8Y&&PX^L^FC 9@1ASO,!G,YCRZ M9+)9"7'MPQ$1_ 3,F$8%.0O9/&FC2B0]>3V;J/&G*-E>_3?>J-_>]0, 1,#.#%9(BZ^=!B*HCU MQ!%+$8WE8U$S3-6'B%.ZLU07*PRS4YD'C/#=NE<(H=*T6;&8J_),U.'BM 1 B#:ZF+&7'UK01((3BK:V_.0T M)EP$SPYB/1>.YTN)H@PS=03,WU!M>DR-,M!62[SCN7.^AB E$LRTP8Q'O))1 MI4G+!L&=\EG!CSG49MI$M3'>:^NU[%Q$P VM;#.W!SQJQ"KG$[16V<#B\:2D MN+B8[BO;J>]3,-V,5^;8)]]!2$(62$D+EN7!_6F0%-KSB(RL7FB'C0*R<+*P MS4&7$9=HB+TPH@<%>V?.>W+&J18F$F>H\W]8U%!8M8^A/R^5 ]-'!CI\9GNXXD(=)##U0;3/B.* MNH LI28F_H5S\IPX64FDPP-#+)55E]]%+(H39:1E''D#RZ$L6"()M'WD=.6D M&<&5NX221O6G*)^1ZC9C^,5I:0)?S@VC;]]!"%QP4U9;[D[&)TW,2YGM_/.) M:_R>#X?IJ1M1<_.[AQ7$3LHCB:FC[^N-L2ZB:4;"SE.,D20[WG23 6 /?%R? M7K4'8" )QO&_CLXU-WA29QAF+,1S)).I04-/!KBB'F+8?%H1,8"XIDP$[S Q M,PSHYES$S%PL.&_I%Q(L,K%)[%KTS$1L(\ (97F[O;U&8LLR\$;3QG>J*(B* MTE,&!,8YRD1Q.E$+B?Q8"?PXU,C$)OB*]RV#ZQHMO@A-F)MC!58M(C0 #,,M MUS'[Q&DEB1]7U3VC-Z 2."(G8YOMFFI)-&U)F.I]&IYV@JK*H4D]YE7$T$05 M%;R.F09B@]($WS+#)S6G*18<9BE,$8SRV>&0+)ZYWKGY2K8T(DF/]6G1P_1^ M\8T%EI*0J1!B/4MKT.9JJG8?4HJ"5/F-M,IR,QUCTF4\EP, ME*8I-BA V-G3/=:G<$IC$/$ '59YTR-6O3&8>7N9\NE11F1<^>9B)V?;4V44 MM^,2!,UL-FE1 LA'L;BO6&C%8=I12=RW:\'[%+HY)M)%!O'I<=YK4*Q^REX] M6$VS$83"14X[[OO&CEU"+M8;XF?/52(&$B PU81^WW,:4UL3CHG&V-O&G )& M)*AD9WWQ@!TDUHT9V(&SE7$]:L>C@34 IX,X/?5Q+HZVF^\[S3OI9L*S;7[8 M^^34:!G>]FMC8^=\_P"4QIU(B2L&V<3UOI+@A+6=]J?')$C6H$G:(VS;B)8) M\2Y@)#%C*F-GM\7BXT;0!5"(,U[3L^72V2)R?"5B-TXM#.IZK&"%&(KOFIA@ MV%@S-24LS)SM8X<$Y-I#@;YXFG&.=,8@[V6*&(GNENHNB5/H6/1IJ=!49A#( MI9T7S\Q!K<#YQ+XECN]5# 1!$RQ)VT[X#>M1*'.1A)GCULHC&A$"@H)A=LN> M)BXTAFWA<9VWVH4BJ-1PB,2OG,;E7W[: 1P\W9.G 3'S]/R^#4Y#-^<)/$YLW.V)P30E M*2??G;C+8L$0>N:FKXCOT:V )I\B[2:F@P-PW QPKCS,8*,HMX MP.\XRMY-1"D?LG&,^N(=)![6U9=B9)>/C.44,VP/HST346XS&C=@9B%:D7N! M@QW,&H+JS+J8(6XWVC?;1)2D$\_7C/$]Z1B*)^F6#,_$<$1VC>F>9,ML08;F9 M'2+ O/H[LX]GUC602&8+VOT?ODSK)W&9")KYXN3G.A"0U?>_Q[5'!+$H59ES M @Y6DP7M4Z=,3(P152XS.^*WQJ/#1(QM:O9"8GG MO,]UZ[%)@JFQ"-R!BF2.-()#@@F)>PN9+W[TZ00D0\3QQ.T\RZ@Y>!-_S8/A M>0=2DPN M2#3P%QAF=YV(W):[7HH3F#Z'YWG_ %,Q%K4FW-9DAG^S5\YY]H)]O)$SJ)(6 MF(VKZ;;$3I65!=XQ#&U,,3,\23IR!H>2')#G\K<Y(U*FB8'>L_'HN(K )(,1X5_:6:0!%$J8(G%L+LL$SI!$ MB!Y6RGD%/I&I8DD=I@WFY7-SB^N "R6)S+UR@--DKLAF.IC:=.Z+FOC&8NM$ M]58Z5$U'BIV.A (R/^3HBUF8AP?/S6O?BXOGKOATS6%;)LXJOV#9SI;)*$VI@8]//OH:P )P$7 M\0^">.="BY_*]\[5O:*0'*.XWZ=\/;5Y7/ M/']O;O.D!$KO'TSOMR1&B O4[YW.L[7.-8_U)J!C;WTTLN_(5)>-KCBVVDS) MC+O!#E<,Y!F.=7!PO-.%(N5]/:U)RD8H24WWP;>?KQHT_-G\CSMJ!' M1'5P^,?-ZR2Z6?69C:I_!G(1$^"Q)YP8>7)0!:"XM(QW]4] M6?",J&^M!1 Q+>_I-[Y9YK4EBF O$+:CS*;G-Z0TN*8:7\) MQXIG4!59B+6B.%O/Y&@PD@PRA0P[GPGOJ1%)D\,?AYVB?\@*&80\N-*ZIDCB M/FD.\A)& M=#G-J)[JIM G!O=N@H2 Z;S!R$%HQ/&H$$X25*?6\9)WT1$)(A<$(S!<3[^V M@V3"GQ+.WCD\Z&"+)+7EN]7'PZ01523<4[SQUZYSG$6+5F2,5'!XV=6F223G M>VIMX\SHI3N][@Y82]YU]9T T?5U'BCXW=$!R!H$T7J/%3S+H@Y@P[S%M_MF+C0C M:\+QUB+?N[FCH;#$D[R'#OF7J'(FZWB>XC%YZTUH2ZF_/ M48#[Y$21D_U.:Y:04&^(K/M<=92KU#MY[]V:\Z@,QB[O*UM^;[-9)?/I[Q6^ MV5TK@>[C>HC>OMO!HE"@3:BO5(/$=SJD2 6D31P/'6-053K#).,"$IOF(U"@ M;(4J17-8)] TG9K6#CJ0BXSOEEA)BEZ:F(\>?G3-T2Q AN$D/JP2WQI9(-3O MU@8]=EZO4B*@*Q4^WF,1&(T!HB"NJG>YKFX1VTW4L'5UUT^O%Z@6X'S7OUOU MJ 56&,;^^=_1O2$-@7.(CJYA BZ]-4T8ILVS(WTQF<[:E(RCB><7DN=I-#Z( MR8O^<3MO.D&1$87UJ*[S-5>CL\HFTVQ;?K-->1DA$I"2;S&_IOS[BD2/;7'F M8^&8S:G5 8+>)^.<0=4""1$Z9_R" #>GCS'4I&]FHAR"#@FP=/5.VI"F9B)3 M+EX,++;M&IB63G!UO6:BO,RUM&)FPCUCZPQ44Q#M*)B&/FG^9T@J<(5/QVW9 MB#!"W%%)N;CJNXWVBYZ@IDP4#%F_K;C BE;YZGBH,H7N>8WX2IN$U('BXS MO.(L\Y@'&HH[PJ..>/S%.E0*"!%HJ)K)]"B0TNA J#YEDCVE.#2][S<<05"= M;1F"M3O'J=J?W?5QI5B;;GB2+C9KVK&AL@W:.O>MO4'.DIE_?\\?ZHC(9G;Y MT \Q](N+S>=[Q#J&$L<98%(]3$S68#40,+O=1(RNU3/S6@A%L>VAD#GQ.R7%MGEP$*SG5%5,$5:QC NHPQ98O:UG@^X9TD@@"B] MA%^\YZ(J $3?I'QG>S]M2BYXCI@@_;GDA&)9VP#9XSC2";L;"HU':;8??4S- MS%;1BLN#.(8XTY!<(3L[.S&<-IH1@A<6F]IP_OOI4I,2J'@9GMKHQH2$S(QV M)]UZ-0_ 3)"(75E A'&4-]3QF^W M)JX=YE9.X(HK DUQ&@@^+].)ZSC&F\$&F[-\X[X_>6M:M]I,R=3.(;T?7J5Q MQ=+,T];D:+!Y_P >K($)CC/&\#,N$9=6JS!9YAD^FZ2SOHA\_B[S<7SRZ+KL MXPQUC/?QIR6+"U#X9@,F9;N-&5J%E@K/SQL[:,!<,.*1AH\3,;3+J2,F%6(S M?Q>&/,ZEC+&1C%;[J MWVK,Z9F6%;,S!*$^:QQ>B#,@HD'B8=UC<"FG60[7UYY[_BM6H49Q*[;5/QC& MH11+,$8DFMH!/[-#8@V<8<\<^7;C0-MEANR(BHVCR6;P)%0558.?&Q/.K!9\ M[;YV\U%/< +*JF:B=L1>H8#NJ-K)R1/]M1TX2)2>#&;KBL:$I (LXP3!@+>( MR3!J[8(@FY;+R2$XH>-14GN&LLQOM\3D )J&_/\ 8:=0+,9Q'K@,]9QH9!Y) M_P!3DN48Q^?UI&4DJ^O?/=>J[2&@NHPLOF.O.ZFP3BX1YR2W)-3Q;IX.<)"X M@.<..7B:T00Q)9!:BX^,W42V>R"O*7O>KB7:GREK F3BN?G M'@]M1 YQ$QU?$WJ%*(.KNK7-= M31W3VO)%_07&K\)220O>KC<^@L:')Y.9*\Y-BC&'4ID+B6#Y=R7TG$8A2YK*$BZNWE[8CM*%G9+ M )J8G9JF.J3%Z55.!R!,^V\%)KJHUX9EC9@NY@NR8[YF"%DN-X5#&*G&.]8$0&-V,[ M?2GBUH1L1G$$#WSG!9(DFP-^.)J)?%@8J)996-WD@%/J" MZB0EN?;J-^(TRQVELYF(]F<9U#M%IB'+GWVGQI2'M_J6-788,QWWFN9\&H2% M.STYS3$7$#!4:(!*W=\0OGO4;1E2,%*W%W$5J D S)]=H(U1&:/?>O,UB\DZ)120K%BPU?/[SI%D*82:J63M'# MM(TYU( ;1OF5PL6VKQ*3B9/.0GZNI'9%1S<2D[X"-L8-2H)4RT0X+,5;MXJ# M*,%"3MQ/W]=/F@2XEXF\3U?EU @5 )D*);J8+"5F93J#89@C@L/BXBH722S!QLN(KO/@FS1C$KB-^=_=[XTB>%H#9.%7,9]R M]QQ&:#M>(CC=XXT\%Q9ZDV9P;D1\FF%" PB\3>2G%F QINH&,"\_#X^AJ&". MQ*:P_P Y3-8OBR I&();>2WW,Z:8(4@5#4+41RS=Q/"K7FWGZ4='<;[+[2-0:.(4 WVGFZ<\Z<\* X M*(ZQZ[9K2\"WUCKSYG+G2;C$^YB;-_KXSY7NM[L[;YASJ61C>7T??KU*'18@ MR.TX6/9JL56HPJ8%VR?;%NV\Z:EJ+;SU-8W3N3;4Z(2"0/&2;:=OI)JP+1OD05A]I-RZ0I A13#F(#)>\S*3 M R$6(B,ED..=D7>3PD^T7R>-"8% 3F1;_^H 6JB9Q!WMD4K@9TT*=";%H[\U6 MSBM&"9Q6A) +;'\;N<^-3RAD(9"MKWNJFZQI46 MA&$L,\#,;& MA083K:CEFO4<?[O2")&F&"Z#^8R1YU$?MOMG M0**GB;/3'KS[U(C=9B:^L]$[!HR4,8FT.F$XZWAV7 +!9"4&'N'W:U% + RZ MW",\QR1.MVZLC-;54OUEU.4)"/8[8]I_@0%[?G@Q[:,'@_U))!:D:5/,=^MZ M[EH.*^/SSJ,EH!]#(UZQEYSI5F"Q#;K+!MK\1FXC\QS._$0.8!]8^WYQB M(%HAL_6Q>3C.H*4.W[]\)/"1$.0QB0^6]_3U-2)3>+D/1\5->9-7C]:G:,]@(4))<1?S!$7-/6B#H"55 M&#$HWG8%J-&P$7/;GZKSW,(.* @S)%'.V,;\H,0(RLF7F;\W"#W !,53%.V' M?=GE<:B0PR$FF:F8(9.+8Y(&0>0??_&H(B2.3G4B%+5;;'PG5.=#)6=QV?[\ M?;00S%DG;?DS&()T!@C-DP5/4^MLRG*PR2L@MN]C/#JMIDV^IMH"B0%&=GN<[&I>;+W-K+5 MN-\U6F[F)VVGOYS3MI4B(B>)#?UF]QK?017+3NUSOWS?&BD2X'P*/1YL-I=% MD9 =FZ]K??/$ZE$;Q5Q7CZ\8F=")O%RXY])F-#")K;G[UG#H29;BY\_F;^S) M6<_:G\]&-+,7ZQ^>_5:D#8*K4".W[?GG.HW@B$+O$8;KK:P MTHR"RSR3QZ=3WB3DI$IXXCUWYY+D6:S3]]MZ.XM8&)$PSCR[U\T;Q.@!%! C M+ODYB#YTL)E.SAT+HA2F)CSU"MHZT<01B#CUF??::C39F@CE3CDJ MX@^NF6=)"M\%LD7U[UJ<)J(0C=)J$*7QUHL! M?6_ ]DYFV &$C[3$1')+NF M^C"1<+!P7/.W[ZBF +$^BLRVY"(XT3D$,L6SGQ)#WS IA6D;(N8VPS]-+M84 M]6STA_O1&()L;PY8MWPQ)C24SU'Y\?XZ%0LGU_KW]M2(=L7(@B*7\'C4HT4F M-UM\8_:-$>HB7BVN;W8DPRZ!5@A9>1Q.\IM\;+$%$Q42J7]N3R#4REK,$V^E M=Z4E"T=&-_&=M]M+5=OJ<[N)VMWT)B9I!M,1OBG?'1J+Z@\D!73"Y-"42K9^ MO./F;F]$L,3@\>C7R\2:&4&Q.K]";F>#8-$'9$0[D?$W'PYT2PJ6,8D9VQM] MM(0&-U*N?O#Z,SC0"96G4DW+S[RH1F T5[=2;;P1XSH6'?GVC\J\:@'$19'' MGX-,($'0O6 K&=1 JKY]NJN(S@T @BJQ^>GZF8<[/Y^?,RFZ_SC&T>/ 0! M?/KQC\R_ZGFJ:F-.2*39SO\ 6_II8/*[V]X8VBO&H8@SSF?C;/-9U.A82]3E M\L\5T:###):QEG'T6_;.C")KWWZYX\79J! 48G/3YS<_U#%)WS?[#O&;X(LA MRYYKK;V#@C128F[KB_-'IIHD9QCN)Z)BYU$)MO\ >9(SAQJI.8EYO@_-\.DU M7TW]8J/634&$"8F"\SN2>(W- %N8G#?O M7.\\C$>=2AS$N)&[B,;8SYA)U,4\B:4!O/L,U!.=WT!V+SC9S!6YIT6')"<% M+C:YV9T$E /9)B]\WF$)M0A),=P0-2YHNM, !GSCE4& ;Q/@$!M_C@6$M-X M).]^_/FT8AV<3F<4I./6]& D@DZFF;+QO$,;1$ K J 6$JHG*\;3NXS%C";E ML]WM4E6'14Q2'M'#S-9WN- -<+"F9@VQ\09:72;#85MBYGB1XS.=+0I3!5>W M%D7$[8USU0Q,XFGW*YG>M4#&"=K_ '[WT (0ML9CACSZ1H(#:M]*\R77EVU* M(48YG[=Q5?.G>!R76T-3&+C)Z5I0Q 6&[XC?K?C0 9?3$_4^=\:A50T&SOZ M^-X[@!6075_?WS$Z$(0;[L9*AJV?V6B(EUQ&(OZ158-!D\M;X_-^3$+8,L_$ M=QGSXLT6#S_K*E\N(ER3BWF:C$Q&BZA)S5$QS41.-\KJ(RK\=ML3?QJ!M^?G M[Y_2!-$\_/YY(-!%Y,U:N/W^FD#(K)7=$3_/II(J<,L->39B/LQJ90->=[K( MSC'C&EC (E;)SG;\F- D88N0GY&'-X'-UI9829O;DV_K&A$,X!W/O[V5QH&Y MH<8&_9FO&G%]MS&B@;4 MA^9B,M&_-!$3$YGJQ^%\:(#2%#>44!]&)S-3JP%!VXK,'6 M]SF'4<2@(%JLF-I,76\(7$,F/%QBVYATRMHHV97J(AWK?"4D$DL$XG=?KZ]" M3$A2B,$E9W$:NPA-$E+@0EB.)NJ_@B9"'"JWES[YW9<^ LHVS^^G,)(TS$-= M_.,>$92K,SW,.TG$8>[4J24R1.Z8N-HQG0!8R>GB/PT8C$&;@9_/.@4I&QN' MCD.NPT0H(X1YQCSUH3@ 6: GB7\P<: X1G_6H# 'I_Q(((RRGGN?SWTB$8N^ M]OOQ6H,42R_$U]=,Y0OI/60^YSP@WLTAB'TVGS>\:",J2F8!=IQ)ZXU*(2,T M_7%=:";VUWN@\]8G&A2&:2^;]2IV]M@!B#.U;K,J08/+>VD1C+Q?I[3'I4FI MJD)CS/T@GK[RB$\#USS1>VGW!F+HF8\&\^Y%:24*M6S-CQ6(]=[TF&!)92OK M%K5[03,("J""SS3-K5OC1OVC!/IA=R9XVT2"H"DV=.U;+,L8%B!D5129IVI/ MMQH("081G$%"3A#?>IU,D..J&B<.ZO?L0,;KO/SQ\<5_CL302,UCL>7\RH$; MS"+,5!S-_P #@> 1R,]S.\[ 'B=1Q)G]I9"&YHLVTJAV!O;J]HF\KAU@)#!; MO'SM[RL3BI$A4@(ZGVQ-Z(1LQ@D"8$Y3Q3QH=$"I(R9Q%AS7$S.CG !E[SN? M8]742696QD88VG@]JC4LP389SL[Q>^6L6*#;2AF;+W@O!!2Z63T_'CXZ\63X MW%1N',[-]S$X@K+( H\KFI)3FA322B$C0LE2PC'(BS/$0' %GB_,W5>(=;62 M,JQ%R?DY9XT R#U^,T?QI2+.T1AXF/V].4F&Q$=1(6+*S,N9IVYIJG20(Y! MFZ(SMM.Q4MPZ,ED5$3BX;,;ZK/6G890V4W$8^9#SMIH;E:WM//]5OJA)C$G]L9GP.E55IFHJ\4S&\I" M^9:6*UXOJHIA^70(4;NZ\]?GG3&4Q;$OO&*ZCZ:<2,BUCNGW.RAS<5-F7N*> MB1ACK>QG*6%DCUQ&^\;$LNG43-,.T5PGWQRLNA(H]$VKHGVUQ@(G:(;[QF-M MHT@,NYC-V%7F,7S>@!#9,4F#S[>N-1:I)@)(HMV/!B=XTI!.492]H7<"(WLC M2"8P4F2/+!+M]-(NJ9C,K#MAQ6!D-2C%(.:5.+BMWT\,A"/O7T(Q\X_QS";@ M+P*^<;W-ZD!9?1BL\1.-XY@E"ZF&)?.\3?G4",1LG:G?&3QMH2,2)9C(E?8O M+W)H9+ D21O)*!-.),YB9)"%$4%B48XW](T@U PEKY;F^)G<9--ZR39PO,V_ M'6A";I$3$V=9N?,K>H64J4&8Q<%61Q2IH@7CKE(_;?R:> !2+\5-=7],FC1 M.,1,'7Q&2-+I ,I!=EG?EI[-*BI&.&S9'@O>,. 9P A 11,]1V"Q1G4A#00T M&V.,\^'2(!$4]3&.)QZ;Z'(S(8<\K#:>W1.LN67"XZAQQ^^BLMWYM]OR+C4Z MK8;3[,;UZ9W"DY)G8*G:(N).2R%&B2T3/EXXHNI:"0R>@]OQKKMC_6W24:*$ M(X[F>MHWEQ',VE84G@?/TSC(0FH-$\1J-O-/H 9TA1!P*)3:4KWLO0XV$$=9 MQOS],Q,UI6L9.?2(X9QJ5P";'%\D%=KLZ3536Z 0!B[67WV1 )D]/N;EVX]- M2$)D?DG:2YW!WTR'(XGCK@\8PZ2J>'SZ6N<#'&DU!H)ILR8?,,9TAV1;&"]Y MPCZ>=$:3+#OZWT1$=56BVI)9@V?.&!F/K#V"'/@]XJL.W.3BW>1+,S[7[: R MQ,&<38YK#WQ,:CY 21E6'B:NBB4P1 9F,2P_09<0Y@T R 2S)AVV?:8QIN" M8"6;@DW@FLX@AF049)&HOB=O:?)JL6RN_KYCF%-!E%FN6)S>_$>NA$;*#F;AB[G>5FC&A B!5AC>*5J9 MMWT200YSAAB=^HYSM&E&1O;$;XKKKR$&H5B,V;DYVC,1+Z006** QDVWSDW MZT.0 O#NXDKVU.H1C!))SZ-JVW@V D;(FN2^9YQMJ)91L$;16#QEWT,"Q34/ M;?.WQC2)W>/SUTB B@RX]+6&#-5 .D<5-51-9,! MF(AWS+IQ&._/IID 3&8]CQ^R3XA==< MW&T1YT]%$)>\*?;8CHX*+@KC'3[K#OOH"D5-1,7W%0P>=02A+S"DZ )Q3<6[_XMR)E2?E_U#,:1-D\3)V<_?J,1:;!@QEJ<37WXG64L MA",]OMGTTZJMA8^*]XB]KP)R"CO4,8BY(VYY=$%G,LYGS]/YU2"50!>\WBMH MBVB'.H>#!"9J8SE?:L;Z@P59]=F\]'SM /$#D?+'AZ8U3$@PYVM-IWXXT0BQ M/N_G>;[TA; $FZCTSX-_&E Q', 27NJGL3O2A4 1?M,QW7#>HF$$8,/VJOD MO33S5DVDGN_O=E:H9XB>,GQ7NA'EPD.3#9YG:=&;.74 MC#%")6,1&G*MRY9VG=@K$OHZZ:YR0GG$[CM#Y HSE.088XOB>LZ"13N#PXGT MVFM[O4!@#_VWJ%"@(EE(A 841PG_ #[G@VNA9!U-!()!!D0 M'4B 1B$71H;S(O-B & BUF:@8 P@B,(V(EQ,(V8UYA#*]23F;)VBDC)"I0$I M&HA,!C*+'_=@^'Z:_.?.I9( M"LD3..3>RG-&:T4%F*#"\UYB/#8Z9C<2.Y.4SA9OU=]+K W:NJBR("PRUH6& MK!C,,8I$0D*H@J6-(H3>\$S/9\[\2Q2%.4"UO'H;7$=JJYAV3AM8WCF-^4U2 M@H.M]I?WG.\&HQ/2(\P-YV:SHE"E@5O=>Q+9!Z%9?Z'U[VF62:U2Z(1,;9DV MHQ=Q"R Y"8]TW$C2 O.-+B +CL3)NUM M#W.GD&2,S,NV\>+G2&BJ(HN*9]:B2@SI;22+U&2-D>FMME=*0D"8-NC]_'+_ M (I,XQ[ZB)!:LQ?7!!$5.^]*!&&;;Q9,VLTXIFM*$F1B)G.>](PYP#@JFS,D2><-// 20MLY-XW=]HG7,$^?#I.;E$F=U?0D9M>M9 B4;;P[5]X7C0 MBKQEEK0 M9;TB.]>,5G:HU,D-#O;O%Q9L!;MI1<72$2$'IB:B*WN5+7G!CEW3G=>T0#(A M_-OSN/\ BM2QJT"L!-0&\L$KETV3/&?&HL;A5YDIIQ9B3.G:P0@@-39)H)@4 M$D?H\H'22"(BA;6"6KS(8I)@$PPPC&$1[(T /I#;[]5#WT*R.*:8"4%& F:2 MH/\ XKTF"(%)%I8:2Z,BT]/C(C$K,"!3,6+G]/QO.OY_E_[#&7A]>@" E(!$ MX1IU#^ZECL IF"8+))*.@7LBA$)&=Q"1+D1!$1!$9$;$2D2Q,_KKO%E"%Z[@ M,)D2$81$-6XII8@Y2K055 MKK^I<_NT7#0NS$!1+"1P.OS/[Z_,_OH]C2H"8 MD*21_P")6QYYI&2-T0-+*:=@W%9^ F8T!6*'E@8E281B=S]$* 279D;%P!ZT MJSL120)4+!E$&\:_.F:2F2(Y]/K.8VTQW+TD[/B2/: M(QM""YZ+(9'1921@*DCMBIC$S,/"S&MLDIN5, MB,WT8T00ZVF_F8GM8]-1%\ MY3:_9WX9DW6 @$*$3?0AY>NH5Z25RXWV,&#.>-.^@6/(EYK^YK43)!0EHP6N M8[+N)-,E1)#9>=YF &L;:^R)C?X*S\[Z P0$M[<8/'N.JE!9C%7LS/CTXX@ M_/:]=AH1Q_B._/M]3K3'*FJVYA2.',][) +"RU!M=*4AFR$74CAX:@-NHW\3 M&VIR@2G)?M"<.YI$-JB[WQLX-BR:+B$B-B;_ )Q I8ZT,>)BF!PSQ%8P\DI9CR**\)$_UH,RTSE>.#&7 M4=&&L)>_*N?RM90$4=YQPT^Q9$W89Q_,S+)UYQN14+Z/Y3?<>D!N.\/V8CK" M\:DM(QOF)\/)WO)_T-F8]X8QWBQX)[M>I)Q\"(NX!@9X12DI0F[YE/-A4F&@ M)_23\O7!G4",Y (CPFBB*2+%\JI,!B00!I,$Q,V]VA>UTGU#@,J&@ 57;7YG M]]?F?WTP"134D@J84L_XXT)"N"4"NP2K0+I#+\B^RM0*PI* 4Q,N9,&3D_0$ M6TF4"8D0)J4)J=&9,P!:X 4*L -N/^'ZWH@&YW',839&307 !$0 .YE\/&HY MY:'\I)>_T?C>=1;\)BUF.8ZF2))SHZ:F!]=%?+#0@$% B(B)(B4B6)2?]1C+ MP^O]1C!ZD$:)NG"\QBO:%>U_3633KJN0B"(DB:%@$MD;%3N1CA:U(L 42+ @ M$B4#B(34JEE6PA+S :C"X5Q-O6GPZ1R=]L'$8,,3%Q+H/JXU3/=1'J:AYWH2 M+I !,'OHQC.%1(6X&!-QG]*S_ D+IZZ>PY1910: 62<4QH-A!=UN8-G:->^A M $M:@B(0M81"7IHJ:0FD1D(,A'"6>BD3P,KM.2&9)HC28^YM&PF I( 7<+_. M>]]X:NC4343../7\(SID<+CEQ1>W);-S&DZI$B-O.QAWKO M;4"!,%W/MMZ=^TYRLLG!UQLA4>N+[U/(%S M;%4'YNSOJKLEB??'7/.:U% J1P*F]1,,SC-[:>*2!OZ,[0]&D92)B.)FW/$9 M^'2F+(8J"9;1-ZXC+5RQ-G*#+B[7.?>W1";#$1.&VQHEV:JQQH,KN(%P4_-M M>L.D(S,'->DWO<8W-6RL#$!.3NQC;-1IGG"2D/!:2$,QL7X4QF8'#?:7Y\Z0 MD0!<\1G\(WTW2&Q.[GE:/O=NB;J<9#&[!O1M-9G0@$P@^_\ B$4:5,3UH$@8 ML(J>",Y1XF49W$$M"ZV&.-ID@\,1HR"B8FH_GC/IHM%FBJ&\(3F9$W#G4H4F M%AMAR,5),$>C65;(! .6:2)JH21Y8O6; =F.HXAFO;0S'4[$3>SS'XZ@5!$0 MPN.L(R$[\&HLP,#?8UCZ3MF=1$&Z;[2]E1_(Z0C$J7, -&99,=?F'CN9G0$V, MQUCTTU$F/S$<&SXJS8<,)]-OI5["XF6=VS?9SZ3SMK^2OR-/#*7YN?.\<\\Z M9E!Q=QGUXOF=! 9W?S\QQ_TMHWD(W /K/T<&!S$9/$S.U_22O\\I1!+ *L1T M_28D-+@BA>IRFD\6W$S(LJ0=C4I5"D48$J&Q*!L$&]7I9O<0/6>!TE(MWI3I M.QPB]![G=A0C.F9DCATPP,;V9SVK\S"=0YE5V_3\;SJ"T ,B2$.70H:2B@&0,9D)_2,6F/2:>Y]=4Y#".$ZN9+V_J830&A4$0 M 47O>B'5,5!"554!:JY?T==&0R+4["1WIAE8)6$86 1B0I!@V7AB^,2QXQ@J-!1 O*XAICSS>2I-,HB+N\[V0$1 M#,^NBJIM#90= M*@"5&+;Q+ZQ=<6,J(N\(P3WWC$:B$FTD\(88X]-BM2R&%18\R; M(-S/)&A'\;_$((CAT[8DE2H/2N,[3?>H)8F]L=[S-%>P;K Q[H=CQ.>/%:!P MRF;&$D*DKP3%QHP802R@QMPR&(J/.F*CDVYX[Q=073"6&(W)G[U+Q5UQHK=' M(_5E#L:K)E785>7CWCTIWJ72"6!-N9>6L3OOHAXE@FO#O753G33%&,1>8]L= MO&A;)G>?I5W[:@-1G,^$BGZR[0Z9!E))M'>T1V'!X60PQ&%=F,C)],=L6.+\ M^OZH.W[^^= %'_:VC6A&Y1])_P"#IT, >6*RM2 L@6 >R0B?5_4)!0"2$KD@S, M16GRB)9:V6@A0,5._P"K6\L(- "A&&M!1G0(AU+W>5+3@%ZT_$2.!P$*M$$8 MJ" L!:4'8;'7#O6^EX$S?:#V>)'_ O4S289&0=RLM,7)$*69:V49IBHDT(!! 1&1$D1W$L=?C>=?S_ "_H !$87XHY ML>E?]1C+P^O] H4).3AE2DL@* F&# HA(FQ 1[B%0 P!0'0?KKO6BFA M62 AD@<'-#2)J59F%M:[+++>3D-+PT<(>03+XASHN8=B00W$RBB2P&CAM=H# M) 2YQ0A(A0 1$)$2D1D2DU'V 4U'##@[,0[:.,X< D!1!$11&1_5!$21I' M"<.H%,2$A( @K"BP( '?B(3:51V">CI+"),022'DE;D.32/*D(H!R!FB85!0 M5)Y30 'NJT$J *AK\YPUM=>F("MYC>QH6*)>10#(!2BV()^K9L &,P%J" "S M&T=8"4P-=3];Q/+[Z1%49ECGGK\V("4BI]^[ MS_>F4 _L3EW].LYTC8XI]YW??V&]*85LA#+&<5Z;>AJ#(09;.6?M?.8T\-B3 MN>:SG&WAT*17;)B-XD?VAU,)D_1O0(! (!'UBSU\=(#)K$3T MDZ$67LIZ=#QUMJ!51 QXWJ]Y\>J H+(1D;CB'F0AF,ZD)$<402[4M5M$Z4L$ M(M^>'2Q1*2A-3E>/OY=- 2082R( M_>_6G1EQ Q=J4%%[]7Y%@1"99FP?KH7 W79^WK//&L?XDS#C\_CVTE,0$GM/ MK+COLIT;-1DGY&FOJQQ]O/_@;+X&E!U95J) 9(#0RLI<7,L62R M &QPV/N_//AB&S@?I)^7KG>U(,FJ>1+ESJ(+/",V!T2SE0#!$H2=04D-KB!$ ME$N*YTCDD3;G$SE%T[T>5"$T]$L20A7F2&B0\)EB0B)ON8@%#0J*(AT$HB*% MH7&DA.D3 %0@!%%F$8A/^ 0I23!1J =T)<9@TE<[TP*2]>\&B86'R8F)V!4L M23*:!0%E:$@V@Q%68A.FF@S2F?L(&!(Q*1']$5CDSNOLY,$2.'6UU&=I<@I1 M5557]&UH?!,*/,(-O.I42E[*E/BD#ET?C>=2EDS5@R>5A)+"1"I1,] -U^ R MJ *AHE4*W4X%LD">% 9#_IAKLM9&@PC1B"X-;2)R@P4Q+$XEC+JT%9@7:'QC MH@"HLY-Q8NP_M;S1"U +)7!*+ ! U&3*@C6.6)!+B9$U<&U+!H2 DI'(I>L MYTED.,P,J<5@02S M4SH65IB\D:0@("V2C*RI:C_LOF+]/.8GYT V-0<'MK!UF>+]/RM+2<1]YVL< M9QJ#@]C4'![&@6[G7WSM]/69 2W%Y8R?F\Y=)JRWW,E/';Q>H2!N+>\$$UCJ MUVC14H&)+"_7WK&>]((IG;EP1:27\$9U-[D;#NV.;BQ)'B(YL).C&(?!>AB. M &KD@XB/CZZV$.B(N;-+(G'[>\T96.-OM6JH$0#P4S\OQWJH..I^=O?TO!B#$W3?2XA@QVS;) -@/C M_&3$9?QO:IV= HC)UL\?E9Y@#L\?O/WXV-4B#Z;[5=$'C&G61@&4H:P;YXPF M*T8)&6(ZFI]ROI*:NV];=[WZ]\Z/"*E3!;G[5]'$.B//T)G?W?=Y2UR?@3$K M$<7&AM*EL%, F7*72[AH14A*,(*FVXRS*O[RYR9)R&(])?":KNF5.(53Z?([ MSJ4IY/H?GF?^Z+?*/B0P")2.*49JFFB@BID#H%P4W;I0 W!\@-((N &4G:$%"0S4M5L$P/$&0: D2@!4%> M01#FC"(-W!)4?H$63%L69Y8@222PPNDBE496:%H0H&H!(\1PY0N<3S(BXDE9 MY&!$6'(Y)(M!)0'A@.DD4.)82!NF$ &*C>"0%A,H _\C00ZR))30Q-8672 MI0\D"K8CARR0F!8$[5 14DS&;!!< Z/7-T* %C=B5NJ_XF"/KWZ+6TQ&WM I M8)9*S]!F9T 8 M$=Q].L5)XK0I1+/FLU_/S>BC%YVKG;?Y.F/\;'-X8_B:O2=&1@3]V?-77KHY MI6)\YSV5O6DC&)@WG(??W.9TZ!$$3M,@[W%D'-LP0!$8(1SQ7FB67.I% E<1 M=;<<8OF6(089(RGL&3SZQKP3OBL^9_C>="0*8G'/AQ)#!3U.IC$X;:Y4+WM' MJVZO@A)$D0^WXN)IT*R@L;X<7_% M1JD67"+E6._VG0 (>I'%4VU!XS*FAPV8-\-7209[OC2!2O$G,AR);%+[NH]IY8P" H7%U$;S'7-EZ2:'NI\.?R M+T8AWM_C\^)Y"'U2'YT"(!O>_P"?E5!+">/SCVC;3A6]3.S5+[43+:RZ:%1^ M;P3^ZODAJ"\B=_M&T![.L9G;>Z]=H_?=U3'&+W]+G'MI,?,S)QCC9(2.9TT$ MLQX4@ST]Z&0[[5"5[J'K !0OF:WG8ZQ'K&L %@1I*# I0LWVF,W93QH$ /,$,>E[>K=:B!2DPFWM$&7T\:;DH.+WY4Z6 M[J4U1*X'!FL>))]]2IWE@.>LQ$=1YTP029G.W>4V[C)&B+&RWP;F)]3-870@ M7B7/[FSOD\NBF L^.3H>/J9&)FY(!:]!^/.@BT[Z4D=JZ]]((P7?OVC;\-%)C^(GVTHL0DSWTQ/ ?D:3W?$P5 MDN?7IDT%A V=^]L[9^"/]Q 0V.H:2^.YK'XWO.C1',.Y!)%;V-=: 6Q-75V& M28IB\]Z9N#!O/$>=^#SI(:CWQS&Y/TXPF0R[['\1\:2$P<5D:X[#DCWY(]H%Y',OZ^,F=]6J82);-L,[7L MY\ZR-['C;W[\Z$,+Q/G8\X>/70(5 P>7+^=:9$$P_GY]-!DIB&KSW^!@TLJ\ M_P"Z@"),CG2!)8QX)Y]3J<$:=+ *OG[E>O_.:=X8\_3WTCE;?X5F%BJWWU*E6J1$[8GT7! M[:<$3E)8)>V]$I@S<:8@\0NV*EB8O:7$8U+$9R;(*DQR9QZZ6 217V](/#G4 M4HK\^M>>S493^?GYSIRQC;_=L('03,8Q_//G)IP"OVD]?7YT]A^X5M4]F=;Q MGQOXTQZU9KOVDS.C#6+(OWBL9C4!E)@FS+]$9R,T1:79@GES">L3&T7LP"] MQ,_GFW??8R03K;_BB14?GYW!OI!3RYJV=V_@?$:5$'@3^$5$F]L6X@P#=403 MFZ):CWEP.890;=W'KBZO?2,%EB=_0SP^O.VA"_G]W6F@F0Q,Y^6_3UTE&/KW M^?4?]Y B>?SWTA(?SN*'1*]F?/&[[[]ZF9A.8*OZDXR\:05@A,OU9OSM/,9: M T*"^(W..]N27E>RV-YOJ6)*Q=5I0,HP1XFH\F87.VD<*HU]Y]W?$S"8+OPLZ1C,[B< M]]?,O&AA9B/[^ET.F4@)S_7Y#H^48F)T&8)CN_I^>TR 8KN6JNOIQ=6XIE2# MF>MU7GZY0"!;H]5(Q<:%CS22YVMF2]Z]]22B*KY_JN) MB-#Y%N-L]LSZXU$+S7GS\7WIV.)^O\?[R,(\:,%WB\UOOYTX3)Y_.MOM,!6! M2K\>-](S6SCZ-,3DSM)&C0E#,)MV>2M]\Z+6RHSF$8]N9>[D:Q*G&WKD3P<1 MMH,2[1V6?../M.FJ.?R.O,5_R'5MP.^T_GBI0SDYVP8^689V<:NF6LU\/GXW MIT,V?^\0$5D#32B F5N8LJ MLW&(*O6UEB-A'+CTB,0Y&DJ3EAB6?>=!6-9]NOY@ORG"I'6)K:38>#YTDY5> MI(F$P/(;>8=-#NC'U\$[R1?D4J5D(=\QWXVS-# 1NSXV]SZ:'0CD0[CBGB MV2#>]2>RJK@)CTVDJ,I>E21)*685XK#[$E4: 2A.WUZ^N#4)+ ^GH9G%E[ZS M_O3M/R]OB:_?26BLL[8Y^DAEC4AEC45OF[?$7U]\Z:>R3E,[?5KXT-W" (B4SL#GUE,S&DJF M)2"RAN9Z:S,,1J8/CX/_ &YM'\_F^CDG,4\O7+P%N(X<.2140)$UZ6^F%U!: M8(1+0YW\^:ZTD F5"7*7;'=X7S- J+X2/;^T];:+CF4M $ 1.;\>'3O=@($I M%79"->)9BBT +B$5OAVB??C5DE]?%^G[;:A,8:R9/..3,;XU%"S@]$TXIAD< MMXTHE'"!,.Y%^9YE[TS!E9M(]_278HK0 M7BYF>>)FOB MXT04Y(A@V7<=X)D."&!"W?/[5Q](HT8BL;)K]MG\#0DH?S^?]ZD3Z=^F@)), M!%.9_'K2<+2AQX\3?P3;H6(;OC;SRGTBY--;F:&0C;IO&?$7:C-+9]),[?LN ME-G"$@WJ[ZN#EJ]3B7GSXDB;YQB0F2%%%'H!OS'M-=:*0N8EXG@9QF_1VLD3 MBSHRU'Y.E&@;;?A][G.H0^'U9\<^9:,L<$J*C!>3,C'GVTY)1A%,,7-5^VIQ M//#!ZX\<[+2)E"Q7K6UF\D+XE ([C/K^/_LD?1]=+* 65F$N'AJ9WGTTAE(D M)9J>,XS\'$14$,W-U08S6\P$:6&!+<2N3!:,WOP:&&*&0DI>+Q=S.B14 5X- MX\[',$Z8D$F+,I-G4>PUPY#@Y$4S7GI^[JEL0V6)DWBV/X=;ZELX;MG'BP@ M:74*J[L&'$7$%V3B7F54HGJY1 MD0;[]?E<:"$S/:ZYQ&*,6[",V25BZ@8HQ?C874H(-N8N]^GZ:)9KF3G=_N76 M#A4[ZXYWU X(*.)S2BS60QQG24F8"A,& M_,XW:KUC+0(&ZS(6S>2.%-)""YEVS6SME]J-3$;@G;Z%VSW%8U)1>XL57=6R M;>A.D@6029'?C"QM&^ITV&8EZF)S[MIQ>E/I(3"T'';TVQ:%H MZB,=>0BR)L6#GC:NLB;C'?CQ#IQ!(P_B3OB/#I,UI7-\_F)KNA M#VA.V?K[^^^H!DJ!W.(]YOXATZ@PD[*XQ&.IQ)A="I-S%1OMR,\S-Z462C 1 M&4Q$K')U,K)%BBL4=)NE\,[9TX!3V0N]9-XIGO$DA4#$$SRY%Q/$XXT8,+"Y MS/VSC M;P-=2B-HK#Q?4;RSJ3N"*:;U8"0P12\92"L14,6F(F2M61E/EH[H"=$%')"_:,;NN-]\B.\H-6I# M<=E][G9$X="T*11-X:A[7OOIA5;3*$2CNR8M.8ES2++(-#\&\4Z.A![&&S!;+W9;HMS-B;%M(XZJ,=:E0!!8B?B6 MV6KK:LD02 S$*3&UM4QT^"DD9L3&[B?IB)(TA,DS->;[#D]^-]-!N$B[Y7$]QX:YE9G25!"G1BQ=[[6#F-+!(H3 <$PWO)AN6B."]# M:1!P0?M3J(1*"HF6L3XFT>JC6X2'(ODK?.X8.@Z(7 6$O-4^*?J%DU,J\,R5 MVD]\0ZE9F#.<&?SX_P#6B>)G:?7.>-/'$>)]&?VLYU.\2IH>"-N1MC!UIDAV M,2\.WJ6(W%!)'$J9V>C'F&#B<1)4,Y$_.7QM#HV5Q<&)P%QVZ-V]&LHV9Y7T MYJ")N9-)B8,!03S7 (,7ZI@@E$,D_P XY49T[B0B 6\6N9C$X<:4(42(3#&\ MW,QQ8U+.K9%-MHWIEOCS6Z3."F1N7M<;GSUB6=L3>B @C M]OS]]_\ ==KF!VG\G8?2]$H+%^.>'R5VHS855:CPN$,$Y)S%DXL91-3*"(8R:28W\N3,8TMID!WQ."9S$8\8OM, M"C WOD)N9W\.@KM"3-X9LQ7#&FH "FY@8;W MBO\ =*N_G3.\U<>%ZN3=V0TF5,0/I_,XPYVPH21AVC/=V)N*6:: M6P@C8Y=F)BF%-M3HF9$D5'R71A@V<%*T2,3$9CXO%[S&H1 ()).-ISTTG$ZD MY"HM.&)S'!@+AU'F@8#*8Q=B-2U'G1DLAD&B(EQ4W=D"<:&B&5*(14F(Y3B M#4-%N:GZ=34EI&@5[B;&^]>-WQH+7%#,N MS^V<]_\ M8MZ'G;5&S?M;E$./C&71R&;+US4YGC?O2$Q@,' _+U+(:03 M#,0>D^]5A53+8$3 _ PY(NMM7(3*N+F?G.Y+J$A)*UECF]XR<[QHD*0#6]"= ML2,[>C-=AD6+\>6.+C>1)5+EGS\[%$/=:>,]!*1]/.,=: Y&'"Y%3JXU,0(",B>M MR\1G!IF+"(6&^_CB^"8TRD[7(9,P.:^/2II";S.[ZN7'J5'^[*$ZKS^<:00P M#XQ5W_4SH+H*;8"R(]9YS'C2G2$ARQ(?V9B!2ECG,$9F\X!RQIZT=YLJ1VGZ;WC04+)@WNWTF]#%$@DX3,5/CR3%5.V)H7%9+N]_011'U M0V\F]@Z"!1+F)F4E(1<6=Y=@44PH!Q,'C?$U\:5D%.R -6P\8FWF5U=$"RU( M\\XX^;@UA,,2^K$XC$3.L_M/@S%G/$9OMPH>#%P>7$;3L$ZP6RB3I?'O' 7< MHC@)67,P>F9N)FYAI2*E"!/]]M,=(GD+_>.XFGTT"E'5=*(#MU7MI!!$RD2; MR=>V'O3IMB&I,"%23$[7!-Z.DQ-!EG%L[? ;FAC66Q<]7XH,%6,:D4QEHT#" M]+#<[;9BPU!95WC.$B)RYC$@?G7L>3&S>II#%!GGY]V/D,'@Z^-O]UQ!.[NW M^-&UB%[_ )^G7C3T01$U#N$Q_/G04T!)HV]FL_&XLL),YH^03=D[9UQE)!FN M.%EC/O6AM-*G?&\&1MQM@T")D F$EF#C4C:^RJ@D8FIFWGBUG,9'&? M)G.V<8T*DX43(12<1;V+8Z2M"(+N8+#>'(WUOIDSJVP%%(7?/F9IC3!9RS?, M')6Q,Q,FI(A9Y[]/,7D4TBT"P*S#F>3QOF[4B:5449I$4:>7?;2)9F2W>CCW MGVW=0\ B+YK/'T\Z @OC4J3K.VUQ&;Q$RZ MY"VA2'C@]W0VS$5_,V8SD[TLD#5^._P6,29X$D[R0 ^KFB-]]%P2#.QO[0XS M4SX#C(XE&>"1_%G16@4H=IN8=R_5Z$^*,H#&0G&+J+W=)/?)#O7<=-;;ZA,! MNDN8?;[#R:@@*@=)W6B"?.;B=# QI4'TB]U(,WDTA72[3M]OVYT*.F4,1>YF M(R^/.A:]=\SGMDS)#MJ$Q5!4&$O>L5WG&G-YL\9>!NNO.A*-5J(S-WN;GVT$ MUL3)<3[L;;N=\/!-GI(]-QY^TZG07?J(Q4G/M'4:+/]U4CP:2 M4YLG>YC,_A#.@Y&XY8WK9^^,XU=YE214LU,8.OC3'I(1Q.X7SZ<,VZFBD/L^ M'!&Q3ME*1H95CP$XE;W8 TJ1S,JK,.&YOB(BHU0:2Q;\1@,^=0::5OW=^[?K MLZO@=QN;1]MFF""R2@PW('WVQ,,QG0-D';$<1Q]/-Z;5("[!"XPU3UF(TS($ M9CN(_GK1Y@*K$Q P>;FT8N=108DYF*8WWCIB,3 M)N^LFB!+!![I,1YQ?UE9$5@/+RM?!S%1&@PL)0R14'U_CC70YR?^?&HR_M<^ MTQU6:HE77@E!:SQ+L?>4K3B%$AS7/.T7YV;U%'[O28Q/LQ M&^A4\"]BY<57C2*:4.^-L5GBMY=(()4B0D&_-GU7;00>B8)/*S,7-8H=#17S M07C>&:G/$3$"QF89C,\.8G*3>.T@6Y^]9VV".,PJPDX9EY9CK-2=SJ"D$"$- M,7=QR9SZZ4T*4LXVV9%YA(OD&P'YN9ETJ1-/TXOW^*TDK$D#'[?[HDB^TN_;/8O+(>S[08SO 3+)4XGZ7Z M;WJLH$7F\PLN[M$4R :5HT52;PG:1>/#H2T3#B)4SOD>LSG3H02QZ[1'T+Y[ M"3A;LVVV=UI2LR6G&-BICA*C2%!$ MWKE7A^DO&@=@O)-GSAFWK!T4=A'&W!16.>M@UT@5%0/OB,.8QIEJ2*DX<1U3 M/>9-0KD N:DVWKGW#S@881)MM; M:2(0)18@-^VCEJ)<:D"()*IJ6#QFBIHT,-ZSX(WYXGVU)9AB:S6'8.I",L:0 M-"ME)K%$.:KQ5$FV#BC/+C4RI0P7$ MXN(Q'K$ Z6!W%GGU.)(GO?1&&5VKMS$]$_(&K1 S9\K,0K,+)@F-*@A0W5<. M.]X'2P%054;23"=WQ"RZ<2 6X(Q/BKG,3O, 9&3!6*SAWC>DK:-2H$@W?F\8 MCUCDTX2&44C,Q&/S$[2 ##_N9HM3T@@*Y^:"HK/(@ M-S.'?=)B=ZPKPA'#QS)B\SW.C@,SG>N+"'O>L2#8#C9OM%)O[M&H< 8R62.S M%(L$O-W&I6(N(3,AO$TH8S;,F@E*T1D#''O1S$NF20Y3NK+PF+XGD(88J$)] M6%'LJK(:T)OP28-]\[L._P A8K'IZ/MBXBGA7#7&^U3"/Y,,$GF!Q?4;FQ7> M-"AF"3SQU],-_P#C4G 7VTAE8)".9JJDM.(]]"894U>+WF#A<#(.EH6[K#<= M<%*\89T"0<\KXQD[8SRZ4)4;OIC%<1Q5:("*"@9)=ZTY$-4KGS\3O%$ MNA.J_G^LYZVT(C%NTW2=];9WPTB;.-CDO-;FZ;0Z;&9GOQ^\^G^YOI!!,TKC M[^_::@SVF+K:/G54&6F]N1K;,G6^H8<*+;#IFR[N6EF6#0EE[S8D8F]_5"ZA MR57$YL:EJ)@HQ[Z$B(894A"L?L3!,LZ"?ODAX^:)G/.HD6&#F)Q^8YIT$*@) MD'!,SR^ISAU,-#(X*W)SG%UJ+O60N"(W3%VI$T8T%R8*!5#F,%H;119J"P H MG:-\.#B/&HX3OXO!V7Q^Q/E,QSWP0F:'&((94L5&'UYXN8SP:5):DS(<#AH) M\[.'@)&-G!.P>E,G6F*PJ%IQ^VV MBG,$D<,(Q=7 <3(N!+(D-(O$1P,3F,4\ZF-(UP=/(/6_Q$T+F#L;YC'DJ2M$ M0PD_^(H0J(S@_/PLU!F@O)F7,&/$2[S6@$3!A IR4XJ;>^$-YJ3S&?'7OA'0 MKDJ)9XW%N00-A/.4WCV(%*)P MIA92.X:Y2+W=$#_B(2WEDW8K?0($+I>-K?WF6--"P^MH=14='?&E92&\SGH! MZX(G%FE$QCORR^,UCQ.I0T%H&L9.\A$KO6-/,))(7$,TKGOB*J=!45!/2QQR M6=UG5$)7DGEW[-[^'08Q'V74).K EF)3DA3@ES,Z"B=X'&Z#GM^^ MB/"1,C*4-1!LXC$;Z48I@AK$O+.*9/A%Z^ZVU\=E=96-%,D&R1[U&_1/JI9C MU53!94MLQMY=8I!6(C'$37/7,?[D[PQ)G?> MNL9?MJ=62RDK,&_JP08XD6$43*^CEK?FY,;:AS2(8N?G[E8Q@A,.R9@W PYR M/FJ5Y06;5+F6*Z\NDC!C9B>>^+Q*;Z#234"I';+5^RO>@-A)53?YF<+U>C!B M\))C/[CS$3,.@'@1Q+U1$&_'%: 104(A6?4,M^D%:F468.KC#-1 [:$H!'H?B>(,S.8R:"V"4CE\[XN6+>XU)HW&V_[XTWD3%;IY;R7M,;QH965E4SAG/?&TY-2_,)AR69N^,3>^='.0&&9NH,D$ M5B<7F)M8$&3;\V^VE2-T0?U,?O6^IB"B_F^CX/KI^;85BR' M,5@M_AVD1#%($^0H7>?NS_X5#<+'\Z0F7*Q4-H<351$YTX$BJ;J/L$XZT0"M MI"0O+F J"8\Z1HN8;9@VO->+.-02, #,RY3/79=XT6 ^_._PG;FYT2)#)226 MR,1=0Q?.T(.2P/@(_7B6KWTX^R,RU,''F/KI()(1.)1[VW;S!%Z2'$5I9FAQ MAW\-@1I\OOPXA^MPYSI K#E/6*[QD@WWT:8T)N&99Q?S&V(P&.F=[:B=JC?C M3'E).(B)J5\F#NM!(F$#BC>I?;K;69"%PLXXZQZ:=B\;^\6)].K=2B3BH]X] MIJ7L-()G]CP]8^SH5B!=3@%J3(JIRQO5[R]FA2CEK83O-V>310G4#;,%/MW]G2C8)83IQO]CU M!,HRD>NT^_Y,_P"XNT$QZP'0R3.*]Q!7]>FLV+C))W^^)&*U BPKB\.R>[,8B<9,,**7VWB9W](9 MF]9V&:0Q)9">WDRFK0RL*\O&V\1@X#4,-+&;F<:5K"VK!N MS?\ 2%1.E L)#Q.%YC(O^='DADM- M-[T2(#$3B&+3KQZ:;,DAJ:R3(,U'+GPHZ:DBR%>!/]1%XT!!G^/OSW_X.X"- M5)3X+.':4(520&;U!*LI0$@2ML']6-E2IH"DP5$GK,3/M0WB16$@][\7)%:C/!4BA3+WG)P5OH MHE,?(DB.=QG&UZ#!* %$2;'*F IK0$$&X'"YEMB;J(.<&@,K#4^+Q$L&T8K4 M"-1(1FHCU-L8O@T"*BQB&BYB>?%Q&G'/$2S)O#MW2"XTZDWKW_,2<=:FZE"L MT1AEVY=IK2AI($JTEFAWO,[,5%\0O=>(CT*/,:2:"2IK:N>_.#>J")3-9_/W M]]/Y4I0W9X-IJ.62BHV5&$WEB,03CBC>]+BT454\T/MQOHI*0I9$I&//%XNW M0$B!7YM.%F,WVL!BJ$+*];=SX M+F+T(@F'_;P56['Y^B,5NNH*J0)@W3.(?6O.I4F"2WZQ&*VK;SH M LK,4$):U!F3,[:&DHFR=NDACD&)4O4$16CZIX*SBIVU)M#+Q,QUFKRYASD M>BGW^X8/ATH)*!B.2B?7XYK0NSXL?: X!Y&)CD_#>2M&8\F.*S/EC/& MG/ R9G=VYE=IO8N)1>K F^\0Q/SUG3TT3!LC&_N,;MW%D[&5BH3> KOAY6&6 M=\1ZQR?OI$*V.8COT+Z(WT=XF-BW:+$O!S+H'N38-R5FA8F.-H=.LK4=T''B M;\>9D))1B,8Z?4N2-]9>$+++2+MB)\QN5H"$%').';Z21YG3M;N-SF^Q_==- M0*AY*K8R9SQE,O@4K<.:6YYO.=J=$DXWC%%EVXXT09BQ$RF-K:U, MMF FI"3S>W#UR:3("Q)>YC)T@-0ZK:TC#$,QCG(>?$F8V#10U)'H5/(3)H"4 MP&V^\7B(]\AI(Q'<%.RB%W P0!G0(ENB&-Z5#.V>S16YG;%W.8"NTEF78QB+ MPO:''=\7I5;F"2 X(:KSSDT)@P3)6$C[^L5SIL(+2(FO MBX]_ EQ9%L[Q(;"4_/):E#&+H]/SP[K,H28\P\J]GG'<1?'X=7_>DDA2H\?F M\=(]H,;9U!HO?[8,9YNM.JRL&/7YNN=M M;4,W$64XNO/#OHI2'=<0\_E;&A25D%NZTO7]W.DX25W1$C@WNS#SZ@,P$)O@ MX%ZO>\XTC(QE2V3!1LKI1\BE(>4< 50 F]0IAD6LLACMOZQI*2@7/)D-LRO$F-+,&P1%4'J?2U8J(C5!" M(Q9DOB<,85G8G0$P22#=)Q4;>.M.DFP#$[?7XET#I!8SGSO-WL>FBN<@01RO M/$4]S;J688HX-ZN%V]^I0N!VE(KNK2+GU:!@02WXV90W#)4-R9%((-^_/C8_ M<61,L2U.QYN:GN"8F\;T M!I"P]T1(VL;1C8WOF M9^^FLD$QN$WGOUGC;0XC>#-[F[CS-[P)-I:B[(ZN;B(SH#4O9-^M3&/VQJ1( MJL^D^J1F4AF= & C_6 9 Y0'NP:!D#E">Y)_P E 58"UMU:-3"Y:X(69F';$1O+.JM)=OCC[;[3A(!4G!F?L M,"1&9QI4 ;<;]^QM;;UH-82&%M#:!U/$C57I@#(N7<.*BR[ON=07Q(4 Y\XL M&9Q9HP8 $Q%)EF(SF5V-56JYE??/M=:8)QOB)_*SXG5$1/,^CV'$X]=109!$ MP05OO,,Q4H[8D"0=X]JE&.>_.E(SD4_;$3]/.Z)"L$IAMN1%8VO1>3"A%0S# M'7"8B8F4Y+ ,$8A];"XS2;&I&'^B2I8)!$^N0SC&9G5 2<93!G ?D&^@*,%(Q-2 1Y MC4DO0W3>#XGS6?\ O0+.QR\?G["J!BT8_K.)HN'20A97^_%=3IH,NURDSG+< MFU]QI&&4,[AO<%RXJ^M D@+8I*5%3#.P2YA;U.!,(S4+%XL6#J5WTRQ,L<_7 MJV]LV&@FR9*QBH.2=ZW:JD[XARN8S\3%FB,@B8R;/,8\2-[RJ0N;:V(VN]N" MEC3Q&H&.JB)-K'=RK4*,T#*B,EUW5SMGO;P4VI6;S;>Z>C#,$,\Q%]X?8YZU MPI0]:V<)/#Z=,W!@]S;OP5+Q J@0Q!43%>[[YM32##$RGY) MQZE1OH U?]XD['C3E$^B];7X]- DJB-U$XY<3##OG4!*-N4\_:GQ-R::#DVC M/AW9E^VGK9ESU"W/P+W&D F3T>_SBLRZ!X8RVEVC(U*.'TTB!,PA-^QM7UGS MHC8)\'$5[3Z^?_>#('* ]V#0,@7PC MZK0HVP5[N/#H^C0#P+B%B)2?U_X#/YSA^K8GEZ:HB"!8A!:8TS,A^1">&&$V M9'_P@7#L&3\SMJ9@3L1MBN[,1AS4-$#VH1+C]W%UK:G3(DOA.>1CTT0R6H-X M9*VCKJZT4,7396\XE8])-M0U$5-'S^YU/9O3_$7 MMMWE8U4"+,.9/G:/=W="J\HRD+OW7/C.@$I#.<%LU/? M&A>39A+\DS5P[ 0Z02PS6"+VH9RV1B=+0D)*DOC==XCVS L;@]##N"QDCQ) M;!"6,KM79N]B-*ED5%U8U\I3L1RNS0RCTWP8IB3,;:>P(16:ZC;TN!\2QJR&PJ(PE$?/&1,9:(6<>#& M=_?'_H]^M"6[J3 M3-QB9Y58Q>J(03*Q#6,\P$2S P.+OP9DB=>F[Q MC2MYQ3F?H:FPD!?9X_B/ET?H"<-[<^]7S:Q4THD5*N?$$STV&HR;"R0%^N,8 MP&W(1%APX.#P\>M16D64 D#:='GR3&CJD1-E+B2<;N+;)UZT'C->DYA)C4LS M*RV4U9/5Y]M3RY_:(ZS][_YGGQL0HP$ )RS,[1>J2M1RZ'@SXGR-($B 0UV! M-.)$N-Q^A6C )DP*$H!8R@3P:-]?$/NT,2,U&,N@6J)%"&&$V9']/F/HZ_%\?^S-B$NC+;=ZKA MA0E<(#>GMQT#++)(D.JP5 $8$T%520 (E * 0@(80?HZ.$A!0,8"2"DQ,+ MSH*!G(H?1U5&*I,%R&,I8H.IR4$Q9Q>OQK[Z&0%7 M,O@'_DI"]4O=E.LLYUP5SL'.TLOO]8+:PDSXD&>HTA B""(PHE)V:_.D.X4\QNQ$+:P9MKNP%5/ZP7#4/835X0,]1H\9I" M!R!1.Q_[9^H5FH^:TUE?%'V)]LZ!TI9"OW]>]F-!"@(GI%Q=UGOG4*(K9)0Y M(]VB3F+:B!RLI>^S;'-[.I<0P;.*7"N9YYLD(9+"8@XV':F+R[NA(W1/*2S; MB.=W=T29Q6^?MF/G2Z/BYWNF]F7OSHI6>/V<=>=F=]5V_%?'[.Y>E!$1%K?. M>,>MNI.DE.;/BVB[MX&$BJ8]^*<^\WK!D2"&Y$;9!5DG M<3EEIJ*F"%V;UG9YETP(B))!""\!0SMG=(T!&17> >*XACTFM.L5D[HQM#S> MU).H4VFTSA:EOU")Q.H8K(FC:[<$\NQH*09B,G&\.,/MUIH*"/DF+V)9HO0J M0A4IVD5DV;[Q&B,59E)6B3B>?FPE)AC+888Q&(&+)JS/IYP7.I?V* I+ M.P[1= '.VF(IN!),$I]8WIVS,\4BRA*/.\MY*VC4BP$[&5S%1!Q1M=:")9C$ M1GT@^IP@ "EHF$^#CUF8DR::B64SS$/\7-R[^(OVE)DB&%HT["-I9)N"I.; M7OY1G+XR5X^N_8*#.PS<8]=ZFOC*E+6+=[F"0RNSZ:(5))Y58JYCCA)BK9*A MRDS5]SWX*T)1V5^4GT_,:2":CUI&8K,;.(WG3)8_(Y^KYU<@=<16?7^D,V-5DXW+;]8#NI;0HM5D>,9CB&8$U(1?F?CSU6V*T M1:EL KBBX3L'Z1GF1$CT463D[K8T-52J"CM<[$QF)G;3!VK%02./-;_;1)5- MY#G.YEK/KIP0]=^?;;>_?_HUN+Q'(RBU5M6UTN3(D ^R3(V3)LB5HT@P0)@) M@"$(0@"K1+I"-P!=P%0ATK:CJD,D,2",())2#I8A/Z*$2,B";V+.+U^-??0R JX!E\ _\ *R#21H9B=I-3SI0'W LQ M; YJ_P!8+:PDSXD&>HTA B""(PHE)V:_.D M.X4\QNQ$+:P9MKNP%5.OS'#K\7QK&_.]!J66H0R3B1N&?N#TNV <,P MRG"GS")H>LA\#"J\4,S1F?U@KJ92H^)S(LI/0Z9F)XAC;3V1TA2P AVJ>PH, M8,G3*S*O4P@,3 F!L$;/^V(Y#//Y4_DZ8,KE;DZI]?!F-1G,;6"+NSFBIC)> MI(%2H5?/S+;PUJ>-B(C,LU?H0Y\Q%1#BMWGDECW]70R@4#[8NM^)C@QIZ'(. M4=)C"^'A#2C'/[_7V.D-)W_O+6S]HX:!<>;(K&\:$+*K^OPGXT"'7-[Q;ZXC M;.X9*YO/9DYB(\XG3*A$C7O(R^SI8$;FJKP!?C1L6V78A:9M.?6)&984L M331$6;#N069IW%) MLI5U>_U]8U66'E_,7=L8/^E0)6#5L9?F^- !$1)]].!!94QRSG3&53+?)++> M#-Q'TTH237K6G.3$I]WJTSE\3I@%[A]GE"V M6.'L+B%8GUO:Y>#J"(TN<)B8F%K%&8W'UT)!$F)D*IF6WJ;&I8TM(+!.ZYB[ MSFK[QIB#)8G)ZL_QUHCO$^[$/IQCLS!93-]?O[GMJQB:;_J;W\;Q6IY!)X]I MMYO-;YTS8B;G;S?GCWTI5O4[$?EXVK2)G065F_'Y_/JYL)S6QL-&"'C%PJ69 M!1(WEG,/IGB- D1:F^+-SEEJ#?5L02WC>8ECUO?:X1 @GUFCUR[<& T$ G( M_P 4?0F\.@34XBM_+S-FB0N\OYN[[_W_ -.N\0M@0EA5S:5H0ZH T0$J,*=PDCC@.7!'-93<4K^CAR34*! M1 2:H!0U^B=M4B+$R!9\@[_09,/3@F7L"RDXJ?U"\EA))BC(QXT@,DFBI 3B MD&0P$&PHAH'A^POBZAWA@)RF=+1*GD;I;BO+.^H 1=PR3B1N&?N#TNV <,PRG"GS")H>LA\#"J M\4,S1F?T_,<.B6*78A G.(@R(V3J2!$IVMHMC.7Y:;B:PHD41#98)(7 R#2H MJ%K4PL*#0 _^F;@>#Z?HHP#B4!17;H W4-] PKKP@SZ'UV_1TXZ0H&H+K("! M W,"F0$\XA5A(@P5*8A7^X0N5WH@&X,M1CP"@, 0!_>E 58 57 %J^-(Z266 MS*>GZM5$0H00TD209)$G(ZW465R\X :0EAM^L 5 RRD2X&9&2"**!-2[$HH1 M0E8(*@:1AX%)860T0L@)TZ"*AD5#N!H/Q3#M[+&Z4?U,_G.&E_Z#')Z Z;T0 M4H7""!"K0W?TX+I P3+ADD(@;E.^K1!RRQA+M6]/_""X3"!$U(A%RC8V'FTB MEQ$W4#V(' !B/^VB(4$]?S/4V7J21[8>WGC\G0,B$;28FI*";N,F_P"]82(.N(R_6YC;D0BH7,?#-QV_)>@$!W[?Q97I MRZD8-\E]9WB*B-M%@8NI]>/M!WP '(!A/O+2SGGC5N0L$'9,E^)B/!SIU)K! M,C%D1QOY]-$(NB'V(,%^N:Z1!)6[SM6]VSLE3>E+$791\BSPCB"8D;9M,;H*[5?Y@K[Y_Z,@9,,3,A?GU+U$2+A).[EM\0G#. MIJT+S87M<;S4P+6R$99N%WFR=R.N8TH$=R&Y1$>>(R2[=XZS#1RK6,!%,;1NV3'L*!8R#N\ MQ_&VS.) TY@Z-^)Q^VF9B>;WQP;\+OMIZ@B)DQ4?-_E1H)B*9NXXB(M]NKC2 MY&=XFHY\SJY(G/(UC:ZS4\DBWB8X6KX2X'DFRM,4L)^ZBH#%$J718 M@2))+624PF?J=6AOHD0;2?A/ BV"'%F)**2([0*),!3B-)WW"&S*K!&S10HQ MF@L9*@, 2[ZBZRY;%@&++P*8TK(*!=E")HEC!N:*O!%6>$[=D$*H01?\45>I M":]S?KKEL0!"@,*$%@%BJ2%R<5X W9#U:#I!8T#F^Y W$W_0"02 )#@91&BA M!R:_.<-5E0P-CF&R?A@6":8*'<0G#(E-S#4)9U!/PV!S Y34"9"$A-4_01P$ MB)Q7=P>/T@@8!!$D)(,I!*8DG)^CQ291J@WP0-B,#1"4E1(A0[R7?_:4DO)Z MW+[/S3MH652XXS/M'S<;B0;&6>NIX/@=]*$B@;86Y+Q!,1$YC&I 88&9B<&Z MSM_,:.23*U-C#B/A-\Q>DJ$"*4\CS3M1ZZ:=K!+%D01XY9S$XTHB3Q-OO?UT M6VQ_/C/L1OIJS%+1CCTKTW\JHJIHK\OXF- , M[]R6^WOPUH"+*%D6U+XWJ-^]3YP8%)<694AS/O6FR(WA'3R")>[USY.>VHT9S(Q@A9F8X';%\VPR_.,3B*B99,2$M: MAXB,L1)_>>@@=3N/9=UJ9BCSJ3T#^7S[D;)I(8?R'$>P\4-5=$ED_.YK&-+, M(P_&_>O@GFR@./^G7>QG3WB$%F'"$&-5HWTGR*DR6)5P")2'M M^C8+;KMQW'9(!8 1!TQ-,A&:A$@9)#$!5"R=P6"(QYA(J"40!HH48S06,E0& M )=]1=9$#+ .(2(DL*"* $;GZB>I. MX<([( + "(:5Z"AIDM4F#V#HDJ9DJF8!:F %K$7I3;7C(AQ* E)0%I^H$N$2 MI;5T@A1@#JJUC-9B.UO>?5:+FT!Y;DR60F*ID2HZ*&#T :2 PME,AW6$G80# MHV @32*B&$M:RI9=3_6,#A1&3(&DA$)R,Z#B(8X'9B';3\M*G/*;?26*4)UA MD\[H6]S=B_K-"04@*29)$H)K1+E;2(Y'@V7$1$UH,!),U#$9R$ "%0'P1:M$ MSB7U.,:/W$@,RP%") 60H @ * " *#_ +1:]4YQGVCUU+(,S/C'I-^I MV3C>/B/7\N-&RI+/'/41,Q%.VD2+?;/Y&F%9,\GM/UW]=0*&\(Q>P9H2,,!7N&]S.:9]50A'NQ=1 1[( MBHSI9T0VLBQ_ C&B2.PH9Q]GEF=ZI48U'%-VW@S4][;^= ('AFWV M8Y;C%D:!%EYV]V %=E%KK4J,(!W'KZDU'_$%XN7Z/V^-2*0@W9(68KP=D-]Y M@"L?#MN$1Y\ZI [T>A&Z1VIC$2F>E(IDFKKEQ$M@:8-7.\J5WJ6,Q,XU$CA! MO-".(N/-IRYX)9G97FL<;F(U)*CP;WG^BELKHD);<]//WJ^M,H$,D,\_MZ]Z MGO B2!2_7,[YO5/%&XQS/6<2<.L:P&_;/5D,Y7Q4!#-FXEXM"^Z-Y-0ZJ!DF MPYQMQ>8Z6+97:1Z=9H-,E%')T#'HL+N8XR%RE$\+,SF>.9:U&LEP6\S MY$\("*Y*A2# 'YQ]?T)ZD[APCL@ L (AI7H*&F2U28/8/Z$+ "1+%B,DF E6 M/U,UB$UWBW !3"E&B4.THQ*=T+>YNQ?UFA(*0%),DB4$UHJ:F6).2!)D @1!K3L:EVHE( M"%@"!8$EI0H>(FQ2_0TJRK'X(L-.P8)"6^F$;!I;!!+E64M%95_P4U4F$=8, M I5!HW8$4X)-&/X9#II70H0H%<5SH 2 SQ'4PP%J0<4A!AG_ 1N;Q^>W[F^ MK&X?I.Q[QIV,3]?%V?;O2RQ1\=N(Q&^$B=(:(GC?K+SM&T)O/<.2G;'6(C/T MU$06?F,?;YT5S59\YE]3RU$T"89]8S<1&V9S-1J JXW_ 'NF?3;9TE,06F?3 MCUN^9-,994BI4=K.\8.8B-*2U1"7$X9YN'U+/?BW9TH.@QM;A,7 M6<4+G0 EA[S^_P :%0EI#GG>Z^T9TQE"$/2R\"2>/.FFFX\SMY.J/EU)G!.9 M@+LLYC@04&]$0G.?/?[SYF92TJW*$\1$0XWS]-+2%AV\AW"'/G+FM/EC-8BEWS,2@8# [7$ 0W"$UF&)8B7N\2QR.(69O9QH(( MDMZ&H6>H%73U."&%GB8';YU6S4L[YE)H6H=G!!7_%D"F"3 M*Z^8);IO:MC6! V*7C?C&\\7J:B*02;F#,J["E%@2$G* M;4HGQ,Q#'H0:#$$%QSQZ=P'#J0LE8O[=\R_.@:R>%FFNR-'1 29+9WB6I)B< MY"288"5(98]2-MWXT)()S-=SBMY,&S&E>1R;CM.?2_$QIFI$&!PQVD3Q[7F4 MB5%"JH[THG%YT2)02!$2[OIPD55NH#F%P9K,_2]5++M^]16,_P "3>.:^RQM MU6JQ(C!WJ/N?F[*,JG#8]=[WU3G!-1\PS\M63%F/^!L"=_7\_;06WU_=?G01 M1_XIJI,(ZP8!2J#1NP(IP2:,?PR'32NA0A0*XKG0 D!GB.IA@+4@XI"##/\ MEVR (I3(4(ED4.EE2M18$[P4&\"[&C0(S"3I'',GPF@NW X#E=T;0I:5G_"= M1,LI&*B8W'=B,\ZG30D70?1*\V6$F@4&$B*^^(]KOU@(+Y?SF\\>OZ.U+X-] M_M[WS+!<.?F?%W\QUWD9TB:Y'F1ZV=LW6^H78 M;13[_7^I*W+$K&!JINHN?$:\L$UJ(C*$69(IS6)CGQI@FD89&'S438(5I-B)W4 M*]66YN&V,Z +%DHFKFKLQ[<0SMP%>(GO'[:2 M$%UAL1$=4!E XAJ\;29F6>-0Y. M% 60N^8J]_64T"P4$YSL^O89SIZ-D&>(C1L !B1&8 M),$GQG;1!FI7K_3O/O\ \4$1PZ$DWFE"]PU:@F()=J M\7O>8+TL8K:16&(X@KKQ3IF&+("!OMT9.;WC4BN)]!BZA/V:S6B F8&;QQ1\ M22].I1"QF/,_,TV4(SG;4B485J(!@D]/3+;.GGR PQ&!7@.7CM MT+NG *3!Z>;2KA'0 T1[3<^8B+6"=F8@]#:VW^,_;2VP<[1UY\NT=2&RI3<^ M_5DUJ$SNN(O$O,[1$N-'83,C<"][8_@8 AOL\_?ZQS&/_.V0!%*9"A$LBATL MJ5J+ G>"@W@78T:!&82=(XYD^$T%VX' .XCUWXXU!!Q V28@GP_%NJ2P,V%(D,4UXG;3"!)EEMD MOQ&A6AN@K=WW\8VE-!Z"(D84;BQN>/?0C@+"$ZJ(QU.9=%"Y+("/*W4GD>M0 M+)-EEQ-XEV:*]-&4EWV,S5%\QMS+H4B!'0F]M55S=S>BT5),SC[_ #6V-.@R M()8Z<7^!Q,1Q-NU;SNL\_P R';)D<\"LXP8B0-)"R8XEFJGRT>4FYL"44AM@ M4]KWM9Y @BI+R'6'AZ@]1S:A\UF.[=O75#B0@:C#AQC@WC;25;'VCZ;7&JB2 MY5\0BUW?CDLPW(??]_\ E%B=MOO^9WU61'=[W,1/P[\A(VIFJZZ:+]33M-"D M([>(P/91IPR,0$K#'&_K+QRV5 F9N=MWWCUXNAL.F?SU>S@,AA4VX_:M\XRU M' @10H[ZKXVV=*)5LX'[??4!,5'-/GTZZK.B#"1SC'[>VTNS%0LJ1&+GI/LX M#0(#V2^]!P?733U5@E=F=\EP-$3SJ 2",7)NDQZT;QJ(38;9SCC9CE()K5"% M0!E!V]\,T7<)H116W ^I>YX:<3BD3B5P-D3B;8@MUL,S+$R\7G=B-L3$Z48# MP%9'.:B>X+QKWXKRA;X^L9O3)6:##+0[^GC5[1,+PV9*(WFH9G5ML698G:0] M8(X+P::",2L^W(86I;5-2COACJ,]:&U0DP0':SCBY:. M$$62QC-;?)ZG"*]_,CB9K8,\'!8IMC/B;G+>*7Z0QOQONF0MA\?NQC M.,W,9A;3$]]/=!6HE<3=4K.RQ%Q#K'K/.^BF$*V3'I;W!F=]- MF14$C![W6^8)G)--_7G;.U5"3J.@,CSN3FI(OI8U!5$BA!6YW$U'=1J@@N-X M3:3/?,\NH-$3F/'UW_*(A@(_)7Z_\L'YMK*8!+SM'B(SB'>= "ENY,MV1GSB M_K84@&41/6V<;IL.AJ3:,9Z)GZ>I6FD9&6\8DCPQN,,L:%22?MQO\15;:A(L MUS^+J"*2&97P$\>.>@8) #-@WWC:<;5-BPP1>:VV//CRQI6%;<#L>Q;^7I*R M)EJL'G/]Z"&&$F*GU0A*YG%5&A/#=,A$RS/I7L$]Q7SGI=21*#:;W\ MSX'G%Z5-O.8]L&)*XT LF,8^8H\0^^HJ-T),&]9?-8BK-$,J(3[YCS7YG/[7-"I' 6(*8IDG M,,RR8QH=Y%)\ ^SUY@TTN&J/O'+3DG&-"]V%@W3>: M% IU,2]EQQ[^B9-XA8XE[>XK$&^AMH0OYL^O=50KN2N2B^ZO?%>D<(:!6^CP MN>:NM"YQ.2OL?D[:%3!M9]H#YQG;4-*$C!.)SRN'W*=3,6.R0'KX.'=T"B7N MQ#UW_4((F@AB87TKAG>:V69MT1I)#+MQQMP15W&B= 4\&E@B;@$B=LZ)3EC8 M;;Y1!FV9G:X6B!Q*372Q+/#G?.B>\MQL>G-7WZ/_ #,@_,:A4G GQOGTG:P@ M=!9F)N3KQ\\]IJ*U?K^?D>HB 6;(>[8DV:YG?3I;3L7$QQ4UM&+FM+"$&8A, M-W338A05[]?$U(:$U5[\7)$_OMMDQH"&U(7QS#,9S<9TQH$"LO$C'. M*^I.BR$.9-XN8N>*(ZIEF9D,NRYQ5-3.^E452PWRU'G:.."-5* \^?F<\_N3 M)1ZO6WQDTFQS_4>/$]-.D"J7K&V7TJ8S.-"F,$["[;)&V;RX- %(N*(1DVA] M+K!K:+(JBXG%)6%=B'2A$E6,P>X68VC>G4F#=AA#-KCRT,8NH8B 5_KQ[GG6 M"![0_/MUJ#@]C_X")H5;OZUUT_4TR0$#GQ9U\$FVC!(1N%F\#Q_<&KSP,.%; M1=;%$$>(T9L146$X_/;3%@*1-OT\XVXQ#R;>7ZW/*2H6KC4@@12#LU M")DHJESF-T,;U4N-$CM3;!C,XS)1-YF'QI;YYWVG/.8B-!B++#<=F)SS;0SJ M!J X0^OK*R8>-3&;"8L2*Z^O.VVD8,U$29;O'8P.VL$R@P_=*VV_C1(< <7'89CG^DJ MKR_D;?\ .%U_8/N?&_KH2!73^?'WT\A:>B<%17>L0"7/,U.U9NW?4@CDWW[G MO?UTE41;Y2#J;GP;3!C3#"$/5<9O^-N=2("&X-WWM^/#HX@I#AO-+U#[U+A? M=(F2WH_//%*"6,;9OU]8Q>'185$+00UO[_31Q$G]RZPPY06%_&^S8-+(P([4PMA,=W(6UI(!0E9AGYB/KCA 1 MGTGB"+X_(TR**WBZ>BO.*T,:MB9*CL1)ZMGK0#EJ.+CTQ_)F="*&!@AKKGCN M]/*4FZB&Y">YZ*)TY?+_ ,/I_?X:88D\1'U_G0!%2;Q/>Q]](E?P_24PQXT* M2$D!ZS?TF:KQ!)8@;'?C;K;:>K]_[WU!RA8EJ[FF0^=+H\I@SV5([3P9U/(,,P69[@OLPZ3@$8BQM MR3$8G(!9$=\(!G/KC/QQ]-! '!'ZYLAY-=EY+^9^FDXM5A&, M^)ZQHM199@QQ^R^YOJ%@YOFJ?WPS\Z;XDYYYYZ*X('_X*A3O4>OGGUIBN".&MF.]"I(-SQ,8W]9O%%Z5"R<-S,]JY:'JDT*0 9(S6<=YF<[.FC K'' M@Q7?AU#R!Y_9<^:*YMX=_KG[?5K0,B"$^;_/;0 J8@-\\GISZZW0%@B"9F., M;3[3H$4R52[7UO\ ;TLD?57'WQ$1&>HT)#)[K69]-\=2&U>:WJ:]L73AT9T ME9\TU-^U[83#8((V_J9KTG#,2L>G/>[O@?.D-YCV"HWVS/#ZZ$@GCS!'/B?X MK1 +?'C\^@.HV"\K%5#UONXG5'K,N-C'F/>/.A<[-SS^?SO_ ,%@S'Y]-O6K MC3NKC&KI*MBO!$RQ]JT!(,*+\D3\?BZ$H2S4<>E;W5=:)\KZ4;KC"<83S I M52BS^8GE6"X-0LO'!N^OOB,6_P#/.NE_\'GVXZ)WN-L_?F= ;>9A*SQ_!UK) M!B*CVJ9!V<1>^@[-=,J>EQC]]/IQL^7CXX@N=21-][G\]?J:Q^GQD]ZT46]G M+9_4>E:'&\!Q"W?.6+GDK2(0O886]EMB')Z6B,*!PWMG".?:IH5RS5OR>-Z MYZ/C'Z),$_G&=6PXW?V^L\.A/4-/YSH21.+?ZSS&FE./U/)BZEB?C[_30C5/ M//PPKWOWI,G&-X_X98?GY]L:KD$*2GXST8T<'$H;O,<_3&FD4;ZF*W[@S2QQ M*[9[OX)CKOMTQ)(W9(B^.>?J: 06[O\ \/$O-P^?S\K4%+ FZR#L#Q3B$^^B0D+6S7SU'-9T%O1N9%K M/IZ9K?5X%C3\WXKDQYU:")_/6OMJ(10E;?G\N<:8*(=WDX?&W?I%AJ&L^A@[ MS$Q[:!$MA]T[N=O?$Z62:9>N,4\\F)N]1+((,V[9N7KOQMHR#/!UYZ]6.^5Y M4XBIC/WP]7JW@W_8F6]W?]?SVU-9'-) ^F=P^L:)N((CQ_)B.I'O<014? MGRZ3#\],Z( 0P,OMC>M*N;_YRMUF8YO)AF?>6-385FJA3:6"LT^C6@1$OR.Z MN_B./_C4$0NYC/P8*^\Z0NA](QADO"(8*TXD862#T4$?34/-BD&Y7IXV<8NU MY';Q7TE\Z$A.;CIVEO\ -\Z&3'@<_F?-3&@@ V(]OTQHH$0G)T8S'[XG3FU3 M,69VNI\[7TAB"((#*_Q]^=M&QO'Y^.D2@,RK,5CX_/&B;FWKP8GU_C0R8C\] M/T&,:'-M.?XT0DY=YSS;AKK18-L7WSY_K1+/S. M>?7]]2F<)//%K5?U/ 1+LFY_'X^GZ$RSS7Y[?F?^01/;/Y^7_P#)@$.I9,^" M#YC;1$".?S\[_P"9D\Z(P\1QB#\F^.=-"G+]?IW7VU'F#-GCOKCUUPYZQ^>/ M_G JD?S\_,Z4(8_CTC/\=Z4Y?3;_ /H19J9C>,3T\Z@Y^8_8USU\#J7,?PV9 MT"80D621/33N?@__ ([G,S,S,S,S,S,S,S,S,<*0W%[$3GS]=*\GA_>==WP_ M;4>7L?\ SG,5W>E?2-?V#^^I>7W?_P 7QF9F9F9F9F9F9F9F9D+@778]G0_[ M#J@(F(QW^Y_\WLU,QO&)Z>=3X>_\:ZGSKK]C^^ER)@Z ^<_/_P"$,__$ "X1 M 0$ @(" 0,# P4! 0$! $1(3$ 05%A<8&1H;'!\!#1X2 P4&#Q0'# D/_: M @! @$!/Q#_ /UN$I?ES]>+1/P3^GS_ /G*\AD$*A0SPJ H)]C]'61ZWD*$ M8 M]AZ?WZXXG0@^I$[]S[<,+%)$59 NW/!$$:.1/_P V&1RP^#XX#B *Y^%RS]- M_P#;U#:'RSDJT52^R_\ DX& HF0LLN1OGJ:DRE($( *OGJ#4[Z[X(@C1R)_T M.MZ"67J/CP/O$TG D=/US_GKK5,!%HE(8^<9V=[Y3P.$4WFQ9IRWSRF!X:QC MS<'?X[8<5@0)E Q3W-!<>O%.FFU^!=F/;^O!)(*%OX-OV_1_[9@W!C%L\>M_ M;/$M[@!4=9(W^/?%6YUD7UJ/DQZX )5.LM\YOU\ZR\+M#PP;Q0^??V+Q:XY^ M<8+\:_M_T,1*@#2X8GU_?OEN -O5,]G^/G@%GURK%I\8=WZ\0&Q<0WQ5W@_< MG )C4[N @.B7Q],CF*A0H,$U>XF,_/! T2,5E]]F+GXUQ&)'!M!'ZSQG7U8D ML)8&)FV_C/ E8A7&SXXBAC\ QF$7NWU// MUTNN]KOZ7&>G@)! 1-(_]E8$# M:H?JG+Y",#"G5O\ /?)8@4!@0&8\YNZ>IS-(,G8O7CYT]R\,-QF$%/[[<'KK MF0%$[.[L&^']>'ZC*:V>(XGC?ZI<><>L=\:S4(72KX=]/YX;HMQ,5N=5_?WRMP A2J 5 \D"9T^\Q^/ MFWE!H1[ X^N_D^EY.^S'X=7[G5[O&T #DF"?:(^;ES.+KH#=P$6YN_\ L,C( M7:=;[X&$'L1_3^A:@B5,H=>>->JB@0? ]>K=ZV.:6X=?Q[06/9/S)RIPV1!:8-J;S)B\<30"()U7/>?UX4!((\7O[9^/1P=@ M063LQDWAG\/^;;D:%2DP3>]D\-X02NPEQG-;-S@0S ;^-YF.M?:\0J] T6.7 M'J8R>>")H,FK[4[^@/#H2P4JV+%SO:GGPI3C .Q[@^+ZGCC\)LI7\IVW=?KS M-SF IUG^9^W&NEQNM0'Z\8IU==8/F^5G3['=(B$DP'[?SO_ *^! M\0K,KB3S+WW."=!() 77QJ8Q/4Y=*Q8+E?.=_4E]>WR5AU\??'G? CJ?T\<+ M<1@]2'QX._=XR5PF#\=V>)@XW ""8]3O&/H(W,Y"E8-R_IC\G8;3#7I7^D>( M>5#'UXU4^ =?7_DW(GG@A>9(+OV>==>'C]=M!.KTKCWK5Y0:" $,,4T;?M+B MP>0VJYF[_;YE)LC04+"\9\'?7!4(H$3L/G].^:0I*V7%-??.[WQ L5F$[P9] M]8DD\L4&,2 W/,U_?$#DDH!Q@T;ALGN3/">)0A;=W,P18+ZY\5I)'8[OWO&' M N>NY=4_]]\!"!&(RX U6:CDZ[_ !?*[&HY M6 -OH9[[V_C@JAHY)-'G_P ,_(ZR$,XKLDOM_''"\@S*-""ND)7/ M4^FSUP3!>\B0*LQ(=\031LO+[_ #BJ^P!9;U]?[\FD& V_;KWQP!*79XSG(1T= MX0X>-D;4[R]GT_SP0+@EFV 3)E\]?/,)(6W+HS]4/W6_\GC$-'RD[^+\R8XT ME!_J7Q,@AYTGEY.U0)8%?_/FO&^579'ZN->'X\7@%0IQ ##3O TNN(L8AF0$ MOC6.CYXF>%6G9]^]&?GA!, *ZAW-]8\PS-CF=(0I@ P[8:]LT$Z^!"2TE0=- M&/*[- F#"$K&3-]?;A8&<&<9S?6+G,WXY-QD0,66-3/KQ<&T3TV7J=Y<./CU MY8X+4.&!-[QBOTX3)25%N@N0P>_QPP""F.LAZP9_FN8'.9E\3O6+)U-:Y'5L M 8X"3WCD#H[2 ,_3##/B9$M$4SI2I]-9/^P%Z F=_3]?DX)'G .G&H?1Z[SP M:@6)(8\_?W$J<:BIKE'.7$S^WXX%0I1V1WKK>7[:>=Q;K+/%SU/.(N.7@9U< M@(X7&M=!R\L,KG"^;[Z^3WBV6\$-7UK;\\DN&\%/.CNX3&6 M.3J@2 [>!M*?YZY!!$Y4QXSX\E.IO1@#Y />M3'V?GAI1NF,]YWOOU[XMDAD M4V=N7^:R\4!XHIMQ+]%S\\Z2,&P\F?KG?TYKV<(6) =SO_(<6*MA>11P]$^I MWR+T 4CHQ/QX\7_DB1&53 #?(QJ:"*;,=U^*<3PU@6E[CW3&9.*@R)"1 M%F[?+V.]1P6HM WY'1XS?'!)/3P&W YSX]ZX9WPZ0IA9[^>^IS!L,3ML-P_G MR7E#V+0 K^S\>6SCJ5T"PM$7..@N!_0M&@ZPRS/A>!.ZM2C1O5]2+'D,B M:"4R%8W_ ([."BN0;;:-V'OV.970@HBF&OP;XB3<*U5@XN\9U]3:01?DQ^$X MCJ,^P #+U,?)[[E;IZ[+H*=^SXX9%0QA)@-+B!YKB7AVD&1OO?O??A7,, PV MH='OQER=>^$,0"@VDL?>>_\ KY4@*K@(7/*E!E&,_EZ!)'+1XP5JL[^'7CQ9 MQAJ,@81QOP7?AX]8197H_N+/UUS- #LV8AECT#F;+6B7@Y!379X'UQ@M>4/ MY/E<0ZX"(75#'S/?^+S[VV$MGBX[N_SQM/D&Y*'GIR$T3 M/ T,7.76N^77@$#WK!\]H.\:H)(H*O??CO'K5X4 ZN2H[$(+COX.9:3E1A: M\ZS>_K P)(=A<&NBGK?7 JHY-)N =;OG)QZ<7/2@XM"^:^^,Y(XSZ^/1BVU2 M9?\ D'O![*"AT7]?/+>DK8V63:Y^O@G":Y53VLWW?>NY+P685)'3O]OWXN4W M9JNUSW;^G&PYJI@&%<'QNZMG#"J,,,%01PF:G>^0(>4*&6QC%N?O4@HF(D=2 M=1U<^?B(9B]C 3V0SKF2P"[5A.874)?@XQ+3$@4I5"#:L.9&@SD.YD]Y/I+G2*0&8!IOO]3U MP+4RP.R %,(9^%SI4&BA$FX!B'P>3X[7-,+-'B];_P *@T%1(M#5OQN0V/+$ MS,\G6*&@1!=07#;@Q.*11@"#1=H4UZSA#DTH M]Q BAQ<(R!XMU[LP 5#15-9IUX'/F-!01,(3/^'F1[1+-("_7OV[X.8W(.PN M03)([\SA+.;$Q/8N#.B)E\=>R/*V5P1\FV8#]O/=LQ(0S?F M/BA\!Q=P9$%90F.M9S/7.L1*=PMN\T\P?0 T#);Q,WR?.Y,\;)6 *"5+Z=M[ MCQ6B50X"!?@#^S7E9:,1A.F,2EO@3D*P3#S@>3J7ZWAY'6XE*@ U=[=KQ&J) M&]C#MC,NLZYD>.C)FI0'57KOPNHB >@7'N9.J[O'0='J(2NR>]?L[\\9H5"0 M4JY 7TG#*(H@Q"1+DZ:/0"%U,G6IE#LZYK&(*KH7-?9;V\GH5W?6W>^TX9K* MY80GQ6?Q.!83 ("^L[U0_;_D!4W ^%^?OP R-(+KX/?T.4:X&X^_TQWIS;P4 M@S'KW\=GTP3!P:!0691423#IE\??C=)D$V? 5-]XM@TV"T0P*^_KDEUR+"/P M%UXDF(7WR%PS3L84.NE+PUX$8VHWW+TZK\NW7(6B!F.6[[QUP7B6H(,FT^/$ MDRW@9' ? $$ILHCP<83@"V=7:&:[*^*KY5;PA<\)$9 ^?I&G_ +.8*%AI=A]>*F]27(]MD>G[ MY>#3[T"_4/T_ZY18@(NV7[?.*9G3HGL][)\YGCA@D$7JZ?_8^\<$WU$D; M.A?,=ZWR"<$0.%^$^EZH7@A0,"([&?\ ,//"E&JZ3,M,RGST9XE)8SA2.:,J MQ^6PC!E* LMG8WDP8.[00@+:DH-].I^>5-HAIIT:@B9!!T7[[7L>@GN64A9*8Q=NTY@N'6\"2?'6\V3EK M3M&+$=$#R_2MOL%*!:C8.@\>IP@E-S1Y.X8E]7@(MX(3[PS@UC+C7&H:23_W MT>^-^:QRV^_GX^NIP8&A*!!*0FBWOKFV85]!GZB?\@[P^0X9,4: (HSZ>GX[ MXO0$Y7YFY,>L.N#N21U]4P'OB(B8#,B:9--.S'DC1=V!$#!E GB'E#3MX=)&@@)RP4^&?;',H719-S<+UO]9+ T9B^7WL].3R\ $5IQ@4&%^^(';SN3>R3 M>M9ZL/77&R0AL.LL<8P^[WP].)'S0?\ K2.=@S9F^'U\=9Y40*9*3/?CYXY" M!_G\_P#.49[&=N'%Z[4_5*0,$%317QO?7TKP9Y^5(F,3R4NS>(O"F6"UJU+< M*QT'6.7/2+81+WH-Q#P.K MQ6Y.2-@5&0<*D\8XPF0#(WL#VN'.NL\@B%B(J=YU:69?.>%,5M0H;W'%A\^" MWV JF:,#,-S63A&@]":9:=XSUKW0 (KC'\E?GJ=9XE!Q%\WP=DO7VO)/E/8Q M^9UGX]*+40HMV!/H!?\ DF(K<"Z!KXAW\(L:LY8H*S5N%CERTF0''2OU M&MF<>_G'$)C)1AF[[=]XUH$)I*D0@<7=?JPSC@IUG&Q?37:>;B]<(8S?KEX]$,-)7$WYKUOSA#@ $Q13ZIGT[S MEQ!*?6 ,^/?OQO@7C-Q)K#<_7ZSB6N(LT9/TWXX;< 1]#W_/GADB:1']/^KN M5 4^ X=P%)QX.;TSQ*MTX]7)069<@W.6<1 T0 M26=C&/Y'OB7N #0@]=AX/WXY$J0B@U>WZ#)TK3@Z8\T,!:.()<3MF>/WT,@2 M^3Z8I:"\?;E> H.'X?(,K0OBN0,);$NQW\TQP-HA&1F5AXSD\XSQAT+:A2%- MDP_7Q1O*HMB)$P.$MFO''B\5 K+"9J'U33E&8_JI9B> MQCDJK98 *] /?3 MF\EN2W&:^+]/5N]<8(L:;\:>5*4!2":[O>L=&"<%%+2!CNF"9#]IP(0 MT8/^2-404?"N.111'553'G;ZGCAO*]1VA]/M]W-!O1(A08$$JV[?99,G&D K M6W;WFXSQW6% F!2&?'>KXW!$TD!\K5U?9KOA.@1M@9P)IZ8FX*L)UA0!/L\. M>$B69A&J+:CWNWU11#4\!8&6 X)KZ<8D?K9A++,%S\ARZ;C5S&.@8TX-YG#Z MZLQA#$G883O..-\T1557R_\ OUX1(5)P"42GEP?C/*!8 ","0G5$<,]E%QDNQNG>TQO)1A9!ICO6,&KYX^O2@&3+K,/M&?'$A"UB(_*_ M5[V9IMG,[R69T?GYIG@B MEP:D/Y=_")I+^XSC&<^M> 9 $362_]6:MIOQ,_ M;?&)7)M9W N7W\7B.1<+\6_XPZAQ?OQ$94H[E08] MIO& QQVQ@/B-\>BUA= M1#..8$IK):8*7?D?":..E!G!D744%>L^)'(PG2(@"!X-.J=3DI#;D)3&DUGZ MW=X+$2TC8P>9&?IQ'. Q090>TE+Y#/ 7IHJ0 "A9EQ@Q+PY"6!(>7>7>=[O$ M36P(;T6YV>-7.N*/(AF3/7Y\?%LU_P FX4!54(&W/CA:T9=E ]=X\7SK@1)@ M2,%IW\?S'" ($>KU\^?5/CCQY5N\+;JDQ730=<6, 2F#4,R>?-N#2#:/V"?+ M0Z[U\'&Y6=HS$SYAM>L+Q,@B*%&*?E;VWLX5"94#S59\^CU.+!/9D;^P[OW' MDTS+)%2LW7=/O=(7C)C<#,*A3&:ZQQD/Y"-@GG$ZSYQQF*0 DAX\3%\3M3E9 M4Q%NJX/(,6EQZ3(!@F J:SC9G#C5. *>LBD'-<5A\\VS*)+;,>L=:_/&B"ZH MQ73Y&/H>S1^<(")$"%QG$WXRVBRI3%%0!DSGJU @K@5@AE9+TH%Q5G /J>"1 M!-:^O]ZHM#*[@?I]$+;R=;.-TSYL^Q>)+ JF\$]_Q\BG"$$UD']_^IJ!7 <+ MDA WKR0)K9O6>L[_ (SG6RIO !V=\2JCEC!Q@\+^>V\0 \('6$.?'5 M?>.0PXLZI@AX3XZI!#$-K& S\8==IVI'M$)E>6J-766^N-0I:#@)C.54J8S= MV??4(*A\)WB<64[M 4+[1F1#&<<(Q=Y:#*CN>M8=',%EY1 1-C6(W5>$>L0+ M&)JQLBXS8X -L,^;Z8*3[\H0$+)BKGUC-]M;!FN:BHRH1'-\GIX!I%C2%GFK M,:.QX+?, '@TS)@Z^G'200F :.YS(EZ\92'_ *<*:">O?$I27A2IXN1-O#R M:V)2;6AT'5"!Q%&$6,Z$Q2N&3W?Y^__ %)0%6!E7@+F&1DGU/OWJ\92DY:[7MOU_3@%*N8& MV,?YW7&+9.!58"+ER?*WCEX6 !-DNR1^L[X6*T,4#<63()?O-"A 2*!&N I MO-^UY44"XQ2A+MO>A^T=G4 B'P3NY\\'2-# 7=7J7Y;\<'RVG0&"A"YN_P 3 MD! HHPTPG8IYU>N2X%!M"*B_7"^L7@>?'0US.HAE/$$EV[(A<1.P+MV\$[EDLI!P M)>QR+JCQUP+K1;B2;21]XDXZ64@LVQI[//U-\-(RC=QPW\7?5P/2A+I>GT>R M_KQ6)!O4!TZUCU?MPD9A$HC_ ,G:IN)E?'>OMW3@:QO;F5Z6^<:U]7)+7J=_ MY\=3.N$ZRTZ:=:Z?[9T\PIGX3-;U^M+X=V(1LA)#NO::U>!^H3U%C!M^/!>[ MPO6(U$RVRW+@7S@Y&'J!X#=\37QGE/N\&=XN:&<^._J2HH'DWFWSG.-4?)!A M&T+C?[?H3/*&#"% 6)^OI;)A]$:ZHOCKD9=L AX@6$POJ/!;25I),G]YU)MX_6!,%&Z,TZ_'GB#.19=D42^2WS>1LR,GA,+9+X]W?'8C%8H/+JUOZ/ YT.&:>?!?F_3@ , ^#_J3R MH7$V7%^E_P \;I);OOK]SXO7 5)2V;M/\'<]9!0-R/VOLQ,7ODTG0=BL:#0# MF3H-\"'.# T@E):0VMM3B8!..F5 *#H*.U MC7?(AKL!@WE;B?'X9(AO<\DPQ,8WG/'"& 3T1U=YPLN.2P[1 ES!F:.CS&-. MG@Z)7#)-#=N7/ N3+*T^#IKWX, NFMZ(L!7NW/4Y<".F54ZMF_>?7#!BK!$/ M/>B]9]\#7!1<-\FI@ZQ7/"0U!0W>CKU[[XP0ML+11I;E6$S2Q;K&1AEBZ37Z M[C4V9!C %!*4;G0#XXN@$GV$+K.YK&N -#C.UQOMR^]]^]>9WQ3%A#+U;]/Y>0O,K!=(_7IW-7AL[L.4U["9GTQGA!S:#"1 M*PTV_0LT[77"D!C&'[8R^Y(;D)UF./BYN^+ 9FSO'><:G6W&^4[LY_CFZ]&' M@*&373_)UV=7F.'VP,K58ZWG.1F.+*JP+$J4ZR0P&<]WB; (L7#(=XJ[^MP0 MD1(9) FMN)8>7UQH 86SZ[9[I^O92@: )_'Z#CSUK0$,^<0//6LI].(@$"$K MDOG?[\S,%:;*-87PL\<3&S1V WSR@RW!>]?J>*)$2871&W/4K]/)NHM&=5[SU;[];XC8 1-9+^_P#U,<;F"^?G MQ_C$[XPJ1+\"_3KQW7$X4&;$;E!#H?C,(N.% M!D@NJ7&8V[ABYODN*06A)D\2 MS>+NV1:- KL&;AVQX[P!"2HK C75'\N/;EXI%RN?+GZQSE&E9DTL[/'G6K>8 M4 ,>._RZSO.R'H)2=)F6?KH\O+P00*^Q!1EJ2YWGA:S%.+99E,&@#2<\,XH# M'.68]6CG'*Y%<-2$!N'K-/6G(;.=RO[9[W\1I/TOJYXVG8PU,\5&BB=4LUG].M;696D7,&<;\[V9^925IA,'R9Q,=,UPQ=[92@7;HN9V8XV MRLZ,,B7>P?C'$PL ]]?C9Z\9SR,Y/+\S4?&;I<\O1!4_SKKX_5EFK0._";SY MGSEH\H4<,=X_;&=UE'@'8AJ[(+FADW^>3E-;N$@*N]:V^. '$H\QCPKF N] MF&>1 _59%T#>7>GCL(6 K49J]),/SR!2K<-E1SY\?3%X(^W;GZ9FJX.*^!@L%J-W ( M-[QB<($@5SDZIKQ,>O-"$, !]Z??[_!U,R@!!F[/A_QPHDH71Q$EH97O@(F4 M> &7%N7./J8Y"X!ES()CZN(:_3ESF/;O?=]=:]<468S[.R1[WZ[]'0L*[MA/ M!??XY,\# [B@!K3(CKMO-+)1B)#3T*&M)"4(YV1 M),.G2! :0.9'#,&47-]/E]< 15KU:E_\ )> T!'S2_\<;: 5^A>>BJG71W9#J;< MF I;+Z=_C/.GC\C+^,?SH5A3M 7/7?7R3"HA$Q)6 5N].>L\<+')L+:2BA[ M^2013\B3P8AB^>\\5886:*U[P6OJ@^5C5<;KL $WYA\<7 I[>7&+_/7.NFAW M-Y^=R=]XSR&A!JI@G6<:WC.WC[(P.#<#6\MZYE4_-*[@$%RXOS^OOA[K6'A:2IXIZY"4LH"&8+@-:#\/, I A&#O M<\"MBS''+^%1Q=XKWT9\>"$'=@8"!]2+2;< G SMU'/XQM35X1T/E_+X[DKQ M5=P9RX$S,[B>_JO8!^Y?^IPQ@2[P9CY^R;O$2/[C^>^^!*,QRUIL^&GGT7@X MH@5DK A+<4:)M.*"EK-46"(#4V]"A6>+55 5\-0*=/W[?QC08+.LF,W%UP$1 MC'*15<5\UJ]\[8A2AF6-^O[<<-7T7P?3ZYS-/"10TOQ8X,'3^OC@$^#WL?@5 MWXWQTL9E8.7O[Z/6X@(\AH(*;&'GS'?)T"EVK\?#GACU47..O@S\?,O!=EDEU;YS[SCO <8:FKZ?_ 'ST>)DVF#BPBF5M MSO/G2KD.;[U_#IINY$(X: W7XA_.L<8VH0S22.,_OWGAVP*/0!<7NF\SSC_C MLTRAG'4WRU-09\B]YS+V]SF& J_6O\];YGM&CUI]F?\ $XP*S!#M[OYV?(@N MD'98 J+K/A'? _#P)-LP.#"W(KK3 TE+6@^F.JR=!R1.J'600_27-_'")DA M5388\OO'TY"QX!F/.'MW@?'>8)P0W,4TX-^#^_%]0( (BF!\Z#=F,\+^QJST M4@RMSC\<;$)U,HR!VR-S"3/&;8MD!CPOXZ>1# M(J5_3K+)KBB0K9-PSFX^? MH7B/A2/+9^_T_16J#*S;U_?Z[X1C+X,_."?7U]G: (YNQRW.MX] SA*1*F4I ME<9U[Q\BX# 8HF"V=V>8S@@$I9H69(R32;WEYY_#(;M&D^'H #FE=!_(*3/ M?R<"OE?G%^US]3BL;^[<^/N$'KWUPK4*"$H&F")%Q8G0E4%BLKU;UC#]>^5 6 M-[#0K%MZ5;.*VW+!J(/ BS),.U4M"=8P\!)?IF8.3B$(S'NLSO(]X\M[UEM\ M^34D/NWR<%"XWF8^X?&_.8\0!J[5^?[?KPGJT7FP?'1\?.RDK$::M?4KWYQ6 M4@8QS2J@#\_.YPR*1&1!I"^F?+UFF E//@_'&$.P7,SC/MAXE\\.@HN,WP> ML?XO%QBBY\>YC^'>R2"*SZ\O[^?'"^%PK-".)0QNH!"'"SB2A(PE'6,[&,XP M(\80@3"8!,AA;PB#C6> %B=8'[O%@K4!\OG/Z9^5H,BS.1%^DW^>MJ2YI/\ M./)U_GAE;,%PJ8E?_=UG_' .PI\P=_;[^>7(K5E[>=^N]S>V",+^B>//UGSP M(,!1CR>=1?\ $XOVT",)"#FY!<8\)Q?*4@I:,:AIVELX-"D[-P7K!QOZ@,T9UZA@34]52$!LI" [SC][QSW*Z!"4N!_G#Q7*5 MI1&8(9[W]^+:8Y-[C5Q_/FB&4"XL7,UK^]D<\>F?N9UG5'KY\Y5L#.L)=7'S M\QXE>Y3%63QU_/'%3:_M?]2R!(V^,/&06[+Y/-??C@-E#YU2ZW9<3]D 4#N$ M\B1-B9^-TLT,K%H75K?.4=\ 2HT"S7"'LZ]'@Y:TET!BDWN'>B\$RX*X%&O. M,^)^$I#50V0P3T/OU."S8I>YWFCUG],\SR9<:+_:/G-\\PH IG'G_/%,L-DZ[Q/GZ;QGD6:L,57HF]2X\QY7]D(SI,X1(?GOF%>3Q,%!JA M!2,#T)Q@*([2'+6==Y/TYU+$?)C_ =]:DXO0:^G?V_'G/4/L'-K7+;_ #7G MI(2@"!$?UZ+OUP(%=*%::=5C/K,FE^I@R"H_Q3/HT\?@$*C+.=_'WM\8O3R8F]")2J MB7 EOO%G!])?F&C&N<;BSURXT;1,[K*:H2:Q3E^+6+AO0T>_'IX=)89$HD98W6[+AXIR 8"5% JDK@Q,]#DH4)+%M &Y>LU M5+*J"CA?3N[E/QQ9!4/M3ZF;_)QJ=M#ECJ^_+:]9Y!+,P*"X"@9SC/@XRW9! M[G>S&SX-CS"P82QDFYW[UOMY@]@:1F+;';G4=>^+8,!!'X[[]NCF)*HU[?7B MU_3F0:?SOQ?/>,705C-X#]?-S\/!4QI%&SQ#']S@0A8)*AOI]OU>4%@J(F)O M6+/L;X8LA@58&L='Z<$%!R?5;\=9NL.+PPBT!CWHOSG6Z9P #:[>VQZ^ORXT M?S'@_P"I(OO?\\^>%%M6?BN\_?OC-:!OP/7E_?@DG 2+-D?3^N3/$P5;D&X[ MQ]=^)LQP>EPC!7.!+ SD*V\D4C8=DQY5OS,;$)1T 9,=GV MMT+_;Z<7K(BI@GN=;_ +3F<\:?\OPKCMY?+3E+ M7N^,YGQYXL:1#Y3=Z\_OGBJ*'$9"ZN)X\OUS/:,@BB$=FNL<[6,,E"U3>88= M[QQEB*#J]2Q]M.F',D$:$5+(WXA@N,O)ED4:[1'P$G\+P)4K1FS$)O;C:=< M.DB\I%T8=W&??$],DY0)ELS3QC!A&(?:;^N2.GSOQ<\-$GZG0=>]=GTX#8A 4692XN)/ M$O%^Y8"+(C%1C>3&*G3K08P4+UZYL!#3N%QDO8=_?.0_0P!A"+@I%N^K.91>-,S.O=L>F\:RBZ M39^QCN=<3(!Z,A.\V$_SQ-H3:?)1N^W[\D"C)E_&?']^IS(96/T8AG^V'[OZ M/SK[5S+]]>FC1?)#X^U8?VXP:K>8]8;K$-9SV+$0,\+ZF"?SX0&B6#-3Z1/E MWQ@D(I'ZFL^UN8[XWTA=F?D6Y>IE[P<>C14&(+?\1WXX(#L!^/\ J0Y<(/V> M%F.P-F//U<=7XX ([ SY_P#7T_&1V^]YT_G1;<\>)196P9K#[[Z]8/-#";(3 MP_HXS-<.J./ 0'H,!X ]O*;.F&;*$S3X'Z=BM#DI!T8^#+XX!BDGWUCZ%0[,B0[=WQ-9X<=O-!#9N?KU@Z.(7F"H8&LDSC]F="%S/1_@SN_ %/ M)@S-2)XION9'@!QIT02WJ6^9F\/TI.@& : E4*@AGA1 7:E \-;)Z//':24< MN YO\WKL1 T#/OH^G>L\#1\WWGGB6485I=59#K 2YG4N0(G2YD9'NPPW@)C4!%*1*$:-MZT,7H M0(M3 ]I:9(:I,%E -NQ"8Q9>W=UPPD@JYF"I/Y'1NS(++!DP^'Z=N>4ZHB7] M2,C+LQW@@ "A+//]5A'<4TR4]_STX0K;73XO6-)YX&"&)(_3P>C]/\ J?YK M]'D.Z,._5/5[UO.8GH%&&$WW_?\ MRAZ*!+ G6?'1Y\U!-C'">-9[X\"8N^@ MWF?IB]\76N! 1P=SZGSY>!#P>0F,37KQC?)86&@N_P"_VV